Glyconix SB-2 Registration Dated 10-13-05

-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
QGusfhUvjEX2CLAoFaKXdby0pX+OGvT/lKK41NM76JX4o1V43RF/x1uFrtuHooyI
Cjx/w8teAnZCY4lAlfF2xg==
<SEC-DOCUMENT>0001193125-05-201017.txt : 20051013
<SEC-HEADER>0001193125-05-201017.hdr.sgml : 20051013
<ACCEPTANCE-DATETIME>20051013165125
ACCESSION NUMBER: 0001193125-05-201017
CONFORMED SUBMISSION TYPE: SB-2
PUBLIC DOCUMENT COUNT: 21
FILED AS OF DATE: 20051013
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: GLYCONIX CORP
CENTRAL INDEX KEY: 0001303041
IRS NUMBER: 000000000
FILING VALUES:
FORM TYPE: SB-2
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-128986
FILM NUMBER: 051137187
BUSINESS ADDRESS:
STREET 1: 350 5TH AVE
STREET 2: SUITE 7415
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 212-404-7050
MAIL ADDRESS:
STREET 1: 350 5TH AVE
STREET 2: SUITE 7415
CITY: NEW YORK
STATE: NY
ZIP: 10118
</SEC-HEADER>
<DOCUMENT>
<TYPE>SB-2
<SEQUENCE>1
<FILENAME>dsb2.htm
<DESCRIPTION>FORM SB-2
<TEXT>
<HTML><HEAD>
<TITLE>Form SB-2</TITLE>
</HEAD>
<BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
As filed with the Securities and Exchange Commission on October
13, 2005. Registration No. 333-
 
 <HR
SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> SECURITIES AND
EXCHANGE
COMMISSION Washington, D.C. 20549
 FORM SB-2 REGISTRATION
STATEMENT
 UNDER THE SECURITIES ACT OF 1933 <HR WIDTH="21%"
SIZE="1" NOSHADE COLOR="#000000"> GLYCONIX CORP.
SIZE="1"> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">
<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center">Delaware</TD>
<TD VALIGN="bottom"> </TD>
SIZE="2">2833</TD>
<TD VALIGN="top" ALIGN="center">11-
3626401</TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> (State or Other
Jurisdiction of Incorporation or
Organization)</TD>
ALIGN="center">(Primary Standard
Industrial Classification Code Number)</TD>
ALIGN="center">(I.R.S.
Employer Identification No.)</TD></TR>
</TABLE> 
<TR>
<TD VALIGN="top" ALIGN="center">350 Fifth
Avenue, Suite 4811, New York, NY</TD>
SIZE="2">10118</TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center">(Address
of principal executive offices)</TD>
<TD VALIGN="top" ALIGN="center">(Zip
Code)</TD></TR>
ALIGN="center">Registrants
telephone number, including area code: (212) 404 - 7050 <HR
SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"> (Name, address, including
zip code, and telephone number, including area code, of agent for service of
process) Copies of
communications to: JOSEPH I. EMAS
 1224 WASHINGTON AVENUE MIAMI BEACH, FLORIDA 33139 TELEPHONE NO.:
(305) 531-1174 FACSIMILE NO.:
(305) 531-1274
SIZE="1"> Approximate date of proposed sale to
public: From time to time
after the effective date of this registration statement. If
any of the
securities being registered on this form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act, check the
following box. x <P
this form is filed to register additional securities for an offering pursuant to
Rule
462(b) under the Securities Act, please check the following box and list the
Securities Act registration statement number of the earlier effective registration
statement for the same offering. ¨
 If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering.
¨ <P
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the
Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering. 

<HR SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">
If delivery of the prospectus is
expected to be made pursuant to Rule 434, please check
the following box. CALCULATION OF
REGISTRATION FEE 
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD COLSPAN="9" VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> Title of Each Class of Securities to be Registered</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> </TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">
Roman" SIZE="1">Amount to be Registered</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Proposed Maximum Offering Price
Per Share (1)</TD>
FACE="Times New Roman" SIZE="1">Proposed Maximum Aggregate Offering
Price</TD>
FACE="Times New Roman" SIZE="1">Amount
of Registration Fee</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> Common
Shares, $.01 par value (2)</TD>
FACE="Times New Roman" SIZE="2">3,610,000</TD>
FACE="Times New Roman" SIZE="2">2.00</TD>
FACE="Times New Roman" SIZE="2">$7,220,000</TD>
FACE="Times New Roman" SIZE="2">$850</TD></TR>
<TR>
left:1.00em; text-indent:-1.00em">Represents
shares of Common Shares, $.01 par value underlying warrants (3)</TD>
<TR>
left:1.00em; text-indent:-1.00em">Common
Shares, $.01 par value (4)</TD>
<TR>
<TD VALIGN="top"> Total</TD>
<TD VALIGN="bottom" ALIGN="center">10,720,000</TD>
SIZE="2">$2,312</TD></TR>
<TR>
<TD COLSPAN="9" VALIGN="bottom"><HR SIZE="3" NOSHADE COLOR="#000000"></TD></TR>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"
WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated
solely for the purpose of calculating the registration fee required by
Section 6(B) of the Securities Act and computed pursuant to Rule 457 under
the Securities Act.
</TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Represents
shares to be sold by our Selling Shareholders. </TD></TR></TABLE> 
<TR>
shares of common stock underlying warrants. In addition to the shares set forth in
the table, the amount to be registered includes an indeterminate number of shares
issuable upon exercise of the warrants; as such number may be adjusted as a result
of stock splits, stock dividends and similar transactions in accordance with Rule
416. The number of shares of common stock registered hereunder represents a good
faith estimate by us of the number of shares of common stock issuable upon
exercise of the warrants. For purposes of estimating the number of shares of
common stock to be included in this registration statement, we calculated a good
faith estimate
of the number of shares of our common stock that we believe will be issuable upon
exercise of the warrants to account for market fluctuations. Should the any
exercise price adjustment result in our having insufficient shares, we will not
rely upon
Rule 416, but will file a new registration statement to cover the resale of such
additional shares should that become necessary. In addition, should a decrease in
the exercise price as a result of an issuance or sale of shares below the then
current
market price, result in our having insufficient shares, we will not rely upon Rule
416, but will file a new registration statement to cover the resale of such
additional shares should that become necessary. </TD></TR></TABLE> 
<TR>
shares of common stock to be offered by the Issuer. </TD></TR></TABLE> No
exchange or over the counter market exists for our common stock. The most recent
price paid for our common stock in a private placement was $0.50. The registrant hereby amends this registration statement on such date
or dates as may be
necessary to delay its effective date until the registrant shall file a further
amendment which specifically states that this registration statement shall
thereafter become effective in accordance with Section 8(a) of the
Securities Act
of 1933 or until this registration statement shall become effective on such
date as the Securities and Exchange Commission, acting pursuant to said
Section 8(a), may determine. <HR
SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">
THE INFORMATION CONTAINED IN THIS PROSPECTUS IS NOT COMPLETE
AND MAY BE CHANGED. THESE SECURITIES MAY NOT BE
SOLD UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION IS DECLARED EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE
SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE
WHERE THE
OFFER OR SALE IS NOT PERMITTED. SUBJECT
TO COMPLETION, DATED OCTOBER 13, 2005 PROSPECTUS
 GLYCONIX CORP. 10,720,000 SHARES OF OUR COMMON STOCK Glyconix Corp. (we, us, our or the
Glyconix
Corp.) is offering up to 3,500,000 shares of common stock which, as of this
date, have not been issued. Additionally, the Selling Shareholders named in this
prospectus are offering to sell up to 3,610,000 shares of our common stock and up
to
3,610,000 shares of common stock issuable upon exercise of warrants held by the
Selling Shareholders. The prices at which the Selling Shareholders may sell the
shares will be determined by the prevailing market price for the shares or in
negotiated
transactions. We will not receive proceeds from the sale of our shares by the
Selling Shareholders but we will receive proceeds from the exercise of the
warrants, which have an exercise price of $1.50 per share. We
are offering for sale, on a self- underwritten basis, up to 3,500,000 shares of
our common
stock at a price of $2.00 per share. There is no minimum number of shares we will
sell. Proceeds from the sale of the shares will be deposited in our operating
account and there will be no refunds. This offering will continue for a period of
180
days from the effective date of this prospectus and may be terminated sooner in
our sole discretion. There are no minimum share purchase requirements for
individual investors. The Selling Shareholders, and any broker-dealers
or agents that are involved in selling the shares, may be deemed to be
underwriters within the meaning of the Securities Act in connection
with such sales. In such event, any commissions received by such broker-dealers or
agents and any profit on the resale of the shares purchased by them, may be deemed
to
be underwriting commissions or discounts under the Securities Act. The Selling
Shareholders have informed us that they do not have any agreements or
understandings, directly or indirectly, with any person to distribute the common
stock. 
 Investing in our securities involves risk, see 
<A HREF="#tx97153_4">Risk Factors</A> page 5. Any investor who cannot afford to sustain the total loss of
their
investment should not purchase the securities offered herein. Neither the
Securities and Exchange Commission, nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus is
truthful or
complete. Any representation to the contrary is a criminal offense.
 This is our initial public offering. No public market currently exists
for our shares, although we intend to apply for listing on the Over-the-Counter
Bulletin Board in the future. We know of no market makers for our common stock.
The
offering price may not reflect the market price of our shares after the offering.
The shares will be offered and sold by our officers and directors without any
discounts or other commissions. We currently have no agreements, arrangements or
understandings with any broker/dealers to sell shares. 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-
COLLAPSE:COLLAPSE" ALIGN="center">
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Price to public <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Underwriting Discounts and Commissions (1) <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Proceeds to Company (1) (2) <HR SIZE="1"
NOSHADE COLOR="#000000"></TD></TR>
<TR BGCOLOR="#cceeff">
FACE="Times New Roman" SIZE="2">Per Share</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.00</TD>
SIZE="2">0</TD>
SIZE="2">0</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Total Maximum</TD>
SIZE="2">7,000,000</TD>
SIZE="2">0</TD>
SIZE="2">7,000,000</TD></TR>
</TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">We plan to
have our officers offer and sell the shares. They will receive no discounts or
commissions. We do not have any agreements or understandings with any
broker/dealers,
although we may, at our discretion, retain such to assist in the offer and sale of
units. In such event, we will update this prospectus accordingly.
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Proceeds to us
are shown before deducting offering expenses payable by us estimated at $100,000,
including legal and accounting fees and printing costs. </TD></TR></TABLE>
The
total costs of this offering, estimated at $100,000, shall be borne by us but the
Selling
Shareholders will pay all of their selling commissions, brokerage fees and related
expenses. Our common stock is presently not traded on any
market or securities exchange. 
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of
these securities or passed upon the adequacy or accuracy of this prospectus. Any
representation to the contrary is a criminal offense. All
dealers that effect transactions in these securities whether or not participating
in this offering may be required to deliver a prospectus. This is in addition to
the
dealers obligation to deliver a prospectus when acting as underwriters and
with respect to their unsold allotments or subscriptions. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%">This prospectus contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E
of the Securities Exchange Act of 1934, as amended. Such forward-looking
statements include statements regarding, among other things, (a) our
projected sales and profitability, (b) our growth strategies,
(c) anticipated trends in our
industry, (d) our future financing plans, and (e) our anticipated needs
for working capital. Forward-looking statements, which involve assumptions and
describe our future plans, strategies, and expectations, are generally
identifiable by
use of the words may, will, should,
expect, anticipate, estimate,
believe, intend, or project or the negative of
these words or other
variations on these words or comparable terminology. This information may involve
known and unknown risks, uncertainties, and other factors that may cause our
actual results, performance, or achievements to be materially different from the
future
results, performance, or achievements expressed or implied by any forward-looking
statements. These statements may be found under Managements Discussion
and Analysis of Financial Condition and Results of Operations and
Business, as well as in this prospectus generally. Actual events or
results may differ materially from those discussed in forward-looking statements
as a result of various factors, including, without limitation, the risks outlined
under
Risk Factors and matters described in this prospectus generally. This
prospectus contains market data related to our business. This data has been
included in articles published by independent industry sources. Although we
believe these
sources are reliable, we have not independently verified this market data. This
market data includes projections that are based on a number of assumptions. If any
one or more of these assumptions turns out to be incorrect, actual results may
differ
materially from the projections based on these assumptions. In light of these
risks and uncertainties, there can be no assurance that the forward-looking
statements contained in this filing will in fact occur. In addition to the
information
expressly required to be included in this filing, we will provide such further
material information, if any, as may be necessary to make the required statements,
in light of the circumstances under which they are made, not misleading.
 Each forward-looking statement should be read in context with, and
with an
understanding of, the various other disclosures concerning our company and our
business made elsewhere in this prospectus as well as other public reports that
may be filed with the United States Securities and Exchange Commission (the
SEC). You should not place undue reliance on any forward-looking
statement as a prediction of actual results or developments. We are not obligated
to update or revise any forward-looking statement contained in this prospectus to
reflect
new events or circumstances, unless and to the extent required by applicable law.
FACE="Times New Roman" SIZE="2">The Date of this Prospectus is: October 13,
2005 

Roman" SIZE="2">
<A NAME="toc"></A>TABLE OF CONTENTS 
<TR>
<TD></TD></TR>
<TR>
SIZE="1">PAGE <HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">
<A HREF="#tx97153_1">Prospectus Summary</A></TD>
<TR>
<A HREF="#tx97153_2">The Resale Offering</A></TD>
<TR>
<A HREF="#tx97153_3">Summary Financial Data</A></TD>
<TR>
<A HREF="#tx97153_4">Risk Factors</A></TD>
<TR>
<A HREF="#tx97153_5">Where You Can Find More Information</A></TD>
<TR>
<A HREF="#tx97153_6">Capitalization</A></TD>
<TR>
<A HREF="#tx97153_7">Use of Proceeds</A></TD>
<TR>
<A HREF="#tx97153_8">Determination of Offering Price</A></TD>
<TR>
<A HREF="#tx97153_9">Dividends</A></TD>
<TR>
<A HREF="#tx97153_10">Dilution</A></TD>
<TR>
<A HREF="#tx97153_11">Equity Compensation Plan Information</A></TD>
<TR>
<A HREF="#tx97153_12">Comparative Data</A></TD>
<TR>
<A HREF="#tx97153_13">Selling Shareholders</A></TD>
<TR>
<A HREF="#tx97153_14">Plan of Distribution</A></TD>
<TR>
<A HREF="#tx97153_15">Penny Stock Rules / Section 15(g) of the Exchange
Act</A></TD>
<TR>
<A HREF="#tx97153_16">Legal Proceedings</A></TD>
<TR>
<A HREF="#tx97153_17">Directors, Executive Officers and Control
Persons</A></TD>
<TR>
<A HREF="#tx97153_18">Executive Compensation</A></TD>
<TR>
<A HREF="#tx97153_19">Security Ownership of Certain Beneficial Owners and
Management</A></TD>
<TR>
<A HREF="#tx97153_20">Description of Securities</A></TD>
<TR>
<A HREF="#tx97153_21">Disclosure of Commission Position of Indemnification for
Securities Act Liabilities</A></TD>
<TR>
<A HREF="#tx97153_22">Organization within Last Five Years</A></TD>
<TR>
<A HREF="#tx97153_23">Description of Business</A></TD>
<TR>
<A HREF="#tx97153_24">Business Strategy</A></TD>
<TR>
<A HREF="#tx97153_25">The Market</A></TD>
<TR>
<A HREF="#tx97153_26">Consultants</A></TD>
<TR>
<A HREF="#tx97153_27">Managements Discussion and Analysis or Plan of
Operation</A></TD>
<TR>
<A HREF="#tx97153_28">Summary of Significant Accounting
Policies</A></TD>
<TR>
<A HREF="#tx97153_29">Description of Property</A></TD>
<TR>
<A HREF="#tx97153_30">Certain Relationships and Related
Transactions</A></TD>
<TR>
<A HREF="#tx97153_31">Market for Common Equity and Related Stockholder
Matters</A></TD>
<TR>
<A HREF="#tx97153_32">Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure</A></TD>
<TR>
<A HREF="#tx97153_33">Additional Information</A></TD>
</TABLE>

SIZE="2">
<A NAME="tx97153_1"></A>PROSPECTUS SUMMARY This
summary highlights
important information about our company and business. Because it is a summary, it
may not contain all of the information that is important to you. To understand
this offering fully, you should read this entire prospectus and the financial
statements
and related notes included in this prospectus carefully, including the Risk
Factors section. Unless the context requires otherwise, we,
us, our, and the Company and
similar
terms refer to Glyconix Corp., and our subsidiaries collectively, while the term
Glyconix refers to Glyconix Corp. in its corporate capacity
 We were incorporated under the laws of the State of Delaware in August,
2001. Our business plan is to expand its innovative proprietary anti-infective and
oncology
drugs, supply a unique compound currently being used in Phase II for a new cancer
therapy treatment, and using our proprietary technology to assist other companies
in their management of pharmaceutical product life cycles. We are authorized to
issue
40,000,000 shares of common stock, par value $.01 per share, of which 19,450,000
shares are issued as of October 13, 2005. We are authorized to issue 5,000,000
shares of preferred stock, $.01 par value, of which none are issued and
outstanding as of
October 13, 2005. Where You Can Find Us Our
principal executive offices are located at 350 Fifth Avenue, Suite 4811, New York,
NY
10118. Our telephone number is (212) 404-7050. About Our
Business
 Glyconix is a development stage company that uses
its proprietary
processes to create proprietary drugs with unique and enhanced properties by
chemically binding small sugar molecules to novel and existing pharmaceuticals, a
process known as Glycosylation. It holds multiple patents on the resultant
compounds. The
Companys expertise in sugar and medicinal chemistries is focused on three
major market opportunities. First, the Company is expanding its pipeline of
innovative proprietary anti-infective (e.g. antifungal, antibiotic) and oncology
drugs. Lead
drugs resulting from this work are already in preclinical development. Second, it
is supplying a unique compound currently in Phase II trials for a cutting-edge
mode of cancer therapy; this effort is already generating revenue. Third, it is
applying
its proprietary technology toward meeting the needs of other companies in their
management of pharmaceutical product life cycles. This effort is eliciting strong
interest among pharmaceutical companies seeking to extend the life of certain
product
lines. The companys proprietary compounds offer substantial upside
potential, while the glycosylation technology is generating early revenue that
will mitigate the companys financial needs and risk. Glyconix was incorporated in 2001 and acquired its intellectual property
from both Glycosyn
Pharmaceuticals, Inc., an eight-year old company that previously operated as a
subsidiary of Harrier, Inc. (a publicly traded U.S. company), and New Concept
Therapeutics, a four-year old company devoted to the research and manufacture of
Boron
Neutron Capture Therapy (BNCT) compounds. <P
Companys
leadership team has extensive experience developing compounds, bringing compounds
to market, raising capital and building successful companies. The Chairman is the
founder of Cell Pathways Inc. (CPI), who recently concluded the sale of CPI to OSI
Pharmaceuticals for $82 million. To assist with the commercialization efforts, the
Company maintains a Scientific Advisory Board (SAB), the members of which bring
scientific expertise and significant pharmaceutical drug development experience.
Among
others, the SAB includes: the former CSO of Phoenix Drug Discovery and Lion
Pharmaceuticals, who 


also served as an executive in drug
development at Human Genome Sciences, Bristol-Myers Squibb and Schering Corp.;
Senior Investigator and Head of
Translational Research at the Translational Genomics Research Institutes
(Tgen) Translational Drug Development Division and Head, Pancreatic Cancer
Research Program in Phoenix, Arizona. He is also Chief Scientific Officer for US
Oncology, an
Associate Professor at Harvard Medical School who also serves as the Director of
Radiological Sciences at Tufts New England Medical Center, President of
International Society of Neutron Capture Therapy (ISNCT); and the former head of
R&D of Drug
Delivery of Enzon Corporation. Proprietary Technologies and
Market
Opportunities 1) Expanding the Pipeline of Innovative Anti-
infective
and Oncology Drugs Glycosylation is the process of
chemically combining
sugar molecules with existing compounds to alter their physical and chemical
properties. These alterations can, for example, lead to improved targeting of a
drug, or enhance an otherwise insoluble drugs absorption when taken orally.
These
changes could increase the drugs efficacy, lessen certain toxicities, or do
both. In some cases, such improvements to drug classes with already known clinical
activity may lessen some of the overall risk inherent in novel drug development.
FACE="Times New Roman" SIZE="2">The Company owns several glycosylated
pharmaceutical compounds. A number of
these are patented, and others are in various stages of development. These, and
other early-stage compounds, are currently being developed and synthesized at the
Companys chemical research and development laboratory located in North
Carolina.
Key patented molecules with demonstrated preclinical in vitro or animal
efficacy are analogues of the naturally occurring 1, 2-dithiins, a promising new
class of anti-fungal agents, and of the camptothecin class of oncology drugs.
Other novel
molecules for use as anti-infective and analgesic agents have also been
synthesized and patented. 2) Supplying L-BPA for Late-Stage Oncology
Clinical Trials This near-term opportunity, which is already being
exploited and generating revenue, involves the supply of L-BPA to research
institutes conducting Phase II & Phase III clinical trials of L-BPA-F (L-
BPA
complexed to fructose, a small sugar molecule) in Boron Neutron Capture Therapy
(BNCT) in cancers of the brain (glioma) and other malignancies. Glyconix is an
exclusive world-wide distributor for a Swedish manufacturer of L-BPA. Glyconix
also
supplies L-BPA, a compound containing boron-10, a non-radioactive isotope of
boron, to Harvard/MIT, Studsvik (Sweden), and The National Commission of Atomic
Energy in Argentina, Yliopiston Apteekki in Finland and Cancer Research UK. Once
BNCT
receives regulatory approval, the Companys proprietary manufacturing process
will position the Company, in managements opinion, to become the preferred
supplier of L-BPA to the global market. In the interim, the Company will continue
to
develop an enhanced second-generation proprietary compound. BNCT may be far
superior to current methods of treating certain cancers. In fact, some forms of
cancer might only be treated by BNCT. It works by generating a high burst of
energy within cancer cells that destroys those cells while leaving normal tissue
relatively
unaffected. The energy burst develops when a low-level beam of neutrons bombard
tumor cells that are laden with boron-10 as a result of a patients being
administered L-BPA-F which accumulates preferentially in tumor cells. 
Management believes Phase II trials in Europe are demonstrating L-BPA-
Fs and
BNCTs promise as a cutting-edge cancer treatment. BNCT can be administered
in a matter of hours with few or no side effects (based on current trial results).
In one case, a patient with liver cancer having just a couple of months to live,
received treatment and after 18 months has experienced no recurrence or side
effects. 2 

SIZE="2">3) Management of Pharmaceutical Product Life Cycle The market for life cycle extension of existing
drugs is expected to be over $50 billion between 2000 and 2010. The Companys
proprietary glycosylation process could potentially be applied to numerous types
of drugs with an immediate addressable market opportunity of up to $10 billion.
SIZE="2">
<A NAME="tx97153_2"></A>THE RESALE OFFERING 
<TR>
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">Glyconix
Corp.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top">Securities Being
Offered to New Investors</TD>
<TD VALIGN="top">Up to a maximum of
3,500,000 with no minimum.</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Securities Being
Offered By Selling Shareholders</TD>
<TD VALIGN="bottom">3,610,000 shares of our
common stock may be resold by our Selling Shareholders and up to 3,610,000 shares
underlying warrants may be resold by our Selling Shareholders. The offering price
will be determined by market factors and the independent decisions of the Selling
Shareholders.</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Offering
Price</TD>
<TD VALIGN="bottom">We are offering our
shares of common stock at $2.00 per share. The Selling Shareholders can sell our
shares at $2.00 per share until our shares are quoted on the OTC Bulletin Board,
and
thereafter at prevailing market prices or privately negotiated prices. We
determined this offering price arbitrarily based upon the companys progress
since the last sale of our common stock to investors.</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Terms of the
Offering</TD>
<TD VALIGN="bottom">We are offering our
shares for a period not to exceed 180 days following the effective date of this
registration. The Selling Shareholders will determine when and how they will sell
our
common stock offered in this prospectus.</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Securities
Outstanding</TD>
<TD VALIGN="bottom">We are authorized to
issue 40,000,000 shares of common stock, $.01 par value, of which 19,450,000
shares are currently issued and 19,350,000 shares are outstanding. We are
authorized to issue
5,000,000 shares of preferred stock, $.01 par value, of which none have been
issued or are outstanding.</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Use of
Proceeds</TD>
<TD VALIGN="bottom">We will not receive any
proceeds from the sale of the underlying common stock currently held by the
Selling Shareholders but will receive proceeds from the exercise of the warrants,
which
have an exercise price of $1.50 per share.</TD></TR>
<TR>
<TR>
<TD VALIGN="top"> </TD>
<TD VALIGN="bottom">We will receive proceeds
from the offering; see Use of Proceeds.</TD></TR>

Roman" SIZE="2">
<A NAME="tx97153_3"></A>SUMMARY OF FINANCIAL DATA (in
thousand, except share and per share amounts) The summary of
financial
data as of and for the years ended December 31, 2004 and 2003 is derived from
and should be read in conjunction with our audited financial statements for the
year ended December 31, 2004, including the notes to those financial
statements,
which are included elsewhere in this registration statement along with the section
titled Managements Discussion and Analysis or Plan of Operation.
The summary of financial data is derived from and should be read in conjunction
with unaudited financial statements including the notes to financial statements
for six-months ended June 30, 2005 and 2004. 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> Six-
month period ended June 30,<HR SIZE="1" NOSHADE COLOR="#000000"></TD>
bottom:0px" ALIGN="center">August 21, 2001 (Inception) Through Year
ended December 31,<HR SIZE="1"
NOSHADE COLOR="#000000"></TD>
SIZE="1">August 21, 2001 (Inception) Through December 31,<HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR>
SIZE="1">2005 <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TR>
SIZE="1">(unaudited)</TD>
<TD COLSPAN="2" VALIGN="bottom"> </TD>
FACE="Times New Roman" SIZE="2">Net sales (Note I[4])</TD>
<TD VALIGN="bottom">$</TD>
SIZE="2">54</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE ALIGN="right" COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom"><HR WIDTH="0" SIZE="1" NOSHADE ALIGN="left"
COLOR="#ffffff"></TD>
COLOR="#ffffff"></TD></TR>
FACE="Times New Roman" SIZE="2">Costs and Expenses:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cost of Sales</TD>
<TD VALIGN="bottom"> </TD>
FACE="Times New Roman" SIZE="2">Research and development</TD>
SIZE="2">1,214</TD>
<TR>
FACE="Times New Roman" SIZE="2">General and administrative</TD>
SIZE="2">2,302</TD>
SIZE="2">1,758</TD>
<TR>
SIZE="2">3,795</TD>
SIZE="2">2,996</TD>
<TR>
FACE="Times New Roman" SIZE="2">Interest expense, net</TD>
<TR>
FACE="Times New Roman" SIZE="2">Net loss</TD>
SIZE="2">(750</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
SIZE="2">(3,585</TD>
SIZE="2">(2,835</TD>
SIZE="2">)</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Basic and diluted loss per common
share</TD>
SIZE="2">(0.04</TD>
SIZE="2">(0.05</TD>
SIZE="2">(0.08</TD>
SIZE="2">(0.12</TD>
<TR>
FACE="Times New Roman" SIZE="2">Weighted average number of shares outstanding
basic and diluted</TD>
SIZE="2">19,450</TD>
SIZE="2">8,323</TD>
SIZE="2">10,886</TD>
SIZE="2">6,364</TD>
FACE="Times New Roman" SIZE="2">The following table provides a summary
of our balance sheet data at June 30, 2005 (unaudited): 
<TR>
<TD WIDTH="4%"> </TD>
SIZE="2"></TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">on actual
basis </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">on as adjusted
basis to further reflect the receipt of the net proceeds from our sale of 3,500
shares of common stock in this offering, at the initial offering price of $2.00
per
share after deducting our estimated offering expenses and the anticipated
application of the estimated net proceeds. </TD></TR></TABLE> 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">June 30, 2005 (unaudited) <HR SIZE="1"
<TR>
SIZE="1">Actual <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">As Adjusted <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">Balance sheet data:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cash, cash equivalents and
investments</TD>
SIZE="2">7,663</TD></TR>
FACE="Times New Roman" SIZE="2">Working capital (deficiency)</TD>
SIZE="2">6,770</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Total assets</TD>
SIZE="2">1,058</TD>
SIZE="2">7,958</TD></TR>
FACE="Times New Roman" SIZE="2">Stockholders equity</TD>
SIZE="2">7,056</TD></TR>

SIZE="2">
<A NAME="tx97153_4"></A>RISK FACTORS An investment in
our common stock
involves a high degree of risk. You should carefully consider the risks described
below and the other information in this prospectus before investing in our common
stock. If any of the following risks occur, our business, operating results and
financial condition could be seriously harmed. The trading price of our common
stock could decline due to any of these risks, and you may lose all or part of
your investment. This prospectus also contains forward-looking statements that
involve
risks and uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements as a result of certain factors,
including the risks faced by us described below and elsewhere in this prospectus.
We
caution you to review the cautionary statements set forth in this prospectus.
Please refer to Risks Associated with Forward-looking Statements on
page 16. Risks Related To Our Business 
 Because we have a limited operating history, it will be difficult for
you to evaluate our business. Glyconix is a development stage company that was
incorporated in August, 2001. We have only conducted operations since 2001;
however we
acquired our intellectual property from both Glycosyn Pharmaceuticals, Inc., an
eight-year old company that previously operated as a subsidiary of Harrier, Inc.
(a publicly traded U.S. company) and New Concept Therapeutics, a four year old
company
devoted to the research and manufacture of Boron Neutron Capture Therapy
(BNCT). Our future operations are contingent upon increasing revenues
and raising capital for expansion to advance research. Because we have a limited
operating
history you will have difficulty evaluating our business and future prospects. You
should consider our prospects in light of the risks, uncertainties, expenses and
difficulties we will face as an emerging business. If we are unable to obtain financing to support our future growth
plans, we will have to
curtail our operations and our growth plans, which will negatively affect the
value of your investment. Our Plan of Operations involves substantial
research and development and marketing costs. We are dependent upon the proceeds
from this offering as well as future financing efforts to implement our Plan of
Operations
and to expand our business. In addition, we may need additional funding from bank
financing or financing from a debt or equity offering. If we are unable to obtain
financing when needed on favorable terms, we may be forced to curtail our
operations
and our growth plans, which will negatively affect the value of your investment.
SIZE="2">If we fail to keep pace with the ever-changing market of proprietary
drugs, our revenues and financial condition will be negatively affected.
proprietary drug market is rapidly changing with the evolving industry standards.
Our future success will depend in part upon our ability to introduce new drugs,
therapies, and proprietary research to meet 
 
changing customer requirements and emerging
industry standards; however, there can be no assurance that we will successfully
introduce new drugs or therapies
to our existing drugs or develop new drugs that will achieve market acceptance.
Any delay or failure of these drugs to achieve market acceptance would adversely
affect our business. In addition, there can be no assurance that drugs or
technologies
developed by others will not render our drugs or technologies non-competitive or
obsolete. Should we fail to keep pace with the ever-changing nature of the
proprietary drug market, out revenues and financial condition will be negatively
affected.
FACE="Times New Roman" SIZE="2">The report of independent Registered Public
Accounting firm contains
explanatory language that substantial doubt exists about our ability to continue
as a going concern The independent auditors report on our
financial statements contains explanatory language that substantial doubt exists
about our ability to continue as a going concern. The report states that we have
not been
able to generate sufficient cash flows from operations and have incurred net
losses since inception, delinquent on certain obligations and have been dependent
on equity and debt financing to support our business efforts. If we are unable to
obtain
sufficient financing in the near term or achieve profitability, then we would, in
all likelihood, experience severe liquidity problems and may have to curtail our
operations. Our dependence upon regulatory approval may
negatively affect our operations and revenues. <P
Company has extensive proprietary technology for the manufacture of L-BPA, an
active
pharmaceutical ingredient (API) which is being used by centers conducting BCNT
clinical trials world wide. Once BCNT receives regulatory approval, the
Companys superior proprietary manufacturing process will position it to
become the preferred
supplier of L-BPA to the global market. However, regulatory approval of BCNT is
not absolute, and neither the FDA nor European regulatory bodies have yet approved
BCNT or the products used in BCNT, and delay in such approval may negatively
affect
our operations and the Companys financial conditions. The FDA
regulatory process is costly, lengthy and requires specific expertise, and even if
we invest the time, money and other resources required to advance through the FDA
approval process, we may never receive FDA approval. <P
will rely initially on consultants with prior experience working with the FDA. We
expect
to hire experienced employees and consultants to analyze, prepare and present our
application to the FDA. The process of obtaining regulatory approvals can be
extremely costly and time-consuming and there is no guarantee of success. If we do
not
receive approval of our application, we will not be able to proceed with clinical
testing. In addition, clinical testing is not predictable. Even if the FDA
approves our application, we cannot guarantee that the FDA will approve our
clinical
results. Our failure to obtain required regulatory approvals would have a material
adverse effect on our business, financial condition and results of operations and
could require us to curtail or cease our operations. <P
FDA and comparable agencies in foreign countries impose substantial requirements
on the
introduction of therapeutic and diagnostic pharmaceutical and biological products
through lengthy and detailed laboratory and clinical testing procedures, sampling
activities and other costly and time-consuming procedures. Satisfaction of these
requirements typically takes several years or more and varies substantially based
on the type, complexity and novelty of the product. The regulatory review may
result in extensive delay in the regulatory approval process. Regulatory
requirements
ultimately imposed could adversely affect our ability to clinically test,
manufacture or market potential products. Government regulation also applies to
the manufacture and marketing of pharmaceutical and biological products.
 The effect of government regulation may be to delay marketing of new
products for a considerable period of time, to
impose costly procedures on our activities and to furnish a competitive advantage
to larger companies that compete with us. There can be no assurance that FDA or
other regulatory approval for any products developed by us will be granted on a
timely
basis or at all. Any such delay in obtaining, or failure to obtain, such approvals
would adversely affect the marketing of any contemplated products and the ability
to earn product revenue. Further, regulation of manufacturing facilities by state,
local and other authorities is subject to change. Any additional regulation could
result in limitations or restrictions on our ability to utilize any of its
technologies, thereby adversely affecting our operations. We may be unable to overcome competitive forces in the proprietary
drug industry, which
would negatively affect our ability to generate revenues and our results of
operation. We are in competition with numerous competitors in
the proprietary drug industry. Glyconixs niche is in creating proprietary
compounds, patentable as new composition of matter, out of existing small
molecules
with its proprietary glycosylation technology. Our competitors have substantially
similar or superior financial, operational, research and development, marketing
and other resources business models to Glyconix with one fundamentally difference
in
that Glyconix is the only company glyconsylate small molecules. Other competitors
are developing drugs that may compete with Glyconixs proprietary compounds
in various clinical indications. There can be no assurance that we can compete
successfully with these companies. Competitive pressures or other factors could
cause us to lose or fail to develop market share, or result in significant price
erosion, either of which would have a materially adverse effect on our revenues
and
results of operations. We have no marketing
experience, are dependent on
third parties for marketing services, and we may never be able to successfully
market our product, even if it receives FDA approval. <P
have no marketing and sales personnel and no experience with respect to marketing
biochemical or pharmaceutical products. Significant additional expenditures and
management resources would be required to develop an internal sales force, and
there can be no assurance that such funds would be available. Further, there can
be no assurance that, with such a sales force, we would be successful in
penetrating the
markets for any products developed. We will seek to enter into development and
marketing agreements which grant exclusive marketing rights to our corporate
partners in return for royalties to be received on sales, if any. Under certain of
these
agreements, our marketing partner may have the responsibility for all or a
significant portion of the development and regulatory approval. In the event that
the marketing and development partner fails to develop a marketable product or
fails to
market a product successfully, our business may be adversely affected. The sale of
certain products outside the United States will also be dependent on the
successful completion of arrangements with future partners, licensees or
distributors in each
territory. There can be no assurance that we will be successful in establishing
any additional collaborative arrangements, or that, if established, such future
partners will be successful in commercializing products. We are directly or indirectly subject to extensive regulations which
may increase our
costs, lead to delays, fines or restrictions on our business and negatively affect
our potential profitability. <P
operations may be, directly or indirectly, subject to United States federal, state
or local laws. These United States regulations will subject us to increased
regulation costs, and possibly fines or restrictions on conducting our operations.
In addition, potential future foreign markets have different regulations related
to the environment, labor relations, currency fluctuations, exchange controls,
customs, foreign tax increases, import and export, investment and taxation which
will also subject us to increased regulation costs and possibly fines or
restrictions on conducting our operations. If we are unable to meet the 
requirements of the regulations in any
jurisdictions, our operations in such jurisdictions may be delayed or prohibited.
Any of these regulations may
increase our costs and negatively affect our potential profitability. 
SIZE="2">We
face patent protection risks that may negatively affect our brand name reputation,
revenues, and potential profitability. Glyconixs competitive advantage is its proprietary technology which
enables it to glycosylate small molecules. The Company owns the rights to new
glycosylation
techniques that have several distinct advantages over traditional methods. We are
dependent upon a variety of methods and techniques that we regard as proprietary
trade secrets. We are also dependent upon a variety of trademarks, service marks
and
designs to promote brand name development and recognition. We rely on a
combination of trade secrets, copyright, patent, trademark, unfair competition and
other intellectual property laws as well as contractual agreements to protect our
rights to
such intellectual property. Our products may violate the proprietary rights of
others which may subject us to damage awards or judgments prohibiting the use of
our technology. There is no assurance that any of our rights in any of our
intellectual
property will be enforceable, even if registered, against any prior users of
similar intellectual property. In addition, if we fail to provide adequate
proprietary protection, our names, brand name reputation, revenues and potential
profitability
may be negatively affected. The sales cycle involved in
the sale of our
products to government agencies, Universities or educational/research centers,
grants, and foundations, or large corporations may extend from months to years; as
a result, our costs may increase and our revenues may fluctuate, both of which
will
negatively affect our potential profitability and the value of your investment.
SIZE="2">Sales of our products to the government agencies, Universities or
educational/research centers, grants, and foundations, or large corporations may
be delayed by months or years due to the following: 
<TR>
<TD ALIGN="left" VALIGN="top">cumbersome
funding application procedures and proposals; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">bidding and
other internal procedures particular to governmental agencies and large
corporations; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">individual
budgeting constraints or other financial considerations of governmental agencies
and large corporations; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">protracted
contract negotiations; </TD></TR></TABLE> 
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">fluctuating
tax revenues of government agencies; </TD></TR></TABLE> 
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">sudden
reduction or cancellation of government funds spent for security-related products;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">time involved
in assessing and determining a customers environment and needs; and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">substantial
expenses involved in developing new features to our existing products and
developing new products. </TD></TR></TABLE> <P
there are significant delays or protracted sales cycles in our product sales as a
result
of these factors, our revenues will be delayed and fluctuate from quarter to
quarter. In addition, we will be subject to increasing operating and marketing
costs from delayed sales. These increasing costs and fluctuating revenues may
negatively
affect our potential profitability and, as a result, the value of your investment.
SIZE="2">If our products are found to have defects or fail to meet industry
standards, we will incur substantial litigation, judgment, product liability and
product recall costs, which will increase our losses and negatively affect our
brand name
reputation and product sales. Because our proprietary drugs
may be used to
provide experimental or developing drug therapies, we may be subject to liability
for errors that occur with our drugs or technologies due to claims of negligence
or product malfunction. Although we plan to obtain product liability insurance, we
do
not currently maintain 
liability insurance coverage for such
claims. If we are unable to obtain such insurance, product liability claims could
increase our costs and adversely
affect our brand name reputation, revenues and, ultimately, lead to additional
losses. In addition, product defects could result in product recalls and warranty
claims. A product/drug recall could delay or halt production of our product until
we are
able to remedy the product defects. The occurrence of any claims, judgments or
product recalls will negatively affect our brand name image and product sales,
lead to additional costs, and adversely affect our financial condition and results
of
operation. Because we have no liability insurance, our
revenues and
potential profitability may be adversely affected. Certain municipal
customers require product vendors to have product liability insurance to even bid
on product order agreements. Although we plan to obtain such insurance if we
receive sufficient proceeds from this Offering, we do not have any product
liability
insurance coverage. Our failure to obtain product liability coverage could
prohibit us from bidding for orders from municipal customers and have a materially
adverse effect on our business, financial condition and results of operations.

SIZE="2">Our results of operations may highly fluctuate from quarter to quarter
as we continue
to grow, therefore you cannot use these results to predict how we may perform in
the future. As a result of our limited operating history, we
do not have historical financial data for a significant number of periods in which
to base our planned operating expenses. Our expense levels are based in part on
our
projections as to future revenues that are expected to increase. It is anticipated
that as we mature, our sales and operating results may fluctuate from quarter to
quarter and from year to year due to a combination of factors, including, among
others: 
<TR>
<TD ALIGN="left" VALIGN="top">general
domestic and international legal, economic, political and market conditions;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">demand for our
products and services; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">number, timing
and significance of product enhancements and new product introductions by us and
our competitors; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">volume, timing
of, and ability to fulfill orders from operators; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">changes in the
level of operating expenses; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">expenses
incurred in connection with our plans to fund greater levels of sales and
marketing activities and operations and develop new distribution channels and
services;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">product
defects and other product or service quality problems; </TD></TR></TABLE>
 
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">manufacturing
delays; </TD></TR></TABLE> 
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">increases in
our costs of borrowing; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">seasonal
variations in the sale of our products; and </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">pricing
changes in the industry. </TD></TR></TABLE> Any
unfavorable changes in these or other factors could have a material adverse effect
on our business, financial conditions and results of operation. If we lose our key personnel, our business and prospects may be
adversely affected.
FACE="Times New Roman" SIZE="2">Our performance is dependent on the services of
certain key employees and
consultants, particularly Dr. Ivan Kanevski, our President, Chief Executive
Officer and Director, Dr. Rifat Pamukcu, our Chairman, and Director, Lucy
Ostrovsky, our Vice President of Finance, J.R. LeShufy, our Executive Vice
President,
Treasurer and Director, and Norman Heyman, our Vice President and Director. The
loss of services of any of our key consultants could have a material adverse
effect on our business and financial condition. There is no 
assurance that we would be able to hire and
retain other management if we lose the services of our key consultants.
 We may need additional capital. <P
capital requirements in connection with our operations will be substantial. Our
management anticipates that we will require additional working capital in the
future even if we raise the maximum amount in this offering. There are no
assurances that such additional capital will be available or on terms that are
acceptable to us.
Further, even if available, additional equity or convertible debt financing, if
used, could result in substantial dilution of shareholder interests. Currently,
our plan of operation includes looking for private capital after we become a
reporting
company. There can be no assurances that such capital can be raised or that if
capital is raised, it will be sufficient for our needs. Risks Related To This Offering Our shares will be Penny Stocks which are subject to
certain restrictions that could adversely affect the liquidity of an investment in
us. 
intend to initially trade our common stock in the over-the-counter market. The
stock
price will likely be at less than $5.00 per share. Such shares are referred to as
penny stocks within the definition of that term contained in Rules
15g-1 through 15g-9 promulgated under the Securities Exchange Act of 1934, as
amended.
These rules impose sales practices and disclosure requirements on certain broker-
dealers who engage in certain transactions involving penny stocks. These
additional sales practices and disclosure requirements could impede the sale of
our securities,
including securities purchased herein, in the secondary market. In general, penny
stocks are low priced securities that do not have a very high trading volume.
Consequently, the price of the stock is volatile and you may not be able to buy or
sell
the stock when you want. Accordingly, the liquidity for our securities may be
adversely affected, with related adverse effects on the price of our securities.
SIZE="2">Under the penny stock regulations, a broker-dealer selling penny stocks
to anyone other than an established customer or accredited investor
(generally, an
individual with a net worth in excess of $1,000,000 or annual income exceeding
$200,000 or $300,000 together with his or her spouse) must make a special
suitability determination for the purchaser and must receive the purchasers
written
consent to the transaction prior to the sale, unless the broker-dealer is
otherwise exempt. In addition, unless the broker-dealer or the transaction is
otherwise exempt, the penny stock regulations require the broker-dealer to
deliver, prior to any
transaction involving a penny stock, a disclosure schedule prepared by the
Securities and Exchange Commission relating to the penny stock. A broker-dealer is
also required to disclose commissions payable to the broker-dealer and the
Registered
Representative and current quotations for the securities. A broker-dealer is
additionally required to send monthly statements disclosing recent price
information with respect to the penny stock held in a customers account and
information with
respect to the limited market in penny stocks. There is no
public market
for our common stock, and even if a market develops, it will likely be thin and
subject to manipulation. Our common stock is not listed on any exchange or
quoted on any similar quotation service, and there is currently no public market
for our common stock. We have not taken any steps to enable our common stock to be
quoted on the OTC Bulletin Board, and can provide no assurance that our common
stock will ever be quoted on any quotation service or that any market for our
common stock will ever develop. As a result, stockholders may be unable to
liquidate their
investments, or may encounter considerable delay in selling shares of our common
stock. Neither we nor our selling stockholders have engaged an underwriter 
for this offering, and we cannot assure you
that any brokerage firm will act as a market maker of our securities. A trading
market may not develop in the
future, and if one does develop, it may not be sustained. If an active trading
market does develop, the market price of our common stock is likely to be highly
volatile due to, among other things, the nature of our business and because we are
a new
public company with a limited operating history. Further, even if a public market
develops, the volume of trading in our common stock will presumably be limited and
likely be dominated by a few individual stockholders. The limited volume, if any,
will make the price of our common stock subject to manipulation by one or more
stockholders and will significantly limit the number of shares that one can
purchase or sell in a short period of time. The market price of our common stock
may also
fluctuate significantly in response to the following factors, most of which are
beyond our control: 
<TR>
<TD ALIGN="left" VALIGN="top">variations in
our quarterly operating results; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">changes in
securities analysts estimates of our financial performance;
WIDTH="100%">
<TR>
general economic conditions and in the healthcare industry;
WIDTH="100%">
<TR>
market valuations of similar companies; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">announcements
by us or our competitors of significant new contracts with artists, acquisitions,
strategic partnerships or joint ventures, or capital commitments;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">loss of a
major customer, partner or joint venture participant; and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">the addition
or loss of key managerial and collaborative personnel. </TD></TR></TABLE>
equity markets have, on occasion, experienced significant price and volume
fluctuations that have affected the market prices for many companies
securities and
that have often been unrelated to the operating performance of these companies.
Any such fluctuations may adversely affect the market price of our common stock,
regardless of our actual operating performance. As a result, stockholders may be
unable
to sell their shares, or may be forced to sell them at a loss. Obtaining
additional capital through the future sale of common stock and derivative
securities will result in dilution of stockholder interests. <P
plan to raise additional funds in the future by issuing additional shares of
common stock or securities such as convertible notes, options, warrants or
preferred stock
that are convertible into common stock. Any such sale of common stock or other
securities will lead to further dilution of the equity ownership of existing
holders of our common stock. If the selling shareholders sell a large number
of shares all at once, or in blocks, the market price of our shares would most
likely
decline. The Selling Shareholders are offering 3,610,000
shares of our
common stock through this prospectus. The Selling Shareholders are required to
sell their shares at $2.00 per share until our shares are quoted on the OTC
Bulletin Board and thereafter they can sell at prevailing market prices, or
privately
negotiated prices. Our common stock is presently not traded on any market or
securities exchange, but should a market develop, shares sold at a price below the
current market price at which the common stock is trading will cause that market
price to
decline. Moreover, the offer or sale of a large numbers of shares at any price may
cause the market price to fall. The outstanding shares of common stock covered by
this prospectus represent all of the common shares outstanding as of the date of
this prospectus. If a market for our common stock develops, the
market
price for our common shares is particularly volatile given our status as a
relatively unknown company with a small and thinly traded public float, limited
operating history and lack of profits which could lead to wide fluctuations in our
share
price. The price at which you purchase our common shares may not be indicative of
the price 
that will prevail in the trading market.
You may be unable to sell your common shares, at or above your purchase price,
which may result in substantial
losses to you. Our operating results are likely to fluctuate
significantly
in the future due to a variety of factors, many of which are outside of our
control. If market for our common stock develops and our operating results
fluctuate negatively in any future quarter, the volatility in our share price is
attributable to a
number of factors. First, as noted above, our common shares are sporadically and
thinly traded. As a consequence of this lack of liquidity, the trading of
relatively small quantities of shares by our shareholders may disproportionately
influence the
price of those shares in either direction. The price for our shares could, for
example, decline precipitously in the event that a large number of our common
shares are sold on the market without commensurate demand, as compared to a
seasoned issuer
which could better absorb those sales without adverse impact on its share price.
Secondly, we are a speculative or risky investment due to our limited
operating history and lack of profits to date, and uncertainty of future market
acceptance for our potential products. As a consequence of this enhanced risk,
more risk-adverse investors may, under the fear of losing all or most of their
investment in the event of negative news or lack of progress, be more inclined to
sell
their shares on the market more quickly and at greater discounts than would be the
case with the stock of a seasoned issuer. Many of these factors are beyond our
control and may decrease the market price of our common shares, regardless of our
operating performance. We cannot make any predictions or projections as to what
the prevailing market price for our common shares will be at any time, including
as to whether our common shares will sustain their current market prices, or as to
what
effect that the sale of shares, or the availability of common shares for sale at
any time, will have on the prevailing market price. Shareholders should be aware that, according to SEC Release No. 34-
29093, the market for penny stocks has suffered in recent years from patterns of
fraud and abuse.
Such patterns include (1) control of the market for the security by one or a
few broker-dealers that are often related to the promoter or issuer;
(2) manipulation of prices through prearranged matching of purchases and
sales and false and
misleading press releases; (3) boiler room practices involving high-pressure
sales tactics and unrealistic price projections by inexperienced sales persons;
(4) excessive and undisclosed bid-ask differential and markups by selling
broker-dealers; and (5) the wholesale dumping of the same securities by
promoters and broker-dealers after prices have been manipulated to a desired
level, along with the resulting inevitable collapse of those prices and with
consequent
investor losses. Our management is aware of the abuses that have occurred
historically in the penny stock market. Although we do not expect to be in a
position to dictate the behavior of the market or of broker-dealers who
participate in the market,
management will strive within the confines of practical limitations to prevent the
described patterns from being established with respect to our securities. The
occurrence of these patterns or practices could increase the volatility of our
share
price. To date, we have not paid any cash dividends
and no cash dividends
will be paid in the foreseeable future. We do not
anticipate paying cash
dividends on our common shares in the foreseeable future. We may not have enough
funds to legally pay dividends. Even if funds are legally available to pay
dividends, we may nevertheless decide in our sole discretion not to pay dividends.
FACE="Times New Roman" SIZE="2">Volatility in our common share price may
subject us to securities
litigation, thereby diverting our resources that may have a material adverse
effect on our results of operations. As
discussed in the preceding risk factor, the market for our common shares is
characterized by significant price volatility when compared to seasoned issuers,
and we
expect that our share price will continue to be more volatile than a seasoned
issuer for the indefinite future. In the past, plaintiffs have 
often initiated securities class action
litigation against a company following periods of volatility in the market price
of its securities. We may in the
future be the target of similar litigation. Securities litigation could result in
substantial costs and liabilities and could divert managements attention and
resources. We are subject to the certain anti-takeover
provisions under Delaware law, which could discourage or prevent a potential
takeover of our
company that might otherwise result in you receiving a premium over the market
price for your common shares. <P STYLE="margin-top:0px;margin-
a Delaware corporation, we are subject to certain provisions of the Delaware
Business Corporation Law anti-takeover rules and may inhibit a non-negotiated
merger or
other business combination. These provisions are intended to encourage any person
interested in acquiring us to negotiate with, and to obtain the approval of, our
Board of Directors in connection with such a transaction. However, certain of
these
provisions may discourage a future acquisition of us, including an acquisition in
which the shareholders might otherwise receive a premium for their shares. As a
result, shareholders who might desire to participate in such a transaction may not
have
the opportunity to do so. The trading price of our
common stock may
decrease due to factors beyond our control. The stock market
from time to
time has experienced extreme price and volume fluctuations, which have
particularly affected the market prices for emerging growth companies and which
often have been unrelated to the operating performance of the companies. These
broad market
fluctuations may adversely affect the market price of our common stock. If our
shareholders sell substantial amounts of their common stock in the public market,
the price of our common stock could fall. These sales also might make it more
difficult
for us to sell equity, or equity related securities, in the future at a price we
deem appropriate. We have broad discretion in the use of the net
proceeds from this offering and may not use them effectively. <P
will have broad discretion in the application of the net proceeds from this
offering and could spend the proceeds in way that do not improve our results of
operations
or enhance the value of our common stock. Our failure to apply these funds
effectively could have a material adverse effect on our business, delay the
development of our products and services and cause the price of our common stock
to decline.
FACE="Times New Roman" SIZE="2">If you purchase our common stock in this
offering, you will incur immediate
and substantial dilution in the book value of your shares. <P
assumed
initial public offering price of our common stock is substantially higher than the
net tangible book value per share of our common stock. Investors purchasing common
stock in this offering will pay a price per share that substantially exceeds the
book value of our tangible assets after subtracting liabilities. As a result,
investors purchasing common stock in this offering will incur immediate dilution
of price per share. If the holders of outstanding options or warrants exercise
those
options or warrants, you will suffer further dilution. We will incur
increased costs as a result of being a public company, which could adversely
affect our operating results. As a public company, we will incur significant
legal, accounting and other expenses that we did not incur as a private company.
In addition, the Sarbanes-Oxley Act of 2002 and the new rules subsequently
implemented by
the Securities and Exchange Commissions, the Nasdaq National Market and the Public
Company Accounting Oversight Board have imposed various new requirements on public
companies, 
including requiring changes in corporate
governance practices. We expect these rules and regulations to increase our legal
and financial compliance costs and
to make some activities more time-consuming and costly. We also expect these new
rules and required to incur substantial costs to obtain the same or similar
coverage. These costs could materially adversely affect our results of operations.
FACE="Times New Roman" SIZE="2">Forward-Looking Statements This prospectus includes forward-looking statements that involve risks
and uncertainties.
These forward-looking statements include statements under the captions
Prospectus Summary, Risk Factors, Use of
Proceeds, Managements Discussion and Analysis of Financial
Condition and Results of
Operations, Business and elsewhere in this prospectus. You
should not rely on these forward-looking statements which apply only as of the
date of this prospectus. These statements refer to our future plans, objectives,
expectations
and intentions. We use words such as believe, anticipate,
expect, intend, estimate and similar
expressions to identify forward-looking statements. This prospectus also contains
forward-looking statements attributed to third parties relating to their estimates
regarding the growth of certain markets. You should not place undue reliance on
these forward-looking statements, which apply only as of the date of this
prospectus.
Our actual results could differ materially from those discussed in these forward-
looking statements. Factors that could contribute to these differences include
those discussed in the preceding pages and elsewhere in this prospectus.
 Risks associated with forward-looking statements. This prospectus contains certain forward-looking statements regarding
managements
plans and objectives for future operations, including plans and objectives
relating to our planned marketing efforts and future economic performance. The
forward-looking statements and associated risks set forth in this prospectus
include or relate
to: 
<TR>
<TD ALIGN="left" VALIGN="top">Our ability to
obtain a meaningful degree of consumer acceptance for our products now and in the
future, </TD></TR></TABLE> 
<TR>
market our products on a global basis at competitive prices now and in the future,
WIDTH="100%">
<TR>
maintain brand-name recognition for our products now and in the future,
WIDTH="100%">
<TR>
maintain an effective distributors network, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Our success in
forecasting demand for our products now and in the future,
WIDTH="100%">
<TR>
maintain pricing and thereby maintain adequate profit margins,

WIDTH="100%">
<TR>
achieve adequate intellectual property protection and </TD></TR></TABLE> 
<TR>
obtain and retain sufficient capital for future operations.
</TD></TR></TABLE> 
<A NAME="tx97153_5"></A>WHERE YOU CAN FIND MORE INFORMATION <P
have filed
a registration statement with the U.S. Securities and Exchange Commission, or the
SEC, on Form SB-2 under the Securities Act to register the shares of our common
stock being offered by this prospectus. This prospectus omits some information
contained in the registration statement and its exhibits, as permitted by the
rules and regulations of the SEC. For further information about us and our
securities, you should review the registration statement and its exhibits, which
may be
inspected, without charge, at the SECs public reference facilities at 450
Fifth Street, N.W., Washington, D.C. 20549. Copies of all or any portion of the
registration statement may be obtained from the public reference facilities of the
SEC on
payment of prescribed fees. Please call the SEC at 1-800-SEC-0330 for further
information regarding the public reference facilities. The SEC maintains a
website, http://www.sec.gov, that contains reports, proxy statements and
information statements
and other information regarding registrants that file electronically with the SEC,
including the registration statement. Statements in this prospectus as to the contents of any contract or other
document referred to in this prospectus are not necessarily complete and, in each
instance,
reference is made to the copy of that contract or other document filed as an
exhibit to the registration statement, each statement being qualified in all
respects by that reference. We are not required to deliver annual reports to
stockholders, and we do not intend to voluntarily send annual reports with audited
financial statements to stockholders. However, on completion of this offering, we
will become subject to the informational and periodic reporting requirements of
the Securities Exchange Act of 1934, as amended (the Exchange Act),
and, in
accordance with the requirements of the Exchange Act, will file periodic reports,
proxy statements, and other information with the SEC. These periodic reports,
proxy statements, and other information will be available for inspection and
copying at
the regional offices, public reference facilities and Web site of the SEC referred
to above. We have not filed any reports or statements with the SEC prior to filing
this registration statement and prospectus. 
<A NAME="tx97153_6"></A>CAPITALIZATION The following
table sets forth our
capitalization as of June 30, 2005: 
<TR>
<TD ALIGN="left" VALIGN="top">on actual
basis </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">on an as
adjusted basis to further reflect the receipt of the net proceeds from our sale of
3,500,000 shares of common stock in this offering, at the initial offering price
of $2.00
per share after deducting our estimated offering expenses and the anticipated
application of the estimated net proceeds. See also Use of Proceeds
and Capitalization. </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">1,262,000
shares of our common stock reserved for issuance upon the exercise of options
granted to our employees, consultants and members of our Scientific Advisory Board
and Board
of Directors. </TD></TR></TABLE> 
<TR>
shares of our common stock reserved for issuance upon the exercise of the warrants
granted to consultants and Selling Shareholders. </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">100,000 shares
of common stock issued to Glyconixs name as result of release agreement with
Mrs. Spilvogel, dated August 1, 2005 </TD></TR></TABLE> You
should read this table in conjunction with our financial statements, including the
notes
to our financial statements, which appear elsewhere in this prospectus.
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">June 30, 2005 (Unaudited) <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TR>
SIZE="1">Actual <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">As adjusted <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
FACE="Times New Roman" SIZE="2">Convertible promissory notes (including accrued
interest of $7,000) past due</TD>
SIZE="2">27,000</TD>
SIZE="2">27,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Stockholders equity :</TD>
<TR>
FACE="Times New Roman" SIZE="2">Preferred stock - $.01 par value, 5,000,000
authorized cumulative dividend right preferred stock; none issued</TD>
FACE="Times New Roman" SIZE="2">Common stock - $.01 par value, 40,000,000 shares
authorized; 19,450,000 shares issued and outstanding as June 30, 2005 and
22,950,000 as
adjusted</TD>
SIZE="2">195,000</TD>
SIZE="2">230,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Additional paid-in capital</TD>
SIZE="2">3,552,000</TD>
SIZE="2">10,417,000</TD>
<TR>
SIZE="2">3,747,000</TD>
SIZE="2">10,647,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Less: subscriptions receivable</TD>
SIZE="2">(6,000</TD>
SIZE="2">(6,000</TD>
FACE="Times New Roman" SIZE="2">Deficit accumulated during the development
stage</TD>
SIZE="2">(3,585,000</TD>
SIZE="2">(3,585,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total stockholders equity</TD>
SIZE="2">156,000</TD>
SIZE="2">7,056,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total capitalization</TD>
SIZE="2">183,000</TD>
SIZE="2">7,083,000</TD>
<TR>

SIZE="2">
<A NAME="tx97153_7"></A>USE OF PROCEEDS We will not
receive any proceeds
from the sale of 3,610,000 common stock offered through this prospectus by the
Selling Shareholders, except that we will receive proceeds if all warrants, which
have an exercise price of $1.50 per share, would be exercised. The following table sets forth managements estimate of the
allocation of net
proceeds expected to be received from the sale of 3,500,000 shares of common stock
included in this offering. Actual expenditures may vary from these estimates.
Included such uses, we will invest the net proceeds in investment-grade, short-
term,
interest bearing securities. 
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TD VALIGN="bottom"> Total Proceeds</TD>
SIZE="2">7,000,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Less:</TD>
FACE="Times New Roman" SIZE="2">Estimated offering expenses and filing
fees</TD>
SIZE="2">100,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Net Proceeds</TD>
SIZE="2">6,900,000</TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom">%</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Use of Net Proceeds</TD>
<TR>
FACE="Times New Roman" SIZE="2">General and Administrative</TD>
SIZE="2">1,600,000</TD>
SIZE="2">23.2</TD>
FACE="Times New Roman" SIZE="2">Research and Development</TD>
SIZE="2">4,400,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Working capital</TD>
SIZE="2">900,000</TD>
<TR>
<TD VALIGN="top" COLSPAN="3"> Total use of net
proceeds</TD>
SIZE="2">6,900,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">We plan to have our officers offer and
sell the shares. They will receive no discounts or commissions. We do not have any
agreements, arrangements or understandings with any broker/dealers to offer or
sell our shares, although we may, at our discretion, retain such to assist in the
offer
and sell of shares. We will receive a maximum of approximately $5.4 million in
gross proceeds if all the warrants included as part of the units that were sold in
our November 2004 private placement are exercised in full. Because our warrants
are
subject to certain anti-dilution provisions, the aggregate exercise price of our
warrants may be significantly less than approximately $5.4 million. 
<A NAME="tx97153_8"></A>DETERMINATION OF OFFERING PRICE <P
offering
price of $2.00 per share was arbitrarily determined by us based solely upon the
Companys progress since the last sale of our common stock to investors. It
is not based upon an independent assessment of the value of our shares and should
not be
considered as such. The facts considered in determining the offering price were
our financial condition, prospects, our limited operating history and the general
condition of the securities market. The offering price is not an indication of and
is
not based upon the actual value of our company. The offering price bears no
relationship to book value, assets or earnings of our company or any other
recognized criteria of value. The offering price should not be regarded as an
indicator of the
future market price of the securities. The Selling
Shareholders are required
to sell their shares at $2.00 per share until their shares are quoted on the OTC
Bulletin Board, and thereafter at prevailing market prices or privately negotiated
prices. </A>DIVIDENDS We do not anticipate paying cash
dividends on our common shares in the foreseeable future. We may not have enough
funds to legally pay dividends. Even if funds are legally available to pay
dividends, we may nevertheless decide in our sole discretion not to pay dividends.
<A NAME="tx97153_10"></A>DILUTION The common stock to be sold by
the
Selling Shareholders is common stock that is currently issued and outstanding.
SIZE="2">We have a negative net tangible book value of $80,000 and/or $.001 per
share as of June 30, 2005. The dilution of our current shareholders resulting
from the sale of our shares in our offering will vary depending on the total
number of
shares sold. If all 3,500,000 shares offered hereunder were sold, there would be a
total of 22,950,000 common shares issued and outstanding. Adding the net offering
proceeds after expenses to the negative net tangible book value, our total net
tangible book value would be $6,820,000 and/or $.30 per share. Therefore, the
shareholders who purchase in this offering will suffer an immediate dilution in
book value of their shares of approximately $1.70 and our present shareholders
will receive
and immediate book value increase of almost $.30 per share. 
<A NAME="tx97153_11"></A>EQUITY COMPENSATION PLAN INFORMATION 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"> Plan category<HR WIDTH="72" SIZE="1" NOSHADE
ALIGN="left" COLOR="#000000"></TD>
SIZE="1">Number of shares of common stock to b
e issued on exercise of outstanding options, warrants and
rights <HR
SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Weighted-
average exercise price of outstanding options, warrants&nb
sp;and rights <HR SIZE="1" NOSHADE COLOR="#000000"></TD>

SIZE="1">Number of securities remaining
available for future
issuance under equity compensation plans (excluding securi
ties reflected in the previous columns) <HR SIZE="1"
FACE="Times New Roman" SIZE="2">Equity compensation plans approved by
security holders (1)</TD>
SIZE="2">586,000</TD>
SIZE="2">.06</TD>
SIZE="2">1,484,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Equity compensation plans not</TD>
FACE="Times New Roman" SIZE="2">approved by security holders</TD>
<TR>
SIZE="2">586,000</TD>
SIZE="2">.06</TD>
SIZE="2">1,484,000</TD></TR>
WIDTH="100%">
<TR>
SIZE="2"></TD>
<TD ALIGN="left" VALIGN="top">Consists of our 2001 Stock Option and 2005 Stock Option
Plans.</TD></TR></TABLE> 
<A NAME="tx97153_12"></A>COMPARATIVE DATA <P STYLE="margin-
chart illustrates
our pro forma proportionate ownership, upon completion of the offering, assuming
the maximum number of units is sold, of present stockholders and of investors in
the offering, compared to the relative amounts paid and contributed to our capital
by
present stockholders and by investors in this offering, assuming no changes in net
tangible book value other than those resulting from the offering. If maximum offering of 3,500,000 was sold
 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Shares Owned <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Approximate Percentage Total
Shares Outstanding <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Total Consideration <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Approximate Percentage Total Consideration <HR
SIZE="1">Average Price / Share <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">New Investors</TD>
SIZE="2">3,500,000</TD>
SIZE="2">%</TD>
SIZE="2">7,000,000</TD>
SIZE="2">2.00</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Existing Shareholders</TD>
SIZE="2">19,450,000</TD>
SIZE="2">2,943,000</TD>
<TR>
<TD VALIGN="bottom"><HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
SIZE="2">22,950,000</TD>
SIZE="2">9,943,000</TD>
<TR>

SIZE="2">
<A NAME="tx97153_13"></A>SELLING SHAREHOLDERS <P STYLE="margin-
table
presents information regarding the Selling Shareholders. Unless otherwise stated
below, to our knowledge no Selling Shareholders nor any affiliate of such
shareholder has held any position or office with, been employed by, or otherwise
has had any
material relationship with us or our affiliates, during the three years prior to
the date of this prospectus. None of the Selling Shareholders are members of the
National Association of Securities Dealers, Inc. The Selling Shareholders may be
deemed
to be underwriters within the meaning of the Securities Act of 1933.
The number and percentage of shares beneficially owned before and after the sales
is determined in accordance with Rule 13d-3 and 13d-5 of the Exchange Act,
and
the information is not necessarily indicative of beneficial ownership for any
other purpose. We believe that each individual or entity named has sole investment
and voting power with respect to the securities indicated as beneficially owned by
them,
subject to community property laws, where applicable, except where otherwise
noted. The total number of common shares sold under this prospectus may be
adjusted to reflect adjustments due to stock dividends, stock distributions,
splits, combinations
or recapitalizations. The Selling Shareholders named
in this prospectus are
offering all of the 3,610,000 shares of common stock offered through this
prospectus. These shares were acquired from us in a private placement that was
exempt from registration under Regulation D of the Securities Act of 1933. None of
our Selling
Share holders are broker-dealers or have any affiliation with any broker dealers.
SIZE="2">The following table provides information regarding the beneficial
ownership of our common stock held by each of the selling shareholders, including:
 
<TR>
SIZE="2">1.</TD>
<TD ALIGN="left" VALIGN="top">the number of
shares owned by each prior to this offering; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">the percentage
owned prior to the offering; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">the total
number of shares that are to be offered for each; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">the total
number of shares that will be owned by each upon completion of the offering; and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">the percentage
owned by each upon completion of the offering. </TD></TR></TABLE> 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
New Roman" SIZE="1">Name of selling stockholder<HR WIDTH="157"
SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
<TD VALIGN="bottom" ALIGN="center">Shares
of common Stock owned prior to offering <HR
SIZE="1">Percent of Common Stock owned prior to offering
(1) <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
of common stock to be sold <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
of common Stock underlying the warrants owned prior to
the offering <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
of common Stock underlying the warrant to be
sold <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Shares
of common Stock owned After offering(2) <H
R SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">Altamura Resources Inc.(1)</TD>
SIZE="2">4,700</TD>
SIZE="2">4,700</TD>
SIZE="2">4,700</TD>
SIZE="2">4,700</TD>
SIZE="2">*</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Altavilla, Anthony D.</TD>
SIZE="2">250,000</TD>
SIZE="2">250,000</TD>
SIZE="2">250,000</TD>
SIZE="2">250,000</TD>
FACE="Times New Roman" SIZE="2">Anosto, Vito</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Beech Glen Inc.(2)</TD>
SIZE="2">150,000</TD>
SIZE="2">150,000</TD>
SIZE="2">150,000</TD>
SIZE="2">150,000</TD>
FACE="Times New Roman" SIZE="2">Colluccio, Rocco Peter</TD>
SIZE="2">60,000</TD>
SIZE="2">60,000</TD>
SIZE="2">60,000</TD>
SIZE="2">60,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Corso, Joseph</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
FACE="Times New Roman" SIZE="2">Domaco Inc.</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Egan, Ronald</TD>
SIZE="2">14,000</TD>
SIZE="2">14,000</TD>
SIZE="2">14,000</TD>
SIZE="2">14,000</TD>
FACE="Times New Roman" SIZE="2">Gagliardi, Rosemary</TD>
SIZE="2">20,000</TD>
SIZE="2">20,000</TD>
SIZE="2">20,000</TD>
SIZE="2">20,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Gottlieb, Norman</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
FACE="Times New Roman" SIZE="2">Greenwood, Douglas</TD>
SIZE="2">50,000</TD>
SIZE="2">50,000</TD>
SIZE="2">50,000</TD>
SIZE="2">50,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Horowitz, Harry</TD>
SIZE="2">20,000</TD>
SIZE="2">20,000</TD>
SIZE="2">20,000</TD>
SIZE="2">20,000</TD>
FACE="Times New Roman" SIZE="2">Jordan, Frank T.</TD>
SIZE="2">50,000</TD>
SIZE="2">50,000</TD>
SIZE="2">50,000</TD>
SIZE="2">50,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Kasten, Mitchell</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
FACE="Times New Roman" SIZE="2">Marinelli, John</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Marinelli, Vito</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
FACE="Times New Roman" SIZE="2">Mediate, Josephine</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Meringer, Stanley</TD>
SIZE="2">1,000,000</TD>
SIZE="2">1,000,000</TD>
SIZE="2">1,000,000</TD>
SIZE="2">1,000,000</TD>
FACE="Times New Roman" SIZE="2">Miranda, Daniel</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Morales, Melissa</TD>
SIZE="2">150,000</TD>
SIZE="2">150,000</TD>
SIZE="2">150,000</TD>
SIZE="2">150,000</TD>
FACE="Times New Roman" SIZE="2">Panache Holdings LLC (3)</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
SIZE="2">100,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Parise, Michael</TD>
SIZE="2">5,300</TD>
SIZE="2">5,300</TD>
SIZE="2">5,300</TD>
SIZE="2">5,300</TD>
FACE="Times New Roman" SIZE="2">Payne, Tommy J.</TD>
SIZE="2">300,000</TD>
SIZE="2">300,000</TD>
SIZE="2">300,000</TD>
SIZE="2">300,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Preda, Florentina</TD>
SIZE="2">6,000</TD>
SIZE="2">6,000</TD>
SIZE="2">6,000</TD>
SIZE="2">6,000</TD>
FACE="Times New Roman" SIZE="2">Retas, Steven P</TD>
SIZE="2">40,000</TD>
SIZE="2">40,000</TD>
SIZE="2">40,000</TD>
SIZE="2">40,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Savarese, Gabriel</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
SIZE="2">10,000</TD>
FACE="Times New Roman" SIZE="2">Savarese, Marco F.</TD>
SIZE="2">45,000</TD>
SIZE="2">45,000</TD>
SIZE="2">45,000</TD>
SIZE="2">45,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Teitelbaum, Mark</TD>
SIZE="2">900,000</TD>
SIZE="2">900,000</TD>
SIZE="2">900,000</TD>
SIZE="2">900,000</TD>
SIZE="2">3,610,000</TD>
SIZE="2">3,610,000</TD>
SIZE="2">3,610,000</TD>
SIZE="2">3,610,000</TD>
WIDTH="100%">
<TR>
SIZE="2">*</TD>
<TD ALIGN="left" VALIGN="top">less than one
percent </TD></TR></TABLE> 
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Based on 19,450,000 shares of common stock issued as of October
13, 2005. </TD></TR></TABLE> 
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Assumes the sale of all shares registered by each selling
shareholder. </TD></TR></TABLE> 
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Altamura Resources Inc. is controlled by Mark Moro, President

WIDTH="100%">
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Beech Glen Inc. is controlled by Raffade Atar, President
WIDTH="100%">
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Panache Holdings LLC is controlled by Edward Rudigerse, Managing
Member </TD></TR></TABLE> The named party beneficially owns and has sole
voting and investment power over all shares or rights to these shares. The numbers
in this
table assume that none of the selling shareholders sells shares of common stock
not being offered in this prospectus or purchases additional shares of common
stock, and assumes that all shares offered are sold. Except as disclosed below, none of the Selling Shareholders: 
(a) has had a material relationship with us other
than as a
shareholder at any time within the past three years; or (b) has never been one of our officers or
directors. 
<A NAME="tx97153_14"></A>PLAN OF DISTRIBUTION Currently we plan
to have
our officers sell the common shares on a self-underwritten basis. They will
receive no discounts or commissions. Our officers will deliver prospectuses to
these individuals and to others who they believe might have interest in purchasing
all or a
part of this offering. We also may retain licensed
broker/dealers to assist us
in the offer and sell of the shares of our common stock, if we deem such to be in
our best interest. At this time we do not have any commitments, agreements or
understandings with any broker/dealers. The maximum underwriting discounts and
commissions we are willing to pay to engage broker/dealers is 10%. In the event we
retain any broker/dealers to assist in the offer and sell of shares of our common
stock we will update this prospectus accordingly. In
order to buy shares of our common stock you must complete and execute the
subscription
agreement and return it to us at 350 Fifth Avenue, Suite 4811, New York, NY
10118. Payment of the purchase price must be made by check payable to the
order of Glyconix. The check may be delivered directly to 350
Fifth
Avenue, Suite 4811, New York, NY 10118, telephone (212) 404-7050, or
to us at the abovementioned address. <P STYLE="margin-top:0px;margin-
have the right to accept or reject subscriptions in whole or in part, for any
reason or for no reason. All monies from rejected subscriptions will be returned
immediately to the subscriber, without interest or deductions. Subscriptions for
securities will be accepted or rejected within 48 hours after we receive them.
SIZE="2">Our officers will not register as a broker/dealer under Section 15
of the Securities Exchange Act of 1934 (the Exchange Act) in reliance
upon Rule
3a4-1. Rule 3a4-1 sets forth those conditions under which a person associated with
an issuer may participate in the offering of the issuers securities and not
be deemed to be a broker/dealer. The conditions are that: 1. The person is not statutorily disqualified, as that term is
defined in
Section 3(a)(39) of the Act, at the time of his participation; and,
SIZE="1"> 2. The person is not at the time of their
participation, an associated person of a broker/dealer; and, 3. The person meets the conditions of Paragraph (a)(4)(ii) of Rule
3a4-1 of the Exchange Act, in that he (A) primarily performs, or is intended
primarily to perform at the end of the offering, substantial duties for or on
behalf of the issuer otherwise than in connection with transactions in securities;
and (B) is not a broker or dealer, or an associated person of a broker or
dealer,
within the preceding twelve (12) months; and (C) do not participate in
selling and offering of securities for any issuer more than once every twelve
(12) months other than in reliance on Paragraphs (a)(4)(i) or (a)(4)(iii).
FACE="Times New Roman" SIZE="2">Our officers and directors are not statutorily
disqualified, are not being
compensated, and are not associated with a broker/dealer. They are, and will
continue to be, our officers and directors at the end of the offering, and have
not been, during the last twelve months, and are currently not, broker/dealers or
associated
with broker/dealers. They have not, nor will not, participate in the sale of
securities of any issuer more than once every twelve months. After our
registration statement is declared effective by the SEC we intend to advertise,
through tombstones,
and hold investment meetings in various states where the offering will be
registered. We will not utilize the Internet to advertise our offering. We will
also distribute the prospectus to potential investors at meetings and to our
friends and
relatives who are interested in us and a possible investment in the offering.

SIZE="2">We intend to sell our shares in the United States of America, and/or
offshore. <P
are also registering the shares of our common stock covered by this prospectus for
the
Selling Shareholders. As used in this prospectus, Selling Shareholders
includes the donees, transferees or others who may later hold the Selling
Shareholders interests. The Selling Shareholders will act independently of
us in
making decisions with respect to the timing, manner and size of each sale. The
Selling Shareholders may, from time to time, sell all or a portion of its shares
of common stock on the OTC Bulletin Board or on any national securities exchange
or
automated inter-dealer quotation system on which our common stock may be listed or
traded, in negotiated transactions or otherwise, at prices then prevailing or
related to the current market price or at negotiated prices. One or more
underwriters on
a firm commitment or best efforts basis may sell the shares of common stock
directly or through brokers or dealers or in a distribution. The methods by which
the shares of common stock may be sold include: 
<TR>
<TD ALIGN="left" VALIGN="top">a block trade
(which may involve crosses) in which the broker or dealer engaged will attempt to
sell the shares of common stock as agent, but may position and resell a portion of
the block, as principal, to facilitate the transaction, </TD></TR></TABLE>
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">purchases by a
broker or dealer, as principal, and resale by such broker or dealer for its
account pursuant to this prospectus, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">ordinary
brokerage transactions and transactions in which the broker solicits purchasers or
through market makers, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">transactions
in put or call options or other rights (whether exchange-listed or otherwise)
established after the effectiveness of the registration statement of which this
prospectus
is a part, and </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">privately-
negotiated transactions. </TD></TR></TABLE> <P STYLE="margin-
addition, any of the shares of common stock that qualify for sale pursuant to Rule
144 promulgated under the Securities Act of 1933 may be sold in transactions
complying with that Rule, rather than pursuant to this prospectus. For
sales
to or through broker-dealers, these broker-dealers may receive compensation in the
form of discounts, concessions or commissions from the Selling Shareholders or the
purchasers of the shares, or both. We have advised the Selling Shareholders that
the anti-manipulative provisions of Regulation M under the Securities Exchange Act
of 1934 may apply to its sales in the market and have informed it that it must
deliver copies of this prospectus. We are not aware, as of the date of this
prospectus,
of any agreements between any Selling Shareholders and broker-dealers with respect
to the sale of the shares of common stock. Any
broker-dealers or agents participating in the distribution of our shares may be
deemed to be underwriters within the meaning of the Securities Act of
1933, and any commissions received by any broker-dealer or agent and profit on any
resale of shares of common stock may be deemed to be underwriting commissions
under the Securities Act of 1933. The commissions received by a broker-dealer or
agent
may be in excess of customary compensation. At a time a
particular offer of
shares is made by a Selling Shareholders, a prospectus supplement, if required,
will be distributed that sets forth the names of any underwriters, dealers or
agents and any discounts, commissions and other terms constituting compensation
from a
Selling Shareholders and any other required information. <P
connection with
distributions of a Selling Shareholders shares, or otherwise, the Selling
Shareholders may enter into hedging transactions with broker-dealers or others,
prior to or after the effective time of the 
arrangement. These broker-dealers may engage
in short sales of shares or other transactions in the course of hedging the
positions assumed by them or
otherwise. A Selling Shareholders may also: 
<TR>
<TD ALIGN="left" VALIGN="top">enter into
option or other transactions with broker-dealers or others that may involve the
delivery to those persons the shares, and broker-dealers may resell those shares
pursuant
to this prospectus, and </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">pledge the
shares to a broker-dealer or others and, upon a default, these persons may effect
sales of the shares pursuant to this prospectus. </TD></TR></TABLE> <P
have advised the Selling Shareholders that open positions in shares of common
stock
covered by this prospectus prior to the registration statement, of which this
prospectus is a part, being declared effective by the U.S. Securities and Exchange
Commission may constitute a violation of Section 5 of the Securities Act of
1933.
Each of the Selling Shareholders advised us that it did not have an open position
in the common stock covered by this prospectus at the time of its response to our
inquiry. In order to comply with securities laws of some
states, if applicable, the shares of our common stock may be sold only through
registered or
licensed broker-dealers. The Selling Shareholders will be
subject to
applicable provisions of the Securities Exchange Act of 1934 and its rules and
regulations, including without limitation, Rule 102 under Regulation M. These
provisions may limit the timing of purchases and sales of our common stock by the
Selling
Shareholders. Rule 102 under Regulation M provides, with limited exceptions, that
it is unlawful for a Selling Shareholders or its affiliated purchaser to, directly
or indirectly, bid for or purchase or attempt to induce any person to bid for or
purchase, for an account in which the Selling Shareholders or affiliated purchaser
has a beneficial interest in any securities that are the subject of the
distribution during the applicable restricted period under Regulation M. All of
the above may
affect the marketability of our common stock. Because it is
possible that a
significant number of shares could be sold at the same time under this prospectus,
these sales, or that possibility, may have a depressive effect on the market price
of our common stock. We will receive none of the proceeds from the sale
of the shares of common stock by the Selling Shareholders, except upon exercise of
the
outstanding common stock purchase warrant. We will pay all
costs and expenses
incurred in connection with the registration under the Securities Act of 1933 of
the shares of common stock offered by the Selling Shareholders, including all
registration and filing fees, listing fees, printing expenses, and our legal and
accounting fees. The Selling Shareholders will pay all of their own brokerage fees
and commissions, if any, incurred in connection with the sale of its shares of
common stock. We cannot assure you, however, that the Selling
Shareholders will sell all or any of the shares of common stock they may offer. In
order to
comply with state securities laws, if applicable, the securities will be sold only
through registered or licensed brokers or dealers. In various states, the
securities may not be sold unless the securities have been registered or qualified
for sale
in such state or an exemption from registration or qualification is available and
is complied with. Under applicable rules and regulation of the Securities Exchange
Act of 1934, as amended, any person engaged in a distribution of the securities
may
not simultaneously engage in market-making activities in these securities for a
period of one (1) or five (5) business days prior to the commencement of
such distribution All of the foregoing may affect the marketability of the securities.
Pursuant to the various agreements we have with the
Selling Shareholders, we will pay all the fees and expenses incident to the
registration of the securities, other than the Selling Shareholders pro rata
share of the underwriting discounts and commissions, if any, which are to be paid
by the
Selling Shareholders. Should any substantial change
occur regarding the status
or other matters concerning the Selling Shareholders, we will file a Rule 424(b)
prospectus disclosing such matters. </A>PENNY STOCK RULES / SECTION 15(G) OF THE EXCHANGE
ACT Our shares are covered by Section 15(g) of
the Securities Exchange Act of 1934, as amended, and Rules 15g-1 through 15g-6
promulgated thereunder. They impose additional sales practice requirements on
broker/dealers who sell our securities to persons other than established customers
and accredited investors who are generally institutions with assets in excess of
$5,000,000, or individuals with net worth in excess of $1,000,000 or annual income
exceeding $200,000, or $300,000 jointly with their spouses. Rule 15g-1 exempts
a number of specific transactions from the scope of the penny stock rules. Rule
15g-2 declares unlawful broker/dealer transactions in penny stocks unless the
broker/dealer has first provided to the customer a standardized disclosure
document.
FACE="Times New Roman" SIZE="2">Rule 15g-3 provides that it is unlawful for a
broker/dealer to engage in a
penny stock transaction unless the broker/dealer first discloses, and subsequently
confirms to the customer, current quotation prices or similar market information
concerning the penny stock in question. Rule 15g-4 prohibits broker/dealers from completing penny stock
transactions for a customer
unless the broker/dealer first discloses to the customer the amount of
compensation or other remuneration received as a result of the penny stock
transaction. Rule 15g-5 requires that a broker/dealer executing a penny stock
transaction, other than one exempt under Rule 15g-1, disclose to its customer, at
the time of, or
prior to, the transaction, information about the sales persons compensation.
SIZE="2">Rule 15g-6 requires broker/dealers selling penny stocks to provide their
customers with monthly account statements. Rule 15g-9 requires broker/dealers to approve the transaction for the
customers account; obtain a written agreement from the customer setting
forth the identity and
quantity of the stock being purchased; obtain from the customer information
regarding his investment experience; make a determination that the investment is
suitable for the investor; deliver to the customer a written statement for the
basis for the
suitability determination; notify the customer of his rights and remedies in cases
of fraud in penny stock transactions; and, contact the NASDs toll free
telephone number and the central number of the North American Administrators
Association
for information on the disciplinary history of broker/dealers and their associated
persons. The application of the penny stock rules may
affect your ability to resell your shares due to broker-dealer reluctance to
undertake the above described regulatory burdens. </A>LEGAL PROCEEDINGS We are not a
party to any
pending material legal proceedings and are not aware of any threatened or
contemplated proceeding by any governmental authority against us. In October 2001, the Company acquired certain patents and related
intellectual property rights (the Property
Rights) from Glycosyn Pharmaceutical, Inc., a Delaware corporation owned
primarily by foreign persons (Glycosyn) pursuant to an Intellectual
Property Purchase Agreement (the Agreement). The Agreement called for
the sale
of the Property Rights in exchange of a $750,000 Promissory Note (the
Note) and the assumption of approximately $334,000 of liability to
University of Michigan. In addition, Glycosyn subscribed for 810,000 shares of
common stock of the
Company. At the request of certain representative of Glycosyn and its
stockholders, the Company issued all of the shares that it was required to issue
under the Agreement directly to Glycosyns stockholders. However, the Company
subsequently
learned that Glycosyn breached the Agreement since they did not have proper title
to the Property Rights and therefore did not have ability to transfer certain of
the intellectual property sold to the Company under the Agreement. As a result of
the
deficiencies in the Agreement, the Company stopped making payments under the Note.
The Company contends that because of the material breach in the Agreement and
Glycosyns inability to transfer title to the Property Rights as required by
the
Agreement, the Company has been materially and adversely affected, did not receive
the consideration it was supposed to receive under the Agreement and therefore, is
not required to repay the Note. To date, no claim or litigation has been filed in
any court by Glycosyn or its stockholders. The Company is currently in discussion
with Glycosyn to resolve this matter. <P STYLE="margin-top:0px;margin-
Companys management believes that, after consultation with outside counsel,
should the Swiss investors attempt to collect on the Note, the Company will have
one
or more meritorious affirmative defenses, counterclaims and/or rights of offset as
against Glycosyn or its stockholders. </A>DIRECTORS, EXECUTIVE OFFICERS AND CONTROL PERSONS
SIZE="2">Our directors, executive officers and control persons their respective
ages as of October , 2005 are as follows:
<TR>
<TD></TD>
<TR>
New Roman" SIZE="1">Name<HR WIDTH="31" SIZE="1" NOSHADE
<TD VALIGN="bottom">Age <HR
WIDTH="24" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD>
New Roman" SIZE="1">Position<HR WIDTH="46" SIZE="1" NOSHADE
ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
<TD VALIGN="top">Rifat Pamukcu,
MD</TD>
<TD VALIGN="bottom">48</TD>
<TD VALIGN="bottom">Chairman,
Director</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TR>
<TD VALIGN="top">Ivan Kanevski, MD,
PhD</TD>
<TD VALIGN="bottom">President, Chief
Executive Officer, Director</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Norman S. Heyman,
MBA</TD>
<TD VALIGN="bottom">Vice President,
Director</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Lucy Ostrovsky,
MBA</TD>
<TD VALIGN="bottom">Vice President
Finance</TD></TR>
<TR>
<TR>
<TD VALIGN="top">J.R. LeShufy</TD>
<TD VALIGN="bottom">Executive Vice
President, Treasurer, Director</TD></TR>
<TR>
<TR>
<TD VALIGN="top">John J. Baldwin,
Phd</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR>
<TR>
<TD VALIGN="top">Dan McKinney</TD>
SIZE="2">Director</TD></TR>

SIZE="2">Business Experience <P
of our directors serve until their successors are elected and qualified by our
shareholders, or until their earlier death, retirement, resignation or removal.
The
following is a brief description of the business experience of our executive
officers, director and significant employees: Rifat Pamukcu M.D., Chairman, Director. 
SIZE="2">Prior to his involvement with Glyconix at its inception in August 2001
from 1989 to 2003, Dr. Pamukcu was a Founder and Director of Cell Pathways,
Inc. (CPI), an
emerging pharmaceutical company recently acquired by OSI Pharmaceuticals whose
mission was to develop drugs directed toward the prevention and treatment of
cancer. As Chief Scientific Officer and Executive Vice President of Research and
Development
at CPI, Dr. Pamukcu directed the basic science, preclinical drug development,
clinical research, regulatory programs, and various aspects of chemical scale-up
and manufacturing over the last decade. Since CPIs founding in 1989,
Dr. Pamukcu has been instrumental in raising over $140 million of investment
capital and participated in the transformation of CPI from a private to a publicly
traded company. Dr. Pamukcu received his B.A. degree from the
Johns Hopkins University and his M.D. degree from the University of Wisconsin
School of
Medicine. He completed his residency in Internal Medicine at Rush-Presbyterian St.
Lukes Medical Center prior to his fellowship in Gastroenterology at the
University of Chicago. During his fellowship, he co-founded Cell Pathways with one
of
his patients, Mr. Floyd Nichols, who suffered from Familial Polyposis, the
disease which CPIs first drug was designed to treat. Dr. Pamukcu
subsequently was appointed Assistant Professor of Medicine at the University of
Cincinnati,
where, as a consultant, he nurtured Cell Pathways during its infancy. In 1993,
Dr. Pamukcu became adjunct faculty at the University of Cincinnati (a
position he held until 1995) so that he could devote his efforts full-time to Cell
Pathways.
FACE="Times New Roman" SIZE="2">Dr. Pamukcu has been a member of the Advisory
Council to the National
Prostate Cancer Coalition, the GI Oncology Task Force of the American
Gastroenterological Association, Executive Steering Committee of the
Gastroenterology Research Group and Scientific Advisory Board of the Hereditary
Colon Cancer Association. He
was one of twenty-five invited members to the Clinical Trials Summit, a
high level think-tank directed at changing the paradigm by which breast cancer
drugs are developed, convened by the National Breast Cancer Coalition. He was an
invited
speaker at the first International GI Malignancy Conference in Israel, a meeting
established through the joint efforts of President Bill Clinton and the Israeli
Prime Minister. He was most recently honored with addressing the international
think-tank of the British Gastroenterology Society, Royal Society of Medicine on
GI malignancies and their prevention. Since 1985, Dr. Pamukcu has authored or co-authored over 110 journal
articles, book chapters and abstracts in the fields of gastroenterology, cancer,
cancer
chemoprevention and signal transduction systems. He is an inventor on over 280
issued or pending patents in the areas of drug discovery and development of agents
for cancer prevention, cancer chemotherapeutics and inflammatory bowel disease.
FACE="Times New Roman" SIZE="2">Ivan Kanevski, M.D., Ph.D. President and
Chief Executive Office,
Director Dr. Kanevski has an M.D. degree and a Ph.D.
degree
in Molecular Biology from the Ukrainian Academy of Sciences. Previously, from 1990
to 2000, Dr. Kanevski served as a Chief Scientific Officer of Biocoordination
Science, Inc. and as a Director of Research & Development of Prochem
Pantechnologies, Ltd., both biotechnology companies. Dr. Kanevski
was a
post-doctoral fellow and Research Associate in Molecular Genetics at the Waksman
Institute at Rutgers University, NJ. He has significant domestic and international
business and scientific contacts. He has been a visiting scientist at
UNESCOs
International Biological Center in Hungary and the Laboratory Director of the
Institute of Cell Biology and Genetic Engineering in Kiev, Ukraine. Dr. 
Kanevski has significant experience in early
stage technology companies in the drug and biotechnology fields, has authored a
number of publications and has
worked with leading drug and biotech companies. Norman S.
Heyman,
Vice President, Director Mr. Heyman,
who joined the
Company at its inception in August 2001, has 28 years of experience (from 1964 to
1993) as a drug and biotech analyst for Lord Abbett & Co., a major
investment firm. In addition, he has 10 years of experience in the drug and
chemical
industry as a chemical engineer with American Cyanamid, Lummus and Esso Research
and Engineering. Mr. Heyman has extensive startup experience
with a variety of enabling technology companies in the drug (chemical libraries,
urokinase plasmingogen activation receptors), advanced protein separation science,
fermentation, materials science (metal/ceramic binding), medical software
(clinical data capture) and device (ultrasonography) fields. Mr. Heyman
maintains wide contacts in the drug, biotech industry, and the investment
community. He has a B.S.
Ch. Eng. from Lafayette College and an M.B.A. from Rutgers University. He was
Chairman of Securitron, the worlds leading electromagnetic lock company, and
played a key role in its growth and eventual sale to the Swedish company, Assay
Abloy.
FACE="Times New Roman" SIZE="2">Lucy Ostrovsky, Vice President
Finance Mrs. Ostrovsky joined the Company at its inception in August 2001.
Mrs. Ostrovsky
has an M.B.A. in Finance from Kennedy-Western University, an M.S. in Accounting
from State University, and an M.S. in Physics from Polytechnic University, St.
Petersburg, Russia. She has over fourteen years of experience of providing
comprehensive
accounting and reporting functions for a number of private and public firms. She
has participated in a several equity financings, through both public and private
offerings of securities, totaling $150 million. J. R. LeShufy, Executive Vice President, Treasurer,
Director 
SIZE="2">Mr. LeShufy joined the Company at its inception in August 2001.
Mr. LeShufy has
had extensive business experience in a variety of industries for over 40 years,
devoting the last 15 years to the management, financing and development of early
stage technology companies in the drug discovery, biotechnology, communication,
minerals
and consumer products industries. For a period from 1991 to 1993,
Mr. LeShufy was involved with various divisions of the Russian Academy of
Sciences, with the purpose of transferring intellectual property to the West.
Working with the Komarov Institute of St. Petersburg, he created a joint venture
in the
pharmaceutical area now known as Inkine Pharmaceutical Corp. (INKP Nasdaq:NM) and
served on its Board of Directors. He was the founder and president of Consolidated
Fine Arts Ltd. and its wholly owned subsidiary, The Collectors Guild. He
worked with such art luminaries as Chagall, Picasso, Dali, and Miro. He also sits
on the board of the Artwork and Beyond Corp., a company engaged in art auctions
for charitable foundations. Dr. John J. Baldwin - Director 
Dr. John J. Baldwin joined the Company in 2002.
Dr. John J. Baldwin,
from 1993 to the present is the Co-Founder, President and Chief Scientific Officer
of VITAE Pharmaceutical, Inc. Prior to joining VITAE Pharmaceutical, Inc.
Dr. Baldwin spent nine years, from 1993, to 2001, Dr. Baldwin at
Pharmacopeia,
where he was a co-founder and served as Chief Science and Technology Officer.
Prior to that, he was a Distinguished Senior Scientist at Merck, where he spent 33
years in various scientific and management positions. He has authored more than
100
publications; has been a guest-lecturer at over 125 national and international
scientific programs; holds over 180 United States issued patents; and has 
been associated with several successful
drugs including Trusopt, (dorzalamide ophthalmic solution), a drug for preventing
glaucoma, Cosopt, Crixivan and
Agristat. Dr. Baldwin, received his B.S. in chemistry from University of
Delaware and his Ph.D. in organic chemistry from University of Minnesota.
SIZE="2">Dan McKinney - Director Mr. McKinney joined the Company in 2005 From 2001 to the present,
Mr. McKinney was a Partner and Co-founder of NextStage Capital. Prior to co-
founding NextStage
Capital / NextStage Advisors, from 1999 to 2001, Mr. McKinney was a Vice-
President and Officer of Safeguard Scientifics (NYSE: SFE), a publicly traded
venture capital firm. During his tenure at Safeguard, he led approximately $75.5
million,
evaluated hundreds of businesses, and structured and negotiated numerous deals. He
created Safeguards 90-day acceleration framework (a core component of the
NextStage Methodology) that helped Safeguards portfolio companies accelerate
execution and compress time-to-market. While at Safeguard, Dan served as an active
board member for many companies, successfully recruited CEOs and CFOs, and led
several business development efforts on behalf of portfolio companies. An example
of
one of Dans investments at NextStage is TurnTide (acquired by Symantec in
2004). Examples of Dans venture investments while at Safeguard include:
Atlas Commerce (Sold to Verticalnet NAS: VERT), AgWeb (Sold to Farm
Journal), and
while at IBM; SystemCorp (acquired by IBM). Prior to
Safeguard Dan was an
executive with IBM for over 10 years, where he held several marketing and had
profit & loss responsibility for one of IBMs businesses. During
part of his IBM career, Mr. McKinney was in IBMs mergers &
acquisitions
group. There Mr. McKinney was responsible for one of IBMs only minority
investments made during the 90s. That investment in a software company returned
greater than 30% IRR to IBM before being acquired by IBM in late 2004. During his
tenure with IBM, Mr. McKinney developed an alliance that ultimately became
one of IBMs top 20 Global Alliance Partners, was integral in launching
IBMs largest Internet initiative in the Financial Services industry, and was
responsible for launching a new software product that produced tens of millions of
dollars in incremental revenue. Mr. McKinney graduated magna cum laude from the University of
Cincinnati with a degree in Accounting and began his career as a CPA with KPMG.
During his 3
years at KPMG, Mr. McKinney was involved in both the audit and tax groups.
SIZE="2">Scientific Advisory Board Our Scientific Advisory Board members as of October
 , 2005 are as follows: 
<TR>
New Roman" SIZE="1">Position<HR WIDTH="45" SIZE="1" NOSHADE
<TR>
<TD VALIGN="top" NOWRAP>Michael J.
Antonaccio, PhD, FACC</TD>
New Roman" SIZE="2">Chief Scientific Officer at Phoenix Drug Discovery and Lion
Pharmaceuticals Formerly held senior drug development position at
Human Genome Sciences, Bristol Meyers Squibb, Schering Co.</TD></TR>
<TR>
<TR>
<TD VALIGN="top" NOWRAP>Daniel Von Hoff,
MD</TD>
<TD VALIGN="bottom">Senior Investigator and
Head of Translational Research at the Translational Genomics Research
Institutes (Tgen) Translational Drug Development Division and Head,
Pancreatic Cancer
Research Program in Phoenix, Arizona. He is also Chief Scientific Officer for US
Oncology.</TD></TR>
<TR>
<TR>
<TD VALIGN="top" NOWRAP>Robert G. Zamenhof,
PhD</TD>
New Roman" SIZE="2">Director of Radiological Services, Tufts New England Medical
Center and Associate Professor of Radiology, Harvard Medical School Since 2002, President of International Society of Neutron Capture Therapy
(ISNCT)</TD></TR>
<TR>
<TR>
<TD VALIGN="top" NOWRAP>Robert Shorr,
PhD</TD>
New Roman" SIZE="2">CEO, CornerStone Pharmaceuticals, Former Director
of
R&D of Drug Delivery at Enzon Corp.</TD></TR>
<TR>
<TR>
<TD VALIGN="top" NOWRAP>Phillip
Sussman</TD>
<TD VALIGN="bottom">Managing Partner of The
Channel Group LLC, Advisor to PhychoGenis Inc., Automated Cell, Inc and SCIUS
Capital Group. Former member of senior management (Head of Business Development,
CFO and
CEO) of several Biotechnology companies, including Perlegen Sciences, Inc., Cadus
Pharmaceutical Corp., Memory Pharmaceuticals Corp., Ciba-Geigy (now
NovartisAG)</TD></TR>
<TR>
<TR>
<TD VALIGN="top" NOWRAP>Beth Hollister, RN,
MBA</TD>
New Roman" SIZE="2">President of Piedmont Research Center, recent subsidiary of
PPD Former executive of Glycosyn Pharmaceutical
Inc.</TD></TR>
<TR>
<TR>
<TD VALIGN="top" NOWRAP>Jane E. Rosen,
PhD</TD>
New Roman" SIZE="2">Consultant to Drug Industry Former Director
of
Phototoxicology Lab, American Health Foundation</TD></TR>
FACE="Times New Roman" SIZE="2">The following is a brief description
of the experience of the members of the Scientific Advisory Board: Dr.
Michael J. Antonaccio, Member of SAB Most recently,
Dr. Antonaccio served as the Chief Scientific Officer for Phoenix Drug
Discovery and Lion Pharmaceuticals. Prior to that, in his role as Vice President
of Strategic Drug Development for Human Genome Science, he was responsible for
organizing
discovery efforts for proteins of interest and for preclinical and clinical
development of selected compounds. He served a number of years at the Bristol-
Myers Squibb Research Institute in various capacities, including Senior Vice
President for
Cardiovascular Research and Development as well as Director of Pharmacology at
Squibb. Dr Antonaccio previously served as Vice President for New Drug Discovery
at Schering Corp. Throughout his career, he has managed large groups of
biologists,
chemists and clinicians in the drug discovery and development field.
Dr. Antonaccio received a B.S. in Pharmacy from Duquesne University and a
Ph.D. in Pharmacology from the University of Michigan Dr. Daniel Von Hoff, Member of SAB 
Daniel D. Von Hoff, M.D., is currently Senior Investigator and Head of
Translational
Research at the Translational Genomics Research Institutes (Tgen)
Translational Drug Development Division and Head, Pancreatic Cancer Research
Program in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology.
 Dr. Von Hoffs major interest is in the development of new
anticancer agents, both
in the clinic and in the laboratory. He and his colleagues were involved in the
beginning of the development of many of the agents we now use routinely,
including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11,
and others. At
present, he and his colleagues are concentrating on the development of molecularly
targeted therapies. Dr. Von Hoffs laboratory interests and
contributions have been in the area of in vitro drug sensitivity testing to
individualize treatment for the patient. He and his laboratory are now
concentrating
on 
discovery of new targets in pancreatic
cancer. Dr. Von Hoff has published more than 515 papers, 129 book chapters,
and more than 861 abstracts.
FACE="Times New Roman" SIZE="2">Dr. Von Hoff was appointed to President
Bushs National Cancer
Advisory Board in June 2004 March 2010. Dr. Von Hoff is the past
President of the American Association for Cancer Research, a Fellow of the
American College of Physicians, and a member and past board member of the American
Society of
Clinical Oncology. He is a founder of ILEX Oncology, Inc. (recently acquired
by Genzyme). He is founder and the Editor Emeritus of Investigational New
Drugs The Journal of New Anticancer Agents; and, Editor-in-Chief of
Molecular Cancer Therapeutics. He is also proud to have been a mentor and
teacher for multiple medical students, medical oncology fellows, graduate
students, and post-doctoral fellows. Dr. Robert G. Zamenhof, Member of SAB
 Dr. Zamenhof serves as a Director of Radiological Sciences at New
England Medical
Center and associate Professor at Harvard Medical School. Since 2002 he serves as
a President of the International Society of Neutron Capture Therapy (ISNCT).
SIZE="2">Previously Dr. Zamenhof held prominent academic positions at Tufts
University, School of Medicine, Harvard Medical School, MIT and adjunct professor
at Boston
University. He had also held numerous hospital appointments at New England Medical
Center and Beth Israel Deaconess Medical Center. He is Board certified in
Radiological Physics. Dr. Zamenhof has authored or co-authored over
100 book chapters, papers, and technical reports in the areas of boron neutron
capture
therapy. He is the author of two patents in the field of radiation microdosimetry
and treatment planning and is the author of a commercial software product for the
evaluation of X-ray exposure to patients undergoing diagnostic procedures. His
current research interest is primarily in the area of boron neutron capture
therapy supported by the U.S. Department of Energy. Dr. Zamenhof has been the
recipient (as a Principal Investigator) of over $10,000,000 in Federal and private
foundation research grants. Dr. Zamenhof received his
undergraduate
degree in 1996 from the Polytechnic of North London, U.K. in Electronics and
Communications, his M.Sc. in 1971 from the University of Strathclyde, Glasgow,
Scotland in bioengineering and his Ph.D. in 1977 from the Massachusetts Institute
of
Technology, USA, in Nuclear Engineering & Applied Radiation Physics.
SIZE="2">Dr. Robert Shorr, Member of SAB Dr. Shorr received his Ph.D. in biochemistry from the Imperial
College of Science and Technology at the University of London. His experience
includes directorships in molecular pharmacology and research for major
corporations. He has
done extensive research in separation science and drug delivery, including serving
as head of R&D for drug delivery at Enzon Corporation. He is the recipient of
U.S. and foreign fellowships at the institute and university level. He has
received
several awards, including the Gallo Award for cancer research. Shorr has published
over 150 scientific articles and has more than 30 inventions and patents to his
credit. Philip Sussman, Member of SAB
SIZE="2">Mr. Sussman is Managing Partner of the Channel Group LLC, a life
sciences venture formation and management firm. Previously, he served as a member
of senior
management (Head of Business Development, CFO, and CEO) of several public and
private biochenology companies, including Perlegen 
Sciences, Inc., Memory Pharmaceuticals
Corp., and Cadus Pharmaceutical Corp. Prior to his joining the biotechnology
industry, he was Director of
Strategy & Business Development at Ciba-Geigy Corp.s Pharmaceutical
Division (now Norvartis AG). He currently is an advisor to PhychoGenics Inc.,
Automated Cell, Inc., and SCIUS Capital Group LLC. Sussman has a B.S. in Physics from SUNY Stony Brook, a Masters Degree
from the MIT Sloan
School of Management and a M.S. in Biotechnology from Manhattan College. He is a
member of the Review Panel for the Innovative Technology Research Grant Program,
Center for Biotechnology, NY State Science and Technology Foundation. 
Beth Hollister, Member of SAB
 Ms. Hollister has worked in the clinical trial field for many years.
From 1993 to 1997,
Hollister managed the operations and preclinical of Glycosyn and was responsible
for Glycosyns hiring and managing of key scientists, third party research
and development contracts as well as day-to-day operations. For Harrier,
Glycosyns
parent company, she evaluated new technology and regulatory submissions and had
preclinical science as well as Phase I clinical trials. Since 1997 she has headed
Piedmont Research Center in Morrisville, North Carolina, a company providing early
stage pre-clinical services in cancer research for numerous major drug companies.
Ms. Hollister is a registered intensive care nurse. Dr. Jane E. Rosen, Member of SAB
 Dr. Rosen has a Ph.D. in Biophysics and Biochemistry, an M.S. in
Biology an M.S. in Chemistry from New York University, and a B.S. in Chemistry
from American
University. Since 1995, Dr. Rosen has been an investigator and has published
on photogenotoxicity of quinolones and other anti-bacterials, and their effects on
organs. Dr. Rosen has consulted extensively with drug companies and a medical
communications company with expertise in analytical techniques, instrumentation
and DNA analysis. Prior to that, she created and directed the laboratory on
Phototoxicity and Photocarcinogenesis at the American Health Foundation in
Valhalla, New
York. She has been a Post-doctoral NIH fellow at Columbia Presbyterian, a research
investigator at the Population Council at Rockefeller University in receptors and
steroids, and has held Post-doctoral research positions at New York University and
Harvard Medical School. Significant Consultants
 <P
addition to consulting agreements with the officers and directors described above,
in May
2005 the Company signed and agreement with Millennium Management Services LLC. The
Company engages it services as a Preclinical Consultant to set up proper
procedures for toxicology tests and all communication with FDA to support IND
filling.
FACE="Times New Roman" SIZE="2">Family Relationships There are no family relationships between any two or more of our
directors or executive
officers. There is no arrangement or understanding between any of our directors or
executive officers and any other person pursuant to which any director or officer
was or is to be selected as a director or officer, and there is no arrangement,
plan
or understanding as to whether non-management shareholders will exercise their
voting rights to continue to elect the current board of directors. There are also
no arrangements, agreements or understandings to our knowledge between non-
management
shareholders that may directly or indirectly participate in or influence the
management of our affairs. Involvement in Certain Legal Proceedings To the best of our knowledge, during the past five
years, none of the following occurred with respect to a present or former director
or
executive officer of the Company: (1) any bankruptcy petition filed by or
against any business of which such person was a general partner or executive
officer either at the time of the bankruptcy or within two years prior to that
time;
(2) any conviction in a criminal proceeding or being subject to a pending
criminal proceeding (excluding traffic violations and other minor offenses);
(3) being subject to any order, judgment or decree, not subsequently
reversed, suspended
or vacated, of any court of any competent jurisdiction, permanently or temporarily
enjoining, barring, suspending or otherwise limiting his involvement in any type
of business, securities or banking activities; and (4) being found by a court
of
competent jurisdiction (in a civil action), the Securities and Exchange Commission
or the commodities futures trading commission to have violated a Federal or state
securities or commodities law, and the judgment has not been reversed, suspended
or
vacated. Board Committees and Independence
 <P
of the directors serve until the next annual meeting of common shareholders and
until
their successors are elected and qualified by our common shareholders, or until
their earlier death, retirement, resignation or removal. Our Bylaws set the
authorized number of directors at not less than one nor more than nine, with the
actual
number fixed by our board of directors. Our Bylaws authorized the Board of
Directors to designate from among its members one or more committees and alternate
members thereof, as they deem desirable, each consisting of one or more of the
directors,
with such powers and authority (to the extent permitted by law and these Bylaws)
as may be provided in such resolution. <P STYLE="margin-
board of directors has established three committees to date, an Audit Committee,
Management Committee and a Compensation Committee. Our Board of Directors has also
established a Scientific Advisory Board. The principal functions of the Audit
Committee are to recommend the annual appointment of the Companys auditors
concerning the scope of the audit and the results of their examination, to review
and
approve any material accounting policy changes affecting the Companys
operating results and to review the Companys internal control procedures.
The principal functions of the Compensation Committee are to review and recommend
compensation and benefits for the executives of the Company. The principal
functions of the Management Committee are to review and recommend financing and
investment opportunities for the Company, business strategy, and the
Companys structure
and operations. The Companys Board of Directors resolved
that there are
no members of the Board appointed to consulting Audit and Compensation Committees,
and the initial number of the Board members shall be later amended by the Board.
FACE="Times New Roman" SIZE="2">The entire Board of Directors will perform the
function of the Audit Committee until we appoint directors to serve on the Audit
Committee.
FACE="Times New Roman" SIZE="2">Currently, there are two members of the Board of
Directors appointed as
members of Management Committee and initial number of the Board members consulting
Management Committee shall be two until later amended by the Board. The Scientific
Advisory Board has been formed to evaluate and monitor the Company as it is
engaging in one or more business requiring sophisticated scientific and technical
knowledge in the fields of medicine, biotechnology, chemistry, pharmacology and
similar fields. There are six members of the Scientific Advisory Board.
 
<A NAME="tx97153_18"></A>EXECUTIVE COMPENSATION Summary
Compensation
Table The following table shows the compensation paid
over the past three
fiscal years with respect to our named executive officers as that term
is defined by the under the Securities and Exchange Act of 1934. 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Annual Compensation <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Long Term Compensation <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
SIZE="1">Awards <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Payouts<HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
New Roman" SIZE="1">Name and Principal Position<HR
SIZE="1">Year <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Salary <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Bonus <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" ALIGN="center">Other
Annual Compensation <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Restricted Stock Award (s) <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TD VALIGN="bottom" ALIGN="center"> Securities Underlying Options/ SARs (#)<HR
SIZE="1">LTIP Payouts <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TD VALIGN="bottom" ALIGN="center">All
Other Compensation <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TD VALIGN="top" ROWSPAN="3"> Ivan
Kanevski President, Chief Executive Officer
and Director</TD>
<TD VALIGN="top" ALIGN="right">$</TD>
SIZE="2">120,000</TD>
<TD NOWRAP VALIGN="top">(1)</TD>
<TD VALIGN="top">$</TD>
SIZE="2">25,000</TD>
<TD VALIGN="bottom">200,000(4) shares of common
stock</TD>
COLOR="#000000"></TD>
<TD VALIGN="bottom">30,000 shares of
common stock</TD>
<TD VALIGN="top"> </TD></TR>
COLOR="#000000"></TD>
<TD VALIGN="bottom">150,000 shares of common
stock</TD>
<TR>
<TD VALIGN="top" ROWSPAN="3"> J. Robert LeShufy Executive Vice
President, Treasurer and Director</TD>
COLOR="#000000"></TD>
SIZE="2">35,000</TD>
<TR>
COLOR="#000000"></TD>
stock</TD>
<TR>
COLOR="#000000"></TD>
stock</TD>
<TD VALIGN="top" ROWSPAN="3"> Lucy
Ostrovsky Vice President
Finance</TD>
COLOR="#000000"></TD>
SIZE="2">7,500</TD>
COLOR="#000000"></TD>
stock</TD>
COLOR="#000000"></TD>
stock</TD>
WIDTH="100%">
<TR>
COLOR="#000000">(1) -</TD>
COLOR="#000000">To permit the closing on the $1.8 million private placement in
August November, 2004,
Dr. Ivan Kanevski agreed to forego salary of $46,000, which accrued in years
2002 and 2003. </TD></TR></TABLE> 
<TR>
COLOR="#000000">(2) -</TD>
August November, 2004,
Mr. J. R. LeShufy agreed to forego salary of $234,000, which accrued for the
period from August 2001 through June 30, 2004. </TD></TR></TABLE> 
<TR>
COLOR="#000000">(3) -</TD>
August November, 2004, Mrs Ostrovsky agreed to forego salary of $8,000,
which accrued in years
2002 and 2003. </TD></TR></TABLE> 
<TR>
COLOR="#000000">(4) -</TD>
COLOR="#000000">200,000 options vested immediately. </TD></TR></TABLE> Options/SAR Grants in Last Fiscal Year 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center">Number
of Securities Underlying Options/SARs Granted <HR
<TD VALIGN="bottom" ALIGN="center">% of
Total Options/SARs Granted
to Employees in Fiscal Year <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Exercised or Base Price <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Expiration Date <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">Ivan Kanevski, President, Chief Executive Officer
and Director</TD>
SIZE="2">200,000</TD>
SIZE="2">March 1, 2004</TD></TR>
FACE="Times New Roman" SIZE="2">Employment Agreements
FACE="Times New Roman" SIZE="2">On March 30, 2005 Ivan Kanevski exchanged his
consulting agreement
to an employment agreement to compensate him for acting as our President and Chief
Executive Officer. The employment agreement is for a period of three years, with
two renewal options for an additional two years and providing for an annual salary
of
$160,000. In addition, Dr. Kanevski will receive options to purchase 100,000
shares of our common stock with an exercise price of $0.50, which vested on
September 1, 2005 and expire on March 30, 2010 and additional options to
purchase
150,000 shares of our common stock with an exercise price of $0.50, vesting in
three (3) equal installments on March 30, 2006, 2007 and 2008, and shall
expire on March 30, 2010, as well as standard benefits and any bonus as
determined
by our Board of Directors. On March 30, 2005 J.R.
LeShufy exchanged his
consulting agreement to an employment agreement to compensate him for acting as
our Executive Vice President, Secretary and Treasurer. The employment agreement is
for a period of three years, with two renewal options for an additional two years
and
providing for an annual salary of $96,000. In addition, Mr. LeShufy will
receive options to purchase 100,000 shares of our common stock with an exercise
price of $0.50, which vested on September 1, 2005 and expire on
March 30, 2010
and additional options to purchase 100,000 shares of our common stock with an
exercise price of $0.50, vesting in three (3) equal installments on
March 30, 2006, 2007 and 2008, and shall expire on March 30, 2010, as
well as standard
benefits and any bonus as determined by our Board of Directors. On
August 1, 2005 Lucy Ostrovsky exchanged her consulting agreement to an
employment agreement to compensate her for acting as our Vice President Finance.
The employment agreement is for a period of three years, with two renewal options
for an
additional two years and providing for an annual salary of $84,000. In addition,
Mrs. Ostrovsky will receive options to purchase 50,000 shares of our common
stock with an exercise price of $0.50, which vested on September 1, 2005 and
expire on August 1, 2010 and additional options to purchase 30,000 shares of
our common stock with an exercise price of $0.50, vesting in three (3) equal
installments of 10,000 shares on August 1, 2006, 2007 and 2008, and shall
expire
on August 1, 2010, as well as standard benefits and any bonus as determined
by our Board of Directors. Aggregated Option Exercises and Fiscal Year-End Option Value Table
 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Shares Acquired on Exercise <HR SIZE="1"
SIZE="1">Value Realized <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Number of Securities Underlying Unexercised Options
/SAR at December 31,
2004 Exercisable/ Unexercisable <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
ALIGN="center">Value of Unexercised In-the- money Options/SAR at
December 31, 2004 Exercisable/ Unexercisable<HR SIZE="1"
FACE="Times New Roman" SIZE="2">Ivan Kanevski, President, Chief Executive
Officer</TD>
SIZE="2">230,000</TD>
SIZE="2">11,500</TD>
SIZE="2">0</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">J. Robert LeShufy, Executive Vice
President</TD>
SIZE="2">30,000</TD>
SIZE="2">1,500</TD>
FACE="Times New Roman" SIZE="2">Lucy Ostrovsky, Vice President
Finance</TD>
SIZE="2">30,000</TD>
SIZE="2">6,600</TD>
FACE="Times New Roman" SIZE="2">Compensation of SAB Members
FACE="Times New Roman" SIZE="2">We currently have six (6) SAB Members. Our
current compensation
policy for our SAB Members, is to compensate them through options to purchase
common stock as consideration for their joining our advisory board and/or
providing continued services as a advisors. We do not currently provide our
advisors with cash
compensation, although we do reimburse their expenses. No additional amounts are
payable to the Companys advisors for committee participation or special
assignments. There are no other arrangements pursuant to which any scientific
advisor was
compensated during the Companys last completed fiscal year for any service
provided as scientific advisor. </A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT The following table sets forth certain information
regarding beneficial ownership of the common stock as of December 31, 2004
and June 30, 2005, by (i) each person who is known by the Company to own
beneficially more than 5% of the any classes of outstanding Stock, (ii) each
director of the Company, (iii) each of the Chief Executive Officers and the
two (2) most highly compensated executive officers who earned in excess of
$100,000 for all services in all capacities (collectively, the Named
Executive Officers) and (iv) all directors and executive officers of
the Company as a group. The number and percentage of
shares beneficially owned is determined in accordance with Rule 13d-3
and 13d-5 of the
Exchange Act, and the information is not necessarily indicative of beneficial
ownership for any other purpose. We believe that each individual or entity named
has sole investment and voting power with respect to the securities indicated as
beneficially owned by them, subject to community property laws, where applicable,
except where otherwise noted. Unless otherwise stated, the address of each person
is 350 Fifth Avenue, Suite 4811, New York, NY 10118. 
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
New Roman" SIZE="1">Name of Beneficial Owner<HR WIDTH="138"
SIZE="1">Number of Shares of Common Stock (1) <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Percent of Class (1) <HR SIZE="1"
FACE="Times New Roman" SIZE="2">Dr. Ivan Kanevski</TD>
SIZE="2">1,753,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">J. R. LeShufy</TD>
SIZE="2">1,800,000</TD>
FACE="Times New Roman" SIZE="2">Rifat Pamukcu</TD>
SIZE="2">239,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Norman S. Heyman</TD>
SIZE="2">1,200,000</TD>
FACE="Times New Roman" SIZE="2">Lucy Ostrovsky</TD>
SIZE="2">460,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">John J. Baldwin</TD>
SIZE="2">133,000</TD>
FACE="Times New Roman" SIZE="2">Dan McKinney</TD>
SIZE="2">17,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">All directors and officers of the Corporation as a
group including those named above (7 persons)</TD>
SIZE="2">5,639,000</TD>
SIZE="2">27.49</TD>
<TR>
FACE="Times New Roman" SIZE="2">Henry L. Hoffman</TD>
SIZE="2">1,845,000</TD>
FACE="Times New Roman" SIZE="2">JED Management</TD>
SIZE="2">4,900,000</TD>
SIZE="2">25.19</TD>
<TR>
FACE="Times New Roman" SIZE="2">MAK LLC(8) </TD>
SIZE="2">1,000,000</TD>
FACE="Times New Roman" SIZE="2">Stanley Merdinger</TD>
SIZE="2">2,000,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Quantum FS and Jack Simony,
collectively(10)</TD>
SIZE="2">1,050,000</TD>
WIDTH="100%">
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Calculated based on 19,450,000 shares of common stock outstanding
as October 1, 2005, as calculated in accordance with Rule 13d-3 under the
Exchange act. Unless
otherwise indicated, this includes shares owned by a spouse, minor children and
any entities owned or controlled by the named person. </TD></TR></TABLE> 
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Dr. Ivan Kanevski is our President, Chief Executive Officer
and Director. The number of shares of common stock that Dr Kanevski could be
deemed to beneficially
own includes: </TD></TR></TABLE> 
<TR>
shares of common stock owned of record by Dr. Kanevski,
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">an option to
purchase 223,000 shares (calculated through October 1, 2005 in order to
reflect options that have or will vest within the next 60 days) at an exercise
price of
$.50 per share, and </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">an aggregate
of 200,000 of our common stocks owned of record by various relatives of
Dr. Kanevski, as follows: 100,000 shares owned by each of Ivan Kanevski Jr.
(Dr
Kanevskis son) and Elena Kanevkaya (Dr. Kanevskis daughter).
WIDTH="100%">
<TR>
COLOR="#000000"></TD>
COLOR="#000000">J. R. LeShufy is our Executive Vice President, Treasurer and
Director. The number of shares of common stocks that Mr. LeShufy could be
deemed to beneficially
WIDTH="100%">
<TR>
of common stock owned of record by Mr. LeShufy, </TD></TR></TABLE> 
<TR>
price of
$.50 per share, and </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top"> an aggregate of 1,255,000 of our common stock owned of record by various
relatives and affiliates of Mr. LeShufy, as follows: 1,200,000 shares owned
by Karen
LeShufy (Mr. LeShufys daughter), 30,000 shares owned by Norman Eisner,
10,000 owned by Neal Nissel, 
</TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top"> 
10,000 shares owned by William Nissel, 2,000
shares owned by Noelle Geiger, and 3,000 shares owned by Dr. Weiser (Mr.
LeShufy associates).
</TD></TR></TABLE> 
<TR>
COLOR="#000000"></TD>
COLOR="#000000">Rifat Pamukcu is our Chairman and Director. The number of shares
of common stock that Mr. Pamukcu could be deemed to beneficially own
includes:
WIDTH="100%">
<TR>
of common stock owned of record by Mr. Pamukcu, and </TD></TR></TABLE>
WIDTH="100%">
<TR>
price of
$0.05 per share for 121,000 shares and $.50 per share for 17,000 shares.
WIDTH="100%">
<TR>
COLOR="#000000">(5)</TD>
COLOR="#000000">Lucy Ostrovsky is our Vice President Finance. The number of shares
of common stock that
Mrs. Ostrovsky could be deemed to beneficially own includes:
WIDTH="100%">
<TR>
of common stock owned of record by Mrs. Ostrovsky, </TD></TR></TABLE>
WIDTH="100%">
<TR>
price of $.50
per share, and </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">210,000 of our
common stocks owned of record by Eugene Ostrovsky (Mrs. Ostrovskys son).
WIDTH="100%">
<TR>
COLOR="#000000">The number of shares of common stock that Mr. Hoffman could
be deemed to beneficially
WIDTH="100%">
<TR>
shares of common stock owned of record by Mr. Hoffman, and
WIDTH="100%">
<TR>
of 466,000 of our common stock owned of record by various relatives and affiliates
of Mr. Hoffman. </TD></TR></TABLE> 
<TR>
COLOR="#000000">JED Management is controlled by John DeNobile.
</TD></TR></TABLE> 
<TR>
COLOR="#000000">MAK LLC controlled by Gary Rogers. The number of shares of common
stock that MAK LLC could be
deemed to beneficially own includes: </TD></TR></TABLE> 
<TR>
of common stock owned of record by MAK LLC, </TD></TR></TABLE> 
<TR>
of common stock owned of record by Hammock LLC, which controlled by MAK LLC and
Mr. Rogers, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">15,000 of our
common stocks owned of record by various relatives of Mr. Rogers, as follows:
5,000 shares owned by each of Matthew Rogers (Mr. Rogers son), Eric Rogers
(Mr. Rogers son) and Georgia Rogers (Mr. Rogers daughter), and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">An aggregate
of 85,000 of our common stock owned of record by various relatives and affiliates
of MAK LLC and Mr. Rogers. </TD></TR></TABLE> 
<TR>
COLOR="#000000">The number of shares of common stock that Mr. Merdinger could
be deemed to beneficially
WIDTH="100%">
<TR>
shares of common stock owned of record by Mr. Merdinger, and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">A warrant to
purchase 1,000,000 shares of common stock at an exercise price $1.50 per share.
WIDTH="100%">
<TR>
COLOR="#000000">Quantum FS controlled by Jack Simony. The number of shares of
common stock that Quantum FS
and Jack Simony, collectively could be deemed to beneficially own includes:
WIDTH="100%">
<TR>
of common stock owned of record by Quantum FS, </TD></TR></TABLE> 
<TR>
of common stock owned of record by Jack Simony, and </TD></TR></TABLE> 
<TR>
of 125,000 of our common stock owned of record by various affiliates of Quantum FS

SIZE="2">Changes in Control We are not aware of any arrangements that may
result in a change in control of the Company. </A>DESCRIPTION OF SECURITIES General
FACE="Times New Roman" SIZE="2">Our authorized capital stock consists of
40,000,000 shares of common
stock, par value $ .01, and 5,000,000 shares of preferred stock. Common
Stock The shares of our common stock presently
outstanding, and any
shares of our common stock issues upon exercise of stock options and/or warrants,
will be fully paid and non-assessable. Each holder of common stock is entitled to
one vote for each share owned on all matters voted upon by shareholders, and a
majority vote is required for all actions to be taken by shareholders. In the
event we liquidate, dissolve or wind-up our operations, the holders of the common
stock are entitled to share equally and ratably in our assets, if any, remaining
after
the payment of all our debts and liabilities and the liquidation preference of any
shares of preferred stock that may then be outstanding. The common stock has no
preemptive rights, no cumulative voting rights, and no redemption, sinking fund,
or
conversion provisions. Since the holders of common stock do not have cumulative
voting rights, holders of more than 50% of the outstanding shares can elect all of
our Directors, and the holders of the remaining shares by themselves cannot elect
any
Directors. Holders of common stock are entitled to receive dividends, if and when
declared by the Board of Directors, out of funds legally available for such
purpose, subject to the dividend and liquidation rights of any preferred stock
that may
then be outstanding. Preferred Stock Dividend Policy
FACE="Times New Roman" SIZE="2">We have never declared or paid any cash dividends
on our common stock. We
currently intend to retain future earnings, if any, to finance the expansion of
our business. As a result, we do not anticipate paying any cash dividends in the
foreseeable future. Options <P STYLE="margin-
August 2001, the Company adopted the 2001 Stock Option Plan (the
Plan), which was approved by the sole officer, director and
shareholder on that date. The
purpose of the Plan is encourage and enable employees, directors and other persons
upon whose judgment, initiative and efforts the Company largely depends upon, to
acquire a proprietary interest in the Company. Under the Plan, the board of
directors, or a stock option committee appointed by the board of directors, may
grant stock purchase options (Options) relating to a maximum of
2,000,000 shares of Common Stock (subject to adjustment due to certain
recapitalizations,
reorganizations or other corporate events). The board of directors or the
Companys stock option committee shall have discretion to determine which of
this amount may be granted as incentive stock options (ISOs),
stock
appreciation rights (SARs), and non-statutory options. If any
Option expires, terminates or is cancelled without having been exercised the
shares subject to the option will again be available for issuance under the Plan.
At
December 31, 2003 there were 
1,420,000 Options issued under the Plan,
1,100,000 were exercised and 25,000 were canceled. At December 31, 2004,
570,000 options were outstanding, and
185,000 exercisable. The Company adopted the 2005 Stock Option Plan
(the
2005 Plan), which was approved by the Board of Directors on
December 23, 2004 and by shareholders on August 8, 2005. The purpose of
the 2005 Plan is to encourage and enable employees, directors and other persons
upon whose
judgment, initiative and efforts the Company largely depends upon, to acquire a
proprietary interest in the Company. Under the 2005 Plan, the Board of Directors,
or a stock option committee appointed by the Board of Directors, may grant stock
purchase options relating to a maximum of 1,500,000 shares of Common Stock
(subject to adjustment due to certain recapitalizations, reorganizations or other
corporate events). The Board of Directors or the Companys stock option
committee shall
have discretion to determine which of this amount may be granted as incentive
stock options (ISOs), stock appreciation rights
(SARs), restrictive stock awards, and non-statutory options. If
any Option expires,
terminates or is cancelled without having been exercised the shares subject to the
option will again be available for issuance under the 2005 Plan. As of
October 1, 2005 692,000 options have been granted pursuant to the 2005 Plan.

SIZE="2">Warrants: On January 15, 2004 the Company issued
245,000 warrants to purchase common stock at a price $.05 per share in a
connection with certain
convertible promissory notes in an amount of $380,000. Such warrants were
exercised in July 2004. On July 1, 2004, the Company issued 30,000
warrants to purchase common stock at a price $1.50 per share to a consultant in
connection with a termination of an agreement. During 2004, the Company sold 3,610,000 units, consisting of one share of
common stock and
one redeemable 5-year warrant, vested immediately, for the Companys common
stock at $1.50 per share. Those warrants are subject to redemption at the
Companys sole option after one year from date of issuance if the common
stock price has
averaged 150% of the warrant exercise price of $1.50 per share for 10 trading days
during the 20 trading day period ending 1 day prior to the notice date at a
redemption price of $.10 per warrant. As of June 30, 2005, outstanding warrants to
acquire
shares of the Companys common stock are as follows: 
<TD></TD></TR>
<TR>
New Roman" SIZE="1">Exercise Price<HR WIDTH="74" SIZE="1"
NOSHADE ALIGN="left" COLOR="#000000"></TD>
SIZE="1">Expiration Date<HR WIDTH="84" SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Number of Shares Reserved <HR SIZE="1"
FACE="Times New Roman" SIZE="2">$1.50</TD>
<TD VALIGN="bottom">July 1, 2009</TD>
SIZE="2">30,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">$1.50</TD>
SIZE="2">January 15, 2008</TD>
SIZE="2">3,610,000</TD></TR>
<TR>
SIZE="2">3,640,000</TD></TR>
FACE="Times New Roman" SIZE="2">Convertible Securities
FACE="Times New Roman" SIZE="2">The Company has issued 9% convertible promissory
notes which
(i) bear interest at a rate of 9% per annum. (ii) become due and
payable as to all outstanding interest and principal on the earlier of 24 months
from date of issuance or September 1, 2004, (iii) may be converted into
the
Companys common stock at any time at least 90 days after the first closing
of any private or public financing with a gross closing amount of not less than
$3,000,000, or the Companys merger with or acquisition by another entity, or
the
liquidation of all or substantially all of the Companys assets,
(iv) become convertible at a price set to 50% of the offering price of the
common stock in such offering, or, if no common stock was issued, to 50% of the
conversion price of
preferred stock, convertible notes or other securities issued in 
such offering. During the years ended
December 31, 2004, 2003, 2002, and 2001 the Company issued promissory notes
of $135,000, $338,000, $299,000 and
$60,000, respectively. On January 15, 2004, the
Companys Board of
Directors agreed to increase the interest rate to 9.5% on all funds borrowed from
one investor from their original issuance date. Such change in the interest rate
resulted in additional interest expense of approximately $4,000 on
January 15,
2004. In addition, such note holder was granted a warrant to purchase 245,000
shares of common stock which was value a $7,000 and treated as interest expense.
SIZE="2">On July 1, 2004, the Company entered into Debt Discharge, Release
and Satisfaction agreements with certain note holders. Under the agreements one
note holder
converted principal of $800,000 and accrued interest of approximately $100,000
into 600,000 shares of common stocks, and another note holder agreed to convert
principal of $10,000 and accrued interest of approximately $2,000 into 25,000
shares of
common stock. A beneficial conversion feature was not calculated since the
conversion price of the common stock was greater than the estimated fair value of
such shares issued. Amendment of our Bylaws <P
bylaws may be adopted, amended or repealed by the affirmative vote of a majority
of our outstanding shares. Subject to applicable law, our bylaws also may be
adopted,
amended or repealed by our board of directors. 
<A NAME="tx97153_21"></A>DISCLOSURE OF COMMISSION POSITION OF INDEMNIFICATION FOR
SECURITIES ACT LIABILITIES; ANTI-TAKEOVER, LIMITED LIABILITY AND INDEMNIFICATION
PROVISIONS Certificate of Incorporation and Bylaws.
Pursuant to our amended certificate of incorporation, our board of directors
may issue
additional shares of common or preferred stock. Any additional issuance of common
stock could have the effect of impeding or discouraging the acquisition of control
of us by means of a merger, tender offer, proxy contest or otherwise, including a
transaction in which our stockholders would receive a premium over the market
price for their shares, and thereby protects the continuity of our management.
Specifically, if in the due exercise of its fiduciary obligations, the board of
directors
were to determine that a takeover proposal was not in our best interest, shares
could be issued by the board of directors without stockholder approval in one or
more transactions that might prevent or render more difficult or costly the
completion
of the takeover by: 
<TR>
<TD ALIGN="left" VALIGN="top">diluting the
voting or other rights of the proposed acquirer or insurgent stockholder group;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">putting a
substantial voting block in institutional or other hands that might undertake to
support the incumbent board of directors; or </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">effecting an
acquisition that might complicate or preclude the takeover.
SIZE="2">Delaware Anti-Takeover Law. We are subject to the provisions of
Section 203 of the Delaware General Corporation Law concerning corporate
takeovers. This
section prevents certain Delaware corporations from engaging in a business
combination with any interested stockholder, under certain circumstances. For
these purposes, a business combination includes a merger or sale of more than 10%
of our assets,
and an interested stockholder includes a stockholder who owns 15% or more of our
outstanding voting stock, as well as affiliates and associates of these persons.
Under these provisions, this type of business combination is prohibited for three
years
following the date that the stockholder became an interested stockholder unless:
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">the
transaction in which the stockholder became an interested stockholder is approved
by the board of directors prior to the date the interested stockholder attained
such status;

WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">upon
consummation of the transaction that resulted in the stockholders becoming
an interested stockholder, the interested stockholder owned at least 85% of the
voting stock of
the corporation outstanding at the time the transaction was commenced, excluding
those shares owned by persons who are directors and also officers; or
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">on or
subsequent to that date, the business combination is approved by the board of
directors and authorized at an annual or special meeting of stockholders by the
affirmative vote
of at least two-thirds of the outstanding voting stock that is not owned by the
interested stockholder. </TD></TR></TABLE> This statute could prohibit or delay mergers or other takeover or change-
in-control attempts with respect to us and, accordingly, may discourage attempts
to acquire us.
FACE="Times New Roman" SIZE="2">Limited Liability and Indemnification. Our
certificate of incorporation
eliminates the personal liability of our directors for monetary damages arising
from a breach of their fiduciary duty as directors to the fullest extent permitted
by Delaware law. This limitation does not affect the availability of equitable
remedies, such as injunctive relief or rescission. Our certificate of
incorporation requires us to indemnify our directors and officers to the fullest
extent permitted by Delaware law, including in circumstances in which
indemnification is otherwise
discretionary under Delaware law. Under Delaware law, we may
indemnify our
directors or officers or other persons who were, are or are threatened to be made
a named defendant or respondent in a proceeding because the person is or was our
director, officer, employee or agent, if we determine that the person: 

<TR>
<TD ALIGN="left" VALIGN="top">conducted
himself or herself in good faith; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">reasonably
believed, in the case of conduct in his or her official capacity as our director
or officer, that his or her conduct was in our best interests, and, in all other
cases,
that his or her conduct was at least not opposed to our best interests; and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">in the case of
any criminal proceeding, had no reasonable cause to believe that his or her
conduct was unlawful. </TD></TR></TABLE> These persons may be indemnified against expenses, including attorney
fees, judgments, fines,
including excise taxes, and amounts paid in settlement, actually and reasonably
incurred, by the person in connection with the proceeding. If the person is found
liable to the corporation, no indemnification shall be made unless the court in
which
the action was brought determines that the person is fairly and reasonably
entitled to indemnity in an amount that the court will establish. Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to our directors, officers, and controlling persons
pursuant to the
foregoing provisions, or otherwise, we have been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act of 1933 and is, therefore,
unenforceable.
FACE="Times New Roman" SIZE="2">In the event that a claim for indemnification
against such liabilities is
asserted by one of our directors, officers, or controlling persons in connection
with the securities being registered, we will, unless in the opinion of our legal
counsel the matter has been settled by controlling precedent, submit the question
of
whether such indemnification is against public policy to court of appropriate
jurisdiction. We will then be governed by the courts decision. 
 

SIZE="2">Certain Relationships and Related Transactions Certain Related Party Transactions Within The
Past Two Years. The following are certain transactions or proposed
transactions during
the last two years to which we were a party, or proposed to be a party, in which
certain persons had a direct or indirect material interest. Loan and Advances From Officers 
SIZE="2">During the years ended December 31, 2004, 2003, 2002 and 2001
certain officers and stockholders advanced to the Company approximately $25,000,
$9,000, $30,000 and
$29,000, respectively. Such advances are non-interest bearing and have no date of
repayment. During the years ended December 31, 2004, 2003, 2002 and 2001 the
Company made repayments of $15,000, $0, $10,000 and $0, respectively. 
<P
addition, certain advances due to stockholders and officers were offset against
payments
for stock purchased or options/warrants exercised. During the years ended
December 31, 2004, 2003, 2002 and 2001 the Company made repayments of
$15,000, $0, $10,000 and $0, respectively. <P
July 1, 2004, certain officers and stockholders agreed to forgive certain
fees and
advances. Under the term of the agreement, unpaid fees in the amount of $438,000
were forgiven. In addition, advances to the Company from officers aggregating
$11,000 were forgiven. Such forgiveness has been treated as a capital
contribution. At
December 31, 2004, the remaining unpaid balance of loans made to the Company
by officer was $8,000. Whitehall Financial <P
September 1, 2001 the Company entered into an agreement with Whitehall
Financial, LLC (former Quantum Financial Partners, LLC) (Whitehall) a
major
stockholder. Whitehall will provide the Company with marketing, management and
financial consulting services, assist the Company in preparing a business plan,
and provide the company with office facilities. The President and major
stockholder of
Whitehall, served as a Director of the Company. The agreement provides for the
Company to pay Whitehall $1,250 per month for space and office facilities for the
period from August 2001 through May 2002, $2,000 for the period from June 2002
through
May 2003, and $1,000 thereafter through September 30, 2004. </A>ORGANIZATION WITHIN LAST FIVE YEARS </A>DESCRIPTION OF BUSINESS Glyconix is a
development stage company that employs its proprietary processes to create drugs
with unique and enhanced properties by chemically binding small carbohydrate
(sugar) molecules to both novel and existing pharmaceuticals. The Companys
expertise
in sugar and medicinal chemistries is focused on three major market opportunities:
SIZE="1"> 1) The Company intends to expand its pipeline of
innovative proprietary anti-infective (e.g. antifungal,) and oncology drugs. Lead
drugs resulting from this work are already in preclinical development. 
2) The Company is supplying a unique compound currently in Phase
II trials for a cutting-edge mode of
cancer therapy. Currently, the Company generates revenues from the supply of this
compound. 3) The Company may apply its proprietary
technology toward meeting the needs of other companies in their management of
pharmaceutical product life cycles. This effort is eliciting significant interest
among
pharmaceutical companies seeking to extend the life of certain product lines.
SIZE="2">The Companys proprietary compounds offer substantial upside
potential, while the glycosylation technology is generating early revenue that may
mitigate the Companys financial needs and risk. A. CARBOHYDRATES AND
BIOLOGICAL
ACTIVITY Complex carbohydrates are chains
of sugar molecules
(monosaccharides). In living cells, these chains range in size from
two (disaccharides) to over one hundred
(oligosaccharides). The complexity of oligosaccharides arises from the
fact that their component
monosaccharides are diverse in number as well as in structure, thus giving rise to
a large number of potential combinations. For example, five given amino acids can
be arranged to give 120 different peptides whereas five given monosaccharides
(hexoses) can be arranged in 2,144, 640 oligosaccharides. It
is now known that
carbohydrates play a critical role in the way cells interact and communicate with
each other and their environment. Carbohydrate-containing molecules are involved
in blood clotting, inflammation, immune responses, tissue repair and regeneration,
as
well as bacterial and viral infections. Each cell type
(e.g., white blood
cells, cancer cells, etc.) carries a characteristic set of bioactive
carbohydrates, which allows them to be selectively recognized by other cells,
antibodies, and viruses, bacteria and toxins that bind to cell-surface
carbohydrates. For example,
migration of neutrophils, specialized white blood cells, to sites of acute
inflammation is initiated by cells lining the blood vessels, which recognize
neutrophil-specific carbohydrates as the neutrophils pass through the bloodstream.
Similarly,
cancer cells can be distinguished from normal cells by antibodies that recognize
the cancer-specific cell-surface carbohydrate antigens. Many pathogenic viruses,
bacteria and microbial toxins target their host cells through recognition of
specific
cell-surface carbohydrate receptors. Because of the role that bioactive
carbohydrates play in the body, numerous opportunities exists for therapeutic
products to be engineered that take advantage of carbohydrates to improve their
therapeutic
properties. B.
CARBOHYDRATES AND
THEIR EFFECT ON DRUG
ACTIVITY Recently, there has been renewed interest in
carbohydrate chemistry with the discoveries of the roles that carbohydrates and
carbohydrate moieties play in cell surface receptors, cell adhesion,
immunoglobulins, serum
proteins and tumor antigens. Management believes these discoveries are of major
importance to such fields as glycochemistry and glycobiology. Despite this renewed
interest in carbohydrate research, the number carbohydrate-containing drugs are
still
small. There are now more than numerous carbohydrate-containing drugs that have
been approved by the FDA or are in clinical trials. HIB (H. Influenzae)
vaccine, heparin and antibiotics like erythromycin are well-known carbohydrate-
containing
drugs currently in the marketplace. The expansion of drug
development in the
field of glycochemistry has been limited by the complexity of synthesizing or
scaling-up the production of complex carbohydrate-containing compounds. Most of
the carbohydrate-containing drugs that have been in use for a long time (e.g.
cardiac
glycosides, some 
antibiotics and antibiotic-derived cancer
chemotherapeutic agents) either occur in nature or are derived from naturally
occurring compounds that already have
sugar molecules attached. While the techniques to design
new and innovative
drugs composed completely of complex carbohydrates may eventually develop,
Glyconix is developing proprietary compounds by the addition of individual sugar
molecules or short chains of sugars to: 1) existing small molecule drugs which can
benefit
from improvement or; 2) innovative chemical compounds otherwise stymied in
development due to problematic physiochemical properties. A
valuable aspect of Glyconixs technology is its ability to capitalize on the
number of existing drugs which are coming off-patent during this decade. According
to
CIBC research (2001), SG Cowen Estimates from Pharmaceutical Industry Pulse, March
2003, the market for franchise extension, as illustrated by Figure 1 below, is
expected to be approximately $58.9 billion dollars over the years 2001 to 2010.
ALIGN="center">
<IMG SRC="g97153graph1.jpg" ALT="LOGO"> Source: CIBC
Research, FDA, IMS
Health and Company Estimates Attaching carbohydrates to
pharmaceutical
agents can substantially improve the properties of the agent. Carbohydrates are
easily absorbed in the digestive tract and when linked to pharmaceuticals that are
otherwise difficult to deliver orally, often enhance their solubility and
absorption.
Carbohydrates attached to drugs have demonstrated the ability to enhance the
ability of drugs to selectively target cancer cells, infectious organisms, and
cross the blood-brain barrier which limits or blocks the distribution of a drug to
the brain
and spinal cord. An example of a few compounds that have been recently reported
that increase the base drugs activity by specifically targeting or
exploiting the specific sugar transporters found in human or microbial cell
membrane. Some
examples are shown in Figure 2, below. 

bottom:0px" ALIGN="center">Figure 2 -
Glycosylated drugs
used for specific targeting or to exploit transmembrane glucose transport.
FACE="Times New Roman" SIZE="2">C. THE
COMPANYS GLYCOSYLATION
PROCESSES Management of the Company believes that its small molecule glycosylation
processes possess significant advantage compared to those currently used by other
pharmaceutical
organizations. These advantages, as determined by management, are detailed in the
Table 1 below: Table 1: Comparison of
Glyconixs Glycosylation Processes 
<TR>
New Roman" SIZE="1">Reaction Characteristics<HR WIDTH="91"
New Roman" SIZE="1">Conventional Glycosylation
Methods<HR WIDTH="88" SIZE="1" NOSHADE ALIGN="left"
COLOR="#000000"></TD>
New Roman" SIZE="1">Glyconixs Patented Glycosylation
Method<HR WIDTH="85" SIZE="1" NOSHADE ALIGN="left"
COLOR="#000000"></TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Catalyst</TD>
FACE="Times New Roman" SIZE="2">Harsh, very acidic</TD>
FACE="Times New Roman" SIZE="2">Mild, weakly acidic</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Temperature</TD>
FACE="Times New Roman" SIZE="2">High (> 50°C)</TD>
FACE="Times New Roman" SIZE="2">Room Temp (20°C)</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Time</TD>
FACE="Times New Roman" SIZE="2">Long (days)</TD>
FACE="Times New Roman" SIZE="2">Short (2- 4 hours)</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Yield</TD>
FACE="Times New Roman" SIZE="2">Low-Moderate</TD>
FACE="Times New Roman" SIZE="2">High</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Stereoselectivity</TD>
FACE="Times New Roman" SIZE="2">Moderate</TD>
FACE="Times New Roman" SIZE="2">Moderate</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Toxicity</TD>
FACE="Times New Roman" SIZE="2">Moderate-High</TD>
FACE="Times New Roman" SIZE="2">Low</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Cost</TD>
FACE="Times New Roman" SIZE="2">High</TD>
FACE="Times New Roman" SIZE="2">The iodine catalyzed glycosylation
reaction, shown in Figure 3, below, has several advantages over previously
developed methods. The reaction provides excellent yields of glycosylated primary,
secondary and tertiary alcohols ranging from 73-97% and glycosylated phenols from
59-75%. A
number of aprotic solvents can be used, in glycosylation process. Glycosylation
with disaccharides such as hexa-O-acetyl-D-maltal or hexa-O-acetyl-
D-lactal proceed equally well. These glycals along with other
monosaccharides and trisaccharide nona-O-acetyl-D-maltotriol can be
easily made utilizing a novel, general, one-pot preparation also developed in our
laboratories. Starting with compounds that would otherwise be damaged using the
conventional process, which applies to the majority of current drugs, can more
often be glycosylated using Glyconixs process. An
example of
one of the Companys glycosylation methods is illustrated in Figure 4, which
illustrates the glycosylation of cholesterol molecules, which are naturally
insoluble in water, as proof of principle. Cholesterol is the precursor of the
five major
classes of steroid hormones: progestagens, glucocorticoids, mineral corticoids,
androgens, and estrogens. Using Glyconixs proprietary method, various
sugar derivatives, the glucal, maltal, and lactal derivatives, of cholesterol can
all
be made extremely conveniently and efficiently in excellent yields. Subsequent
hydrolysis of the acetates provides the glycosylated cholesterols with free
hydroxyls that resulted in a significant increase in water solubility. 


Glycosylation of
Cholesterol The glycosylation of other compound classes (shown
in Figure
5), which represent some of the various chemical functional groups that can be
glycosylated, demonstrates the broad utility of this glycosylation method. Acid
sensitive functional groups, such as epoxides (as in epoxycholesterol), benzylic
alcohols
(chloramphenicol), and ß-hydroxy-d-lactones
(mevinolin), remain unaffected by the conditions employed and are thus
successfully glycosylated with
excellent yields. Phenols can also be glycosylated even in the presence of amides,
as in the case of acetaminophen (Tylenol®). Even anti-aromatic systems such
as 1,2-dithiins (a family of anti-fungal compounds) provide excellent substrates
for this glycosylation method. Several
pharmaceutical molecules have
been targeted as candidates for glycosylation. The initial candidate criterion
involves chemical feasibility, physical properties of the candidate, empirical
information on the drugs mechanism of action and the potential market of the
glycosylated
analog. The Company is also giving consideration to compounds with physical
drawbacks such as lack of solubility, poor absorption, high toxicity or poor
targeting. Classes of compounds the Company has targeted for
development includes anti-neoplastics (anti-cancer drugs and carbohydrate-
containing
compounds for use in boron neutron capture therapy [as described below]) and anti-
infectives where success in enhancing activity has already been established.
Roman" SIZE="2">D. PRODUCTS Glyconix has successfully glycosylated and demonstrated the enhancement
of activity and solubility of the camptothecins, a known class of anti-cancer
drugs, and
1,2-dithiins, a new class of anti-fungal agents. The company is also selling L-
BPAfor use in ongoing worldwide clinical oncology trials. 
<TR>
SIZE="2">1)</TD>
<TD ALIGN="left" VALIGN="top">ANTI-CANCER
AGENTS </TD></TR></TABLE> 
<TR>
SIZE="2">a)</TD>
<TD ALIGN="left" VALIGN="top">Glycosylated Camptothecin Derivatives 
STYLE="margin-top:0px;margin-bottom:0px">A
biologically important compound that has been a significant focus of our research
is camptothecin, the active anti-cancer component isolated from stem wood of the
Chinese tree Camptotheca acuminata. Camptothecin is responsible for single
strand breaks in DNA and RNA, and its mode of action was specifically established
as that of a topoisomerase I inhibitor by Dr. Wall at Research Triange
Institute. Development of camptothecin analogs led to the eventual approval of two
drugs (Figure 6), topotecan (Hycamtin® - GlaxoSmithKline), and irinotecan (Camptosar®, CPT-11 - Pfizer) by the FDA. Management believes that there
still exists the
need for an active topoisomerase I inhibitor without the serious side effects
present in the drugs that are currently sold on the market. With the initial aim of the solubility, delivery and activity of the
camptothecins, glycosylated analogs of 7-hydroxymethyl camptothecin were prepared
and submitted for
in vitro testing. The six analogs demonstrated significant growth
inhibitory activity against a broad range of tumor cell lines: P-388 (leukemia),
B16 (melanoma), HT-29 (colon cancer), and MCF-7M (breast cancer). The inhibition
of
topoisomerase I catalyzed relaxation of supercoiled SV40 DNA was also confirmed.
ALIGN="center">

Glycosylated Analogs
of 7-Hydroxymethyl Camptothecin The initial goal of increasing
the
solubility of camptothecin was successfully achieved with HAR6 (maltal derivative,
80 times more soluble than camptothecin by weight) and HAR7 (glucal derivative,

17 times more soluble than camptothecin).
The topoisomerase I IC50 for HAR7 was significantly lower than that for 7-
hydroxymethyl camptothecin (HAR8) and for
camptothecin itself (HAR1). Based on our studies the in
vitro
topoisomerase I activity and cell culture growth inhibition, the four analogs HAR
4-7 were advanced to in vivo screens while additional glycosylated analogs
are being prepared for in vitro and in vivo studies. In the B16
melanoma in vivo test results using ten animals per group, HAR5 was found
to be comparable to topotecan with Treatment/Control (T/C) survival ratios of 239%
and 235%, respectively; but, HAR5 was vastly superior with respect to long term
survivors (3 vs. 0). The T/C ratio is a standard measure of the survival used by
the National Cancer Institute where 100% indicates that the length of survival of
the treated group is equal to that of the control group. A T/C ratio of 200%,
therefore, indicates that the length of survival of the treated group is twice
that of the control group. In the P388 leukemia model, HAR6, HAR7 and topotecan
each had three long-term survivors, with HAR6 having the highest T/C (320%,
considered
curative), followed by topotecan (297%) and HAR7 (223%). Finally, in the
human breast tumor (MX-1) xenograft model, remarkably all ten mice treated with
HAR7 had mean tumor shrinkage of 98% as opposed to six of the topotecan treated
mice with a
mean shrinkage of 94%. Because of its superior
topoisomerase I inhibitory
activity and remarkably good results in both the B16 melanoma and P388 leukemia
models as well as its near curative results in the MX-1 breast tumor xenograft,
HAR7 was further evaluated in two additional in vivo efficacy modes each
using two
different treatment schedules with topotecan as an internal positive control.
SIZE="2">Against both of these tumor models, HAR7 out-performed
GlaxoSmithKlines topotecan both as a single dose as well as when
administered once daily for five days (Figure 8). Significantly, in the SK-MES
human lung cancer xenograft model,
HAR7, when administered at a dose of 30mg/kg/day for 5 days, had two complete
responses and comparable growth inhibition to topotecan at 4 mg/kg/day with two
partial shrinkages. However, at these doses the mice treated with topotecan
suffered a 22%
weight loss whereas the mice treated with HAR7 had a 4.7% weight gain. In the PC-3
human prostate cancer xenograft model, HAR7 easily out-performed topotecan in both
the single dose as well as the 5-day schedule. Interestingly, HAR7 has very good
activity even when it is administered as a single dose, whereas topotecan is
essentially inactive at its maximum tolerated dose. 

Activity of
Glycosylated Analog of Camptothecin in Animal Models of Human Prostate & Lung Cancer 
In 2004 The Company developed a proprietary derivative compounds of HAR
series. The compounds, designated as GLY 100X are
singe alpha anomers of the predecessorss mixture of alpha and betta anomers.
The company is in the process of appllying for the new US and International
patents To verify the biological activities of these
single anomers, Glyconix carried out a small animal tests at Arizona Canncer
Center in 2005.for
2 compounds, namely, glucal and rhamnal analogs of the methyl camptothecin, GLY
1001 and GLY 1002 respectively. <P STYLE="margin-top:0px;margin-
these studies GLY-1001 and GLY-1002 were submitted for evaluation against HT-29
colorectal cancer in severe combined immune deficient (scid) mice by Glyconix,
Inc.
GLY-1002, GLY-1001, and CPT-11 (Pfizers drug Camptosar) were administered by
intraperitoneal injection every other day for a total of six injections The GLY-
1001 35 mg/kg and GLY-1002 5 mg/kg had marked tumor volume reduction as compared
to
controls. This was significant for survival, ( See Figure 8A) but not in tumor
growth or latency. 

bottom:0px">Fig. 8A. <P
demonstrated in Figure 8A, the tumor volume reduction was greatest and shifted to
the
right in the mice treated with GLY-1001 35 mg/kg and the GLY-1002 5 mg/kg. This
coincides with each group respectively having the longest survival (Figure 6) with
a median survival time of 65 days post pair-matching followed closely with a
median
survival time of 60.5 days. This is highly statistically significant (Table 5 of
Appendix A) compared to the CPT-11 25 mg/kg treatment group (median survival time:
53.5 days) and the negative control (median survival time: 35 days). 
in vitro and in vivo
studies
with GLY 1001. The compound will be scaled-up for manufacture of a clinical grade
material and undergo animal pharmacology and toxicology studies with the goal of
submitting an IND for Phase I clinical trials in18-20 months. The strategic goal
is to
develop the compound through Phase IIA clinical studies and license the compound
for the remainder of the clinical development process to an appropriate partner
company. Clinical development, up to Phase IIA, will be done within 3 years.


WIDTH="100%">
<TR>
SIZE="2">b)</TD>
<TD ALIGN="left" VALIGN="top">Boron
Neutron Capture Therapy Products </TD></TR></TABLE> Boron Neutron Capture Therapy (BNCT) is a form of cancer treatment that
brings together two components that individually have little effect on normal
tissue. The first
component is a chemical compound that contains boron-10, a non-radioactive isotope
of boron, and the second is a beam of neutrons. When injected into the body, the
boronated compound (L-BPA-fructose) concentrates preferentially in cancerous
cells.
When exposed to a neutron beam, the L-BPA-fructose (L-BPA-F) will absorb a
neutron. The ensuing fission reaction generates a high burst of kinetic energy
limited in range to the diameter of cancer cells. Under the proper conditions,
cancerous cells
can be effectively destroyed while neighboring healthy cells are unaffected.
SIZE="2">Glyconixs research team has developed a large body of intellectual
property over the course of its BNCT activities, including patent and a client
list that includes leading research and medical centers in the United States and
abroad.
Glyconix is currently supplying L-BPA, a precursor compound containing boron-10,
to clinical trials worldwide. L-BPA is poorly water soluble, does not accumulate
well in cancer cells and does not cross the blood-brain barrier effectively. The
complexing of the L-BPA with carbohydrate, fructose, alters these characteristics
by increasing solubility of the compound at physiological conditions, and
facilitates the crossing of the blood-brain barrier and preferential uptake into
the cancer
cells. Although treatments such as surgery, chemotherapy,
and radiation have
successfully treated many types of cancer, there are some forms for which BNCT may
be the best treatment option. In recent years there have been two groups in the
United States using the epithermal neutron beam approach to treat patients on an
experimental basis. In 1994, the Brookhaven Medical Research Reactor received
approval from the Food and Drug Administration (FDA) to treat 28 patients dying of
GBM (glioblastoma multiforme).In 1995 MIT began clinical BNCT trials. Phase I/II
trials
in Sweden are demonstrating L-BPA-Fs and BNCTs promise as a cutting-
edge cancer treatment. BNCT can be administered in a matter of hours as a one-time
outpatient procedure with few or no side effects (based on current trial results).
FACE="Times New Roman" SIZE="2">In one case, a patient with just a couple of
months to live with metastatic
cancer in the liver, received treatment and after 18 months has experienced no
recurrence or serious side effects. (Source: 10th ISNCT Congress, Essen, Germany 2002) Glyconix is supplying L-BPA to Harvard/MIT, Studsvik (Sweden), and The
National Commission of
Atomic Energy in Argentina, and fulfilled the orders in the UK and Finland.
Clinical trials are currently in Phase I/II in Europe and are anticipated to
progress to larger scale Phase III trials in the near future. Once BNCT receives
regulatory
approval within the next 3-4 years, the Company will position itself to become the
preferred supplier of L-BPA to the global market. Glyconix also holds the
proprietary rights on the high yield synthesis of L-BPA-fructose and is developing
an
enhanced second-generation proprietary compounds. Glyconix will
selectively
continue to explore BNCT therapy and continue developing and supplying BNCT
products and delivery systems, albeit on a secondary level. The company will exert
the majority of its efforts on its core glycosylation chemistry for discovery and
development of its proprietary small molecule therapeutics for use in oncology and
infectious disease. 
<TR>
SIZE="2">ANTI-INFECTIVE
AGENTS </TD></TR></TABLE> 
<TR>
SIZE="2">a)</TD>
SIZE="2">Antifungal Glycosylated 1,2-Diithin Derivatives 
SIZE="2">Fungal infections (mycoses) cause a wide variety of diseases in humans.
Superficial fungal infections routinely affect the nails, skin and hair. Serious
fungal infections
can be a devastating event for those that have compromised immune systems as the
result of other underlying diseases (e.g. AIDs and cancer) or treatment for
disease (e.g. anti-rejection drugs associated with organ transplantation,
chemotherapy).
According to the Centers for Disease Control, we have seen a rise of 100% in the
incidence of serious fungal infections during the past 20 years. For
the past 40 years, serious fungal infections have been treated with the polyene
and azole classes of drugs with significant expense and toxicity associated with
the
former and rapid development of drug resistance to the latter. A new class of
antifungal agent, the echinocandins, has emerged in the past two years. In
managements opinion, these agents are extremely expensive, parenterally
administered and
are exhibiting drug-drug interactions and resistance. Management believes a new
class of less expensive, and more affective anti-fungal agents would be welcome.
It appears to management that Glyconix may have an entirely new class of anti-
fungal
agents. In the mid 1980s, a new family of compounds,
thiarubranes, were
isolated from the leaves of Aspilia africana which were being ingested by
chimpanzees in the wild (Source: Towers G.H.N. et al., Planta Medica 1985, 3 3225-
3229). Due to the wide spectrum of antifungal, antiparasitic and anti-viral
activity
exhibited by this class of compounds, an increasing amount of attention has been
paid to this class of sulfur containing heterocyclic compounds. The 1,2-dithiins
display similar activity to thiarubranes A but like the parent compound are poorly
soluble in water. It was envisioned that the low water solubility could be
increased in this class of compounds, while also taking advantage of active
transmembrane glucose transport by the fungi, by preparing glycosylated analogs of
3,6-bis
(hydroxymethyl) 1,2-dithiin (Figure 9). 

Some Active
Anti-Fungal Dithiins. As expected, the glycosylation
of the 1,2-dithiins
significantly enhanced their water solubility. These derivatives were then tested
against four different fungi responsible for human disease and the results
demonstrated a significant increase in activity (Figure 10). The di-glycosylated
analogs,
synthesized using Glyconixs proprietary process, showed a large reduction in
the Minimum Inhibitory Concentration (MIC) of the analogues required
to inhibit 90% of the growth of the various fungi. The decrease by up to
thirteen-fold in the MICs of the analogues, when compared to the parent 3,6-
hydroxymethyl 1,2-dithiin, represents a substantial increase in intrinsic in vitro
anti-fungal activity. Additional analogs are presently being prepared and tested
in vitro
in order to establish the most active of this series for testing in vivo.

The Effect of
1,2-Dithiins and Glycosylated Derivatives on Pathogenic Fungi in vitro and in vivo studies
with several existing and additional analogs to advance further at least one
candidate compound currently in development. The compound will be scaled-up for
manufacture
of clinical grade material and undergo animal pharmacology and toxicology studies
with the goal of submitting an IND for Phase I clinical trials in just over 18
months. The strategic goal is to develop the compound through Phase IIA clinical
studies
and license the compound for the remainder of the clinical development process to
an appropriate prospective partner company. Management has not identified such
prospective partner company as of this date. 
<A NAME="tx97153_24"></A>BUSINESS STRATEGY Glyconix is
initially focused
on developing proprietary pharmaceuticals for the treatment of cancer and
infectious diseases. Glyconixs in-house organization concentrates on the
identification of lead chemical compounds and the management of all other aspects
of discovery
and development which will be outsourced using academic collaborators, private and
governmental research institutes, consultants, partner companies, commercial
vendors and eventually clinical research organizations (CROs).
The
Companys proprietary technology enables it to eventually capitalize on the
high margin returns of successful pharmaceutical agents while mitigating some of
the risks of proprietary drug development. Glyconix is mitigating risk three
separate
ways: 1) Mitigating risk by enhancing
the activity of drug
classes with previously established clinical activity. A number of factors, in
managements opinion, can result in the failure of proprietary drugs during
the development process. These factors include poor absorption or delivery of the
drug, toxicity, or failure to have a clinical effect. By glycosylating classes of
drugs with established clinical activity while improving their properties, the
risks of proprietary drug development are reduced. Often the addition of
carbohydrates
to small chemical molecules will increase their solubility and deliverability,
enhance targeting of the drug and potentially reduce toxicity. 2) Mitigating risk by developing diverse proprietary drugs in
diverse clinical indications. The enabling technology allows for the
glycosylation of
up to 30% of the over $58.9 billion worth of drugs coming off-patent (2001 -
2010); it also allows for the development of compounds that were otherwise stymied
in development due to factors such as poor water solubility. The ability to
development
of different proprietary agents in different clinical indications simultaneously
reduces the exposure of the Company to the failure of any specific clinical
program. 3) Mitigating risk by early
revenue generation. The Company is currently generating revenue through the
supply of a
chemical compound to later stage clinical trials. This near-term opportunity,
which is already being exploited, involves the supply of L-BPA to research
institutes conducting Phase I & Phase II clinical trials of L-BPA-F (L-BPA
complexed to
fructose, a small sugar molecule) in BNCT in cancers of the brain (glioblastoma)
and other malignancies. A. PRODUCT
DEVELOPMENT STRATEGIES <P STYLE="margin-
Company is developing several promising compounds that management believes benefit
from glycosylation. The Company plans to take compounds through pre-clinical
development, which include determining a safe starting dose for human clinical
trials, clinical protocol design and securing the manufacturing of clinical supply
material. The company will then file an IND (Investigational New Drug) application
with
the U.S. Food & Drug Administration (FDA) or its international regulatory
counterparts. Upon acceptance of the IND by the FDA, Phase I clinical trials will
be performed to establish the safe dose range of the investigational drug.
Following
successful Phase I studies, Phase II studies will be conducted in limited
populations to determine the most efficacious dose prior to larger 
Phase III studies in broader populations in
a disease indication. Anticipated time frame from the lead compound to the
completion of the Phase IIA is 3.5 to
4 years. Anytime during the preclinical and clinical
development programs, the
Company will have the option to proceed on its own or to seek a suitable partner.
Given the Companys size, it is anticipated that the Company will seek a
suitable partner for drug development beyond the early-stages of clinical
development for
the foreseeable future. Management has not identified such prospective partner
company as of this date. 
<TR>
SIZE="2">GLYCOSYLATED CAMPTOTHECIN
DERIVATIVES </TD></TR></TABLE> The Company plans to perform additional limited
in vitro and in vivo studies with GLY 1001 and a few additional
analogs to
advance further at least one candidate compound currently in development. The
compound will be scaled-up for manufacture of clinical grade material and undergo
animal pharmacology and toxicology studies with the goal of submitting an IND for
Phase I
clinical trials in just over one year for the point of adequate financing. The
strategic goal is to develop the compound through Phase IIA clinical studies and
license the compound for the remainder of the clinical development process to an
appropriate partner company. Management has not identified such prospective
partner company as of this date. The currently marketed camptothecin analogs are
indicated for the treatment of colon cancer (irinotecan) and ovarian and small
cell lung cancer (topotecan). Initial animal efficacy studies of the
Companys
compounds demonstrated activity in a broad range of tumor types including non-
small cell lung cancer, prostate cancer and breast cancer. The initial clinical
indications for Phase II studies will be determined on the basis of additional
animal
efficacy studies, animal tissue distribution studies, and patient response
information obtained during Phase I human pharmacokinetic and safety trials. The
choice of initial indications studied in Phase II will be influenced by an
analysis of: 1)
the disease populations that have high unmet needs which may lend themselves to
accelerated approval strategies; 2) the stage of development of other competing
agents which may impact routes to approval and patient availability for clinical
trials.
WIDTH="100%">
<TR>
SIZE="2">GLYCOSYLATED 1,2-DITHIIN
DERIVATIVES </TD></TR></TABLE> The Company plans to perform additional in
vitro and in vivo studies with several existing and second generation
of analogs to
advance further at least one candidate compound currently in development. The
compound will be scaled-up for manufacture of clinical grade material and undergo
animal pharmacology and toxicology studies with the goal of submitting an IND for
Phase I
clinical trials in 18 to 24 months. The strategic goal is to develop the compound
through Phase IIA clinical studies and license the compound for the remainder of
the clinical development process to an appropriate partner company. Serious fungal infections have been treated with the polyene, azole, and
more recently,
echinocandin classes of drugs. The parenterally administered polyene and
echinocandin classes are very expensive; the former is associated with kidney
toxicity while drug resistance is already being seen with the latter. The azoles,
although
inexpensive and may be administered orally, exhibiting a high level drug-drug
interactions and resistance by many species of fungi. There is a need for a new
class of less expensive, orally administered agents. <P
initial clinical indications for the glycosylated 1,2-dithiin derivatives will be
in
patients with serious fungal infections. It is our expectation that these agents
will likely be orally administered or can be made 
into topically administered formulations
allowing for the eventual expansion into the larger superficial fungal disease
indications. 
<TR>
SIZE="2">BORON NEUTRON CAPTURE
THERAPY PRODUCTS
</TD></TR></TABLE> Glyconix is generating revenue by supplying L-BPA to Harvard/MIT,
Studsvik (Sweden), and The
National Commission of Atomic Energy in Argentina, Cancer ResearchUK and Boneca in
Finland. Clinical trials are currently in Phase I/II in Europe and are anticipated
to progress to larger scale Phase III trials in the near future. Management believes that once BNCT receives regulatory approval, the
Companys
proprietary knowledge of the manufacturing process will position it to become the
preferred supplier of L-BPA to the global market. Glyconix also holds a patent on the process for high yield synthesis of
L-BPA-fructose. Currently, clinical trial sites are acquiring L-BPA and performing
complexing
procedure with fructose on site. Scaled-up manufacturing of L-BPA under cGMP
conditions is currently carried out in Sweden by Syntagon AB. Glyconix has an
exclusive worldwide distribution rights to this product Fructose was originally explored as a complexing agent with L-BPA since
it was known to form
an effective complex with boronic acid. The Companys recently issued patent
includes numerous monosaccharides, disaccharides and polyols with similar
complexing properties to that of fructose. Some of these compounds may enhance
selective
uptake by specific organs and any tumor cells present in those organs. Glyconix is
also developing enhanced second-generation proprietary compounds with
characteristics that will optimize further the BNCT therapy. The Company
intends to
collaborate with qualified institutions and or commercial partners to explore the
efficacy of these new compounds. Glyconix will selectively continue to explore BNCT therapy and continue
developing and supplying BNCT products and delivery systems, albeit on a secondary
level. The
Company will exert the majority of its efforts on its core glycosylation chemistry
for discovery and development of its proprietary small molecule therapeutics for
use in oncology and infectious disease. 
<TR>
SIZE="2">OTHER PRODUCT
OPPORTUNITIES </TD></TR></TABLE> Management estimates that the market for life
cycle extension of existing drugs is expected to be over $58.9 billion between
2001 and 2010.
The Companys proprietary glycosylation process could potentially be applied
to numerous types of drugs with an immediate addressable market opportunity of up
to $10 billion. No assurances can be given that the Company will achieve such
revenues. Although it is not the primary focus of the Company, Glyconix will be
opportunistic in developing collaborative relationships for drug development with
other pharmaceutical and biotechnology companies that may benefit from the
proprietary
technology to extend their existing drug franchise or advance compound classes
stymied in development. Limited revenue from these partnerships may also serve to
mitigate some of the risk associated with Glyconixs proprietary drug
development
programs. B.
INTELLECTUAL
PROPERTY Glyconix, incorporated in August
2001, acquired its
intellectual property from Glycosyn Pharmaceuticals, Inc. (Glycosyn)
and New Concept Therapeutics, Inc. (NCT). Glycosyn was founded in
March 1993 as a wholly owned subsidiary of Harrier, Inc. Glycosyn was established
as a
research company to exploit unique glycosylation chemistry and to apply this
chemistry toward development of novel anticancer and 
anti-fungal compounds. In 1996, Glycosyn
established a laboratory in Cary, NC with research commencing there in October of
that year. New
Concept Therapeutics, Inc., a North Carolina corporation, was formed in June 1997
to
position itself as the leading producer of neutron capture therapy compounds and
as a developer of novel drug compounds using the Glycosyn chemistry. Production
and initial sales of BNCT compound L-p-BPA began in June, 1998. Based on extensive laboratory work and acquired technologies, the Company
has an amount of
patentable drug, drug delivery and process know-how in both basic glycosylated
drug molecules and in the BNCT compound L-BPA-Fructose. <P
Companys patent portfolio has several wholly owned patents and five
exclusive options to license patents and consists of five patent families:
Camptothecin,
Dithiin, Fusidic Acid, Glycoside, and P-Boronophenylalanine. These families
includes 11 issued U.S. Patents, 2 Swiss Patents, 2 German Patents 2 French
Patents, 3 British Patents, 2 Swedish Patents, 1 Taiwanese Patent, 1 Spanish
Patent, 1 Italian
Patent, and 1 Irish Patent. In addition 1 Japanese and 2 Canadian Applications are
currently pending. 
<TR>
<TD ALIGN="left" VALIGN="top">The
Camptothecin family consists two U.S. Patents: No. 5,677,286 and
No. 5,932,709. In addition, the International Application No. PCT/US96/05766
was submitted.
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">The Dithiin
family includes one U.S. Patent No. 5,453,500. In addition, the International
Application No. PCT/US95/06715 was submitted and a European National Entry
Application
in this family was granted and subsequently validated in Switzerland (CH), Germany
(DE), Spain (ES), France (FR), Great Britain (GB), Italy (IT), Ireland (IE), and
Sweden (SE). </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">The Fusidic
Acid family consists of three U.S. Patents: No. 6,103,884, No. 6,462,182
and No. 6,720,307. The Glycoside family includes four U.S. Patents:
No. 5,278,296, No. 5,496,806, No. 5,693,767 and No. 6,093,805.
The Company owns Patens No. 5,278,296 and No. 5,496,806.
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">The Glycoside
family also includes two PCT Applications submitted to the United States receiving
office. The first of these in International Application No. PCT/US92/06063 and a
European National Entry Application in this family was granted and subsequently
validated in Switzerland (CH), Germany (DE), France (FR), Great Britain (GB) and
Sweden (SE), and that a Taiwanese (TW) patent has also issued. Moreover, national
entry
applications were also filed in Israel, China, Japan and Canada, and only the
Canadian national entry application is still pending. </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">The P-
Boronophenylalanine family includes one U.S. Patent No. 6,169,076, owned by
the Company. Corresponding Japanese and Canadian patent applications are currently
pending,
and the European National Entry Application was granted and subsequently validated
in Great Britain (GB). </TD></TR></TABLE> C. FACILITIES Glyconix has a fully equipped and functional chemical research and
working space for up to 7
chemists in Research Triangle Park, North Carolina. The laboratory is
approximately 3,000 square feet. Previously, the Company conducted its research
and development through leased lab space in Cary, North Carolina The lab had
capacity to synthesize
L-BPA product on a kilogram scale. The Companys corporate office is located
in New York. 
<A NAME="tx97153_25"></A>THE MARKET. A.
PHARMACEUTICAL INDUSTRY OVERVIEW
SIZE="2">Glyconixs technology provides for proprietary drug development
across the full range of the worldwide pharmaceutical market. According to
Intercontinental Marketing Services (IMS), the worldwide
pharmaceutical market for
2002 was estimated to be over $406 billion, of which $169 billion was in the
United States. The total market is broken down into individual therapeutic
categories such as cancer, cardiovascular, infectious disease, metabolic
(diabetes), inflammation
and pain, central nervous system, gastrointestinal and respiratory. There exists a
wide variety of disease states within each of these categories. Each market segment has its own size, competitive dynamics, growth rate
and new discovery characteristics. Glyconix has targeted markets with the highest
medical,
technological and economic unmet needs, taking into consideration where the
Companys specific technologies are of the greatest value. Specific target
markets that meet these criteria include the anti-cancer and anti-infectives
markets.
Products in these categories tend to have significant toxicities, problems with
solubility and delivery, or the development of disease resistance to the available
drugs. These are problems which may be addressed by Glyconixs technologies
and
are the initial focus of the Company. B.
THE
ANTI-CANCER MARKET <P
immense
size of the market for cancer therapeutics is well known within the industry. In
2005, there are estimated to be approximately 1,440,000 new cases of cancer
diagnosed in the U.S. alone, excluding basal and squamous cell cancers of the
skin. Western
Europe and Japan have reported an even higher number of cases. (Source: S.G. Cowen
Research, March 2005, Therapeutic Categories Outlook). Most patients will receive
some form of chemotherapy during the course of their disease. The cancer
chemotherapeutics market was valued at $15 billion in 2004 and is expected to grow
to $23,755 billion by 2009, with the majority of cases and expenditures occurring
outside of the United States.(Source: S.G. Cowen Research, March 2005, Therapeutic
Categories Outlook). This chemotherapeutics market falls squarely within the
scientific target markets for Glyconix. Table 2: Common Cancers
and Their U.S. Market Characteristics 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
New Roman" SIZE="1">Cancer Type<HR WIDTH="67" SIZE="1" NOSHADE
SIZE="1">Annual Cases <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Cases Amenable to Treatment <HR SIZE="1"
ALIGN="center">Maximum New Product Penetration Rate<HR SIZE="1"
New Roman" SIZE="1">Present Market Condition<HR
WIDTH="138" SIZE="1" NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">Prostate</TD>
SIZE="2">220,900</TD>
SIZE="2">90,000</TD>
<TD VALIGN="bottom">Hormonal therapy,
estramustine</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Breast</TD>
SIZE="2">212,900</TD>
SIZE="2">176,000</TD>
<TD VALIGN="bottom">Many products
active</TD></TR>
FACE="Times New Roman" SIZE="2">Lung</TD>
SIZE="2">171,900</TD>
SIZE="2">153,000</TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="top">Taxanes, platinum
compounds, navelbine</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Colon</TD>
SIZE="2">147,500</TD>
SIZE="2">75,000</TD>
<TD VALIGN="bottom">5-FU, irinotecan,
oxaliplatin</TD></TR>
FACE="Times New Roman" SIZE="2">Melanoma</TD>
SIZE="2">54,200</TD>
SIZE="2">30,000</TD>
<TD VALIGN="bottom">No effective agents for
metastases</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Non-Hodgkins Lymphoma</TD>
SIZE="2">53,400</TD>
SIZE="2">55,000</TD>
<TD VALIGN="bottom">Many compounds
FACE="Times New Roman" SIZE="2">Leukemia</TD>
SIZE="2">30,600</TD>
SIZE="2">28,000</TD>
<TD VALIGN="bottom">Many compounds

SIZE="2">The annual disease incidence for some common cancers and their market
characteristics are listed in Table 2. (Source;
University of Pennsylvanias OncoLink; SG Cowen Research, March 2005 and
National Cancer Institute estimates). An ideal area for drug development is one in
which there are many patients for whom there are presently few or no effective
treatments, such as lung, colo-rectal and prostate cancers. Most cancer drugs
are characterized as being highly toxic, only marginally effective and often
require the patient to receive protracted intravenous infusions at the
oncologists office or requiring hospitalization. Glycosylation of cancer
drugs may address and
improve on some of these shortcomings. Carbohydrates, when linked to
pharmaceuticals that are otherwise difficult to deliver orally, often enhance the
drugs solubility and absorption. Carbohydrates attached to drugs have demonstrated
the ability to
enhance the ability of drugs to selectively target cancer cells and cross the
blood-brain barrier which limits or blocks the distribution of a drug to the brain
and spinal cord, a common site of metastases. <P
Company has patents on camptothecin derivatives for cancer treatment. Glyconix has
also
researched the feasibility of applying its chemistry and expertise toward the
development of glycosylated analogs of the platinum compounds (i.e. cisplatin,
carboplatin) and of the taxanes (e.g. paclitaxel). The platinum compounds and the
taxanes
are among the most widely used classes of cancer drugs. C.
THE ANTI-FUNGAL MARKET
SIZE="2">The worldwide market for treatment of serious invasive fungal infections
reached $3.8 billion in 2004 , one of the largest categories of the anti-infective
market, excluding anti-virals and cephalosporins. (Source: S.G. Cowen, 2005
Therapeutic Categories Outlook) For hospital-based indications, mortality rates
associated with invasive fungal infection remain high. Existing products have
serious shortcomings including low tolerability, drug delivery limitations, and
drug-drug
interactions. There remains a significant need for a broad-spectrum therapy with
an improved safety profile. Until recently, there were only two major products in
the category, Pfizers Diflucan and Johnson & Johnsons
Sporanox.
Fungi are also often difficult to treat and fungal infections have been a serious
complication of the AIDS epidemic. While the somewhat successful treatment of AIDS with anti-virals (AZT)
serves as a partial solution to this problem, several major companies continue to
work on new
antifungal drugs (Ravuconozole, Bristol Myers;. Cancidas, Merk). In addition, Elan
introduced a lipsomal form of Amphotericin-B and Gilead Science sells liposomal
Amphotericin-B overseas. While they may modestly reduce the toxicity to the
kidneys
associated with Amphotericin therapy, the liposomal formulations are expensive.
SIZE="2">Glyconixs candidates in this category are glycosylated analogues of
the 1,2-dithiin molecules. The Company has been able to increase the anti-fungal
properties in vitro while solving the solubility problems of the original
parent dithiin molecules. While the initial clinical indications for the
glycosylated 1,2-dithiin analogues will be in patients with systemic fungal
infections, it is our managements expectation that these agents will likely
be orally
administered or can be made into topically administered formulations allowing for
the eventual expansion into the larger superficial fungal disease indications
which comprised the larger portion of the worldwide market for antifungals
projected to
exceed $5.0 billion in 2005. Antifungals are a natural and
highly promising
therapeutic category for Glyconix to complement its work in camptothecin and BNCT.
Glyconix possesses a patent for the glycosylated analogues of the dithiins.

Roman" SIZE="2">D. THE BORON NEUTRON
CAPTURE
THERAPY (BNCT) MARKET BNCT therapy
is a potential new drug treatment mode in what is now a growth market, with an
initial emphasis on cancers of the brain. Although the compounds used in BNCT were
first made in the 1950s and 1960s, the market for them did not develop
until research provided many improvements in the technology for producing neutron
beams in the late 1980s and early 1990s. Since the technological
improvements, there has been an accelerating pace in the clinical development of
testing
of neutron excitation of boron-10 based compounds to selectively kill cancer
cells. Management believes that indications are that research will grow rapidly in
the near future for the treatment of glioblastoma, melanoma and other more common
solid
tumors including metastatic disease to the brain and liver (Source: 11th ISNCT Congress, October 2004,
Boston).
FACE="Times New Roman" SIZE="2">The company is currently selling L-BPA to centers
conducting BCNT clinical
trials worldwide. The first clinical indications that are being pursued are two
uniformly fatal diseases, glioblastoma multiforme and melanoma. According to the
American Cancer Society, glioblastoma multiforme is a highly malignant brain tumor
which
accounts for approximately 9,000 of the 17,000 new cases of primary brain tumors
diagnosed annually in the United States. The disease has a 91% mortality rate at
two years even when treated with surgery, chemotherapy and radiation. Most
patients
currently receive radiation therapy five days per week for 5 to 7 weeks. While
patients initially respond to radiation therapy, recurrence is the rule.
Management believes, based on general knowledge in the industry, that the U.S.
market for
radiation therapy for glioblastoma patients alone is approximately $125 million.
SIZE="2">The Harvard-MIT BNCT program is desegned to conduct the following
clinical trials: 1) A Phase I/II trial in patients with glioblastoma multiforme
and intracranial melanoma; 2) A Phase II trial in patients with melanoma. Phase II
clinical
BNCT trials for treatment of glioblastoma multiforme are occurring in Sweden,
Finland, the Czech Republic, and Japan. The Phase II trials in Sweden are being
conducted at Studsvik Medical AB in patients who have not received any therapy
other than
surgery and as a palliative treatment for patients with recurrent glioblastoma
following conventional or BNCT therapies. Successful clinical trials in glioblastoma patients will likely, in
managements opinion, cause the expansion of clinical trials into other brain
tumors including
those from metastatic lesions from other solid tumors (e.g. lung cancer, breast
cancer). Our current clinical trials indicate that the targeted BNCT therapy
requires only one treatment to effect tumor regression unlike the conventional
daily
fractionated dose approach with radiation therapy as described above. This may
provide an advantage to patients by reducing the overall time spent receiving
therapy. The incidence of side effects may also be reduced since the neutron beam
does not
appear to induce significant injury to normal tissues. BNCT may eventually become
an alternative to radiation therapy in a broader range of cancer indications.
Management believes, based on general knowledge in the industry, that the
worldwide
market for radiation therapy for all tumor types is approximately $3 to $5
billion. The Company has proprietary technology for the manufacture of L-BPA. Once
BNCT receives regulatory approval, management believes that the Companys
superior proprietary manufacturing process will position it to become the
preferred
supplier of L-BPA to the global market. Scaled-up manufacturing of L-BPA under GMP
conditions has been achieved. Glyconix has an exclusive rights to distribute
world-wide cGMP product. Glyconix also holds the proprietary rights on the
process for high yield synthesis of L-BPA (trade secrets). The Company has also
received a
patent for a freeze-dried version of the L-BPA-fructose complex used in BNCT
therapy. The purity and low manufacturing cost of the Companys L-BPA and L-
BPA-fructose should continue to enhance the Companys ability to take a very
significant share of the market. The unique requirement of a nuclear reactor or
accelerator to produce the requisite neutron beam 
limits the number of customers in need of L-
BPA. The marketing resources required, therefore, are significantly reduced and
can be handled by a small
company. While clinical trials worldwide are in Phase II
and are projected to
enter larger scale Phase III trials in the next 2 years (managements
estimate) neither the FDA nor European regulatory bodies have yet approved BNCT or
the products used in BNCT. There can be no assurance that any products will be
approved in
the future. E.
COMPETITION &
COMPETITIVE ADVANTAGES 
<TR>
SIZE="2">1)</TD>
SIZE="2">GLYCOSYLATION
TECHNOLOGY </TD></TR></TABLE> Glyconixs niche is in creating proprietary
compounds, patentable as new composition of matter, out of existing small
molecules with
its proprietary glycosylation technology. There are really two classes of competitors. <P
first class of
competitors are those companies that, similar to Glyconix, are creating compounds
that can be covered by new composition of matter patents through glycosylation.
Neose Technologies, Inc., Momenta Pharmaceuticals, Inc., GlycoGenesys Inc, and
Pro-Pharmaceuticals, Inc. all have business models that are similar to Glyconix.
Glyconix is focused exclusively on glycosylating small molecules. In comparison,
Neose is exclusively glycosylating proteins. GlycoGenesys is working on
carbohydrate-based drug candidates. Pro-Pharmaceuticals is attempting to enhance
the delivery of anti-cancer agents using proprietary formulation with
carbohydrates. Momenta Pharmaceuticals is focused on improving existing and
developing novel drugs
based on the complex carbohydrates (heparin). The second class
of competitor
is those companies that are developing drugs that may compete with Glyconixs
proprietary compounds in various clinical indications. Cell Therapeutics, Inc.
(CTI) and Enzon Inc. are trying to develop camptothecin derivatives which improve
upon
the poor water solubility of the current commercial compounds, irinotecan and
topotecan. CTI is using a proprietary glutamic acid polymer which is a large
molecule making it a less desirable, and potential more expensive to manufacture,
end product
than Glyconix small molecule products. Enzon is using polyethylene glycol in
a similar manner to develop its camptothecin derivative. CTI and Enzons
polymer derivatives are delivered intravenously and will not be orally
bioavailable.
Glyconixs products are targeting oral delivery which is an advantage in the
marketplace. Glyconixs competitive advantage is its
proprietary technology which enables it to glycosylate small molecules. The
glycosylation of most small molecules is extremely difficult especially in
scaling-up the
synthesis process to commercial levels. Glyconix holds the patent on what amounts
to an opportunity to exclusively synthesize glycosylated analogues of 30% of all
the small molecules drugs that are currently in the marketplace in a one-pot
method.
FACE="Times New Roman" SIZE="2">The Companys process has proven to be
milder, less expensive to perform,
and occurs rapidly with higher yields than traditional methods currently being
utilized. The Companys glycosylation processes can be applied to a broad
range of small molecule compounds, many of which cannot be glycosylated by other
conventional methods. Table 3: Comparison of Glyconixs Glycosylation Processes
 
<TR>
New Roman" SIZE="1">Reaction Characteristics<HR WIDTH="76"
New Roman" SIZE="1">Conventional Glycosylation Methods<HR
New Roman" SIZE="1">Glyconixs Patented Glycosylation
Method<HR WIDTH="120" SIZE="1" NOSHADE ALIGN="left"
COLOR="#000000"></TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Catalyst</TD>
FACE="Times New Roman" SIZE="2">Harsh, very acidic</TD>
FACE="Times New Roman" SIZE="2">Mild, weakly acidic</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Temperature</TD>
FACE="Times New Roman" SIZE="2">High (> 50°C)</TD>
FACE="Times New Roman" SIZE="2">Room Temp (20°C)</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Time</TD>
FACE="Times New Roman" SIZE="2">Long (days)</TD>
FACE="Times New Roman" SIZE="2">Short (2- 4 hours)</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Yield</TD>
FACE="Times New Roman" SIZE="2">Low-Moderate</TD>
FACE="Times New Roman" SIZE="2">High</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Stereoselectivity</TD>
FACE="Times New Roman" SIZE="2">Moderate</TD>
FACE="Times New Roman" SIZE="2">Moderate</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Toxicity</TD>
FACE="Times New Roman" SIZE="2">Moderate-High</TD>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Cost</TD>
FACE="Times New Roman" SIZE="2">High</TD>
FACE="Times New Roman" SIZE="2">Many of todays drugs are large
organic molecules that have several functional groups. Under the harsh conditions
of standard glycosylation techniques, many important functional groups in major
drugs would be destroyed during the reaction. In contrast, Glyconixs mild
process
allows it to successfully glycosylate those molecules. Glycosylation of a
compound in general can enhance its solubility, pharmacokinetics, and targeting
with a potential to increase efficacy and decrease its toxicity, a major factor in
Glyconixs commercial development strategy. 
<TR>
SIZE="2">2)</TD>
<TD ALIGN="left" VALIGN="top">BNCT
TECHNOLOGY </TD></TR></TABLE> One
of the compounds of choice in BNCT clinical trials is L-p-Boronphenylalanine
(BPA), normally complexed with fructose for producing L-BPA-Fructose (L-BPA-F).
There are
currently, to managements knowledge, only two other small companies in the
world producing L-BPA; but, Glyconix has been the preferred provider to many of
the drug trial sites worldwide because the high quality of the L-BPA produced.
FACE="Times New Roman" SIZE="2">Currently L-BPA is complexed only with fructose.
The Company is developing a
new series of complexing agents for boronated compounds with better
pharmacokinetics than fructose. To the Companys knowledge, no other
complexing agents have been evaluated in humans by any of the research
institutions currently engaged in
BNCT clinical trials. The Company is immediately prepared to market these new
compounds to the research community upon completion of the patent application.
<A NAME="tx97153_26"></A>CONSULTANTS The Company has
entered into various
agreements for research, professional services and consulting services, including
consulting agreements with the Companys executives. Such agreements provided
for aggregate monthly payments of approximately $13,000 as of June 30, 2005.
Consulting agreements are normally subject to termination on 30 days notice.
SIZE="2">On May 20, 2004 the Company issued 5,900,000 shares of common stock
to JED Management LLC in connection with a private placement, subject to an escrow
agreement requiring completion of certain conditions. On November 9, 2004
such
conditions were met on completion of private placement of units. On July 15, 2003, the Company entered into an agreement with Next
Stage Advisors LLC (NSA) to act as its
investment banking agent in connection with the Companys capital raising and
business combination activities. Under the agreement, NSA will use its best
efforts for a period of not more than four months to effect a transaction, while
on of
their employees will be appointed interim CEO and will dedicate 33% of his time to
the Company. On January 15, 2004 the NSA agreement was terminated and the
interim CEO hired to act as the Companys Chief Executive Officer. As part of
the
termination, the Company issued on July 1, 2004 to NSA 30,000 five year
warrant to purchase the Companys common stock at $1.50 per share. The
Company owed NSA approximately $26,000 and $45,000 as of June 30, 2005 and as
of
December 31, 2004 , respectively. 
<A NAME="tx97153_27"></A>MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF
OPERATION You should read the following discussion and
analysis of our plan of operations together with our financial statements and
related notes appearing elsewhere in this prospectus. This discussion and analysis
contains
forward-looking statements that involve risks, uncertainties and assumptions. The
actual results may differ materially from those anticipated in these forward-
looking statements as a result of certain factors, including, but not limited to,
those
presented under Risk Factors and elsewhere in this prospectus.
SIZE="2">Plan of Operations We were incorporated in Delaware
in August
2001 as Glycosylation Technology Inc. and changed our name to Glyconix Corp. in
November 2001. The Company acquired its intellectual property from both Glycosyn
Pharmaceuticals, Inc., a subsidiary of Harrier, Inc. (a publicly traded U.S.
company),
and New Concept Therapeutics, a company devoted to the research and manufacture of
Boron Neutron Capture Therapy (BNCT) compounds. <P
intellectual property has several patents and options to license certain patents.
The Companys patent portfolio consists of five patent families:
Camptothecin,
Dithiin, Fusidic Acid, Glycoside, and P-Boronophenylalanine. These families
include 11 issued U.S. Patents, 2 Swiss Patents, 2 German Patents 2 French
Patents, 3 British Patents, 2 Swedish Patents, 1 Taiwanese Patent, 1 Spanish
Patent, 1 Italian
Patent, and 1 Irish Patent. In addition 1 Japanese and 2 Canadian Applications are
currently pending. The Company has applied for several composition of
matter and process patents and maintains several production and chemical synthesis
trade secrets. The Company is developing several promising
compounds that management believes benefit from glycosylation. Our goal is to take
compounds
through pre-clinical development, which include determining a safe starting dose
for human clinical trials, clinical protocol design and securing the manufacturing
of clinical supply material. The company will then file an Investigational New
Drug
(the IND ) application with the U.S. Food & Drug
Administration (the FDA) or its international regulatory counterparts.
Upon acceptance of the IND by the FDA, Phase I clinical trials will be performed
to establish
the safe dose range of the investigational drug. Following successful Phase I
studies, Phase II studies will be conducted in limited populations to determine
the most efficacious dose prior to larger Phase III studies in broader populations
in a
disease indication. Anticipated time frame from the lead compound to the
completion of the Phase IIA is 3.5 to 4 years. Anytime during the preclinical and clinical development programs, the
Company will have the option to proceed on its own or to seek a suitable partner.
Given the
Companys size, it is anticipated that the Company will seek a suitable
partner for drug development beyond the early-stages of clinical 
development for the foreseeable future.
Management has not identified such prospective partner company as of this date.
 <P
have a limited operation history, small customer base and have generated limited
revenues. Our plan of operation for the next twenty four months is to focus
primarily on the development of two compounds and file IND with FDA to start human
clinical trials. The estimated cost for the development of each compound to
IND/Phase I
human clinical trials are approximately two ($2) million dollars. This includes
additional animal studies, assay development, pharmacokinetic studies, toxicology
panel, scale-up and cGMP manufacturing of the drug for the studies. <P
Company is currently supplying L-BPA to Harvard/Beth Israel Medical Center in
Boston,
Studsvik (Sweden), and The National Commission of Atomic Energy in Argentina, and
fulfilled orders in the UK and Finland. Clinical trials are currently in Phase
I/II in Europe and are anticipated to progress to larger scale Phase III trials in
the
near future. We also hold the proprietary rights position on the high yield
synthesis of L-BPA-fructose and are developing an enhanced second-generation
proprietary boronated compound. Our present available cash, cash equivalents and
investments are approximately $763,000 at June 30, 2005. During the next
twelve
months, we expect to use our available cash and expected cash inflows to pay for
the following costs and expenditures: 
<TR>
<TD ALIGN="left" VALIGN="top">Our general
and administrative expenses (including salary, general legal and other
professional fees, consulting fees), </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">The costs
associated with making certain upgrades to our intellectual property portfolio,
new patent application fees, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">The cost
associated with our research facilities in North Carolina.
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Preliminary
tests for new compounds, which are developed in our laboratory.
believe our available cash of approximately $763,000 and expected revenue will be
sufficient to complete our immediate planned operations through the next twelve
months based on our current burn rate of approximately $85,000 per month. However,
if we are required to pay outstanding debts to Glycosyn Pharmaceuticals and
Michigan University, our current available cash will not be sufficient to repay
those
debts and continue our immediate planned operations through the next twelve months
unless we scale back our immediate planned operations (including scaling back on
personnel, consulting fees and legal and other professional fees), or use funds
that
we receive through exercise of our warrants, if any, and/or raise additional
capital in the next twelve months in order to maintain our operations. 
proposed work with two compounds, camptothecin derivatives and 1,2-dithiin
derivatives, within the next twenty four months include: (i) to complete all
animal
tests and complete our initial IND applications, (ii) commencement of our
Phase I clinical trials, (iii) continuation of our research and development
of a pipe line of proprietary compounds including boronated compounds for BNCT
treatment.
All of those tasks and payment for the operations and overhead expenses that we
will incur during pre-clinical study and clinical trials are dependent on a raise
of additional funds within the next twelve months. If we fail to generate enough
cash
resources, either from future equity or debt sales or revenue from operations,
there can be no assurance that we will be able to implement our business plan,
complete these operations, or continue our operations beyond the next twelve
months.
FACE="Times New Roman" SIZE="2">As discussed in our risk factors, we engage in a
highly competitive
environment. A continued slowness in the economy, as a result of terrorist
attacks, market decline, the war in Iraq, or a combination thereof appears to have
resulted in a general reduction in capital available to emerging pharmaceutical
industry.

In addition, new drugs could be developed
with could compete with our compounds. This may significantly and negatively
affect our revenue stream. 
SIZE="2">Research and Development of Products <P
Company currently has two promising compounds that management believes benefit
from
glycosylation. The Company is supplying certified product of L-BPA to clinical
trials that are currently in Phase I/II in Europe, and are anticipated to progress
to larger scale Phase III trials in the near future. In addition, we plan to use
our
proprietary glycosylation process to generate revenue through a developing
collaborative relationship with other pharmaceutical and biotechnology partners.
WIDTH="100%">
<TR>
SIZE="2">GLYCOSYLATED CAMPTOTHECIN
DERIVATIVES. The Company plans to perform additional limited in
vitro and in vivo studies with GLY 1001
and a few additional analogs to advance further at least one candidate compound
currently in development. The compound will be scaled-up for manufacture of
clinical grade material and undergo animal pharmacology and toxicology studies
with the goal
of submitting an IND for Phase I clinical trials in just over one year the point
of adequate financing. The strategic goal is to develop the compound through Phase
IIA clinical studies and license from the compound for the remainder of the
clinical
development process to an appropriate partner. Management has not identified such
prospective partner as of this date. </TD></TR></TABLE> The currently marketed camptothecin analogs are indicated for the
treatment of colon cancer (irinotecan) and ovarian and small cell lung cancer
(topotecan). Initial animal efficacy studies of the Companys compounds
demonstrated activity in a broad range of tumor types including non-small cell
lung cancer, prostate cancer and breast cancer. The initial clinical indications
for Phase II
studies will be determined on the basis of additional animal efficacy studies,
animal tissue distribution studies, and patient response information obtained
during Phase I human pharmacokinetic and safety trials. The choice of initial
indications
studied in Phase II will be influenced by an analysis of: 1) the disease
populations that have high unmet needs which may lend themselves to accelerated
approval strategies; 2) the stage of development of other competing agents which
may impact
routes to approval and patient availability for clinical trials. The company plans to file an IND application with FDA and/or its
international regulatory counterparts in the last quarter of 2006. Depending on
whether the FDA accepts our IND application, the management believes that we could
begin Phase
I clinical trials by the end of the first quarter of 2007. We estimate that our operational expenses will
include: 
<TR>
<TD ALIGN="left" VALIGN="top">Approximately
$50,000 for assay development, </TD></TR></TABLE> 
<TR>
$120,000 for compound to be scaled-up for manufacture of clinical grade material
(cGMP), </TD></TR></TABLE> 
<TR>
$260,000 for animal pharmacology, </TD></TR></TABLE> 
<TR>
$1,400,000 for toxicology studies, including regulatory preclinical consulting
fees, and </TD></TR></TABLE> 
<TR>
$500,000 for Phase I clinical trials </TD></TR></TABLE> 
<TR>
SIZE="2">GLYCOSYLATED 1,2-DITHIIN
DERIVATIVES. The Company plans to perform additional in
vitro and in vivo
studies with several existing and second generation of analogs to advance further
at least one candidate compound currently in development. The compound will be
scaled-up for manufacture of clinical grade material and undergo animal
pharmacology and
toxicology studies with the goal of submitting an IND for Phase I clinical trials
in 18 to 24 months. The strategic 

WIDTH="100%">
<TR>
goal is to develop the compound through
Phase IIA clinical studies and license the compound for the remainder of the
clinical development process to an
appropriate partner company. </TD></TR></TABLE> The initial
clinical indications for the glycosylated 1,2-dithiin derivatives will be in
patients with serious fungal infections. It is our expectation that these agents
will likely be orally administered or can be made into topically administered
formulations
allowing for the eventual expansion into the larger superficial fungal disease
indications. The company plans to file an IND application with
the FDA and/or its international regulatory counterparts in early 2007. Depending
on whether the FDA accepts our IND application, the management believes that we
could
begin Phase I clinical trials by the beginning of the third quarter of 2007.
left:8%; text-indent:4%">We estimate that our operational expenses will
include: 
<TR>
$150,000 for lead optimization and analytical development
WIDTH="100%">
<TR>
$120,000 for compound to be scaled-up for manufacture of clinical grade material,
WIDTH="100%">
<TR>
$1,300,000 for toxicology studies, including regulatory preclinical consulting
fees, and </TD></TR></TABLE> 
<TR>
$500,000 for Phase I clinical trials </TD></TR></TABLE> 
<TR>
SIZE="2">BORON NEUTRON CAPTURE
THERAPY ( THE BNCT)
PRODUCT S.
Glyconix is generating revenue by supplying L-BPA to Harvard/ Beth Israel
Medical Center in Boston, Studsvik (Sweden), and The National Commission of Atomic
Energy in Argentina, Cancer Research UK and Boneca in Finland. Clinical trials are
currently in Phase I/II in Europe and are anticipated to progress to larger scale
Phase III trials in the near future. Management believes that once BNCT receives
regulatory approval, the Companys proprietary knowledge of the manufacturing
process will position it to become the preferred supplier of L-BPA to the global
market. </TD></TR></TABLE> Glyconix also holds a patent on the process for high yield
synthesis of L-BPA-fructose. Currently, clinical trial sites are acquiring L-BPA
and performing
complexing procedure with fructose on site. Scaled-up manufacturing of L-BPA under
cGMP conditions is currently carried out in Sweden by Syntagon. The Companys recently issued patent includes numerous
monosaccharides, disaccharides and polyols with similar complexing properties to
that of
fructose. The Company also filed a patent application for the enhanced second-
generation proprietary compounds with characteristics that will optimize further
the BNCT therapy. The Company intends to collaborate with qualified
institutions and
or commercial partners to explore the efficacy of these new compounds. 
Roman"
SIZE="2">We plan to continue developing and supplying BNCT products and delivery
systems, albeit on a secondary level. The Company will exert the majority of its
efforts on its core glycosylation chemistry for discovery and development of its
proprietary small molecule therapeutics for use in oncology and infectious
diseases. 
<TR>
SIZE="2">OTHER PRODUCT
OPPORTUNITIES. Based on IMS studies the Companys
management estimates that the market for
extension of life cycle existing drugs is expected to be over $58.9 billion
between 2001 and 2010. The Companys proprietary glycosylation process could
potentially be applied to numerous types of drugs with an immediate addressable
market
opportunity of up to $10 billion. No assurances can be given that the Company will
achieve such revenues. Although 

WIDTH="100%">
<TR>
it is not the primary focus of the Company,
Glyconix will be opportunistic in developing collaborative relationships for drug
development with other
pharmaceutical and biotechnology companies that may benefit from the proprietary
technology to extend their existing drug franchise or advance compound classes
stymied in development. Limited revenue from these partnerships may also serve to
mitigate some of the risk associated with Glyconixs proprietary drug
development programs. </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">OVERHEAD
COSTS. The Company estimates that our overhead costs for the next sixteen to
twenty months to support our operation will be approximately $1.6 million dollars
which
includes the following: </TD></TR></TABLE> 
<TR>
$400,000 for laboratory rent, equipment, maintenance and materials,
WIDTH="100%">
<TR>
$800,000 for administrative expenses including salaries, office rent and
maintenance, and </TD></TR></TABLE> 
<TR>
$400,000 in legal and other expenses, including the patent filling fee, the costs
associated with additional funding and professional fees.
</TD></TR></TABLE>
SIZE="2">Result of operation We are a development stage company and have
generated limited revenues from sales of L-BPA. The Company currently has revenue
of
approximately $212,000 and $25,000 for the years ended December 31, 2004 and
2003, respectively. The Company has revenue of approximately $54,000, $212,000 and
$411,000 for the six-months ended June 30, 2005 and 2004, and since inception
through June 30, 2005, respectively. Until the
consummation of our
private placement in August November 2004, we had limited financial
resources to engage in any significant research and development activities.
However, we used cash received through sales and the issuance of promissory notes
to support our
research activities, as well as administrative costs. <P
Company has incurred
losses of approximately $818,000 and $737,000 for the years ended
December 31, 2004 and 2003, respectively. The Company has incurred losses of
approximately $750,000, $378,000 and $3,585,000 for the six-months ended
June 30, 2005 and 2004,
and since inception through June 30, 2005, respectively. <P
losses
include of approximately $354,000 and $302,000 for the years ended
December 31, 2004 and 2003, respectively in research and development.
Research and development costs for the six-months ended June 30, 2005 and
2004, and since inception
through June 30, 2005 were approximately $216,000, $174,000 and 1,214,000,
respectively. The losses include of approximately $443,000 and
$375,000 for the years ended December 31, 2004 and 2003, respectively in
general and administrative costs. General and administrative costs for the six-
months
ended June 30, 2005 and 2004, and since inception through June 30, 2005
were approximately $544,000, $183,000 and 2,302,000, respectively. The general and
administrative costs were primary for salaries, consulting fees, rent and legal
expenses. In connection with the Agreement with Glycosyn the Company determined
that rights to certain property were not transferable to the Company.
Consequently, during 2002 the Company charged to general and administrative
expenses approximately
$478,000 relating to the cost of those rights not obtained. The interest expenses for the years ended December 31, 2004 and 2003
were approximately $65,000, $75,000,
respectively. The interest expenses or the six-months ended June 30, 2005 and
2004, and since inception through June 30, 2005 were approximately $10,000,
$56,000 and $215,000, respectively. Such interest expenses related to convertible
promissory notes. In July 2004, $912,000 of principal and accrued interest was
converted into 625,000 shares of common stock. <P STYLE="margin-
receive interest income of approximately $9,000 and $0 for the years ended
December 31, 2004 and 2003, respectively, and $5,000, $0 and $14,000 for the
six-month
ended June 30, 2005 and 2004 and since inception through June 30, 2005,
respectively. The increase in interest income was a result of funds received from
private sale of the Companys securities. 
<TR>
<TD ALIGN="left" VALIGN="top">Salary
increase in 2005 and hiring a research chemist, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Rent costs
increase due to the fact that we leased in 2005 new research facilities in North
Carolina, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Estimated fair
value of options issued to Scientific Advisory Board members and consultants,
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Legal costs
increase due to the fact that we filed several new patents, and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Our cost
associated with preparing this registration statement. </TD></TR></TABLE>
2004 certain officers and stockholders agreed to forgive certain fees and
advances. Under the term of the agreement, unpaid fees in the amount of $438,000
were
forgiven, and advances to the Company from officers aggregating $11,000 were
forgiven. Such forgiveness has been treated as a capital contribution. 
SIZE="2">Liquidity and Capital Resources <P STYLE="margin-
November 2004 we completed a private placement of our securities and sold
3,610,000 units at $.50 per unit and raised gross proceeds of $1,805,000. Each
unit consisted
of one share of common stock and one warrant. The warrant is exercisable at $1.50
per share through January 15, 2008. The warrants are subject to redemption at
the Companys sole option after one year from the date of issuance if the
common stock price trading on a national public market averages 150% of the
warrant exercise price or $2.25 per share at $.10 per warrants. Since inception through June 30, 2005 the Company issued various of
promissory notes
totaling approximately $830,000. Of this amount $810,000 plus accrued interest has
been converted into the Companys common stock. In addition, certain advances
due to stockholders and officers amounting to approximately $11,000, as well as
unpaid consulting fees of approximately $438,000 and treated as a capital
contribution. We will not receive any proceeds from the sale of 3,610,000 shares of the
common stock offering through this prospectus by Selling Shareholders. However, we
will receive proceeds if any or all of the warrants, which have an exercise price
of $1.50 per share, are exercised. The company expects to receive proceeds from the sale of 3,500,000 share
of common stock including in this offering. The
net proceeds from the sale of all 3,500,000 shares, after deduction of estimated
offering expenses and filling fees, would be $6,900,000. Those funds will be used
as the following: 
<TR>
$1,600,000 for general and administrative expenses (including salaries, legal and
other professional fees, consulting and advisory fees, the costs associated with
new
patent filling, and associated with raising additional capital),
WIDTH="100%">
<TR>
$4,400,000 for research and development expenses (including all associated costs
to prepare and file IND applications, and start Phase I clinical trials for two
compounds) </TD></TR></TABLE> Our uses of capital during the
past two fiscal years
have been for: 
<TR>
<TD ALIGN="left" VALIGN="top">Administrative
expenses, including salaries of officers and other employees and consultants,
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Research and
development of our two proprietary compounds, </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Rent expenses
for New York office and research facilities in North Carolina,
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Expenses of
professionals, including accountant and attorneys. </TD></TR></TABLE> <P
believe our available cash, cash equivalents and investments of approximately
$763,000 and expected revenue will be sufficient to complete our immediate planned
operations through the next twelve months, based on our current burn rate of
approximately $85,000 per month. However, if we are required to pay outstanding
debts to Glycosyn Pharmaceuticals and Michigan University, our current available
cash will
not be sufficient to repay those debts and continue our immediate planned
operations through the next twelve months unless we scale back our immediate
planned operations (including scaling back on personnel, consulting fees and legal
and other
professional fees), or use funds that we receive through exercise of our warrants,
if any, and/or raise additional capital in the next twelve months in order to
maintain our operations. We will have to fund our liquidity requirements
through public or private equity offerings or debt financings. We may be unable to
obtain
any required additional financing on terms favorable to us, if at all. If adequate
funds are not available on acceptable terms, we will be unable to fund our
expansion, successfully promote our brand, develop our products and respond to
competitive
pressures or take advantage of acquisition opportunities, any of which may have a
material adverse effect on our business. If we raise additional funds through the
issuance of equity securities, our stockholders may experience dilution of their
ownership interest, and the newly issued securities may have rights superior to
those of our common stock. If we raise additional funds by issuing debt, we may be
subject to limitations on our operations, including limitations on the payments of
dividends. There can be no assurance that we will be able to secure additional
financing, or obtain favorable terms on such financing if it is available.
Continued negative cash flows create substantial doubt about our ability to fully
implement our
operating plan and we may have to reduce the scope of our planned operations,
which may jeopardize our ability to continue our business. If cash and cash
equivalents, together with any cash generated from operations, are insufficient to
satisfy our
liquidity requirements, we may not have sufficient resources to continue
operations. 
<A NAME="tx97153_28"></A>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SIZE="2">Use of Estimates Managements Discussion and
Analysis of
Financial Condition and Results of Operations are based upon our consolidated
financial statements, which have been prepared in accordance with generally
accepted accounting principles in the United States. When preparing our financial
statements,
we make estimates and judgments that affect the reported amounts on our balance
sheets and income statements, and our related disclosure about contingent assets
and liabilities. We continually evaluate our estimates, including those related to
revenue, allowance for doubtful accounts, reserves for income taxes, and
litigation. We base our estimates on historical experience and on various other
assumptions, which we believe to be 
reasonable in order to form the basis for
making judgments about the carrying values of assets and liabilities that are not
readily ascertained from other
sources. Actual results may deviate from these estimates if alternative
assumptions or condition are used. Revenue Recognition Revenue recognized
when from product sales is recognized when product is shipped. Revenue from sales
of L-p-BPA is recorded when shipped and title has passed, and the Company has no
further obligation. Patents and Other Intangible Assets
SIZE="2">Patents with finite useful lives are stated at cost and are amortized
using the straight-line method over the remaining useful lives, ranging from
twelve to nineteen
years. The Company evaluates the remaining useful life of
intangible assets
with finite useful lives each reporting period to determine whether events and
circumstances warrant a revision to the remaining period of amortization. If the
evaluation determines that the intangible assets remaining useful life has
changed,
the remaining carrying amount of the intangible asset is amortized prospectively
over that revised remaining useful life. The Company evaluates its intangible
assets with finite useful lives for impairment whenever events or other changes in
circumstances indicate that the carrying amount may not be recoverable. The
testing for impairment includes evaluating the undiscounted cash flows of the
asset and the remaining period of amortization or useful life. The factors used in
evaluating
the undiscounted cash flows include projected future operating results and cash
flows and any other material factors that may effect the continuity or the
usefulness of the asset. If impairment exists, the intangible asset is written
down to its
fair value based upon discounted cash flows. In connection
with the Agreement
with Glycosyn the Company determined that rights to certain property were not
transferable to the Company. Consequently, during 2002 the Company charged to
general and administrative expenses approximately $478,000 relating to the cost of
those
rights not obtained. Assets with infinite lives include manufacturing
process
which is stated at costs and is not amortized, but tested for impairment at least
annually as of December 31 or between annual tests if an event occurs or changes
in circumstances that would indicate that the carrying amount may not be
recoverable.
The testing for impairment includes evaluating the undiscounted cash flows of the
asset. The factors used in evaluating the undiscounted cash flows include
projected future operating results and cash flows and any other material factors
that may
effect the continuity or the usefulness of the asset. If impairment exists, the
intangible asset is written down to its fair value based upon discounted cash
flows. Net Income (Loss) Per Share <P
Company has presented basic and diluted net income (loss) per share pursuant to
SFAS No. 128, Earnings per Share, and the Securities and Exchange
Commission SAB No. 98. In accordance with SFAS No. 128, basic net income
(loss) per share has been computed by dividing net income (loss) by the weighted-
average number of shares of common stock outstanding during the period. Diluted
net
income (loss) per share includes the effect, if any, from the potential exercise
or conversion of securities, such as stock options, which would result in the
issuance of shares of common stock. Basic and diluted loss per share is based on the net loss divided by the
weighted average
number of common shares outstanding during the period. No effect has been given to
outstanding potential common shares such as options, warrants and convertible
instruments in the diluted computation as their effect would be antidilutive.
FACE="Times New Roman" SIZE="2">Off-Balance Sheet Arrangements 
<P
have not entered into any off-balance sheet arrangements that have or are
reasonably
likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, 
results of operations, liquidity, capital
expenditures or capital resources and would be considered material to investors.
Certain officers and directors of
the Company have provided personal guarantees to our various lenders as required
for the extension of credit to the Company. Recent Accounting Pronouncements <P STYLE="margin-
December 2004, the FASB issued Statement of Financial Accounting Standards
No. 123 R (As amended) Accounting for Stock-Based Compensation. This
statement is a
revision of FASB Statement No 123 and supersedes APB Opinion No. 25,
Accounting for Stock Issued to Employees, and its related implementation guidance.
This statement establishes standards for the accounting for transactions in which
an entity
exchanges its equity instruments for goods and services. It also addresses
transactions in which an entity incurs liabilities in exchange for goods and
services that are based on the fair value of the entitys equity instruments
or that may be
settled by the issuance of those equity instruments. This Statement focuses
primarily on accounting for transactions in which an entity obtains employee
services in share-based payment transactions. For public entities that are not
small business
issuers, the implementation of this Statement is required as of the beginning of
the first interim or annual reporting period after June 15, 2005. For public
entities that are small business issuers, like Glyconix, the implementation of
this
Statement, is required as of the beginning of the first interim or annual
reporting period after December 15, 2005. Management is required to implement
this Statements beginning in fiscal year beginning on January 1, 2006 and
they are
currently evaluating the impact of implementation of this Statement on the
Company. 
<A NAME="tx97153_29"></A>DESCRIPTION OF PROPERTIES Minimum future office and laboratory annual rental
payments are as follows: 
<TD></TD>
<TD></TD></TR>
<TR>
New Roman" SIZE="1">Year ended December 31,<HR WIDTH="136"
<TD COLSPAN="2" VALIGN="bottom"> </TD></TR>
FACE="Times New Roman" SIZE="2">2005</TD>
SIZE="2">112,000</TD></TR>
<TR>
SIZE="2">131,000</TD></TR>
SIZE="2">140,000</TD></TR>
<TR>
SIZE="2">106,000</TD></TR>
SIZE="2">37,000</TD></TR>
<TR>
SIZE="2">526,000</TD></TR>
FACE="Times New Roman" SIZE="2">From August 2002 through October 2004,
the Company rented office space on a month-to month arrangement from a company
whose principal stockholder was a Director and shareholder. Such arrangement
ceased September 30, 2004 and rent expenses to this related party amounted to
$9,000 and
$16,000 during the years ended December 31, 2004 and 2003 respectively.
SIZE="2">Total rent expense including amount paid to related parties were
2003, respectively. The Companys rent expense including amounts paid to
related parties,
for six month period ended June 30, 2005 and 2004 were $37,000 and $34,000,
respectively. </A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
SIZE="2">Except as described below, none of the following parties has, since our
date of incorporation, had any material interest, direct or indirect, in any
transaction with us or in any presently proposed transaction that has or will
materially
affect us: 
<TR>
<TD ALIGN="left" VALIGN="top">Any of our
directors or officers; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Any person
proposed as a nominee for election as a director; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Any person who
beneficially owns, directly or indirectly, shares carrying more than 10% of the
voting rights attached to our outstanding shares of common stock;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Any of our
promoters; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Any relative
or spouse of any of the foregoing persons who has the same house address as such
person. </TD></TR></TABLE> </A>MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
SIZE="2">No Public Market for Common Stock There is
presently no
public market for our common stock. We anticipate applying for trading of our
common stock on the over the counter bulletin board upon the effectiveness of the
registration statement of which this prospectus forms a part. However, we can
provide no
assurance that our shares will be traded on the bulletin board or, if traded, that
a public market will materialize. Stockholders of Our Common Shares Rule 144 Shares Apart from the founders shares, most of our common stock will be
available for resale to the public in accordance with the volume and trading
limitations of Rule
144 of the Securities Act of 1933, as amended. In general, under Rule 144 as
currently in effect, a person who has beneficially owned shares of a
companys common stock for at least one year is entitled to sell within any
three month period a
number of shares that does not exceed the greater of: 1.
1% of the number of
shares of the companys common stock then outstanding which, in our case,
will equal approximately 200,000 shares of common stock as of the date of this
prospectus; or 2. the average weekly trading volume of the
companys common stock during the four calendar weeks preceding the filing of
a notice on
Form 144 with respect to the sale. Sales under Rule 144 are also
subject to
manner of sale provisions and notice requirements and to the availability of
current public information about our company. Under Rule 144(k), a person who is not one of our companys
affiliates at any time during the three months preceding a sale, and who has
beneficially owned the
shares proposed to be sold for at least two years, is entitled to sell shares
without complying with the manner of sale, public information, volume limitation
or notice provisions of Rule 144. Stock Option Grants There were 586,000, 570,000 and 295,000
outstanding options for the six month period ended June 30, 2005, for the
years ended
December 31, 2004 and 2003, respectively. Registration
Rights
FACE="Times New Roman" SIZE="2">We have not granted registration rights to the
Selling Shareholders or to
any other persons. Interests of Named Experts and Counsel None of the experts named herein was or is a
promoter, underwriter, voting trustee, director, officer or employee of our
company. Further,
none of the experts was hired on a contingent basis and none of the experts named
herein will receive a direct or indirect interest in our company. Legal Matters The validity of the common stock offered hereby
will be passed upon for us by our independent legal counsel, Joseph I. Emas, Esq.,
1224 Washington Avenue, Miami Beach, Florida. Accounting Matters Our financial statements as of December 31,
2004, and for each of the years in the two year period then ended, and for the
period
August 21 2001 (inception) through December 31, 2004 included in this
prospectus have been audited by Eisner LLP, an independent Registered Public
Accounting Firm, as set forth in their report included herein (which contains an
explanatory
paragraph relating to the existence of substantial doubt about our ability to
continue as a going concern). The financial statements referred to above are
included in reliance on the report of such firm given on their authority as
experts in
accounting and auditing. 
<A NAME="tx97153_32"></A>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE <P STYLE="margin-
have had no disagreements on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedures with any of our
accountants for the year ended December 31, 2004. <P
have not had any
other changes in nor have we had any disagreements, whether or not resolved, with
our accountants on accounting and financial disclosures during our two recent
fiscal years or any later interim period. </A>ADDITIONAL INFORMATION Currently, we are
not
required to deliver our annual report to security holders. However, we will
voluntarily send an annual report, including audited financial statements, to any
shareholder that requests it. We are subject to the information requirements of
the
Securities Exchange Act of 1934 and in accordance therewith will file reports,
proxy statements and other information with the Commission and provide
shareholders with the information required under the Securities Act of 1934.
 <P
are filing this registration statement on form SB-2 under the Securities Act of
1933, as
amended, with the Securities and Exchange Commission with respect to the shares of
our common stock offered through this prospectus. This prospectus is filed as a
part of that registration statement and does not contain all of the information
contained in the registration statement and exhibits. Statements made in this
registration statement are summaries of the material terms of the referenced
contracts, agreements or documents of Glyconix Corp. and are not necessarily
complete. We
refer you to our registration statement and each exhibit attached to it for a more
detailed description of matters involving Glyconix Corp. , and the statements we
have made in this prospectus are qualified in their entirety by reference to these
additional materials. 
<A NAME="index"></A>Financial Statements Index to
Financial
Statements: 
<TD></TD></TR>
<TR>
SIZE="1">Page <HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Financial Statements</TD>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">
<A HREF="#fin97153_1">Report of independent registered public accounting
firm</A></TD>
<TD VALIGN="bottom" ALIGN="right">F-
1</TD></TR>
<TR>
<TR>
<A HREF="#fin97153_2">Balance sheets as of June 30, 2005 (unaudited) and
December 31, 2004</A></TD>
2</TD></TR>
<TR>
<TR>
<A HREF="#fin97153_3">Statements of operations of the six-month period ended
June 30, 2005 and 2004, and for the period August 21, 2001 (inception)
through June 30, 2005 (unaudited), and for the years ended December 31,
2004 and
2003, and for the period August 21, 2001 (inception) through
December 31, 2004</A></TD>
3</TD></TR>
<TR>
<TR>
<A HREF="#fin97153_4">Statements of changes in stockholders equity (capital
deficiency) for the period August 21, 2001 (inception) through
December 31, 2001 and for the years ended December 31, 2003 and 2004,
and for the six
month period ended June 30, 2005 (unaudited)</A></TD>
4</TD></TR>
<TR>
<TR>
<A HREF="#fin97153_5">Statements of cash flows for the six-month period ended
June 30, 2005 and 2004 (unaudited), and for the period August 21, 2001
(inception) through June 30, 2005 (unaudited), and for the years ended
December 31, 2004 and 2003, and for the period August 21, 2001
(inception) through December 31, 2004</A></TD>
6</TD></TR>
<TR>
<TR>
<A HREF="#fin97153_6">Notes to financial statements</A></TD>
8</TD></TR>
</TABLE>

SIZE="2">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 Board of Directors and Stockholders Glyconix Corp. We have audited the accompanying balance sheet of
Glyconix Corp. (a development stage company) (the Company) as of
December 31, 2004, and the related statements of operations, changes in
stockholders equity (capital deficiency) and cash flows for each of the
years in the two-year period ended December 31, 2004, and for the period from
August 21, 2001 (inception) through December 31, 2004. These financial
statements are the responsibility of the Companys management. Our
responsibility is to express an opinion on these financial statements based on our
audits. We conducted our audits in accordance with the
standards of the Public Company Accounting Oversight Board (United States). Those
standards
require that we plan and perform the audits to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the
financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a
reasonable
basis for our opinion. In our opinion, the financial
statements enumerated
above present fairly, in all material respects, the financial position of Glyconix
Corp. as of December 31, 2004, and the results of its operations and its cash
flows for each of the years in the two-year period ended December 31, 2004,
and for the period from August 21, 2001 (inception) through December 31,
2004 in conformity with accounting principles generally accepted in the United
States of America. The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed
in Note A
to the financial statements, the Company has not been able to generate sufficient
cash flow from operating activities to sustain its operations and since it has
incurred net losses since inception and is delinquent on certain obligations, it
has
been dependent on equity and debt financing to support its business efforts. These
factors raise substantial doubt about the Companys ability to continue as a
going concern. Managements plans in regard to these matters are also
described
in Note A. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty. Eisner LLP New York, New York April 20, 2005 F-1 

SIZE="2">GLYCONIX CORP. (a development stage company) Balance
Sheets 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">June 30, 2005<HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">December 31, 2004 <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TR>
FACE="Times New Roman" SIZE="2">ASSETS</TD>
<TR>
FACE="Times New Roman" SIZE="2">Current assets:</TD>
FACE="Times New Roman" SIZE="2">Cash and cash equivalents</TD>
SIZE="2">414,000</TD>
SIZE="2">176,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Marketable securities held to
maturity</TD>
SIZE="2">349,000</TD>
SIZE="2">1,174,000</TD>
FACE="Times New Roman" SIZE="2">Prepaid expenses and other assets</TD>
SIZE="2">9,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total current assets</TD>
SIZE="2">772,000</TD>
SIZE="2">1,350,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Fixed assets, net</TD>
SIZE="2">20,000</TD>
SIZE="2">29,000</TD>
FACE="Times New Roman" SIZE="2">Acquired intangible assets, less accumulated
amortization of $77,000 and $67,000, respectively</TD>
SIZE="2">236,000</TD>
SIZE="2">246,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Other assets</TD>
SIZE="2">30,000</TD>
SIZE="2">11,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total assets</TD>
SIZE="2">1,058,000</TD>
SIZE="2">1,636,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">LIABILITIES</TD>
<TR>
FACE="Times New Roman" SIZE="2">Current liabilities:</TD>
FACE="Times New Roman" SIZE="2">Accounts payable</TD>
SIZE="2">51,000</TD>
SIZE="2">106,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Due to officer</TD>
SIZE="2">8,000</TD>
SIZE="2">8,000</TD>
FACE="Times New Roman" SIZE="2">Accrued expenses</TD>
SIZE="2">68,000</TD>
SIZE="2">126,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Due to Glycosyn Pharmaceuticals, Inc. past
due</TD>
SIZE="2">414,000</TD>
SIZE="2">405,000</TD>
FACE="Times New Roman" SIZE="2">Due to The University of Michigan</TD>
SIZE="2">334,000</TD>
SIZE="2">334,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Convertible promissory notes (including accrued
interest of $7,000 and $6,000) past due</TD>
SIZE="2">27,000</TD>
SIZE="2">26,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total current liabilities</TD>
SIZE="2">902,000</TD>
SIZE="2">1,005,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Commitments and other matters (Note
I)</TD>
<TR>
FACE="Times New Roman" SIZE="2">STOCKHOLDERS EQUITY</TD>
FACE="Times New Roman" SIZE="2">Preferred stock - $.01 par value, 5,000,000
authorized cumulative dividend right preferred stock; none issued</TD>
<TR>
FACE="Times New Roman" SIZE="2">Common stock - $.01 par value, 40,000,000 shares
authorized; 19,450,000 shares issued and outstanding</TD>
SIZE="2">195,000</TD>
SIZE="2">195,000</TD>
FACE="Times New Roman" SIZE="2">Additional paid-in capital</TD>
SIZE="2">3,552,000</TD>
SIZE="2">3,277,000</TD>
<TR>
SIZE="2">3,747,000</TD>
SIZE="2">3,472,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Less: subscriptions receivable</TD>
SIZE="2">(6,000</TD>
SIZE="2">(6,000</TD>
FACE="Times New Roman" SIZE="2">Deficit accumulated during the development
stage</TD>
SIZE="2">(3,585,000</TD>
SIZE="2">(2,835,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total stockholders equity</TD>
SIZE="2">156,000</TD>
SIZE="2">631,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total liabilities and stockholders
equity</TD>
SIZE="2">1,058,000</TD>
SIZE="2">1,636,000</TD>
<TR>
ALIGN="center">See notes to
financial statements Statements
of Operations 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
bottom:0px" ALIGN="center">Six-month
period ended (Inception)
Roman" SIZE="1">Through Year ended December 31, <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
ALIGN="center">(Inception)
Roman" SIZE="1">Through December 31,<HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Net sales (Note I[4])</TD>
SIZE="2">54,000</TD>
SIZE="2">212,000</TD>
SIZE="2">411,000</TD>
SIZE="2">212,000</TD>
SIZE="2">25,000</TD>
SIZE="2">357,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Costs and expenses:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cost of sales</TD>
SIZE="2">39,000</TD>
SIZE="2">177,000</TD>
SIZE="2">279,000</TD>
SIZE="2">177,000</TD>
SIZE="2">10,000</TD>
SIZE="2">240,000</TD>
FACE="Times New Roman" SIZE="2">Research and development</TD>
SIZE="2">216,000</TD>
SIZE="2">174,000</TD>
SIZE="2">1,214,000</TD>
SIZE="2">354,000</TD>
SIZE="2">302,000</TD>
SIZE="2">998,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">General and administrative</TD>
SIZE="2">544,000</TD>
SIZE="2">183,000</TD>
SIZE="2">2,302,000</TD>
SIZE="2">443,000</TD>
SIZE="2">375,000</TD>
SIZE="2">1,758,000</TD>
<TR>
SIZE="2">799,000</TD>
SIZE="2">534,000</TD>
SIZE="2">3,795,000</TD>
SIZE="2">974,000</TD>
SIZE="2">687,000</TD>
SIZE="2">2,996,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Other income (expenses):</TD>
<TR>
FACE="Times New Roman" SIZE="2">Interest expense</TD>
SIZE="2">10,000</TD>
SIZE="2">56,000</TD>
SIZE="2">215,000</TD>
SIZE="2">65,000</TD>
SIZE="2">75,000</TD>
SIZE="2">205,000</TD>
FACE="Times New Roman" SIZE="2">Interest income</TD>
SIZE="2">(5,000</TD>
SIZE="2">(14,000</TD>
SIZE="2">(9,000</TD>
SIZE="2">(9,000</TD>
<TR>
SIZE="2">(750,000</TD>
SIZE="2">(378,000</TD>
SIZE="2">(3,585,000</TD>
SIZE="2">(818,000</TD>
SIZE="2">(737,000</TD>
SIZE="2">(2,835,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Basic and diluted loss per common
share</TD>
SIZE="2">(0.04</TD>
SIZE="2">(0.05</TD>
SIZE="2">(0.08</TD>
SIZE="2">(0.12</TD>
<TR>
FACE="Times New Roman" SIZE="2">Weighted average number of shares outstanding
basic and diluted</TD>
SIZE="2">19,450,000</TD>
SIZE="2">8,323,000</TD>
SIZE="2">10,886,000</TD>
SIZE="2">6,364,000</TD>

of Changes in Stockholders Equity (Capital deficiency) 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Common Stock <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> Additional Paid-in Capital<HR
<TD VALIGN="bottom" ROWSPAN="2"> </TD>
SIZE="1">Deficit accumulated During the Development
Roman" SIZE="1">Stage<HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Subscriptions Receivable<HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">Total <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" ROWSPAN="2"> </TD></TR>
<TR>
SIZE="1">Shares <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Amount <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
FACE="Times New Roman" SIZE="2">Shares issued to founders at $.01 per share -
August 22, 2001</TD>
SIZE="2">3,390,000</TD>
SIZE="2">34,000</TD>
SIZE="2">(11,000</TD>
SIZE="2">23,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Shares issued to founders for services at $.01 per
share - August 22, 2001</TD>
SIZE="2">530,000</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
FACE="Times New Roman" SIZE="2">Sale of shares at $.01 per share - September 1,
2001</TD>
SIZE="2">285,000</TD>
SIZE="2">3,000</TD>
SIZE="2">(3,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Shares issued to stockholder of New Concept
Therapeutics, Inc. at $.01 per share - October 12, 2001</TD>
SIZE="2">300,000</TD>
SIZE="2">3,000</TD>
SIZE="2">3,000</TD>
FACE="Times New Roman" SIZE="2">Shares issued to Glycosyn Pharmaceuticals Inc. at
$.01 per share -October 18, 2001</TD>
SIZE="2">810,000</TD>
SIZE="2">8,000</TD>
SIZE="2">8,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Shares issued to consultant at $.05 per share -
November 1, 2001</TD>
SIZE="2">500,000</TD>
SIZE="2">5,000</TD>
SIZE="2">20,000</TD>
SIZE="2">25,000</TD>
FACE="Times New Roman" SIZE="2">Net loss for the period since
inception</TD>
SIZE="2">(210,000</TD>
SIZE="2">(210,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Balance - December 31, 2001</TD>
SIZE="2">5,815,000</TD>
SIZE="2"> </TD>
SIZE="2">58,000</TD>
SIZE="2">20,000</TD>
SIZE="2">(210,000</TD>
SIZE="2">)</TD>
SIZE="2">(14,000</TD>
SIZE="2">(146,000</TD>
SIZE="2">)</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Shares issued to director at $.05 per share -
January 18, 2002</TD>
SIZE="2">60,000</TD>
SIZE="2">1,000</TD>
SIZE="2">2,000</TD>
SIZE="2">(1,000</TD>
SIZE="2">2,000</TD>
FACE="Times New Roman" SIZE="2">Estimated fair value of shares transferred by
stockholders to note holder February 1, 2002</TD>
SIZE="2">35,000</TD>
SIZE="2">35,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Collection of subscription receivable
February 2, 2002</TD>
SIZE="2">2,000</TD>
SIZE="2">2,000</TD>
FACE="Times New Roman" SIZE="2">Shares issued to members of the Scientific
Advisory Board at $.05 per share -February 27, 2002 through March 5,
2002</TD>

SIZE="2">125,000</TD>
SIZE="2">1,000</TD>
SIZE="2">5,000</TD>
SIZE="2">(1,000</TD>
SIZE="2">5,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Collection of subscriptions receivable -
July 10, 2002</TD>
SIZE="2">1,000</TD>
SIZE="2">1,000</TD>
FACE="Times New Roman" SIZE="2">Estimated fair value of options issued to
Scientific Advisory Board members and consultants</TD>
SIZE="2">2,000</TD>
SIZE="2">2,000</TD>
<TR>
October 20, 2002</TD>
SIZE="2">1,000</TD>
SIZE="2">1,000</TD>
SIZE="2">1,000</TD>
SIZE="2">1,000</TD>
<TR>
December 12, 2002</TD>
SIZE="2">1,000</TD>
SIZE="2">1,000</TD>
FACE="Times New Roman" SIZE="2">Net loss for the year</TD>
SIZE="2">(1,070,000</TD>
SIZE="2">(1,070,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Balance -December 31,
2002</TD>
SIZE="2">6,000,000</TD>
SIZE="2">60,000</TD>
SIZE="2">64,000</TD>
SIZE="2">(1,280,000</TD>
SIZE="2">(10,000</TD>
SIZE="2">(1,166,000</TD>
<TR>
May 19, 2003</TD>
SIZE="2">8,000</TD>
SIZE="2">8,000</TD>
FACE="Times New Roman" SIZE="2">Estimated fair value of shares transferred to note
holder and consultant May 19, 2003</TD>
SIZE="2">17,000</TD>
SIZE="2">17,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Exercise of options September 1,
2003</TD>
SIZE="2">1,100,000</TD>
SIZE="2">11,000</TD>
SIZE="2">44,000</TD>
SIZE="2">55,000</TD>
Scientific Advisory Board members and consultants</TD>
SIZE="2">2,000</TD>
SIZE="2">2,000</TD>
<TR>
SIZE="2">(737,000</TD>
SIZE="2">(737,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Balance December 31,
2003</TD>
SIZE="2">7,100,000</TD>
SIZE="2">71,000</TD>
SIZE="2">127,000</TD>
SIZE="2">(2,017,000</TD>
SIZE="2">(2,000</TD>
SIZE="2">(1,821,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Estimated value of warrants issued to convertible
note holders January 15, 2004</TD>
SIZE="2">7,000</TD>
SIZE="2">7,000</TD>
FACE="Times New Roman" SIZE="2">Options exercised March 1,
2004</TD>
SIZE="2">200,000</TD>
SIZE="2">2,000</TD>
SIZE="2">8,000</TD>
SIZE="2">(10,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Sale of shares to employees at $.05 per share -
March 1, 2004</TD>
SIZE="2">1,640,000</TD>
SIZE="2">17,000</TD>
SIZE="2">65,000</TD>
SIZE="2">(82,000</TD>
FACE="Times New Roman" SIZE="2">Fair value of shares issued to consultant at $0.01
per share - May 20, 2004</TD>
SIZE="2">5,900,000</TD>
SIZE="2">59,000</TD>
SIZE="2">(59,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Conversion of promissory notes July 1,
2004</TD>
SIZE="2">625,000</TD>
SIZE="2">6,000</TD>
SIZE="2">906,000</TD>
SIZE="2">912,000</TD>
FACE="Times New Roman" SIZE="2">Estimated fair value of warrant issued to
consultants July 1, 2004</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Contribution of payable and advances by
officers/stockholders July 1, 2004</TD>
SIZE="2">449,000</TD>
SIZE="2">449,000</TD>
July 1, 2004</TD>
SIZE="2">88,000</TD>
SIZE="2">88,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Exercise of warrants July 15,
2004</TD>
SIZE="2">245,000</TD>
SIZE="2">3,000</TD>
SIZE="2">9,000</TD>
SIZE="2">12,000</TD>
FACE="Times New Roman" SIZE="2">Options exercised by officers and consultants
SIZE="2">130,000</TD>
SIZE="2">1,000</TD>
SIZE="2">5,000</TD>
SIZE="2">6,000</TD>
<TR>
consultant August 1, 2004</TD>
SIZE="2">7,000</TD>
SIZE="2">7,000</TD>
Scientific Advisory Board members August 1, 2004</TD>
SIZE="2">14,000</TD>
SIZE="2">14,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Sale of Units at $0.50 per unit
SIZE="2">1,000,000</TD>
SIZE="2">10,000</TD>
SIZE="2">490,000</TD>
SIZE="2">500,000</TD>
FACE="Times New Roman" SIZE="2">Sale of Units at $0.50 per unit
SIZE="2">2,610,000</TD>
SIZE="2">26,000</TD>
SIZE="2">1,279,000</TD>
SIZE="2">1,305,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cost of offering</TD>
SIZE="2">(35,000</TD>
SIZE="2">(35,000</TD>

of Changes in Stockholders Equity (Capital deficiency) (Continued) 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Common <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Stock <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Additional Paid-in Capital<HR
SIZE="1">Deficit accumulated During the Development
Roman" SIZE="1">Stage<HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Subscriptions Receivable<HR SIZE="1" NOSHADE COLOR="#000000"></TD>
Roman" SIZE="1">Total <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
<TD VALIGN="bottom" ROWSPAN="2"> </TD></TR>
<TR>
SIZE="1">Amount <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="2">(818,000</TD>
SIZE="2">(818,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Balance December 31,
2004</TD>
SIZE="2">19,450,000</TD>
SIZE="2">195,000</TD>
SIZE="2">3,277,000</TD>
SIZE="2">(2,835,000</TD>
SIZE="2">(6,000</TD>
SIZE="2">631,000</TD>
SIZE="2"> </TD></TR>
<TR>
consultant March 1, 2005</TD>
SIZE="2">238,000</TD>
SIZE="2">238,000</TD>
Scientific Advisory Board members March 1, 2005</TD>
SIZE="2">30,000</TD>
SIZE="2">30,000</TD>
<TR>
consultant May 23, 2005</TD>
SIZE="2">7,000</TD>
SIZE="2">7,000</TD>
FACE="Times New Roman" SIZE="2">Net loss for six- month period ended June 30,
2005</TD>
SIZE="2">(750,000</TD>
SIZE="2">(750,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Balance June 30, 2005
(unaudited)</TD>
SIZE="2">19,450,000</TD>
SIZE="2">195,000</TD>
SIZE="2">3,552,000</TD>
SIZE="2">(3,585,000</TD>
SIZE="2">(6,000</TD>
SIZE="2">156,000</TD>
SIZE="2"> </TD></TR>
<TR>

of Cash Flows 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Six-Month Period Ended June 30, <HR SIZE="1"
SIZE="1">August 21, 2001 (Inception) Through June 30,<HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Year Ended December 31, <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
Roman" SIZE="1">December 31,<HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">Cash flows from operating
activities:</TD>
<TR>
SIZE="2">(750,000</TD>
SIZE="2">(378,000</TD>
SIZE="2">(3,585,000</TD>
SIZE="2">(818,000</TD>
SIZE="2">(737,000</TD>
SIZE="2">(2,835,000</TD>
FACE="Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash used
in operating activities:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Depreciation and amortization</TD>
SIZE="2">21,000</TD>
SIZE="2">21,000</TD>
SIZE="2">158,000</TD>
SIZE="2">41,000</TD>
SIZE="2">41,000</TD>
SIZE="2">137,000</TD>
FACE="Times New Roman" SIZE="2">Value assigned to equity and compensatory
stock</TD>
SIZE="2">286,000</TD>
SIZE="2">31,000</TD>
SIZE="2">405,000</TD>
SIZE="2">80,000</TD>
SIZE="2">19,000</TD>
SIZE="2">119,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Charge for patents Rights not
obtained</TD>
SIZE="2">478,000</TD>
SIZE="2">478,000</TD>
FACE="Times New Roman" SIZE="2">Accrued interest</TD>
SIZE="2">10,000</TD>
SIZE="2">48,000</TD>
SIZE="2">147,000</TD>
SIZE="2">56,000</TD>
SIZE="2">56,000</TD>
SIZE="2">137,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Changes in:</TD>
FACE="Times New Roman" SIZE="2">Prepaid expenses and other assets</TD>
SIZE="2">(27,000</TD>
SIZE="2">5,000</TD>
SIZE="2">(38,000</TD>
SIZE="2">(1,000</TD>
SIZE="2">30,000</TD>
SIZE="2">(11,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Accounts payable & accrued
expenses</TD>
SIZE="2">(125,000</TD>
SIZE="2">221,000</TD>
SIZE="2">647,000</TD>
SIZE="2">114,000</TD>
SIZE="2">212,000</TD>
SIZE="2">772,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Net cash used in operating
activities</TD>
SIZE="2">(585,000</TD>
SIZE="2">(52,000</TD>
SIZE="2">(1,788,000</TD>
SIZE="2">(528,000</TD>
SIZE="2">(379,000</TD>
SIZE="2">(1,203,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cash flows from investing
<TR>
FACE="Times New Roman" SIZE="2">Purchase of fixed assets</TD>
SIZE="2">(2,000</TD>
SIZE="2">(2,000</TD>
SIZE="2">(63,000</TD>
SIZE="2">(23,000</TD>
SIZE="2">(61,000</TD>
FACE="Times New Roman" SIZE="2">Redemption and (purchase) of
investments</TD>
SIZE="2">825,000</TD>
SIZE="2">(349,000</TD>
SIZE="2">(1,174,000</TD>
SIZE="2">(1,174,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Payment to Glycosyn Pharmaceuticals,
Inc.</TD>
SIZE="2">(70,000</TD>
SIZE="2">(5,000</TD>
SIZE="2">(70,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Net cash provide by (used in) investing
SIZE="2">823,000</TD>
SIZE="2">(2,000</TD>
SIZE="2">(482,000</TD>
SIZE="2">(1,202,000</TD>
SIZE="2">(1,305,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cash flows from financing
<TR>
FACE="Times New Roman" SIZE="2">Bank overdraft</TD>
SIZE="2">(7,000</TD>
SIZE="2">(7,000</TD>
SIZE="2">(4,000</TD>
FACE="Times New Roman" SIZE="2">Proceeds from sale of common stock and exercise of
options and warrants</TD>
SIZE="2">1,854,000</TD>
SIZE="2">1,776,000</TD>
SIZE="2">48,000</TD>
SIZE="2">1,854,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Capital lease payments</TD>
SIZE="2">(8,000</TD>
SIZE="2">(25,000</TD>
SIZE="2">(8,000</TD>
SIZE="2">(12,000</TD>
SIZE="2">(25,000</TD>
FACE="Times New Roman" SIZE="2">Proceeds from issuing of convertible promissory
notes</TD>
SIZE="2">135,000</TD>
SIZE="2">831,000</TD>
SIZE="2">135,000</TD>
SIZE="2">338,000</TD>
SIZE="2">831,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Advances from officers/stockholders,
net</TD>
SIZE="2">24,000</TD>
SIZE="2">10,000</TD>
SIZE="2">9,000</TD>
SIZE="2">24,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Net cash provided by financing
SIZE="2">120,000</TD>
SIZE="2">2,684,000</TD>
SIZE="2">1,906,000</TD>
SIZE="2">379,000</TD>
SIZE="2">2,684,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Net increase in cash and cash
equivalents</TD>
SIZE="2">238,000</TD>
SIZE="2">66,000</TD>
SIZE="2">414,000</TD>
SIZE="2">176,000</TD>
SIZE="2">176,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cash and cash equivalents at beginning of
period</TD>
SIZE="2">176,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cash and cash equivalents at end of
period</TD>
SIZE="2">414,000</TD>
SIZE="2">66,000</TD>
SIZE="2">414,000</TD>
SIZE="2">176,000</TD>
SIZE="2">76,000</TD>
<TR>

SIZE="2">Statement of
Cash Flows (Continued) 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Six-Month Period Ended June 30, <HR
Roman" SIZE="1">June 30,<HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Year Ended December 31, <HR SIZE="1"
Roman" SIZE="1">December 31,<HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
SIZE="1">2004 <HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">Supplemental disclosures of cash flow
information:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Cash paid for interest</TD>
SIZE="2">1,000</TD>
SIZE="2">12,000</TD>
SIZE="2">1,000</TD>
SIZE="2">7,000</TD>
SIZE="2">12,000</TD></TR>
FACE="Times New Roman" SIZE="2">Noncash investing and financing
activities:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Fixed asset acquisitions under capital
leases</TD>
SIZE="2">25,000</TD>
SIZE="2">25,000</TD></TR>
FACE="Times New Roman" SIZE="2">Acquisition of intangibles:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Due to Glycosyn Pharmaceuticals,
Inc.</TD>
SIZE="2">453,000</TD>
SIZE="2">453,000</TD></TR>
FACE="Times New Roman" SIZE="2">Due to The University of Michigan</TD>
SIZE="2">334,000</TD>
SIZE="2">334,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Issuance of common stock</TD>
SIZE="2">11,000</TD>
SIZE="2">11,000</TD></TR>
FACE="Times New Roman" SIZE="2">Due to New Concept Therapeuticals,
Inc</TD>
SIZE="2">15,000</TD>
SIZE="2">15,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Convertible promissory notes and accrued interest
exchange for common stock</TD>
SIZE="2">912,000</TD>
SIZE="2">912,000</TD>
SIZE="2">912,000</TD></TR>
FACE="Times New Roman" SIZE="2">Officers and shareholders contributions of payable
and advances</TD>
SIZE="2">449,000</TD>
SIZE="2">449,000</TD>
SIZE="2">449,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Advances exchanged for payment for common stock
and exercise of options/warrants</TD>
SIZE="2">115,000</TD>
SIZE="2">100,000</TD>
SIZE="2">15,000</TD>
SIZE="2">115,000</TD></TR>

FACE="Times New Roman" SIZE="2">(unaudited with respect to June 30, 2005 and six-
months
ended June 30, 2005 and 2004) NOTES
TO
FINANCIAL STATEMENTS NOTE
A - THE COMPANY Glyconix Corp.
(the
Company) (formerly Glycosylation Technologies, Inc.) was incorporated
on August 21, 2001 and is in the development stage. The Company is engaged in
the discovery of proprietary small molecule therapeutics and related carbohydrate
chemistry, as well as the development of proprietary L-p-Boronophenylalanine
(L-p-BPA or boron) manufacturing and boron delivery
technologies. The Companys efforts had been principally devoted to research
and
development, capital formation and organizational development. Currently the
Companys revenue source is from the sale of boron to foreign customers.
Companys financial statements have been prepared assuming that the Company
will continue as a going concern which contemplated the realization of assets and
satisfaction of liabilities in the normal course of business. The Company has
incurred cumulative losses of $3,585,000 and $2,835,000 for the period August 21,
2001 (inception) through June 30, 2005 and December 31, 2004,
respectively, and
has been dependent on funding operations through the issuance of convertible debt
and private sale of equity securities and is past due on certain obligations.
Managements plans include continuing to finance operations through
attempting a
private or public placement of debt and/or equity securities, reducing
expenditures and increasing sales volume. However, no assurance can be given at
this time as to whether the Company will be able to achieve these objectives.
These factors, among
others, raise substantial doubt about the Companys ability to continue as a
going concern for a reasonable period of time. The financial statements do not
include any adjustment relating to the recoverability and classification of
recorded
asset amounts or the amounts and classification of liabilities that might be
necessary should the Company be unable to continue as a going concern. 
SIZE="2">NOTE B - SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES
 
<TR>
SIZE="2">[1]</TD>
<TD ALIGN="left" VALIGN="top">Unaudited
interim periods: </TD></TR></TABLE> The accompanying financial statements as of June 30, 2005 and
for the six-month periods ended June 30, 2005 and 2004 and for the period
August 21, 2001 (inception) through June 30, 2005 are unaudited but, in
the opinion of management of the Company, reflect all adjustments (consisting only
of normal and recurring adjustments) necessary for fair presentation. The results
of
operations for six-month periods are not necessarily indicative of the results
that may be expected for the full year ending December 31, 2005. 
WIDTH="100%">
<TR>
SIZE="2">[2]</TD>
<TD ALIGN="left" VALIGN="top">Fixed
assets: </TD></TR></TABLE> Fixed assets are stated at cost. Depreciation (including
depreciation on assets held under capital leases) is provided using the straight-
line method over
the estimated useful lives of three years. 
<TR>
SIZE="2">[3]</TD>
<TD ALIGN="left" VALIGN="top">Patent and
other intangibles: </TD></TR></TABLE> Purchased patents and patent rights, are stated at cost and are
being amortized using the straight-line method over the remaining useful lives of
the
underlying patents and is being charged to research and development expense (see
Note C). The Company reviews its patents for impairment whenever events or
changes in circumstances indicate that the carrying amount of the patents may not
be
recoverable. In performing the review, the Company estimates undiscounted cash
flows from products under development, which are covered by these patents.

SIZE="2">GLYCONIX CORP. NOTES TO FINANCIAL
STATEMENTS
(CONT.) NOTE B -
SUMMARY
OF SIGNIFICANT ACCOUNTING
POLICIES (CONTINUED) Impairment based on the estimated fair value of the patents would
be recognized if those estimated
cash flows were less than the unamortized costs. Related patents are grouped in
estimating future cash flows to determine whether patents are impaired and in
measuring the amount of the impairment. Acquired intangibles consisting of manufacturing process is stated
at costs
and is not amortized, but tested for impairment at least annually as of December
31 or between annual tests if an event occurs or changes in circumstances that
would indicate that the carrying amount may not be recoverable. The testing for
impairment includes evaluating the undiscounted cash flows of the asset. The
factors used in evaluating the undiscounted cash flows include projected future
operating results and cash flows and any other material factors that may effect
the
continuity or the usefulness of the asset. If impairment exists, the intangible
asset is written down to its fair value based upon discounted cash flows.
WIDTH="100%">
<TR>
SIZE="2">[4]</TD>
<TD ALIGN="left" VALIGN="top">Research
and development: </TD></TR></TABLE> Research and development costs are charged to expense as incurred.
WIDTH="100%">
<TR>
SIZE="2">[5]</TD>
<TD ALIGN="left" VALIGN="top">Cash and
cash equivalents: </TD></TR></TABLE> The Company considers all highly liquid investments with a
maturity of three months or less when purchased to be cash equivalents.
 
<TR>
SIZE="2">[6]</TD>
<TD ALIGN="left" VALIGN="top">Marketable
securities: </TD></TR></TABLE> The Company classifies its marketable securities as held to
maturity (maturity through December 31, 2005) and are carried at amortized
cost.
Marketable securities at June 30, 2005 and December 31, 2004 consist
principally of debt securities issued by U.S. Government agencies. The market
value of such securities at June 30, 2005 and December 31, 2004 was
approximately
$349,000 and $1,174,000, respectively. 
<TR>
SIZE="2">[7]</TD>
<TD ALIGN="left" VALIGN="top">Loss per
common share: </TD></TR></TABLE> Basic and diluted loss per share is based on the net loss divided
by the weighted average number of common shares outstanding during the period. No
effect
has been given to outstanding potential common shares such as options, warrants
and convertible instruments in the diluted computation as their effect would be
antidilutive. The number of potentially dilutive securities excluded from
computation of
diluted loss per share was as follows: 
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
ALIGN="center">June 30,<HR
bottom:0px" ALIGN="center">Year
ended December 31,<HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Options</TD>
SIZE="2">586,000</TD>
SIZE="2">700,000</TD>
SIZE="2">570,000</TD>
SIZE="2">295,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Unearned shares</TD>
SIZE="2">5,900,000</TD>
FACE="Times New Roman" SIZE="2">Warrants</TD>
SIZE="2">3,640,000</TD>
SIZE="2">245,000</TD>
SIZE="2">3,640,000</TD>
<TR>
SIZE="2">4,226,000</TD>
SIZE="2">6,845,000</TD>
SIZE="2">4,210,000</TD>
SIZE="2">295,000</TD></TR>
<TR>
WIDTH="100%">
<TR>
SIZE="2">[8]</TD>
<TD ALIGN="left" VALIGN="top">Stock-based
compensation: </TD></TR></TABLE> As permitted under SFAS No. 148, Accounting for Stock-
Based compensation Transition and Disclosure, which amended SFAS
No. 123, Accounting for Stock-Based Compensation, the Company has
elected to continue to follow the intrinsic value method in accounting for stock-
based employee compensation arrangements as defined by Accounting Principles Board
Opinion No. 25, Accounting for Stock Issued to Employees
(APB No. 25). Under the provisions of APB No. 25,
compensation cost for stock options is measured as the excess, if any, of the fair
price of the
Companys common stock at the date of the grant over the amount an employee
or director must pay to acquire the stock. If the Company had applied the fair
value recognition provision of SFAS No. 123 to Stock-based Compensation, the
effect
on net loss and net loss per share would have been as follows: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Year ended December 31, <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TR>
FACE="Times New Roman" SIZE="2">Net Loss</TD>
SIZE="2">(750,000</TD>
SIZE="2">(378,000</TD>
SIZE="2">(818,000</TD>
SIZE="2">(737,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Total stock-based compensation expense determined
under fair value based method for all awards net of related tax
effect</TD>
SIZE="2">(2,000</TD>
SIZE="2">(7,000</TD>
SIZE="2">(2,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Pro forma net loss attributable to common
stockholders</TD>
SIZE="2">(750,000</TD>
SIZE="2">(380,000</TD>
SIZE="2">(825,000</TD>
SIZE="2">(739,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Net loss per common shares (basic and
diluted):</TD>
<TR>
FACE="Times New Roman" SIZE="2">As reported</TD>
SIZE="2">(.04</TD>
FACE="Times New Roman" SIZE="2">Pro forma</TD>
FACE="Times New Roman" SIZE="2">The weighted-average fair value per
stock option granted was $.03 for six-month period ended June 30, 2004, and
$.03 and $.02 for the years ended December 31, 2004 and 2003, respectively.
No options were granted to employees or directors during the six-month period
ended
June 30, 2005. We estimated fair value using the Black-Scholes option pricing
model with the following assumptions: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Six month period ended Year ended December 31, <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
<TR>
FACE="Times New Roman" SIZE="2">Expected life in years</TD>
<TR>
FACE="Times New Roman" SIZE="2">Interest rate</TD>
FACE="Times New Roman" SIZE="2">Volatility</TD>
<TR>
FACE="Times New Roman" SIZE="2">Dividend yield</TD>
WIDTH="100%">
<TR>
SIZE="2">[9]</TD>
<TD ALIGN="left" VALIGN="top">Fair value
of financial instruments: </TD></TR></TABLE> The carrying value of the convertible promissory notes
approximates its fair value. 
<TR>
SIZE="2">[10]</TD>
<TD ALIGN="left" VALIGN="top">Use of
estimates: </TD></TR></TABLE> The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America requires
management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenue and expenses during the
reporting period. Such estimation include the selection of assumptions underlying
the calculation of the fair value of options. Actual results could are not differ
from those estimates. 
<TR>
SIZE="2">[11]</TD>
<TD ALIGN="left" VALIGN="top">Revenue
recognition: </TD></TR></TABLE> Revenue from sales of L-p-BPA is recorded when shipped and title
has passed, and the Company has no further obligation. 
<TR>
SIZE="2">[12]</TD>
<TD ALIGN="left" VALIGN="top">Recent
accounting pronouncement: </TD></TR></TABLE> In December 2004, the FASB issued SFAS No. 123 (revised
2004), Share-Based Payment which amends SFAS No. 123 and 95
(FAS
123R). FAS 123R is applicable for all interim and fiscal periods beginning
after December 15, 2005. Therefore, the Company expects to adopt it during
fiscal 2006. FAS 123R sets accounting requirements for share-based
compensation to employees and requires companies to recognize in the statements of
operations the grant-date fair value of stock options and other equity-based
compensation issued to employees for share-based compensation. The Company is
currently
evaluating the impact that FAS 123R will have on its result of operations.
WIDTH="100%">
<TR>
SIZE="2">[13]</TD>
<TD ALIGN="left" VALIGN="top">Income
Taxes: </TD></TR></TABLE> The Company accounts for income taxes using the asset and
liability method described in SFAS No. 109, Accounting For Income
Taxes the
objective of which is to establish deferred tax assets and liabilities for the
temporary differences between the financial reporting and the tax bases of the
Companys assets and liabilities at enacted tax rates expected to be in
effect when
such amount are realized or settled. A valuation allowance related to deferred tax
assets is recorded when it is more likely then some portion or all of the deferred
tax assets will not be realized. NOTE C - ACQUISITION OF
TECHNOLOGY 
<TR>
SIZE="2">[1]</TD>
<TD ALIGN="left" VALIGN="top">Agreement
with Glycosyn Pharmaceuticals, Inc. (Glycosyn):
</TD></TR></TABLE> In October 2001, the Company acquired certain patents and related
intellectual property rights (the Property Rights) from Glycosyn
Pharmaceutical, Inc., a Delaware corporation owned primarily by foreign persons
(Glycosyn) pursuant to an Intellectual Property Purchase Agreement
(the Agreement). The Agreement called for the sale of the Property
Rights in
exchange for $750,000 (the Note) and the assumption of approximately
$334,000 of liability to University of Michigan. In addition, Glycosyn subscribed
to 810,000 shares of common stock at $.01 per share, ($8,000) payment for which
has
been offset against the amount owed. NOTE C -
ACQUISITION OF TECHNOLOGY
(CONTINUED) The $750,000 is payable $5,000 per month until the Company
completes a private placement of
approximately $3,000,000, thereafter, the monthly payment will increase to
$10,000, with the balance payable in full on completion of a secondary offering.
During the period ended December 31, 2001, the Company paid certain
liabilities of
Glycosyn of approximately $65,000 in lieu of the monthly payments. The Agreement
did not provide for interest payments, consequently the principal payments have
been discounted to their present value at an interest rate of 9% resulting in a
principal amount of $453,000. At December 31, 2004 future minimum payments
are due as follows: 
<TD></TD>
<TD></TD></TR>
<TR>
New Roman" SIZE="1">Year Ended December 31,<HR WIDTH="131"
SIZE="1">Amount <HR SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
SIZE="2">124,000</TD></TR>
<TR>
SIZE="2">60,000</TD></TR>
SIZE="2">60,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Thereafter</TD>
SIZE="2">430,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Total minimum payments</TD>
SIZE="2">674,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Less amounts representing interest</TD>
SIZE="2">269,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Present value of future payments</TD>
SIZE="2">405,000</TD></TR>
<TR>
left:4%">The Company has
learned that Glycosyn breached the Agreement since they did not have proper title
to the Property Rights and therefore did not have ability to transfer certain of
the intellectual property sold to the Company under the Agreement (see Note E). As
a
result of the deficiencies in the Agreement, the Company stopped making payments
under the Note. The Company contends that because of the material breach in the
Agreement and Glycosyns inability to transfer title to the Property Rights
as
required by the Agreement, the Company has been materially and adversely affected,
did not receive the consideration it was supposed to receive under the Agreement
and therefore, is not required to repay the Note. To date, no claim or litigation
has
been filed in any court by Glycosyn or its stockholders. The Company is currently
in discussion with Glycosyn to resolve this matter. The Companys management believes that, after consultation
with outside counsel, should the Swiss investors attempt to collect on the Note,
the
Company will have one or more meritorious affirmative defenses, counterclaims
and/or rights of offset as against Glycosyn or its stockholders. 
<TR>
SIZE="2">[2]</TD>
<TD ALIGN="left" VALIGN="top">Agreement
with New Concept Therapeutics, Inc. (NCT):
Roman" SIZE="2">On October 12, 2001, the Company acquired certain technology
from NCT for the manufacture of boron for $15,000, payable $1,500 per month. In
addition, the sole stockholder of NCT was granted 300,000 shares of common stock
valued at $3,000. On September 1, 2001, the Company acquired certain fixed
assets from NCT for $17,000. NOTE D - FIXED ASSETS
 Fixed assets are summarized as follows: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">June 30, 2005 <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">December 31, 2004 <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">Computers</TD>
SIZE="2">17,000</TD>
SIZE="2">15,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Furniture & Fixture</TD>
SIZE="2">5,000</TD>
SIZE="2">5,000</TD></TR>
FACE="Times New Roman" SIZE="2">Laboratory equipment</TD>
SIZE="2">66,000</TD>
SIZE="2">66,000</TD></TR>
<TR>
SIZE="2">88,000</TD>
SIZE="2">86,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Less accumulated depreciation</TD>
SIZE="2">68,000</TD>
SIZE="2">57,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Net</TD>
SIZE="2">20,000</TD>
SIZE="2">29,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Depreciation expenses the six month
periods ended June 30, 2005 and 2004, and years ended December 31, 2004
and 2003 were $10,000, $10,000, $20,000 and $21,000 respectively. NOTES
TO
FINANCIAL STATEMENTS (CONT.)
SIZE="2">NOTE E - ACQUIRED
INTANGIBLES ASSETS Acquired intangibles are summarized as follows: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">June 30, 2005 <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">December 31, 2004 <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
SIZE="1">Gross Carrying Amount <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Accumulated Amortization <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Net <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Gross Carrying Amount <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Accumulated Amortization <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Net <HR SIZE="1" NOSHADE COLOR="#000000"></TD>
SIZE="1">Amortization Period <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
FACE="Times New Roman" SIZE="2">Amortized intangible assets:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Patents</TD>
SIZE="2">295,000</TD>
SIZE="2">78,000</TD>
SIZE="2">217,000</TD>
SIZE="2">295,000</TD>
SIZE="2">67,000</TD>
SIZE="2">228,000</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">12-
19 Yrs</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Unamortized intangible assets:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Manufacturing process</TD>
SIZE="2">18,000</TD>
SIZE="2">18,000</TD>
SIZE="2">18,000</TD>
SIZE="2">18,000</TD>
<TR>
<TR>
<TD></TD>
<TD></TD></TR>
FACE="Times New Roman" SIZE="2">Aggregate amortization expense:</TD>
<TR>
FACE="Times New Roman" SIZE="2">For six-month period ended June 30,
2005</TD>
SIZE="2">11,000</TD></TR>
FACE="Times New Roman" SIZE="2">For six-month period ended June 30,
2004</TD>
SIZE="2">11,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">For the year ended December 31,
2003</TD>
SIZE="2">21,000</TD></TR>
2004</TD>
SIZE="2">21,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Estimated amortization expense:</TD>
2005</TD>
SIZE="2">21,000</TD></TR>
<TR>
2006</TD>
SIZE="2">21,000</TD></TR>
2007</TD>
SIZE="2">21,000</TD></TR>
<TR>
2008</TD>
SIZE="2">21,000</TD></TR>
2009</TD>
SIZE="2">21,000</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Thereafter</TD>
SIZE="2">123,000</TD></TR>
<TR>
SIZE="2">228,000</TD></TR>
<TR>
left:4%">In connection with the
Agreement with Glycosyn the Company determined that rights to certain property
were not transferable to the Company (see Note C). Consequently, during 2002 the
Company charged to general and administrative expenses approximately $478,000
relating to
the cost of those rights not obtained. NOTE F -
STOCKHOLDERS EQUITY 
<TR>
SIZE="2">[1]</TD>
<TD ALIGN="left" VALIGN="top">Common
stock: </TD></TR></TABLE> On August 22, 2001 the Company issued 3,920,000 shares of
common stock to its founders (payable $34,000 in cash and $ 5,000 in lieu of
services)
left:4%">On September 1, 2001, the
Company sold 285,000 shares of
common stock for $3,000. TATEMENTS (CONT.) NOTE F - STOCKHOLDERS
EQUITY
Roman" SIZE="2">On October 12, 2001, the Company issued 300,000 shares of
common stock valued at $3,000 to the
principal stockholder of NCT for the acquisition of a certain technology from NCT
for the manufacture of L-BPA (See Note C [2]). On October 18, 2001 the Company issued 810,000 shares of
common stock to Glycosyn Pharmaceuticals Inc. for acquisition of certain
patents
rights and technologies (See Note C [1]). On November 1,
2001, in connection with a consulting agreement the Company issued 500,000 shares
of common stock at their estimated fair value of $25,000, which was charged to
operations. On January 18, 2002 the
Company issued 60,000 shares of common stock to a member of the board of director
and valued
the shares at $3,000 (payable $1,000) and charged $2,000 to expense. 
Roman"
SIZE="2">On February 1, 2002 certain shareholders transferred 700,000 shares
of common stock to another shareholder who is also a convertible promissory note
holder (see Note G). Such shares were value to their estimated fair value of
$35,000
and charge to interest expenses. During the
period
February 27, 2002 through March 5, 2002 the Company sold an aggregate of
125,000 shares of common stock to members of the Scientific Advisory Board at par.
The difference between the fair value of the stock and its par value of $5,000 was
recorded as an expense. On May 19, 2003 certain
shareholders transferred 230,000 shares of common stock to shareholders who are
also a convertible promissory note holders (see Note G). Such shares were value to
their estimated fair value of $12,000 and charge to interest expenses. In
addition,
the stockholders transfer 100,000 shares of common stock to a consultant. Such
shares were value at their estimated fair value of $5,000 and expensed.
Roman" SIZE="2">On September 1, 2003 1,100,000 shares were issued in
connection with the exercise of options. On March 1, 2004 200,000 options were exercised by an
employee/officer,
which payment was made on July 1, 2004 through the offset of amounts due to
such employee/officer. On March 1, 2004 1,640,000 shares of common stock at $.05 per
share were issued to the employees. Such payment of $78,000 was offset against
amounts
due to such employees effective July 1, 2004 and $4,000 remains unpaid.
left:4%">On May 20, 2004 the Company issued 5,900,000
shares of common to JED Management LLC in connection with a private placement,
subject to an escrow agreement requiring completion of certain conditions. On
November 9, 2004 such conditions were met on completion of private placement.
left:4%">On July 1, 2004 the Company issued 625,000
shares of common stock in exchange for certain notes and accrued interest
aggregating $912,000. In addition, 245,000 warrants to buy the Companys
common stock at
$.05 per share were exercised in July 2004 (See Note F[3]). On August 1, 2004 130,000 shares of common stock were issued in
connection with the exercise of options. During the period from August 23, 2004 through
November 9, 2004 the Company completed a
private placement of its securities and sold 3,610,000 units at $.50 per unit and
raised gross proceeds of $1,805,000. Each unit consisted of one share of common
stock and one warrant. The warrant is exercisable at $1.50 per share through
January 15, 2008. The warrants are subject to redemption at the
Companys sole option after one year from date of issuance if the common
stock price has average 150% of warrants exercise price per share at redemption
price $.01 per
warrant. (See Note F[3]). 
<TR>
SIZE="2">[2]</TD>
<TD ALIGN="left" VALIGN="top">Stock
options: </TD></TR></TABLE> In August 2001, the Board of Directors and the stockholders of the
Company approved a 2001 Stock Option Plan (the 2001 Plan) that
provides for
the granting of options to purchase up to 2,000,000 shares of common stock,
pursuant to which officers, directors, employees and scientific advisors are
eligible to receive stock options. Options granted under the 2001 Plan are
exercisable for a
period of up to 5 years from date of grant at an exercise price which is not less
than the fair value of the common stock on date of grant, except that the exercise
period of options granted to a stockholder owning more than 10% of the outstanding
capital stock may not exceed five years and their exercise price may not be less
than 110% of the fair value of the common stock at date of grant. Generally, 2001
Plan options generally vest 50% immediately and 50% on the anniversary date of the
grant. On December 23, 2004, the
Board of Directors and
on August 8, 2005 the shareholders of the Company approved a 2005 Stock
Option Plan (the 2005 Plan) that provides for the granting of options
to purchase up to 1,500,000 shares of common stock pursuant to which officers,
directors,
employees, consultants and scientific advisors are eligible to receive stock
options. During the years ended December 31, 2004,
2003 and 2002 the Company granted to members of Scientific Advisory Board 30,000,
55,000 and 25,000 options to purchase common stock, respectively. In connection
therewith the Company recorded charges of $24,000, $7,000, $19,000, $1,000 and
$1,000 for the six-month ended June 30, 2005 and 2004 and the years ended
December 31, 2004, 2003 and 2002, respectively based on the Black-Scholes
option pricing
model. During the years ended December 31,
2004, 2003, 2002,
and 2001 the Company granted to consultants 365,000, 30,000, 150,000 and 100,000
options to purchase common stock, respectively. In connection therewith the
Company recorded charges of $255,000, $17,000, $49,000, $1,000 and $1,000 for the
six-month
ended June 30, 2005 and 2004 and the years ended December 31, 2004, 2003 and 2002,
respectively based on the Black-Scholes option pricing model. On May 22, 2005, the Company has retained a consultant to
perform regulatory consulting and related medical research services for the
Company. The
Company issued options to purchase 16,000 shares of common stock at $.50 per share
pursuant to the Companys 2005 Plan. Such grant vests at 7,000 options per
month. During the six months ended June 30, 2005 the Company recorded a charge of
$7,000 relating to the vested options. The Company will record additional charges
when these options vest at the then market price. NOTE F -
STOCKHOLDERS EQUITY (CONTINUED)
Roman" SIZE="2">Stock option activity under the 2001 Plan and 2005 Plan are
summarized as follows: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
Roman" SIZE="1">Six-Months Ended June 30, 2005 <HR
SIZE="1">Year Ended December 31, <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
<TR>
SIZE="1">Weighted Average Exercice Price <HR SIZE="1"
FACE="Times New Roman" SIZE="2">Options outstanding at beginning of
year</TD>
SIZE="2">570,000</TD>
SIZE="2">295,000</TD>
SIZE="2">1,225,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Granted</TD>
SIZE="2">16,000</TD>
SIZE="2">605,000</TD>
SIZE="2">195,000</TD>
FACE="Times New Roman" SIZE="2">Exercised</TD>
SIZE="2">(330,000</TD>
SIZE="2">)</TD>
SIZE="2">(1,100,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Canceled</TD>
SIZE="2">(25,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Options outstanding at the end of
SIZE="2">586,000</TD>
SIZE="2">570,000</TD>
SIZE="2">295,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Options exercisable at end of
SIZE="2">331,000</TD>
SIZE="2">185,000</TD>
SIZE="2">198,000</TD>
<TR>
left:4%">The following table
presents information relating to stock options outstanding under the plans as of
June 30, 2005 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Options Outstanding <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Options Exercisable <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
SIZE="1">Shares <HR WIDTH="37" SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Weighted Average Exercise Price <HR SIZE="1"
SIZE="1">Weighted Average Remaining Life in Years <HR
SIZE="2">25,000</TD>
SIZE="2">25,000</TD>
<TR>
SIZE="2">545,000</TD>
SIZE="2">302,000</TD>
SIZE="2">16,000</TD>
SIZE="2">4,000</TD>
<TR>
SIZE="2">586,000</TD>
SIZE="2">331,000</TD>
<TR>
left:4%">The following table
presents information relating to stock options outstanding under the plans as of
December 31, 2004: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Options Outstanding <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Options Exercisable <HR SIZE="1" NOSHADE
COLOR="#000000"></TD></TR>
<TR>
SIZE="1">Shares <HR WIDTH="37" SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Weighted Average Remaining Life in Years <HR
SIZE="2">25,000</TD>
SIZE="2">25,000</TD>
<TR>
SIZE="2">545,000</TD>
SIZE="2">160,000</TD>
<TR>
SIZE="2">570,000</TD>
SIZE="2">185,000</TD>
<TR>
left:4%">As of June 30,
2005, 1,484,000 options were available for future grants under the 2005 Plan. As
of December 31, 2004 and June 30, 2005, no options were available for
grants under 2001 Plan. 
<TR>
SIZE="2">[3]</TD>
<TD ALIGN="left" VALIGN="top">Warrants:
Roman" SIZE="2">Warrants activity under the Plans and warrants are summarized as
follow: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Year Ended December 31, 2004 <HR SIZE="1"
<TR>
SIZE="1">Weighted Average Exercice Price <HR SIZE="1"
FACE="Times New Roman" SIZE="2">Warrants outstanding at beginning of
<TR>
FACE="Times New Roman" SIZE="2">Granted</TD>
SIZE="2">3,885,000</TD>
FACE="Times New Roman" SIZE="2">Exercised</TD>
SIZE="2">(245,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Warrants outstanding at the end of
SIZE="2">3,640,000</TD>
<TR>
FACE="Times New Roman" SIZE="2">Warrants exercisable at end of
SIZE="2">3,640,000</TD>
<TR>
left:4%">On January 15,
2004 the Company issued 245,000 warrants to purchase common stock at a price $.05
per share in a connection with certain convertible promissory notes in an amount
of $380,000. Such warrants were exercised in July 2004. Such warrants were valued
at
$7,000 and treated as interest expense. On July 1, 2004,
the Company issued 30,000 warrants to purchase common stock at a price $1.50 per
share to a consultant in connection with a termination of an agreement. Such
warrants were valued at approximately $5,000 and expensed (see Note I[2]).
 During 2004, the Company sold 3,610,000 units, consisting of one
share of
common stock and one redeemable 5-year warrant, vested immediately, for the
Companys common stock at $1.50 per share. (see Note F[1] ). No warrants were issued during six month period ended
June 30, 2005. As of December 31, 2004 and June 30, 2005,
outstanding warrants to
acquire shares of the Companys common stock are as follows: 
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Exercise Price <HR WIDTH="76" SIZE="1" NOSHADE
COLOR="#000000"></TD>
New Roman" SIZE="1">Expiration Date<HR WIDTH="86" SIZE="1"
NOSHADE ALIGN="left" COLOR="#000000"></TD>
SIZE="1">Number of Shares Reserved <HR SIZE="1"
SIZE="2">$1.50</TD>
<TD VALIGN="bottom">July 1, 2009</TD>
SIZE="2">30,000</TD></TR>
<TR>
SIZE="2">$1.50</TD>
SIZE="2">January 15, 2008</TD>
SIZE="2">3,610,000</TD></TR>
<TR>
SIZE="2">3,640,000</TD></TR>
<TR>

SIZE="2">NOTE G - CONVERTIBLE
PROMISSORY NOTES 
Roman" SIZE="2">The Company has issued 9% convertible promissory notes which
(i) bear interest at a rate of 9% per annum, (ii) become due and
payable as to all outstanding interest and principal on the earlier of 24 months
from date of issuance or September 1, 2004, (iii) may be converted into
the
Companys common stock at any time at least 90 days after the first closing
of any private or public financing with a gross closing amount of not less than
$3,000,000, or the Companys merger with or acquisition by another entity, or
the
liquidation of all or substantially all of the Companys assets,
(iv) become convertible at a price set to 50% of the offering price of the
common stock in such offering, or, if no common stock was issued, to 50% of the
conversion price of
preferred stock, convertible notes or other securities issued in such offering.
During the years ended December 31, 2004, 2003, 2002 and 2001 the Company
issued promissory notes of $135,000, $338,000, $298,000 and $60,000, respectively.
left:4%">On January 15, 2004, the
Companys Board of
Directors agreed to increase the interest rate to 9.5% on all funds borrowed from
one investor from their original issuance date. Such change in the interest rate
resulted in additional interest expense of approximately $4,000 on
January 15,
2004. In addition, such note holder was granted a warrant to purchase 245,000
shares of common stock which was value at $7,000 and treated as interest expense
(See Note F [3]). On July 1, 2004, the Company
entered into Debt Discharge, Release and Satisfaction agreements with certain note
holders
.. Under the agreements one note holder converted principal of $800,000 and
accrued interest of approximately $100,000 into 600,000 shares of common stocks,
and another note holder agreed to convert principal of $10,000 and accrued
interest of
approximately $2,000 into 25,000 shares of common stock. A beneficial conversion
feature was not calculated since the conversion price of the common stock was
greater than the estimated fair value of such shares issued. NOTE H - LOAN AND
ADVANCES
FROM OFFICERS AND
STOCKHOLDERS During the years ended December 31, 2004, 2003, 2002 and 2001
certain officers and stockholders advanced to the Company approximately $25,000,
$9,000, $30,000 and $29,000, respectively. Such advances are non-interest bearing
and have no date of repayment. During the years ended December 31, 2004,
2003, 2002 and 2001 the Company made repayments of $15,000, $0, $10,000 and $0,
respectively. In addition, certain advances due
to
stockholders and officers were offset against payments for stock purchased or
options/warrants exercised. During the years ended December 31, 2004, 2003,
2002 and 2001 such amounts were $12,000, $15,000, $0 and $23,000, respectively.
left:4%">On July 1, 2004, certain
officers and stockholders
agreed to forgive certain fees and advances. Under the term of the agreement,
unpaid fees in the amount of $438,000 were forgiven. In addition, advances to the
Company from officers aggregating $11,000 were forgiven. Such forgiveness has been
treated as a capital contribution. At June 30, 2005 and December 31,
2004, the remaining unpaid balance of loans made to the Company by officer was
$8,000. NOTE I - COMMITMENTS AND
OTHER MATTERS
WIDTH="100%">
<TR>
SIZE="2">[1]</TD>
<TD ALIGN="left" VALIGN="top">Leases:
Roman" SIZE="2">The Company occupies laboratory facility in North Carolina under a
lease agreements expiring through March 2008. On November 1, 2004 the Company
signed a five years lease to rent space in New York Minimum future office and
laboratory annual rental payments are as follows: 
<TD></TD>
<TD></TD></TR>
<TR>
New Roman" SIZE="1">Year ended December 31,<HR WIDTH="143"
<TD COLSPAN="2" VALIGN="bottom"> </TD></TR>
SIZE="2">112,000</TD></TR>
<TR>
SIZE="2">131,000</TD></TR>
SIZE="2">140,000</TD></TR>
<TR>
SIZE="2">106,000</TD></TR>
SIZE="2">37,000</TD></TR>
<TR>
SIZE="2">526,000</TD></TR>
<TR>
left:4%">In addition, the
Company rented office space on a month-to-month arrangement from an entity whose
principal stockholder is a Director and shareholder of the Company (see Note I
[3]). Such arrangement ceased in September 2004 and rent expenses to this related
party
amounted to $9,000 and $16,000 during the years ended December 31, 2004 and
2003 respectively. Total rent expense including amount paid to related parties were
2003
respectively. The Companys rent expense including amounts paid to related
parties, for six-month period ended June 30, 2005 and 2004 were $37,000 and
$34,000 respectively. 
<TR>
SIZE="2">[2]</TD>
<TD ALIGN="left" VALIGN="top">Consulting
agreements: </TD></TR></TABLE> The Company has entered into various agreements for research,
professional services and consulting services. Such agreements provided for
aggregate
monthly payments of approximately $13,000 and $32,000, at June 30, 2005 and
at December 31, 2004, respectively. Consulting agreements are normally
subject to termination on 30 days notice. On May 20, 2004 the Company entered into agreement with JED
Management
LLC (the JED) and issued 5,900,000 shares of common stock to JED for
their services in connection with a private placement, subject to an escrow
such
conditions were met on completion of private placement. On
July 15, 2003, the Company entered into an agreement with NextStageAdvisors
LLC (NSA) to act as its investment banking agent in connection with
the Companys capital raising and business combination activities. Under the
agreement, NSA will use its best efforts for a period of not more than four months
to effect a transaction, while one of their employees will be appointed interim
Chief Executive Officer (the CEO) and will dedicate 33% of his time to
the
Company. In return, NSA will receive a $10,000 monthly retainer fee as well as
compensation based on the size and nature of any transaction executed in the form
of cash, warrants or any combination thereof. On January 14, 2004 the NSA
agreement
was terminated and the interim CEO was hired to act as the Companys Chief
Executive Officer with 1/3 of his time to be dedicated to the Company. 

OTHER MATTERS (CONTINUED)
Roman" SIZE="2">As part of the termination, the Company granted NSA 30,000 5-year
warrants with an exercise price of
$1.50 per share, which fully vest on July 1, 2004. The Company owed
approximately $26,000 and $45,000 as of June 30, 2005 and December 31,
2004, respectively under the agreement and is included in account payable.
 On May 23, 2004, the Company has retained a consultant to
perform
regulatory consulting and related medical research services for the Company. The
Company agrees to retain the consultant at a fee of $2,000 per month, commencing
May 1, 2005 and options to purchase 16,000 shares of common stock at $.50 per
share equally vested monthly over eight months (see Note F[2]). 
<TR>
SIZE="2">[3]</TD>
<TD ALIGN="left" VALIGN="top">Related
party transactions: </TD></TR></TABLE> On September 1, 2001 the Company entered into an agreement
with Whitehall Financial, LLC (former Quantum Financial Partners, LLC)
(Whitehall) a major stockholder. Whitehall will provide the Company
with marketing, management and financial consulting services, assist the Company
in preparing a business plan, and provide the company with office facilities. The
President and major stockholder of Whitehall, served as a Director of the Company.
The agreement provides for the Company to pay Whitehall $1,250 per month for space
and office facilities for the period from August 2001 through May 2002, $2,000 for
the period from June 2002 through May 2003, and $1,000 thereafter (see Note I[1]).
Such agreement ended in September, 2004. 
<TR>
SIZE="2">[4]</TD>
<TD ALIGN="left" VALIGN="top">Major
customer: </TD></TR></TABLE> Percentage of the sales from major customers was as follows:
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
SIZE="1">Six-months ended June 30, <HR SIZE="1"
SIZE="1">Year ended December 31, <HR SIZE="1"
<TR>
FACE="Times New Roman" SIZE="2">A</TD>
<TR>
FACE="Times New Roman" SIZE="2">B</TD>
FACE="Times New Roman" SIZE="2">C</TD>
WIDTH="100%">
<TR>
SIZE="2">[5]</TD>
<TD ALIGN="left" VALIGN="top">Employment
agreements: </TD></TR></TABLE> On March 30, 2005, the Company entered into a three year
employment agreement with its Executive Vice President and provides for an annual
base
salary of $96,000 (plus annual increases at the discretion of the Board of
Directors. The agreement also provides for the granting of options to purchase
200,000 shares of common stock at an exercise price of $.50 per share effective
September 1, 2005. On March 30, 2005, the
Company
entered into a three year employment agreement with its President and Chief
Scientific Officer and provides for an annual base salary of $160,000 (plus annual
increases at the discretion of the Board of Directors. The agreement also provides
for the
granting of options to purchase 250,000 shares of common stock at an exercise
price of $.50 per share effective September 1, 2005. On August 1, 2005, the Company entered into a three year
employment agreement with its Vice President Finance and provides for an annual
base salary
of $84,000 (plus annual increases at the discretion of the Board of Directors. The
agreement also provides for the granting of options to 

OTHER MATTER (CONTINUED)

purchase 80,000 shares of common stock at an
exercise price of $.50 per share effective September 1, 2005. In connection with these option grants the Company will record a
charge over
the vesting period representing the difference between the exercise price and the
market value of the common share. NOTE J - INCOME TAXES
Roman" SIZE="2">At December 31, 2004 the Company had approximately $1,828,000
and $69,000 of net operating loss carry forward and research and development
credits
for federal income tax purposes, which expire as follows: 
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
New Roman" SIZE="1">Year<HR WIDTH="21" SIZE="1" NOSHADE
SIZE="1">Net Operating Loss <HR SIZE="1" NOSHADE
COLOR="#000000"></TD>
SIZE="1">Research and Development Credits <HR
SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
SIZE="2">66,000</TD>
<TR>
SIZE="2">508,000</TD>
SIZE="2">28,000</TD></TR>
SIZE="2">546,000</TD>
SIZE="2">19,000</TD></TR>
<TR>
SIZE="2">708,000</TD>
SIZE="2">22,000</TD></TR>
<TR>
SIZE="2">1,828,000</TD>
SIZE="2">69,000</TD></TR>
<TR>
left:4%">The Company has a
deferred asset of $924,000 and $553,000 as December 31, 2004 and 2003,
respectively, representing the benefits of its net operating loss carry forward,
research and development credits and the benefits of certain expenses not
currently
deductible for tax purposes. The Companys deferred tax asset has been fully
reserved by a valuation allowance since realization of its benefit is uncertain.
The difference between the statutory federal tax rate of 34% and the
Companys
effective tax rate is due to increase in the valuation allowance $371,000 (year
2004) and $266,000 (year 2003) and certain non deductible expenses. The
Companys ability to utilize its carry forwards may be severely limited and
subject to an
annual limitation pursuant to Section 382 of the Internal Revenue.
SIZE="2">NOTE K - SUBSEQUENT
EVENTS On August 1, 2005 the Company entered into an
agreement with Pamela Spielvogel, the deceased spouse of David Spielvogel, who was
a sole stockholder, board member and officer of NCT. The parties agreed to reduce
the number of shares issued to the sole stockholders under the sale agreement from
300,000 to 200,000 shares of common stock (see Note C[2]). The 100,000 shares of
common stocks have been placed in treasury. In addition, liabilities in the amount
of
approximately $4,000 owed to NCT were discharged in full in lieu of $2,000
payment. On August 1, 2005 the Company granted to two
Directors 50,000 options each to purchase the Companys common stock with an
exercise price of $0.50, expiring on August 1, 2010. On September 1, 2005 the Company issued to a Directors,
10,000 options
to purchase common stock with an exercise price of $0.50, expiring on
September 1, 2010. On September 1, 2005 the Company issued an
employee 6,000 options to purchase common stock with an exercise price of $.50 per
share, expiring on September 1, 2010. In connection with grants to directors and employees the Company
will record
a change over the vesting period representing the difference between the exercise
price and the market value of the common share. On September 1, 2005 the Company issued to members of our
Scientific Advisory Board an aggregate of 30,000 options to purchase common stock
with an
exercise price of $0.50, expiring on September 1, 2010. The Company will record a charge when the options vest at the market
price based on Black-Scholes option pricing model. You
may inspect the registration statement, exhibits and schedules filed with the
Securities and Exchange Commission at the Commissions principal office in
Washington, D.C. Copies of all or any part of the registration statement may be
obtained from the Public Reference Room of the Securities and Exchange Commission,
450 Fifth Street, N.W., Washington, D.C. 20549: l-800-SEC-0330. Please call the
Commission at 1-800-SEC-0330 for further information on the operation of the
public reference rooms. The Securities and Exchange Commission also maintains a
web site at http://www.sec.gov that contains reports, proxy statements and
information
regarding registrants that file electronically with the Commission. Prospectus 10,720,000 Shares of Common
Stock
FACE="Times New Roman" SIZE="2">No person is authorized to give any information or
to make any
representation other than those contained in this prospectus, and if made such
information or representation must not be relied upon as having been given or
authorized. This prospectus does not constitute an offer to sell or a solicitation
of an
offer to buy any securities other than the securities offered by this prospectus
or an offer to sell or a solicitation of an offer to buy the securities in any
jurisdiction to any person to whom it is unlawful to make such offer or
solicitation in
such jurisdiction. The delivery of this prospectus shall not, under
any
circumstances, create any implication that there have been no changes in the
affairs of the company since the date of this prospectus. However, in the event of
a material change, this prospectus will be amended or supplemented accordingly.


SIZE="2">
<A NAME="tx97153_34"></A>PART II INFORMATION NOT REQUIRED IN PROSPECTUS
SIZE="2">Anti-Takeover, Limited Liability and Indemnification Provisions
SIZE="2">Certificate of Incorporation and Bylaws. Pursuant to our amended
certificate of incorporation, our board of directors may issue additional shares
of common or preferred stock. Any additional issuance of common stock could have
the
effect of impeding or discouraging the acquisition of control of us by means of a
merger, tender offer, proxy contest or otherwise, including a transaction in which
our stockholders would receive a premium over the market price for their shares,
and
thereby protects the continuity of our management. Specifically, if in the due
exercise of its fiduciary obligations, the board of directors was to determine
that a takeover proposal was not in our best interest, shares could be issued by
the board
of directors without stockholder approval in one or more transactions that might
prevent or render more difficult or costly the completion of the takeover by:
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">diluting the
voting or other rights of the proposed acquirer or insurgent stockholder group;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">putting a
substantial voting block in institutional or other hands that might undertake to
support the incumbent board of directors; or </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">effecting an
acquisition that might complicate or preclude the takeover.
SIZE="2">Delaware Anti-Takeover Law. We are subject to the provisions of
Section 203 of the Delaware General Corporation Law concerning corporate
takeovers. This
section prevents certain Delaware corporations from engaging in a business
combination with any interested stockholder, under certain circumstances. For
these purposes, a business combination includes a merger or sale of more than 10%
of our assets,
and an interested stockholder includes a stockholder who owns 15% or more of our
outstanding voting stock, as well as affiliates and associates of these persons.
Under these provisions, this type of business combination is prohibited for three
years
following the date that the stockholder became an interested stockholder unless:
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">the
transaction in which the stockholder became an interested stockholder is approved
by the board of directors prior to the date the interested stockholder attained
such status;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">upon
consummation of the transaction that resulted in the stockholders becoming
an interested stockholder, the interested stockholder owned at least 85% of the
voting stock of
the corporation outstanding at the time the transaction was commenced, excluding
those shares owned by persons who are directors and also officers; or
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">on or
subsequent to that date, the business combination is approved by the board of
directors and authorized at an annual or special meeting of stockholders by the
affirmative vote
of at least two-thirds of the outstanding voting stock that is not owned by the
interested stockholder. </TD></TR></TABLE> This statute could prohibit or delay mergers or other takeover or change-
in-control attempts with respect to us and, accordingly, may discourage attempts
to acquire us.
FACE="Times New Roman" SIZE="2">Limited Liability and Indemnification. Our
certificate of incorporation
eliminates the personal liability of our directors for monetary damages arising
from a breach of their fiduciary duty as directors to the fullest extent permitted
by Delaware law. This limitation does not affect the availability of equitable
remedies, such as injunctive relief or rescission. Our certificate of
incorporation requires us to indemnify our directors and officers to the fullest
extent permitted by Delaware law, including in circumstances in which
indemnification is otherwise
discretionary under Delaware law. II-1 

SIZE="2">Under Delaware law, we may indemnify our directors or officers or other
persons who were, are or are threatened to be
made a named defendant or respondent in a proceeding because the person is or was
our director, officer, employee or agent, if we determine that the person:
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">conducted
himself or herself in good faith; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">reasonably
believed, in the case of conduct in his or her official capacity as our director
or officer, that his or her conduct was in our best interests, and, in all other
cases,
that his or her conduct was at least not opposed to our best interests; and
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">in the case of
any criminal proceeding, had no reasonable cause to believe that his or her
conduct was unlawful. </TD></TR></TABLE> These persons may be indemnified against expenses, including attorney
fees, judgments, fines,
including excise taxes, and amounts paid in settlement, actually and reasonably
incurred, by the person in connection with the proceeding. If the person is found
liable to the corporation, no indemnification shall be made unless the court in
which
the action was brought determines that the person is fairly and reasonably
entitled to indemnity in an amount that the court will establish. Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to our directors, officers, and controlling persons
pursuant to the
foregoing provisions, or otherwise, we have been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public
unenforceable.
FACE="Times New Roman" SIZE="2">In the event that a claim for indemnification
against such liabilities is
asserted by one of our directors, officers, or controlling persons in connection
with the securities being registered, we will, unless in the opinion of our legal
counsel the matter has been settled by controlling precedent, submit the question
of
whether such indemnification is against public policy to court of appropriate
jurisdiction. We will then be governed by the courts decision. 
SIZE="2">Other Expenses of Issuance and Distribution 
<TD></TD>
<TD></TD></TR>
FACE="Times New Roman" SIZE="2">Securities and Exchange Commission
Fee</TD>
<TD VALIGN="bottom">$</TD>
SIZE="2">2,312</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">Accountants Fees and
Expenses</TD>
FACE="Times New Roman" SIZE="2">Legal Fees and Expenses</TD>
<TR>
FACE="Times New Roman" SIZE="2">Blue Sky Fees and Expenses</TD>
FACE="Times New Roman" SIZE="2">Printing and Mailing Costs</TD>
<TR>
FACE="Times New Roman" SIZE="2">Miscellaneous</TD>
<TR>
FACE="Times New Roman" SIZE="2">TOTAL</TD>
<TD VALIGN="bottom">$</TD>
SIZE="2">*</TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">* To be filed by amendment.

SIZE="2">Sales of Unregistered Securities. On August 22,
2001 the Company issued 3,920,000 shares of common stock to its founders.
 <P
September 1, 2001, the Company sold 285,000 shares of common stock. The offer
and
sale of such shares of our common stock were effected in reliance on the
exemptions for sales of securities not involving a public offering, as set forth
in Rule 506 promulgated under the Securities Act and in Section 4(2) of the
Securities
Act, based on the following: (a) the investors confirmed to us that they were
accredited investors, as defined in Rule 501 of Regulation D
promulgated under the Securities Act and had such background, education and
experience in
financial and business matters as to be able to evaluate the merits and risks of
an investment in the securities; (b) there was no public offering or general
solicitation with respect to the offering; (c) the investors were provided
with
certain disclosure materials and all other information requested with respect to
our company; (d) the investors acknowledged that all securities being
purchased were restricted securities for purposes of the Securities
Act, and
agreed to transfer such securities only in a transaction registered under the
Securities Act or exempt from registration under the Securities Act; and
(e) a legend was placed on the certificates representing each such security
stating that it
was restricted and could only be transferred if subsequent registered under the
Securities Act or transferred in a transaction exempt from registration under the
Securities Act. On October 12, 2001, the Company issued
300,000 shares of common stock to the principal stockholder of NCT for the
acquisition of a
certain technology from NCT for the manufacture of L-BPA. 
November 1, 2001, in connection with a consulting agreement the Company
issued 500,000 shares of common stock. On January 18, 2002 the Company issued 60,000
shares of
common stock to a member of the board of director. On
February 1, 2002
certain shareholders transferred 700,000 shares of common stock to another
shareholder who is also a convertible promissory note holder. During the period February 27, 2002 through March 5, 2002 the
Company sold an aggregate of 125,000 shares of common stock to members of the
Scientific Advisory
Board. The offer and sale of such shares of our common stock were effected in
reliance on the exemptions for sales of securities not involving a public
offering, as set forth in Rule 506 promulgated under the Securities Act and in
Section 4(2)
of the Securities Act, based on the following: (a) the investors confirmed to
us that they were accredited investors, as defined in Rule 501 of
Regulation D promulgated under the Securities Act and had such background,
education and
experience in financial and business matters as to be able to evaluate the merits
and risks of an investment in the securities; (b) there was no public
offering or general solicitation with respect to the offering; (c) the
investors were
provided with certain disclosure materials and all other information requested
with respect to our company; (d) the investors acknowledged that all
securities being purchased were restricted securities for purposes of
the Securities
Act, and agreed to transfer such securities only in a transaction registered under
the Securities Act or exempt from registration under the Securities Act; and
stating
that it was restricted and could only be transferred if subsequent registered
under the Securities Act or transferred in a transaction exempt from registration
under the Securities Act. On May 19, 2003 certain shareholders transferred 230,000 shares of
common stock to shareholders who are also
convertible promissory note holders. In addition, the stockholders transfer
100,000 shares of common stock to a consultant. On March 1, 2004 1,640,000 shares of common
stock were issued to the employees. On July 15, 2004 245,000 shares of common
stock were
issued in connection with the exercise of warrants. On August 1,
2004
130,000 shares of common stock were issued in connection with the exercise of
options. On May 20, 2004 the Company issued 5,900,000 shares of common to JED
Management LLC in connection with a private placement, subject to an escrow
such
conditions were met on completion of private placement of units. The offer and
in Rule 506
promulgated under the Securities Act and in Section 4(2) of the Securities
promulgated
under the Securities Act and had such background, education and experience in
with certain disclosure materials and all other information requested with respect
to our company; (d) the investors acknowledged that all securities being
Act, and agreed to transfer such securities only in a transaction registered under
the Securities Act or exempt from registration under the Securities Act; and
stating that it was restricted and could only be transferred if subsequent
registered under the Securities Act or transferred in a transaction exempt from
registration
under the Securities Act. On July 1, 2004 the Company
issued 625,000 in
exchange for certain notes and accrued interest aggregately $912,000. In addition,
245,000 warrants to buy the Companys common stock at $.05 per share were
exercised in July, 2004. The offer and sale of such shares of our common stock
were
effected in reliance on the exemptions for sales of securities not involving a
public offering, as set forth in Rule 506 promulgated under the Securities Act and
in Section 4(2) of the Securities Act, based on the following: (a) the
investors confirmed to us that they were accredited investors, as
defined in Rule 501 of Regulation D promulgated under the Securities Act and had
such background, education and experience in financial and business matters as to
be able
to evaluate the merits and risks of an investment in the securities;
(b) there was no public offering or general solicitation with respect to the
offering; (c) the investors were provided with certain disclosure materials
and all other
information requested with respect to our company; (d) the investors
acknowledged that all securities being purchased were restricted
securities for purposes of the Securities Act, and agreed to transfer such
securities only in a
transaction registered under the Securities Act or exempt from registration under
the Securities Act; and (e) a legend was placed on the certificates
representing each such security stating that it was restricted and could only be
transferred
if subsequently registered under the Securities Act or transferred in a
transaction exempt from registration under the Securities Act. During the period from August 23 through November 9,
2004 the Company completed a private
placement of its securities and sold 3,610,000 units at $.50 per unit and raised
gross proceeds of $1,805,000. Each unit consisted of one share of common stock and
one warrant. The warrant is exercisable at $1.50 per share through
January 15,
2008. The warrants are subject to redemption at the Companys sole option
after one year from date of issuance if the common stock price has average 150% of
warrants exercise price per share at redemption price $.01 per warrant. The offer
and
in Rule 506 promulgated under the Securities Act and in Section 4(2) of the
Securities
promulgated under the Securities Act and had such background, education and
experience in
with
certain disclosure materials and all other information requested with respect to
our company; (d) the investors acknowledged that all securities being
Act, and
agreed to transfer such securities only in a transaction registered under the
Securities Act or exempt from registration under the Securities Act; and
stating that it
was restricted and could only be transferred if subsequently registered under the
Securities Act or transferred in a transaction exempt from registration under the
Securities Act. The offers and issuances of the options to
purchase shares of our common stock described in the preceding paragraph were
effected in
reliance on the exemption for offers and sales under certain compensatory benefit
plans as set forth in Rule 701 promulgated under the Securities Act, based on the
following: (a) the offers and issuances were made under a written
compensatory
benefit plan established by us for the compensation of our officers, employees,
directors, consultants and other permitted persons; (b) the recipients of
such options were officers, employees, directors, consultants or other permitted
persons
at the time of the issuance of the options (and any recipients that were
consultants provided bona fide services unrelated to a capital-raising transaction
or the promotion of a market for our stock in exchange for such options);
(c) we were
not subject to the reporting requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended, at the time of issuance of the
options; (d) the aggregate sale price, calculated in accordance with Rule
701, if the
options issued in reliance on Rule 701 during any 12-month period did not exceed
$1.0 million; (e) all recipients were provided with certain disclosure
materials and all other information requested with respect to our company,
including a copy
of the governing compensatory benefit document; (f) the option recipients
acknowledged that all securities being purchased were restricted
securities for purposes of the Securities Act, and agreed to transfer such
securities only in
a transaction registered under the Securities Act or exempt from registration
under the Securities Act; and (g) the governing option agreement requires
that, unless otherwise permitted by law, a legend be placed on the certificates
representing
each such equity security stating that it was restricted and could only be
transferred if subsequently registered under the Securities Act or transferred in
a transaction exempt from registration under the Securities Act. Undertakings The undersigned registrant hereby undertakes:
FACE="Times New Roman" SIZE="2">(a) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers
and
controlling persons of the registrant pursuant to the provisions described under
Item 14 above, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against
public
unenforceable. In the event that a claim for indemnification against such
liabilities 
(other than the payment by the registrant of
expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled
by
controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the
Securities Act of 1933 and will be governed by the final adjudication of such
issue.
FACE="Times New Roman" SIZE="2">(b) The undersigned registrant hereby undertakes:
 (1) To file, during any period in which offers or sales are being
made, a
post-effective amendment to this Registration Statement; (2)
To include any prospectus required by section 10(a)(3) of the Securities Act of
1933; (3) To reflect in the prospectus any facts or
events arising after the effective date of the Registration Statement (or the most
recent post-effective amendment thereof) which, individually, or in the aggregate,
represent a fundamental change in the information set forth in the Registration
Statement; notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not
exceed that
which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than a 20% change in the maximum aggregate offering price
set forth in the Calculation of Registration Fee table in the
effective Registration Statement; and (4) To include any material information with respect to the plan
of
distribution not previously disclosed in the Registration Statement or any
material change to such information in the Registration Statement (i) That, for the purpose of determining any
liability under the Securities Act of 1933, each post-effective amendment shall be
deemed to
be a new Registration Statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof; and (ii) To remove from registration by means of a
post-effective amendment any of the securities being registered which remain
unsold at the termination of the Offering. (c)
The undersigned registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act, each filing of the registrants annual
report pursuant to Section 13(a) or Section 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plans annual report pursuant to Section 15(d) of the Securities
Exchange Act of
1934) that is incorporated by reference in the Registration Statement shall be
deemed to be a new Registration Statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial
bona fide offering thereof. 
<A NAME="ii97153_32"></A>Exhibits 
<TD></TD>
<TR>
ALIGN="center">Exhibit Number<HR WIDTH="37" SIZE="1" NOSHADE
COLOR="#000000"></TD>
New Roman" SIZE="1">Description<HR WIDTH="54" SIZE="1" NOSHADE
<TR>
SIZE="2"> 3.1</TD>
<TD VALIGN="bottom">Amended Certificate of
Incorporation (1)</TD></TR>
<TR>
<TR>
<TD VALIGN="bottom">By-Laws
(1)</TD></TR>
<TR>
<TR>
<TD VALIGN="bottom">2005 Stock Option Plan
(1)</TD></TR>
<TR>
<TR>
<TD VALIGN="bottom">Legal opinion of Joseph
I. Emas, Attorney At Law with consent to use (1)</TD></TR>
<TR>
<TR>
<TD VALIGN="bottom">Employment Agreement for
Ivan Kanevski (1)</TD></TR>
<TR>
<TR>
J. R. LeShufy (1)</TD></TR>
<TR>
<TR>
Lucy Ostrovsky (1)</TD></TR>
<TR>
<TR>
<TD VALIGN="bottom">Consulting Agreement for
Rifat Pamukcu (1)</TD></TR>
<TR>
<TR>
<TD VALIGN="bottom">Consent of Independent
Registered Public Accounting Firm (1)</TD></TR>
<TR>
<TR>
<TD VALIGN="bottom">Consent of Joseph I.
Emas (included in Exhibit 5.1) (1)</TD></TR>
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Filed
herewith. </TD></TR></TABLE> Signatures <P
accordance with the requirements of the Securities Act of 1933, the registrant
certifies
that it has reasonable grounds to believe that it meets all of the requirements of
filing on Form SB-2 and authorized this registration statement to be signed on its
behalf by the undersigned, on the 13 day of October, 2005. <DIV
ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">
<TR>
<TR>
<TR>
<TD VALIGN="top">By:</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/S/ IVAN
KANEVSKI </TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center">Ivan
Kanevski</TD></TR>
<TR>
SIZE="1">President, CEO, Director</TD></TR>
</TABLE></DIV> ALL MEN BY THESE PRESENT, that
each person whose signature appears below constitutes and appoints J.R. LeShufy,
his true and lawful attorney-in-fact and agent, with full power of substitution
and re-substitution, for him and in his name, place and stead, in any and all
capacities, to sign any and all pre- or post-effective amendments to this
registration statement, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission,
granting unto
said attorneys-in-fact and agents, and each of them, full power and authority to
do and perform each and every act and thing requisite or necessary to be done in
and about the premises, as fully to all intents and purposes as he might or could
do in
person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or any one of them, or their or his substitutes, may lawfully do or cause
to be done by virtue hereof. In accordance with the requirements of the
Securities Act of 1933, this registration statement was signed by the following
persons in the
capacities and on the dates stated: 
<TR>
SIZE="1">Signatures<HR WIDTH="60" SIZE="1" NOSHADE
COLOR="#000000"></TD>
ALIGN="center">Title<HR
WIDTH="25" SIZE="1" NOSHADE COLOR="#000000"></TD>
ALIGN="center">Date<HR
WIDTH="26" SIZE="1" NOSHADE COLOR="#000000"></TD></TR>
<TR>
<TR>
<TD VALIGN="top"> /S/ IVAN
KANEVSKI <HR SIZE="1" NOSHADE
COLOR="#000000">
Roman" SIZE="1">(Ivan Kanevski)</TD>
FACE="Times New Roman" SIZE="2">President, Chief Executive Officer,
Director</TD>
<TD VALIGN="top" ALIGN="center">October 13,
2005</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">/S/ J.R.
LESHUFY <HR
SIZE="1" NOSHADE COLOR="#000000">
Roman" SIZE="1">(J.R. LeShufy)</TD>
FACE="Times New Roman" SIZE="2">Executive Vice President, Treasurer,
Director</TD>
2005</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">/S/ RIFAT
PAMUKCU <HR SIZE="1" NOSHADE
COLOR="#000000">
Roman" SIZE="1">(Rifat Pamukcu)</TD>
FACE="Times New Roman" SIZE="2">Chairman, Director</TD>
2005</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">/S/ NORMAN
HEYMAN <HR SIZE="1" NOSHADE
COLOR="#000000">
Roman" SIZE="1">(Norman Heyman)</TD>
FACE="Times New Roman" SIZE="2">Vice President, Director</TD>
2005</TD></TR>

Roman" SIZE="2">
<A NAME="tx97153_35"></A>EXHIBIT INDEX 
<TD></TD>
<TR>
SIZE="1">Exhibit No. <HR WIDTH="62" SIZE="1" NOSHADE
COLOR="#000000"></TD>
New Roman" SIZE="1">Description<HR WIDTH="65" SIZE="1" NOSHADE
<TR>
<TR>
SIZE="2"> 3.1 </TD>
<TD VALIGN="bottom">Amended Certificate of
Incorporation</TD></TR>
<TR>
<TR>
SIZE="2"> 3.2 </TD>
<TD VALIGN="bottom">By-Laws</TD></TR>
<TR>
<TR>
SIZE="2"> 3.3 </TD>
<TD VALIGN="bottom">2005 Stock Option
Plan</TD></TR>
<TR>
<TR>
SIZE="2"> 5.1 </TD>
<TD VALIGN="bottom">Legal opinion of Joseph
I. Emas, Attorney At Law with consent to use</TD></TR>
<TR>
<TR>
SIZE="2">10.1 </TD>
Ivan Kanevski</TD></TR>
<TR>
<TR>
SIZE="2">10.2 </TD>
J. R. LeShufy</TD></TR>
<TR>
<TR>
SIZE="2">10.3 </TD>
Lucy Ostrovsky</TD></TR>
<TR>
<TR>
SIZE="2">10.4 </TD>
<TD VALIGN="bottom">Consulting Agreement for
Rifat Pamukcu</TD></TR>
<TR>
<TR>
SIZE="2">23.1 </TD>
<TD VALIGN="bottom">Consent of Independent
Registered Public Accounting Firm</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>dex31.htm
<DESCRIPTION>AMENDED CERTIFICATE OF INCORPORATION
<TEXT>
<HTML><HEAD>
<TITLE>Amended Certificate of Incorporation</TITLE>
</HEAD>

Roman" SIZE="2">Exhibit 3.1 Amended Certificate of Incorporation 
<TR>
<TD ALIGN="left" VALIGN="top">Name.
The name of the corporation is GLYCONIX CORP. (the Corporation).
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Registered
Office and Registered Agent. The address if the Corporations registered
office in the State of Delaware is 615 South DuPont Highway, in the City of Dover,
County of Kent, 19901. The name of the Corporations registered agent at such
address is National Corporate Research, Ltd. </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Corporate
Purposes. The purpose of the Corporation is to engage in any lawful act or
activity for which corporations may be organized under the General Corporation law
of the
State of Delaware (the Corporation Law). </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Authorized
Capital. The total number of shares of all classes of capital stock which the
Corporation shall have authority to issue is 45 million shares from which
40 million share of common stock, par value $.01 per share (the
Stock), and 5 million of cumulative dividend right preferred
stock (the Preferred Stock), convertible to the Stock, and can be
issued on multiple
series, each with its own provisions, par value $.01 per share. The powers,
preferences and rights and the qualifications, limitations and restrictions of the
Stock are as set forth below: </TD></TR></TABLE> 
<TR>
SIZE="2">a.</TD>
SIZE="2">Dividends. When, as and if dividends are declared of the Stock,
whether payable in cash, in property or in securities of the Corporation, the
holders of shares of the Stock
shall be entitled to share equally, share for share, in such dividends.
WIDTH="100%">
<TR>
SIZE="2">b.</TD>
<TD ALIGN="left" VALIGN="top">Voting
Rights. Except as otherwise provided by law and this Certificate of
Incorporation, the holders of shares of the Stock shall be entitled to one vote
per share on all
matters to be voted on by the Stockholders of the Corporation.
WIDTH="100%">
<TR>
SIZE="2">c.</TD>
<TD ALIGN="left" VALIGN="top">No Pre-
Emptive Rights. No holder of the Stock shall, except as provided herein, be
entitled as a matter of right to subscribe for or purchase, or have any preemptive
right
with respect to, any part of any new or additional issue of stock of any class
whatsoever, or of securities convertible into any stock of any class whatsoever,
whether now or hereafter authorized and whether issued for cash or other
consideration or
by way of dividend. </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Management
of Business. The following provisions are inserted for the management of the
business and for the conduct of the affairs of the Corporation, and for further
definition, limitation and regulation of the powers of the Corporation and of its
directors and stockholders: </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Bylaws.
The original Bylaws of the Corporation shall be adopted by the sole
incorporator. In furtherance and not in limitation of the powers conferred by
statute, the Board
of Directors is expressly authorized to adopt. Amend or repeal the Bylaws of the
Corporation. </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Number and
Election of Directors. The number of Directors from time to time shall be
fixed by, or in the manner provided in, the Bylaws of the Corporation. The
election of
directors need not be by written ballot unless the Bylaws of the Corporation so
provide. </TD></TR></TABLE> 
<TR>
SIZE="2">Indemnification by the Corporation; Liability of Directors. The
directors of the Corporation shall be entitled to the benefits of all limitations
on the
liability of directors generally that are now or hereafter become available under
the Corporation Law, and the Corporation shall indemnify all persons whom it is
permitted to indemnify to the full extent permitted by Section 145 of the
Corporation Law, as amended from time to time. Without limiting the generality of
the foregoing, no director of the Corporation shall be liable to the Corporation
or its stockholders for monetary 
</TD></TR></TABLE>

WIDTH="100%">
<TR>
damages for breach of fiduciary duty as a
director, except for liability (i) for any break of the directors duty
of loyalty to the Corporation or
its stockholders, (ii) for acts or omissions not in good faith or which
involve intentional misconduct or knowing violation of law, (iii) under
Section 174 of the Corporation law, or (iv) for any transaction from
which the
director derived an improper personal benefit. Any repeal or modification or this
Section 7 shall be prospective only, and shall not affect, to the detriment
of any director, any limitation on the personal liability of a director of the
Corporation existing at the time of such repeal or modification.
</TD></TR></TABLE> 
<TR>
SIZE="2">Incorporator. The name and mailing address of the sole
incorporator is as follow: </TD></TR></TABLE> 
<TR>
New Roman" SIZE="1">Mailing address<HR WIDTH="85" SIZE="1"
NOSHADE ALIGN="left" COLOR="#000000"></TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">J. R. LeShufy</TD>
New Roman" SIZE="2">14 Bound Street, Suite 234 Great Neck, NY
11021</TD></TR>
indent:4%">The undersigned,
being the sole incorporator hereinbefore named, for the purpose of forming a
corporation pursuant to the General Corporation Law of the State of Delaware, does
make this Certificate, hereby declaring and certifying that the facts herein
stated are
true, and accordingly has hereunto set his hand this 21th day of August, 2001. <DIV
ALIGN="right">
<TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
FACE="Times New Roman" SIZE="2">/s/ J. R.
LESHUFY </SMA
LL></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>dex32.htm
<DESCRIPTION>BY-LAWS
<TEXT>
<HTML><HEAD>
<TITLE>By-Laws</TITLE>
</HEAD>

SIZE="2">BY-LAWS of GLYCONIX CORP. ARTICLE I Stockholders Section 1.01 Annual Meeting. The annual meeting of the
stockholders of the Corporation shall be held annually at such place within or
without the State of
Delaware, at such time and on such date as may from time to time be designated by
the Board of Directors, for the election of directors and for the transaction of
any other proper business. Section 1.02 Special Meetings. Special meetings of the
stockholders of the
Corporation may be called at any time and from time to time by the President or by
a majority of the directors then in office, and shall be called by the Secretary
upon the written request of stockholders holding of record at least a majority in
number of the issued and outstanding shares of the Corporation entitled to vote at
such meeting. Special meetings shall be held at such place within or without the
State of Delaware, at such time and on such date as shall be specified in the call
thereof. Section 1.03 Notice of Meetings.
Written notice of each
meeting of the stockholders, stating the place, date and hour thereof and, in the
case of a special meeting, the purpose or purposes for which it is called, shall
be given, not less than ten nor more than sixty days before the date of such
meeting
(or at such other time as may be required by statute), to each stockholder
entitled to vote at such meeting. If mailed, such notice is given when deposited
in the United States mail, postage prepaid, directed to each stockholder at his or
her
address as it appears on the records of the Corporation. Section 1.04
Waiver of Notice. Whenever notice is required to be given of any annual or
special meeting of the stockholders, a written waiver thereof, signed by the
person entitled to notice, whether before or after the time stated in such notice,
shall
be deemed equivalent to notice. Neither the business to be transacted at, nor the
purpose of, any regular or special meeting of the stockholders need be specified
in any written waiver of notice. Attendance of a person at a meeting of the
stockholders shall constitute a waiver of notice of such meeting, except when the
person attends a meeting for the express purpose of objecting, at the beginning of
the meeting, to the transaction of any business because the meeting is not
lawfully
called or convened. Section 1.05 Adjournment. When any
meeting of
the stockholders is adjourned to another time or place, notice need not be given
of the adjourned meeting if the time and place to which the meeting is adjourned
are announced at the meeting at which the adjournment is taken. At the adjourned
meeting any business may be transacted which might have been transacted at the
original meeting. If the adjournment is for more than 30 days, or if after such
adjournment the Board of Directors shall fix a new record date for the adjourned
meeting,
a notice of the adjourned meeting shall be given to each stockholder of record
entitled to vote at such meeting. Section 1.06 Quorum. At any meeting of the stockholders the
presence, in person or by proxy, of the holders of a majority of the issued and
outstanding shares
of the Corporation entitled to vote at such meeting shall be necessary in order to
constitute a quorum for the transaction of any business. If there shall not be a
quorum at any meeting of the stockholders, the holders of a majority of the shares
entitled to vote present at such meeting, in person or by proxy, may adjourn such
meeting from time to time, 

without further notice to the stockholders
other than an announcement at such meeting, until holders of the amount of shares
required to constitute a quorum
shall be present in person or by proxy. Section 1.07
Voting. Each
stockholder shall be entitled to one vote for each share of capital stock held by
such stockholder. Voting need not be by ballot, except that all election of
directors shall be by written ballot unless otherwise provided in the Certificate
of
Incorporation. Whenever any corporate action is to be taken by vote of the
stockholders, it shall, except as otherwise required by law or by the Certificate
of Incorporation, be authorized by a majority of the votes cast at a meeting of
stockholders
of the holders of shares entitled to vote thereon, except that all elections shall
be decided by a plurality of the votes cast. Section 1.08 Action Without a Meeting. Any action required or
permitted to be taken at any annual or special meeting of stockholders may be
taken without a
meeting thereof, without prior notice and without a vote, if a consent in writing,
setting forth the action so taken, shall be signed by the holders of outstanding
stock having not less than the minimum number of votes that would be necessary to
authorize or take such action at a meeting at which all shares entitled to vote
thereon were present and voted. Prompt notice of the taking of such corporate
action without a meeting by less than unanimous written consent shall be given to
those
stockholders who have not consented in writing. Section 1.09 Record Date A. The Board of
Directors may fix, in advance, a record date, which shall not be more than sixty
nor less than ten days before the date of any meeting of stockholders, nor more
than sixty days prior to any other action, as the record date for the purpose of
determining the stockholders entitled to notice of or to vote at any meeting of
the stockholders or any adjournment thereof, or to express consent to corporate
action in writing without a meeting, or entitled to receive payment of any
dividend or
distribution or allotment of any rights, or entitled to exercise any rights in
respect of any change, conversion or exchange of stock or for the purpose of any
other lawful action. B. In order that the Corporation
may determine the stockholders entitled to consent to corporate action in writing
without a
meeting, the Board of Directors may fix a record date, which record date shall not
precede the date upon which the resolution fixing the record date is adopted by
the Board of Directors, and which date shall not be more than ten (10) days
after
the date upon which the resolution fixing the record date is adopted by the Board
of Directors (or such later date as the stockholder may request). Any stockholder
of record seeking to have the stockholders authorize or take corporate action by
written consent shall, by written notice to the Secretary of the Corporation,
request the Board of Directors to fix a record date. The Board of Directors shall
promptly, but in all events within ten (10) days after the date on which such
a
request is received, adopt a resolution fixing the record date. If no record date
has been fixed by the Board of Directors within ten (10) days after the date
on which such request is received, the record date for determining stockholders
entitled to consent to corporate action in writing without a meeting, when no
prior action by the Board of Directors is required by applicable law, shall be the
first date on which a signed written consent setting forth the action taken or
proposed
to be taken is delivered to the Corporation by delivery to its registered office
in the State of Delaware, its principal place of business, or any officer or agent
of the Corporation having custody of the book in which proceedings of
stockholders meetings are recorded, to the attention of the Secretary of the
Corporation. Delivery shall be by hand or by certified or registered mail, return
receipt requested. If no record date has been fixed by the Board of Directors and
prior action by the Board of Directors is required by applicable law, the record
date for determining stockholders entitled to consent to corporate action in
writing without a meeting shall be at the close of business on the date on which
the Board
of Directors adopts the resolution taking such prior action. 

SIZE="2">Section 1.10 Proxies. Each stockholder entitled to vote at a
meeting of stockholders or to express consent or
dissent to corporate action in writing without a meeting may authorize another
person or persons to act for him or her by proxy, but no such proxy shall be voted
or acted upon after three years from its date, unless the proxy provides for a
longer
period. Section 1.11 Advance Notice for New
Business. No business
may be transacted at an annual meeting of shareholders, other than business that
is either (a) specified in the notice of meeting (or any supplement thereto)
given by or at the direction of the Board of Directors (or any duly authorized
committee thereof), (b) otherwise properly brought before the annual meeting
by or at the direction of the Board of Directors (or any duly authorized committee
thereof) or (c) otherwise properly brought before the annual meeting by any
shareholder of the Corporation (i) who is a shareholder of record on the date
of the giving of the notice provided for in this Section 11 and on the record
date for the determination of shareholders entitled to vote at such annual meeting
and (ii) who complies with the notice procedures set forth in this
Section 11. In addition to any other applicable requirements,
for business to be properly brought before an annual meeting by a shareholder,
such shareholder must have given timely notice thereof in proper written form to
the
Secretary of the Corporation. To be timely, a
shareholders notice to the Secretary must be delivered to or mailed and
received at the principal executive offices of the Corporation not less than
ninety (90) days prior to the anniversary date of the immediately preceding
annual
meeting of shareholders; provided, however, that in the event that the annual
meeting is called for a date that is not within thirty (30) days before or
after such anniversary date, notice by the shareholder in order to be timely must
be so
received not later than the close of business on the tenth (10th) day
following the day on which such notice of the date of the annual meeting was
mailed or such public disclosure of the date of the annual meeting was made,
whichever first
occurs. To be in proper written form, a
shareholders
notice to the Secretary must set forth as to each matter such shareholder proposes
to bring before the annual meeting (i) a brief description of the business
desired to be brought before the annual meeting and the reasons for conducting
such
business at the annual meeting, (ii) the name and record address of such
shareholder, (iii) the class or series and number of shares of capital stock
of the Corporation which are owned beneficially or of record by such shareholder,
(iv) a description of all arrangements or understandings between such
shareholder and any other person or persons (including their names) in connection
with the proposal of such business by such shareholder and any material interest
of such
shareholder in such business and (v) a representation that such shareholder
intends to appear in person or by proxy at the annual meeting to bring such
business before the meeting. In addition, notwithstanding anything in this
Section 11
to the contrary, a shareholder intending to nominate one or more persons for
election as a Director at an annual or special meeting must comply with
Section 12, Article I of these By-Laws for such nomination or nominations to
be properly
brought before such meeting. No business
shall be conducted at
the annual meeting of shareholders except business brought before the annual
meeting in accordance with the procedures set forth in this Section 11,
provided, however, that, once business has been properly brought before the annual
meeting in
accordance with such procedures, nothing in this Section 11 shall be deemed
to preclude discussion by any shareholder of any such business. If the Chairman of
an annual meeting determines that business was not properly brought before the
annual
meeting in accordance with the foregoing procedures, the Chairman shall declare to
the meeting that the business was not properly brought before the meeting and such
business shall not be transacted. 

SIZE="2">Section 1.12 Advance Notice for Nominations of Directors.
Only persons who are nominated in accordance with
the following procedures shall be eligible for election as Directors of the
Corporation, except as may be otherwise provided in the Certificate of
Incorporation with respect to the right of holders of preferred stock of the
Corporation to nominate
and elect a specified number of directors in certain circumstances. Nominations of
persons for election to the Board of Directors may be made at any annual meeting
of shareholders, or at any special meeting of shareholders called for the purpose
of
electing directors, (a) by or at the direction of the Board of Directors (or
any duly authorized committee thereof) or (b) by any shareholder of the
Corporation (i) who is a shareholder of record on the date of the giving of
the
notice provided for in this Section 12 and on the record date for the
determination of shareholders entitled to vote at such meeting and (ii) who
complies with the notice procedures set forth in this Section 12. 
In addition to any other applicable requirements, for a nomination
to be made
by a shareholder, such shareholder must have given timely notice thereof in proper
written form to the Secretary of the Corporation. To be timely, a shareholders notice to the Secretary must be
delivered to or mailed and received at the principal executive offices of the
Corporation (a) in the case of an annual meeting, not less ninety
(90) days prior to the anniversary date of the immediately preceding annual
meeting of shareholders; provided, however, that in the event that the annual
meeting is called
or a date that is not within thirty (30) days before or after such
anniversary date, notice by the shareholder in order to be timely must be so
received not later than the close of business on the tenth (10th) day
following the day on
which such notice of the date of the annual meeting was mailed or such public
disclosure of the date of the annual meeting was made, whichever first occurs; and
(b) in the case of a special meeting of shareholders called for the purpose
of
electing directors, not later than the close of business on the tenth
(10th) day following the day on which notice of the date of the special
meeting was mailed or public disclosure of the date of the special meeting was
made, whichever first
occurs. To be in proper written form, a
shareholders
notice to the Secretary must set forth (a) as to each person whom the
shareholder proposes to nominate for election as a director (i) the name,
age, business address and residence address of the person, (ii) the principal
occupation
or employment of the person, (iii) the class or series and number of shares
of capital stock of the Corporation which are owned beneficially or of record by
the person and (iv) any other information relating to the person that would
be
required to be disclosed in a proxy statement or other filings required to be made
in connection with solicitations of proxies for election of directors pursuant to
Section 14 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), and the rules and regulations promulgated thereunder;
and (b) as to the shareholder giving the notice (i) the name and record
address of such shareholder, (ii) the class or series and number of shares of
capital stock of the Corporation which are owned beneficially or of record by such
shareholder, (iii) a description of all arrangements or understandings
between such shareholder and each proposed nominee and any other person or persons
(including their names) pursuant to which the nominations) are to be made by such
shareholder, (iv) a representation that such shareholder intends to appear in
person or by proxy at the meeting to nominate the persons named in its notice and
(v) any other information relating to such shareholder that would be required
to be disclosed in a proxy statement or other filings required to be made in
connection with solicitations of proxies for election of directors pursuant to
Section 14 of the Exchange Act and the rules and regulations promulgated
thereunder. Such notice must be accompanied by a written consent of each proposed
nominee to being named as a nominee and to serve as a director if elected.
 No person shall be eligible for election as a director of the
Corporation
unless nominated in accordance with the procedures set forth in this
Section 12. If the Chairman of the meeting determines 

that a nomination was not made in accordance
with the foregoing procedures, the Chairman shall declare to the meeting that the
nomination was defective and
such defective nomination shall be disregarded. ARTICLE II Directors
SIZE="2">Section 2.01 Number; Qualifications. The Board of Directors
shall consist of one or more members. The number of directors shall be fixed by
the Board of
Directors, but shall not be less than three or more than eight. Directors need not
be stockholders of the Corporation. Section 2.02 Term of Office. Each director shall hold office
until his or her successor is elected and qualified or until his or her earlier
death,
resignation or removal. Section 2.03
Meetings. A meeting of the
Board of Directors shall be held for the election of officers and for the
transaction of such other business as may come before such meeting as soon as
practicable after the annual meeting of the stockholders. Other regular meetings
of the Board of
Directors may be held at such times as the Board of Directors of the Corporation
may from time to time determine. Special meetings of the Board of Directors may be
called at any time by the President of the Corporation or by a majority of the
directors then in office. Meetings of the Board of Directors may be held within or
without the State of Delaware. Section 2.04 Notice of Meetings; Waiver of Notice;
Adjournment. No notice need be given of the first meeting of the Board of
Directors after the annual
meeting of stockholders or of any other regular meeting of the Board of Directors.
Notice of a special meeting of the Board of Directors, specifying the place, date
and hour thereof, shall be delivered personally, mailed or telegraphed to each
director at his or her address as such address appears on the books of the
Corporation at least two business days (Saturdays, Sundays and legal holidays not
being considered business days for the purpose of these By-Laws) before the date
of such
meeting. Whenever notice is required to be given under any provision of the
Certificate of Incorporation or these By-Laws, a written waiver thereof, signed by
the person entitled to notice, whether before or after the time stated therein,
shall be
deemed equivalent to notice. Attendance of a director at a special meeting shall
constitute a waiver of notice of such meeting, except when the person attends a
meeting for the express purpose of objecting, at the beginning of the meeting, to
the
transaction of any business because the meeting is not lawfully called or
convened. Neither the business to be transacted at, nor the purpose of, any
regular or special meeting of the stockholders, the directors or any committee of
directors need
be specified in any written waiver of notice unless so required by the Certificate
of Incorporation or these By-Laws. A majority of the directors present whether or
not a quorum is present, may adjourn any meeting to another time and place. Notice
need not be given of the adjourned meeting if the time and place to which the
meeting is adjourned are announced at the meeting at which the adjournment is
taken, and at the adjourned meeting any business may be transacted that might have
been
transacted at the original meeting. Section 2.05 Quorum;
Voting. A
majority of the total number of directors shall constitute a quorum for the
transaction of business. The vote of the majority of the directors present at a
meeting at which a quorum is present shall be the act of the Board of Directors.

SIZE="2">Section 2.06 Participation by Telephone. Members of the Board
of Directors or
any committee thereof may participate in a meeting of the Board of Directors or
such committee by means of a conference telephone or similar communications
equipment by means of which all persons participating in the meeting can hear each
other, and
participation in a meeting by such means shall constitute presence in person at
such meeting. 
SIZE="2">Section 2.07 Action Without a Meeting. Any action required or
permitted to be taken at any meeting of the
Board of Directors or of any committee thereof may be taken without a meeting if
all members of the Board of Directors or such committee, as the case may be,
consent thereto in writing, and the writing or writings are filed with the minutes
of
proceeding of the Board of Directors or of such committee. Section 2.08
Committees. The Board of Directors may, by resolution passed by a majority
of the whole Board, designate one or more committees, each committee to consist of
one or more of the directors. Any such committee, to the extent provided in the
resolution of the Board of Directors, shall have and may exercise all the powers
and authority of the Board of Directors in the management of the business and
affairs of the Corporation, and may authorize the seal of the Corporation to be
affixed by
the officers on all papers which may require it, but no such committee shall have
the power or authority in reference to (a) amending the Certificate of
Incorporation (except that a committee may, to the extent authorized in the
resolution or
resolutions providing for the issuance of shares of stock adopted by the Board of
Directors, fix the designations and any of the preferences or rights of such
shares relating to dividends, redemption, dissolution, any distribution of the
assets of
the Corporation or the conversion into, or the exchange of such shares for, shares
of any other class or classes or any other series of the same or any other class
or classes of stock of the Corporation, or fix the number of shares of any series
of
stock or authorize the increase or decrease of the shares of any series);
(b) adopting an agreement of merger or consolidation; (c) recommending
to the stockholders the sale, lease or exchange of all or substantially all of the
Corporations property and assets; (d) recommending to the stockholders
a dissolution of the Corporation or a revocation of a dissolution; or
(e) amending these By-Laws and, unless the resolution expressly so provides,
no such
committee shall have the power or authority to declare a dividend or to authorize
the issuance of stock. The Board of Directors may designate one or more directors
as alternate members of any such committee, who may replace any absent or
disqualified member at any meeting of such committee. In the absence or
disqualification of a member of a committee, the member or members thereof present
at any meeting and not disqualified from voting, whether or not constituting a
quorum, may
unanimously appoint another director to act at the meeting in the place of such
absent or disqualified member. Section 2.09 Removal; Resignation. Any
director or the entire Board of Directors may be removed with or without cause, by
the holders of a majority of the shares then entitled to vote at an election of
directors. Any director may resign at any time, upon written notice to the
Corporation. Section 2.10 Vacancies. Vacancies and newly created
directorships resulting from any increase in the authorized number of directors
may be filled by a majority of directors then in office, although less than a
quorum, or by a
sole remaining director. When one or more directors shall resign from the Board of
Directors, effective at a future date, a majority of the directors then in office,
including those who have so resigned, shall have power to fill such vacancy or
vacancies, the vote thereon to take effect when such resignation or resignations
shall become effective, and each director so chosen shall hold office as provided
above in the filling of other vacancies. A director elected to fill a vacancy
shall
hold office for the unexpired term of his or her predecessor and until his
successor is elected and qualified. Section 2.11 Compensation. The Board
of Directors may fix the compensation of directors. ARTICLE III Officers Section 3.01 Election; Qualifications. As soon as practicable
after each annual meeting of stockholders, and otherwise to fill any vacancies,
the Board of
Directors shall elect or appoint a Chairman of the Board, a President, a Chief
Executive Officer, a Secretary and a Treasurer, and may elect or appoint at such
time 

or from time to time such Vice Presidents
and additional officers as it deems advisable. No officer need be a director of
the Corporation. The office of
Chairman of the Board may be shared by two or more persons. Any number of offices
may be held by the same person, except that there shall always be two persons who
hold offices which entitle them to sign instruments and stock certificates.
FACE="Times New Roman" SIZE="2">Section 3.02 Term of Office;
Vacancies. Each officer shall hold
office until the election and qualification of his or her successor or until his
or her earlier death, resignation or removal. Any vacancy occurring in any office,
whether because of death, resignation or removal, with or without cause, or other-
wise, shall be filled by the Board of Directors. Section 3.03
Removal;
Resignation. Any officer may be removed from office at any time with or
without cause by the Board of Directors. Any officer may resign his or her office
at any time upon written notice to the Corporation. Section 3.04 Chief Executive Officer. The Board shall appoint
a chief executive
officer of the Corporation who shall have the general charge and supervision of
its business affairs. The chief executive officer shall from time to time make
such reports concerning the Corporation as the Board of Directors of the
Corporation may
require. The chief executive officer is not required to hold any other office, but
the Board shall nominate and do each thing in its power to cause the election of
the chief executive officer as a Director, and the chief executive officer shall
seek
a Directorship if nominated and accept and fulfill the responsibilities of such
position if elected. Section 3.05 Executives. The Board may
appoint, if it chooses, one or more of the following subordinate executive
officers: chief operating officer, chief financial officer, chief administrative
officer,
general counsel, each of whom may be, but is not required to be, a Director, the
Secretary, the Treasurer, the President, and/or the Chairman of the Board. Such
subordinate executive officers shall have the powers and perform such duties as
may from
time to time be assigned to him or her by the Board of Directors. Section 3.06 Powers and Duties of the Chairman of the Board.
The Chairman of the Board shall preside at all meetings of the stockholders and
the Board of Directors. The Chairman of the Board shall have such other powers and
perform such other duties as may from time to time be assigned to him or her by
the Board of Directors. Section 3.07 Powers and Duties of the
President. The President, if not the same person as the Chairman of the Board,
shall be act for the Chairman of the Board when the Chairman is unable to fulfill
his
duties, and shall perform such other duties as may from time to time be assigned
to him or her by the Board of Directors. Section 3.08 Powers and Duties of the Vice-Presidents. Each
of the Vice-Presidents shall be given such titles and designations and shall have
such powers and
perform such duties as may from time to time be assigned to him or her by the
Board of Directors. Section 3.09 Powers and Duties of the
Secretary. The Secretary shall record and keep the minutes of all meetings of
the stockholders and of the Board of Directors in a book to be kept for that
purpose. The
Secretary shall attend to the giving and serving of all notices by the
Corporation. The Secretary shall be the custodian of, and shall make or cause to
be made the proper entries in, the minute book of the Corporation and such other
books and
records as the Board of Directors may direct. The Secretary shall be the custodian
of the corporate seal of the Corporation and shall affix or cause to be affixed
such seal to such contracts and other instruments as the Board of Directors may
direct. The Secretary shall have such other powers and shall perform such other
duties as may from time to time be assigned to him or her by the Board of
Directors. 

SIZE="2">Section 3.10 Powers and Duties of the Treasurer. The
Treasurer shall be the custodian of all funds and
securities of the Corporation. Whenever required by the Board of Directors, the
Treasurer shall render a statement of the Corporations cash and other
accounts, and shall cause to be entered regularly in the proper books and records
of the
Corporation to be kept for such purpose full and accurate accounts of the
Corporations receipts and disbursements. The Treasurer shall at all
reasonable times exhibit the Corporations books and accounts to any director
of the Corporation
upon application at the principal office of the Corporation during business hours.
The Treasurer shall have such other powers and shall perform such other duties as
may from time to time be assigned to him or her by the Board of Directors.
FACE="Times New Roman" SIZE="2">Section 3.11 Delegation. In the event
of the absence of any
officer of the Corporation or for any other reason that the Board of Directors may
deem sufficient, the Board of Directors may at any time or from time to time
delegate all or any part of the powers or duties of any officer to any other
officer or
officers or to any director or directors. ARTICLE IV Stock
Roman" SIZE="2">The shares of the Corporation shall be represented by certificates
signed by the Chairman of the Board, the President or any Vice-President and by
the
Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary. Any of
or all the signatures on the certificate may be a facsimile. ARTICLE V Execution of Documents All contracts,
agreements,
instruments, bills payable, notes, checks, drafts, warrants or other obligations
of the Corporation shall be made in the name of the Corporation and shall be
signed by such officer or officers as the Board of Directors may from time to time
designate. ARTICLE VI
 Seal The seal of the Corporation shall contain the name of the
Corporation, the words Corporate Seal, the year of its organization
and the word
Delaware. ARTICLE VII 
Indemnification The Corporation shall indemnify all persons to the full extent
permitted, and in the manner provided, by the Delaware General Corporation Law, as
the same
now exists or may hereafter be amended. ARTICLE VIII Amendment
of By-Laws These By-Laws may be amended or
repealed, and any new By-Law may be adopted, by the stockholders entitled to vote
or by the
Board of Directors. 
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>dex33.htm
<DESCRIPTION>2005 STOCK OPTION PLAN
<TEXT>
<HTML><HEAD>
<TITLE>2005 Stock Option Plan</TITLE>
</HEAD>
Exhibit 3.3 Glyconix Corp. 2005 Stock Option Plan
 
<TR>
SIZE="2">1.</TD>
SIZE="2">Establishment and Purpose. </TD></TR></TABLE>
SIZE="2">There is hereby adopted the Glyconix Corp. 2005 Stock Option Plan (the
Plan). The Plan is intended to promote the interests of Glyconix Corp.
(the
Company) and its present and future subsidiaries, by providing
employees of the Company, advisors and consultants to the Company and other
persons or entities providing goods or services to the Company to acquire a
proprietary interest
in the long-term success of the Company through the ownership of shares of stock
in the Company; and to reward the performance of individual officers, other
employees, consultants and directors and other persons or entities providing goods
or
services to the Company in fulfilling their responsibilities for long-range
achievements. 
<TR>
SIZE="2">2.</TD>
SIZE="2">Definitions. </TD></TR></TABLE> (a) Administrator shall mean the Board
or any of its Committees authorized to administer the Plan. (b)
Agreement shall mean the written agreement between the Company and a
Participant evidencing an Award. (c) Award means any
Option,
Restricted Stock SAR, or Other Stock-Based Award granted under the Plan.
FACE="Times New Roman" SIZE="2">(d)
Beneficial Owner shall have the meaning set forth in Rule 13d-3 under
the Exchange Act. (e) Board shall mean the Board of
Directors of the Company. (f) Cause or Termination for
Cause or similar terms for purposes of this Plan shall be as defined in such
Participants employment agreement, if any exists. If no agreement exists,
Cause
shall mean (1) the willful and continued failure by the Participant
substantially to perform his or her duties and obligations to the Company (other
than any such failure resulting from his or her incapacity due to physical or
mental illness);
(2) the willful engaging by the Participant in misconduct which is materially
injurious to the Company; (3) the commission by the Participant of a felony;
(4) the commission by the Participant of a crime against the Company which is
materially injurious to the Company, (5) the voluntary termination by the
employee. For purposes of this Section 2(e), no act, or failure to act, on a
Participants part shall be considered willful unless done, or
omitted
to be done, by the Participant in bad faith and without reasonable belief that his
or her action or omission was in the best interest of the Company. Determination
of Cause shall be made by the Committee in its sole discretion. (g)
Change in Control means the occurrence of any one of the following
events:
FACE="Times New Roman" SIZE="2">(1) any Person is or becomes the Beneficial Owner,
directly or indirectly, of
securities of the Company (not including in the securities beneficially owned by
such person any securities acquired directly from the Company or its Affiliates)
representing 50% or more of the combined voting power of the Companys
then
outstanding voting securities; 

SIZE="2">(2) there is consummated a merger or consolidation of the Company with
any other corporation, other than (A) a
merger or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving or
parent
entity) more than 50% of the combined voting power of the voting securities of the
Company or such surviving or parent entity out standing immediately after such
merger or consolidation or (B) a merger or consolidation effected to
implement a
recapitalization of the Company (or similar transaction) in which no Person,
directly or indirectly, acquired 50% or more of the combined voting power of the
Companys then outstanding securities (not including in the securities
beneficially
owned by such person any securities acquired directly from the Company or its
Affiliates); or (3) the stockholders of the Company approve a plan
of complete liquidation of the Company or there is consummated an agreement for
the sale or disposition by the Company of all or substantially all of the
Companys assets (or any transaction having a similar effect), other than a
sale or disposition by the Company of all or substantially all of the
Companys assets to an entity, at least 50% of the combined voting power of
the voting
securities of which are owned by stockholders of the Company in substantially the
same proportions as their ownership of the Company immediately prior to such sale.
FACE="Times New Roman" SIZE="2">(h) Code shall mean the Internal
Revenue Code of 1986, as amended from time to time, and any regulations
promulgated thereunder.
FACE="Times New Roman" SIZE="2">(i) Committee means the committee
established by the Board to
administer the Plan, the composition of which shall at all times satisfy the
provisions Section 162(m) of the Code. Company means Glyconix Corp., a corporation organized under
the laws of the State of Delaware, or any successor corporation, and all
subsidiaries of the
Glyconix Corp., as may exist from time to time. (k)
Director shall
mean a member of the Board. (l) Disability shall
be as defined in
Participants employment agreement, if any exists. If as such agreement
exists, then Disability shall mean: (1) any physical or mental condition that
would qualify a Participant for a disability benefit under the long-term
disability plan
maintained by the Company and applicable to him or her; (2) when used in
connection with the exercise of an Incentive Stock Option following termination of
employment, disability within the meaning of Section 22(eX3) of the Code, or
(3) such other condition as may be determined in the sole discretion of the
Committee to constitute Disability. (m)
Effective Date shall mean the effective date of the Plan, provided
that the Plan had been approved by the stockholders of the Company prior to the
Initial
Public Offering (if any). (n) Exchange Act
shall mean the
Securities Exchange Act of 1934, as amended from time to time. (o)
The
Fair Market Value of a share of Stock as of a particular date shall
mean (i) if the Shares are not traded on a national exchange nor on the over-
the-counter market, the fair market value as determined by the Committee based on
such
relevant facts as may be available to it, which may include the price at which
securities of reasonably comparable companies in the same industry are being
traded (subject to appropriate adjustments for the absence of a public market and
other
dissimilarities between the Company and such companies), the earnings history,
book value and prospects of the Company in light of market conditions generally,
the prices for recent sales of the Common Shares, opinions of independent experts,
recent
issuances or sales of such Shares by the Company or its shareholders, and such
other evidence as 

the Committee determines it may rely on in
making a good faith valuation; or (ii) if the Shares are traded on a national
exchange, the closing sales
price of the Shares first preceding the time at which Fair Market Value is to be
determined on the national securities exchange having the greatest volume of
trading in the Shares during the thirty-day period preceding the day the value is
to be
determined; or (iii) if the Shares are not traded on any national securities
exchange, the closing sales price of the Shares first preceding the time at which
Fair Market Value is to be determined, as reported on the National Association of
Securities Dealers Automated Quotation System (NASDAQ) National Market System, or
any successor system; or (iv) if the trading of the Shares are not reported
by the NASDAQ National Market System, the average of the closing bid and asked
prices
of the Shares on the over-the-counter market first preceding the time at which
Fair Market Value is to be determined, as reported by NASDAQ, or any other
national quotation service. The closing sales prices and closing bid and asked
prices in
clauses (ii), (iii) and (iv) shall be those published in The Wall
Street Journal. If such prices are not reported for the day Fair Market Value
is to be determined, prices reported for the first preceding day for which such
information is available shall be used. (p)
Incentive Stock Option
shall mean an Option that is an incentive stock option within the
meaning of Section 422 of the Code, or any successor provision, and that is
designated by the Committee as an Incentive Stock Option. (q)
Initial Public Offering shall mean the initial public offering of
shares of
Stock of the Company. (r) Issue Date shall
mean the date
established by the Company on which certificates representing Restricted Stock
shall be issued by the Company pursuant to the terms of Section 8(e).
STYLE="margin-top:0px;margin-bottom:0px">(s)
Non-Qualified Option shall mean an Option other than an Incentive
Stock Option. (t) Option shall mean an option to
purchase a number of shares of Stock granted pursuant to Section 7.
 (u)
Other Stock-Based Award shall mean an award granted pursuant to
Section 9 hereof. (v) Partial Exercise
shall mean an exercise
of an Award for less than the full extent permitted at the time of such exercise.
SIZE="2">(w) Participant shall mean (1) an employee, consultant
or director of the Company to whom an Award is granted pursuant to the Plan and
(2) upon the death of an individual described in (1), his or her successors,
heirs,
executors and administrators, as the case may be. (x)
Performance
Goals means performance goals based on one or more of the following
criteria: (i) pre-tax income or after-tax income, (ii) operating profit,
(iii) return on equity, as sets, capital or investment, (iv) earnings or
book
value per share, (v) sales or revenues, (vi) operating expenses,
(vii) Stock price appreciation, (viii) net cash flow from operations
(after reasonable reserves), and (ix) implementation or completion of
critical projects or
processes. Where applicable, the Performance Goals may be expressed in terms of
attaining a specified level of the particular criteria or the attainment of a
percentage increase or decrease in the particular criteria, and may be applied to
one or
more of the Company, a Subsidiary or Affiliate, or a division or strategic
business unit of the Company, or may be applied to the performance of the Company
relative to a market index, a group of other companies or a combination thereof,
all as
determined by the Administrator. The Performance Goals may include a threshold
level of performance below which no vesting will occur, levels of performance at
which specified vesting will occur, and a maximum level of performance at which
full
vesting will occur. Each of the foregoing Performance Goals shall be determined in
accordance with generally accepted 

accounting principles unless otherwise so
designated, and shall be subject to certification by the Administrator; provided
that the Administrator shall have
the authority to make equitable adjustments to the Performance Goals in
recognition of unusual or non-recurring events affecting the Company or any
Subsidiary or Affiliate or the financial statements of the Company or any
Subsidiary or Affiliate, in
response to changes in applicable laws or regulations, or to account for items of
gain, loss or expense determined to be extraordinary or unusual in nature or
infrequent in occurrence or related to the disposal of a segment of a business or
related
to a change in accounting principles. (y) Person shall
have the
meaning set forth in Section 3(a)(9) of the Exchange Act, as modified and
used in Sections 13(d) and 14(d) thereof, except that such term shall not include
(1) the Company, (2) a trustee or other fiduciary holding securities
under an
employee benefit plan of the Company, (3) an underwriter temporarily holding
securities pursuant to an offering of such securities or (4) a corporation
owned, directly or indirectly, by the stockholders of the Company in substantially
the
same proportions as their ownership of shares of Stock of the Company. 
STYLE="margin-top:0px;margin-bottom:0px">(z)
Plan means the Glyconix Corp. 2004 Stock Option Plan, as amended from
time to time. (aa) Reload Option shall mean a Non-
Qualified Stock Option granted pursuant to Section 7(c)(5). (bb) Restricted Stock shall mean a share of Stock which is
granted pursuant to the terms of Section 8 hereof and which is subject to the
restrictions set
forth in Section 8(c). (cc) Securities Act
shall mean the
Securities Act of 1933, as amended from time to time. Stock means
shares of the common stock, par value $.001 per share, of the Company. 
SIZE="2">Stock Appreciation Rights or SARs shall mean the
right to receive an amount equal to the appreciation, if any, in the Fair Market
Value of a share of Stock from the date of the grant of the right to the date of
its
payment. (ff) Subsidiary means any corporation
in an unbroken
chain of corporations beginning with the Company if, at the time of granting of an
Award, each of the corporations (other than the last corporation in the unbroken
chain) owns stock possessing 50% or more of the total combined voting power of all
classes of stock in one of the other corporations in the chain. (gg)
Vesting Date shall mean the date established by the Administrator on
which Restricted Stock may vest. 
<TR>
SIZE="2">3.</TD>
<TD ALIGN="left" VALIGN="top">Stock
Subject to the Plan. </TD></TR></TABLE> The maximum number of shares of Stock reserved for the grant or
settlement of Awards under the Plan shall be One Million, Five Hundred Thousand
(1,500,000) shares subject to adjustment as provided here in. No more than
One Million (1,000,000) shares of Stock may, at the discretion of the
Administrator or Board, be awarded in respect of Qualified Stock Options, which
amounts shall
be subject to adjustment as provided herein. Determinations made in respect of the
limitation set forth in the preceding sentence shall be made in a manner
consistent with Section 162(m) of the Code. Such shares may, in whole or in
part, be
authorized but unissued shares or shares that shall have been or may be reacquired
by the Company in the open market, in private transactions or otherwise. If any
shares subject to an Award are forfeited, canceled, exchanged or surrendered or if
an
Award otherwise terminates or expires without a distribution of shares to the
holder of such Award, the shares of Stock with respect to such Award shall, to the
extent of any such forfeiture, cancellation, exchange, surrender, termination or


expiration, immediately and without any
further action by any partner, again be available for Awards under the Plan.
 Except as provided in an Award Agreement, in the event that the
Administrator
shall determine that any dividend or other distribution (whether in the form of
cash, Stock, or other property), recapitalization, Stock split, reverse split,
reorganization, merger, consolidation, spin-off, combination, repurchase, or share
exchange, or other similar corporate transaction or event, affects the Stock such
that an adjustment is appropriate in order to prevent dilution or enlargement of
the rights of holders of Awards under the Plan, then the Administrator shall make
such
equitable changes or adjustments as it deems necessary or appropriate to any or
all of (i) the number and kind of shares of Stock or other property
(including cash) that may thereafter be issued in connection with Awards,
(ii) the number
and kind of shares of Stock or other property (including cash) issued or issuable
in respect of outstanding Awards, (iii) the exercise price, grant price, or
purchase price relating to any Award; provided that, with respect to Incentive
Stock
Options, such adjustment shall be made in accordance with Section 424(h) of
the Code, (iv) the Performance Goals, if any, and (v) the individual
limitations applicable to Awards. 
<TR>
SIZE="2">Administration of the Plan. </TD></TR></TABLE> The Plan shall be administered by any authorized Administrator.
The Administrator shall have the authority in its sole discretion, subject to and
not
inconsistent with the express provisions of the Plan, to administer the Plan and
to exercise all the powers and authorities either specifically granted to it under
the Plan or necessary or advisable in the administration of the Plan, including,
with
out limitation, the authority to grant Awards; to determine the persons to whom
and the time or times at which Awards shall be granted; to determine the type and
number of Awards to be granted, the number of shares of Stock to which an Award
may
relate and the terms, conditions, restrictions and Performance Goals relating to
any Award; to determine whether, to what extent, and under what circumstances an
Award may be settled, canceled, forfeited, exchanged, or surrendered; to make
adjustments in the Performance Goals in recognition of unusual or non-recurring
events affecting the Company or the financial statements of the Company (to the
extent not inconsistent with Section 162(m) of the Code, if applicable), or
in
response to changes in applicable laws, regulations, or accounting principles; to
construe and interpret the Plan and any Award; to prescribe, amend and rescind
rules and regulations relating to the Plan; to determine the terms and provisions
of
Agreements; and to make all other determinations deemed necessary or advisable for
the administration of the Plan. Any powers granted to a Committee to act as
Administrator shall be non-exclusive and the Board may act on its own accord.

Roman" SIZE="2">The Administrator (including the Board) may, in its absolute
discretion,
without amendment to the Plan, (a) accelerate the date on which any Option
granted under the Plan becomes exercisable, waive or amend the operation of Plan
provisions respecting exercise after termination of employment or otherwise adjust
any
of the terms of such Option, (b) accelerate the Vesting Date or waive any
condition imposed hereunder with respect to any Restricted Stock and
(c) otherwise adjust any of the terms applicable to any Award; provided,
however, in each case,
that in the event of the occurrence of a Change in Control, the provisions of
Section 10 hereof shall govern vesting and exercisability schedule of any
Award granted hereunder. The Administrator also may make
or enforce limitations so that the number of shares of Stock underlying Options
and the
total amount of Common Stock available for issuance under existing plans or bonus
plans, do not exceed the applicable percentage as calculated in accordance with
Section 260.140.45 of the California Code, or in accordance with such other
securities laws of any State, the compliance with which the Administrator in its
sole discretion believes is in the best interest of the Company. 

Roman" SIZE="2">No member of the Administrator shall be liable for any action,
omission or determination relating to the
Plan, and the Company shall indemnify (to the extent permitted under Delaware law)
and hold harmless each member of the Administrator and each other director or
employee of the Company to whom any duty or power relating to the administration
or
interpretation of the Plan has been delegated against any cost or expense
(including counsel fees) or liability (including any sum paid in settlement of a
claim with the approval of the Committee) arising out of any action, omission or
determination
relating to the Plan, unless, in either case, such action, omission or
determination was taken or made by such member, director or employee in bad faith
and without reasonable belief that it was in the best interests of the Company.
 
<TR>
SIZE="2">Eligibility. </TD></TR></TABLE> Incentive Stock Options shall be granted only to key employees
(including, without limitation officers and directors who are also employees) of
the
Company or any of its Subsidiaries. All other Awards may be granted to officers,
independent contractors, key employees and non-employee directors and members of
SAB Board of the Company or of any of its Subsidiaries and Affiliates. 

<TR>
<TD ALIGN="left" VALIGN="top">Awards
Under the Plan; Agreement. </TD></TR></TABLE> The Administrator may grant Options, Restricted Stock and Other
Stock-Based Awards in such amounts and with such terms and conditions as the
Administrator
shall determine, subject to the provisions of the Plan. Each Award granted under
the Plan shall be evidenced by an Agreement which shall contain such provisions as
the Administrator may in its sole discretion deem necessary or desirable. By
accepting an Award, a Participant thereby agrees that the award shall be subject
to all of the terms and provisions of the Plan and the applicable Agreement.


SIZE="2">Options. (a)
Identification of Options. Each Option shall be clearly identified in the
applicable Agreement as either an Incentive Stock Option or a Non-Qualified
Option.
FACE="Times New Roman" SIZE="2">(b) Exercise Price. Each Agreement with
respect to an Option shall set
forth the exercise price per share of Stock payable by the grantee to the Company
upon exercise of the Option. The exercise price per share of Stock shall be
determined by the Committee; provided, however, that in no case shall an Option
have an
exercise price per share of Stock that is less than the Fair Market Value of a
share of Stock on the date the Option is granted. Term and Exercise of Options. (1)
Unless the applicable Agreement provides otherwise, an Option shall become
cumulatively exercisable as to 25% percent of the Stock covered thereby on each of
the
first, second, third and fourth anniversaries of the date of grant. The Committee
shall determine the expiration date of each Option; provided, however, that no
Option shall be exercisable more than 10 years after the date of grant. Unless the
applicable Agreement provides otherwise and except in the event of a Change in
Control, no Option shall be exercisable prior to the first anniversary of the date
of grant. (2) An Option may be exercised for all or any
portion of the Stock as to which it is exercisable, provided that no Partial
Exercise of an
Option shall be for an aggregate exercise price of less than $500.00. The Partial
Exercise of an Option shall not cause the expiration, termination or cancellation
of the remaining portion thereof. <P
An Option shall be exercised by delivering notice to the Companys principal
office,
to the attention of its Secretary. Such notice shall be accompanied by the
applicable Agreement, shall specify the number of shares of Stock with respect to
which the Option is being exercised and the effective date of the proposed
exercise and
shall be signed by the Participant or other person then having the right to
exercise the Option. Payment for Stock purchased upon the exercise of an Option
shall be made on the effective date of such exercise by one or a combination of
the following
means: (i) in cash or by personal check, certified check, bank cashiers
check or wire transfer; (ii) subject to the approval of the Administrator, in
Stock owned by the Participant for at least six months prior to the date of
exercise and valued at their Fair Market Value on the effective date of such
exercise; or (iii) subject to the approval of the Administrator, by such
other provision as the Administrator may from time to time authorize. 
<P
Certificates for Stock purchased upon the exercise of an Option shall be issued in
the
name of the Participant or other person entitled to receive such Stock, and
delivered to the Participant or such other person as soon as practicable following
the effective date on which the Option is exercised. <P
The Administrator shall have the authority to specify, at the time of grant or,
with
respect to Non-Qualified Options, at or after the time of grant, that a
Participant shall be granted a new Non-Qualified Option (a Reload
Option) for a number of shares of Stock equal to the number of shares of
Stock surrendered by the
Participant upon exercise of all or a part of an Option in the manner described in
Section 7(c)(3)(ii) above, subject to the availability of Stock under the
Plan at the time of such exercise; provided, however, that no Reload Option shall
be
granted to a Director who is not an employee of the Company. Reload Options shall
be subject to such conditions as may be specified by the Administrator in its
discretion, subject to the terms of the Plan. 

SIZE="2">(d) Limitations on Incentive Stock Options. (1) To the extent that the aggregate Fair Market
Value of Stock with respect to which Incentive Stock Options are exercisable for
the first
time by a Participant during any calendar year under the Plan and any other option
plan of the Company (or any Subsidiary) shall exceed $100,000, such Options shall
be treated as Non-Qualified Options. Such Fair Market Value shall be determined as
of the date on which each such Incentive Stock Option is granted. <P
No
Incentive Stock Option may be granted to an individual if, at the time of the
proposed grant; such individual owns (or is attributed to own by virtue of the
Code) Stock possessing more than ten (10) percent of the total combined
voting power of
all classes of stock of the Company or any Subsidiary unless (i) the exercise
price of such Incentive Stock Option is at least 110 percent of the Fair Market
Value of a share of Stock at the time such Incentive Stock Option is granted and
(ii) such Incentive Stock Option is not exercisable after the expiration of
five years from the date such Incentive Stock Option is granted. (e)
Effect of Termination of Employment. <P STYLE="margin-
Unless the applicable Agreement provides otherwise, in the event that the
employment, directorship or consultancy (together, hereinafter referred to as
employment) of a Participant with the Company shall terminate for any
reason other than for Cause, Disability or death, (i) Options granted to such
Participant, to the extent that they are exercisable at the time of such
termination, shall remain exercisable until the date that is 90 days after such
termination, on which date they shall expire, and (ii) Options granted to
such Participant, to the extent that they were not exercisable at the time of such
termination, shall expire at the close of business on the date of such
termination. The 90 day period described in this Section 7(e)(1) shall be
extended to one year from such termination, in the event of the Participants
death during
such 90 day period. Notwithstanding the foregoing, no Option shall be exercisable
after the expiration of its term. <P STYLE="margin-top:0px;margin-
Unless the applicable Agreement provides otherwise, in the event that the
employment of a Participant with the Company shall terminate on account of the
Disability or
death of the Participant, (i) Options granted to such Participant, to the
extent that they were exercisable at the time of such termination, shall remain
exercisable until the first anniversary of such termination, on which date they
shall
expire, and (ii) Options granted to such Participant, to the extent that they
were not exercisable at the time of such termination, shall expire at the close of
business on the date of such termination; provided, however, that no Option shall
be exercisable after the expiration of its term. (3) In the event
of the
termination of a Participants employment for Cause, all outstanding Options
granted to such Participant shall expire as of the commencement of business on the
date of such termination. 
<TR>
SIZE="2">Restricted Stock. </TD></TR></TABLE> Issue Date And Vesting Date. At the time of the grant of Restricted Stock,
the Administrator shall establish an Issue Date or Issue Dates and a Vesting Date
or
Vesting Dates with respect to such shares of Restricted Stock. The
Administrator may divide such shares of Restricted Stock into classes and
assign a different Issue Date and/or Vesting Date for each class. If the grantee
is employed
by the Company on an Issue Date (which may be the date of grant), the specified
number of shares of Restricted Stock shall be issued in accordance with the
provisions of Section 8(e). Provided that all conditions to the vesting of
Restricted
Stock imposed pursuant to Section 8(b) are satisfied, and except as provided
in Section 8(g), 

upon the occurrence of the Vesting Date with
respect to Restricted Stock, such Restricted Stock shall vest and the restrictions
of Section 8(c) shall
lapse. (b) Conditions to Vesting. At the time of
the grant of
Restricted Stock, the Administrator may impose such restrictions or
conditions to the vesting of such Restricted Stock as it, in its absolute
discretion, deems appropriate, including the attainment of Performance Goals.
 (c) Restrictions on Transfer Prior to Vesting. Prior to the
vesting of any
Restricted Stock, no transfer of a Participants rights with respect to such
Restricted Stock, whether voluntary or involuntary, by operation of law or
otherwise, shall be permitted. Immediately upon any attempt to transfer such
rights, such
Restricted Stock, and all of the rights related thereto, shall be forfeited by the
Participant. (d) Dividends on Restricted Stock The
Administrator in its discretion may require that any dividends or
distributions paid on Restricted Stock be held in escrow until all restrictions on
such Restricted Stock
has lapsed. (e) Issuance of Certificates. 
<P
Reasonably promptly after the Issue Date with respect to Restricted Stock, the
Company
shall cause to be issued a certificate, registered in the name of the Participant
to whom such shares of Restricted Stock were granted, evidencing such shares of
Restricted Stock; provided that the Company shall not cause such a certificate to
be
issued unless it has received a power of attorney duly endorsed in blank with
respect to such shares of Restricted Stock. Each such certificate shall bear
substantially the following legend in addition to any other legends required under
securities
or other Rule: THE TRANSFERABILITY OF THIS CERTIFICATE AND THE
STOCK
REPRESENTED HEREBY ARE SUBJECT TO THE RESTRICTIONS, TERMS AND CONDITIONS
(INCLUDING FORFEITURE PROVISIONS AND RESTRICTIONS AGAINST TRANSFER) CONTAINED IN
THE GLYCONIX CORP. STOCK OPTION PLAN AND AN AGREEMENT ENTERED INTO BETWEEN THE
REGISTERED OWNER
OF SUCH STOCK AND GLYCONIX CORP. A COPY OF THE PLAN AND AGREEMENT IS ON FILE WITH
THE SECRETARY OF THE COMPANY. Such legend shall not be removed until such Stock vests pursuant
to the terms hereof. (2) Each certificate issued pursuant to this
Section 8(e), together with the powers relating to the Restricted Stock
evidenced by such
certificate, shall be held by the Company unless the Administrator determines
otherwise. (f) Consequences of Vesting. Upon the
vesting of any Restricted Stock pursuant to the terms hereof, the restrictions of
Section 8(c) shall lapse with respect to such Restricted Stock. Reasonably
promptly
after any Restricted Stock vests, the Company shall cause to be delivered to the
Participant to whom such shares of Restricted Stock were granted a certificate
evidencing such Stock, free of the legend set forth in Section 8(e).
 (g)
Effect of Termination of Employment Other Than for Cause. Subject to such other
provision
as the Administrator may set forth in the applicable Agreement, and to the
Administrators amendment authority pursuant to Section 4, upon the
termination of a Participants employment for any reason other than Cause,
any and all
Stock to which restrictions on transferability apply shall be immediately
forfeited by the Participant and transferred to, and reacquired by, the Company;
provided that if the Administrator, in its sole discretion, shall within
thirty
(30) days after such termination of employment notify the Participant in
writing of its decision not to terminate the Participants rights in such
shares of Stock, then 

the Participant shall continue to be the
owner of such shares of Stock subject to such continuing restrictions as the
Administrator may prescribe in such
notice. In the event of a forfeiture of Stock pursuant to this section, the
Company shall repay to the Participant (or the Participants estate) any
amount paid by the Participant for such shares of Stock. In the event that the
Company requires
a return of Stock, it shall also have the right to require the return of all
dividends or distributions paid on such Stock, whether by termination of any
escrow arrangement under which such dividends or distributions are held or
otherwise.
FACE="Times New Roman" SIZE="2">(1) In the event of the termination of a
Participants employment for
Cause, the Administrator may require that all shares of Restricted Stock granted
to such Participant which have not vested as of the date of such termination shall
immediately be returned to the Company, together with any dividends or
distributions
paid on such shares of Stock, in return for which the Company shall repay to the
Participant any amount actually paid by the Participant for such shares of Stock.
FACE="Times New Roman" SIZE="2">(h) Special Provisions Regarding Awards.
Notwithstanding anything to the contrary contained herein, Restricted Stock
granted pursuant
to this Section 8 to Executive Officers may be based on the attainment by the
Company (or a Subsidiary or division of the Company if applicable) of Performance
Goals pre-established by the Administrator. 
<TR>
<TD ALIGN="left" VALIGN="top">Other
Stock-Based Awards. </TD></TR></TABLE> Other forms of Awards such as, without limitation Stock
Appreciation Rights, valued in whole or in part by reference to, or otherwise
based on, shares of
Stock (Other Stock-Based Awards) may be granted either alone or in
addition to other Awards under the Plan. Subject to the provisions of the Plan,
the Administrator shall have sole and complete authority to determine the persons
to whom
and the time or times at which such Other Stock-Based Awards shall be granted, the
number of shares of Stock to be granted pursuant to such Other Stock-Based Awards,
the exercise of or purchase price, the vesting and expiration dates, and all other
terms, conditions, or forfeiture provisions of such Other Stock-Based Awards,
including the attainment of Performance Goals. 
<TR>
<TD ALIGN="left" VALIGN="top">Change
in Control and Other Events. </TD></TR></TABLE> Consolidations or Mergers. If the Company is to be consolidated with or
acquired by another entity in a merger, sale of all or substantially all of the
Companys assets or otherwise (an Acquisition), unless the Board
shall otherwise determine by resolution adopted at least ten (10) days prior
to the closing of the Acquisition, all outstanding Awards shall remain exercisable
in
accordance with their terms. In addition, the Board or Committee (or, if
authorized, the board of directors of any entity assuming the obligations of the
Company hereunder (the Successor Board)) may take one or more of the
following
actions: (1) make the appropriate provision for the
continuation of such
Awards by substituting on an equitable basis for the shares then subject to such
Awards the consideration payable with respect to the outstanding shares of Common
Stock in connection with the Acquisition; or <P
make appropriate provision for the continuation of such Awards by substituting on
an
equitable basis for the shares then subject to such Awards any equity securities
of the successor corporation; or <P STYLE="margin-top:0px;margin-
upon written notice to the holders of the Awards, provide that all Awards must be
exercised, to the extent then exercisable, within a specified number of days of
the
date of such notice, at the end of 

which period the Awards shall terminate and
all stock issued thereunder and all Restricted Stock that has vested shall be
exchanged or sold with the same
terms as all other holders of Common Stock, in accordance with the terms of the
Acquisition. The Administrator may allow any exercise herein to be conditioned on
consummation of the Acquisition or other events; or <P
terminate all Awards in exchange for a cash payment equal to the excess of the
fair
market value of the shares subject to such Awards (to the extent then exercisable)
over the exercise price thereof; or Recapitalization or Reorganization. In the event of a recapitalization or
reorganization of the Company (other than a transaction described in paragraph
(f) above) pursuant to which securities of the Company or of another
corporation are issued with respect to the outstanding shares of Common Stock,
upon exercising
an Award, the holder thereof shall be entitled to receive for the purchase price
paid upon such exercise the securities he would have received if he had exercised
his Award prior to such recapitalization or reorganization. <P
Dissolution or Liquidation. Upon dissolution or liquidation of the Company, all
Options
and other Awards granted under this Plan shall terminate, but each holder of an
Option shall have the right, immediately prior to such dissolution or liquidation,
to exercise his or her Option to the extent then exercisable. (d)
Initial Public Offering. Upon an Initial Public Offering, the Board may require
reasonable lock up or similar restrictions for all Stock not yet issued under an
Award, and all Restricted Stock, to the extent that such restrictions are demanded
by the underwriter(s) for such offering. In the event of such a restriction all
stock
or Restricted Stock shall be locked up pro rata. 
<TR>
<TD ALIGN="left" VALIGN="top">Rights
as a Stockholder. </TD></TR></TABLE> No person shall have any rights as a stockholder with respect to
any shares of Stock covered by or relating to any Award until the date of issuance
of a
certificate with respect to such shares of Stock. Except as otherwise expressly
provided in Section 3(b), no adjustment to any Award shall be made for
dividends or other rights prior to the date such certificate is issued.
 
<TR>
<TD ALIGN="left" VALIGN="top">No
Special Employment Rights; No Right to Award. </TD></TR></TABLE> Nothing contained in the Plan or any Agreement shall confer upon
any Participant any right with respect to the continuation of employment by the
Company
or interfere in any way with the right of the Company, subject to the terms of any
separate employment agreement to the contrary, at any time to terminate such
employment or to increase or decrease the compensation of the Participant.
 No person shall have any claim or right to receive an Award
hereunder. The
Administrators granting of an Award to a participant at any time shall
neither require the Administrator to grant any other Award to such Participant or
other person at any time or preclude the Administration from making subsequent
grants to
such Participant or any other person. 

WIDTH="100%">
<TR>
SIZE="2">Securities Matters. </TD></TR></TABLE> <P
The Company shall be under no obligation to effect the registration pursuant to
the Securities Act of any interests in the Plan or any Stock to be issued
hereunder or
to effect similar compliance under any state laws. Notwithstanding anything herein
to the contrary, the Company shall not be obligated to cause to be issued or
delivered any certificates evidencing Stock pursuant to the Plan unless and until
the
Company is advised by its counsel that the issuance and delivery of such
certificates is in compliance with all applicable laws, regulations of
governmental authority and the requirements of any securities exchange on which
shares of Stock are
traded. The Administrator may require, as a condition of the issuance and delivery
of certificates evidencing shares of Stock pursuant to the terms hereof, that the
recipient of such shares of Stock make such agreements and representations, and
that
such certificates bear such legends, as the Administrator, in its sole discretion,
deems necessary or desirable. <P STYLE="margin-top:0px;margin-
The transfer of any shares of Stock hereunder shall be effective only at such time
as counsel to the Company shall have determined that the issuance and delivery of
such shares of Stock is in compliance with all applicable laws, regulations of
governmental authority, the requirements of any securities exchange on which
shares of Stock are traded. The Administrator may, in its sole discretion, defer
the
effectiveness of any transfer of Stock hereunder in order to allow the issuance of
such Stock to be made pursuant to registration or an exemption from registration
or other methods for compliance available under federal or state securities laws.
The
Administrator shall inform the Participant in writing of its decision to defer the
effectiveness of a transfer. During the period of such deferral in connection with
the exercise of an Option, the Participant may, by written notice, withdraw such
exercise and obtain the refund of any amount paid with respect thereto.
WIDTH="100%">
<TR>
SIZE="2">14.</TD>
SIZE="2">Withholding Taxes. </TD></TR></TABLE> Whenever shares of Stock are to be delivered pursuant to an Award,
the Company shall have the right to require the Participant to remit to the
Company in
cash an amount sufficient to satisfy any federal, state and local withholding tax
requirements related thereto. With the approval of the Administrator, a
Participant may satisfy the foregoing requirement by electing to have the Company
withhold from
delivery shares of Stock having a value equal to the amount of tax to be withheld.
Such shares of Stock shall be valued at their Fair Market Value on the date of
which the amount of tax to be withheld is determined (the Tax Date).
Fractional shares of Stock amounts shall be settled in cash. Such a withholding
election may be made with respect to all or any portion of the Stock to be
delivered pursuant to an Award. 
<TR>
SIZE="2">Notification of Election Under Section 83(b) of the
Code. </TD></TR></TABLE> If any Participant shall, in
connection with the acquisition of Stock under the Plan, make the election
permitted under
Section 83(b) of the Code (i.e., an election to include in gross income in
the year of transfer the amounts specified in Section 83(b)), such
Participant shall notify the Company of such election within 10 days of filing
notice of the
election with the Internal Revenue Service, in addition to any filing and a
notification required pursuant to regulation issued under the authority of
Section 83(b) of the Code. 
<TR>
SIZE="2">Notification Upon Disqualifying Disposition Under
Section 421(b) of the Code. </TD></TR></TABLE> Each Participant shall notify the
Company of any disposition of Stock issued pursuant to the exercise of an
Incentive Stock
Option under the circumstances described in Section 42 1(b) of the Code
(relating to certain disqualifying dispositions), within 10 days of such
disposition. 

WIDTH="100%">
<TR>
SIZE="2">Amendment or Termination of the Plan.
</TD></TR></TABLE> The Board may, at any time, suspend or terminate the Plan or
revise or amend it in any respect whatsoever; provided, however, that stockholder
approval
shall be required if and to the extent the Board determines that such approval is
appropriate for purposes of satisfying Section 162(m) or 422 of the Code or
is otherwise required by law or applicable stock exchange requirements. Awards may
be
granted under the Plan prior to the receipt of such approval but each such grant
shall be subject in its entirety to such approval and no award may be exercised,
vested or otherwise satisfied prior to the receipt of such approval. Nothing
herein
shall restrict the Committees ability to exercise its discretionary
authority pursuant to Section 4, which discretion may be exercised without
amendment to the Plan. No action hereunder may, without the consent of a
Participant, reduce
the Participants rights under any outstanding Award. 
<TR>
SIZE="2">Transfers Upon Death; Nonassignability.
Roman" SIZE="2">Upon the death of a Participant, outstanding Awards granted to
such Participant may be exercised only by the executor or administrator of the
Participants estate or by a person who shall have acquired the right to such
exercise by will or by the laws of descent and distribution. No transfer of an
Award by will or the laws of descent and distribution shall be effective to bind
the
Company unless the Administrator shall have been furnished with (a) written
notice thereof and with a copy of the will and/or such evidence as the
Administrator may deem necessary to establish the validity of the transfer and
(b) an
agreement by the transferee to comply with all the terms and conditions of the
Award that are or would have been applicable to the Participant and to be bound by
the acknowledgments made by the Participant in connection with the grant of the
Award.
indent:4%">During a Participants
lifetime, the Administrator may
permit the transfer, assignment or other encumbrance of an outstanding Option
unless (y) such Option is an Incentive Stock Option and the Administrator and
the Participant intend that it shall retain such status, or (z) such Option
is
meant to qualify for the exemptions available under Rule 16b-3, nontransferability
is necessary under Rule 16b-3 in order for the award to so qualify and the
Administrator and the Participant intend that it shall continue to so qualify.
Subject to
any conditions as the Administrator may prescribe, a Participant may, upon
providing written notice to the Secretary of the Company, elect to transfer any or
all Options granted to such Participant pursuant to the Plan to members of his or
her
immediate family, including, but not limited to, children, grandchildren and
spouse or to trusts for the benefit of such immediate family members or to
partnerships in which such family members are the only partners; provided,
however, that no such
transfer by any Participant may be made in exchange for consideration. 
WIDTH="100%">
<TR>
SIZE="2">Expenses and Receipts. </TD></TR></TABLE> The expenses of the Plan shall be paid by the Company. Any
proceeds received by the Company in connection with any Award will be used for
general
corporate purposes. 
<TR>
SIZE="2">Failure to Comply. </TD></TR></TABLE> In addition to the remedies of the Company elsewhere provided for
herein, failure by a Participant (or beneficiary) to comply with any of the terms
and
conditions of the Plan or the applicable Agreement, unless such failure is
remedied by such Participant (or beneficiary) within ten days after notice of such
failure by the Administrator, shall be grounds for the cancellation and forfeiture
of such
Award, in whole or in part, as the Administrator, in its absolute discretion, may
determine. 

WIDTH="100%">
<TR>
SIZE="2">Effective Date and Term of Plan.
Roman" SIZE="2">The Plan became effective on the Effective Date and, unless
earlier terminated by the Board, the right to grant Awards under the Plan will
terminate on
the tenth anniversary of the Effective Date. Awards outstanding at Plan
termination will remain in effect according to their terms and the provisions of
the Plan. - 
<TR>
SIZE="2">Applicable Law. </TD></TR></TABLE> Except to the extent preempted by any applicable federal law, the
Plan will be construed and administered in accordance with the laws of the State
of
Delaware, without reference to its principles of conflicts of law. 
<TR>
SIZE="2">Participant Rights. </TD></TR></TABLE> No Participant shall have any claim to be granted any award under
the Plan, and there is no obligation for uniformity of treatment for Participants.
Except as provided specifically herein, a Participant or a transferee of an Award
shall have no rights as a stockholder with respect to any shares of Stock covered
by any award until the date of the issuance of a certificate or certificates to
him
or her for such shares of Stock. 
<TR>
SIZE="2">Unfunded Status of Awards. </TD></TR></TABLE>
Roman" SIZE="2">The Plan is intended to constitute an unfunded plan
for incentive and deferred compensation. With respect to any payments not yet made
to a
Participant pursuant to an Award, nothing contained in the Plan or any Agreement
shall give any such Participant any rights that are greater than those of a
general creditor of the Company. 
<TR>
SIZE="2">Beneficiary. </TD></TR></TABLE> A Participant may file with the Administrator a written
designation of a beneficiary on such form as may be prescribed by the
Administrator and may, from
time to time, amend or revoke such designation. If no designated beneficiary
survives the Participant, the executor or administrator of the Participants
estate shall be deemed to be the grantees beneficiary. 
<TR>
SIZE="2">Interpretation. </TD></TR></TABLE> The Plan is designed and intended to comply, to the extent
applicable, with Section 162(m) of the Code, and all provisions hereof shall
be construed
in a manner to so comply. 
<TR>
SIZE="2">Severability. </TD></TR></TABLE> If any provision of the Plan is held to be invalid or
unenforceable, the other provisions of the Plan shall not be affected but shall be
applied as if the
invalid or unenforceable provision had not been included in the Plan. 
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>dex51.htm
<DESCRIPTION>LEGAL OPINION OF JOSEPH I. EMAS
<TEXT>
<HTML><HEAD>
<TITLE>Legal Opinion of Joseph I. Emas</TITLE>
</HEAD>

FACE="Times New Roman" SIZE="2">(JOSEPH I. EMAS, ATTORNEY-AT-LAW LETTERHEAD)
 Board of Directors Glyconics, Inc. 
<TR>
SIZE="2">RE:</TD>
<TD ALIGN="left" VALIGN="top">Glyconics,
Inc. </TD></TR></TABLE> Registration Statement on Form SB-2
left:2%; text-indent:-2%">Ladies and
Gentlemen: <P
counsel for the Company, I have examined the Companys certificate of
incorporation,
by-laws, and such other corporate records, documents and proceedings and such
questions of laws I have deemed relevant for the purpose of this opinion.
STYLE="margin-top:0px;margin-bottom:0px">I
have also, as counsel for the Company, examined the Registration Statement (the
Registration Statement) of your Company on Form SB-2, covering the
registration under the Securities Act of 1933 of up to 10,720,000 shares of Common
Stock, $.01 par value of the Company. My
review has also included the form of prospectus for the issuance of such
securities (the Prospectus) filed with the Registration Statement.
 On the basis of such examination, I am of the
opinion that:
FACE="Times New Roman" SIZE="2">1. The Company is a corporation duly authorized
and validly existing and in
good standing under the laws of the State of Delaware, with corporate power to
conduct its business as described in the Registration Statement. <P
The shares of Common Stock currently issued and outstanding described in the
Registration
Statement are duly and validly authorized and, upon the issuance thereof, will be
duly and validly issued as fully paid and non-assessable. This opinion includes my opinion on Delaware law including, all
applicable provisions of Delaware statutes, and reported judicial decisions
interpreting those laws.
FACE="Times New Roman" SIZE="2">I hereby consent to the use of my name in the
Registration Statement and
Prospectus and I also consent to the filing of this opinion as an exhibit thereto.
FACE="Times New Roman" SIZE="2">Very truly yours, 
<TR>
<TR>
FACE="Times New Roman" SIZE="2">October 13, 2005</TD>
SIZE="2">/S/ JOSEPH I.
EMAS </TD></T
R>
<TR>
<TD VALIGN="bottom" ALIGN="center">JOSEPH
I. EMAS, ESQUIRE</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>dex101.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT FOR IVAN KAVENSKI
<TEXT>
<HTML><HEAD>
<TITLE>Employment Agreement for Ivan Kavenski</TITLE>
</HEAD>

FACE="Times New Roman" SIZE="2">Employment Agreement for Ivan Kavenski 
THIS EMPLOYMENT AGREEMENT (the
Agreement) is dated
as of March 30, 2005, between Glyconix, Corp., a Delaware corporation (the
Company) and Dr. Ivan Kanevski (the
Executive). W I T N E S S E T H: A. WHEREAS, the Company has employed the Executive for 4 years on
an at-will basis and the Company wants to continue and formalize the relationship.
indent:4%">B. WHEREAS, the Executive has, in
the past, foregone and/or
discharged a significant amount of his salary, despite having worked diligently
for the Company. B. WHEREAS, the parties desire for the Executive
to act as President and Chief Scientific Officer of the Company commencing the
date hereof and during the term hereof. C. WHEREAS, the parties desire to execute and deliver this
Agreement to
provide for the continued employment of Executive by the Company. NOW, THEREFORE, in consideration of the foregoing premises and for this
good and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the parties agree as follows: AGREEMENT: 1. Engagement. The Company hereby engages
the Executive and the Executive hereby accepts such engagement upon the terms and
conditions hereinafter set forth. 2. Term. This Agreement
shall
commence on the date hereof (the Commencement Date), and shall remain
in effect for a period of three (3) years thereafter (the Term).
This Agreement shall also terminate at such time as the Company, or the Executive,
gives written notice of termination of this Agreement pursuant to Section 13
of this Agreement. The Term shall be automatically renewed for successive two-year
periods. Unless either party provides notice to the other of their intent not to
renew which notice must be provided not less than ninety (90) days prior to
the expiration of the then current Term. With respect to termination by the
Company, such determination not to renew shall only be made in accordance with a
vote of a
majority of the members of the Board of Directors, other than the Executive (if he
is a Director at such time). Duties. The Company hereby engages the Executive to serve as the President
and Chief Scientific Officer of the Company and, as such, he shall perform all
duties
commonly incident to the office of President and Chief Scientific Officer,
including such additional duties not inconsistent with such position as the Board
of Directors of the Company (the Board) shall prescribe from time to
time.
FACE="Times New Roman" SIZE="2">4. Performance of Duties. During the term
of this Agreement, the
Executive shall devote his best efforts, ability and attention to the business of
the Company. 

SIZE="2">5. Compensation. Salary. For all continued services rendered by the Executive under
this Agreement as President and Chief Scientific Officer of the Company shall pay
the one
hundred and sixty thousand Dollars ($160,000) per annum (the Base
Salary). The Executives Base Salary shall be payable within the
established payroll cycle for the Companys salaried officers or employees.
Salary payments
shall be subject to federal withholding and other applicable payroll deductions
and taxes. Salary may be taken in the form of cash or in the common stock of the
Company at the option of the Executive. The Executive shall be entitled to an
increase
in the Base Salary (such an increase to be then considered as the Base
Salary) as shall be determined by the Board of Directors of the Company.
SIZE="2">Options The Company shall grant to the Executive options to
purchase shares of the Companys common stock as follows options to purchase 100,000 shares of the Companys common
stock with
an exercise price of $0.50, vesting on September 1, 2005 and expiring on
March 30, 2010; and <P STYLE="margin-top:0px;margin-bottom:-
stock with an exercise price of $0.50, vesting in three (3) equal
installments of
50,000 shares each, commencing on September 1, 2005 and at each anniversary
of the Term, which options shall expire on March 30, 2010. Benefits. The Executive shall be eligible to participate in all
group insurance plans, cafeteria/FSA plans, 401(k) plans and other plans of the
Company, and other
existing or new perquisites or benefits offered to executive management of the
indent:4%">D. Bonus. The Executive shall receive
additional annual and/or performance bonuses, in an amount as determined by the
Companys Board of Directors. Reimbursement of Expenses. The Company shall reimburse the Executive for
all
reasonable and necessary expenses incurred in carrying out his duties under this
Agreement upon presentation by the Executive to the Company of appropriate
documentation indicating the amount and purpose for such expense. Vacation. Executive shall be entitled to four (4) weeks vacation (28
calendar
days) during each year of the Term. 8. Agreement Not to Disclose
Trade
Secrets or Confidential Information. During the term of this Agreement and
after its termination, the Executive shall not disclose or utilize any trade
secrets, confidential information, or other proprietary information acquired by
the Executive
during the course of his employment with the Company, its successors or assigns,
or any of its affiliates (collectively, the Company
Affiliates). As used herein, trade secret means the whole or
any portion or phase of
any formula, chemical or molecular pattern or formula, any pattern, device,
combination of devices, source-code of any proprietary software, or compilation of
any scientific, technical or commercial information, including any design and
improvements
thereon, list of suppliers, list of customers, as well as pricing information or
methodology, contractual arrangements with vendors or suppliers, research and
development information and reports, results, reports or other information
relating to the
Companys proprietary, acquired or licensed drug or chemical compositions or
methods, any information or technology relating to the Companys
glycosylation technologies, any business development plans or activities, or
financial
information of the Company or any of the Company Affiliates that is for use, or is
used, in the operation of the Company or any of the Company Affiliates
businesses that is not commonly known by or available to the public and that
derives
economic value from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value from
its disclosure or use and is the subject of efforts that are reasonable under the
circumstances to 

maintain its secrecy. The Executive agrees
to return to the Company any and all such trade secrets, confidential information
or other proprietary information
immediately upon the termination of this Agreement, for any reason. Non-Solicitation of Customers and Suppliers. Executive agrees that during
his employment hereunder, he shall not, whether as an individual or sole
proprietor, or as a principal, agent, officer, director, employer, employee,
consultant,
independent contractor, partner or shareholder of any firm, corporation or other
entity or group or otherwise, directly or indirectly, solicit the trade or
business of, or trade, or conduct business with, any customer, prospective
customer,
supplier, or prospective supplier of the Company for any purpose other than for
the benefit of the Company. Executive further agrees that for two (2) years
following termination of his employment hereunder. For cause (as hereinafter
defined) or
termination by him other than for Good Reason (as hereinafter defined), Executive
shall not, directly or indirectly, solicit the trade or business of, or trade, or
conduct business with any customers or suppliers, or prospective customers or
suppliers, of the Company. 10. Death or Disability.
 A.
In the event of the Executives death during the term of this Agreement, this
Agreement and the Executives future Base Salary, incentive compensation and
benefits shall automatically be terminated. In such event, the Company shall pay
severance to the Executives estate (i) any unpaid Base Salary; and
(ii) all accrued but unpaid allowances and expense reimbursements.
FACE="Times New Roman" SIZE="2">B. If
the Executive becomes unable to perform his employment duties during the term of
this Agreement because of the disability of the Executive, the Company
may terminate this Agreement and the Executives employment hereunder. In
such
event, the Company shall pay to the Executive (i) any unpaid Base Salary; and
(ii) all accrued but unpaid allowances and expense reimbursements. For
purposes of this provision, the term disability shall mean the Executive is unable
to
perform his material duties as an employee for the Company or any of the Company
Affiliates, due to mental or physical illness or injury, for a period of at least
one hundred (180) days, in the opinion of a qualified physician selected
mutually
by the Company and the Executive. 11. Termination by the
Company or the
Executive. A. Termination by the Company for Cause.
The Company may
terminate this Agreement and the Executives employment hereunder for
cause at any time. As used herein, for cause shall mean the
determination by the majority of the Directors, other than the Executive, that
Executive
shall be terminated as a result of any one of the following: 
<TR>
<TD ALIGN="left" VALIGN="top">The willful
breach or intentional neglect by the Executive of his job duties and
responsibilities; </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">Conviction of
Executive of any felony involving an act of moral turpitude;
WIDTH="100%">
<TR>
<TD ALIGN="left" VALIGN="top">Commission by
the Executive of any material act of fraud, embezzlement or misappropriation
against the Company; or </TD></TR></TABLE> 
<TR>
<TD ALIGN="left" VALIGN="top">A material
breach of this Agreement by the Executive. </TD></TR></TABLE> B.
In the event the Company terminates the Executives employment for cause, the
Executives Base Salary and benefits shall automatically terminate as of the
effective date of such termination and the Company shall pay to the Executive
(i) any unpaid Base Salary through the date of termination; and (ii) all
accrued but unpaid allowances and expense reimbursements, and the Executive shall
not be
entitled to receive any other compensation or severance allowance, including any
incentive compensation earned after termination, under this Agreement. In
addition, all options received and not exercised shall be cancelled and the
Executive shall
not be entitled to any options thereunder. 

SIZE="2">With respect to matters set forth in subsections (1), (3) and
(4) above, the Company shall give prompt notice
to the Executive if it believes grounds for termination under any of such
provisions exist, and the Executive shall have a reasonable period of time (not to
exceed ten business days, to respond and to cure any such grounds for
cause as
may be alleged or to reply to any such claims or charges. Termination under such
provisions shall be warranted only after the Board of Directors of the Company has
determined, in good faith, that such cause exists after having
afforded
the Executive the opportunity to respond or to cure as set forth above.
FACE="Times New Roman" SIZE="2">C.
Termination by the Executive Without Good Reason. The Executive may
terminate this Agreement and his employment with the Company without good
reason (as defined below) upon 30 days prior written notice to the
Company. In
such a case, the Executive may be required to perform his business duties and
shall be paid his regular salary up to the date of the termination. At the option
of the Company, the Company may require the Executive to depart from the Company
upon
receiving said 30 days notice from the Executive of the termination of this
Agreement. In such event, the Company shall pay to the Executive (i) an
amount equal to 30 calendar days of his Base Salary at the then-effective rate;
and
(ii) all accrued but unpaid allowances and expense reimbursements, and the
Executive shall not be entitled to receive any of this compensation or severance
allowance, including any incentive compensation earned after termination, under
this
Agreement. In addition, all options received and not yet visited shall be
cancelled and the Executive shall not be entitled to any options hereunder.
STYLE="margin-top:0px;margin-bottom:0px">D.
Termination by the Company Without Cause or the Executive for Good
Reason. The Company may terminate this Agreement and the
Executives
employment without cause at any time upon 30 days prior written notice to
the Executive. The Executive shall have the right to terminate this Agreement at
any time for good reason. 
<TR>
SIZE="2">(i)</TD>
<TD ALIGN="left" VALIGN="top">the assignment
to the Executive of duties and responsibilities that are inconsistent, in a
material and adverse respect, with the scope of the duties and responsibilities
usually
vested in similarly situated executives; </TD></TR></TABLE> 
<TR>
SIZE="2">(ii)</TD>
<TD ALIGN="left" VALIGN="top">a material
reduction in the benefits payable to the Executive; </TD></TR></TABLE> 
<TR>
SIZE="2">(iii)</TD>
<TD ALIGN="left" VALIGN="top">the Executive
is removed by majority vote or otherwise from the Board of Directors, as the case
may be; </TD></TR></TABLE> (iv) a change in control of the
Company such that one entity (directly or through affiliates) purchases control of
over 50%
of the Companys common stock, that was not approved, consented to or caused
by the Executive; provided, however, that if Executive did not vote for, consent
to, cause or approve the transaction leading to the change of control, then
Executive
shall have sixty (60) days from the consummation of such change of control to
give notice of his termination of this Agreement for Good Reason. The Company shall pay to the Executive on the date of termination
without cause or for good reason (i) a severance allowance of the remainder
of the
Base Salary through the end of the Term at the then-effective rate or two years
Base Salary, whichever is greater; (ii) an additional severance allowance of
two hundred thousands (200,000) shares of Common Stock of the Company (and
the
Company hereby agrees to increase the authorized shares of common stock of the
Company if necessary to satisfy this provision); and (iii) all accrued but
unpaid allowances and expense reimbursements. All options granted hereunder shall
vest
immediately. 12. Indemnification. The Executive shall be
entitled to
indemnification from the Company to the fullest extent permitted under the
Companys then current Certificate of Incorporation and Bylaws and under the
law of the jurisdiction of the Companys incorporation as may be in effect
from time to
time. 

SIZE="2">13. Notices. All notices, requests, demands and other
communications provided for in this Agreement shall be in
writing. Any notice, request, demand, claim or other communication hereunder shall
be deemed duly given if it is sent by registered or certified mail, return receipt
requested, postage prepaid, and addressed to the intended recipient as set forth
below: 
<TR>
<TD VALIGN="top">To the Executive:</TD>
New Roman" SIZE="2">Dr. Ivan Kanevski 141 Birchview Drive
Piscataway, NJ 08854</TD></TR>
<TR>
<TR>
SIZE="2">To the Company:</TD>
New Roman" SIZE="2">Glyconix, Corp. 350 Fifth Avenue Suite 4811 New York, NY 10118</TD></TR>
<TR>
<TR>
<TD VALIGN="top">With Copy to:</TD>
New Roman" SIZE="2">Ronniel Levy, Esq. Meister Seelig & Fein
LLP 2 Grand Central Tower 140 East 45 Street, 19 Floor New York, NY
10017</TD></TR>
indent:4%">Any party may send any
notice, request, demand, claim or other communication hereunder to the intended
recipient at the address set forth above using any other means (including personal
delivery, expedited courier, messenger service, facsimile, ordinary mail or
electronic
mail), but no such notice, request, demand, claim or other communication shall be
deemed to have been duly given unless and until it actually is received or refused
by the intended recipient. Any party may change the address to which notices,
requests, demands, claims and other communications hereunder are to be delivered
by giving the other party notice in the manner herein set forth. Assignment. Neither this Agreement nor any of the parties rights and
obligations hereunder may be assigned by a party without the prior written consent
of the other party hereto. 15. Arbitration.
 <P
Any controversy or claim arising out of or relating to this Agreement, the
employment
relationship between the Executive and the Company, or the termination thereof,
including the arbitrability of any controversy or claim, which cannot be resolved
amicably after a reasonable attempt to negotiate such a resolution shall be
submitted
to arbitration by the American Arbitration Association in accordance with its
Commercial Dispute Resolution Procedures and Rules, as such rules may be amended
from time to time, and at its office in New York. The award of the arbitrator
shall be
final and binding upon the parties, and judgment may be entered with respect to
such award in any court of competent jurisdiction. Any arbitration under this
Arbitration Agreement shall be governed by and subject to the confidentiality
restrictions
set herein. The Executive acknowledges reading, prior to the signing of this
Agreement, the Commercial Dispute Resolution Procedures and Rules of the American
Arbitration Association, which are available via the internet at the site of the
American
Arbitration Association at http://www.adr.org. Notwithstanding the foregoing, any
controversy or claim arising out of or relating to any claim by the Company for
temporary or preliminary relief with respect to Sections 8, 9 and 10 herein need
not be
resolved in arbitration and may be resolved in a court of competent jurisdiction.
SIZE="2">B. The Executive acknowledges that this agreement to submit to
arbitration includes all controversies or claims of any kind (e.g., whether in
contract or in tort, statutory or common law, legal or equitable) now existing or
hereafter
arising under any federal, state, local or foreign law (except that any claim by
the Company for temporary or preliminary relief with respect to Sections 8, 9 and
10 herein may 

be brought in a court of competent
jurisdiction), including, but not limited to, the Age Discrimination in Employment
Act, Title VII of the Civil Rights Act
of 1964, the Civil Rights Act of 1866, the Employee Retirement Income Security
Act, and the Americans With Disabilities Act, and the Executive hereby waives all
rights thereunder to have a judicial tribunal resolve such claims. Voluntary Agreement. The Executive acknowledges that before entering into
this
Agreement, the Executive has had the opportunity to consult with any attorney or
other advisor of his choice, and that this constitutes advice from the Company to
do so if he chooses. The Executive further acknowledges that he has entered into
this
Agreement of his own free will, and that no promises or representations have been
made to him by any person to induce him to enter into this Agreement other than
the express terms set forth herein. The Executive further acknowledges that he has
read
this Agreement and understands all of its terms, including the waiver of rights
set forth in Section 17. 17. Binding Effect. This Agreement shall
bind the parties hereto, their respective successors and permitted assigns.
Amendment. No provisions of this Agreement may be amended, modified, waived
or discharged unless such amendment, waiver, modification or discharge is agreed
to
in writing signed by the Executive and on behalf of the Company by such officer as
may be specifically designated by the Board. No waiver by either party hereto at
any time of any breach by the other party hereto of, or compliance with, any
condition or provision of this Agreement to be performed by such other party shall
be deemed a waiver of similar or dissimilar provisions or conditions at the same
or at any prior or subsequent time. Entire Agreement. This Agreement constitutes the entire agreement between
the
parties, pertaining to the subject matter hereof, and supersedes all prior or
contemporaneous written or verbal agreements and understandings with the Executive
in connection with the subject matter hereof. Governing Law. This Agreement and the rights and obligations hereunder
shall be
governed by the laws of the State of New York without regard to its conflicts
principles and the parties to this Agreement specifically consent to the
jurisdiction of the courts of the State of New York over any action arising out of
or related to
this Agreement. 21. Survival. All covenants, agreements,
representations and warranties made herein or otherwise made in writing by any
party pursuant hereto shall survive the termination of this Agreement and the
employment of the Executive hereunder. Severability. If any provision of this Agreement is held by a court of
competent
jurisdiction to be invalid, void or unenforceable, the remaining provisions shall,
nevertheless, continue in full force and effect without being impaired or
invalidated in any way. 23. Counterparts. This Agreement may be
executed by the parties in one or more counterparts, each of which when so
executed shall be
an original and all such counterparts shall constitute one and the same
instrument. Confirmation of execution by electronic transmission of a facsimile
signature page shall be binding upon any party so confirming. 

Roman" SIZE="2">IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date first set forth above.
SIZE="1"> <DIV ALIGN="right">
<TR>
<TR>
<TD VALIGN="top" COLSPAN="3">EXECUTIVE:</TD></TR>
</TABLE></DIV><DIV ALIGN="right">
<TR>
<TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">
FACE="Times New Roman" SIZE="2">Name:</TD>
<TR>
FACE="Times New Roman" SIZE="2">Title:</TD>
SIZE="1">President and CSO</TD></TR>
<TR>
<TR>
SIZE="2">COMPANY:</TD></TR>
<TR>
<TR>
1.00em">Glyconix Corp.</TD></TR>
<TR>
<TR>
<TR>
<TR>
<TD VALIGN="bottom" ALIGN="center">J.R.
LeShufy</TD></TR>
<TR>
ALIGN="center">Executive Vice
President, Director and Secretary</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<DESCRIPTION>EMPLOYMENT AGREEMENT FOR J.R. LESHUFY
<TEXT>
<HTML><HEAD>
<TITLE>Employment Agreement for J.R. LeShufy</TITLE>
</HEAD>

FACE="Times New Roman" SIZE="2">Employment Agreement for J.R. LeShufy 
Agreement) is dated
as of March 30, 2005, between Glyconix, Corp., a Delaware corporation (the
Company) and J. Robert LeShufy (the
Executive). A. WHEREAS, the Company has employed the Executive for 4 years on
an at-will basis and the Company wants to continue and formalize the relationship.
indent:4%">B. WHEREAS, the Executive has, in
the past, foregone and/or
for the Company. B. WHEREAS, the parties desire for the Executive
to act as Executive Vice President of the Company commencing the date hereof and
during the term hereof. C. WHEREAS, the parties desire to
execute and deliver this Agreement to provide for the continued employment of
Executive by
the Company. NOW, THEREFORE, in consideration
of the foregoing
premises and for this good and valuable consideration, the receipt and adequacy of
which is hereby acknowledged, the parties agree as follows: AGREEMENT: Term. This Agreement shall commence on the date hereof (the
Commencement
Date), and shall remain in effect for a period of three (3) years
thereafter (the Term). This Agreement shall also terminate at such
time as the Company, or the Executive, gives written notice of termination of this
Agreement
pursuant to Section 13 of this Agreement. The Term shall be automatically
renewed for successive two-year periods. Unless either party provides notice to
the other of their intent not to renew which notice must be provided not less than
ninety
(90) days prior to the expiration of the then current Term. With respect to
termination by the Company, such determination not to renew shall only be made in
accordance with a vote of a majority of the members of the Board of Directors,
other
than the Executive (if he is a Director at such time). Duties. The
Company hereby engages the Executive to serve as the Executive Vice President of
the Company and, as such, he shall perform all duties commonly incident to the
office of Executive Vice President, Secretary and Treasurer, including such
additional
duties not inconsistent with such position as the Board of Directors of the
Company (the Board) shall prescribe from time to time. Performance of Duties. During the term of this Agreement, the Executive
shall devote his best efforts, ability and attention to the business of the
Company.


SIZE="2">5. Compensation. Salary. For all continued services rendered by the Executive under
this Agreement as Executive Vice President, Secretary and Treasurer of the Company
shall pay the
Ninety Six thousand ($96,000) per annum (the Base Salary). The
Executives Base Salary shall be payable within the established payroll cycle
for the Companys salaried officers or employees. Salary payments shall be
subject to
federal withholding and other applicable payroll deductions and taxes. Salary may
be taken in the form of cash or in the common stock of the Company at the option
of the Executive. The Executive shall be entitled to an increase in the Base
Salary
(such an increase to be then considered as the Base Salary) as shall
be determined by the Board of Directors of the Company. Options The Company shall grant to the Executive options to
purchase shares of the Companys common stock as follows <P STYLE="margin-top:0px;margin-bottom:-
stock with an exercise price of $0.50, vesting in three (3) equal
installments of
33,333 shares each (with the third vesting to be for 33,334 shares), commencing on
September 1, 2005 and at each anniversary of the Term, which options shall
expire on March 30, 2010. Benefits. The Executive shall be eligible to participate in all
group insurance plans,
cafeteria/FSA plans, 401(k) plans and other plans of the Company, and other
existing or new perquisites or benefits offered to executive management of the
FACE="Times New Roman" SIZE="2">D. Bonus. The Executive shall receive
Companys
FACE="Times New Roman" SIZE="2">6. Reimbursement of Expenses. The Company
shall
reimburse the Executive for all reasonable and necessary expenses incurred in
carrying out his duties under this Agreement upon presentation by the Executive to
the Company of appropriate documentation indicating the amount and purpose for
such
expense. 7. Vacation. Executive shall be entitled to
four
(4) weeks vacation (28 calendar days) during each year of the Term.
FACE="Times New Roman" SIZE="2">8.
Agreement Not to Disclose Trade Secrets or Confidential Information. During
the term of this Agreement and after its termination, the Executive shall not
disclose or utilize any trade secrets, confidential information, or other
proprietary
information acquired by the Executive during the course of his employment with the
Company, its successors or assigns, or any of its affiliates (collectively, the
Company Affiliates). As used herein, trade secret
means
the whole or any portion or phase of any formula, chemical or molecular pattern or
formula, any pattern, device, combination of devices, source-code of any
proprietary software, or compilation of any scientific, technical or commercial
information,
including any design and improvements thereon, list of suppliers, list of
customers, as well as pricing information or methodology, contractual arrangements
with vendors or suppliers, research and development information and reports,
results,
reports or other information relating to the Companys proprietary, acquired
or licensed drug or chemical compositions or methods, any information or
technology relating to the Companys glycosylation technologies, any business
development
plans or activities, or financial information of the Company or any of the Company
Affiliates that is for use, or is used, in the operation of the Company or any of
the Company Affiliates businesses that is not commonly known by or available
to the public and that derives economic value from not being generally known to,
and not being readily ascertainable by proper means by, other persons who can
obtain economic value from its disclosure or use and is the subject of efforts
that are
reasonable under the circumstances to maintain its secrecy. The Executive agrees
to return to the Company any and all such trade secrets, confidential information
or other proprietary information immediately upon the termination of this
Agreement,
for any reason. 

SIZE="2">9. Non-Solicitation of Customers and Suppliers. Executive agrees
that during his employment hereunder, he shall
not, whether as an individual or sole proprietor, or as a principal, agent,
officer, director, employer, employee, consultant, independent contractor, partner
or shareholder of any firm, corporation or other entity or group or otherwise,
directly or
indirectly, solicit the trade or business of, or trade, or conduct business with,
any customer, prospective customer, supplier, or prospective supplier of the
Company for any purpose other than for the benefit of the Company. Executive
further
agrees that for two (2) years following termination of his employment
hereunder. For cause (as hereinafter defined) or termination by him other than for
Good Reason (as hereinafter defined), Executive shall not, directly or indirectly,
solicit
the trade or business of, or trade, or conduct business with any customers or
suppliers, or prospective customers or suppliers, of the Company. Death or Disability. A. In the event of the Executives death
during the term of this Agreement, this Agreement and the Executives future
Base Salary, incentive compensation and benefits shall automatically be
terminated. In
such event, the Company shall pay severance to the Executives estate
(i) any unpaid Base Salary; and (ii) all accrued but unpaid allowances
and expense reimbursements. B. If the Executive becomes unable to perform his
employment duties during the term of this Agreement because of the
disability
of the Executive, the Company may terminate this Agreement and the
Executives employment hereunder. In such event, the Company shall pay to the
Executive (i) any unpaid Base Salary; and (ii) all accrued but unpaid
allowances and
expense reimbursements. For purposes of this provision, the term disability shall
mean the Executive is unable to perform his material duties as an employee for the
Company or any of the Company Affiliates, due to mental or physical illness or
injury, for a period of at least one hundred (180) days, in the opinion of a
qualified physician selected mutually by the Company and the Executive.
Termination by the Company or the Executive. Termination by the Company for Cause. The Company may terminate this
Agreement and the Executives employment hereunder for cause at
any time.
As used herein, for cause shall mean the determination by the majority
of the Directors, other than the Executive, that Executive shall be terminated as
a result of any one of the following: 
<TR>
breach or intentional neglect by the Executive of his job duties and
bottom:-6px">
<TR>
Executive of any felony involving an act of moral turpitude;
WIDTH="100%">
<TR>
the Executive of any material act of fraud, embezzlement or misappropriation
against the Company; or </TD></TR></TABLE> 
<TR>
breach of this Agreement by the Executive. </TD></TR></TABLE> B.
In the event the Company terminates the Executives employment for cause, the
Executives Base Salary and benefits shall automatically terminate as of the
effective date of such termination and the Company shall pay to the Executive
(i) any unpaid Base Salary through the date of termination; and (ii) all
accrued but unpaid allowances and expense reimbursements, and the Executive shall
not be
entitled to receive any other compensation or severance allowance, including any
incentive compensation earned after termination, under this Agreement. In
addition, all options received and not exercised shall be cancelled and the
Executive shall
not be entitled to any options thereunder. With respect to
matters set forth
in subsections (3) and (4) above, the Company shall give prompt notice
to the Executive if it believes grounds for termination under any of such
provisions exist, and the Executive shall have a reasonable period of time (not to
exceed ten
business days, to respond and to cure any such grounds for cause as
may be alleged or to reply to any such claims or charges. Termination under such
provisions shall be warranted only after the Board of Directors of the Company has
determined, in good faith, that such cause exists after having
afforded the Executive the opportunity to respond or to cure as set forth above.


SIZE="2">C. Termination by the Executive Without Good Reason. The Executive
may terminate this Agreement and his employment
with the Company without good reason (as defined below) upon 30
days prior written notice to the Company. In such a case, the Executive may
be required to perform his business duties and shall be paid his regular salary up
to the
date of the termination. At the option of the Company, the Company may require the
Executive to depart from the Company upon receiving said 30 days notice from
the Executive of the termination of this Agreement. In such event, the Company
shall pay to the Executive (i) an amount equal to 30 calendar days of his
Base Salary at the then-effective rate; and (ii) all accrued but unpaid
allowances and expense reimbursements, and the Executive shall not be entitled to
receive any
of this compensation or severance allowance, including any incentive compensation
earned after termination, under this Agreement. In addition, all options received
and not yet visited shall be cancelled and the Executive shall not be entitled to
any
options hereunder. D. Termination by the Company Without Cause or
the
Executive for Good Reason. The Company may terminate this
Agreement and the Executives employment without cause at any time upon 30
days prior written notice to the Executive. The Executive shall have the
right to
terminate this Agreement at any time for good reason. 
<TR>
SIZE="2">(i)</TD>
<TD ALIGN="left" VALIGN="top">the assignment
to the Executive of duties and responsibilities that are inconsistent, in a
material and adverse respect, with the scope of the duties and responsibilities
usually
vested in similarly situated executives; </TD></TR></TABLE> 
<TR>
SIZE="2">(ii)</TD>
<TD ALIGN="left" VALIGN="top">a material
reduction in the benefits payable to the Executive; </TD></TR></TABLE> 
<TR>
SIZE="2">(iii)</TD>
<TD ALIGN="left" VALIGN="top">the Executive
may be; </TD></TR></TABLE> 
<TR>
SIZE="2">(iv)</TD>
<TD ALIGN="left" VALIGN="top">a change in
control of the Company such that one entity (directly or through affiliates)
purchases control of over 50% of the Companys common stock, that was not
approved,
consented to or caused by the Executive; provided, however, that if Executive did
not vote for, consent to, cause or approve the transaction leading to the change
of control, then Executive shall have sixty (60) days from the consummation
of
such change of control to give notice of his termination of this Agreement for
Good Reason. </TD></TR></TABLE> The Company shall pay to the Executive on the date of termination
without cause or for good reason (i) a severance allowance of the remainder
of the
two hundred thousands (200,000) shares of Common Stock of the Company (and
the
unpaid allowances and expense reimbursements. All options granted hereunder shall
vest
FACE="Times New Roman" SIZE="2">12. Indemnification. The Executive shall be
entitled to
indemnification from the Company to the fullest extent permitted under the
Companys then current Certificate of Incorporation and Bylaws and under the
law of the jurisdiction of the Companys incorporation as may be in effect
from time to
time. 13. Notices. All notices, requests, demands
and other
communications provided for in this Agreement shall be in writing. Any notice,
request, demand, claim or other communication hereunder shall be deemed duly given
if it is sent by registered or certified mail, return receipt requested, postage
prepaid, and addressed to the intended recipient as set forth below: 
<TR>
<TR>
FACE="Times New Roman" SIZE="2">To the Executive:</TD>
New Roman" SIZE="2">Mr. J.R. LeShufy 215 East 68 Street, Apt.
32H New York, NY 10021</TD></TR>
</TABLE>
<TR>
<TR>
SIZE="2">To the Company:</TD>
bottom:0px">Empire State Building
350
Fifth Avenue, Suite 4811 </TD></TR>
<TR>
<TR>
<TD VALIGN="top">With Copy to:</TD>
10017</TD></TR>
electronic
Assignment. Neither this Agreement nor any of the parties rights and
obligations hereunder may be assigned by a party without the prior written consent
of the other party hereto. 15. Arbitration.
 <P
Any controversy or claim arising out of or relating to this Agreement, the
employment
relationship between the Executive and the Company, or the termination thereof,
including the arbitrability of any controversy or claim, which cannot be resolved
amicably after a reasonable attempt to negotiate such a resolution shall be
submitted
shall be
restrictions
American
not be
SIZE="2">B. The Executive acknowledges that this agreement to submit to
arbitration includes all controversies or claims of any kind (e.g., whether in
contract or in tort, statutory or common law, legal or equitable) now existing or
hereafter
arising under any federal, state, local or foreign law (except that any claim by
the Company for temporary or preliminary relief with respect to Sections 8, 9 and
10 herein may be brought in a court of competent jurisdiction), including, but not
limited to, the Age Discrimination in Employment Act, Title VII of the Civil
Rights Act of 1964, the Civil Rights Act of 1866, the Employee Retirement Income
Security Act, and the Americans With Disabilities Act, and the Executive hereby
waives all
rights thereunder to have a judicial tribunal resolve such claims. Voluntary Agreement. The Executive acknowledges that before entering into
this Agreement, the Executive has had the opportunity to consult with any attorney
or other advisor of his choice, and that this 

constitutes advice from the Company to do so
if he chooses. The Executive further acknowledges that he has entered into this
Agreement of his own free will,
and that no promises or representations have been made to him by any person to
induce him to enter into this Agreement other than the express terms set forth
herein. The Executive further acknowledges that he has read this Agreement and
understands
all of its terms, including the waiver of rights set forth in Section 17.
SIZE="2">17. Binding Effect. This Agreement shall bind the parties hereto,
their respective successors and permitted assigns. Amendment. No provisions of this Agreement may be amended, modified, waived
or discharged unless such amendment, waiver, modification or discharge is agreed
to
in writing signed by the Executive and on behalf of the Company by such officer as
may be specifically designated by the Board. No waiver by either party hereto at
any time of any breach by the other party hereto of, or compliance with, any
condition or provision of this Agreement to be performed by such other party shall
be deemed a waiver of similar or dissimilar provisions or conditions at the same
or at any prior or subsequent time. Entire Agreement. This Agreement constitutes the entire agreement between
the
parties, pertaining to the subject matter hereof, and supersedes all prior or
contemporaneous written or verbal agreements and understandings with the Executive
in connection with the subject matter hereof. Governing Law. This Agreement and the rights and obligations hereunder
shall be
governed by the laws of the State of New York without regard to its conflicts
principles and the parties to this Agreement specifically consent to the
jurisdiction of the courts of the State of New York over any action arising out of
or related to
this Agreement. 21. Survival. All covenants, agreements,
representations and warranties made herein or otherwise made in writing by any
party pursuant hereto shall survive the termination of this Agreement and the
employment of the Executive hereunder. Severability. If any provision of this Agreement is held by a court of
competent
jurisdiction to be invalid, void or unenforceable, the remaining provisions shall,
nevertheless, continue in full force and effect without being impaired or
invalidated in any way. 23. Counterparts. This Agreement may be
executed by the parties in one or more counterparts, each of which when so
executed shall be
an original and all such counterparts shall constitute one and the same
instrument. Confirmation of execution by electronic transmission of a facsimile
signature page shall be binding upon any party so confirming. 
IN WITNESS WHEREOF, the parties have
executed this Agreement as of the date first set
forth above. 
<TR>
SIZE="2">EXECUTIVE:</TD></TR>
<TR>
<TR>
<TR>
<TR>
<TD VALIGN="bottom" ALIGN="center">J.R.
<TR>
ALIGN="center">Executive Vice
President Secretary &
Treasurer</TD></TR>
<TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> COMPANY: 
<TR>
<TR>
<TR>
SIZE="1">President and CSO</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<DESCRIPTION>EMPLOYMENT AGREEMENT FOR LUCY OSTROVSKY
<TEXT>
<HTML><HEAD>
<TITLE>Employment Agreement for Lucy Ostrovsky</TITLE>
</HEAD>

Roman" SIZE="2">Exhibit 10.3 Employment Agreement for Lucy Ostrovsky Agreement) is dated as of August 1, 2005, between
Glyconix, Corp., a Delaware corporation
(the Company) and Lucy Ostrovsky (the
Employee). A. WHEREAS, the Company has employed the Employee for 4 years on an at-
will basis and the Company wants to continue and formalize the relationship.
Roman" SIZE="2">B. WHEREAS, the Employee has, in the past, foregone and/or
for the
indent:4%">C. WHEREAS, the parties desire
for the Employee to
act as Vice President Finance of the Company commencing the date hereof and during
the term hereof. D. WHEREAS, the parties desire to execute and deliver this
Agreement to provide for the continued employment of Employee by the Company.
 NOW, THEREFORE, in consideration of the foregoing premises and for
this good
and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the parties agree as follows: 1. AGREEMENT:
indent:4%"> 2. Term. This Agreement shall commence on the date hereof
(the
Commencement Date), and shall remain in effect for a period of three
(3) years thereafter (the Term). This Agreement shall also
terminate at such time as the Company, or the Employee, gives written notice of
termination
of this Agreement pursuant to Section 13 of this Agreement. The Term shall be
automatically renewed for successive two-year periods. Unless either party
provides notice to the other of their intent not to renew which notice must be
provided not
less than ninety (90) days prior to the expiration of the then current Term.
With respect to termination by the Company, such determination not to renew shall
only be made in accordance with a vote of a majority of the members of the Board
of
Directors, other than the Employee (if he is a Director at such time). 
Roman"
SIZE="2">3. Duties. The Company hereby engages the Employee to serve as the
Vice President Finance of the Company and, as such, she shall perform all duties
commonly incident to the office of Vice President Finance including such
additional
duties not inconsistent with such position as the Board of Directors of the
Company (the Board) shall prescribe from time to time. 4. Performance of Duties. During the term of this
Agreement, the Employee shall devote his best efforts, ability and attention to
the business of
the Company. 

Roman" SIZE="2">5. Compensation. A. Salary.
For all continued services rendered by the Employee under this Agreement as Vice
President
Finance of the Company shall pay the eighty four thousand ($84,000) per annum (the
Base Salary). The Employees Base Salary shall be payable within
the established payroll cycle for the Companys salaried officers or
employees.
Salary payments shall be subject to federal withholding and other applicable
payroll deductions and taxes. Salary may be taken in the form of cash or in the
common stock of the Company at the option of the Employee. The Employee shall be
entitled to
an increase in the Base Salary (such an increase to be then considered as the
Base Salary) as shall be determined by the Board of Directors of the
Company. B. Options.
The Company shall grant to the Employee options to purchase shares of the
Companys
common stock as follows 
<TR>
SIZE="2">(a)</TD>
<TD ALIGN="left" VALIGN="top">options to
purchase 50,000 shares of the Companys common stock with an exercise price
of $0.50, vesting on September 1, 2005 and expiring on August 1, 2010;
and
WIDTH="100%">
<TR>
SIZE="2">(b)</TD>
<TD ALIGN="left" VALIGN="top">options to
purchase 30,000 shares of the Companys common stock with an exercise price
of $0.50, vesting in three (3) equal installments of 10,000 shares each,
commencing
on August 1, 2005 and at each anniversary of the Term, which options shall
expire on August 1, 2010. </TD></TR></TABLE> C. Benefits. The Employee shall be eligible
to participate in all group insurance plans, cafeteria/FSA plans, 401(k) plans and
other plans of the Company, and other existing or new perquisites or benefits
offered to executive management of the Company. D. Bonus. The Employee shall receive
Companys
indent:4%">6. Reimbursement of
Expenses. The
Company shall reimburse the Employee for all reasonable and necessary expenses
incurred in carrying out his duties under this Agreement upon presentation by the
Employee to the Company of appropriate documentation indicating the amount and
purpose
for such expense. 7. Vacation. Employee
shall be
entitled to three (3) weeks vacation (21 calendar days) during each year of
the Term. 8. Agreement Not to Disclose Trade Secrets or
Confidential Information. During the term of this Agreement and after its
termination, the Employee shall not disclose or utilize any trade secrets,
confidential
information, or other proprietary information acquired by the Employee during the
course of his employment with the Company, its successors or assigns, or any of
its affiliates (collectively, the Company Affiliates). As used
herein, trade secret means the whole or any portion or phase of any
formula, chemical or molecular pattern or formula, any pattern, device,
combination of devices, source-code of any proprietary software, or compilation of
any
scientific, technical or commercial information, including any design and
improvements thereon, list of suppliers, list of customers, as well as pricing
information or methodology, contractual arrangements with vendors or suppliers,
research and
development information and reports, results, reports or other information
relating to the Companys proprietary, acquired or licensed drug or chemical
compositions or methods, any information or technology relating to the
Companys
glycosylation technologies, any business development plans or activities, or
financial information of the Company or any of the Company Affiliates that is for
use, or is 

used, in the operation of the Company or any
of the Company Affiliates businesses that is not commonly known by or
available to the public and that
derives economic value from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value from
its disclosure or use and is the subject of efforts that are reasonable under the
circumstances to maintain its secrecy. The Employee agrees to return to the
Company any and all such trade secrets, confidential information or other
proprietary information immediately upon the termination of this Agreement, for
any reason.
indent:4%">9. Non-Solicitation of
Customers and Suppliers.
Employee agrees that during his employment hereunder, he shall not, whether as an
individual or sole proprietor, or as a principal, agent, officer, director,
employer, employee, consultant, independent contractor, partner or shareholder of
any firm,
corporation or other entity or group or otherwise, directly or indirectly, solicit
the trade or business of, or trade, or conduct business with, any customer,
prospective customer, supplier, or prospective supplier of the Company for any
purpose
other than for the benefit of the Company. Employee further agrees that for two
(2) years following termination of his employment hereunder. For cause (as
hereinafter defined) or termination by him other than for Good Reason (as
hereinafter
defined), Employee shall not, directly or indirectly, solicit the trade or
business of, or trade, or conduct business with any customers or suppliers, or
prospective customers or suppliers, of the Company. 10. Death or Disability. A. In the event of the Employees death
during the term
of this Agreement, this Agreement and the Employees future Base Salary,
incentive compensation and benefits shall automatically be terminated. In such
event, the Company shall pay severance to the Employees estate (i) any
unpaid
Base Salary; and (ii) all accrued but unpaid allowances and expense
reimbursements. B. If the Employee becomes unable to perform his
employment duties during the term of this Agreement because of the
disability
of the Employee, the Company may terminate this Agreement and the Employees
employment hereunder. In such event, the Company shall pay to the Employee
(i) any unpaid Base Salary; and (ii) all accrued but unpaid allowances
and expense
reimbursements. For purposes of this provision, the term disability shall mean the
Employee is unable to perform his material duties as an employee for the Company
or any of the Company Affiliates, due to mental or physical illness or injury, for
a
period of at least one hundred (180) days, in the opinion of a qualified
physician selected mutually by the Company and the Employee. 11. Termination by the Company or the Employee. 
FACE="Times New Roman" SIZE="2">A. Termination by the Company for Cause.
The Company may terminate this Agreement and the Employees employment
hereunder
for cause at any time. As used herein, for cause shall
mean the determination by the majority of the Directors, other than the Employee,
that Employee shall be terminated as a result of any one of the following:

WIDTH="100%">
<TR>
breach or intentional neglect by the Employee of his job duties and
bottom:-6px">
<TR>
Employee of any felony involving an act of moral turpitude;
WIDTH="100%">
<TR>
the Employee of any material act of fraud, embezzlement or misappropriation
against the Company; or </TD></TR></TABLE>

WIDTH="100%">
<TR>
breach of this Agreement by the Employee. </TD></TR></TABLE> B. In the event the Company terminates the
Employees employment for cause, the Employees Base Salary and benefits
shall
automatically terminate as of the effective date of such termination and the
Company shall pay to the Employee (i) any unpaid Base Salary through the date
of termination; and (ii) all accrued but unpaid allowances and expense
reimbursements, and the Employee shall not be entitled to receive any other
compensation or severance allowance, including any incentive compensation earned
after termination, under this Agreement. In addition, all options received and not
exercised
shall be cancelled and the Employee shall not be entitled to any options
thereunder. With respect to matters set forth in subsections
(3) and (4) above, the Company shall give prompt notice to the Employee
if it believes grounds for termination under any of such provisions exist, and the
Employee shall have a reasonable period of time (not to exceed ten business days,
to respond and to cure any such grounds for cause as may be alleged or
to reply to any such claims or charges. Termination under such provisions shall be
warranted only after the Board of Directors of the Company has determined, in good
faith, that such cause exists after having afforded the Employee the
opportunity to respond or to cure as set forth above. C. Termination by the Employee Without Good
Reason.
The Employee may terminate this Agreement and his employment with the Company
without good reason (as defined below) upon 30 days prior
written notice to the Company. In such a case, the Employee may be required to
perform his
business duties and shall be paid his regular salary up to the date of the
termination. At the option of the Company, the Company may require the Employee to
depart from the Company upon receiving said 30 days notice from the Employee
of the
termination of this Agreement. In such event, the Company shall pay to the
Employee (i) an amount equal to 30 calendar days of his Base Salary at the
then-effective rate; and (ii) all accrued but unpaid allowances and expense
reimbursements, and the Employee shall not be entitled to receive any of this
compensation or severance allowance, including any incentive compensation earned
after termination, under this Agreement. In addition, all options received and not
yet
visited shall be cancelled and the Employee shall not be entitled to any options
hereunder. D. Termination by the Company Without Cause or
the Employee for Good Reason. The Company may terminate this
Agreement
and the Employees employment without cause at any time upon 30 days
prior written notice to the Employee. The Employee shall have the right to
terminate this Agreement at any time for good reason. As used herein, good reason shall mean
the
occurrence of any of the following without the Employee s prior written
consent: (i) the assignment to the Employee of duties and
responsibilities that are inconsistent, in a material and adverse respect, with
the scope
of the duties and responsibilities usually vested in similarly situated
executives; (ii) a material reduction in the benefits payable
to the Employee; (iii) the Employee
may be;
left:4%; text-indent:4%">(iv) a change in
control of the Company such
that one entity (directly or through affiliates) purchases control of over 50% of
the Companys common stock, that was not approved, consented to or caused by
the Employee; provided, however, that if Employee did not vote for, consent to,
cause
or approve the transaction leading to the change of control, then Employee shall
have sixty (60)


days from the consummation of such change of
control to give notice of his termination of this Agreement for Good Reason.
 The Company shall pay to the Employee on the date of termination
without
cause or for good reason (i) a severance allowance of the remainder of the
two
hundred thousands (200,000) shares of Common Stock of the Company (and the
unpaid
allowances and expense reimbursements. All options granted hereunder shall vest
indent:4%">12. Indemnification. The Employee shall be
entitled to indemnification from the Company to the fullest extent permitted under
the Companys then current Certificate of Incorporation and Bylaws and under
the law of the jurisdiction of the Companys incorporation as may be in
effect from time to time. 13. Notices. All notices, requests, demands and other
communications provided for in this Agreement shall be in writing. Any notice,
request,
demand, claim or other communication hereunder shall be deemed duly given if it is
sent by registered or certified mail, return receipt requested, postage prepaid,
and addressed to the intended recipient as set forth below: 
<TR>
<TD VALIGN="top" ALIGN="right">To the
Employee:</TD>
New Roman" SIZE="2">Mrs. Lucy Ostrovsky 102-40
67 Road, Apt 3N Forest Hills, NY
11375</TD></TR>
<TR>
<TR>
<TD VALIGN="top" ALIGN="right">To the
Company:</TD>
bottom:0px">Empire State Building
 </TD></TR>
<TR>
<TR>
<TD VALIGN="top" ALIGN="right">With Copy
to:</TD>
10017</TD></TR>
electronic
Roman" SIZE="2">14. Assignment. Neither this Agreement nor any of the
parties rights and obligations hereunder may be assigned by a party without
the prior
written consent of the other party hereto. 15.
Arbitration. A. Any controversy
or
claim arising out of or relating to this Agreement, the employment relationship
between the Employee and the Company, or the termination thereof, including



the arbitrability of any controversy or
claim, which cannot be resolved amicably after a reasonable attempt to negotiate
such a resolution shall be submitted
shall be
restrictions
American
not be
FACE="Times New Roman" SIZE="2">B. The Employee acknowledges that this agreement
to submit to arbitration includes all controversies or claims of any kind (e.g.,
whether
in contract or in tort, statutory or common law, legal or equitable) now existing
or hereafter arising under any federal, state, local or foreign law (except that
any claim by the Company for temporary or preliminary relief with respect to
Sections
8, 9 and 10 herein may be brought in a court of competent jurisdiction),
including, but not limited to, the Age Discrimination in Employment Act, Title VII
of the Civil Rights Act of 1964, the Civil Rights Act of 1866, the Employee
Retirement Income
Security Act, and the Americans With Disabilities Act, and the Employee hereby
waives all rights thereunder to have a judicial tribunal resolve such claims.
Roman" SIZE="2">16. Voluntary Agreement. The Employee acknowledges that
before entering into this Agreement, the Employee has had the opportunity to
consult with
any attorney or other advisor of his choice, and that this constitutes advice from
the Company to do so if he chooses. The Employee further acknowledges that he has
entered into this Agreement of his own free will, and that no promises or
representations have been made to him by any person to induce him to enter into
this Agreement other than the express terms set forth herein. The Employee further
acknowledges that he has read this Agreement and understands all of its terms,
including the waiver of rights set forth in Section 17. 17. Binding Effect. This Agreement shall bind the parties hereto,
their respective successors and permitted assigns. 18. Amendment. No provisions of this Agreement may be
amended, modified, waived or discharged unless such amendment, waiver,
modification or
discharge is agreed to in writing signed by the Employee and on behalf of the
Company by such officer as may be specifically designated by the Board. No waiver
by either party hereto at any time of any breach by the other party hereto of, or
compliance with, any condition or provision of this Agreement to be performed by
such other party shall be deemed a waiver of similar or dissimilar provisions or
conditions at the same or at any prior or subsequent time. 19. Entire Agreement. This Agreement constitutes the entire
agreement
between the parties, pertaining to the subject matter hereof, and supersedes all
prior or contemporaneous written or verbal agreements and understandings with the
Employee in connection with the subject matter hereof. 20. Governing Law. This Agreement and the rights and
obligations
hereunder shall be governed by the laws of the State of New York without regard to
its conflicts principles and the parties to this Agreement specifically consent to
the jurisdiction of the courts of the State of New York over any action arising
out
of or related to this Agreement. 

Roman" SIZE="2">21. Survival. All covenants, agreements, representations
and warranties made herein or otherwise
made in writing by any party pursuant hereto shall survive the termination of this
Agreement and the employment of the Employee hereunder. 22. Severability. If any provision of this Agreement is
held by a court of competent jurisdiction to be invalid, void or unenforceable,
the
remaining provisions shall, nevertheless, continue in full force and effect
without being impaired or invalidated in any way. 23. Counterparts. This Agreement may be executed by the
parties in one or more counterparts, each of which when so executed shall be an
original
and all such counterparts shall constitute one and the same instrument.
Confirmation of execution by electronic transmission of a facsimile signature page
shall be binding upon any party so confirming. IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date
first set forth above. <DIV ALIGN="right">
<TR>
<TR>
SIZE="2">Employee:</TD></TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">By:</TD>
<TR>
<TD VALIGN="bottom" ALIGN="center">Lucy
Ostrovsky</TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center">Vice
President Finance</TD></TR>
<TR>
<TR>
SIZE="2">COMPANY:</TD></TR>
<TR>
<TR>
<TR>
<TR>
FACE="Times New Roman" SIZE="2">By:</TD>
<TR>
<TD VALIGN="bottom" ALIGN="center">J. R.
<TR>
SIZE="1">Executive Vice President</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>9
<DESCRIPTION>CONSULTANT AGREEMENT FOR RIFAT PAMUKCU
<TEXT>
<HTML><HEAD>
<TITLE>Consultant Agreement for Rifat Pamukcu</TITLE>
</HEAD>

SIZE="2">Consultant Agreement for Rifat Pamukcu January 15, 2004 Dr. Rifat Pamukcu Spring House, PA 19477 
<TR>
SIZE="2">Re:</TD>
<TD ALIGN="left" VALIGN="top">Consulting
Agreement </TD></TR></TABLE> Dear Rifat, The purpose of
this letter is to record the terms of a consulting agreement between you and
GLYCONIX CORP. (hereinafter, together with its subsidiaries and affiliates,
referred to as the Company). The Company wishes to engage you to serve
the Company
as Chief Executive Officer, functioning as an independent contractor and not an
employee of the Company. The period of the consulting will be, as the Company deems
necessary and may be terminated by either party with sixty (60) days notice.
Consultation
will take place at times and places mutually agreed upon by you and
representatives of the Company. In consideration for your consulting services, the Company agrees
to pay you in accordance with services rendered as stipulated in the invoice for
the
services, with a minimum payment of $5000 per month. The calculations are based on
a $15,000 per month rate paid for over 180 (200) hours services provided, and
are modified to account for the complexity of the service as well as a premium for
a faster completion of the task. The amount will be accrued until the Company
receives monies from its private placements totaling $500,000. At that time, the
Company will pay you one-third (1/3) of the accrued balance and will, from
that time
forward, remain current in its payments. The remaining two-thirds (2/3) of
the accrued balance will be paid upon receipt of an additional $1.5 MM in
investment. In addition to the above
consulting fee, the Company will reimburse you your reasonable out-of-pocket
expenses (airline
travel consistent with the Company personnel airline travel, other travel, hotel,
food) and a health insurance cost incurred by you by reason of your consultancy.
Payment will be made within approximately thirty (30) days of the Company
receiving your itemized statement of such expenses. In
recognition of your past service to the operation, the Companys founders
will transfer to your name as gift 100,000 shares of the Companys common
stock at no cost. We will also recommend the Board of Directors offer you a
Incentive Stock
Option covering 365,000 shares of the Companys Common Stock. All terms of
your stock option grant will be governed solely by the Companys Stock
Option/ Stock Issuance Plan and the Stock Option Agreement that will be asked to
sign in
order to receive the option grant. The exercise price for the shares will be the
fair market value as of the date of the grant ($0.05 per share). The option shares
will vest 33.3% on your first anniversary date and 1/36 per month thereafter for the
following two years. The Company understands that you
are available to perform the consulting services as provided herein and that you
warrant
that this will not cause a direct conflict of interest because of your
relationship with the Company, any other research facility or any other corporate
entity or because of 

work you may have undertaken with others. It
is not the Company desire to be afforded access to information which is
confidential or in any way
proprietary to any third party, nor to receive any information the receipt of
which implies any obligations. You warrant that during the time period of your
retainer as a consultant under this agreement, you will not knowingly enter into
any
agreement or relationship to render services as an employee of, adviser or
consultant to any other individual, firm or corporation that would be inimical to
or in direct conflict with those aspects of the Companys business, the
development of
glycosylated derivatives of drugs for the treatment of various diseases and sugar-
drug complexes and their derivatives for use in boron neutron capture therapy, to
which this agreement relates. This agreement does not prevent you from engaging in
ongoing and future consultancies, particularly in the fields of oncology,
infectious disease or gastrointestinal diseases. You further warrant that no other
party has any right, title or interest to any information, ideas, developments and
inventions which may be submitted to the Company by you in your capacity as the
Company consultant. During your engagement as a consultant, it may be necessary for
you to have access to certain the Companys technical information and
material. You
agree to consider such information as confidential and agree to take all
reasonable precautions to prevent disclosure of any such information to third
parties. You also agree not to use such information or materials without the
Company express
written consent. These obligations of confidentiality and non-use shall continue
beyond the term of this agreement and shall automatically terminate five
(5) years from the effective date of this agreement, but shall cease to apply
as to any
specific portion of the Company information or material which is or becomes
available to the public through no fault on your part. You agree to disclose promptly and fully to the Company all
creative ideas, developments and inventions conceived or reduced to practice by
you as a
direct result of your consulting work with the Company. All such ideas,
developments and inventions shall be the property of the Company, and accordingly,
you agree to assign to the Company the entire rights, title and interests to such
ideas,
developments and inventions, without payment other than the consulting fee
provided herein. Furthermore, you agree to execute any and all documents, which
the Company deems necessary or convenient to fully implement its proprietary
rights in any
such ideas, developments and inventions, at no expense to you. The Company wishes to retain the results of your consulting work as
confidential. Therefore, you agree not to publish or otherwise disclose the
results of your consulting work without the express written consent of the
Company. In the event
that the Company in the scientific literature publishes work resulting from your
consulting, acknowledgement will be made to you in the appropriate accepted style.
indent:4%">The Company will indemnify and
hold you harmless from and against any and all losses, liabilities, damages,
expenses and
costs (including reasonable attorneys fees) (Losses) asserted by
third parties in connection with or arising out of your rendering of services
hereunder except to the extent that such Losses were directly caused by or
resulted from
(i) your breach of this agreement or (ii) the gross negligence or
willful misconduct on your part. You will notify the Company promptly upon
learning of a claim, demand, suit, or proceeding that might give rise to a Loss,
and the Company
may control defense and settlement thereof provided it does so diligently, in good
faith and using reasonably experienced counsel with expertise in the relevant
field. You will reasonably cooperate in such defense and/or settlement at the
Companys request and may participate at your own expense using your own
counsel. This agreement constitutes the entire
understanding between the parties and may be amended by a written instrument
executed by both parties and specifically entitled an amendment of this agreement.


Roman" SIZE="2">The laws of the State of New York, U.S.A, shall govern the terms
and conditions of this agreement.
indent:4%">If the terms of this agreement
meet with your approval, please
sign and date both copies of this agreement and return one to the Company and keep
the other for your files. This consulting agreement will become effective on the
date hereinabove written. 
<TR>
<TD COLSPAN="3" VALIGN="top"> </TD>
<TD VALIGN="top" COLSPAN="3">Very truly
yours,</TD></TR>
<TR>
<TR>
<TD COLSPAN="3" VALIGN="top"> </TD>
SIZE="2">BY:</TD>
<TR>
<TD VALIGN="top" ALIGN="center">J. R.
Leshufy</TD></TR>
<TR>
<TR>
<TD VALIGN="top" COLSPAN="3">ACKNOWLEDGED,
ACCEPTED AND AGREED TO:</TD>
<TD COLSPAN="3" VALIGN="top"> </TD></TR>
<TR>
<TR>
<TD VALIGN="top">By</TD>
<TR>
<TD VALIGN="bottom" ALIGN="center">Rifat
Pamukcu, M.D.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML><HEAD>
<TITLE>Consent of Independent Registered Public Accounting Firm</TITLE>
</HEAD>

Roman" SIZE="2">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
hereby consent to the use in the Registration Statement on Form SB-2 and the
related Prospectus of our report dated April 20, 2005, which includes an
explanatory
paragraph as to going concern, relating to our audits of the balance sheet of
Glyconix Corp. as of December 31, 2004 and the related statements of
operations, changes in stockholders equity (capital deficiency), and cash
flows for each of
the years in the two-year period ended December 31, 2004 and for the period
from August 21, 2001 (inception) through December 31, 2004 ended which
appears in such Prospectus. We also consent to reference to us under the caption
Interest of Named Experts and Counsel Accounting Matters in
such Prospectus. 
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top">/s/ Eisner
LLP</TD></TR>
<TR>
<TD VALIGN="bottom">Eisner
LLP</TD></TR>
FACE="Times New Roman" SIZE="2">New York, New York October 12, 2005 
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g97153graph1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97153graph1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```2%P``1#L``%-Z``!@</_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`\0'-`P$1
M``(1`0,1`?_$`/$``0`"`P`#`0$````````````("@8'"0(#!00!`0$`````
M````````````````$``!`P(%`P,"!00#```````&!`4'``,0`0(W""`V%TÙ
M%C`14!(R%!B@(1,58'`Q$0`!!`$"`@0'"P@&!@@'```#`0($!081$@`3$"$4
M!S$BM!5UM78@,$$R(]/4%C:6MD!187%R=#65L4(SLR2%4%)SE,358(%3-"4F
M%S=PD:%BXD.&$@$```````````````````"@$P$!``("`0,"!@(#``,````!
M$0À$#%!(%!1,$#P87&!D:&@P6!PL='A\?_:``P#`0`"$0,1```![^````P`
MA>2`,R,'-KFER4QS7)+F6GU2#!)\Q4S<\B-9+$P\_(8R94?9/29(:[-\D/C?
MA\8_<:M,4/H&[S6)BAX&3$V@````````:W(T$("3I^LD:8Z2G.89L0TP;P,@
M-(F-&Q211&0SPCD2)-%FV#U'X3>Q'(WR9R0[/DDQ#3YBQL8R0UN?L/X8,=.0
M````````````````````````````````````````````````````````````
M```#5!^`W,```````````````````````````#3IAQM(UT2&````````````
M``````````````!\DC0;_-*DF``````````>LT\#:Q^\``````````````'J
M-,&U#0!FQHLSHDV````````8:4-078"3@``````````````/C$,24AJHYD%=
M(Z*%N@````````PXH:`NP$G`````````````"/)&(Z1G@:X-BD;3F.5TCHH6
MZ````````##BAH"[`2<`````````````(CFMSH`>@BP;M-4',@KI'10MT```
M$=3C:9`=_```##BAH"[`2<`````````````(G&BCI,>!K@V*1M.8Y72.BA;H
M```.?!4*,\+X```!AQ0T!=@).`````````````$+#3QTT,2(WF_#5!S(*Z1T
M4+=```!SX*A1GA?````,.*&@+L!)P```^(>D^L?K````````.89YG3D]1H(W
MZ1M.8Y72.BA;H```.?!4*,\+X```!AQ0T!=@).```%*<BV6FSK"````````<
ML3^G4T_(:%-@FJSF05TCHH6Z```#GP5"C/"^`"-I3&!>C,H,.*&@+L!)P```
MI3D6RTV=80```````"%)]0F$?A(QFYS51S(*Z1T4+=```!SX*A1GA?`!&4I.
M@OI&5&'%#0%V`DX"OT?".S9(<%*<BV6FSK"````````0Z-,G2L]!@!L$C:<Q
MRND=%"W0""AQ/-UEC`'/@J%&>%\`$92DZ"^D948<4-`78"3@*'!A1;^)_Ì3
MD6RTV=80``"(YI@D`2?```(N'Z"39^À^2.-4',@KI'10MT`Y+E6LE(76`<^
M"H49X7P`1E*3H+Z1E1AQ0T!=@).`H<&%%OXG\"E.1;+39UA!&`P8WJ;C!5N.
M2AW$+'```!RQ/G'5\&NC8!&TYCE=(Z*%N@')<JUDI"ZP#GP5"C/"^`",I2=!
M?2,J,.*&@+L!)P%#@PHM_$_@4IR+9:;.L(*AQST+%)W3!5N.2AW$+'`````/
MDD1"2!J@YD%=(Z*%N@')<JUDI"ZP#GP5"C/"^`",I2=!?2,J,.*&@+L!)P%#
M@PHM_$_@4IR+9:;.L(*AQST+%)W3!5N.2AW$+'`````!KPSXC:<QRND=%"W0
M#DN5:R4A=8!SX*A1GA?`!&4I.@OI&5&'%#0%V`DX"AP846_B?P*4Y%LM-G6$
M%0XYZ%BD[I@JW')0[B%C@&GS51GYO8``&KC]QJHYD%=(Z*%N@')<JUDI"ZP#
MGP5"C/"^`",I2=!?2,J,.*&@+L!)P%#@PHM_$_@4IR+9:;.L(*AQST+%)W3!
M5N.2AW$+'`*[YPC.KQ:>``/E&DC=1%8YJE>XZ#%L,_IRH*QA)LN7']("E2\S
MDO('](VE,<%Z(R@Q`HR`N;$E#^%&@PTMLD\3^%-(C&6>CJ@?PJ:$`2P<=O#^
M%9`Y2G:XL.`K]'#HZG%GLR,^@`?/-+FS#09GYYG\/68";`/,_AZS`#8![`>H
MU\;"/8#U&O381[0>LUZ;!/:#UF`&?'L/Z>!K\SX]A_3P-?&?GF>1XF/'I,G/
M(\3P->DK0``#&#)P`:R-F@ÙZ;"`!AIF0`,,,N/:`8P?7/H`'PSY!F8!^0Q`
MSH`_AK,V:`#6)LX````$4#"2<9Y`C>1Q)[&4`TF14)CFT`:X("DZ#;(,*.>!
M+\D*#&3G.2-)8@^,0D-Y$@@?C(/&+'18'B0M-5G2@`C::`.B(```!JP@D=#C
M,@:X(+$X#:`,&(2DF3?0,>((&^B2P/`YSF\B5(!S\-@$PP"#I[":Y[P0U,?)
MKGTP18-2DXS[P-(D1CI&>P````&LC9H`-9&S0`:R-F@ÙF;,`!K0V6`#69LP
M`&MS81[@#!S(SZH!CAZ#*@#\Y@9L0````````````````&#$<221^(^D9@``
M````````````````````````#G$1)/`Z*$P@````````````````````````
M````````````````?__:``@!`0`!!0+Z!6]YC0PR3(0N`TXRU'S,XZSP1T5G
M,$;97&0H82-HCJ2],A.-)YR)=#:KEZ.$#@Z2"&LM#)D,F-MHGQ[57+LOQ]IN
MM<XQ^K&G>6HZ85PQ)+(5%J>:B%Q);,BA5]W02_'[WFVRZ&7=#O.\?(1E+*8_
MJO:)8CS6T92W'FIJ>#9O2@#+-$?.K,F?VQQ<&>:5#VXM\H`+HM32_'"MJ>9)
M8&^/R.3R<8?F^=--YZ%)KN.E1F<79!'5TI/C09",X:GQ0DG&XL#F68,UGHS%
MEOD@DMAML\5G#`56WI?$!=>>U\*.2D2C4-4AC,D#2=E=]/YORIX:/K[&ZP\Y
M.(H8Q\8(T\()GVY?C6&!P*3-$*&FDGUP29YM[I!R]2T"PB]CYPDB0S:"5%%Q
M0EE*,8P.'41%8C?!S78@Ò4H'>("9^57(>)W9S>X4=UVA,ÒWA]9&;DC;(,&
M7L?!6P'NHI('(%)F"U;@(K4M4QL+B_@#L#R*^22WP6ZY.D:1B1B[VQQ3:M#"
M:-9"\DQQ$I"*/BR'W>\/WHU?DMG_`*!O&;%8)!@V0D][\8?1C6]O0<+$#:XD
M8ZA)$<3*U:^-/Q9>J_9(0"0;Y2M>7QD84T-?WBKTFK5IMZ?(T>UY&CVDRI,M
M3^NUZ?SZ!8(2#"E:B1KK,-[5EQ\'@5G^14*T.3+&1<[Â(NW$6VD]<XJ=*)
MOB=[*E:\D?\`0/(H:_O%7.#V&N*F]_H2+M_"%MI?5R87JPL?B.52DV)JU?ES
MTCXT+#V>O]$-[5\X/8:XJ;WÂ(NW\(6VE]7-[PH98_B;4MU/M7+=N];C0::$
M=XCNDUE'#7W\5<X/8:XJ;W]<KG5R-@3^<;G33S5<G)UZR+M_"%MI?5S0ZV&L
M)BY(K$9!K//+3DP&`X4:]?Z(;VKYP>PUQ4WOZ^4FR%"O<_61=OX0MM+ZN471
MPNIX)9LF!UI_;[CNQ1PQD34N(VIS=D<-;5<X/8:XJ;W]?*39"A7N?K(NW\(6
MVEZ[CDW6M?\`MVJK-^PHT>AF-DS<"6$VZPD)*UZ]-O2`GEH]1Z_TPWM7S@]A
MKBIO?U\I-D*%>Y^LB[?PA;:7KF[=VN&VTGH9D(]24FA?2I9C6K]O_-8%`]S9
MW0D%V$K10UE]HJYP>PUQ4WOZ^4FR%"O<^$Q7;MB*OD1!7R(@IDSSU,U$7;^$
M+;2]<W;NUPVVD]"?PBT2`^`4.MP(_4I4IT2:/3Y0;.Y(4,`HBAK/+.*N<'L-
M<5-[ÔE)LA0KW/A,^TN#%[)1%V_A"VTN#IS6=6]S_G$[U%1Q=D<#PF[=VN&V
MTGH9U7NK;'\+K!E00U=M6[UMI$QYB<M?Z8;VKYP>PUQ4WOPY"R.01<"_S*EN
MHWY4R85GN'*39"A7N?"9]I<&+V2B+M_"%MI<"3N*N+^Q^$W;NUPVVDZSJ<(Y
MCAX_E?"5`,P@4FJNLS`20G=0H$(A9RI5KTVDT=+?\9,1NKFTHH:VJYP>PUQ4
MWOPYF;35".[N'*39"A7N?"9]I<&+V2B+M_"%MI<"3N*N+^Q^$W;NUPVVDP(Y
MGC`1>/Y&0I0A(`<>V<.9V[%<(.Y>N6S*5!4[B&Q+#(?X#_Q/[:_T0WM7S@]A
MKBIO?AS,VFJ$=W<.4FR%"O<^$S[2X,7LE$7;^$+;2X$G<5<7]C$NW=KAMM)
MARGWPK@]['AS.W8KA!W+])?_`(<D,7Z4JQQ([1-=10U]_%7.#V&N*F]^',S:
M:H1W=PY2;(4*]SX3/M+@Q>R41=OX0MM+@2=Q5Q?V/PF[=VN&VTF'*??"N#WL
M>',[=BN$'<OTQ\I8RFM?Z(;VKYP>PUQ4WOPYF;35".[N'*39"A7N?"9]I<&+
MV2B+M_"%MI<"3N*N+^Q^$W;NUPVVDPY3[X5P>]CPYG;L5P@[EP*#\+"M?GB'
MJ').C\O<.I@9E+6Z$C#\@10U_:*N<'L-<5-[\.9FTU0CN[ARDV0H5[GPF?:7
M!B]DHB[?PA;:7`D[BKB_L?A-V[M<-MI,.4^^%<'O8\.9V[%<(.Y<.<7NU<-M
MW.E<LLMR(2,')[6K5J-#9B!]9+$7\U7-M7L5<7%*9'-/R,>KY$/US"=FI;%=
M0O=M6)8^1CU?(A^N3CTSJX5H7U:=!+\C'J^1#]3$^LE^*L&0A8-+-\B'Z("%
M@U,.$./K)8BGY$/U\C'J(\\M1#7&=Z9DD*?(AÔD8]4T7;5^6*X@.[4BBGY$
M/U\C'JY/J4ZN:ZX4N;:@9/D0_7R,>KF(L2+93KA6O0H"/Y$/U\B'ZYKN"!>Z
M5Q`5I$4K_(QZOW:7]MBK2V5R44"KHZJ=V%D($XO#X*PCN4;QWE7CF/:SCB/,
MZ\:QS0Y#P(RH<HWCO*O',>UXXCVO&L<TRP\"M:G*-HZRKQS'M>.8]KQK'5((
M<!4A!XVCJO',>UXYCVO&L=5X<!?E?C6.J\<Q[7CF/:\;1U2Z'0560^-8ZKQS
M'M>.8]K.-HZSIYAX$<U?C6.:\<1[7CF/:SC>.\Z(X>!7M#XUCFO'$>95XYCV
MLXWCO.BF'01_'?&L=5E'$>95XYCVLXWCS.G2*H_7MC-$X`V-&4;QWE7CF/:S
MCB/,Z\:QS7C'1XKZ[#TU*G3H5F(XA>NAR*F!H<>AY(&8>T]#R_-K#HT:]%S3
MB[O#>Q(DJFTM38N3D@9T(\^H29GQOW["6PPDC,36,?\`RF8R&2!7T)#(97O'
MTC>06UNT(6.\].^7W^V!P=(&1(I_WJG2S)W-(V8%YDWCJ6W=_P!S0:RJQ\>663^>I7EV#Q%X7J\7
MTNON6E$S.I0A^B372/\`,V)'XG9&<>8A_1@3J7Q.AMI7MVT#0LVC]CÈ6.K>
MQZ[;WF_!06D'T.#NI5HFJ_>*+)*#@B!E38:L\\M*]S,,W40`D*:[B3K2Y6O&
MPI*\+L3.\5N:H>%M)>XV[=NS;PD&^2+-#4-+"UX1HTC>EPD1U*D2=")K798V
MM;<S(\"Y45:+@^V/#RARTZ<L_I"X@PAR/H8Q!B'5O0B$&%"2=&H18=93T.(B
MPNS_`-!`(,)0HZ"<493!%;MZ+6C$C'FXJ9D2)&VH\7=K2/C4RLK8/-F-VWHO
M6Q8590YG_`B5U5L3"W3.P/ZU`2#SJN;RT5=K[80L#WK_`!:.8W4CY%&T<&;4
MY`P0;Z2N"PRV&1O_`,2__]H`"`$"``$%ÒZP;__:``@!`P`!!0+^L&__V@`(
M`0("!C\"8-__V@`(`0,"!C\"8-__V@`(`0$!!C\"]XR+(DC]L6AH[6X2)S.3
MVGS;!-,Y'-V$Y?-Y.W=M737P<6V43Z3!(%=!Q@60![/WB-LSC+)=#6-$NHT3
M'UD5(U#(?O)M(K"LV;5UU1U/;Y+#AV@?-S9<=`V$@4:3:M$Z##+-!"?$9,DM
M,CF!<Y#*/Q]NW5>)*NNXR=CRB/A4GY.3\EE$M8Z1Z=?D.LY%E#\9/D_&^-Q=
MA^M4-2XZ58]PQL:Q>Z)*2Q\TI!1&0W=IL"6'R;(XMYB>%K5;U\+>4E@.PK&N
MDC(88SL*`T)SFRXTF&80ID67'<W1X2#:1J_!QF4<-'84L7&9]7%B.MAEB65C
M'LZUMB*;(K#!&6N88;D>)CE5[A.:YR-5=J<2LNM,!BA[OX&32\=L;V#E#95K
M7LBWBT*VIZ(M3&YD1LM6[VL.KT:[7KTXN*N7E,,,[']WGH'9[!WFW;,@U^DD
MC(;@M5TVQ"-OC>.KNK71VF0I:7T6([%5J67S'LDN+!)>CYM.%!"`\DN18L_L
MA@0CW?FUXG%QNU'9MK)+(=@C`RHY(<MX6'[-(%+!'*,[1O3<U4U8[Q7:.14X
MH)]EA=9&QG(\T=A,.;!RX,V]%/6VE4P))L=)5Q3.C.DQ55VPJN:Q=W7Q<QA7
MS94NDA7,Z3'!"L?\2/']4MV5<I\1D&V+`(FTK8Q"J-?C:=?&.Y)96R4K<B@D
MG"@'C6,J3#%&Y;9Q9G98#U#`@%*C"3'(V)KX"<$K;7*8,66'S6X[>5-.&.*Z
M8U]9*D2XT4T0$*6TC=#O>@4W)JY-4XS+$8#)+)V&R01I)2B,T4U7"&LHD=5`
MT;!Q))4%XS]Q5U<U-FCER"DK:#"!QZ+,;#$MUYWCQJ6XG/KY0@+,C4A:8IB-
MD(5.6B/7>_5J+U<,H!7\9]V2YFX^VI04OSAYUK8K9LT+HJQT,P((CT(IU1(Z
MM75'\/C4&2U]C/?5V=I!"]EA#CSAU0B$FM!-/!0!7P]FIV#YA@L\9S-.,7B7
M%Y50,AR>FJ[F+51"SIX'1[09W"D1YWFZ.U]>CHI/ERM"C4;J_;JG&19)761+
MM,>@Q9Y:^/"L84J8&Q/V6MD0_.,*,T]=,D>*DL>^/_\`=X-;R7/GU-?CM/CV
M.7_G,TR8R:@<@64T+9E7(K8Q(J$(!&1T1Q"G<[3EM735;WZS1!5K+8-"8DB/
M819$:XDL4D>!,KY,05C".8;=S>:)FJ=?`+D>1,-#DVDND`,%;<'LR6T`7/G5
M_F,->^Z23#!\H5JQ_$8J.7J5%XM\_I'!OJZ#CECD,#DF4(;(<&&:4T*&43W@
MYK@[%U8KF+X4U33A;4V01(+HE=23[<!A6#4KVWA8\.,4930@]OKO.4E(_:PH
MZ/O\+DXO::LF@E7&/=D9:1/EFM@R+**LRO%),@E'J<'CJC%<YK5ZTZTXH<4B
MXSLSZ1?VE5EN.%L7<G$:VB<UUE?R)[8.LN#)!(CK!^3&V6XVU'>*O%C7PLF@
M%D54:QF2U>DF/%6)4/4=M*ASY`!0+*/6/30[XQ"M%_6TXMKH>3QV5M$E8^VD
M2X5I!6&&Y,V/52G1YL&/)?"L"NT$=C'"=_K:<3.\.M(ZZJ6QE=5,"P\1]O.+
M.\TP((4E@&82S;9S0H]6::+NZTXKHMC@BMQR1=XMC)KY;P3)$VZR=K&_^7*E
M8;B6T"JD.V&<\@".T56LT3AB6..+`P^SDYS"QW)!VC)4J?([O@29-P^;4]E#
MV&/-#!.L54.1SN5HY&[N)7UEQ:10\W"87>-0CK)9,DE6F*V$M80&OB18$<X;
MQIW"UCL0J+S4\;JX/?&ICT#QWMY4>;)1>;,È1/)#_QFC&-#,7E_*#3<C'ZI
MN7P\5U+<X42MQJYR.;B]1=FN`NMYLB!7$LBWC,?'%=_Y;<,+DY_:-[?C.8FJ
M)PTEYBYZ&GML2N<XQ>;'FNNIMG0T4SLTT<RJB0F2(ML\+V'&`*R-['[==R:+
M:9*W$Y<:S3O#_P#3J@QRQE]AFS;:3(@QJ_SP1\9Z4Q-9;G2![3<E!JFKEXI!
MV]"E4>1G]MW89"@K))H:7+8<5\FL2,7L@%L*NYY>QA5:)S'E8BM7K_(\GQZ,
M<<:1>X_<5`)!D<X(#6,`\09BM'XZC&\NJZ=>G$_"*2!C5/D-IB-=CUA?PZ@$
M-)TN("(T\J86+'9-DC/(`XGCJYVKM5Z^,NPFCK[>3#RK.<)R?8?#;<S9,P!:
M#SI(@9A%D&H8M!$%5<UZR4%(&YJB1BH[?Q:)$NL=9C-CWM4/>HY#QK%;SM%>
M^N[;3ZL=V`0-*]%$3QG.7J=MXF5`+>".X'WKV/>?5F1;.)#,2392I(*RQE5Q
M8MK'=V.4K%D1W(03VM<SP<6,>P6N6SNKVPO[+S6:ZE1NTS6@"B.G9!/GV=C(
M;'BL0D@BC4J]>Q/A[T\@HK&D2TS6;03:)MG'FGA5[ZFEAU)DM1QB`*9I>0YS
M>4]/"G#=^F[1-VWXN[3KTUZ]->+'`;3(\4'@%ME$Z^L_-]9;/RF7#EY!]8'U
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MTTQO_P`5QDME5XÒ=I8`=/S"#4R*.+*>:NM$6FEULR;+<,STE03_`.#-U=::
M:\=Y5/`M:J.#,<3[O<9I]T:8C*UN%0^R%?):XLDO(D)IRFH0CF_UE7P\9Y=E
MEU<FASÈ+8`&SM;;>'95=/ÌG@*CF]B?!>*(KT<CN9JJ)IQDUM7P^Y^WCWN;
M6N6QIV58Q:6.25S;&4(PXD>P"8+1=C:%'#T^*5577KXD]Z;[FD?/L9,JFL*=
ME>YL5,'[-%%7"BS>1VWZS`D0T*4SODBM7E>*Q$X[NTR$E;25N)5^;&JJPU;9
M1,F\Z9**\J&Ò&2%:$$*(*P<;</QY"*S<U/C+SQW\$$X?<Y3=V\.QBQ2%/!M
MZLD\OGD+)"-82*A9(WM&O6Y1]?&6LN,AI76.3=W0,-?*'*R:U>2S@V@K$=Q,
ME7LF4?EV.UW-"!!"C]2"&NBJMW=S+BCA7L^)W:3(+(P;"94Q\A[OYTV=LF#.
ML>1+I;!TG9X4*GQM-4T61D][;T`\AM>\/N\RVSAU8)ZTD:HP`)XT:O@OE?XR
M393!R'.>8C6-UT31$;QD+QDQFR):]Y5SG$0-@_(*F1#C6E175PF0LAH9`;.I
MLHQ8.]ZL88)VJC7)U<3^[RTR/SS>S\9O*1]]-[00:%M131QD>Y[B39$:N'):
M)'O52D8/5>M>+BT[PI<*TKJSNH_],*Z'A=%;S;&9!DFAN?;'K]LF0MD.7&#R
M0@W"'HI-6_`"9E?/7,,IF&R3)72V[);9<I@HT**=OA&^)4Q`,<S^H3=QF&;O
M/#=&R7'\?IQ`$)S)X"5/:TDE,?:C59(:4:)HNOR::^!.&P@9#5`3'J/+:O"\
MA8;*)MU$E9&(T>/.+53K5<<IEB@-H9(87=I<B.\1R(O&8QK*ZH>V9;58+"*]
MLK)K=K)&(Y$&UE'E3+V1+G2_.L9CNI.6P3W(Q&;4W+:ÌHSYEI5RZ7(H%>)-
M7V!<<MX5RZO$Q/CFFÀO&-OPD5O%9GH+7#Y./UPX3<=H\BK;Y\JAB2&1WVT^
M-&">)&#DTUN]G.,UZA9M8B)HO$:NM;NL+@U#)[PIN.18<64R_>3O#C38DJ/;
ME,]8/*IA69^2\765RIN1-.(MUE-O361:#!:SNXQQE+%F1T?0ULWMOG*V[:0F
MEM+48FN8+Y)J,ZE77B?CE]:6*LE9KD>6!D8U<6^/R&MN;&=+CQ32J\\221H@
MS=",U4:O1%^!%XFY;:6^'6U)(:Ê@1IT6]DW6/XBK2`)`H3K)'!BVEB!467)
M>PCS$UZ]GB\4DR_O*FSK,)QBRQ+#QUL25'FG@V=D*82POG2'N`R<*+&&!&Ù
M&O6[77JXR2)'N*UEW([WC][&-2#1Y1*^/*9/B3(-=;#:YAR,<P+QE<)>K?JF
MNFG&*4\Q16-SDO?2O>KF-E4Q90Z*G%5M=9/B132-QAB>2+#B1^:J%*Y[G:=2
MZ?\`P!?BSS'\X@IIU[,+V8J5\&%7K7\ULB<Y&@[6X=F,B"9O>@_&=M16[B1Q
M5UO5'\W0;J&*XCQP.LJ2R<9D*UAI&ER]`D<!4<,O*D"U;O&W<G^F8<PAV#KQ
MXOEN/2Q)N[2Y<D)0;#`ZN7M"*J)NU775S?T\#LLCDU!#5N+UN)5K:=9:LD18
M1W'D6LWM80]GE3G-%I'9S&!V+\J_=U,BSY%S&&`W:6/I;VWH)"O:,@]I)--,
MA'*'0GQ'*K-=%TU3C!YD^5(G3)&.5I)$N68DF5(*H&[BG.5SBF*[X7.557_2
M\R:@"R>R19$KLT=NX\CD">7D!;_6*7;HU/SKQYNGDQTTJ1CU?E$=<:GFGAA0
M[`SP.JK-QFHK;*&1&^,FQ"ZK\F/;UI)O+BJI8YG]G%(MK")7`*=6/>@1EF%"
M-Y58Q5VHNNB<8"J=:+C%6J+^=%`BHJ?H7\E<][FL8QJN>]RHUK6M35SG.7J:
MUJ<?;O#?O/2?3N/MWAOWGI/IW`)D.0"7$DB8>-*C%&>/("1NX9@&$YPRB>U=
M4<BJBI^7N8JN1'M5JJQSF/3<FFK7M5',<GP*G6G$N=YSL;F?*C`@-F6;:YA@
MU\8QY#`KYL@5[)4DQY#GR)1D))DOT5[UVIQRYL2+,&S4C1RXXI+&O1JIO1AF
M/:CM%XP'V8K/[A.(4C+KV+1AL2E#"?)9)?V@@&M>5K$C!.[Q&O377\_'V_JO
M]WM?H'$>AQS+J^TMY;3OC00BG,*5L8#Y)]JGB"'\F`3G>'P)^17OH>S\B-T]
MW'L=0^KP_E\Z:0K0,B0Y,EYG#>9H6@"\KBN$/0A6C1NNU.M>#PLIE63GS\4Q
M[)80;0]3.=*?.-.%96=<6GC1AUE89W(1D$V\@O@7P\#E/J,@N$.;LW(QVI/<
M2Q[AD?SBQP*CA@39IN\&Y43X>,`7K37%ZM=%ZE36.U=%3X%3C`?2]UY'"Z,6
M_=<B_#]E^17GH>S\B-T]W'L=0^KP_ED2RA>;1GG9%CU%VVY>\515AN+,,639
MV1!O&YD:+'5W7N1-ZMUZNK@@+CS,ZDR.CO,KQF)!`8-O14U5E"8]7-NU>1[#
M)?!<IPOT:J\IVB;5T3A4=IMT7=N^+M^'77JTTXEKCE55USIBL64M>P;5>T6_
MDA\55Y<4"E=RQ-T&/<NU$U7A_P"R[^CC`?9FL_N$XP'TO=>1PNC%OW7(OP_9
M?D5YZ'L_(C=/=Q['4/J\/Y9-*"-C9QSK.CJ)I<NC#FX[7P+2TC1)-I9P"?\`
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MFNO$_"[W&^[0%U+Q)<BAY#W>4`:)_FQEK%@R:BZC-$TK=\H@R@=U,(C%\+DZ
MN%<Y4:UJ*KG*NB(B=:JJKU(B)Q)'168Y[XC`&*U`RHZNBRU,V).C=J`#ME=+
M6._E2`[P$V+M<NG#_P!EW]'&`^S-9_<)Q@/I>Z\CA=&+?NN1?A^R]XS#]N@_
M$57T8YZ>J/6$?WB\]#V?D1NGNX]CJ'U>'\LNL:)5=WUQ53J:M>&NR[)Q5#["
M2:R*R>,\=Z<P$:)$"TH#L7=STZM%;KQ<Q(V)=W6/QI=>D@\S%<XE9A=R3@D@
M''CRG6!I4L5:,1GJGCHQK]J:=?1=5(3)'-9U-C7B.NN@"389HS#+IUZ#<37@
MW;85W550<=IZPD2_OPY"67?0WF2584Y139WF^G[+M:@T[,PBZ*D<6U=S`5>2
MV6,&&;FDF5D2GF&.)!D:L9X[FOL0-&KG([5K6OU;X=->,`3773%ZM%7X55([
M>M=.K5>,!]+W7D<+HQ;]UR+\/V7O&8?MT'XBJ^C'/3U1ZPC^\7GH>S\B-T]W
M'L=0^KP^\.&6PA#(Q='L)*`Q[5_,YKGHJ+Q_$Z__`'V-\YQS(YA''JJ;PD85
MFJ>%-S%5-4_(NV_5CN0N!0Z.O258=XUP:ON8C"SIPP,<P:<L56\KMÒ<OCE5
MZ<69!47<?6*M(1G:.[*\=:73D6=!=R9H7:[*QVW5SO\`M6L3X>ASWJC6,:KW
MN7P-:U-7*OZ$3@]A%A18L-HH9@*&_J;B2K)K"&$V?$K"E)4R4"C7<LWC>-I_
M57AW[*_T<8#[,UG]PG&`Ê[KR.%T8M^ZY%^'[+WC,/VZ#\15?1CGIZH]81_>
M+ST/9^1&Z>[CV.H?5X?>.\7VMN/*G]$KVPN/(*?\BN:^%W=85EL:BP&-F&<2
M<I;I+FXY"MYW8ZFK<T!FOD0SQ2R&<Y'C1R]2([XQ:6WPWNYI+"^[OH.;UEE@
ME)YI+'IY]H&*;'K-[TWRW1Y'+>CTZEV]:NZMO!@H]1J41!H1&C>H][%;O1A6
MD$]6ZZZ.16K\*<%N+FPJ9<QM'`QJ(VBI/,41U=7R#RFRYT9)<MCYYBGZF#Y8
M([=4&WQUX'"R"O;8Q8YNUA$X\H"-.T1!(_=$.!Z^(14TUTZ^,`1/`F+U:)Î
M([43_P"G&`Ê[KR.%T8M^ZY%^'[+WC,/VZ#\15?1CGIZH]81^GO#,Ì`F%A]
M\\91/<,@WMKSJCF/8J.:Y/T<?QRX_F<WY[C^.7'\SF_/<5#G*KG.K("N<Y55
MSE6*)5557K557HO/0]GY$;I[N/8ZA]7A]X[Q?:VX\J?T2O;"Y\@I_P`BDWLG
M*LQH#3\?%C%E$QVRB0H5G4"D3)/9IXC0)+I(R/FNW-<[8J?!P3(699F633EQ
M],9CIE-G&L1P:EDR/-'&A<N#&($8BQ_%;NV)JO5T2)DLPHT6(`LF3(.]HPQX
MX&.*8QB.5&C$(;55RKU(B<92BMKPU,1E%-QL0#L-9%I[,$M6SK9K2O2/(FOC
M<UH=K7`$1C7_`"FY$9-R&S#5Q9!NR!,=IG-?(<(A$&B`$5VO+&J^#X.,`5.M
M'8O5N1?SHL=JHO\ÙIQ@/I>Z\CA=&+?NN1?A^R]XS#]N@_$57T8YZ>J/6$?I
M[Q_8W(/5Q^FG]%5_D@NB\]#V?D1NGNX]CJ'U>'IL8#>[Ô(V%.EQ&D7()+5>
MD8Y`H]42K5$5R,X_]O*[[PR?^5<4>8GKAU1;?M^Z`*0Z6,/8K.9`3:=P@.?S
M$B[OBIIKIT]XOM;<>5/Z)7MA<^04_P"12)%59WE2JW-`&QE8S',?(?,QK2.R
MV'2J`9%CV"PU<K'NVLZM%5->+)E+EW?-D$GS*]Y(O>/YT6I"%)L)%/$6;71`
M^<D>Y&IHY5Y:OZM->@@3#84)6.$416M>,HWM5KQD8Y%:]CVKHJ+U*G%G:T]5
M#KI=N*$&:L..&.-XZ]#)'1@@L8P?]NN[3XRZ:^#AW[*_T<8#[,UG]PG&`Ê[
MKR.%T8M^ZY%^'[+IC9'C8ZXE@;(8%6Y+..63'[-)B6)R*@PR8KN;OBMT7=II
MKU<?]UP[^3S_`/G/&)8W9QL62ON[V!6S%BU<T4A(\HS1D4)'VI6L(B+U*K5Z
M<P_;H/Q%5]&.>GJCUA'Z>\?V-R#U<?II_15?Y(+HO/0]GY$;I[N/8ZA]7AZ;
M_P!-6GEQ^C"_\]_$=MT]XOM;<>5/Z)7MA<^04_O`J'++>3!LS0`V3ÀJ;*:W
MLAS2`">IHD8HD5Q(K^K77JX^T<_[NWGT'BPAXA:2)\BK`&3,8>ML(&P)R.$-
MS73(X6DU>WP)U^\#L*CO.RK#HS(0HKJJE%7OB$,,IR.F.62)Q.<5I4:OP:,3
MB3-N.\K*,SCGA.BCKKL4!D6.9QP%2:-8HFDY[6"5GATVO7]'1((\RQV#`5[S
MM1'.ÙHW.<9&N:]'*-$U\"_JXO*F/>2[ZHD8]CUY3339&?*4FA.:Q!)NI<N0
MP2TTZY=RU["%O9$8+>+^NUK#U>-663F(;E$AU<NGAF`)1D<LEY+FPK@.&CFH
MW1KG/U=X-->,`7337%ZM53X458[>I=.K5.,!]+W7D<+HQ;]UR+\/V73!]LJC
MU;=]'=S[6T_E3.G,/VZ#\15?1CGIZH]81^GO']C<@]7'Z:?T57^2"Z+ST/9^
M1&Z>[CV.H?5X>F_]-6GEQ^C"_P#/?Q';=/>+[6W'E3^B5[87/D%/TRJ#(\O@
M5=Q"0"RH)@6!"!22`<H&YT>&87RD<S7>'P+Q]OJS_=+?_EW$V1B%[&NQ5QÀ
MFOC#DC[.0[7O"UZ2@`=\HT:Z::^#IKO8JH]:WW1G7H.K\O-[PCJ"GL;.DD8@
M>'BD.KCV<R)/RNPDHÌK=(51,&D^M38\`3D%'4**[F;G.:D['+R59WE1$QVO
MD9A97MW<6D`.4S-DQGU7F3Z2*-3/B2-#PX[WQ!-37G;V[7=%A]5?J[M[8[SI
M]7_-NGG#ÔYP\W=7;/S\SQ^'_LN_HXP'V9K/[A.,!]+W7D<+HQ;]UR+\/V73
M!]LJCU;=]'=S[6T_E3.G,/VZ#\15?1CGIZH]81^GO']C<@]7'Z:?T57^2"Z+
MST/9^1&Z>[CV.H?5X>F_]-6GEQ^C"_\`/?Q';=/>+[6W'E3^B5[87/D%/TY?
M_L<=_#=3T=X'I6C\DG]-=[%5'K6^Z,Z]!U?EYO>YG:1%/'[+(YX`#(8Q@\I_
M-$(0?EBE(S5&M;XRKX.+6\;13<5*:HJ*>!C3\9N*(%10U99KZ\4V9/KH4.UO
M'OEN4J`5XXK-HV*[1Q",;BTZC@3$-K(+?5DZTC.B\LFY@@P+2J(P_,VKN5SD
MT1?%XP#737ZKU>NG@W=G;KI^9->,!]+W7D<+HQ;]UR+\/V73!]LJCU;=]'=S
M[6T_E3.G,/VZ#\15?1CGIZH]81^GO']C<@]7'Z:?T57^2"Z+ST/9^1&Z>[CV
M.H?5X>F_]-6GEQ^C"_\`/?Q';=/>+[6W'E3^B5[87/D%/TY?_L<=_#=3T=X'
MI6C\DG]-=[%5'K6^Z,Z]!U?EYO?+5U%-;8!IK1]/+DB:[LSIHXD281L4ZHC)
M86"FL3F#U&KM415TX?\`LN_HXP'V9K/[A.,!]+W7D<+HQ;]UR+\/V73!]LJC
MU;=]'=S[6T_E3.G,/VZ#\15?1CGIZH]81^GO']C<@]7'Z:?T57^2"Z+ST/9^
M1&Z>[CV.H?5X>F_]-6GEQ^C"_P#/?Q';=/>+[6W'E3^B5[87/D%/TY?_`+''
M?PW4]'>!Z5H_))_37>Q51ZUONC.O0=7Y>;IACRO)*NA)8-,^$RP/RG261U&T
MSAIHNJ#4K=?U\?\`N'C7^^__`(<.JL9RRGNK%L<DM8<&3S#I&$X;"&V[4\1C
MBMU_7[O,)1N0D>[OHEC7M"Y55D0&,8_3JTS-C&B>DFL)HB:ILT_4@XWGG(*3
MD&[1VC';-:N6701&<DIT$7>!=^NW3XR(O&`)U]6+U::KUJND=J:JOPJO&`Ê
M[KR.%T8M^ZY%^'[+I@^V51ZMN^CNY]K:?RIG3F'[=!^(JOHQST]4>L(_3WC^
MQN0>KC]-/Z*K_)!=%YZ'L_(C=/=Q['4/J\/3?^FK3RX_1A?^>_B.VZ>\7VMN
M/*G]$KVPN?(*?IR__8X[^&ZGH[P/2M'Y)/Z:[V*J/6M]T9UZ#J_+S=/=YZ.R
M+RFIZ)'LA<^6U'NIEA)54C08LB9(5J:J@8PG&*J)\*HQB\)7W5+&IY,V@K\J
MJ6Q+-]FA:BP*0/9YRO@0.S6L`B,YS6<T*\U-CUT7CF39<6&-^HVDER!1V.>K
M55&(\SV-5VB<8($US5"*/&JQKQDL8;",=R$U:]CC(YKD_-Q@C8-A!FN';7*O
M;$E@D.8BPX2(KD"1ZM15Z,8/+D`B@;%R!'&D%&`35=06*-12%<UB*Y>/X[3?
MS.%\_P`?QVF_F<+Y[B"&%9U\LOUPJ7\J--C')L2NNM7;!$<[:FOAZ.[TQRC"
M$>5U#R%*]HQC:DIFKGO>J-:U/T\?QVF_F<+Y_C^.TW\SA?/<9<"+;5DD[GT.
MP()\4I7Z9#5JNP;"N>[1/S?!T8\YSD:UMY4N<YRHUK6I/CJKG.7J1$3C^.TW
M\SA?/\?QVG_F<+Y[CO$""YJC%)A]\P8AV,-Y"/6N.C6,8TRN<YR^!$ZUZ:AK
MKRG16UD!%1;.%JBI%%JG]OQ_':?^9POGN+MK;RG5SJBR1$2SA:JJPS:(GRW3
MW>!/<U03#Q"B801+&&P@WI`#JQ['&1S7-7PHO6G'\=IOYG"^>X_CM-_,X7S_
M`!>N:J.:ZYLU:YJHYKD6:=45KDZE14Z,-!*MJR.=GGS>$\^((K-<BME3>-Y4
M>W5.OK^#C^.TW\SA?/<?QVF_F<+Y_CO",`HS!)E=NX91/:09&K*?HYCV*K7(
MOZ.B4&99U\0WUNMW\J3-C`)M6#4:.V%(UVU=./X[3?S.%\]Q_':;^9POG^,M
M/$DÈ`<'']IHY1G$[;CE4UVA!.<Q=JIHO1GK9UA!A.):4BC;+E@CJ]$B3]5:
MAB,5R)Q_':?^9POGN/X[3?S.%\_Q7&A2HTP7U,J6*6*<4@:/2UO55BO$Y[4>
MB*G5X>OHS=TZ;$A-?25C6.ER0QT>J3C*J,4SV;E3]''\=IOYG"^?X_CM-_,X
M7S_'=^Z#.AS4'7YÀ%B20R>6KI%5MW\E[]F[3JU\/1(-,E1H@?JE<,YLHXHX
M]ZS:G1B/*YC5<J)X./X[3?S.%\_QVSM,?LFSF]JYP^S<K_M.?NY>S].NGN),
M*2SF1Y<<T60/P;PG&X16:IU^,QR\+-G7LJ_D@IX..59),2+#[!15Q"%"`B1>
MJ9/.]Z*>0NWF<MNC&Z+JR+>T]5<QA$YP@6U?$L@"/L<-##%,$9C"HQZIN1-=
M%XIJ:=BN(W<RLKX\.3;2L5I^T6!0LVOE&YL>03>5>M=7N7]/'5@6%I^K%J-/
M^!X^PF&_=BD^@\=>!X8OZ\7I/H/'V`PK[JT7T'B3%F8KB-N4]S>V;),C%:;>
M&-;7$RQBUS>9'.O)K(\EH&=:)M&FB-3J3JP+"T_5BU']!X^PF&_=BD^@\?8/
M#/NO2?0>/L!A7W5HOH/&1'DXKB-BRZO76T,)L5I]M3%=5U<#S9'WQRIR$/`>
M;Q48W<9?%UU5>K`<+3]6+4?T'C["8;]V*3Z#Q]A,,^Z])]!X^P.%?=6B^@\9
M#<%Q7$942Y!2BB53\5I^15.JPS!R2`W1WCUL726N?M8S^S377C[`X5]UJ/Z#
MQ]A,-^[%)]!X^PF&_=BD^@\?8'"ONK1?0>/K!]5L2[#]7O,WF/ZJT_9>U^<N
MV^=?[#E<_D_)?V>[;_6^#C[`X5]U:/Z#Q]A,-^[%)]!X^PF&_=BD^@\?8'"O
MNM1_0>,?N18KB,:)3Q;P$NJ9BM/V>T?:LKVQC'V@8/=6K#<K-S'_`-JNFWX?
ML#A7W5HOH/'V$PS[KTGT'C["8;]V*3Z#QUX#A:_KQ:C^@\8Y(C8KB-<.DO/.
MLP`<5IMMO%\TVM=YMD;(XDY/:+`9_&1[=P$\7714^P&%?=6B^@\?8/#/NO2?
M0>/L)AOW8I/H/'7@6%KÔ%J/Z#Q'B0\5Q&H*&YHK)\F/BM-O+&J;B%92J]W+
MC@=R;./&='?UJFTBZHY.I?L!A7W5HOH/'5@>&)__`"])]!X^PF&_=BD^@\=>
M!86OZ\6HU_X'BWIH.*XC22[&$2-'MHV*T_:(!'Z:2!<J/')O9Â[5_3Q]@<*
M^ZM%]!XZL#PQ/U8O1_0>/L)AOW8I/H/'7@6%KÔ%Z-?^!XL8(,*PV$:;!EQ`
MS!XK2<R(61'($<D>V(-V\#G[DT<BZIX>*JMD89AUA(KZV#"//+BM+S9IHL80
M"2R[XA7\R2]F]=7.75?"O'5@6%I^K%Z-/^!X^PF&_=BD^@\=>!X8OZ\7H_H/
M'V`PK[JT7T'C_P!,O.8^5V+L/G#S>WD\GSIYQV>;NT;.5R_DMN_33_Y>\6%(
M"?');50HA["O1_\`BHH)[7NAG()='<F0@W;7)JW5JIX4]S'Q^58H.TDECQF#
M[-,)&'+F,(6%"E6(X[ZZ%.G#$JA"8K"E33:BZIK[B%4V%BR//L'1F1P<J25$
M6;)['"[48(21X#9TSY("G<-#%\1FKNKW-<^ZL`5P[6TCTT$LG<T);.6PQ(L5
MQMJC"Z0D=R-5ZM:KM&ZZJB+[B(Z>1_-L)H*ZNAQA/DSI\R0[J#$BB1Q2\H:*
M0KOBB"QSWJC6JO"/&YKV+X',<CFKIU=2IU+U^X?869U!&:0(6\L)Y4@\B01H
M8\:)$B"/+F2I!7HU@Q,<]R^!.`R@;^5($PK.:$T<R-(U'HTT:0P4B.9J+XS"
M-:]B]2HB^XE6=G*#"@0A./*E'=L$(;?A5?"JJJZ-1-7.<NB=?$*\K4DMASV$
M<)DR.^)+$H3$C&#)BET+'D!.%S7L=XS7)HON#2I)AQXT81#R#F>T80A$Q2%*
M4CU1K!C8U555ZD3B1(II;I+(LA(TEI8LR"<!G`#*&A(MA'BRF,-%D,(-VS:0
M;T<U53W&J^#@L"IM0RI8X_;$`HY,=\F"I5ÈC7]J"!+.M4R;>T1^:#54\;K3
MW+Z&+;!?:M=+&R.X<D+)9*]VRP%72CA'#M"U[T5)#8Y"N`J+OTT7WM];4Y'`
MAV,6RC"R&0(8+&;04J:^<[4,`R\F7YK>\/:^HJ0@$<8K-&<6C)$F%7=X5.VJ
MOJG/J07,B9%160"U]>2?6NED9V"6*E?'G5_-Y#G#;)`YCW,<--=-=.O3J37X
M=$U71.F?6UMM#3*!LBO;`:-)U@&(0X"61X==N8EC;0:3G2PPMW-/RTT8Y%ZS
M5],VGR^TO++%.\6@R&+-;5P,JKL>N,<A3/.PQNE0JV?41V1%<6*-!S8WQ!H9
MKF<1`7-BRUM&L5TZ>**."`QR/<1S8T0>[D10;^6)'.>3EM3>YSM7+T2X89]8
MF4GK)1J"IG2&B[?8*,K*R,]5>)@_.$YG*"CWCYY/$8NO@"R6&H[Q86>1(8:R
M?)>7%9)K3$#R[I^+9;"@BE!#YO1\LP7=F1XSA=&E,UV/6OJ9QFE/&68Y&#D2
MI@(4>3.DRHE5%ES?\9*B5$4S(HB$T>X8D543P)T"2VMJVND2VE[".PE-C#,\
M>U-Q2KJD:(TI&->9^@V*]-5ZTXH63K*@N@W-_75-C"N:5ÒPO,-2"G4%O41C
M;[:DDQB2(K6N5LAKGB-S2@(I!LI"WMED+(\@SXL^X?SK-(YMC^S2I6]W:N07
M?RW:,VAVLT\3<[H%*O;2)6`,7DB?*)MYCT8XC]C4U<K1"8KWKIHQB*YVB<-M
M+RWCS8-7DPH=W55*!K+O$HMO.\V5<VDMH[ROO,8RBEG#9*WH_ML&6XT=[2"0
M/%[(-6U6.QKB7$D1L7H91)E15OBPVQ94P!'0:P(SVSVHXC!1QC1&-5=2.>O2
MZPN)H($-CQCYQW:;BE=L$$;&HXAC$=\5C45R\95+J\H@H+&CMR*NK:^/#66/
M&80T/`SK%KE3[+2:!XSH8)=8KWC+"=R":%X/8EC4=3$F4E3"=`QV18'@W,Z(
MIR/RF6*PB0R0[":`S6*WY8SD_MC$5K-.B18V4H,*#%9S)$F0]!B$W5&IJY?Z
MSG*B-3PN<J(G7Q,%C]GCEL&K;Ò,7QNR@Q2P,N95HPEL6/=E>LFIR:DMM1(W
M;_@'($AA*TVY)]G"(PF*900&7X\(V]EE7%R0:V-W6R@[5`D?SB19(W->J[I)
M&::,:YW0:5*,*-&C"(>1(.1H@@")JO*4I7JC!C&Q-55>I$X)CF/Y+1-JK6CD
M1(4:?![75Y3</[8V[Q2[DH6/94YFTS@%",/+DD#(>=G-:%6<5F4\IL1H[>XD
M3+J7D%G:9//B`!-Q]<(N!%$L*;$H+(&UDOGE89D,16,:\CU;T*JKHB=:JO@1
M/SKQ54^,YC35\&8V=$D6JPH]S&=?/6.E%2V83FCI'JK\':N29CF=L(#E!,U^
MB/QLJE*A,!MG42EFVPCKB@*DHTLL?QQL.FBR+RKR2L[.-)$^2IAP]K"-YPUW
M=):KN[L\?M<J@V</MM=.EM:!M9'F<NW4JM7M"B;L6.IH[3*"0]-S5T5O$ÔH
ME@Q:]N2LM"5U^^1$RONIRYL]MM9I6]CC2@V\8Y3D/%3F@&\<E4:4L0J-;[S4
M5^.\N*^SG'!/O#PO.8:2*"OES&&=7]KA<YTV4!D=KE?M9S-515TX96P_J],E
M7.W-(3%L25]QW>9#.M9B3<@KQK'F'GXU96XI,D`7.896E+%<XH'*K)`Z.GK:
MADLO.DLKH8(;#$1-&J]H&-31B+XJ>!J>#IC#QZ.TDZ=9P*]\L@%EBJ(<LVR5
M;EAH>,Z6V$/ÎO:FY45WBHO&05)4Q[().2V61"L*0TY^.3A7N'6`\<CY_C)D
M99R(85'!A.DBUW1)H^9'*JJHU:8<"J'>2XD5M[;5]='@OMIXQHLN61`#9HDJ
M8YY5;_K/5?#TSY='!\Y6HQC;"B*CGM4ACB"IGC8\3S#B#(IG#:YKB-9M145=
M>,CBV1<9RB1.FAPBXQ^R:VBCYM!%CH,HKY56TKK1L2\HXUY(%)%XT>3':UVH
M2-;K7R["!6%RQ(#8EE>""PUA(;U(P4BU>$4NQ**,,0B22(A)/*1[ÔJ3HLYE
M?"=93XE?,DPJYKD&Z?+!'(6/#:]>ICI)FHS7X->#RK.RQF9;1*K'8#Z^RBOH
M:W)ZO.3V;'8<1ACVZQ[NNLJ17PS:$0HSO$<>GRK8LZSHZD5W%//2K(UH[";1
M4II,A:JB9<$"R1*;45YNSC=_^H7R3%Y:=?0JHFY4151NJ)N7X$U7J37BDN+J
MRH:2TA8V7*X4>TBFJX%4R?85U/<8/?2>U3G2AV7;8R1Y@V-,.;&W(,C'<GB3
M:76,4<&2VY+8XY6MY%L_%XQ11B2(D.P6*!!`/=I(FB`).5&<?Q-%\'34%M+&
MKQH7G;*[2C[;`<QN,GPQLY(5M;SEL%#;4>147/;+;M`HQ3&J)[7,W+97^28O
MC0H=FZLM*^L"<=_"2Z5AW6^2UY3UT)(0<A"L3>)&(IW1N:5.8Y?<-@RC!I*2
M9F4''ZM$K^98A-!KVY-3YO&LGS.S&;"O:YN^(\'*?'$]KG;NOA^19'28A,J+
M.GC=J+5RDN:;*[D!1MKLK@19,(:UCPUG.`KU>0QA':)SWC"QSAA"-@A"8T8A
M#:C!C&Q$:P8V-1&L8QJ:(B=2)TW5>4(HV)<[&,?DA=$>2;D0,PL8U+82JRU9
M+8VKET3I[7!;R"[C#\?5KTTA6%_&Q.^KX,:SHKW(J\PY47-VUTE05C9E"L50
MUUM16@'D4G.+V4W,9'=L,Y&`@P(P(<.*)H8T6,)@(X!,31HQ"&C6,8U/@3IN
M7U08(:6FQ2=D$\]C!+-!?$`XZ2,9:4$V(^K4D`*JID0C]3-5J>(Y'4](5F.7
M]7ADY](?(7R0ELW8NM<Q2X'E-#V-\:;8-&:+O?S.2KQ,D[!G;L45?4P8M=!!
MNY46&%@`L5[E(1VP:(F\A'*YR^%SEU7IA1,:=$@,)!N;";>3JY]K$B$K!Q'0
M:TD5DV"K/.KI#U4NY=K([D1-SD5,;@U7F([:\^,YE4SVVCQ9#W<Q\AY5S98]
M-BMC/?;U\^`23&C:O$XT5[6G;XC3.<Y&M1S]-SD1-7:)HFY?AT3WL\*BB*!D
MN469*,8I),N28CE5B&E&5Q7BBB5!`9KL")J-:B)[F[LJR(K9^0V![&SEG*22
M=Y#F+)6,%Y5<L6O'(.0C`,VC:0CW:;G.5?<6^6!B*Z]N61Q299BD-R0QXT:+
MRH`B.44!DD<(2GY:-4[AMWZ[6Z>X3,BQ%->CK0U8#E*4@(H1/F.Y\6(YW9@S
MR,G/&XZ-YO)\37:KD7W%/DMA#[59T09`JWF%(L4+CE"9)3X>[LYID1XOD"/1
M5"KW*W1W6GN*61>1.V^8IKY\,#RD2*0SQ<O;.C-5!3H[7(TB#)JSF#:JIU>Y
MC5M]')*A1K"-9(!ARQVF+&0K.3)Y+F*>'("=XS"7Q"C<K7:HO#!"8T8QM:,8
MQM1C!L8FUC&,;HUK6M31$3P>XET5LDA8$UT5QNR2CPI.L.9'G!44N,\<@#D/
M&;UL<CN(U?7Q@0H,,(XT2)&&T,>.`+48((1,1&L8QJ=2)[BRIIZ$6%:P)==+
M01'!+V>8!\<O*,SQQ%1A/%<G6U>OB+3U$5L2!#8K1":KGN<YSE(8YS$5QI,N
M29RD*5ZN(4CE<Y5557W!`D3<,K'#(W_68]JM<G_6B\1Z2ABK'A@\9SRE))F2
MS[6,=+GS#N?(F2GL&U-[U71K4:FC6M1/]!6MQ"J9%[(K(99C:F&48I<U@$WF
M%%<1%:Z1R4<K&^%ZIM3K7CN_K\8AR;V7G<ÙRX4<P!?5JFAJ@K"==N=N02QI
MJ/C(-.LAQJU%\&LVKK+ZFL;*M72PKX-G"ES8*H[8J2XH#//'T?U>.B=?$V+5
MY+064JM:]]C'@7%?+/`8+J(^8($A[XS!K\97Z(G!QTUW46Y(K(Y)3*RRASW1
MV2V*2(\Z13%43)(VJX:KIO3P?Z7[\946E3'29';%CXK:;6M:E?)@G.I*_8][
M@1!W$E2JUJ-\9$ZO%33&T/B=_$N,(H,M$<\Z)AE-B]K8V%?*C1JSSQ4C=?9=
M`N9;VO<201JQE\;55XH[>7A=I3!;@.8T%D`>.8OC=/76TN$XL>LK8]-)+8V%
M:XZZ"ES7D<9[NK;XW&-0Y%!'HL@-6B7(42+'%829K9$HB><I`45\H@NT+LWN
M=L:NB:?]$__:``@!`0,!/R'ZÒ4$883+W_,-76=&8IFM)]7FUP`1;N>$`&,T
M2`H:L5TB5IJ@[",?J%<E@$7:X?&&3@NR+2_0L=S'"EXBG5VN8;B=0/R:IF2%
M:!8TTRUYT-1`GIS89[#(B8AJAM>#!!<!AO=S[8``#:/YXV:):`)4QWUGY>OL
MQ$$*2`&0<\QF/AO",&!>3B*)AL)/>'>-;"70%\@,N>:@G2W14:P%58$`\.3"
M0.%X*\\%K6_YC4SJ0,B*`0J#>7O^<H@1L0@M:85&CZ`9+!1NCE3L\[C?F"36
M8F3>GT[2'D!K%@L6<^>GJ%N94QTG;6)J&49A?@QOEE$MA@#R$'>-W8:@2W,Q
MJ*6Q.E@>BIIO@]_T&Y4S[`R"X<*091W1:Q&3OE*EP\&IP+BN1Y76P$BO24PB
M,4*?U_PM>(55:&3`//AH[")7Q80X#<G.852*6E[;4&59#,`:^=H<R110/04*
MF8B9@J@I!'V6E-Q^7PU/<-;SOY:$/E0&XK-,5"OZE^V>@P[$F?5AH91V`:7
MJ:F,M)_:`Y:A43XL!``TE<08S;CJG10%'LSL#WH10LT/%?&.7\MZ<XP'N&]0
M.!!D'+\@/%I53`;UQ5/7I/*]`[6Q<3:!L,S<2D\2NFK@8O)YR;2L#D3GT#&V
M6GP@]^7L!+@Z'DF%B0T$S;V'833YY!;ZLDN>'+D;8SJ"/\`;=P%="JI:%MG!
M9!`@))B`(G$G<[JX54!"@A,/.W=C4L*BS."[2#I;"8X@[(<))3%PC>E!WE56
M,"_"_P"!]AVRL<58X^#\+ZXG?_8W>F\-_.F0G)5P_,?9D#!N=B(3T``F>,&@
M^H#R);G.@HC?YAB[';`@\UZ`D?TSI;+L?<$UM"KEW>#7Q]BJHM4MR>,4"0OC
MM)4%<4:*]#K%W6J9:J;4*(-V#L<42L2?2!NN,`T%.'2$2(+W]]@>QX-BU*<_
M4`L_Z"QJL?BN_AÌC@NSMK/T`6.^R/O&]3'$_8D%%I!-!_<:W=:71W%8'73^
ME:4WQT!#:SO$H]&L/:K[NC1G48W^V\+$U&>2.=E$#QC*NR"\:J`T6L@XA(`@
MT1@:0:/VKWR9G&T(U70<G#A<U!MB)V5!1^_$LSJB,5IV!-F:;HJT#*]$)1'B
MT"*N(1RRQ3-3-`(&@`0#P!AT@9(OJ7T`TWQ%;6X/5-]@$M9[H)&KH-N7A(-*
M&0VX/HY)05D$KW-S``DT>U4+;A#TFBW]T"43P^Z?[9E:1*$?<[J<A;BD15+-
M$VB8B\#A`*V0Ì"$['VNIBTD0EJR=DC=Z/Q+Y>ZS/]LRM6+DI7DAHP33:*%K
M,4!U%?)".!C\>4U2\0(C,V'+#9`Y7;34>-M@@7PHY"CK8!ZJ&K2C4H"'1A3Z
M?^VNY+,((*9K9U6$)M=@OKT20%._9S*T%E/4/S3CH#6&*COXRF4FC'!GY`D
M?T8`JO6:)(^0()+5=J9^)?+W69_MZ6QE:(VQ_P`G`'AH,`C3+1.:#<(`VS#M
M#^BA2L=S>L17(+FZ.YA-MDZ'&KM4-*(#<$HY-)@()0%*S7L'^WI;&5L<F*C[
M_*K)PY^%'&"\OS9=?9&QJ8FFH%JC]DQHKM<FA'"TFRZ8E]48T:\"KCQ-<7QF
M&,;HN`4S:B!VM>ZS/]O2V,K2FVSC])[.<VTP0!]C=<6"-[0\#M"TT+3IA'(A
M3"/_`#.K8%I4F8]8#1M@S7B^"S"-07^##>]#[#_;TME^(O8GG>E"<F3+\XX)
MYRLJNU]A,K2FEX42E(8;5`'SL4A,7C!E%!W6F,#)8Q-D:A!<$9%\/U`,8S#?
M*\7PX;PR89[]TIBWL^[_`-O2VM-3*VL#>1T-*(++P++(ER,$X$[9W2OVQ32H
MZ^?G083A9]X81*Q<*"E%F01B=MVMF94,HCG?EKHPE9R[E(Q(YI%'X:]<S_;$
M%@_AS&&B"\@F%-,[]KE,5A'L?M=+:TU,K=G]3ZO*:5LR>QM&6ZY21.+!CLLC
M`HEBJ/H0N6B(&W_O1><:)';0D9N/:Q=,C>AJ&"=D34[=9HIKQD^CD+*BYÂ1
MJA532B!U(:N328J"U)6,U][_`+9@=I;6FIE;L_J?0Y33O`!P-R`.#%E'
MR-P6JH#;?U3;Z;3"AQ[[+QYOIVTFUH30&%%R?_/1\_E2_P`C/Q+Y??3/]LP.
MTMK34RMV?U/NN4TXEYM\F13DUD]["E!LF&AC56E:M>F\;2I8!\J,PAYLB=W6
M["+8E57H;A][_MF!VEM::F5NSÎ]WRFG$O-OA-\`_P"2G!;@QS\2^7WTS_;,
M#M+:TU,K=G]3[+E-.)>;?;2P483L^7R<_P#UF=R/Y$;:CEXGUWR%):DL&^YH
MK@;/S7LG7:_V$P[1;(_9È5\OWO^V8':6UIJ96[/ZGW7*:<2\V^(F]U+8G^9
MK8\N+R3`78YCCHUHM$CID"[+8+@8N'"^4`B!'"%@XS'@D%U>%.BC`Y$(`NW@
MLGV'G?6]?OP>/9,VWW38A>'^:O[`3GE!P6G*%*><^3XYW4YCZ+D588%Z.$/?
MO)D0]56!P6UCI>G6SN?ES1PO4B"#`*:-\A1[[`T.B)FNZ;+KOQ?/$2H<#8#=
M5Y#1.I'U08`33FNZ#MUEZ_?P67?S$.97U$TG!`<U%E+U0`*AZ<O9HV^,_/B6
M?XK?H^1/).&Y[6S_`'W5&1F#])YUUG?[>"Q=!6R",10#I(\`B"A^/@&*:P=@
MJ]`[Q+!QK#159$IT#TG`WK4?2`5WM+QVGIRP.B0R,=4+HT9T\17*("K&)0-0
M7P\%O_M;<_*?H@6%@4/)`!VOG&<QPÒ&#U&F01/9"54X+2Q<G'()YHKGZG+/
M*[W_`*#C>$@WPL_AX"17)K=0Y;OJS,EZ]\A?ZXWE2*#V*CP$SMMOH-%-Y3&A
M4OD;_)Z-[DYMT!7YM"R':-4":`G2&G[^C>O,=+OWDP;NN/\`S'H,[UY9JB]J
MZ_OG74<O8]:$=HV]!SRO(5+Y6_R\]Z!K;O-48D$@`=`(<+R]>^4O]Y>TK=W@
ME'>[,XA("#?`9_!PO>%WK_899>;+\&]FOTYPY'AWP(_KA>\'/X1QU["S)"WO
M$0.\[*0$NW`.W&IO/(SWM/XX7AX-\*/X>`G\.Q%?^R_KZ`@7?PJS0E46*'I`
MZ._3AE9+RFVR_4HSU]E\4)])82O"N2'#1GI<UF?!R29C"9FJ@=WB%5L`GZ^B
MM228;H"$[9CSLGDIJV-51">@"[0X8=H>*"&H$3!%^L0(+%0$3T.JBLND/S@"
MN+7<KP+`FU$(Â0*`!56`&U5T`8!-VLK8ZDZ$\[T.,6>D%LQ88N'TM]50YI!
MAGO*,QWB,Y42X",8PNXJ5E2-D1'HKS4<'+*/Y/1ZA8*@QC+A-ZY2E'-/A#\1
M$I!\O-1N"J-6/NLAN-FGT(@*UTHV-+KH,0+#RTL>:"Q^D9[$Y*10=K79#P]<
MD&RPJ;BTL,E4;JNY#8G:99`.$UH%<U[/ZLV4]\U2OXK;,(A^P5/A!J%@&1`4
M\'36*61'D_4`Q;XK1-)B1H_8!MCFJ'>ZU"['6D)0):KG/-48TI.F/BE'SS"B
MZG>7$_D`[K4E8!7-<OYVV7T'T<BG\XK+C`V0V@0`4``51T`91!;HM1&]I!,"
MY&0&J>!LJC_16-9I:#I@T2C-8^!_MQUO])D0U^%T"'09C?0'+Q/@8R-C$QZD
M<1&81H2QWY`#R=#_`$8WV-!8I.E@TEPTXRLS,9X/8.."(QEFM7@9*@)Q]>4Y
M&!L;E9_=OG#Z+`?!@Q7SGL<BCDK0!&1-`LNUX9/0-6?9?:BN?A8<CF!]\[8+
MS@+TD`*,*=5T9JA4&J;E54WNZ\-C>'J<?C]Z-`!#)63FUMC2<E*X@CM!1ZN2
M/M>7U^+W(YI@?4+^8%XCIJ#`.SULP``!#FR#Y;[B'[I$7)H:E_;OVTK()X5/
MMAS]@`YTM7V6O7P[$9AN@/K&U7(</$M<")SENH-815>7RHN'^V?N6S\68/GY
MEQWE<Z\@$GU87K%Z/IZQ*;5<7L$7'TKY_6V7@QI2`33/V>LB"#7I^KDAX])5
MOBD^F*DEWN+$$6SQAZ9$-[CR(BIWLGTGP.?7650./E"'#X%4`#@`ÀZ"C<YI
MCT'ZD()AJ1QS0+^``/1<XX,ZL%)Z1&S'=80/3-6\'HY'F_O2SS<<9LR<M39`
M"E[&NE$OQQ5#R:QM!E1OX!EEGAH]FE(AH@BZUZ>O>(>%(A46<`W3')*Q1']8
MH$*V>[Z1A;DT1NS#H.'_`->`Z+V<<[Q9YNZ)-&-9W1A,M2.W$2/@CM?\3__:
M``@!`@,!/R'_`#!O_]H`"`$#`P$_(?\`,&__V@`,`P$`À$#$0``$``````!
M(()((!))!``)``)!``````````()`)`!`!)```(()!)`!!``````````````
M``````````````````````````````````````````````````!(````````
M````````````````````!```````````````````````````!((`````````
M``(``````````````!`!(````````!`(``````````````!!`!``````````
M(`````````````!``(!``````````(``````````````!!`!````!`````(`
M````````````(!`(!```!!`````(```````````````)`!```!!`````(```
M``````````)!)(!```!!`````(```((````````(`!`!```!!`(!``(```((
M````````)`(`!```!!`(```(!(`((````````!`!(!`((!!`(```(`!`((``
M`)````!!)`!`(`!!`(```(`!`((`)`((```)`((!`(`!!`(```(`!`((!!`(
M(````!!`!`(`!!`(```(`!`((!!`((`````((!`(`!!`(```(`!`((!!`((`
M``````!`(`!!`(```(`!`((!!`((`!````)!)()(!)(`)`))`)`!(`)`(``(
M``()(`!()(`!)!)`!)`)``)()!`)```````(`!````!``(`!```````!````
M`)``(`)`!!````(`!````)(`)```````)(`!`!(`!````)(!!`)`!)``````
M`!``(`!```````)``(`)`!`````````````````!))``````````````````
M`````````(``````````````````````````````````````````/__:``@!
M`0,!/Q#Z!-R`!M+Z@_@M;)YUB]NTJC."HT^/"B[(PR5AZ*R7"00T/R)V+%[S
M$WJ:@#!+*,1YO\$&TX>M^B^N/(_4E#NI^K1D]8D;RK+CIQ6B*<9;'R=*?"NB
MA.$W$F9C4A8;(O?<`"*(4F;JC(O10W.VYHXC*`-E[MFD(\;IVE<+R3I]\RVN
MA$$UYYF0A+>.M'@77K?W#(0IM6\FNV3&,Q"232Z7PMN`1PA54'DDJ)^''*0Z
M12(&:D9>XGE\:Y7(._0PH[I:A=@7E\4Q6I,HNJAT#QUQVKTR,A&P%@<">Q/C
MK0!"P-VO:E^(R:3L%<66KA3.U%;!!M?:0=2X,+'"'$,T+=[CJ\&51N&NY!BE
MZLV3,-N+),_G;SGAAB4%Q41`Y9^Y"T`7P*17B/<28K_G:%#F#'=QI9.;I3T8
M1&P%"1L>U,LL+M1"X!OP]H]P&5W;7'B2MA^S;S&+.3_E\I.K":9KV2I5Z452
MFX('9.4!E=?=BAUS8"_%*LM'G,;THY3=8)H/K&&HVP=/C0T8.68*WF(S$@@9
M@8I1"T)2+DB/JO=Q:=IM&3Y<.\+(%IU[`G[6)QX73I%D+2^&U(RR'])3;M&X
M)-AVZJ\%D>4NB@P#?ZH7M3:=T*MFI*L"`]17#+!N!MM`RP:_0%SLM8N,MQR\
MLS@8@)HD3(SJ$3`X3ETNI<,EO#+;)IFHFM%F0L0TKV66$(BRB8U;NQNIW;?P
M"@H>6%!,*JHPP-`T=NKL`V[F$\E,P0TV?.;)L54SG_?MDDY9#F24.AY[:[M?
MTL(6W4#18"45:IP]+%-"Y1.=DF]NUATB>$WS4%;U&$.B;QD8>GYUAFP0V&85
MW_7FN)+V7;S!U0M1\G)P-T,0NEX9&L47:3D*=O3LL5D86G>F"%6FXJR/?[[N
MR]E]>::B$YC2C>X$O_00WQK?&T+&YM>6TRTFVC5(&]Y]3<ÙV&/F4(Z6-$]>
MF_J90NAS3Z&56T1I(EXQ9%?B08<THJ%]W^3Q<B\+?'1YPX#O/N%I/B+'%BSZ
M$I';`"Z0=@?3O"1("B(FOM7K*2?`$%\$J@<A@Q`J1H*;*6Q`C]_;6"(;?`1Q
M$$'&*N3=O!$:4?!+OZVY32,G;(HD$`,`!```@&@QP]#4Y&"*\J4.'K7,PR+V
M7,D!2?9$201-'8C<3R/(D-;OY1_E^_7`7I.WD7BN!CE.KV_2K8=I72J0;KHT
M@P[(9.R#)`0A7<+8)X]T9.BZ[9<E;=T4H!F1#W"37!O[,ZX((I7DD*H$&RKK
M&W*MFT_H=4/[M$:EDZ+KJ3G^*0P"6.*BP/O\*3,RTV\-'WR#):O"<A%PB%"J
MU"4_RSIEC!*8>3YF71BVE2N\]+Q.(@"@Z^FR=`?]O8<^8*)0AA%A5E.BZ1`4
M$#?9RZY.*&P?RG(NDQ$L8J!<,B4]IQ>M5*ZI)Q``5UA7[[2!'F_:/A[LC4LG
M6D:776L!8$.46#'!)<M)2Q4'"\%#B_\`)Z2_BHU%Q4QM^_S=:9^\7MÙ#NM2
M4.&`)D69(<(8@!=`0]@9.M(TNN6P<K8(2XE`[X`?Q?"\Z'NQ1?LD^4)BP\.A
MK9IM_:_P0U@D1P`*UD8Q].T\!EET+Z:XQNY!0"$&"H(`-JOL*EDZTC2Z[\_^
M<W^;XX_%_P!GX^R,S'XZ[9&>.D,:SD=+$IBQ/B`K'!KV.R)90T8/O0D:QP)X
MTXW<].\M^N:5H0$H_50IU*"E56;^P9.M(TS5>K)NZ*HZ>"__`*7Z>5NM52GV
M1)0JWV$NN]6051W:+LG@6&\17;H#"C>$?!P+%8ZG$HFQ@`N=](HCN3?^4>6#
M^?DV`V=%NZ@FV!B@$@``4H._NV3K2-TTRZX$PEC[J)*$@4X^.,.;E8NL*($#
M[>]6=;$BG/4&S2[@3.<YZN_9/B#12J%$M580`BF5D.92C;5BG4(A"##$&$38
MCZU+)T1D&6@ZDQ0%/`)G7NW(G-I)TBU[%I&Z:9==7\^K*A*S,_)QN$`MS41\
MZI_B`(V*1OT#.%!5S$1#+0+5!JPA-I&HJ`7!`#Y<0;F#M$6H:35)1?>%!12Z
MJ.8=5J6QRP#,BS9#A#,E)I2/LK)T<3Z1NFF775_/JRD33O'Z\<L8F<6`Y]![
M7@S.R0D^J^DH2_O%]],ZT$Q19_QY>R$9E<&0MY50SM-+QU^7O*-2R='$^D;I
MIEUU?SZLZQ[Z2HPZ&D&=`T]O$FI#VX5M1TD4-#:T.7SG;+-R(B9S@NF:BD!5
MW[NR='$^D;IIEUU?SZLZQ[Z2LVZ#:OC-<F^&M:@)?N,(C4LG1Q/I&Z:9==7\
M^K.L>^DDMC,;1I5@``NYB`PD/K/<"\56B>I!$2CI'8CV)E@[G@G`WK_.0.Â
M7_=[D(&UU8G\FT(`/@%1?=V3HXGTC=-,NNK^?5G6/?2>QSMVHUW_`$2I`*8<
MEHA8,!9`?2AJ6I^PV#*TR"E8>74Q,.M4R")BO#LS`Q""(2W@;6#R&(397`JS
M@\@"B``*`HO4-/DP4%HÂ9^NZ"I3CM1+B:W^!3YX/-`38!L39O0E_+&R"1,<
M$U2D&Q,0=T#4$6!P%4#@<@@Z"!H;-7;?QCU;3DH=P:"`H.7>%@'I4F$^<_T/
M`7P=-S%M9_Y*J.`.UY/[,<FSN)04!$P1!D`$2H7489\\#A@S^.B%A90(H\7&
MY>+%?T$`(*`2@4$*!8U*A^KP>-EMID?RZ:?/!=X2[K=X6^*.L010%"$!4SJ"
MOP<'E@RG&CAH%=!$X`".#GD/P4++<!+R(!^`&KP>!^9"8)AU`T4.$M&2G$02
M:$64HZ`BH`,JZ`"E7%R`BB)(FD1H1QK"NX+K3?YA-&/;3'=XZR0L(AA[_4/!
M_([PO/H2$Z&?02:H3IO#'1OXT8F$LQAB7U&PM^F`BX2.L%O9<?VSW:WEM2T5
MJ=65G#Q,XRLT:5(QX@FI'H.[BUISZH*(PI\4&:X>)CY`8>Q%"/$$_BD+WZ?A
M848`HUZ(J1@$H\/%!%A(B@CV)V'CB'XV&"*,DBRX0SV%&#8@"(\O'BJJZ[51
M?U<K:K7L27F[GM9P40T:(*/R)J\O'B9[*C#M5)5<>X00JI439[>\>(``0:``
M`Z`X/%3KVQ0`J%@8YPCY)$`/`-500Q\@,'0``#AY$%$(4>*C-X-\BPLW`.!S
MZ">(;#:M8$*O#R6I:*5>Y:7`"&[FB)4^6:X..T7784"P2PX>%@`J!@O:#QQ*
MKTPH#6BM-,`2=?AYBO/\XC-02(.BRSLO#S:/[L(I:2QX@_C[QG_1<?02]>V%
M:`ZZ#)?H+(V.^_+>27I_5EX)(-@TH^Z>BX7F?O@0V[GIPAB+61.Y4>`N?S?4
MM:_W(L"=GH+D`1SR@CV<3#FPU?"-(9`Z>;F]C"B&#)@3\'U<$6N;P0!'+LL2
MCCQ@6<`+@QG-TUV+\XU>3H*>'*``*KH,0'>=)J3.H*O2R@1C/JB8(&]]-=*'
MQA+DTCX@L6,Q9(,`2CM@F3$4XV5BH@:5[Y)MZXT+)%I=>"(*^5`'3\3GP<5M
M<'930`%\O<7$)=\49@83@S@Y%P0DT*P(6)HKGC&@?AN2_,<.KDE.D$ZP3H+%
MEX63:,@.TRLA=,MQNN8HF+RZY]C"!JEQJ+XC87Z#AH:/E`14L/5WM9M6K90N
MEAN*9`7T638OP5Q?"";.HFC/O(@:J;R60)=?%S^["5*E9+K'>M3D0E-(IFC+
MF#@(O`)GO_5`%Q#8,IQ+;8&XHH\SW1_C@`\X0-\Q$I`Y56!D!ZC(.0(BP-QB
M2(Q*">5''HT<(\/Q#I.-H"LSWZ&/TI:T29#2*"GZVP8#Q+B;UDH2V&3$3-IG
MJ=*>,HE!X'C#5>;1IVX$'D/<J7Q&CS`"[6\2;V&2,SZ#E3Z,:N/0B]XUJ4J2
M[](^C")]'=4,14Y)H`+`MAKX4<@4,QN7_$IM!?/F4UG*U8N7AAKRXDWJ2)Q:
MQÀ2NLV7(^Z4+XW[^#CU6<\YFBON^BIV1G[F(C9J32[`-2GR`X(SP$T:#0'C
MD"*R/I;Z<`+X1J-"L4M1(%\.%0*H!K,```<RTZ+;KC0]K@H0+_`H"@;L&X+P
MPN(9#(&?'+,`LZLVKH<1WU!ZW2[BB1-3R$27*#)TD(XE,>=`!Z0+/AV:OD50
M1&R-S.0:A0B0QQ*'H-?3;UAPA4OU$-&^B5CAX-;A97OTZT(3?N?QM=7KTIYR
MMEV]A1_TVF$=*W2MZ<U9$S=!BQJS*JZ;#TJ:SK5@DF.";P7_`-I3;.`*``/0
M^6`&<HO))A-##W5V(KA`/0Q%276P`*@$0],HNS3'`$:PX4V'*.CH"9$8Y#(A
MR^0#$WSV.,QU5G%[9%8[_?L^=,-Y*VID<!$HXLHC57-<$[,B+WG@5-!,(](3
M<FY@J42^[P^B67\]D?,6-4"AD6_?6I2<#@*YG,CXW5<`_>/?R29#X/'_`,2_
>_]H`"`$"`P$_$/\`,&__V@`(`0,#`3\0_P`P;__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<TEXT>
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@``À@````49UA96@```BP````48EA96@```D``
M```49&UN9```È0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<Ò`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4ÈT"
M9P)Q`GH"A`*.Ì@"H@*L`K8"P0++`M4"X`+KÒ4#``,+`Q8#(0,M`S@#0P-/
MÙH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5ÌJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+LÒ("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48ÂD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/À'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39ÊH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>$;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X$?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`)D%D;V)E`&3``````0,`%00#!@H-```P\```DZT``+GR``#B
M.?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M_\(`$0@!"`'/`P$1``(1`0,1`?_$`44``0`"`P$!`0$````````````&!P0%
M"`,"`0D!`0`#`0$!`0$````````````$!08#`@$'"!````4#``4,`00"`@,`
M`````@,$!08``0<0(!,4-C!`$3$2,C,T%346%S=0(2,X<$,D)2)""!$``00`
M!`(!#`L,!P8!#0$``P$"!`4`$1(&(1,4$#%!(C05-765U3:6(%$RLM(CL[1V
MMM8P89%",Y/3)-06!W=`<5)RDG.U@;'18D,EHE#PH<)3@Z-TA)15)A<W$@`!
M`@($!!$'"08$!@,````!`@,`$2$Q$@000;%S(#!`46%Q@9&AP=$B,G+"$W1"
MLC.SPQ0%4/!2@I+2(X.3<&*B-)2TX5/31/%C)*05=34&%A,!`0`"`0(#"`,!
M`0$!`````1$`(3%!41!A<2`P0%#P@9&QH<'QT7!@X?_:``P#`0`"$0,1```!
M_KR;,```````````````````````````&A-P7D``````````".E8'J9Q""1&
MK,0]"`'7)M```````````"ASV+R``````````!J"J#:F018C1)CR-V:,N<W`
M``````````!0Y[%Y````````````````````````````H<]B\@<B$]/H_0`"
MV*^@R?'3+GS,")79GV<^_,CK)\>7#S\>,J1*$3\4VFM>FN]<,3SWU\6_````
M```F)90``````!0Y[%Y`K@C).B:``%24UM,Y?YU)>^PP*.-CW<3YX?=W/LO*
M!]\JOUE:/P-7C>>TV73R>:[DTEE1KT5D6::$]3]-F#\/8^3Y/0'/QT``````
M``4.>Q>0(D0(FQ-``"H+2YGGS\KD=9NXU+BND026!:@`8$.!FRYOERY0+O36
M)\T&/PC_`,7>\C^LQRB3\Y>.A#DTZ*-L:4Z_)Z#GXZ!```````*'/8O('/Y!
M#H@F8`!4%I<SSY^5R.LW?''ZA6RBNC[BKI[5@?,;K&Q>T79Q+,8&!32SU$9K
M?$8C5]H:*TCGJ!&>USKRA3-+*.?2X25E=&G+(.D0<_'0(``````!0Y[%Y`%=
MFP)H``5!:7,\^?E<CK-WX>XD3CW0F?6``!$[G(RRFUPK65165%O<;A&R>\G3
M$4(*6\1H@9:Y$S:DE-X#G,OX```````HTSB\@<ID,.K"9@`%06ES//GY7(ZS
M=Z&Q@ZN!WR?7*0OD4YRXY\]Z:+H!0^G_`#GJWI4X,B%'?Q'9[7]1A_>$^[OC
MVD$?29'AIOQ.RW/[96ZC\:L9%_2]-Z3_`"``.%ÔS7:'C!IWGYR$C7\ONE+B
M(6:\U9W6?@`!RH=1EY`%=FP)H``5!:7,\^?E<CK-W7VDUU@YO(@#PZ0_?G,%
M1Q;NW)-)$KK(RVFUPKF31SRNLLJ1*`&!@)6?OXH``%#EQ3)V#VZZBMK(<>IB
M'R6\1`SS2$4)06H#AXN\O(%#E2'4!,P`"H+2YGGS\KD=9NZ^TFNL'-Y$#X^\
ML&1497&Q%`QKO=.M8;+\CRH=OT!Q^5)9Y+)C[G<VUW]?$7DPI1&FQG.]MOJN
M&?'^B+6_BZL')DU5T'.\F7MMO^C8,B5D_G_Y=HH\79E:$Q(`:PRB6FM)J=)@
MX>+O+R!XE;&[)H``5!:7,\^?E<CK-W7VDUU@YO(@#Y^^/KY['A[B>_B7A>>E
M21KNZ)=!$;C)2*@T>9WE"K)>>M.)H<#`2L_?Q0*4WD6Z\%*?0H2%ZN7\NFX^
M<[<[_NM9!)GGY*B+<-.8!&R[SFL[B+R!P\7>7D"K"%EIDT``*@M+F>?/RN1U
MF[K[2:ZP<WD0``,?I!R.<WX]<JQCV]H]JV,6V6WE+>Y?2:?*YEY^QHF@P,=T
MSMCS_7T4IO(MUX*4Â0'2':5K@//UPK.G_1XYXEZ8@)/3%(P6(0PG)41W\#A
MXN\O(^2I2OBZB9@`%06ES//GY7(ZS=U]I-=8.;R(``&'VJ_;Q*@%G"^ZJRGG
MKEH+'-[.NM,Q8"%2J&:Q;[%[5V=&N?IZ%*;R+=>"E/H4.7N?'WY4/S[I3X(N
M;(L0J@VQGFO(.=E@X>+O+?.)CNPKLV!-``"H+2YGGS\KD=9NZ^TFNL'-Y$``
M`"F;OEZYK17#*HHE<Y&1Y[294B4*LEYZTXFA\.D/WYS`*4WD6Z\%*?0YTZ==
MA;7>CZ]]]1YR.^.>W*N-\:DK<WA8!MBO#N8'#Q=Y)2HC:E9G5Q,P`"H+2YGG
MS\KD=9NZ^TFNL'-Y$```"F;OEZYK17#*HJGV7Y+),+I9/ZU'WY]Q>NH)E<ZG
M1?A<_,U/C[G>1!OS^58?[57>EGX'.GGKJX.JCWB3FV.,BOKEYE1E@GZ:4RC;
MD8.P2V@</%WECE4'0179L":``%06ES//GY7(ZS=U]I-=8.;R(```%,W?+US6
MBN&51``8L>)E2)?ATA^_.8!2F\BW7@Y0'/OWG:/6OQO7C0<+.K/G23FA).1$
MFA!2<$).HS+!P\7>7D#E8AQU.3,``J"TN9Y\_*Y'6;NOM)KK!S>1```ÌF[Y
M>N:T5PRJ(`"-T6:W5K=:J'4[VRO_`*]>A2F\BW7@I3Z%`??%O^XOF\P3G-]W
MK'(H:PUY@EDD=/HMPV)C')I=Y>0/DK4W!-``"H+2YGGS\KD=9NZ^TFNL'-Y$
M```"F;OEZYK17#*H@`(5>8F:T>VQ(T3+DRP*4WD6Z\%*?0YSE^95K.$5M^>!
M^=RX?%]9Y69/2-D-,TEAIC<%M%#$H+N+R!697Q;)-``"H+2YGGS\KD=9NZ^T
MFNL'-Y$```"F;OEZYK17#*H@`*LU_P"561EOTK%Y0L[U8>OGJ*KU\2RLM*_?
MG/WY]Z!]QK(N\=C=HU,9[=P[E)\2O#V+`*^)\1PTY=9UB#AXN\O(%:%8ES$S
M``*@M+F>?/RN1UF[K[2:ZP<WD0```*9N^7KFM%<,JB``C=IFOCUX]8C>1[X#
M#I>>1+[:ÎB;G06=#ÔEZ>N/S]YUMXE:1]TQ&C;DM(@:TDY&CT)R:8IXN\O(
M&&5V;PF@`!4%I<SSY^5R.LW=?Z36V!F\D```!3-WR]<UHKAE40``&+'BY4B4
M`!X=(?OSF4,\WG[X?GWQ3W.5HWK.-*8QY$=/0D)JB:GJ>)31=Y>0.8"''3I,
MP`#EK1:N,2OG963RO(W[3_0LGJ:.74N>N;#?FX``%,W?+US6BN&51```1/AD
MI#YT7UZ]#55U5NK6Z^.\?WYS*%\^;IAU_P`>?%!SK.`Ô605H2@^B!F>2<TQ
M;!U<#A\NXO(`KLV!-```5'9W-N5E,(Y9W(D=93```4S=\O7-:*X95$``!"[W
M%32BVH&+'BY4B5X=(?OSF<2%W```````%1EKEY`HPI,ZL)F``"H[.YMRLIA'
M+.Y$CK*8``8?OY_-[],AZ/\`)?UGN7[D>7Z_7?)U%89$<YP=/T9.S'-DN+U[
M<?GN5ZYC'HN$HYZC7UU=(+?1<_'0(``````!0Y[%Y`%=FP)H``"H[.YMRLIA
M'+.Y$CK*8``#\*5O>5UT74````"&WF-F5'LL6/%RI$KGXZ!```````*'/8O(
M&N.>28$P!]'X?@*(N]%>U)G?HKO7;H6'D<+^GX`#]/PYHV,?I?'2/T_``?I^
M``H^YRUQ56BV597>%C;U!Y^],@``````%#GL7D#$*H-,2\^#^0I_2@M$]"/R
M)>3'B0(LV?:#W@5=4%AFT`*D+;(S;\Y-4=*P)424'X4X7(`0HTKY:1).$>.=
MY%8/O2Q^@``````H<]B\@#2D&+3!`BJB^#=`@13AU``<ZEHDY!KCC<[9`*5-
MB6R#%..#M$À)`"]0#BP[+,@``````%#GL7D````````5"5(>A'B:D$(>6.:
M\W!UZ``````````````4.>Q>0```````!Y'@:\VQ^'D>AHS=@R0`````````
M````"ASX/8```````````````````````````&M/_]H`"`$!``$%È3E+5\I
MW3(U;ID:MTR-6Z9&K=,C5NF1JW3(U;ID:MTR-6Z9&K=,C5NF1JW3(U;ID:MT
MR-6Z9&K=,C5NF1JW3(U;ID:MTR-6Z9&K=,C5NF1JW3(U;ID:MTR-6Z9&K=,C
M5NF1JW3(U;ID:MTR-6Z9&K=,C5NF1JW3(U;ID:MTR-6Z9&K=,C5NF1JW3(U;
MID:MTR-6Z9&K=,C5NF1JW3(U;ID:MTR-6Z9&K=,C5NF1JW3(U;ID:D[E,R)*
MT<?\V=G#TIL!D.,%HKY"B>^%S=@5+$^4&&E61X@G*69)8R$9&0[J5+AD0I"M
M1YK8W*D*PAQ1<W5?DYHX_P";+T*9S1_74/VRJ#Q=;<$,CA;Y]9PSU))B2)I'
M.^/&`)R?&4/2V60*++A#QM%R4K>B);$'-U7Y.:./_P!85?DYHX_T.&6DS9(F
MC(30J:/M/'%Z^TL<U]I8YK[2QS7VECFOM+'-$.9!USEH"JÌ)&$U>64(Q266
M`M268#;%48I*`Ì468';%5MBJ4R!L06^:Q*DL^B"HI5D6%HS/M+'-?:6.:^T
ML<U]I8YK[2QS7VECFOM+'-?:6.:^TL<U]I8YK[2QS7VECFOM+'-?:6.:^TL<
MTRS&*R-1RZK\G-''^@^(QI2[O#(U,,*CG#VJW#'\O<0VN.UNBPR"AFN/D&ZU
MK(:&$)@2R2R=)1!0#*``!=E_%.@^7L2>6T>ZMJ8\EQ0*$I3B@/37,"$03`BN
M,P!8:O?HL`83`Z#/RIRZK\G-''Â:_,[<M>GEK?(5'.'M5NXW<.]1SJV$.CR
MH3HVAF4)UC1JE&`&.]^BP#`&4L`,R2T$TL=W3&3\\?\Ù!*&EP>VIXA#\J=3
MH4LMBE_QUDIK-?X1(EC$LQMEG?ET1G#HAE;3DL^**HUDS<XJ@4-47T#_`"IR
MZK\G-''^B80%',UB^#E,\!CG#VJW<;N'>J;87CDZF$D@C9\>A,32ML9]$34=
M'4"@M-%FM%;T1-7HB:D:4!BX1-KA(9$Q3@ZI25#MLK5=J2#7`B+8":SY\<(Y
M$VO,R"P3\Q%(CF*>!D,>(RT^,BX_*:(#FAGA*J+D9B:.PARRI+5XTEKM+&K0
M/\J<NJ_)S1Q_IE_"<<X>U6[C=P[U7[\CX>CG#VJ@\]H7\4U;Q:<&Y`[(U$3C
M:@#+C"$,B=.U-:0#?$(JT@/QA##UZ=C9DC:R0F,Q].CB<7;@(&QN:BM!B@C[
M3WE-6\IJWE-6\IJWE-6\IJWE-6\IJWE-6\IJWE-6\IJWE-6\IJWE-2@TH636
MCC_1-FN9K9$!!,D&.8YP]JMW&[AWJ.46`N>6PUW0M;?Z6B_EI\;%+RU*2)2G
M*Z,D5T9(J"L4Q;Y0(,EN&/C?3@O">7&/_1-Z+-<[NSF%SN659=8K_DUTN&\_
M\FE8EP;!O>X=:#PJ%#QP^)H8RLT#6P^9QB>H6..C&[X\1,#P\P@DYK*Q^M7I
MTL-3C&Z00XQ4ZPH]N^M\>U];X]KZWQ[7UOCVOK?'M?6^/:;XW'F[_P"@&CC_
M`$R_A..</:K=QNX=ZEG$NH7W=$>]]ID\CH(XM,U3^K7Q=^.5RQ$WI&I:U+T+
MS)&IA$XOD.?&E?.HHR`'D>']M7DJ$HU@7!`9;Y;'_D"Z1LC<!!,HZY#><GP=
M@6M\S8'([0#^R31Q_HD4C=F>0WFREZQ['.'M5NXW<.]2SB72*_9L2;:X.W7;
MIE<#DE'3E$03CC(J24MGVL@O-_62J)D(@R>03PIG0AFZ6]OFR2E&1R27?YLD
MIWGP4J-+.RCTWS9)7S9)3SDI&T(&9P,=FO1CE*0MQB\8]CCNVL.-HXQ-\E@B
M5^2)<;DIV%_QVU/2A7A9G&G>,8-KTNÊ65O`QX-;$(&3%"I`01B%G`KD.'$$
MMN1!%1#GH!_9)HX_T=@%QR@@A-#XYP]JMW&[AWJ6<2ZEK6MI#WJ(3ITH'(HH
M,ZHOWTX(1:0\;4?U:9[[/IQAT_7!HU02TPU@BLCF2,D"%;.CXM-$,\3'KC,L
MI"U=YÂ<)#D+(<>A#:[9,C0%$AG4E!%W6<D",9LJ+R(R>H#(=`/[)-''ÂSF
M3$T/JV3-LFA,<X>U6[C=P[U+.)=<-[=JK""*G!*H,EE%@%ZP;>VD*<[Y;1_5
MIGOL^G&9@2L:G/2(DE.^H%`)7,3F,9611&1F09'<FA4#-)BPE\R0Z-:F,Y<C
M$I6N>:6<1JK)[""WV\,AJ><@J4STP9?7N4;T`_LDT<?UTVO3W"6*0N+S"F%K
M@<<X>U6[C=P[U+.)=>Q!=A;,%1I?ZPV+%UD\AV8*`('J9I1=;,%;,%656^0[
M,%&E%WM:W1IGOL^G%WXYOÛ@7"*TP/AH4Z4S')2>1R+'PTSJ[8E6FN=\4D',
MR*'JRTS)C2'*G6&08DYL><>EI7#ZQ8CB'#$#NBT`_LDT<?K#B4Z;`XD7H52_
MA..</:K=QNX=ZEG$O(P+AYTXUHOWTS2'C:AZD]]GTX[2$+\7NN.8ZZ-<;Q3%
MXVTR&#`=DR;'&RCTCQXA?%9V%T11+KB-N=':/859(V],F#`=D[$[GZL7B-H4
M%#QVL4*4^'A,\6T`_LDT<?S%"Z.<:Q,UN;4RR%@>EDQ):)<V8YCG#VJW<;N'
M>I9Q+R,"X>=.-:+:Y*4XB*>1!#918/\`-1205G.EQAP`!WD0>A370II_N19(
M$7:#HQV-67B^6&926QN`_;K=&)XJE1:9&Z38^+30F>I35B_*Q('MVRTVR*7S
MF<[]>=Y#CD9='N='#4O,^)8V)IGRZ8P=<K<8WH!_9)HX_?4JI:RP"+O,:2U+
M^$XYP]JMW&[AWJ6<2\C`N'G3C75_W4/4GOL^G&IQ*?&@I"P!LGD\>5)WB5EM
MYP,J)3Z69$0MD8494;4[:TY)BSD;(LI02/N\@FL+;:696C3-4GGZ"-J4.4BU
MX2+$A(T`_LDT<?Z)KD)7%Y3\U7/&.XYP]JMW&[AWJ6<2\C`N'G3C75"KZ5.U
MI2JV=6OTVT3WV?3C(LLW&WI37>BV9H*+DK5%#2D+)$D:-R2PLQE!%(.@<+QK
M&25<'$$8-D+_`(WC[R[BA$2)<RH?!W)*[M<(2$+W^/,%>M,]FX,@81K0?V2:
M./\`1>UKU*BBR8A'.'M5NXW<.]2SB7D8%P\Z<:ZMN(J-ZM,]]GTX[3F*L7WB
MSE>S3CX]F+E\.?70A)CV06BTOQJ>]+@834E4HQLXJ)I\$G30!AQ;.1N#9#Y@
MN2-^+Y(G<'/&$C=I6^8Q>Y&ME[#)7M`;C9]:VL']DFCC_0]2MM8%:^4M<BA$
M<X>U6[C=P[U+.)>1@7#SIQKJENK8.3;<BC#R+B`868'IM73:I@B4N#82H(4E
MFGDD``,)@,:F7*QH>[+`%)7AR,#D&8+XZ4CR,XJXO,YC+X^;;)L\/,<\H2`#
MX@S+=4<WYJ<W*3`RFY/"9HRB]F+Y;D&:AED1D,E-#H!_9)HX_P!#W%&J0J7F
M&,#3`XYP]JMW&[AWJ6<2\C`N'G3C75$S-`Q>B,U6;T*:VS+KL`KL`HU.$V@%
M`"$]-88[5B_\<W$&U@F`':02A(Q&AG;)Z6[Y'9V<R^8(E>[EDUC:7$<M@[TE
M;)]!DCSZQC=O3(<CQY6M69*86-_E,S:8V\OLU2QIEC616J3$`_LDT<?Z!J""
MS90>0IA\<X>U6[C=P[U+.)>1@7#SIQKKF]6J+O5B_P#?''8!5BBPVF,9C<A2
M(H%%4C8_Q6'/!?U]!"%+A"8*L=#\4QHLIHQ%"VZFS&2=K+0XY@E.4!AUG(J,
M1EY+D4`;90K;8$F:CP?V2:./]$RASO)7SX:YL&/HYP]JDPN4!FLS89799;JD
M4`?W><36-/CC&L?M2UFB>O`N'G3C77=1[,-@#Z.P*NP*E1)@PAMT!%WJQ?;I
MQP:28,L@@PL$\B;O(+I,?R*T4EV,5#RM!A1Q#0,9O1TQ^(Y&:`L.-\AGNB&-
M3-U2MN,I2D<'C$CC)I+'XBHCR[0#^R31Q_IE_"<<X>UI5XÂX]H9_:->!</.
MG&NN]^%I-[M"[U$0QM03;X$TU\"::^!--?`FFO@337P)IKX$TU\"::^!--?`
MFFO@337P)IKX$TU\"::^!--$Q!H;,G-''^C("B3)&<ESEAV.HYP]K2KQ]#Q[
M0S^T:QYMR",09`G3XSKIYDTK,7K$QJ'3K,#I*)A.\PM<K]8F->L3&F&;9>6S
M3UB8UDB59,0)R5SX,G>WBM[>*,6+K!+&>(!YJ@)M#_*G+JOR<T<?Z9?PG'.'
MM:5>/H>/:&?VCD';CODWSRE#[]#_`"IRZK\G-''Â6J(0I7&7M3]!X])(Z!@
M^31NODT;KY+'+5\ECE?)HW7R:-U-9M$T2GY-&Z^2QRI5-8VVQ^*S6-N4?^31
MNODL<KY-&Z^31NODT;KY-&Z^2QRODT;IZR#"RLG?)HW7R6.7KY-&Z^31NODT
M;KY-&Z^2QRODT;KY-&Z^31NODT;J=Y$C;$A32Z+*T_K36:&TGC0K)W!O<,I<
MNJ_)S1Q_H/()5$%0B+I6)BCN-W1M^%PZA0R'V#@]@E2K*3RT8D1K`PZ%C#\+
MAU.&-L?NH%\:@+6CCK'B8ZQD'AAH"X/#"@?"X=3\S8E2*T48@;DD^%PZOA<.
MKX7#J;FG$-G#X7#J'C+'@W/X7#JD4?Q6734R8Z?$OPN'5\+AU7AD-M9O:\/^
MI?"X=7PN'5\+AU/#3C-EIKB&*UJ>\-B`KHF9H;2Q0V(#$0?C"//W7RZK\G-'
M'ÊQ0DNC?%(V..)=#3&F=D7R;'A;^]-J$EK;M$F:ESVR0[&]HJOTS"!FRQ9'
M&4,>:-"LC>DL8PNEBY^F5PTF5J8E&+QE+H/*"H)8,/%L*C2\,WJYD:A!4==M
M+IAXMQ=2BPDE<LJ_)S1Q_P`QG;VICT89,D=I4QY3*DA;-D=[10LO(]U;ÛY/
M-);3\N/2(MLRXW+7!SRR8G+;\OM:Y?SU5^3FCC_F(P`,#NY'90-J!K2W++$&
MQ9=JW<BMD51+.V)UFQ)JQ15N?*OR<M9)6GDFSR96SR96SR96SR96SR96SR96
MSR96SR96SR96SR96SR96SR96SR96SR96SR96SR96SR96SR96SR96SR96SR96
MSR96SR96SR96SR96SR925BF(W_\`_]H`"`$"``$%Ò\`.99]AW,4A!<0@`%8
M[M'C/`$(#P"#M2Z$>`(2U!8[;4NMJ71!@E`]@=5TYUJN298/Z66Q-*4!C4WN
M-%%@)+4L[<L$8B2N-$MJ)K%2E,2L(;VEO:]*-D:T:O0'POTL?E$W55BC+DI;
M7NJ56O95JEC`(?501@'5C2^S03`"O^DC\HFZJ9)6YL*,,E6%"4O)ZT[?S:`Y
MJ"Q&NZL^^_FUOYM$-[LD&83<1;>6[)TX$;R4NV=J37$FO^DC\HFZJ_\`4?<!
MW-53Y?0'PJ_V?I(_*)NJ@%])%[Ò707:O_&A6"*QO3T_SU_/0#&F]K7:NERL
MW@N<K<0O7\%(U:G>%BQ4E5B^4"%T2J@&Y(^5]$JJ9*YZE3IC#34^L`-AB(;B
MSSE[24B4C#V1<X'Y1-U41[5J"Z]`._2_S&B_@CU9#X/()R#U)RI,J2G<Y'Y1
M-U41[5IM;IN,'1?LUV:[-P!`,(AJ$P#Q60EWK<1T>W@*2M[79R5W8#>GT$ZB
M(_MB/03J<(KOMSH\,LWT$ZO03J0Q8Y:H7)@HU>@HTP@Q%)71$J<92Z."DTT9
MYG.!^43=5$>U:]^JNCHH7BT+V\>G_14A\'3'?/:5%U%B79;+TC=%UTU4-)&W
MN3S@?E$W51'M6O?JJ]KVJX1=NA"MN(@B%I_TT\ICU1>F.^>TA#<8@(3QC,;U
M)=Q!N`7.!^43=5$>U:]S!7MVA4K#<HW;"M?M"H5K[KM1`KM"KM"KM"V/:%0!
MBMJ1WSW/Q^43=5$>U<BX>8%XM"]O'I_T4'4COGM(17`(M>>68>XJ#S!"N*_.
M!^43=5$>U<BX>8%XM"5M0DJJP;J;]OI_EH%U6VJ=.<D;T:84I4)]G**V<HJ0
M.&16TA$H$K2:+]/09O%P$[S8%NGHYP/RB;JHCVKD7#SÒ%U?]M!U([Y[3UUL
MS*N49:_5SD?E$W51'M7(N'F!>+JV4]*C:4:JV-6_>VB.^>U.V*NV/G0_*)NJ
MB/:N1</,"\75Z+>FT9J1WSVD@P))OJZ6EDE+7".,":;S@?E$W51'M7(N'F!>
M+JB2*PM.S,H9)MPB"(-]#(>4F5F%F%"`6,P5[7#<`>V(M$1<9J%*&XP]@7.!
M^43=5$>U<BX>8%XNK9<M#;?UU&K%(J[0J[0J[0J5%*S1I0'DIU:1P47MT]%=
M%ZN&]K\Y'Y1-U41[5R+AY@7BZYFM;JT=H57$*_.KJT^Z)#R.S39(VU$P,+JW
MI762+"%SSKN'F!>+KB1F++V`+H[(J[(J4%#%8-N@-NJKT86,0"BA@!;G2;JT
M(O.K?.Z[AY@7BZZ#OZ3.[5NKGR;JT(O.K?.ZP;=H3RWH"#A`/$K[1M%FJ1&&
M&J0F=HVNT;035-S>T;11XBJL2BZ-BBK8HJ7`[-ND5&''A'SY-U:$7G5OG>0)
M]OY-O\:A=[GR,L0[:&)":XNKZA-;G7D"$2H31R:':[401`$,?\XK7#?GI9IA
M6E,J4(CE*I0M.Y"R]:%/RHBP"O\`YZ__V@`(`0,``04"_P`Y@<"A&GK2R:Ì
M(,`<XE$B-5%%@*5%&`VQ-&*2@`*5%F`VQ-;8JK.::U_5&ZBWAM,"!S0FG_I8
MPALD=CS23.NKBZ#EI@RD:(P9J+1<5[Z0CO>]6M:U'>X?I9GD7KQ*OXJX`C$2
M$`BT6J48`8[WZ+`,`91E[7<*":6._P"DF>1>O$HTL!AJEH2.Y?QI`BMZ&FHZ
M.H5!::+-:*WH::O0TU)B$9RO8@O04I!="+3A5[*U%)BRS_TDSR+UXE"\9+YI
M5YK5;_/Z#O<*MXOZ29Y%Z\2AI5X[@,5%5VUIE?\`(HDU008WB*$7_P!57_54
MK)E(;"#);ACXWPX)Y2P1O_:T26<`XPE0,S^&OX*Z$FP_@I.%+>]_VOKW%T6"
M/M6YR9Y%Z\2DWLNH1X>A3Y>F3R.@/N)FJ5U\@F3*%IZM$K;SN<F>1>O$I-[+
MI&+L!2J`C*VMJVUJN>6I.-1FEE)5:AML-T5A*]9*I(_&GNPUY=ZVMJVMJLL!
M<[:VH)W9JQM;6U;6U".L&P;]JV@@\U,:W2]Y;UKK-'ET5G'&*#><&>1>O$I-
M[+J6M8.DOOT(0AW*O?TZB_?3=-O=:*Z])O=TVZ.D`2!"."GL._1T\X,\B]>)
M2;V77+$':4$8!T6>2%+18;^M'"#;3;W.K&EE:AO=TJ#RTQ*N6-*5*BF#*N*(
M.+4E<X,\B]>)2;V77"C("/8DT0D(+#9M3F`V)-%A*]5/2D"K8DUL2:L23ZCL
M2:4IB1!M:P;:#>[J==='9YT9Y%Z\2DWLO(AZB?;Z+]],TV]UH[JTF]W2`=RQ
M%.2DHU2[*E)HQ7&+G!GD7KQ*3>R\B'J)]OHMKDI3B(IY$$-E%@_S466HWVB`
M)Q7OL;7_`(:_AHH*0=Q6Z+Z`=BXD5F<"IQ]$-5C[%A<X,\B]>)2;V7D0]1/M
M^K_NH[JTF]W2(006WU'0%Z(8`B".W.#/(O7B4F]EY$/43[?JA5]*G:TJ4]BK
M7Z;:#>[IO:PK;NGJR5,&UK6#;G!GD7KQ*3>R\B'J)]OU;<14;U:3>[IO^]NQ
M>@D]FK?MSDSR+UXE)O9>1#U$^WZI;JV#D^W(HU2FZ0&EF`Z;5TVHX8;!L(-[
M"-+!H.,N44>[K`%)7ER,"29<TOG!GD7KQ*3>R\B'J)]OU1,S.,?HC-5VQO)M
ML":V)-;$FAIDY@;DD4,E-<S0(PL-BSRC`<Y,\B]>)2?V7D0]1/M^N;U:IGB5
M>UKU<DJ]@IR06M:UN<W6I=Q3^G'AIGEK2WQ>,O;6C>I:O3.3_KAZB?;]=V'L
MPV+'T=@5=@5*B3!A#;H"9XE7_>QI)@RR"#"P6ZN<I.[H;O<''W#7#U$^WZ[W
MX6DWNT9XG/DG=T-WN#C[AKEB%>Q:=ILP[!#2YN8RDB)N8S4>P0UL$-*$#(!#
ML$-&-J)90E;O86^/%;X\48M7V"68>(L\P^QW/DG=T-WN#C[AR%^]R;YY2A]_
MGR`H9@=$:;3W9[DK:>TO?(7%;M\F[V273%F%G`//`4;SXH\TC2C6JV]0L6JW
M!1R'9#T\G?HN'JH118[_`.>O_]H`"`$"`@8_ÒVYFUS9:YR:\`)YTX*%$6A`
M90)VL>*)BDQ,T&*Q$Q28IH5K16(K$%*$FB.B8Z)BV10/DQF],,@7A#CLE342
M+81:K)KA:KXW;(94!2H4$IUB-:$LMT-I$AM"%/7ANTX2FFTH=&=FHBJ?+";G
M?$V[LI:9B9&,:Q!AR[7!%AGO#1-1V/*)UL"KM>1:856*1DD87[@V&^\(M4DS
ME0*5$U857N[-V;Q.NTLUBF@J(X,*ML<?R8WUU]B'<T<HP*=`/=`B9Q0V!7;&
M6'`:[9RZ)02:9Q..89PIN8[R8HW\%E)I^2F^NOL0[FCE&!Z[7`,R=(F5(2OS
M@1'>AJYBS3S;NR@_:2@*$]@P;RIMD%7_`"TGA(),=!C])O[L6VTLA8_Y3?W8
MF]W2B-=MO[L=!C])O[L=!C])O[L=\_>FG+K>$DE"6+!$EF4E]ZJJ7T::H4EM
M1"R#(F9D=J8GM3A5SOMX:=NI7;`0SW1"I69VN\62)>35C@WVZWMMN[SE9[BT
MJPH65IMJ<ESDS%JQ-,YII`,>5OF'6VCS74`*G(^5:W*4BK:^2F^NOL0[FCE&
M$[4#:T5WS9]8O"K;''@.T./Y*;ZZ^Q#N:.48%NRYB2`3MSED,2,Y1),Y1CBS
MSA$FI2ECCR>&/)X8*2B]6Q1Z0$:]È17%(O$MM/)`;N:'$KD";2IT*2#K;,)
M2BYWM5S!2BV%LAJ2IVUV2NWS.;Y))D0D"9GY7!#C;URO00N80ZI300F1G,@+
M4M5I/-`D)%04:B(0?=+S>6*">Z4VF=-*)K6)$C'9($X*D>X)030#WI(&L3.D
MB*_A^\]RP7S=T?\`B"CNNF.ZKGWUCO.\X[)JQ17\/WGN6+LCX>B[JMWE$U-$
MI(-H64'O%5.$R.P#.N$.OH+;RD@J29<TXQ02*-O1V20D:YJX)PAD7AF:E`>7
MC^H(5=_>6:->U/=DDCABR"%#7%7#+5+?77V(=S1RC!>,ZSD=TA>WQ#!^6WZM
M.$=8\4#K#0W7_P!A=O6C20Q=DJ6^:@*3!:OJ%H?KDJNG;U4WUU]B'<T<HP7C
M.LY'=!+!BC%!=-2M:`DS2":R#(;)V([UJ\W59DD<USZ*0/*":Y13>KIWDNC;
MYV27#'I&/U$Q;%XNZU3J"J:9;&*$W9=XN]V37;=5)ÈM`FG%1'\S</ZAOEC^
M9N/]0URP\X;[<$.M*`"%.C\2JE"N@0)XU"/YFX_U#7+%W:O'Q'X7=6Q?&56W
M+PF7-6"$BQ:5:54FBNN%(;O?P]:`:%"\(D=GG2.^!'\S<?ZAKEC^9N/]0URQ
MW'O?P]`LJ45%])`"4E1,DVE5#$(7=4.MO)096VZ4*V4DRHW,(=:,G!";S:2N
MSB($C1+$`>&/>)I;H`DD"5'6F8+KIFX:]4M]=?8AW-'*,%XSK.1W2!@HA.T>
M+`C/+\UN!MX?K<6"Z_\`L+MZT:!SP5Z_MW-`HW4(-XQ!1(3ND!1X##MXNMTN
MCUX">:E#KA42:*`6DSE.9YPH%<(1\2NK2;ZWS5%]:T*7K*DEI0JV:ZX2;T$"
M\2I"22G<)"3P#5+?77V(=S1RC!>,ZSD=T@8*8"O)IXL"$>5WJCOA'(8$M?#]
M;`PF[I*BF^,+.PE+@*CN#0.>"O7]NYH+*:X".;2?I)Y8LF4Y:Z>6+*J]4M]=
M?8AW-'*,%XSK.1W2)17%@'R$G[20KC@-Z\5PEV=)6H;P2>.-N*XKB<\<5QN:
M!SP5Z_MW-%3JIOKK[$.YHY1@O&=9R.Z5^4WZM,)VCQ8$9Y?FMP.L,/UN+!N:
M!SP5Z_MW-!:37`<YID9]%/)'>&SO`Y1%HUZI;ZZ^Q#N:.48+QG6<CNE?E-^K
M3"=H\6`7?N'009S#F,RG6G'*$*NX7[L)3!4)UTU`8HHE*/)^>[%E9_#G/`PG
M_P"L79Y^^J=FHI1:2E"*2E4OIU=6U2#*$/E=R05I!LJ8>!$\1!>%(CTUP_1=
M_P!>/37#]%W_`%X3_P#GFQ>;\NU/W9ERTEI(F[:FXL65(FD\WHE5(E#=Y6A3
M2UH!*%4*2<:3.56&BN"$`!6W_A$G`"K;_P`(IKU2WUU]B'<T<HP7C.LY'=*_
M*;]6F$[1XM%]7!N:!SP5Z_MW-!1%1B4C%.J6^NOL0[FCE&"\9UG([I7Y3?JT
MPG:/%HK,MB*E;T=&N)X7/!7K^W<T-9BLZJ;ZZ^Q#N:.48+QG6<CNE?E-^K3"
M=H\6B!Q]^?-&`=8:!SP5Z_MW-`'%H2XD>2J<CMV2D[Q$?_'W+_N/]>`M[X;\
M,!ÈS&W&]\-NIGMF"XE"6TD]%,Y#:M%1WR=4M]=?8AW-'*,%XSK.1W2ORF_5
MIA.T>+1!9;<L]]/HFHI$CM148G9,@H194)*PK6\9)-UO"=U;*TI&ZH@1W;J2
ME8Q&+*`2HQ950H19)"=DU1)R\LI1K\\\%F/P;TTL;2T]DP4@A6R*M4M]=?8A
MW-'*,%XSK.1W2ORF_5IA.T>+164O.V1^\KECTSOVU<L#O%J73Y1)KBN*XKA*
M[M>%LR2L&02H&T*#SL:#2-XT0AE]U3SJ4R*S(%6R0*)[4.&[7QU@*;2D22A5
MDA<[:;0K4#9.*4L<4TG#(ZJ;ZZ^Q#N:.48+QG6<CNE?E-^K3"=H\6D#K#1'5
MR&.["G$FLT8OW2.&'?PD@]WMXQ](G`Y\*?NY<O"[=-%FFJ9F%4;%.M#3CMT;
ML3E05D\ZBI:RG'#S]V18:F$RH\D635LC2/RF_5IA.T>+2)-J`L(4K>$XZ1X(
MZ1X.2.D>#D@25C^=42@X2D*IBR5:K=S1RC"UG4Y1#N=5E.D?E-^K3"=H\6D.
M9ASS=!NC+@.KW<T<HPM9U.40[G593HP*H2KWI)FA-`%HT)`G0<8D85W(M75L
M=(\WEI)H`CH\,*"D<V`$HYL='ACH\,%*D<V.CPP23W<P4]$KH(D:B)1Z<_IG
MECTY^P>6/3G[!Y83[F2ZJL\PT2IB@3&]`2D4'=U>[FCE&%K.IRB'<ZK*=)?Z
M[?;TQ69=]6K`G;XM7NV?\OC&%FZL2#EJ=/[O./`(>NK\BY:G1^]SAP'27[R$
M'N+2*=JU/*-,46FUN'NUCFB=:2(L+!"Q"&@"5DT;M`BRKI#5WX9E/"+Q=5E#
MXJ(KIH@WB]+*WS63711I/NB7%^['R9T:9/'@FH4_M[__V@`(`0,"!C\"_;GW
M2@1DHR;L4<Z`L*H(G30=XTB)&91KBG@%)BT"#%HD".D(*@08M'FQTA'2$?C$
M(3KDQZ9O?BUWJ!2:SK&4)N[3B5.*G5L?)B'``%J4H'9LV9;TS%S#1E;OB4G9
M%ARC@B<)VE<4/.(H6EI1&W(PRXY2LM).^,.QA4*)3UAK#!(0SU'.Q\F-9QSV
M<7'QR/,<P)VCQ0\A`FLM*`^R890L26&D@_9&B6$F9GQ")FJ.89PU+$E<]VS@
MLI(*ODIK..>SBX^.1YCF!(5.H\4?^/O=ON'%)G):ACUP08]RNZ[REEHJ`D^\
M/*)IDO7UX]+?/ZE_[\%E]=[4T:P;P_\`?@INAO+:37*\/_?CTM\_J7_OQZ6^
M?U+_`-^'`$N!RZN64FV:;3222:OIRIGKUQ(E4NL8_#MCZW)*$(*5%:PHSM?1
MEL3QZ\5JWS!4)SEEG\E-9QSV<7'QR/,<P)VE<4-]=.6'.NK+HK_XA'J&<+'4
M<[&`]4<?R4UG'/9Q<?'(\QS![VQ+W5N05MKG+9ILFK6@K18[RR95T'$=L8HM
M/=WWN/9V3LZ\>1PP';+2R,2IRGBGNTPI7Q&V72H]"SK[6O5*/]Q_!'^X_@Y(
M:<#WPLLKFJ2;LMM=',%MP.&V>;7+%!"57(*E7)RCAA;_`,5=8<:M+2À!29H
M<4@FDF@V82XPIBP$JZ05:G1K?/7C_;_Q\L*"G$%VR#+G8R98M@P%]XE(J\J/
M*X(\K@B4^?7L[4>5P0;4ZL<45:1.1B<CJIK..>SBX^.1YCF"]9]C(]H=TY3A
MN^:/K%X#XB\>O<PKS*/.<@=8:$]4Z2F[71"G+PJI*1,G'5'NU];6T_+HJ$CO
M:J:SCGLXN/CD>8Y@O6?8R/:`KUHF`JLXMF*E[QBI>\83\/;H<9202KFIK*L=
M72(IUMF04X@MN+2DD)2M)4J7DI$^D:ALQ[K>_A_Q1A)4M8+K$IVW%*D`VMSH
MVI3,IQWP^%_%3=K0_%[D=W+Z73MT'%8G'H+Y^@YR0I"[A?FVRV!:4V)4%RF@
MD\[%1MPD6'0;0K01EBI6]%2MZ"P$KMC8Q:\5*WH)"5GFG%'15O14K>BI6]$[
M*MZ)U80^R9.IJ^9A%\M)<L>2I*9&@CR0#PQ[W-#5`%E*011UK1X8+[QFZHT_
M,:I:SCGLXN/CD>8Y@O6?8R/:&2:L*^MQ#!-1),/#%WC?;P/>$9\]^$]883X<
M>><!ZIT'UAET%-4`$D#Y[,<P\W8_XQ15JEK..>SBX^.1YCF"]9]C(]I"Q,3G
MQ#!S"##K"E#OE*1(;5J>7`Z[Y'NS0W0MZ8W+0WX3,CI#"58NY`W;1.ÈP@`@
MC0?6&70%]Z?=IKD"K@2"3N"'+S^,KNT%4NY>$Y"J9;D-VB"ZVIVR%J3Z)T]$
MRID@RVJ]>$OM3[M0HF".`R(W1JEK..>SBX^.1YCF"]9]C(]I"G)3*HZ*=Z*I
MTXX5?*E-E(EB-JUDE'13O0Y=[`D&$+^TIP5?4A)E+G".BG>CHIWH*+(]%:X2
M*HZ*=Z$B7EB)"K#]89=#*)5:J:SCGLXN/CD>8Y@O6?8R/:6_UV^W@>\(SZQ^
M!UAA/AQYYP)ZXRZ#ZPRZ"VFL0EWF&R0>BGDCO39!ZJ3E$6U5G5+6<<]G%Q\<
MCS',%ZS[&1[2W^NWV\"[_P"^W=:5)LV2QY(*BD3#@-%LTXXDXMKO<10DA(UB
M4J4HF1V::H`44E4M8\L5IWCRQWB];^&F7#@_Z@@)X\42YV^.2*E;XY(J5OCD
MC\6A.R=Z)89.$A&P)\$QEA"[RMQ3`-(L2R+-&O1"E7-3B&-8(F-R:P>"/PR2
MC>Y=4M9QSV<7'QR/,<P7K/L9'M+?Z[?;T7U>/`GKC+H/K#+H+2R`F/2M_:$!
M8=;D1/I"+2#-.J6LXY[.+CXY'F.8+UGV,CVEO]=OMZ*S9V-Z.BK>A/--<Z=B
M)X?K#+H)*I$=!&\(LAM$AL")"K5+6<<]G%Q\<CS',%ZS[&1[2W^NWV]$KP2?
M6*P#K#0?6&70])7!R10M?SW-5-9QSV<7'QR/,<P7K/L9'M+?Z[?;T2FD7A@N
M^ZA,K:9V@XN::ZQC%<=-.^(2CO$6YSE,5`P'&U`H.,'#21TAEB8(E'.4!/`7
MÈ2R,293.U,@<,%5W^'WM;V('NDSW>\,MZ";W\-O32IT24TOMB`X4J03B5*8
MVY$CAU2UG'/9Q<?'(\QS!>L^QD>TM_KM]O1%Q=TNQ63,GNT3)UZH_E+K^DCD
MB5W9:;FH3L)"9[<A'13O1T4[T=%.]%E2!6*J/G.*$)`VH;M-@\X[$Z,>&T2)
M"+:2):J:SCGLXN/CD>8Y@O6?8R/:6_UV^WI`ZPT2-LY#@D:HE93O192D2B0J
MU2B[]T%.I56:*Q^Z0=^%F\79LK;%M!I594*)\XFF2L#OP2\W4NWIP.4R%GG=
M&9F%T;%(Q0RZ]<6K$[/-+BCSA9%#CA3CUMJF'[S=&^[8F$RD!T!9-5%)$])?
MZ[?;TAI7TG4HW5D`'<CIG@Y(Z9X.2.F>#D@27CR[4`&N4(VSD.$I"S/Y[$65
M+I^>OJM[,G*G"QGD><(?SR_..DO]=OMZ1=_&L>L&@^L,N!&V<AU>]F3E3A8S
MR/.$/YY?G'2*H[Q;]F^+6)IK-$Z+-=1G./3G],\L-.L7F;RJZ+7`.CNPZZ_>
MI/)JHL_PUJW(].?TSRQZ<_IGEAMYJ]3?)IHV/HUB4>G/Z9Y8"?3A"DN>E3=I
M%!!'32NWU1*"!<TRG_GI^['\DG]9/W8_DD_K)^['_5,I93:$C;"YF=`J&/?J
M@%:)+VX1)-&_\Z-7O9DY4X6,\CSA#^>7YQTD:8WXN[Ô;P(VSD.KWK/^5QC#
M=[G=BD.V[5-4D<\Z^(1>+G>2DNV[5%4E\\:V(Z2!CTQÒ=YN]U1[PR;3JK(-
MEU"I"0-,AM"LD".\94%M&HBD':,("OGBU>>Z,IX1>KDXIJ\IJ4FNF@\$&]7U
MQ3MY56I5=%`X-)GCTRPJ11,&1I$P9B@ZT2%46E@$_M[_`/_:``@!`0$&/P*Y
MI:.9MVOAT]912W/M::RM),@]P^W1^3XE]4B$(+:YN2:7*JN7CCP_LKU1O/MI
MCP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LK
MU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/M
MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_L
MKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/
MMICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_
MLKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O
M/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP
M_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1
MO/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MIC
MP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU1O/MICP_LKU
M1O/MIAFW+&=MB2ZPVK>7%?,A4=I#2)85D^D@QTF`/N*;TV&_OOJ>UCPO[3)'
M)GC>WB39/O\`=/\`1YUET63-Z%'(?HL1G,D&T)[@;>"?UK^*G'$>3:3Q5$@L
M6/*)`D/23(&V4]!QU&Z!TH,T4ESDY+PJ]IF.:YO!<,BLN8+^V.*07GHWHT@4
MV/7#CO$Y$*]YII^7VJ9-<G'KIBIA5\KO@2VG"A#4"*Q`MD4=A?19KD.@G&@R
M8E<Y&$&CVJ]<NPN136;"T]:]J%JK"2:+)=;!6S[SM>.K@EDV\536"\L2%`G-
M7/+W*X,HK8,N2RHD7(X06E0YHX&3G(!5*,88LTY*TPVA,X9>8-4T\%Q73HPY
M%B&RJ$N!+%Y2:!FGP*B+&)S7CTRCW-D*,YO_`$79J32C5P.MC;:LY5P'I9;J
MLB3J62^HB090XDHW20SW1;$XRE1.C@<XÔ-JM14QWJ906\FV2<2N=#1\$#$E
M+'EV4)O3)$ED56V%+72);%1W!HM#LGN1N*QU=2WDH-Y#E6M+(1D40)M1%KKF
M<LXKRR&]`>9]!*$,!=)7*/5EIXXAV$55=&G18\R.YS58YP)(F&$KF.[9BJ-Z
M<%ZW](H?H'NWZP;+QO;Q)LGW^Z?Z.>#,&I(TEF@C6O()_71S7B,)S"A,)[4<
MQ[%1S'(BHN:8KY'>I>=6`""*3IL_4O(F@L1'E?K/Z[,29'1_.+K*N;N.3G9S
MG2:MKW626R3%0\IBE[^"@ALU309O+<=E:')6Y*Q6YMR55S_>-E?IM]8",.DJ
M7R1/CQK&(Q0P^?T,.8;8^K2Q-:OU.S5$5$M759226+G'&6SM"08;>G@LW!@U
MSYBP84<D^,PCAB&UCEZZ<5Q.F(*86#-@,B=Z#6-F2&V0LR^FR[(W,G/Z;-,2
M_?RGD171-/Q2MSP!`!Y5:V!;P)58[FF9(9;6HKU\D$IQTE0IP+D2'85JJK5]
MSI5$5%Y4*?S"3#S9<A][>$EV9)21TD@MY9+!TBU@2.B#UQY#B`=E[GBN.::O
M*V3SI,CIT>PL8E@IY1%(4SI\:4*6XB->X3%5_P`6![Q-R&YS5**G@`J9"#D,
MK3C20>/4-D5MC5.#75ZRAQHT!L6WDJD8>@"%,XFG7QQ!K8^M8]?#C00*5R.(
MH8@6`$I'(C4<_0/BN2<?Z10_0/=OU@V7C>WB39/O]T_^6:'Z![M^L&R\;V\2
M;)]_NGJ[EI96W[`<7:1]OCMK%TF)K(+=+2,I)5;"8I.DB-,`1A$(4#Q,1'Y.
MSTI87%VL?;<>L-7LEEG3A.AL%<5T"WJR=,<..B//`LP\QJM3EES:BN1-2YIO
M;;BHO%%2SCJBI[:+JXICTUV[Y3C_``L>FNW?*<?X6/37;OE./\+'IKMWRG'^
M%CTUV[Y2C_"P/+W!FZQ%3-XWMTZT=K:W2QKF=;/KX3).9GG[E>MEAKT?DCFH
MY$>BL>F:9Y.8]$<QWWEXXRTN>U$15<-%(O\`L&QKGO5/:3"N14?EEVJ+QXKA
M'*J,SS[55X\%Q^49^'"N1R/R_%1>*XU*J,7/+2KDS_\`-<?E&?AQ^49^'&NR
MEQZ\3G<L991FC80G%=#57+MM*9X](JG_`.\%_P`<<UM]7B3G20Z3R1,?G&DE
MC*_3K=\651:F+V6*BX$R1N&L8,HSD62LH/10H!P&Z3E5Z:'E60FCAQR7'IKM
MWRG'^%CTUV[Y3C_"QZ:[=\IQ_A8]-=N^4X_PL>FNW?*<?X6/37;OE./\+'IK
MMWRG'^%CTUV[Y3C_``L>FNW?*<?X6/37;OE./\+'IKMWRG'^%CTUV[Y3C_"Q
MZ:[=\IQ_A8]-=N^4X_PL>FNW?*<?X6#1:'<%3;R8X4D'CP)@9!A`5Z#0SQL<
MKD'S%RSZV?\`0*'Z![M^L&R\;V\2;)]_NGJK>R*:$:V<K%),>Q7/.HXZ1`](
M'JY,GHX$R'K:[EKQ;DJJN-U1*B$*#'?1WYWL%K744E;)S<YY'/(NE$1K4SR8
MQ$:W)J(F*'Q+5_,0>RW%%U+T>)3[9D1@_BA-./N-LLC.SJ.V(//^XF(&?X\U
M@G??&X1G.9_4KF)A$3K)PPUSF(KLEX\<ÛTZ?P9XF+V6Q3O:OM/8)SF._K:Y
M,1%[)(P"/7^T]XF*YW]:KU%8]-35ZZ87EL1F?7R[/5*YK$1VK+/CV6-5>S[:
M]32-K6-U/=I8U&IJ(Y2/=DF2:GO<JK[:KC;GB[<?OJ7JP-DEFC;N&QIY=Y%A
MJYFI\*(=@%[75S-9?C',R3)6@)_9ZG19-C`CRE$XZ1CRXXCJ$;'D>;DD(TG*
M8,;E5V62(U?:PZ<"?#/"8CU?,#*`2*Q!IF172&/434&G7X\,+-!.AFA)JSEB
MD@)%32N3LY#'J+M5Z_'#&N>UKB*K1M5R(XCD:KU1B+Q<J,:J\.PF'M:]KG"<
MC2-:Y%4;E8TB->B<6.5CT7CV%QK(]HVYM;J>Y&MU/<C&)F[),W/<B)[:KU%5
M51$1,U5>"(B==57L(F&O8YKV/:CV/8J.:]KDS:YKDX.:Y.LO5B_R^L/K'6?T
M"A^@>[?K!LO&]O$FR??[IZL2NG6,6+-FM>^,`Q-"O8//-[G+\6%KE:J,UJW6
MY%1N:IC=4JIF@G1V4=\!Y`*JZ2CKI.;7-<C7)FG%JY9/8J.3-JHN*'Q+5_,0
M>RW7XAV?\YW7BN\8B^0D=2%4FGPQ6DZ/+D0J\D@;9DH$7E=(*`"NYA&"U<<D
M_P!RXM)4LPHT8%?,*>0=[1!$-H'JYY"/5&L:B8JY40XI,8]?#*"0![2A*-P&
M*UXR,56O:J>R,C7(JZD7A[2,:W_?C->LG%<*K'([+KY8HBL:KAQX-Z,[T]R)
M\CO2H6O]I2H%V7]WJ*UKT<J==$['8P>T;ODT2=`V]7;XA$2F$5D>M9<.H1[8
MY'3F"<%(0%U'5,WN>KE9JXX?!J[5]+*<<)$FL6Q1R,&JJ\>=79U$KXS_`#LO
M;1<2P]Y8ELZ9#_A\P>[)AH2C"[:E@Z;=1Y09LR3?J.Y"-19-4Z$Y^1'9:UQ?
M;;B08<?<.XZ*V/810=$!$_>.]BN=+"-[&-B=$B'(@`JJ*G($S4KN*K<5NQI%
MFZ#+BWLOO@>XJ(,*PMK2@G,`C*&&ZMJ*KHMST?2C*_ME;S5,G%J[`%#DRY=Y
MMBS;N&3-L[DLF0VW%0V(\GRC/<LP!;*5RN4N8=#N*:$QN./![XQ8^Y;-;NTL
MZW>#XD>?)LMN"CV498*6<;O=R+,#1HK(YD(/@QPF,34E7([[-AOC;3:B%W+'
M5(T*O-MPLJ$_1SY!=RP;"%,DNGL(SF,>-$(14T-K:ZF[X%O@S]QC[YQMQ)!-
M&KASYK-L$G:;&L9;$-5]'YKR/*YCVJYXBN<N)\=\RUL8-@VRD64$6X@ALSF/
M:[B'!A4UB<HFU,45>:M(1C7B&HA$9Q>Y4=MNKF-:R76T%/È,8Y'L9)AU\>.
M=K'M[5[6D&N2IP7JQ?Y?6'UCK/Z!0_0/=OU@V7C>WB39/O\`=/5K"6$E@X4%
M6N(%D".ZPY@"\^.^!:JY"0FN+P.Q[)#",3)B"=J>[><*3:S919E0>0677DE4
M3^52;=!558&]"F./I[WU0FR,RZ)#M?:M8[0E#XFJ_F(/9;K\0[/^<[KQ7>,1
M?(2.I2[LMK&]":KANBK"@6!(P)#!&:4",,W]9KV_&E0O1W#<77GFU4S6\7OK
MNI[F5-@4:3=TW=K&0HHI2B>2OMIDVODZ",1<BB>W%0/OI?272(,68]S[61%&
MQ\J.,KA1H==T*!$CLU9(T8F^VN;E55[KN/+=KÛ8<$Y[8HG\'C?=6JM<B*B\
M4Z7[:8<V(ZSCM>NIZ"N;5J.5."*OZW[6.Z[CRW:_M6.Z[GRW:_M6).M7YU<E
M`B<CRM<_I%>`KGO5")J73)T]MJZV?7PJ:B<45/RCUZZ>UJXX6S5Q72Â]`1S
M2G&SHW/Z1IY#3<A7\U/=Z=?8SRQ55A];PS%+::V&,$@C4,JKE1VZQ/:][2&(
MFKCEDW)45%Q[HOYTGPL193T*XU>\DF*O.(UK2R02895(QCFL.G(,Y$1Î$7C
MUT1<&WVA9G?@^V0[5>'F#Z!WN#9$M6D:'E<WI?2"*BNUZ=/8[.+*WJFC=8`+
M5@C(6*^<W586\"N<J0QR8;Y16CEJK!\T>I^29I@42ZK+9DV)"NI%S(CU4E@X
M?>:9>QF$DQ$=*Z"Z>#;QB.&IGI'(K1:WJJ.4`)^V)\4RWO>">!+2IE'@2EE0
M8PY#AQC$YT)ZV#/C$5&YYM]TF6+BU#62*N?550K-]=.)'DZ16%,EU4D=(A%>
M`C9,,C'.:UVIB\%XXA5%]6BW+(G;(J-_FL*(,>C!55-A8BJ),4T2RMISYQ(D
MLPW-<-Z.(UZIH33FYM<"DM)B#O24-@<+X2=#DNM;FIK7C`\[2SFV4BAD9(+-
MPT1NO+5B9N4U7(B)&L&U@ZQ9,8LTLR1*AP8(#HU6I7%E3)PVJA]/+8O,7M%1
MRO+84]I7#AK8Q[=5?#E][;&"Z^T0<HIG].Z4#;4M[2BS&W2U%7-V"5=[0DB6
M\[<&X:FC@@DQ##T[=JXMQ/#8312#`::/6$=(UM[4B9#:G,X8D2;R+&A6ÙKY
M718R<`PKJLC7%>Q[VGDA*YL66B:FOS<G%S!N[5.I%_E]8?6.L_H%#]`]V_6#
M9>-[>)-D^_W3[#='T=N_]-DXH?$M7\Q![+=?B'9_SG=>*[QB+Y"1U&?W7_\`
MJ8OO$UI\Q/BA\35?S$'LKWQA&_TBNZNW/%VX_P#?2]1W^6SWQ.H>NM(<6P@2
M6HV1#F`')C':U[2-0H2M<-Z->Q%3-.NF(['4T`;H4$U;`/'CCC2JZ'(`^,0-
M?)`C#0TY)%1.6J99XC"'0UTX\2268*PLH%>>:DHQ6'>4;A1`1XWQHVN1H1C8
MCDU9:LUP846NA1QR`@CR!AC!&P\>-&;#CA*UC40@@1&H-C5X-8F2<,/'6;;H
MX#"A/&(V)60P(^-*0"28[N6),P'2*/4SW*Z&ÛBFF]Z`1Q47-Z!5Q11P532&
M><KC=%:#4)ZDE$5_*<-I]?QR$R;DZFBU5?'J7L*-]:&(%D)XSY\YKXS6<IR%
MU=MFG'$6/7U,/*#WV9",:-')(BQ;JRDVDR"Ò):HX//E.:T:<$&B)AHX&WJ6
M&QA&F8V-6Q`HTS)#9;2MT"3(B2F(3/KZDSP\%9!B5X2'+)(*''%'&^0=ZO,9
MS!-:CB%>N:KU8OQX?_\`/[!/RK.O^\=;P]UCN@'YX?PL=T`_/#^%CN@'YX?P
ML=T`_/#^%CN@'YX?PL=T`_/#^%CN@'YX?PL=T`_/#^%CN@'YX?PL=T`_/#^%
MCN@'YX?PL=T`_/#^%CN@'YX?PL=T`_/#^%CN@'YX?PL4;FE&YK=A;NU*U[51
MO_[!LM>V5%X8WMXDV3[_`'3U:F1MPLL(`05&(PYS`5X99"24G$M!.+FF411<
MC*/,YQ$5B]'RYCMZLD?$RGUTET0&XYAK)PPLV]'%N(RFB2Y14;86XY<B*WFJ
MC6%9VHT^+;0Y=;O-5_,0>RW7XAV?\YW7BN\8B^0D=2+&YC4-(%(*(:H[MQQE
M`DAV:)I31TAG9[.'05DNC"*6.Z3R,T=*BC,PDF`]W78"<)JC>K<G:7+E@<$+
MWN"%7\EL@KC.`%SU<.,-Z]MR(S5T#1<U1B(F>/\Ì_\`BQ,K!V,JI68QHG3Z
MQ_)GA%S6..V*=S7\@IP(X?,1-0]6IO;(F(<?;Y*+HP`<A_?U;:5)^*R&+2<!
M]9>T;VSB*Y[EXYX_*['_`#%]^T8_*['_`#%]^T8WO(/>%F:;*/&EAM;$]CÈ
M23P(MF.37Q&!COJ&QHDT0T:CG(YO:K[E%PY&DHV.5JHU_*G.TNRX.T\U-62]
MC!CVLR!(%S),<+(D0D=[21)AHSR.<\Q$<PG)S1,N&>($JH;2][8L24%W?!IW
M&YLI8NI^85UHQO(_%5OW\^&7N]J?FK?]-B-$8>.P@!MEW(""*1"0Y09X8G0R
M<Q.3_P!RCY\=2\MBHJ)GG@O07L')='>R*5R*^.R6K7\AYP\P;B#:3)7)FF:=
MG`D,Z,XR#9S7,:1K'$TIK<UNI=+5=UDQ_P!#\!/^.,]"<K+1[I.7U_RFG5KQ
M_P!#\!/^.!Z$&N9&\6*J+GFFEO;+UGKA%5-*JG%/:7VO9[6MY&P:.\L";<JY
M!T'14A[2P.4È*[GV'1AE,]SM3E(5N?MYXMK@G\!B.'5UTRP>U^W]AM8K8<<
MAW(]P+F49K<F<5:-[O::O6Q7[@__`(#R4F(Y$6+M_9KXA^5DQ\B&2RG5<HD4
MA=6A5%EDG77%)/KOX:[2C5:;<W9?;D@6.T*63:1A5:4\2"1A(3I$=G>^3:](
M,(:F?("-6,[;!Y\S^%>V7SZZ-!=8<^HH*F$A"U!K(TB2\L:06HCS"0R,@\T:
MMEN>)&.[==((]?\`PGVSFRWIXEJ9:*K(L&!?-5U1(;SJH05G2RA<WH[N"B<P
M@R.U)BKKYO\`"*CJ2VDZQKQDE5.VU"DBJT1YH1DY3&R9`+-D@*B'F]61U,Q'
M"5%Q<RYÛ=ARB0"VPS[0#LZNC3J,4.Y[UUEA9W"1BM@UTV*K)AS2V-1D=RD$
MCFL7#H\'^#NW4.UM%(0LZGJ@P'Q)EE6QKJ0^4RM=T:#70+%)(92HHSB[?)K<
M6"P?X1[;@3V0K"1!670U$USDB2#,%.)7C@!(ZH,..K'2-6D4QS09*JZL>@VT
MO5ZJ_9<>@VTO5ZJ_9<>@VTO5ZJ_9<>@VTO5ZJ_9<>@VTO5ZJ_9<>@VTO5ZJ_
M9<6-17T=3!JI_P#!)>G5D2OBQX$SI.\EC2.DQ!":`W/CM1C]2+J8F2\,;V\2
M;)]_NGV&Z/H[=_Z;)Q0^):OYB#V6Z_$.S_G.Z\5WC$7R$CJ4/BS<'RM'['_:
M_P!^[J[\^D-;]4-M]1?&%Q_J\WJVGT<H?]2W#AG^:S_?[$?^>'WZ?<-D?1FH
M^9CP:78R`180FISSRGM&!C7N0:<QSÛ1'.>B<?;P(M+(AR:X:=&`ZO<-T4:1
MT0?(%R?BV-"B9:4ZV(PY[Y*FEH<@8T&!-LI71XO*Z7-?&@`D&'!A\\?-,Y$&
M-2-S7BF%[XRFGI#6IJPQW].C0>G5I'O>&7*'R&LC.)'TIS'<DZJC.VU9+0!E
MRR12[B"1=O58ZNP=86+(H&%<&'6`B.E<Q@'-TCT(Y4ZR8&,-H^<X[1K#[W0+
M"Q2>8D8<[H5>L.,9)MD.O,R0^./48<=Z$<U&KGB/`)>!)*E4\?<(VQ02IC$V
M_)7)EV8T8!0AJAM740SW(P3%1SE1%SP=638;TBHKI2MDA<D=J:LU/D_XEJ:%
M]UEUL`VNED%UW*I5W!'C-:1PRU/3V5?263$8L-=4XB#1FO6JKP3`B2K*,UAI
M!HK'#?ST0L:.69+YJAYG)'"B`>4SG9-$-JN=DF((8TU_/L9,F'&CR(<R+(Y\
M6&RQ<TP9(!DC(6O,,PE(C4,,K%9GJ3.WK[2[8"5M^,"9>,9$G2&U,64)Q(IY
MY01B"`.2J(P>:]L5[&)VSVHH(PCRXTN1(Z(.)9UEC5RDD.BDG`$6/81HY0NE
MPPD(#4B<YHGZ,]#LNH;^20OKP[&]O$FR??[IZM;"B"@RX!MN[GO9D-\>4ED5
MNW@QNT@S12G!0DB9:16<MT9_:<QVO/2U=ZSK"'TAT6K/&:_;\.7,89+?;4:R
M1B1VOEE1]0^RZ-*?K5NL#W*@_<-H?$U7\Q![+=?B'9_SG=>*[QB+Y"1U*'Q9
MN#Y6C]@J\5RX\.OCK/Z[OQ<_QE7L?UX]R_\`P+CW+_\``N-Q;@D0))8MY8Q)
M\6+5AD6UB-`P8E)H-&B@7KCK&&56*Y&\Q6_B:G%.2CW>U@1O*]S]K6[&M8-J
MO<KGNCHUC41.NO!,3'@@E)T2QF\PU.I[B%^N2231A=(2)%>V2UA^V;HR1,ES
MXY8?LQM<8AVB:N3''[\(7E,D/<^F=";I@LCN5W-YRJN7!G''<-QY*F?H\6)R
M45^QCJ:JCJUM>ISL:&?=O')?'`\AN1*4NEBY9YL=GEADL>V=WVAG3(L8$"'1
M'%)D%D$T-:)TYT6/FG7XO3"*NWMZM5415:NTKC-N:>Y73'<W-/O+ECP!O3U2
MNOV;$*J'M'?$I),1TV1,!MV1RZX6LHA=+BE<.P7GE%I3EB?U^/9QX`WIZI77
M[-CGQ-G[[M#L/'T0HVV)L<Q<RM1VDMAT2*FAO'B],^Q@!C[6WS",4;7DB'VK
M9$+&>J=L$A(K#QWN8O98]S?OX\`;T]4KK]FQX`WIZI77[-ATS]UM\3'\^'%!
M$%MB='+)DSY8848(RSTBQ4>0YT1-3TS7@G'$*Q+6SZ@DL*%?66@QBL(:JJIR
M98Q$,-A4R[#EZNS8LEG,`;:].TC-3V:DZ*)WNAN:].*=A<2J[D&A]):Q.DQY
M,AYA:"L+FQLDI@KGHRXM7@N&P.7)GZ2E+TB5(*,J\Q<].F(^.')N7]G$>/#L
MY]`6-66E(V57H"07O/<]%6QAY6`Y*,>4L`#VF;D8:C[5R9KB]VV6_MYE7=26
M3&M..OZ3`.LIDV604MD1II2S9`T5W.UY=C%7-CRYM-/I[^;NB'*AJ*3_`-]F
MP'USYI@6+)82-8!ZY"R0>?8P&'5WMY30HRB(&+'=$D,4_>R)33'27RXY32@3
MZNNCC>%SN6C@ZVY.5<ZVQDV<\4B%M<FSI"1`5T>//H9I1/MXSHS(B"A/LF@:
MW5'Y:@:GQ6G%U*IY$GOC9"EE01W0HL.5/?.#9Q'6:CK)*38X9@,E8<4@;QO>
MCV/1RHM')L;B<:VJ8ZAYL%L:)&8PQ(#Y<6$UL='Q8I6PW-31HT.,\@T&_3IY
M4V1`.`^X[*9*@ARC_P#8[#:#MEJ'IT*N@<^R2#^L.(H&O(15:XBK\:K[25;6
MTVZ82K-76I>AB-3%K&QXJ/K01XPXHG3:JOBQCZF.UMCH_@17.6RD7U[9$G;@
MVU5;:W&2O##B1["-4$/.C%C@(*2Ô?WX*V3VCU_)H->T5R+4V)[DMK,!=Q[B
MULYP8L:1('64=K2U=?&@5L6-!&UK;@CGEX.[7K.S[7J&_DD+Z\.QO;Q)LGW^
MZ>JTBL8I&-<QI-*:VM>K5>UK_=(UZL3/V\L;H''"(`_W?OG\L(V"9K)7RR$?
MI8C6ZB/<JJO95<4/B6K^8@]ENOQ#L_YSNO%=XQ%\A(ZE#XLW!\K1^QX<.J3^
M\GO&]3EQ@!CCU*_E@$P+-;NN[2-&IJ7+KXVH9HQH8E+NP9"HQJ%>QC]NJQCR
M9:G,:J\$ZW4FKV>]%9Q_^LML#U-1V1AN3-$7)R+P<F?65.J?Z*Q?]7F=0?\`
MGA]^GL*_Z7['^MU-[#9.G+5^[-1EJ7).Y!]=41<.5HA.=EP1KWJOM=;0WK83
MF#:CV\%4KG-5WWÛ&J8@R*V+N";"%67;EA;6D2H\XVYD2`[;J2C0F.EMJ>6V
M6A55A`:U9S&.[7%X_HNZ(V[*B\//KFS`C6-/A6<MS!0AKDD"SC0H!G*K48Q`
MD:U41,DQLYL"1?EHX%S9QMQBV[8&F6=IM5*I>BV$^2Z+"M&;@=8,1&CBD5J:
MER5?Q8JVD7=EC-<V*.U9025!7.K"4<!L;2:M$0P)@=SCENE/@CZ;R5&BNY*Y
M8984Y+F]EFVKMF.]MS73H%-`L"S($>PL.\L:UC0YUC+CF.:0!.62"H4^,<UV
MG`+N;MV&"^1\H#HO0)4EMI9)`B2ZNL@U([8<T"6IBG"ID-)4+HWY-_,[6\):
M1I4VO2LK+0=K=?'MJW/B4Q;MBBZ?":9*=)Q^7':]'32QWIK!DFNEEQWVD8TG
M9]=9DK*5LBL(ZQL2;IBQYK8+SOEOAQKF%5++1Q"MC1R*CU497:I#=Z1I$1NZ
MFPR4IJT!)LC;<XL<-<ÔM1O$:#"/VC)/:--$YS3O<_2]@TH&S)F^!38H]O\`
M?0D*WDUP9%4<>UXIFE2&84<UT*9WT)+R3FL&J.5<N6B;OJNF2YM95+M]D)TN
M26<\,HU:_O@!9IG$,\GQ(GO8YRJUS]7X_'J&_DD+Z\.QO;Q)LGW^Z>K#V]-D
MZ+&563;ES?BM$2L@BD%)+D:RL,X9.AE1O*85<QKJTIQQN^5`Z2)(]';A,&:'
MH\AG/I7S(1E9K>WDSX$D1Q+GFHR)FB+FB4/B6K^8@]ENOQ#L_P"<[KQ7>,1?
M(2.I0^+-P?*T?W`B9IGJ3WK>IVJHO]6-M3&"5T:)6;E%),BMTA),=1K&8Y-6
MK,W1GY9)^+U)9LOBW5L`37YIDI!2K%Y&=?/-K2M_#AG%/RC.S]_JEF:/U9=N
MQXB&S;I62VRE&<'+/5J03T7K=0?^<)?P.X^PK_I?L?ZW4WL-E$?GI;MBH5<F
MN>O<@OQ6(YRX*7,[N6QS]/1);=6E,\M3@(U,_OX<]KC9(0@^Y93ES&[2N>@*
MZ5S['7Q"#`CP2*:INMPRI5L:;#B1ZC;[ZP<]&MB09LQTTG?5BC3E:=+'9]C$
MS=B5H25U;=SZZ:($[F2'002E@PYL-7"8$Q#R""5S7*U$&JJBJJ(B[1J8U+#E
M6>YKN?MB2<\R="K*F_B5RV+19GK6S+*`]C')T@+.7PX9XA2XE1"B1+-Z083K
M6PDH=EFRAK=R2$-%KH$Z1*C.@VHQ!;&:60\S7*K$&FK%/&#MQCY%J"A'(@'G
MKTZ@G[CDQH44][T:.>%%J:^=*:(^1722YZ@B>UKEPE3.@38%E!EVH'&F0FEI
MW6VWSV,>:E389N(5R-JY)1.48W<H;L\G<,'!&I)DNL@DIA[D?9@4#HD#<T^H
MCT,V/#:V6EC$NZ^9),'W*_JV3T9GGB<E?7S9,JOJ9$J&9\80*Z1R+&GJIT$$
M]A"JBU]C:QVR$:W3PS9KR3$J9*I4?/6-MZRJZZM),L#3*Z_+9IRW!!"=-6PK
MH]+((9!B(--0^VXN5M73U-="F,OJR!-IK639:()BS3F1S9+(H))A10Q09\QN
MO6][41,LUQ&W<_;M;&J[RJW)N.MBQ[$K[)(6UIC!68[;."..RQE04^(Y;GLY
MJ(UZHWMNJ;^20OKP[&]O$FR??[IZG!<ÔUOO<%_`N`6-F.01PP!BR(XS<N-8
M`B'/*KQS,F=(R@2Y1",Y1!:E?D36W)N-WURQUM`2*>?+,MQR9KGDK:;HM6FG
MDC"B5<2"$851FI$$BJKGYN6A\35?S$'LMU^(=G_.=UXKO&(OD)'4H?%FX/E:
M/[@YV6>KV^LG]6/<-_`F'SB1V!=WUOH&A'*1--/>V-0,FIR)Q,.$CU3L*[%)
M5I'8YEG"NI+RZE11K5K6(-J#RTN0O3US]K3CW#?P)B1%Y;<APHLG5[;I!Y8G
M-T]9-*14_#AG:HGQC4X<.OCW#?P)CW#?P)@E7R&:&TX;+FZESYA)AXJCY>6G
M2C19YX]PW\"8;VJ)V[>MPZZY8R3K)U:_Z7['^MU-[#9'T9J/F8\+GULN.?6R
M[.?WL9L5KF^VQ45,^SQ3AB'%WC#A6(3E>2)"E4Q;UR*%FF1,Z''ASBABQF&1
M"R'-:(>M$<Y-29RSQ(NW@0;BR)5V,D=8$$"=8U/-=RK"1T9D5_1U`[E/*NAS
MLD8JJJ9TR;G=72VWH91:&#85$B?.L1I':^7WOJG0CSR/?&>F;6BU/:O67"]\
MP;=MC$B0>6Y*+OPLP0V=*A0H#XT"5WPF18\CG]%`KSA`_F*Q!KJQ7FL8FU#2
MI6WG'JE;61)\J5MR*(,%C8#8\:0>1"5EDP`!LSYJF08T<JY8AV5'7T3D1O.B
M'B08@3@TL+%?VJ"9(BG"A7B(UR->-5<QR(N:8D0CCK%L-YV@Y)UF08L@EG,C
M6$*%""](4`<,3*Z;<!8)%:U6N+K5576_%_?6*!C=+H8]5*(%8T9M;4QG0RA9
M"9"CL.YSI,".X:$YZZQM:-$158Z5<07UK&UTX<B98]ZG19:S[O17MMLN@@/(
M[\K\7TL35$;2]$=DQV5C43HE,V1(B19LVG;6DLSDA&)%@PA@K8\:63H[RU8^
M7'"S+XA2(SM7.Q>-J^]L*);,*RXM*NCD50;F"VS;'M.5<=ZQ1[2M62]6S#1R
M/:(;W$<]B?&)U#?R2%]>'8WMXDV3[_=."$.9`#[47,<JMR(=R`"B*WMM;S$1
MK<N*N7%P*MD6DZNC6(Q0["QN94]DX;A..0\2JLQAN:!BR3/UBF-YY29DS5JM
MZFZ/H[=_Z;)Q0^):OYB#V6Z_$.S_`)SNO%=XQ%\A(ZE#XLW!\K1_<B?27>_U
MTO\`&T?%&[O?;<ZDWQ36?/+7#/\`-9_OZI_HK%_U>9U&_P"8S_?["O\Ì?L?
MZW4WL-G0Y*$4!]KT[2((YXI,NBA=VIXI`R!KFGXKDQ8UN=M&Z?"E0^D-O[X[
M@=)"\7.0$FT)',H]6>E[58O93+`*D'?,XP*YW.[\7$)Y7/R4A#"@6$>,I7OS
M7-&-X<.QB(.KN)]!)AU-M0CFB4E@?O3=]#?/$A9<CI3)G.K@.'(0O,'I7V\7
MVV9&X9TRNNI;9S'EB1$FPY#YC)\PBR4[M67(&B_&)FW%+81K";56%#?S=SP3
MHY;)G?B97OKE>0%B0R-AC$152.)1BU=9$Q%BTNY+BGBPB#D`$U@3N?(6HAT,
MWI$E%CRGQIM76QVJ,;Q*PC%<CNV5N*6^[^6U?94=7!KXHJ\<`-/S*LT&;7D2
MI=%>V/#%8UXBOBB(P)-"(O6PM]"M+!+"1,M9EB<8HD4]@ZZ[Z$GA-(CC8;HW
M3+/G#9FJ#<`7]A,;J==V'1^_L^@=`CUPHNJNB[:D#(R6Z4($9#6FXG1A/GD1
MC7&Y3.8KU3/&X)4:9$<$^VVU<"1,&!;"RG%LJ"W,LZ1%BA?%KXA:'DQ@KS61
MQF^*1C&Z%$"XF39T#E08I:?6@([ZNI!9I2UAI</HTPSJJ1<R'](:X;Y&:(]-
M*98A6$O<QR6E+&B0Z.P2NB:QBB,CY2+,"_$3Y9"K)SR08])DR;FS-7[9J[LT
M^'#I[_;^VH]@&/'[S0=UR?\`NAY<N,-QK9\0#]0VN:/7HTYIJU)U#?R2%]>'
M8WMXDV3[_=.+.#2QJR79G9'2-'N)5C"KBZ)D<ADD2JES+`60&.5G+5,R9([M
M<\3@W0[./;/L2NF1;"*H1QVHXC83(<MAY<.Q:Z!RW%>`Q1M,KFY\,L1;:H68
M/+:UE6K+DS!CI:^20-IT&3"BADK-?>K-EBYBDC/C=$15U<UC$QO4)G#@RBUT
MI\6/>&+<\H0=O`CWY]4.Q54[\6@94J/\>NA#M5S&\1)0Y?\`X:K^8@]ENOQ#
ML_YSNO%=XQ%\A(ZE#XLW!\K1_<B?27>_UTO\;1\4;N]]MSJ&G]^ZXS2L0'1R
MU+FIR!DD$CM4@IC'ZA+(7C^-A4(>+S<EY9(P7C"-V7:.>$YS.(K'<5XHBIAN
MIXG.R34O+<F;LN*Y:^&:X]T+_`_X>%F/&WGJ#H[C<-2Q$(0@Q=?W"&>J^WU!
M\@;GN4B+FC<T32O67^\N$7,*9HBY*,F:?>7XS'N@?FW_`*3'N@?FW_I,1TLT
MBD`MG5.#S6N:Q+$=C%?59*XF7/=9()!IV7Y8:[)6JJ9JU>NGWE_JZNSGP`È
M3&[7I^1'DR7PP$=T4/`DD<:8\*:>R@WXN(NW:G;]7=&AO;`G"W,>48),VJ_H
MX9.VHD=9)0HY@W/(QK'N1RKPQ!B[LKJ2WN6N.XLJ9N5\68@7%<H`RVP=OV,4
MAQ-_'85V:9=G%7('$O1A'5W,F5#V8:7,E$W,#H#MOP23(]0>8M3(#TOF/=$Y
M/,1G,_%SNI*1]S!W53WLJ9"ASJLC03ZZREN%%A)G&'#M(\.`=S\@+\20;57+
MK+LR/`D[@[R`N;.!N@U$1;:WG;:2J<^-=R3CJP3HENL]J-;'C-+EJX*[\6(^
MXC;N),.V+&M8^W`*V$.N?1P"Q9(I==`M71)O[S]+;*?%$>4T#1HHT$Y'XV\Z
MA"M]73ME5BVS[';\^/71[MMQ719<@<.(>'+@V,N).)(<$[W<D4=6HB<5QM;;
MU91%J";S[SP%)T:7-MJ;OO6R95G==)`]D&&/:<D2#."0/6=,W-<U,--;4:I*
MCVLJ.DVW@SY3IXB2FDKH;!03QC])FQI#_P!8T='B=&Y;T(KVOQ93JSOY.2NW
M%O`(8%.!I7.L*6XK(M!62H^2(.KF[:'-(O.<P!I2C<KT<YF<NHL$L(6ZI]Y7
MVU$>ICFL`3*>;:LLK&AZ3(@B2&>HKPG&5BM111E$C2D(KEQ42;:UWW%J',UW
M@%F.B58[^'"))LPQQ=&3*A)9.8R.K'*`P\T&YR(N(LB8=\HK9U["9))DI)$.
MMO[.NKSD(U$0[RP(HU4O_55=?9ZIOY)"Ô#L;V\2;)]_NG%M#@LA$FRJZ9'B
M#LG2F5[Y)0/8%LU\%6S&15(J:U$J$1ON>.+-VX;`%M<V\F/.GV4:39N`<S(K
M(_*'!L"G;"9#8-!H\;OUG3S7M:153J;H^CMW_ILG%#XEJ_F(/9;K\0[/^<[K
MQ7>,1?(2.I0^+-P?*T?W(GTEWO\`72_QM'Q1N[WVW/9+_E)[]>HW_,9_O]A7
M_2_8_P!;J;V&RS2"B`$>V*A2%,1HA,3H@DS>1ZHUJ9KA7+=U.3455RL8:\$X
M];G8!)%=5?+D!&<?,GQ1$T%8A&ZQO*CQOTNXHO%,5D2MKI>XIMI'FSX\:J/!
M3_M=8^&.?.;(ERH\8W(+8!:@F.4I%?VJ+DN6YDA;>MI9MM)9%)%9*IAR9,>E
MDBC6Y7"+8M6K?&4R.&*9R"R6ZN4CM#LA[CLJJR#(>&NE.VY$?7VE\*%:SQ0(
M,U\:OF&'T8KC-75JR3W/NN&*>U[RW9(MWM]]]#8,<5\QR]`-8CK6P6R5E&E*
M(#FD>QK@1R*QI'MUMQ3U\BQBUE[=Q13(M'(E`/+Y1^:H$<>&X\+F&8/W/,U(
MJZ535PQ`$4\:?<%N:W;$LL-L;I-+%MSE3I\^7(4.BBCS(J,.X;GM:=6M5-?#
M`4M9<.5-!%[ÛT!T?GS%444LD)HC2CTQIJQD<YN:L(C,UZV>+8]E#D5C8SC(
MZ29U>-ME-JIT"CN8Z&20B(:GFS!!U&5J':F85>UN-L0FUUG;RMXG/%H>][8[
M8LB6*'TX4<TZ8>/%C/EQT51ZUR72N+B4FUKH=/3T<+<DFU)*I%$2CL1'E1)8
MH;+)TY7$KXAC*)1H1$'I5-;D10MCL8,#1#:`8V(,8PHQ$$Q@VHB,8UG63L=4
MW\DA?7AV-[>)-D^_W3U=K;?BU:S!7$:[E33OCV"JI(M/:2Z:NK21HQ8Y)<^?
M7*ALUS`+2NE>9J;O6?.B+8K&K#Q1DV["*5IN^FW(TXPD`Z5([:AE6#XLIR%]
MW'<JM8N;&T/B:K^8@]ENOQ#L_P"<[KQ7>,1?(2.I0^+-P?*T?W(GTEWO]=+_
M`!M'Q1N[WVW/9*WE_P!H?:KFO:*Y<\LL?DR_X,,^+=U\^W[7W.2\.OA%]M$7
MJU_TOV/];J;V&RAE8PHW;8J$<PC4>QR=$%[IKD5%QDM;7JB\%3H<?C_\/#!#
MJZY@Q,:,;&PHZ-8QB:6M3XOK-:F*\M]*!3M"\E?È,N'[><]L_0IZADF/*A.
M/'L.BM5\;-6EY2+I[7%C40!UX8]_*M8TX`93>=.EF9)6RB<Q"](4L<2E^+:N
M8&HN2-1,"%9'IQT[XD,099K`$=A8-.8$V,UMGSQD+'BEC->OQBMX<<1EC6!:
MR?6T%?5"CQ=TSX3Q4FJ1`K'$BLL69M>>6Y@C.34\NGME<UN0!DD58K(%A`C,
M&;<*MF$N`R8EK%8<1)_-D6TF4(<A^M%,=SM3M6I<[*^LANFMD@2'6U3"3X]=
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M)4DY:LM.GQ>]ST*5`"T3>;T9W,.Y&-[;B[AU\&K&7=0ZQCO8,]>VRA+-`0A!
MA&,T5#<\;R&,UJ(K<U<Y$[.#?R2%]>'8WMXDV3[_`'3U4S1%TKFW-/<KDK<T
M]I=+E3Î<;H8(;!,_=^^=H&QK&ZGU\M[W:6HB:GO7-?;7%#XEJ_F(/9;K\0[
M/^<[KQ7>,1?(2.I0^+-P?*T?W(GTEWO]=+_&T?%&[O?;<]D3Q*%?]O3C\?Z^
MHS_-'[[V%?\`2_8_UNIO8;.CBF2:\A=KTZ-F0^C=*Ò10KJ#TN/+C:ERR[8;
MDR7"I^_>\./#@FU47_8J;7S1<%%$_B#_`!#,TQ.:];2WJ;DB.1NG(1;6BF$"
MS+\5JHW$`M-9PI=K"I;RCY^Z`!.)S;Q:\BW'+B5SX;K.`2L:@VK&Y3F%?GEV
M;_;4V91*^7:+;4UK$#+'(CRIDU)=BXX.6QD1=.H8^CN]P]47).&-IV=9+@OD
M[1N[&WKXEU%`D)(DNL6`+;@%JX0'1Z1A-+UU-,7M4S5W#*MC+;0IT6HG4MQ$
MF38Q5L765>/;L$PB9*\;(@H=!S8[D<KDD2'9HB)FL/="$H(J0)RNC%AQY@I;
M(19G?"85T55?!+/LD589D?F+0O2FY2$;IW-/;O"UM1V`9TGO0.?<R32%2<V;
M&K*YYYK'TK9$7FQG$A/`5B$16+FQN6W-UV>Y$A7\"E2E-S#SK":*H-85MDM?
M)FE?S;%T62$YF\UZZRN8PRD$CF*T5]WT='-NJ["PIY\NPL(=99;)D;82[:"S
MFG=%8^]*^9R!DY86OS$U$[5&7)-P0HDVNEULRCKJP1F4HC#A0:.X6S84729*
M6=-4A<WDK'5D@QD>I!JF+K=*#VI!7>6R:S;&X8Y4F29U1,9TEDZUIY0XR"F2
M@`D-:%2<K5R6YJF+FQD3*^"2YHIU$8!"2[(+`1A6E=4M2(1J5^B>"2&9(.C$
MEQS"Y0W*Q7+@M52Q]N5\>+80GP336\Q35[ZZ4*R:`:5TL53-Z2?EM>@BYQU?
MEH<Y'-WK"A0ZF1^\Y8JUY8=A<%FPC=+KD`,S+)RPHD"O$-ZDD!_6"Z&.>CG)
M@W\DQ?7EV-[>)-D^_P!T]6'&L16#12VD<ZP%#>6OB:!',UL@J+S7D(.*1=(6
M&43&:RZ&9.7=\J+TB*D:CLPF#8,'',SIE%T^`7M3%$HY\"8(P^VU:2(CD:[-
MJ4/B6K^8@]ENOQ#L_P"<[KQ7>,1?(2.I0^+-P?*T?W(GTEWO]=+_`!M'Q1N[
MWVW/9$$RQ@N+WJ;'Y;905?SQ39#BATZ\^:-J<6]=,?EA?G&?\<#&AA*]7->C
M$(Q7:&/;J=EGGI;J3#7C>Q[')FU[7(K7)[:*G!<=?'7Q"##'SBCW)M.:]NMC
M<HU?N2LFS"YO<U/B8H'.RZZY<,-/',(X7ZM)1/:0;M#E8[)S55%TO:J+]],.
M(8HQ#8U[WD(Y&L8P;5<][G+P:UK4XKAI!N1['M1['M7-KV.3-KFJG!6N1<;+
M(@BG5NV*A>4'0I7_`*H+@SF/&S/^M4P]T?;]L<R9:!.=7@:_BF>95G/1F2?>
MPY9>VK2*Y%[5HSUTI'-RZZN26+3Q[&*XS)@]NP7UMU:RK"?`CSB%EU*U_1-M
MB":PAPNG7`99B,R/S%Z,NCLY7.X(\BME3MO7LIDZD:!XY!*>5+=$IV''S7RZ
M\SF&8='JUW,0:IEQS39L%I8M;'L[JSHMQ[AM*H?+C#BU3IHMSP0!LRPXU(AF
M*W]:>QZJJ9Y=FN?T"OK3R)6W@V-%+KYBRJ^KF_NV^1>->KQGRL9=R>"!",0+
M"1574YZ.;BZAU-E32XE>:X4+.A,Z66WIBI'A;.'%2<2:Y=Q&:\391&".LD;D
MCB(S2[%T"1M.;"=7\_O>8EB)T68V/8#KRR;*1T1B44`#I`RF,_FH(.MR^XXT
M9`TZKM2SH',E1XZ=-F`W,MK6-$^+8A31/KSUMDQ@$8+XZ4]&JK&YO1'4M2`<
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MQX(K/_L(OZ+'ZM#BQN80:/Z,`0-?')-7*:W5EGCW#?\`"F/<-_PICW#?\*83
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M,JP0-1:6M\)7R:Y3"I"@+QT.1)9V=N`16*CL7D+]Y*>5'KXYQ7K(UJT18(7*
M0!DD$C'')BNU,<W-JM<COOXIMEU!X[!3-N=_:>9#6,M$6$VS'5I$#,0^HED2
M277HTJJMS>YV`2(+XMB,.X9\I\JMD%L9$.XKZJ1;6DR9,62Z3^J48G.<-7N5
M\?(;&.:K68J:LB2:ZRN)DB$"!.Z$,XGCK8ENÀ>3,,-XI\"QCN$HE(NH[6/1
MK]34M-H1Z"\?^ZE'%O+:1!KZ^)3U%"1I$Z6#I<^">9&B!"[4V&$WN5:U%<BM
MQTLÛKVXEP=M3+;OG6=YBCA40WM).?R)]Y"/&5[V-3/DHIU32U7:51`7=U4W
M,,#A2),X'+@'/51H@U+()+='GDB'*C.+`1B'DFX\H;]+]-'*!`LX,;<AY4:F
M-,6K,R6>)7OM""7O59V71WK#`9?C-&2@<U<E5B.-_)(7UX=C>WB39/O]T]4(
M"'"P\GF='"\C&E/R6H\W)&JH\O*:N;LL\DQN@L8PI`^\%\SF`(PK-8J^6,C-
M;%<W4-[514["IBA\2U?S$'LMU^(=G_.=UXKO&(OD)'4HO%FX/E:/[D3Z2[W^
MNE_C:/BC=WOMN?<&?YH_?>R'_>=[QW4V1]&:CYH/'N&_@3&2,;^#ÀW\HE<Q
MPY52V5&L^])9$2U:Q)M.XVI&GBV'11N>'CJ4+5[&+6A#)GDJ[R2U"UI;HQ@A
ME0R=),RN8XFN*9Q`ZCM9Q73QQ!GS71Z[H-A,O8-I6SAU#QVLJ(Z')N&RX[AL
M-.Z*JIS7:E3"#&)D3HXJPXJT5DX,>*Z*>`*)9"A\WXJ1*2ICQGE_ZPPH/!I<
M^8];"1(?7O&6_>CDC6*LE3ML,"\ÎE3=/<A3P^L7/VLL3C5821;4P92P9DB7
M.,.#/-*!81YPQADQRL+#L(HRC5CV.:K>"XK(TPI[.ZA1U.0Y[`C)4M'O@,F'
M=&:37T66D!@"]@HE<QZNUNS#TVV',U[CDS21IK3%@%K9^WEV>R@`DJ826C64
M>EHLRN1"]9NCM,%D!USY5D2'R[4UN^;8-+1%=R>]<[FN+#)'`%L8O(5JOCQV
M#)FC,,N+V_L6VA:.OVU;2)6XDK1[BJX:G*V)=0QNCQI3)O-+S41K=;7.[&)_
M,LW7I+&ELMORI++,1"+23K.5.6&SH2M&-L)TKDB>B:VC8U%55XX25:VE]DÒ
M-@1X5DL(%<YT444RQD"//6;DZ];LR#>KM"MU+C;21K6WD0-LRI<V&"UFGM)*
M%+1FV]%BBE2'?$5L:!,,O+1NIQ="ZD1'(XW\DA?7AV-[>)-D^_W3U8!P=Z!5
M(H+0'E..>+?`F--*>*1',*LE$+%A*5A&@%)@H=ÎAW$&J(W>L0EH.OD2ZHYD
M6E&$P1!J]M1JM^26<%PN9=I7*>3\2CF$.Y&O<J<Q:'Q-5_,0>RO=PMW7)K:F
MUKP110(3V6$EIHLV28#B]_(,Z*("`DO5K`H-!*16)FB:G;/6+O2T-&)N-(TV
M+)Z'6](0M?,(!K9%!7UTEG;QU17*YVC5JTNRTJF?7R3LY_\Ì[.(&YH5X.!`
MB.K\P-(?I34C/:Z1R1.`:$Y2Z$X/S:[\9,6<>-NB?S6C9)RDBKHXE9$(V21J
MEKJT,MKE8-<LG(F?7X8JH5A+2;)T%E..CRDS9-,^4)JO.B$51C*B+_5]P)])
M=[_72_QM'Q1N[WVW/N$5W'XR6"(F7]N65@AN7_E8O7PGQK^M[0_@8_*O_`/X
M&/RK_P``_@89D5?=(G'A[M4:GN$3#47KHU$_`F!_WG>\=U-D\53_`/6:CBG_
M`,F/V\TPYJ%=FOMHU$Z__*W5C2XKL\U7ADJ<?[[57$254+32)<:HO:ED;<#<
MX(37/>UX;L:=[;<))U8^MTL8Z/D]AW]NWK.N]NRRT+)AK<ES27$,TY"@E3IG
M2+!Q`K!$ZO<@7/$Q0D+K8]47),;/GUQJV1^Z%W8V46LN`"BP'5,NL6"/;`N]
M=<YC*MID:]7F#(+VO'5V*P)K6OL&U,^CMPV4ILQMB>56CVW$="*-.:B0HHJ,
MDB.JE(BR)*HHVY<Q0[FEQMM"-#NI,JOL8<V9KB5)[/IDB._;KJ$,*PL;.,Q&
M$D29ABQRO4@'(C&#QN.P+O*=9QI8YLI*P4JTE2E8R>R8&NJ%2.IZA\B!S8W-
MC(I!*]KF-<K$QMS>5E?A@WT.B[Q'Z4:3.GI3&LJZRZ'./R1]/+&D".9-;F*5
MRC&;XO6W`PWKK=T=^ZKF."9*D3)\N'#G;'D;>'=CB3DB2HL9-S%?*&).TCM<
MCANT9.P*V2XJJ\M5,KYU%3UJ&6G0ZU\"COUM'%@#DN2SK*MIF=&2.J2))FD4
MC>W=8[GF@HH+-SU.S@7%7)UV9JNPV[8I;2I45_1W0YYI*`'!X<A.1J?FON'?
MP[KX\&.,>V]I6,"[GU\=L6!)EEC4\0.E48%TDAI,(A,G-U(G;+Q7JF_DD+Z\
M.QO;Q)LGW^Z?8;H^CMW_`*;)Q0^):OYB#V>T?I?!_P!-M^K:>+IWS8N*OQ=!
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MK]''$GS)YY<!8[K`SF."YCFO?JZ^-[>)-D^_W3U84C:CB+8MOZ5I8PH3)BS8
M)IK`R8Q-:IT2,NM'%+^*-J\6YZDWJ6=$FVIF5TL<3OLC*66]A]O`??HNN$#.
M/47198@?$IS!!;D]Z9$=0^)JOYB#V>T?I?!_TVWZMIXNG?-BXJ_%T'YL+V9S
MM"60H0D*D<"-<<ZC8KT"%KWC8I299-S<U,^SBQBO_AA/AK#N[^2LN=9)3PBN
ML[V?/+$C]\(CI!Y,&5(*(FEJL;R^*ZN&*6LF?P[(ZN2%80ZH,63K1XIX:\L^
MU)N!6)7/!#)%9S&:&J-JY<7JQ%]"X_K3$\WXW177G\/!`JJ][DKR.DNJVB5)
M"C$(=G)9(C7:2`=MK"QJ-T_?RQMBMI/X=BD5,]4Z>1LEUHTSE/H,,EK';'C4
MB1@9.U&8Y':NSEECT+C^M,3S?CT+C^M,3S?B\J;3^&X8E)$B*2"7ODT#%<DM
MX@%;<N::'/68#BHF#:X>G-<L\>A<?UIA^;\4?>?9>G7<`(9\="[J5[XSF%CQ
MB!KDA/KQ'?GJ._-J99<,!>6C&,KA#<5G?0/:$<Q%>S\BON7<,>!A^5`_L^/`
MP_*@?V?"=*A#AMY@D:[I3).LCB-0;.U8/2KGY(G]I5RPU7@1CU3MF\U%R_\`
M#V4P)$'P_P`?7S1>*9?B]2+_`"^L/K'6?T"A^@>[?K!LO&]O$FR??[I]ANCZ
M.W?^FR<4/B6K^8@]GM'Z7P?]-M^K:>+IWS8N*OQ=!^;"^X[,\2[S]_MC[H#Q
MM2_ZK$Z@?[SODW=2+_+ZP^L=9_0*'Z![M^L&R\;V\2;)]_NGJR9LEW+C0XYI
M4AÊS]`(XW%*[2Q%<[2QB\$XXWA,;S:Q(U+8`,.T=&`YO?&A2PJWH0<@T9R6
M,">$C$UZTYFER->BM2C8Z_I6N;3UC7-6U@HK7)"`BHJ<_@J+CT@H_*T#]/CT
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M26&`%9;:D\9)4P:NBQ5.*K,K=;TST_\`,W/T@H_*T#]/CT@I/*L#]/CT@H_*
MT#]/CT@H_*T#]/CT@H_*T#]/CT@H_*T#]/CT@I/*L#]/CT@H_*T#]/CT@H_*
MT#]/CT@H_*T#]/CT@H_*T#]/B!D8EV8]K!=T7;ZQK.0(,"4&9*.=K)#6B&P8
MLDS74][D1J+@,H.X:;E'&TK.991!$1KTSTD$4K2"(WK.:Y$"XZ3'G194:
M/S''D1)`9(1:1*K]9Ò>C7,:N:I[6$<FX:-45,T7OM`ZR_\Ò\`?7SH<YH]@
M3VD=#E`DH-R[BK5:CU"]Â7)ULÔ_0*'Z![M^L&R\;V\2;)]_NGJFC2!M,"0
M(@#B>F;"A*Q1D&].RU['9+BSHC0FR:JQ:]UCWT*LUSQLC,B@U2)>M1LK8(!B
MC_\`L!B;E[G`#4E#M6P@A_4V'935I5U1/B5:5Q(G-4G:YYN]TBZN**BX]$]L
M^0:K]EPY6[1VRYR(JM;WCJDU+EP;GT3AFN/XF?O9L3;;J0MIT>TC(';<H6UK
MAD44RJCPQ,Y;312U)D&9\<3M9=#E1.W7ÈMJW9\270FBSG1^]]8,@5N`6%5#
M=,BACJXH9+'F5K7HK44?,_$U(U[-J[7>Q[4<Q[:.I<US7)FUS7)%R<UR8]$]
ML^0:K]EP,<_9>V3L$Y7,3O-!'DJIDOY$(U<B^TO#$B?8;;VI#A1!J4YS4=4T
M8V-_^DS<Y5X-:F;G+P3CCO115>TI[P"6Q47>VOER$#8R#2M:D+&5SD:4RIHS
MS"FEJHWAA6.VIMU$7+B*G@`?P7/@0(!D;_L7",;M3;JHF?$M/`._BN?$A@$(
M[_:N/1/;/D&J_9<0XUU6;1@RX#EO``6MKX[E;%"86HS!1OCAN8=VD+LU*J=J
MU5;PCSX.VMJRH<H331Y`J.J<,@W=94_5."^VB\47@N/1/;/D&J_9<>B>V?(-
M5^RX]$]L^0:K]EP4$"OV;)F[@G3)31-@U<II956P%),%%_5WBCM"^LT<MJHC
MBM(Y$5=:X]$]L^0:K]EP.X=LK;*V(6<L<CO/"[5FAX\N2@NCKVA%3-6YX]$]
ML^0:K]EQ%V_>4VUX1K]"MA`;50HTJ2V(2.X[Q&CQ$>`87E'K>JM:FI,UXXZ;
M44.TI\7FEÌ@4E6J(4+E81CD6(CFKFG#^TU45."HN/1/;/D&J_9<>B>V?(-5
M^RX55VIMA$3BJK152(B)UU5>B];"DAUVTRS=S2G""-]9">.2>G"D)[80BQ.2
M!F0\LVY,._W.I<>B>V?(-5^RX]$]L^0:K]EQZ)[9\@U7[+B$&YH]IP.^\IE;
M!YU%7-21+DO''%'81L)6L(4IVM;J5,W.1.OC]W*ZDVU-_=KH<$P&0XSID=\.
M.@`+)DM&R1*(C.#GJYV9,]7;9X5SMJ;:<YRJKG+15:JJKUU55BYJJX45;5U]
M>)S^:X4"''AC<3)&\QPXXQL<_2U$SZ^28<]Û=MN>Y5<YSJ*K5SG*N:N<JQ<
MU55Q)G1#[?IK<À[=ELA-#!9E+DAE-$8$80PF<,XTU%XH#BUSF\<9IQ1>LOW
M>A^@>[?K!LO&]O$FR??[I]A/K)"O2/8PI4$ZC5$(@98'QR*-7-<U'HPG#-%X
MXF#D3TL9EA*!)E21Q.@A5(5574<%@HO2);F<NLJ0H15([674Y-**C&]2_LZV
M,X$S<]@*SN2*<Y4DS0Q!0AD:,I'L`B1PM32Q&M[/7P6^CV;:V>^MBUJ+WN9*
M&K&1]QUTPTA$DQ22"GJMRE&+MDY!&,?V[<QK`K(ZO6/70HL`"E5%(H8@&1Q*
M16M:U7JP:9Y(G'JS*RMM.\LR3T?E6?1>F.C<J2$Q%&)LF$5A2"&K6%&81@.<
MA!N1[47`YK[9D[DI<G$`%<^$WOEN0U<:]EE*:QL3'9*)5!<QKEYC2*1SR$5_
M:]6!)[])7BK9E=;Q1-JHYC-NJ62DNK*2:TT<QJIQVITJ,_-Q6M1!%!Q505:2
M%E/:>PFR9*C0*'G6UC+MK`@PHXG(`Z=.)RV*YZL'DBN<J:EZDF+SY$7I,<T?
MI,1_*E1^<-P^?&+D[ER!:M3'9+DY,0D!N&7,KHEN*XZ$:LKHY.=7V%U/I@1C
M0&Q01XT<E_(60BA(Z0]45JA1-/L*QYY380H8;*-(-&B?]Y-%LA"$>##M5D:(
M4"6@LI0G`,DAJ(G:99XF#+/[XRITB*4\AD7H0N77U5?1UXQQND2G-<RLJPH1
MRD7F%U.1&(J,;U#`?FC#B(%RMX.TD8K':<T5,\EQ$4-^]\`+]NM-6,KN5'Z)
ML^>MIMT=?JGF[WR7SUYMB3(K9CE70R/["D>LEP&4]V&X>+E\QDWD0I\9D4J*
M]J-:A9C2H[)V3Q)PSXI/LTL'RT,&3"KP+&:#H<"9=3]PR!R2\TO3I"VED721
M&A1`Z6Z55%>O5L[-+]P%LA7\![.]C2/?4[K1[;T4LW36=*LAA?R:^0C1LB!1
M$(*0O;*,+<](AL&W/KZ6-1J9];CDGW>A^@>[?K!LO&]O$FR??[I_H4VUARH,
M$P9=+'Z=9#YT&$&QO*ZMDS)(^DPT<.+&EN?Q*Q.UXKEB%5V2Q;5UC8W%?37M
M0K!0]P+60>^+)%?!Y\OFQR"$<;B!.=@R"1'9:^%ND&FE0#5E+.L5[Y'CZVGC
MPXT@3'PH[WR&QG$.X2D?RT4T<K&ZE8[*NW'NVI<I+4L)(#F`'1L*"16,L#EF
M#E3Y\>N:A6E!#U'5\Y_):U&D,C<5E7ÌG$@R[IM/-L)$X`7U[GU,Z>WI49J%
M2)-Z5%:%(AGLD/YK5TIFU%6YNYE9-0HHKYU!61W1K+9TN3(0:UVX9LF8^#'2
M.S4CGRÂ$YC$3E]LNFSFR84,\.LW`2(X$>.0<H]8'_\`H!',&\DM0MFD'M:.
MB.7M$5S^'%,N0^#/8P\R!7L&X<471)I$EÈQ4DOEHVRE=\8^@0F(TIV-<\37
MHU<;.F1Z=5K-S6YZZ1(#+BSY5>\-I318L$D4)&-6WG@GFUP]?2XRA?\`%OY;
MTQ1P>\]B)MU-/"Z6A8LB-%)TBFBPFN>%Z\XQ9-Z$4D;.VA%:1A>V8O\`3J'Z
M![M^L&R\;V\2;)]_NGÂ*PC6O8[W3'M1S5_K:N:+AK$$-K6(Y!Z&HSE(]%1W
M*5F2B547\7+`H4"**-&"-!,&Q,U5B*]WQI'ZBG>YY'.<YZN<Y[E<JJJKC0YC
M',[7M'-16]HJ*SM53+M53A[6%R&Q-3^:[)C>).'QB\.+^'7Z^")R`Y&7,R<M
MGQR^V7A\8O\`7C\D/CU^T;]_[W_,OX<3;`,,+)EBZ&Z8;)54SX#'BAOTN51C
M<!A'9*U$7CA$Y0LD)S43EMX%5552IP_*9KUÔA,A#3)7.3)C4R<YVMSDX<'.
M?Q7[_P#3J'Z![M^L&R\6MYMZ?MYH+>NIH9XUS`LCE$2G?:*T@2P9\9BC,VRZ
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MXQW;L3R7N#SQC]XK2PVRZ5#VS=4E6"!7VHP=+M)M1.')L%D6)B/C`)4-16#T
MN<CU[;'_V@`(`0$#`3\A"9:3S`3:U!X'R9RY<N7+ERY<N7+ERY<N7+ERY<N7
M+ERY<N7+ERY<N7+ES\&Y<N7+ERY<N7+ERY<N7+ERY=NG/2JU-I]9#X>X3`.J
MIE#YB:%6C+`273(X_=*1R5O`6:CMBI'9LC8<"=OY%EW<3$\M-8)MUD.<,8J-
M;C3B+#9@(JOV$'V8$%KE-_@`7*A<E!$6/:5C>8L8@WG5@%6]FN;#I2L`!\SC
M<":=BT_,-]R,Y.5`Y\E=L#G35A,7P'F]@%BP=G/J+CKKS??Q2P`!X!>=)LXI
M<&>`0Q-!FM`'BD(HOJ"=WG&U-4\YJ<VFB<FG%#X@H&406MIMJ-6'@BT#G-'*
MA<@($JED`Y<EA`QQY"0/0?\`RV^YON/?X[&UZ_:"6)'?AU-2>2%-N8`!ÀAL
M`Q#K[0@0($3`ZS@J4J@5:#@;QLRA*?0U(JN!Y"@P@,R[`#SC]102//E`!7'B
MZT=0-<\7'B_`XH>7,S_.X@R(@^0(<]\W]92:</36/\[G^=PNYH6!H4UQV/`R
MC)*9Q&-EV<4+`/J5?"/"S7;S?OQ`@0($"!`@0($"!`@0V4@(9"<->R?";[E<
MIWH=HH4C-\4.24S$=4<;@C<TKE<KE<KB'H\.U7:)M20F[#%ZOWT>8/M@:D`"
MKH(;=N-:#-BG2B39@_E)"L\A3TPS\R%55KU=9U\!`!BV)1Z3J842&.[8(+5X
M/$NR(#Q/33:.7.P3B/::,^5+MQ8;7*X.90-(:*=`J131K@<H(>E(-BRBQ9RR
MI<)E.#3'.=IJIPL/AZ+C9+A8KPN)2(\&)^@QV+(%D*3PF23K#:F:&+D`;<K@
MLSGP!4(`-N"?=#V;5B(,3*Y7X5EON!#7EI0U$1+4``>F$)W!PRA*#W/;>]0^
M)32#A2M(5XASD5!CYC969QD-!CYC9&>UHIZ+=$_8S`1("CP`57T,##U$[%W'
M[9M!/RDNZJ]]>%J5W5AJ_?!-`]*PN5)B&5KJD_7B4,T-<&N_^(RXA,*7EZ5U
MQ+/.!:4&!V]>]9QWLA.(`+:"3T&8Z!DTM@]1#.]?,!'X1M-MVYH+&A;D%D6^
MZC1FQT#X0BRY^4659A:I/O\`#KJ:04^'I;[CMX,MCLR`8T&`PU(PI4,51*.N(C<UZ#274J1Y#`;)U))J
M_A+M.>"2WR0=J-)C1"2*C"26<R5<*DWQ(9J4=,(5"0FX$*JQ5;GLUN#$'E)"
M,.]DD-<NVX2$#`QD)D,1^!!<2KWUCG"FN7YR,WFA!#"W2(P)*)3#C1S`1K//
M1T7K"%C$K@J[;<^84'G%9&1WBA!0_(JEON*^V][])[^X"!!>#F'MI]]2BKX@
M+4D0GDQ7<:PAK](Z3.`>R`V85&RLM3'DT3SM0$1I@2FWNH[<-U8TP_@7H[,4
M_J]%GU_#^>\*R$VWDKA,M%Ê)G&Q4U[]!;-6EX?(,0[;9<\:%E7Q"R((73RW
M0_`6+%BQ8L6+%BQ8L6+%A]4AO"%`(=7V+@OD4'98DY<@YHQ/B4V%)!8<M'(X
M=EFBS5GN=[T@O-_>]:-*%X6.`'J;7#HS,"P8Y7R1A]$4C:B7/HG_`%EC]]3B
MB5(*P0&;7*-<"!WP$M^.?/O0^DC.[`@`YV;D@[(9B-VQ<1%P/LS`*`]3`+4=
MRL0R-"@L^&;OKF`L?/7//$')^3*#2Q;)AR,*GB3D&WIM&'7/7D%;NYX)7?E^
M\SUY!EO(9"S,HCY&(+$5BL;T4T^WNA?VYJC]7%J!3@/MXB#K..3MTDK(8`P"
MHT<^('JT,'GR]T*@5;S=3'1DDZ613Q+P8L<BQ3\VV*/J<GF>R\9K`:@*>"N*
M8KAF0YX(/JNP1RF.UL[ZS_;=NW;MV[<#ROL`!SY(6$^-N*^V][D84,4?'WU<
ME.\9IE_<Z7)8R:N3*@.D1B$`,87]G;U?B!`)LECAPC?UTP<0>0L85-D00*H!
MN,'$#F',Z2*"$!GK>"7C!Q1;&X6\*UVÙ8%=LJ9`P<SHCO?%-X-XX&GZ5'^8
M"X;K>8[>?'%(YD$@)M,_38]2U%-U[@J557VT$KASH!$88;'0H.>LWPZQZ%``
ME7`0-,.C1[#U/>[WN2J@%@53L93'E:Y<BCC$_2_K)Ê_6:1KA3?]H%C]#-E-
M^>(V#5`-N%<8'[R8_P!9.ABB<WTU':&M!$>!XJ4P`T/,@>D@N4DQB"HO8A"&
MJXCU(UP56'TTKA?`J&"<(:B)6I1#!1A72A`PJ-RBAT2G6#!3;V=`[*#HO$J5
MT++EAW/-KBB!B&^F]B@I`Q-^/$3PXF.)?@Q8'YLAQ-O<XFXX50Z"U5X)B![K
MC[LN:.<`T8P-M?//*!"FWOK7)IJ=DP"E7/Y,1'?\*J2E@3Q%6]UAQ'NYH[RE
M\YE1NL8NBB+6J'/+D,;S\\TD/ZYNUCT0#\N.IDP*8B>VP@KT%7L:"A50<!T9
MBP'UEM3C&^W)7%U"4KZ0J,#$;P9Y8?ME%RFJEV^_[;WN0"`&V!"K7\OLA%C\
MI4A=K%8K,(*H8>H&=10O@34*%@J"!>8*X!UEW:8#5PFSWL7DWX:],BO7"?C`
MW+;2J4(G:\FC`'AC!\3P7GB))4@.Q3Z.G1`*DÎZ:\R^F)/_`,\5'J#>UL2E
M$_D2JN#6)-=0!`/_`$'T&"W6;-7.W-=^J9,PR5OY)DWWMX+%H*'5V<5LV9$L
M7.F832RC*;,C"AV_=&U!P!63;,\QU:1`M]L2N)%.A`*8A'U(01T@KBZT$;?!
M3VNV][D89.!2\7'KX6&*QH8G?*NG8R%!AM!O9KP'UG(P@$%3KIP$H-H@T;/V
MOB%3_6K&CQ1Y\)Y@CJAH5;>@>X;KF74^0UOMZ#G%%_17-7B5`=<#.UVD-=S<
MV#G&H!YHB3M-6L@285BP^5"*[N"G@:8N;(&UO;!`+]A^,U'_`#1N0:;XYQ(Z
ME8Z%UJ;,C,+4K/.@D"YZ7=G60ZH+"K7(UAK=FD)S^FOO&0R9%4=7!8+J:(T&
M+M+>!M<*2T"/9)7`%`45"5(4U0CYX30MMJS'>>K1!9;8.MPN>,KQ)455=7:K
M1?/X'>]R273L`]P'&W/I;^L(!M^5E&22B@H#B!H^#BSVF482W/I;^L=%$JNR
MB00$>K&71T&A;'6^,ÊOZSZ6_K'ZIG8<-`#LM>,ÊOZPTX&R)*!0XC@`"!`.
M@>X;B4(D*7(`;)T`YRMX78==2IO.#`KEÈIUES8P3`&,+3P%%P;X":68>-*C
M)(4F<]@%O&W%`9)4;"4'YN&_SC>W@'R@LO+7=%=B103C(LXI\!0++FK:F;YA
M!EPDH-LW8L(<[AZXM<R!M\0->0O`H^RR/WQ@E<4=R%N+F<FD!O'<G@E0Z2_,
MHOBE?;>]R0'TGC[-1>/U-?<-W$);I!K2=OFN+G.%;-%TC>ZD:C.(#)ODGZF^
M$<DT5*PUBIK8(HXQ^TG;75</*1;D,L1.I%L10[%T60#<KF0!*YBXZ@?1$/*U
M;9E?9K&K[XW`M,WJ:J--':18'%KB6713!$SB6V)FW8=SZ1N83QI5<L\&MPF0
M**ZSR'!@#:;V02N7$*GX6]I1#!9-W3$2``$B"X)0BW>!.^C?5/!R!*]C_FS'
MPQR)KNV:*D+\-O>Y(#[304M<+-N9PIEWCLP@>58&I3K@`$,1D`[SLG3)@.BH
M5>HZM8G!?`L0D@P)!Y8#RN+@=CT2P0B>),GNYT")$*"3<8SA$"CIL$&KQ:#%
M#>)V4O)$FZ3E7X_0V@OP&>IV(:T),AO6CB>$>L,M+-R0:9L$"H(492W2`P!M
M,&J%[)17/,-A`)9`*B[#0NM8^486)@REK2Z=#Q$841U@X*+_`*47!K<##&W=
M:K=1(9>_`=0TYBP2,V3W9GB=BE!YJID2[[:F#?Q$>RDK@/5PJ[W>M`K3)Q.E
M1;^KN:=OCE?;>]R0'U/'ZFON&[I6[3T!\%4VYM,2F@J"UAA19H`-9\$8NDN'
MC7E)'(Z-=<^!8G:8ZQ\@*SO4XRT#3-TZ5KE+B8<65]SP@L1D)PY2E$UD3-(.
MC%5I58I(&.Â%':24^=-L4LIP<_)J6KE@?&)S"UJ\050/`9G*W2OV8E,*QL&
M*(Z`0`2>V2N7*#H[VF/]@0P.2=FCI,128_H0*,.C1Z@]3XK>]R0'R7#W1](A
M;..F?1?_`'&,[NNYX:5;]LZ2:#M2^VWJW%;B@SIU,3(04.!TB<Q,!>R"*/P(
M#RPH#T/=O0G0I(2+.I4G-KCI:`0R\705([;!U6J0@.193BXK80;MBUS4$HDM
MRQOJ@1)_C\L"RE-ISVA[D#F\7AWM.(RAE-[&.!Y<36%G4H`LPWCT%_.\KV#E
M*LNF/%5@"C"(!)BZRQR!W#T8U'G+-E,.@;8'V"5Q9J6@57.[:@=0ZYWH\J?)
M(IRBN_B^V][D@/N+TUNE&QQ1U\"-`>X>3W#<&D7H4,X%-T:L1(&!3#)-#Y@V
M8/\`L`4:B=M4[ERI^38FQ_\`7G%CM?9\"5&&)#8G/VBH,(E>U+`@2/=L3'2>
M.*UNI_<+9K9M%^.`V&8T&NA=FXV+XHÈ#KRS'^P\"%$GF7[?`D#EHU%O-(,K
MDB&:BIY!B-,W,.AB%@$$'\K2RP#)4>>V4H1\BK9P^)Z)O8<7)/5#(6]=T@'Q
M;UT58.U:JXC?BYTWO<D!]T/B8FUMAXCD\#JH^H$$RTEG@IGFM7"0R&>0_)GD
M/R9"J9[>8\;AA(6&/S`-@/UR"=(8UXZ.1J-BF@PM-ZC.U"2)I,)&>/0D%A;T
M1@P$IH2%2*\K)@BFDC1;/--'&F/?P3R`L<@[X-R>58AK3/?"RJAU^,B96,(Y
MXT$`H[>F+EB`Y^KJ>'X9JF[P7DAP2,`QTCP!ZKL>8GODP60TN%(4QX9GJ;"N
M3%'^PB=CJT`Q:$(?`2<$=%E70IZT@PP-%OMB5P1FO=Y69O;&("(@R9P0L`"N
M!25%575VJT5ZK\5O>Y(#YN=)Q30<JC5\%1;G6H+!J`<O%R&C7]/&?6O]9]:_
MUAABV=;)5K?%8PDT3U`%<HCS-!.N[IH=3!`.Q.)T['&:LZ.OBL)!6QT%X.<\
MXD$$\D>$S;YR6CN"($8$B,ELB9Y7C$:PR/'<URFIG>(D._*[K1L@L.-`Y8-1
M.818$@!P@[,]JDEX)&4DG):/S%C>PN)S%"$F4V03\.+#`L3IMQI/"W^.J0`@
M&@U;FZ_9LE<'(LW832@#$;.#ZX$;XJWVA!//9M<25SL7&ZX/&AJK#//PWEPF
M4U<.SW7;>]'V;^7P=`??0>WW#`@$$;B4?+<7$8I'_+"$`[E?NHKEQNZ'[JN`
MC&:861=]%3C921R=)*YIG"KFVNB/(9L<.!U9*KNN?;%R*R(=I0)!RY)WÈ#&
M66$G4'7-_5MP>?H=$W=U343T0!?$ZZ*=!MM9RY^]D:!8'2-5A7IE6CEEJ!(*
MY%48G7B0-(L*FM&X8_7BSV0@25Q[<V1I=+!H0\T\]U[4$I`<+/9`G3+#H;KK
MVB;LC7R-*6(.SB[P$+\E-$9786!P4VVF]@=NKSC>8V;Z:802@H8K,1`[AXZX
MDYL2E1/W/`6M#IKX&`^:Q)1HFX(V;U3C!`V`>D3K7BV;<<=FO,AOQ=W&954]
MT!=[VGBP0(EU@IV8PDGI.(!VF..F!Ê!WG?%6$.A1Y-UC@>'74CLU4.F+F$K
MV1"$Â!XQ:F`#GW9WE^ZCFQ0GJ^"("UXR_N0\'B/506,'%:EU=O3;TEBPS"R
MQUBIN44^6GJÎ8[4)%ZP1FMK]@L1*N@9A"D5CC;GH1/Y:`KBOMV-&H#XUX8(
M+IKJXU^XKJ!^`9,F3)DR9,F3)DR9,F0BMYO29`DX$(GC<?E;E#(02,09K-"U
M2NOA*EP1K%&AIK9*<DZ7X+L:-,0I7$BOS,,H-X=N8ZB:\0"`+<O&1R(>82VM
M6<_]7'=BT)<8&O<1DXT!3P-TVA8=-GB5*E!&D`R>Y@GFASSL=%%1<K-%MS=_
MF)"4CO>3QSXT*"Q1G),6_>1H-Y>^#8U9N.Y.EF1+M'AI7'!-Y]_E=+?<5]NQ
MHU_'+KNM7[OR5)W7TM]Q#X&H!=G4@J0+F@@ZV0J*_79U&-7BIG6!$\2)%À`
MJ3!Q>J7+U-.WI%F^G;XD2)YSS3,)D"1O*#/*?))/4ZL3TB]DN=GXY.A8!,O9
MG-S#,G0L`FWLSNY@O@1'L6%9J.[V^R1(D2*<HTI=Q4IUE/`B1[H*GQJ8V)+X
M`B.@KV&?Q[,B1(D9@L7AU,TSKC[)$B1(JY[9#VT@Z@BQ52.F$UOH04!$S?I!
M2PA*)FS?#)FYP%'=['!4_*9S<!1&C./A-]RP2XV5NG@=1PV'@IML4@$@LAP`
MMI)P/P0H*0*3..D#F>IMCC7IDC_AN@>']"LAQJO!&%(NL$G`VX,SC:8T32>'
M%(.%Y[*(C=-.,T=(B+'"DB405!FY=LHZWT%'!)S>-<&P'/HW"FG3FL:Y-HN?
M3JD-&CPXOK1E21)S51Y04*00M7"#H`9`1/8X\>/.2.*,"1&5)\#BB]LH)KBN
M^.W-"9Q>`\OFW`B*+`^#"&]`\I0%"8\./$,Y(&"H2`Q7'R&E(H[;"E]CCQX[
MC6VD>1_N<-!BD.*3BK0A^52!_P`!)ZK"#M<KMZ$JF4U(P'!B`=F(E(NJNUQ:
M3E^,N57.DKP0"`!!HCL1-(GPF^XY+"WJDL4`Y#E/&1$!G]"5[QXKU(^JV&ZA
M**7'7>ZVO'CYI)8*JM6>H2T@>`>/%-R919W&0AD::*M*<\+(/3V/)2C[@@<*
MZ-RWM;B!KIB[VSQ%.0$5-4%TH$8Y*2=2]C._VD+KIB6*J)'%3:5C['.W:`FD
M?%QA:F!`'1`'31WE-]F)(`KULA[?8(:!@MG#<U9-&"K5R!1O,D3/L4:I:/Z/
M$O#8T<+BG-BZF`/(T?(M]SL?"+:[R<T(!QUSW7%D:%L81,6S(=W):QSXQR$V
MI\O<KF=J+AV%Z;!78T<IMXADO98>*3"8#)QB#=,2M9C*`,:N7W46/%'\S_6-
M:$7-2A5($/.!R&!3D+YCON`9R`/S"BO?-'1Y6`XY-I8X/.*&U(_UM,DSG0/T
M)!G=-@F=GD@\M]#WZ,T]H6^P:^9>+B*BHUKUIR?W.^:GI'(XD\E4M<"`)1!!
M`$C5[R[P<%FXWQ-0MR[<_'[]]3?5S%B=<+=?)>7+ERY<N7+ERY<N7+ERY<N7
M+ERY<N7+ERY<N7+ERY<N7P?+ERY<N7+ERY<N7+ERY<N7*B%3WI0Y!.@0S__:
M``@!`@,!/R'_`-S&0`]`6LT8]VK#;K``]!R[&(['9YFG[8=L("@V[KK7KBIS
MM'.`-]T<_P!;&CA=!VY4,+E.SM?7IG^MG^MFJ+7OUF?X.(SH'3N7%ZR7/G\L
M9]RR`,=,)Y'$KG;:=1)[ZC?)T=N"S#*K`@55==57OE:37\%L;..>Z&=U,F(W
M/,'1S>@_JMZDFAJSPGU,I2(\H-APF!BH%6QL0TT;UXJ!H\DGJ37R=/!5Y^6I
M?7>WB0MEB0T6P7SPEU>LYX82Z'6\\O:$`_\``/WB@K@PU0!VP^S/,>!.!/3Y
M5]=[>)#L2`.X>B'24>(B2#EBY3#D)BTH:P85#.SZJ'FOXX\(!?B(E#!8S(53
MQ0(!-%:-9]!16".@PN#2!0TN@';"\4P^[X!=CI+X5W9LGQ8=]<##/3S,\WZ7
MGG`HX(@3%+U1"E2BGRKZ[V\2$Y>I_>?S7ZS^*_7NQC1]5W^5/KO;Q(7NG1C3
MK_?M=,C\B7S.WWSZ8_YVSZM9MX'J2^<PDQ$=7BD&U$*-UUU-:UM<(5E[(T[7
MAZY73F`H$`$3DX\I$F,G!?<$H)X$VT!$SG]!$Z!$34,I9O9YDXD=Q,518C9<
M`(#2@"[/![&[)L<E/8M/6.AX'JP\(?->1O`(`DK&<-$E3:H52B//VS+9W(]8
M7X'/S%::=0_*'F94A]J[&U27^!@.$/4KTA?D/B?KO;W!"8_6?H\?X'PN#QWZ
M!V]_P"JD=-2%T&]ÒVSFX,*=:O+??K\5]=[>V0F/4&)%3@Z^65W_`"RN_P"6
M&\3"&SQ/ZNN^07((%&4FAR^6%*-3@VZ]T0LOWS7"MS['37/WUWO/H#^\$#%W
M.@IL'FWZ7-^>MD&Q;7#N8%`P///Y[O\`/A-(F:B:$@$#9V!#<N30II(&B(LI
M+6B@WBA6@$>@$8]D=SQFS1Û@-S:05:0VZ%R.CIGR`)]0\;OC1@S[(G\9O&;
MKZ+9ZQ=#$&[LKS*-WKE)AJ@5]"'X/B?KO;W!"85=OC_$_M\`:"&`MU\$2O7$
M::=OCT>O]/=`2\`:W:;T<)>-V;?9VX"B^%;4@9G'(6I]5]@4J%V<?$!*3YB'
MFÊ\3]=[>[(3!;=)_;X<`F..,%/KX-T:Q>0A^[^#`(K"OIX])UV^T/"=EYG5
MIF@KU['N"YR5^8?RPS7Y`M)?2OQAL;!XN=]=O7C&G%\Q_DI\3]=[>[(3`2]&
M>8P.U/)<M^&,>B!6]23_`+GF,'>T7RYC[_QCQMT&_/KGF,\QGX!_BYYC$%O5
MBJUY]P7].<;>[XKZ[V]Z0F./VW2Z9T>O]/#D^KW!<Y*>X/\`#3.(5Q"QLI9]
MMXYD7I_&4?YQ'&_(/X(?$_7>WO2$QQ^+I<:[DXBXA(ZZ=,V(]M4X&"Z<,<NV
M=L(\=.N3N_!P2INBDZ@^À!MI*HNZ3-Z080:E18%#&'>>N\#W#N(SSHH[^?-=C>XM
M:^%V!0X$6Y&+&W5`Q6C=%4XB\CIUR[V,2W@)[APRA:/MVMA2R9(>19*VH`TO
M3WN3%]"3ILKJ2\V6JT'ZYA[#2O3@'5A;E+@J]%$\6>*D2YV@Y!EVAQ=4=`:D
M,!)-2%>WQ)VK7,,]-&(I5!B?QL<7C1<+?M!<^9C^9C^9C^9C^9C^9C^9C^9C
M^9CN64R5W\I..A$EG"GP(6;5_M;>/F8_F8_F8_F8_F8_F8_F8_F8TTL=@[]@
M'%#@JQ?X@7/F8_F8_F8_F8_F8_F8_F8_F8_F8[%EH2_F2=([Q0MRG(CC/F8_
MF8_F8_F8_F8_F8_F8_F8],@^-GL@>^1)AQ?@(N4]YQ'D-9P'-2L"+>."]J'.
MV0>^9-9]W/+52R@H@RJZDUH<9.7([QI6#K,666[#G4:_)A^/AA-)<L6FÊJI
MSVMCAX3W`>?I%Z=3W"PS?4DZ)>D12YP#'Z;Y$1"KE*T'"T+P$)<M>X<(FAS'
M`9(($6#/=`;H>:N:BP`R^0M_H'[IF@G\-#\U:-!MD@Q4-5B((;YJEJVC&>4!
M37-=^55\V5*H9_\`.&:?B>!O`";.!E%0Z)Z09-2=JOW')':-*V0O6P#9V0U\
M5BVVX(,2"54VHQ2N_AE$2[)"9VN8ÛVCDI38H;F;T^=V*2@%W9""RI[^>,&,
MOA8C9[A*&@:OA'N$H0F+U1R-EMF>^Y.PC?"[:[*C.[HZ[5%D8\+?2]\-#\J[
M%9+NCTZ^$6>I)KWW^;(KE"?)_P!E]\=Y+W@<+PL`;,ZJDM&+/S2(<K'\!16Q
M6GU28]_*&(FDJP[G-"$,5@3G,TD%NZ+=[R*2\]LNX?IQ$0TF.R$OX!;`BC`J
M4LP6VÀ<.#>*?B-=^P3E2T"ZQ7$6])4=24K1O$$NJ!SGVY!(1@!6C49SZLM5
M<14%\TN@BZOA&P%DVQG;0X90]PG)FZREU9FP[UFB=>`.2H>[@TXRFT;5^J$K
MIAZ5OAH?CT"D/GI?.J:)CP3RWBSW3&:./)/[+[XM@$/*R`FR?4A([+;_`-8@
M9R;8^0D\+MA6L1&'E#=Z`5O5Y:B'LIP%FQI"(3:AY$?DM)6Y;DV%6ZP.B@#C
MOR;O>YF0%R'\\N&B+4N]4P:U[@@3K9`J`_'":$Z]WCZN)"]+,0*VCNV,04F6
MNI;A=BO>\L%HWPF"')>`B7-:(*$R3>/#/<*O&/UA*BD'1G*PR*+5(SAEY,[X
M8-D`8`=-#$*HAI'+'/-:$MGW0H@_Q+H=/*^(.WYY`T52ZSQ:+W>'UZ-VW3/)
MW]E]\:13TGW%R8$5Q@G/"B_V$-8WR7/?=LSY0!AY0PTFAE;G-$G!+M]]9X8#
MG=RE/(0!6@=<]5!$:>5W[]^_?OW[]T;7I5\T'K";7@X7`_[M;E.(C''CNDJ7
M@)X*I.N]S^5#?"`(4NLAKA5?/`W7#+AQ?VX_FLDZL`==\,4(ID0=G&U8"Y(I
M]Y8S.3ZXUC3.[U;M=+W$]WROC%YJ@/>;R*.>Z@]SS,@M[H?DF_LOOCGHVY-6
MC)K9.3#!.,JF.5\\ZSOZ^++5;TV`T<>4-&G_`(LJ>W%U.:MW%YH8[BCEZH(G
M,X'9H,PK!J!S<`+K:AH'Y\\]"A@<#-;<4Q4IJS`#5*H;1Q,A\3)^Z)1;VP4_
M`&%"I.X'O_ZC#2@A58"T^^>3PQ8U-?*I\`R#!)E*<WOCW'?;GX_'\?C^/Q_'
MX_C\?Q^/X_%V&-?;W_\`?=%WGQ#I+$HH[@8F;!^[R0QGXS._'X_C\?Q^/X_'
M\?C^/Q_'X_C\4*G_`#A^"9[:L:E.G#*<CJFNBDFZ_(ÛV,2X!R?12:<)&"B<
MY0.4A[`*Y^/Q_'X_C\?Q^/X_'\?BYC''M[W^^Z2/YT3VSHMX>2$4[IV89\N&
MY?C\?Q^/X_'\?C^/Q_'X_C\5*G_6!P'\>BF<`H!L=5L2Y"2Q<MAM0%)V%CP^
M["P5!-1F2H+\KX-\.6=@8@\U[L6-<O30/E6\D`P]F,>_7N\GN/SY7Q='V,2K
M`";(/ELA@^T2T^=N&W\*!I^W&\MR=B7JTFLL<Z>%8;G18-V;'8G?K^R^^&'3
MS"JZ[R-9PK/C342H:2ZISVT(.76MEC1[%U\MX^M\JBF3`X-'Y`SN.G$[QK(2
MOC63R,STF_2^4,W-6YPX!+L\=A;(E$!CR``9J@]'H3W@?MX>^9E@J-M.27>]
MFZG(6IB!B4+)W'7JB<SAOAL:G?J0CV&TT]R=<E*TUP2#A1<93UF'?T?M@S5C
M%]<3-D>(:4O5<H"D2""(T(N)&,42(0Z=O#\Y%<C%!DAJ0#Z1DN0YX(AJ<"W+
MPX1&D/:V&^Y>ZE4\J,W'?>]9R'B!&\&K]-OZQ..UWWK?YJW_`+Z_LOOA"T?V
MRN5R$3E/7<M[ÊNO;!52MGVWMT928@LCN=S[L7G57!B$`/(&)0<+IQ)N!='&
M$(`S6B(S;6PWN.U]64?^-\!*P(#FC'Y%&HS^3C^^Z<YN(A^:VEV=L=PACJ&J
MXKA-\G:HR?OC_):_[?5$YG#?#!4$;4U)?+==ILUPQMH\]"&!C8Y^7C-JCM/J
M#,25E4\U3W=;7#6@+E&_0>KC$\<<QY;17]^:BGP-%X_8*#.1+^FSB]AMAW[/
M"_+<J_1"ACA*!PP0^JPIGD$P8C1*\(=UI7I&T<T[B3_XU'Q5QZ`&A+B63")W
M91&[,8MSW6KXF,!6='3"4P'O;^NPP6*D5B)CT#ÛU(:IBX'I^R^^$)9_'-*U
M$4$CO.Q*J=;>SDA5:"AGL=6(>0+A-@.'(K-'KWH`=\9G&<@9[4.0!:)HID_^
MB@8\&G8ODL6,.((@<%-Y[#1.,!0!1@(P6H)P#I(#B!KX!BJE&=[;MX/%(,0<
M(V!C'+)M:I'$VA5*,(C'"8-C1+I+2^[`9!@:,O8"$XJ^5,;!!(&6C1'"L!;=
M:$"$?[4\,1$S#:`N.MVPHW$RU@AWE^+-%IZDG,X;X8+1KF5`PD:3FV[C9+MA
MALD`,.BLV[)^]5MRMN;#C!N6D.U,<DI?*,*M9FL\Z`?F8_/4A`'4EJD,:T!_
M[)T;&]RKI>+V:<88N]/DL+QT;&GLT&KA/!^<9IJ>S$U`@M=S+(1[4_;PI7!!
M!]KCT0N>FD8E9L?N:PO-[4]YAN%F;I`SB.(Q9J=%`+T5ETOV$LN$U1"#[1V"
M4EIC:H*9P,;I#.2U)>U-B^VI73]E]\("_NUJ^P'N51F;+9FP2('6BZN.;`41
M(FA.K?;'<&T.?PD">8I!%%]ZWMB,O5ST5%GJJ?N@JP:!G>CVYH_@!2M`$Y!/
M^1U(M-*AWXX(8WRYK/8]NO@#$.-?*I]R;C#+"&<Z=2-Q6]M-K,2*BW;>A5VK
M515I(DRA[`_<!C!*VVT,V6]GG4=D+OSL"(+C;@/.*]5D]A[&S`]-5.ZA`LUR
M$Q%O<_ZU&G[D[/2$YG!Q^S>K-FCX$MK0.HG-4M;.D3/?I+(+3H.#6<N95SG`
M!J-9PMZ"\HM8VD<XSU'U86I$,4A/F>;OPF4`)#%^V,$-\QIIM"L"_CGTUH]>
M:(,V;L`)3M^,S9@!I4/.('(Z_/9E:/\`?<"8H=30\RSXP%#T[KQ88*D]`&@6
M`&JX28#$C?7&G(CVR4V4&8,FKP`V]*34MA!/#RM!H3SP'F42VY#:E8HK/Y"N
MA=;5U(T[@4Q`'ENLX0(L9QI?39<1)BNC3#FG]E1=9<&I&#M<Y<1V"8X-<PG!
MX:H1=BÒXI`<!R=X(8"*)J#SA)674ZPB=BO"XLI:BLS6VR3"32-CP2?CE2<5
MN$"HYY8XM\!;TZ-Q<6T7_.])#Q#,X-XVH[KCHB,P92B)$OV)<V&02U6@1$56
ML&RF;S4S#Z4C)Q*N:WB'K>!:L;L<33[.^B05HC.#W$^6#=.A2!V5;RU_;#)W
M?R\I:5%?F(+CB^13V1L$"=1,(I6X00?`VZ17(M&Z@FG/.9014K"4\AKNWBBV
M=K=*+1(!'Q7",\6<3C.X0Y:,*?13F/Y(*FPMUO:N#2U;&@1#EZ.9P-EA7;.F
MQW(#!U0I,;6?%A!3I*_.E.GRP0&2G8%_DB>8W\0.4:_1'E_%R25+[*_QY@41
M!^RG\N??IIG`&:V&1M0I;=PWD9LOB'I[>#=94"NEL(1#[JX!<?S*$>94J1NG
MO5YD`6,H@Y+6(FG@=*$;>\B2U9JZRC(Q4>'V3M`Z,E[1S:VFNS;D7"^VXJ":
M(QE'W"'(+9!Z$\0_>Â7CDB]C2"B(%`5&(#H`$"10T\.==8D_H9`W4IR&O0\
MT(S<>I`R7.%>-79V0JZ*'QV@/B5C,>]KDJ;NC/)?H["@*(W^"8+0/@K*NHMQ
M\I68T9Q[U,6=DG2AU'@56Z?J=*?6*"8WXJ9=FN,VHHS/7I4>!AUC*^%T(ZQ%
MEZJ)*<%'MSG+M=7LS68]&X<'_I(6S!;'7E<5-Q8AJNG:19S%NE!7A*'/R#%?
M+JQ&*&YWDZU4;\8M2`]&]_[\"3O)]]%LITB2"C/[1GA9)4`*PD&80RXJ:1L:
M4A;@**@%8^FKU469G`/VHAI&AGLUKA11AXR`**!).L1Q.LS;M*&(`3`3H@5"
MS2X=1`4,*?LB*P@"X'R8UBT*=LB=]MK%3&&3@*FQKPJ$[O\`@JCR7<$]%U@R
M=Y$B!:O4F=E@/'IB4!W#$F<^B4,[F@#HRWNG&%L)30388-D^H[HIA4`2UB]'
M?;Y#`C<H`G#0@>UHX!`>'#I_T5#1G&#,B?#<%;6^]\MP%J<N@.('D#9H5]?=
M.5`%N^09@@,D9R\L!#`$?`75%L8\L@;NC`@]&"=^P[(TY>#9EL<.7.]HU)IA
MC?K2!Y'IS#IBNT$@I>J-L";@Y!R5O3<;K'4`1:@;Q-W?%]Q\E=0M>"QS1X4?
M?<"D3N;*UP0=4K@CT^46#9CC?9P1U-\D?+%<Q'3DM@@,"#)L)&O9[2Q1A]`P
MHU-SCT)L&\3+/<;05!A4]?T>9P8`5"9HYTT#7\YX9'+?5YD7B)Z)5X.T%8Y3
M&Z&8%LQ4R)E=C<SO`C6G(\CQ`9`T_J?C,8OL&KS)>8Z.X<L*/^Y,`*>2#IX5
MQF"Y;G4"T/AN3&_1TT_@363=",$$1GRRYL&!V:(<JRE1,@Y%A.*`M"+O0(>)
MG4TS=0G$(SOB&_I0+4?>0=[$A$FA?05(Z1BK<C-L,=UW/@QA5[P[8@*4Y$;G
M!@7K*JQXUJ$O\FJ[@?Z>>7F$/`.)XU!:<GWSZ87TPOIA?3"^F%],+Z87TPOI
MA?3"^F%],+Z87TPOIA?3"^F%],+Z87TPOIA?3"^F%],+Z87TPOIA?3"^F%],
M+Z87TPOIA?3"^F%],+Z87TPOIA?3"^F%],+Z87TPOIA?3"^F%],+Z87'?I:_
M^4YG^F%],+Z87TPOIA?3"^F%],+Z87TPOIA?3"^F%],+Z821+17R4@#J_'EZ
M?__:``@!`@,!/R'_`(9#_]H`"`$#`P$_(?\ÀD/_V@`,`P$`À$#$0``$!))
M))))))))))))))))))))))))))))))((````````````````````````````
M````((`!((````````````````````````````((`!!)``````(`````````
M```````(````((```((`````((````````````````````((````(`````((
M````````````````````((````(`````((````!```````````````((````
M(`````((````!```````````````((`!!(````````````)``````````(``
M```(!!)((`````((````!````!`````(!`((`)````(`````((````!`````
M!````())```))```(`````((````!`````!````)(!(``(!```(`````((``
M``!`````!````)`(```(``)`)(````((````!`````!````(!!)``(()`))`
M````(`````)````!``````!)(``(!!``)(````((````!`````!````)(`)(
M`(````)(````((````!`````!````(!`((`)````)(````((````!`````!`
M```(!(```((```)(````((````!`````!````(!``(`))!)!!(````((````
M(````!`````()`(``)`!!()(````(``````)````!````)`)((`((```)(``
M``(``````)````!(```)`)`)`()```)(````((`````)`````(```(()`!`(
M````)!````(!`````(````!(```!))))((``(()`````()````!`````!```
M``````((````!)))))`())))((!))(!!)))(````((``)()!````()`!)``!
M(`````(```````((````)(!`)`((``)`!``````)()``````((````)()`!`
M()`)!``)`)``!!!)(`````((````))())`()()!(``()``!))`)`````((``
M`())))`(()!)!)(!(```!)!(((````((```((````!`````!`````(`````(
M````((````!))!````!!!``))`(``)(!``````((````!)`()(`)`!!``)!!
M```(````````((````````````!((```)!``!!`(``````(!))))))))))))
M))))))))))))))))))))`/_:``@!`0,!/Q`V$`?>8`J%0!I?T:_?OW[]^_?O
MW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_P"LOW[]^_?OW[]^_?OW[]^_?OW[
M]^_?OW[]\8@^0--/!4-Q9'_"GLUZ5X713.M#(%YE?,XGN-/!FJ8N2@]R=,@9
ML53*.@T(<H>4C/\`@$UZG9=S0;WJY'S%A^M,CHW,QP\$";>Q3H:GOPX_S`;1
MM1P,6LY.?;PW*.:\)QA4B98XY>L&!E\QFS9LV;-FS9LV;HVS@..P5':`_9/_
M`)E$).=67:!D_0(,V;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L_>]@-D*]:
M_+?037M(^Q.9G6.896(MZ1`_7$69FTF\9+O<ZJQ21UZJK'`6S_\`CT$H66^4
MUZH66S+F%=8!HB#(HX\=@UIA"J4&Ò\`@?*:]4++<YK&-`K!8*6'=N%D=%A4
M25':-)PG^5<IKU0LM]OW*:];F/\`(8,_1$S@UR#",M5'),"#P5>QX_@QP<6T
MN%B#V`51E#`)F=IBH$A0L'!\G1EC0VX2GF!0H4*%"A0H4*%'%M-5VF".C@Z#
MIT<%(#(B.^SY04*%"A0H4*%=J3*R,EZ`F,;.O@:HH@WW]*%"A0H4*%"A0H4*
M%"A0H4*%"@YZ9XVI-"%0&T\IBQ8L6+%BQ8A2V]"ZS0X[9+'PO=2<4&^Z'CL;
MHY!XT<TS$2Y/C;]>DP3$V*6"$V#'%+9AF<A-MN*BO/(C#?T7H66^MY(D>.7U
M8\)89TYD5,R+0/)LJH^3?]:7QNU_.%%VEX]=N^7`=+H-G:'V(M%@Y,#+%5G>
MPV"`-ME&+LCA&+HF<9S%`2Q*(FA5!2_U59*C*I:IX//V>*\ÌI\V>V:+.A/Y
MS^J_W_[>KTC<R+)U-R`$8@2J2(B+_)P0[NDW.CQG6\C9/D<[2OM>U)GZ3U"R
MWV_?T'F5W0NL]EWK-_+LE#%B+K3MW^8:+=RW2THYK\BES`*:?NJO!9K,_)EB
MP0M$)VL3F=!XQ?`XUFMD#-UMW$(C?NE\.8,F^^(]H$*/#)O7;G/VPBUPHN8.
M,.IS-KYUJ/`5QFJ1E]]X;]*I0LM]OW]!YE=T'I:,'9/4NAYCT=V,L=Q//!A5
M>:4@W+5%Q,G^X?Q#O!>;`"RP!`\RB..<+TFN3KLCO4VV/C";W4@JJ\#1FS%L
MFD4T3#*T]$240=]<*2DCI`@7QJ&\9(6"!6E0JJX"#BI`VX4Z31_05EOM^_H/
M,KN@$.XK`C'7%(.9&/NN+LXH,.(7L0:X1@`<"BKA'6JE0E*=9NQ+7^)4S,P/
M+<SD5*Z+G?Q]1-Z(+'W@T/;)PPW8P621XX*#I<2?!P"\#9Z/`9IW5FD]4JGB
MF,]U.FS81K+8N@LW><0QW7E-UR;*&-@=/%%^BE%_0LM]OW]!YE=T1RU</:`@
MH$3E/9X.$CH9V<$`]4U19W2#4!FOAK.(<\FVZ),?8((JPRMF>19CZ-Z5A)8W
MEW1:M\(*(G.>$F]MOX4U;X+F!E'=C&D:\+T1:VHK9.X9%-#GO4W]8#]2%W'C
M[,%"6"PIZ8)Q#D2V1WQYW)%^+?,67`"R4IYU\`71$)#U4@È',+\`$PRV%N\
M-:+6"#27L`,?:=5G2I##6C*-V:X*P.L;+KRL6+%BQ8L6+$>0;ADP9@[T]IQT
MC6!&0D+DEV]_*Q8L6+%BQ8L5FY[^:N`Y;+O';$%3FH:TULU?*Q8L6+%BQ8L0
M7PQ=XG^`GHCU0,@GG1O;JSR<6+%BQ8L6*C=^^$:&"+9=_6"TLC,357=O<M`-
M^"Y851NO2"HKD[RZ2"ZXS]/EQ[\C[0UXCMO3+&3+DLL^Y6T7KR[DO`GD,VR`
MRB$/B-$WJ:&;#5KX<UE#`.5$P)!MB68!Y-L6*ÌWKS=(QV;&@UH(53/DP.Y@
MGY6;7!W+@WZ^:!FVZH]=4!E29!4%"/T11?T++?;]_0>97=#F'0T]B!%F8&:+
M'Z)R+51I<0VI<%/"`8"!P5&F3SPRBL\S*0B$?L7:NZL!88^)&L*/C]6.)+%-
M('D`L,*I[J2_BR",P)O7%U\@`J.+L-C"2)*^V-TFO4)0DQ_FY^S<:9?I51?T
M++?;]_0>97=$$OS35^Z69JHJE30T'0Z03$G7?[5%,Y117-?I.#>ZN2/%[C0@
M$Z!>Z6UL[R'R,AGXB?)%V92#][M[J!@W3`_3Q*0'PR\!-["'TF9C$B7CE$5,
M)1-L<H*$(M%1>!ZMI@?TH@47]"RWV_?T'F5W0>H]IP9:W;3A!%@>&3RZ)0:#
M@;]YQ1_#//(J30&II1V+<CX\Z:@X,G3%H"XT"&I[248P-\&`)*U=2?808:0\
M8M780XO8#!KHP5N*L?!7,0DWH"_0[CCZL!(<""1U8K6A[P0'Z7>Y]=]QXY^T
M47]"RWV_?T'F5W043QRHY$K\B9XT^[(C&=@UZ1Y1GT?C-++!%8S84`7.R)8F
M`5]O]60A]X<Q&A*:6B@)[:8%CF_2B)!I'G$P\BU_4BH>0\+8$[D]&5.UW)O:
MKV3GGK97!#<39S6S(%0,5MS8AA;MU`_:,>D()#_0??\`#KGA..=B.05@ZX9&
M4A(0NZ"K!^B;2RY>*,^MT&ME.BT$7`FV&0Y#(K$@3X0<NN+L$!TA$[F<G4FZ
MG#L8>WE=^_?OW[]^_=\E=7AQ$Z+M.C15)V=?<IV7"P`L$A>8)BSR>_?OW[]^
M_=>N[-T:=A)VRQ"FAT3:*LT>5W[]^_?OW[]TL!B7O%$?R]$]LPE@;94.GR>_
M?OW[]^_?94.K`.G8P[3>;;XKZ&.3*S,^?7*>I]2^!>",,31%FQPQH=#6S#,?
MVY`(*`J=IJ[^7;K=K@'CIZKY4MP?2]C&.#RXQ$';3@%*F9248X)IX<3>KJZ>
MG1K*JJ)\=QC;E7;5O)G5=79=$Z]WI^H9L9`)FN3:$8;[7B#J8F9B^$&V%K'H
M_NL8`@,U+*"/5IN@[?VO./\`H?2DF$0$K8*G<%Q]MDBCVJ3IY6ZZ8KR6U3ZP
M$(4]^GTX=L;NA#D,!/Y+KCUD3Y\C^@\R.Z&5'$8)G0K^)87H369LZ\2S3D*7
M0F<W/X2XY=49-V:)C`;!XJ).K:QQ6NY@$(.6G]=]3Q=,Q.2L,`+`;=RBIO+=
MVMCMH'\/)O:RZ"7?P9@.Y#<,_?+0>X;78+OIL_LD/I=H:5%_0L)T)VX;1&2T
M8S5<F]I)9)H.*\J%VU>0HFT!NXZVFTX]9^$#GV_B^[C+[89MR4A33R/Z#I$)
M'3,R$2CX9K@L]PY%2A:D?R6B0)6;ZM[KS18BNT#E;4D-3@`+0P'RBS"70<9'
M861`8GX'N3&_MPMLJ2J`V(,`^7]JSQS]>C$NJ$VMV@)!T(P#'.7+1)^,<%9%
MFI?8A%B.I-ZC?^#!A/L"445/95=MD\)0:I@.1%X8G%$44/I%%_0L&YY(*?'(
M2PF(K9SHDM#JM,",\K[&HG8G&F5YR8/80K*PAW<H-N;,X@KS7D_RYW$/'_0=
M)#FH1CK/PK:LÀF@J3+(`M"X\GT"&$@.FB93!CÈ"P_A3.8R3`4DB4*A$OIZ
M-B]R?6Y%/\9B:%FD[TM9JV&1DAZ,[PF90/=)(:->W$XP`YD][6*O3\>5UXBI
MS!N*#,TWJ(3>P`*CYWQ'8K!<!"(%H7>_>38P47R[XL_WQNEFNKBZIVV;-MYD
M>$30`,M.JF\,=>4L+K6=:Z$'0B.:U+7&OR;._0>'E':UZ`_.JJK`+/;MQ1MF
MUOA>[6C@CSG0D9RF]^+$/'_0=*%B/P;X.A;K1A`B<@3>L>.;GR%D?V3(>$7@
M;\K1HT:-&C1HT'2F<=?R9$H:^![./95IHS>,&(Y$H9L_F7(C,>K>#=@,2Y!&
MÌ!T(8\@V4$M3(>_#3C`5D#>!5%ÊJ+PI\:@GDHD:E"BB]78J:/!\@3+9389
MR)?*6'DV*8%CA(3Q?F^?[DJ&5_[\ISNU7-R"C-E4Z'4PZ.W'X;VB%GSQN1#(
M9+`M//)R[H\?]!TM)-'(MF.P9;C`]7F&R$EC:[]6'E->Y^N/VOMW+\@/VL<"
M[P)`*<CTX#TP[O(<3"PPC<`"%4I+KM<,V(NE0P.\>T!@G44PM**6YH:SM`FS
M/2:N(+,#RA^%>#&,Z]8-2"ZA32*'([=^1/GSY\^?/L"2%N?;9:0;/;70Q#%=
M0U)HX#-),QU"V*::1V\\FGSY\^?/GS[U9R"U23"?+>,146T$MD*AE%,D-PJ]
M"GTH77@NR#"A,84I?&#R*25EBE>,KSQG.?/GSY\\68*#V92?H='6C`)>`GK8
M"`>1($O>GG66U)7Y%/GSY\^?/M]W(1'24E[JN^)Z&:]-O)T'KF+L&@TPY/8Z
M.;$V!A-66;(BW@P%AX%%\BP,1$=Y[2L(,9B8-L@#+4@['#J;2PEDC6/O\^4L
M`**FE':*-C)J)&ZO/3:"32Y!;A$[+\6CK0GSS0=)I7%H8+(99`NL#>M2!WT3
M^,`"`!`0)1$TB>#MH%`P+*,:09.<Q['"Q82](W-3V"";V=52#)D\!_(5LTTM
MIXRPS_0=)6#9R\&VJLQ8XJ+C?>?9,1[(6.A%O>H;0*RQ*8F^ZX.@L4O1\;($
M5[X8N`<1=_\`&"G0<@Z/+!:%",BF:(%!)ZKE->J+_$^B.#C?<I=#D1?F8JUW
MSX*]<ADA3=@OKVSRG[]LD27SH%A>C78JS`<"1'8IAZMC0U<(`44;QX5CIXAY
MG?IL0</0X6*_MJG<9HH%DZV4^>A5YMUOPJR.#1R_,%EQ>UV%X^136%D*H"P(
M(H)HD[U?=\'8TN4%2UQ(EG4&6JDPR3G/#2%D?7UP>I'<%PGDX8DF%U0#X]^R
M3?T'2>182LMJE`V#"7;1NBL;!D,9G@<(H&(L,;9#F%,MD@1""3:4,XW4B<X4
M3W!7LU@%(BP*1!<J$,09JCV55&!Z*#D9V2V[5V[O=O?9[O/JN4UZHON2%'$H
MB^(1Z#`@Q/LW<A^$L0J"7B;(-SHR(`9@7_[[WF,6#8J<NPH8^?ZJHV\Z*,:T
M?@:Q/"#7UWO6[SD@-<V.Q3D:"8@/"K&"@?SA9QDB%1[EL0[!A;-)Z0[.VI/;
MB*(#K*T!UCT$,H3V_*S9:JW%'BG"N/<$4YÙSQ&1V<>U&O/8DTK8H1HJ>38S_/+80`:3?9;L
MCSPA'=%%B=O3[)NF.EP<518W)P@0,.[4IFEUZSO4&T(W:31.3R2!K5"T)(.&
MP-4S^@Z2[#/SQ<(%"FR!S6.F`/!PK#9(L>NK3P]&9T(*+L-4Z7]HY+940!@]
MA"49R!CS[VC^8N3`LW+I58;&7K@1G!.74KVQB14'"8\>"X\J$_O`]3RFO5%]
M'1-45XZN*11QA!1R5)V,8PZRK&:EK?O`B;%96FG@C`P-$C`'DL-R,]JO!D?I
M::I>)A4,%.S$B]Z2"U+)&'`5J-B@YKX@N/M%H&#*PW%WMZK%`.6!\I)(OO;&
MJ=NK-#6WC542PQF*'_<L+D\DGBNWX8=J?:M)8;!S`<"5+;2\)Z+L[VJ'PPI+
M*.H>VW@B9SPYQ6/8VTS94!=#TVR5V%)X2=.P[I9KE2A8@+"W>T*;IDG:^FLK
M7E[DV$:0[JR@#+61J_AT30-#SIQLN(+]08V,VEJ9:'J3"3?>SM#8WBH`.W"3
M89/V"C8%"O>7<!M\!D'2_P!!TE*XS)2#69'%A"\?:['L_0=VA#$/2RI.3:,F
MX,18V5W$2UN?@:/*DBD#=L1QMF+$]4G$.L,<0]>-$W,-A!<SF%(NW6"$]MS$
MR4I!!L%^[T)>DY37H[VJNL<][AI/X1(/%EIA?@]S4QCH&Q0=UR9\8B]A["8$
M[(LSA8CH'$R@6%=Q#T1._;=5R6"Z5C3AQI%+"/R#OTGO"@4](9R`*0S2@YA2
M5"XR3`S`C1P_*84:4Y'!4RQEK`-Z#<1K.01+R&CS0?9L&[T2T"1&]YL5FW.X
M$4K='%@4J&5%I!#=;(:A")TXM33X[&*E%\D`:#),'P"!RCA#`X2SOG]I*\+J
MV>92,(LÈ0<MY7I3N:3M+'$<R`\N5^BHOQ.Z9`_LBJ;?+*VIW!LY+Z/%YP\6
MB]TG8Z7?)(;0UD3@ZI3+N.L:M_V"L<[8Y`"NQ0NAL6=R7$XY>RE!C8%+NRXL
MWA(>5TUWV&@7)S-[QZ_K5EPSD0I3<ZHUR^-LU*L89^@&#<>>3+EXN]U4:7II
M$-8"`J-X_>/R!QV'*S5.E77N".:Y=PW@O5ZT]3E!)J%4'.)@R+.YEN(NVS$X
M]HD5I#9LT._>)BP3L$8?"[KPSDLI3>N].RW8I@E\L#Y'`T_]_P!N&L#.(I,;
MF>*R;ÀD8:D"GEW220\\"?,^>5G)B+P!FZ;FT.G`5:>CFO0=`,0=/U`?P0>;
M41#^8<W3>`@HT09]S55]_+#ATE./!]:D\P'(91M#NB/@\MFTL*N2::#^1Y@+
M4BFU[N?35Z::]0R-=V>15@Y=&/&E)7YO,<XL7'X?F,3>%GF%@*)"'$&*Z)C;
MFM/EB>:7EIUYTUC!6XPHCC)A_P!E@F?CMD8Z`9=246/N+CE2.BKN6@M1C(5;
M)Q;L6!<DXE(9M0M&$0&4<=I0$10&.]!Q1SKWP/CE2`?WCZWO$4?0P=WBO?SB
M<87(!JSHLH$.P-R/)664BW_";Z14.`QM#T4"0NP23&K1?:ZE`RL<`:QZOQQI
M?&\/9>3@(98\8HRJN91\I^G3P8'$+$#I^M3)S'"N"1RR$Y/!)9OLH&;H&'0`
M!/@C@'GF[X&#DJ+;[UI@<&`XN5R-'Q!JQL`%P]^`:;WSO#\"O%T9H1F$`(A`
MUC[V"!)P>MV60D#0'3PZ.3<@+!EI5]R(%HD6(((?.7<5DQQ`B!T_I`+"RX!6
MJ2[J<WZF:]D/:^@@'$?(IP(74<Q`<X")PCF"S*)`"HGD7U2JXQ&S4JB`MW_)
M2D(M[(EWY%W+LKL6,(E]!6@9PSDIX'R.PV@!?^YG#(&6CO\`_J+4/DDDO0DM
MVUN,+@!QW.THA8)/OHD7YT#5#M[%F%F;00Q#.B):8=N"2W36M.#!`-5YS'-_
MN`XI(L%?AS7`Y(+[2SUFZY1LIUA,.4FLCN]E,4KIL]A+HWUWBF_$DTQ9![J'
MJ/I"<_J2K`B#EQ9;QIV]TT6L9*[I>Z'#<(QB7&;G,F%?FT,BI)6YP1&LAF4'
M@N#Z@&%\N>=`*8T=(\@-JRLHA40>`&N#,!#P!;'(RG%;*[E3#X"T^S'6#QB2
M!M.633LGC8D!Y`)A!3+5_P`\"RI8:L>'VSFIP*A:*,8!L3"0?WFQ:1>#!OZ/
M->B"*B$Q>;\"PTM7:5PD_G@,6I6H86F;CP]AH@QTC3,6*8LN_/8]F_[AR;:`
M!V0CHW(<'C0B5D+]H)^Y#F7>WO\`J:W@\0EF*=5O"1SP',40<N"B^[CQ6*PL
M*_HIU9ZV`-'#DL),"0%WF"Y011@_&W]0\(Y@+^,\*9!T0NAP_9_Y2*KET5=3
MP7Q>]FCE>%J4\?(ETN2#-N^^L*#^S@*@<0]#>M(-TP+(0'YQL9:`J^=-6Z3%
MKS-5WE='+A5PJX5<*N%7"KA5PJX5<*N%7"KA5PJX5<*N%7"KA5PJX5<*N%7"
MKA5PJX5<*N%7"KA5PJX5<*N%7"KA5PJX5<*N%7"KA5PJX5<*N%7"KA2_OBA?
M_,Y=G+A5PJX5<*N%7"KA5PJX5<*N%7"KA5PJX4O,^G-;4Q-(Z.G_V@`(`0(#
7`3\0_P"&0__:``@!`P,!/Q#_`(9#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<TEXT>
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```.*@``2:8``%N-``!K&?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`J`(5`P$1
M``(1`0,1`?_$`-X``0`"`P$!`0$````````````&!P0%"`,"`0D!`0``````
M```````````````0``("`P`!`0<$`@,!``````0%`P8!`@<`,!`@$A05%A=`
M4!$3H#5@,3(F$0`"`P`!`@0#!`4)`P<,`P`#!`$"!1$2$PÀ%`8Q(A5!43(C
M$#!A0C,@4'%24R0E%@=`0S2!8G)C1'0U8)&AL7-4M-1%5;4F=95W$@$`````
M``````````````"@$P$!`0$``00!!`$%`0$````!$0À,1`@,$%10%!A<:!@
M\(&1H>'Q_]H`#`,!``(1`Q$```'^_@```````````````````````````!!R
M($Z-P;4`````````````````````````````@I59<)+3E4D1I#H0WX``````
M``````````````````````!HR&&O-Z<PG<`````````````````````````-
M48QO@`````5B68:\Y;.M@```````````````````````"EC<EH````&M.<C7
MD>.SCZ*;+D```````````````````````*S-R4&=7@````PBK29DJ*8-P0TO
M4S@`````:,I0H4_H"```````````````<1EVEQE5F>3TV@````(B08N<BI11
MT^```#6$3/,UAG%AGZ>@*[)P5R6D``````"J2CCHXG(``!JRK"MCJP]#F0Z;
M`````!RN3TNLJ0ML'F>@``(J<\EF&X-.3HYD.Q0<HG21R,=JFH,DS@````4`
M3XE)LCV```(^08M<YJ)P2<G```````!K3G`VAN"]0``#D\S2S3,(,>I/RACW
M+A,8]3<GR<Q';0``*@)630XB.W0`````#DHZG,X````$!*Q.C`>9RX=3G"1?
M9;ICD!)P:T^2;@``J\AI?AB&8444H=M&6#5&U``!RX38W1H3(-R6@````0(B
M1"3I\_0````1$JLYP.N#V.9CIPIPN$SR*EVD-,\D8``!`2HSIH`KDW)*C[``
M```(H2LUQ7I:8```!%#4D^*N+4`````*7)D3(]"'DP*_/LYG.T#U```````*
M[).;T````$/*"-4=*D=,0W1KSZ).<ME]&><X'4QQ&=4GF6N98```/PIP]SDT
MZ@-^;@AAO3S+2`````````*I+6````!Q<7V6L<*G<!['.QT:81$R<E&DL+&*
M%+D-L04\R?````@IM"3%7%H@K@L<``````````K0Q"U@`````#FPAAV,``5D
M0DD!0QTT6$`<1G9AL```?)09;AJRHCHDPB,$^``````````(*9Q+``````"(
MF62,``'D>I^'Z`````#C@Z;,<A!<I6IDEC@`````````````````````````
M````````````Ì0\#3&R,,VAK#5$Z-28)M#]-:9YZDE+'```*:*Y+*-8?!D&
M&9Q@FL!E&$2LU9H#?EF$N``,4J0GYK3,/,TAL#\-D:,E)$3;FH-N:PV1IRS3
MFPA!-2N"SS7'H1PVQF&C/<VY1Y=1H"Z21'H?I+@`<NGL8Y%#=$K-B;,@Q+CW
M-$99*2OSQ-^6Z;T``CASF:LR"4$'-N99AD/)899-2OS8$(,LE1&3M$Y1/DC1
MO#;&T*T/<WY+2OSX/TVQ\&I-T1\VI&SM<R@#E8WQ\$*/4Z')N````````1$Y
M!(J2\]2&'090):Y#"S"M"4%>F:;0O@NP`Y1*Q(Z607V6V```````````````
M`````"-G"AN#U)";0AY%R:&A+((X;,B9NS((8>QJCO\`/__:``@!`0`!!0+]
MY<OPTGDE\0QR&NUR\L$R!B%^]V1[!6D\'0-6YR)O"^4>7IN,);IJ'++J'S8(
MG54!JJ5_O;%<(U%.J"8XA=!M5O)K*NQYA6WFZ[^Y&G!K15S1<W%]2T8P2-C&
M-<&!BL!6-G:+3OW&[ZQR`5I8:'Z1A&`Q!ÎI666_3BUL"AO?R'.,XSCQ-B)N
M\_;S;C65P&UA11^.6<3M_P"D3!&4.12$9&J9,(C%SC&<8^H(V&5EC-\#V(I&
M821B,^H:R7K=+#9<[1R7VXZ+?U[CF:L!55J9#6B)X(2H<M<5J3#EV;X'\Y@;
MTMGRC3*"Q+7[?QYG7":GUTY>S]`PP9>&?:$:W;%LK>01[HB(.V'B&M.^FDFO
MPZ^W[K0_52)M1H$EP1V$CUK>Z(3+8+O8!W-883MZW[YIHJX..[@;Z-;$:Y\U
MVUDU\KO\-[)ZC+EX+,Q%76XC+QSG>=][-=M=]?>>K/K23[$7*V=1@4CQ.H8<
M,IZ\Q$FTW=_'6SG,CSV'J?IS1G\'TWF9U>/+\-/"6CCDCF0>ET2W$U!8OK2P
M+4=>`)'III%I[[5:*Y6+*OF`S_KRQ6+-%8)6M@>)4J2-/CURQ!CQI;A+7;"U
MBL-A14]3,`9[[:@,6+)%4F\<\]4B)T^V_"@+&L<8LX_UG6S)R):Q;&YA5L<O
M]C5`QC)?I2D(TOQ6\?P)###/]OBP'#75KL#[VUYKFH29Z&[U\[E_K/5;OR#.
MO###A#>DWLJE"7%TI62)[,;:[9N[IJNO/E#_`/I.N.K6<*2"9`P$8LUZ@;#U
MY+XM;`-HV;X%9)\T^Ê^]93QE^2[C36*_332+2$04??.FF=K>>55!?R[/(-!
MOF6'V:@A:2>]#RE$*.#77*LJ6Q%;9)I<-AU)(/IRE*Z8DLO1L3G=*&&\L++`
M]<Q5+3Z9Z0%D='SE1`-/+U[EI.1W[WS[04CZ6X*X2W>32V,/*E2U=0).IE;8
M^-5Z(4:K5W,4'C%$`RD7*@%6GOO$>6V9>6("A_;8)?XWT0I(M<8QKCTX?]WX
M6(,>+5%2\`'T7:X1HLJX`H"7.,;8JNVVT'IL[E"MN]EUQO7-?_/C#_8>6;Ò
MTF*>Q?#:3'V#-/C^#UW:\J0A<Q%:BÊM8$>@UL[!5JT#5&/5=O%+Q6\B*L$I
M$HQD]?A^ZJ]AENS=,MX;'J-.S<`*([(F;'-9KE7Q(]+(K.S6%K),9"\3SKS>
MNN+L4O\`NM4":P+<Z000C0^BSMT$.HA-F%&LKQ1+VLV=U:!_JC%1X=8E(,7R
MEL;D?4GX/@.DSMA^CF@U'MOI0\K)%#KZ8\0WSMD$0T<,,(T6VNN^LM0:[&^$
M#CEP*JVE2R>6(0.RF5[41=#Y;N94J]>`@`JQ/'R_<P=/94[L?T+)\'T850`(
M1X:L536KV(P`Q3?TKMX8`8C*B:MO5NHWWÙ7=2(8Q^[<&):JOTXGYYC=II@E
M*^RV?+RI&&,*K[8.7L$D8FL^@OO9SC&++9!=P%S4!K&W?KTWBZUX:&0SPDQ'
M'A+!D$V2]?TKFO`/,J4BQ'IZK9"E?:?2%7\>]III'KZS49SN^#2@!$LT(+/<
M>G:2S:::1:&UO^)P:Y%&1_PYG>TJ9U+T6K12C=/K$\_Y*J&-M.E5_9M!T2K$
M[:]0I^^#NIUX0$"^55GX-T>J%2G],JX6F_0ZQ&8NOJ-EN-T>ODL]>B5B6,3H
M=2/EKUF!LN??^\1I+,/T!\4.^NZ2OSZ=$K>1R^DU$+PN_H8/+#T1#7\Z]#JV
MV8.EU$B-?U"M&*H^G5Z70?J5)+R)U6H3:EWA4)Y#TJIDQD=;I<8>.EU#<A`V
MC?H_=GFB&A@O22765TG@WS9JWB&%XIF(WL*"/R>WUT;)EF0KV4EGKT<<KU)!
M,KMM=<P#,UIGD-OKQ;3%DKN<?>%:RTBL=>G\S;ZM_?O9*['&PN-<5P^6Q11&
M#-C5Z%ODBK\['AWJG.K2!'7Z(-ÌJG/B]%-2YZN\+KO,Y?!AN<)H"5/.RS-:
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M;@G6;\E#EQ7><JUD2'GVJ5MCBJWZ3!R?<V.'ENNIC&@1,'2WD`@?@G'@8!S.
M.KBF!W*`"/-^5Z_*YXTLRF:T9B)50N1?T!YY5G84CBHI'D,6L$/M.YA$:R=\
M\%=MJOSH2L-E_)(@X5/)!%T]=3[($_Z%ÔD;H8.<6L6";D=CET_&MCT,QS!Y
M#'+R*Q[P.ZK8C#Q^36N.%!SYBOB@Y4VCQ9J4V;-?QFZ_MK_.W"LMESFT:MHN
M66>(K;ES>4ND5XZN@>UY0#6-L6<KL<(I?-;?K/CFKN8^D(RJS6_VISAELH%2
M].'9)Z]TQ4&K5],D!^FVNY4FK+K]LTG0]$&V8JNN'Z"H^CZ9$4]<(7C*[@'5
MUM2MVRG=-8OZQZ_T"5I]NWCZ98U]_94;=5UH*;Y7K>-8@>S?U_WR?T__V@`(
M`0(``04"_P`7_P#_V@`(`0,``04"_P`7_P#_V@`(`0("!C\"+_\`_]H`"`$#
M`@8_`B__`/_:``@!`0$&/P+^>5:&$ZXV]<M$L_-5NX\SZ<?>9(,-.(@*PO.]
M[36L3,5_%:L2*/\`$K+S3-NWH1ENU1R9UZ")G"URE$.Z!ST/2;4M7D%;UDW;
MK,3XHDT:1G)F:.M6.F>F4\HB0G+=?X>Y2^@/BOQMS/W>$]!69LL\JNXO:U9I
M:P&15,*;4M\U)D=X\I^'\^,;+0Y(NJ9`9HBW3TT>T5$)-STWGI!ZKKF(CF8K
MQX8S/;&939;"X\*MSZ$YB5T\W-]ONMN6/=%D]+^J]QA7H*`VZK1:TS6D<^$=
M=<90#=#UR`_3WERTO83"Q>BUAR1<X[4F:S-9F/*>/T?Z=XRK+R?NC?/[C5QF
MU%%-!5=!;,"YLVUDFF%ILC,!!,6'>"5-2OQKU5LPK;W'HDSM:,VWN1=A=0K>
MTSG+*)V8A^M`RA.FJB(;-:#FLTK^5VIF9\03W$MD-GA?W$O54"0V<L,[UL;^
M]IKZ`;V496'CUKY<R2U[WO:U[3/C-RZ$L6F:@FA0MXB+EJFN->I+Q7Y8M>!\
MSQ_/DINCDJ\F48Z8)<<]U%L#RUNL=JW_`"V5J6_;QQ/EX,Y,/*/G<N];0SM-
M_/>@IL_/RSTHRJ<=Z+,)92];B_AS85;\=<1;POE5KUXTS"^;`J%*9;^(2U"]
M(QJ9V-E(!B.X2]R&OS-K22?S)JC1S:+$\=O&5N[3G[K/?EY@9_\`:'IXS/?/
MN=*F/B+>TV?;'ME<K87"K[FCJC.VQID5ZTD#Z2=:@!%2EK>:]/5US2MOYR,]
MH-`236IUG99)4(15YBL3<EYBL<VF(C[YGCQ5W+<7>5M:](,L2I*00=NDHK<>
M="BMY6K/%JS\?UN=CS6+QMZZ29J3\+I+3?5TJ6C]X9D,X@Y_Z?B*UB(B(XB(
M\HB(^$1'V1'AA)T`V5&A7`PN:O6,HB1Q:EJS]DQXTX5T,\*OMW<]O>WE_;#(
M;,:NVMIBQH]9#Q7?6Î-]3O"TQ2]9LM;N3;FW;_G',IZH*S@]Q#1S?54,1$[
M6)4^Y<+_`&*V*%24\XLR6(MV;Q6\1:8BL[.CHV3AWW#J5U2K9\GLDG0>;GY:
MXAE9$L=DUE\^MREL(75>W'3$1'ZIINU9O55<S%J5XZKP`=B36O/ES;I\*`Q`
MSLOOY^*TJHHXG_Q>U+LCSVC]<T5LFOGF,:\\\#I/3%K<5D`4O8'O#W#ND?T<
MMG)PUE&ELQW.&B>WU/:(R%%1-Q;2"5<L^9*6_#6U;5A7W+[\]H9GM;V^BJXJ
MFJEO_7]7-8TB*]>KNRNJ'/JD%=7M=0+7D'>M:_Y?-Z1,3S$^<3'G$Q/VQ^C?
MUCA5/7+U/HF*<B:TL*T03#&K==SM>ICO:C)Q6CKX_)_;/\X?5'==9;/Z=:\M
M$@W:BF'<H]:T\#F8JC8%Ô\`Z/EX;DNL@&B-UAM%,R,(1W<6HXK7O%FHKRPJ
M2+UZ9GF)\9%1+O3B0M=*FN5%E?,*_L/*A8%#+-`__14F`C)$2(A'*TBW5/'Z
MLZIN9$R$H"Q$],R,U)'?BT><3TV\+>3H#(YN7F(-K.E$TB+&(4N>=8OGTM"D
M]XM:8F"4M-+Q:LS'BZRDL%D[)G6VW#69<>=8X[S31[?C+:*Q6.(BM*5BM8BL
M1'B8F.8GRF)\XF)^R?$9&3?)<5<"1G/R]+4L@WE]N?SZ)UHHZ5W(CGFM(K$K
M3\G/;FL#_OWN*N>.8GE?V_G@#?S_`';/ZWU2]_\Ì4$"?Z/`L]OK;]N&-KM4
MU**:CV@HT[I#>B-HXH;J2&#:)O[Q:*1^7\WQ\%@#`3R`DA/`2T)(35_$(L4M
M/;)'W3Y_K>X^ZLI6?P]\U!S?]@ZS/42W[*Q,^,/T>DQ[>RM+8,CH^X7,^$K*
MC#FL.+U7ÔIÊ#72:I45&"BN.?.M?GM2?'N$R0@ZXLWVJV^GL5E!&E_3;_NS
M.2]Q0J05X='IYV2`W;'P&W3R..DE?Y@8T"Z/IKKQ[M;TG.PVW#(=]\[\"'GW
M>L"+@[D4Z:5Y-/W<\>-NT,P\F]J+/8RK"].O!46S0(AS0&FUY*)3IO`+<5L,
M%JB\^GF2K,BH<!Z6&8)*Q<9!WCBU;5GRF)CQ5#3*RXD2]0Y300-:6EW+4(0>
M4ZJF-AU@_9#>P3]$]P=)[GSUZB1],]M,BI;GAK?;!DB_9,*KQIZ?_(0(OÒJ
M%EK.<3WI3H6BW/5/3`H-<A>*TXCF9\Y\^(^'ZN\7?#61ZE<4G/5'1J67HU"=
MIZ>()Z<D6_J\3\?&E*#YSB"LF94-^W51E4W<K76SA,)+:$A)>EA]VMR*D\II
M,_HU>IWZ=U9[8X?XF93N0%QC8I6OSW((EHFM8^:UO*//PBU?V\C[:!F^V9PG
M*I-+'Ô/2RB43O"M8FRB%5#2(C/2S:7+\UKY]7ZAI]PL`416.XT:T6F`K+"L
M8Y9BD6O,#%29\HF?%Q-N3!Z5SIA4*KC3AOJTNQGC5457,PV9GZ:>>@=;6K45
MK6B(CGP#1G82$JSWJ@[Y/3,$(N:R[`(2/`W?5+L4D9!=ON4O$UF(GQ&?-WTR
M$$,JYM/)T\M1JI;V%6%VM!585[R2O$1S$WF8Z>?`V^V/JULB5.[(Z]RI\D]S
MB'4G'5'?6T2S,?<'Q-"4J2EHXM2]8M6T?=-9YB8\?ACX=/PC\/\`5_H_3]&]
M=/K?5_3^?2N>A^H^G]5]-C4]/],Î>G^;L=WN_\`-\&8)U=`!$-?ICFW2*DW
MMTQY<VXCP!;*9]20^&GO_)8!*A3>O(PB8D)B]ER)CSI/_G_7BNF959ES2RLW
MUKE>ZME@TGPI$TV`=T'<&OW>*\WK22VKU3QSX)BPO3W55+_,PK/XX\Y2SLY:
M7M!T!YAW772I;/)OE6:J*]NHM*S%:?-6/;VJUV_5:>'DZ#/:KTB[[J`&3=NO
M5?I'W"3Q',^7ZAK0=-5=-%<S;1[\](5UQV*8ENF)M,4'69\O/PS%LOW`!U:B
MA[9;.9*[]TGI-59^M2&JN-*UU[UO<A*=F\=)>B9CE`/TL8,&FQGM;+%&K:S8
M,_/-]0BYJY*S>*%?UBHJG_OU[5#-YZ?+Q6]+5O2]8M2]9BU;5M'-;5M'E:MH
M_0UJ_B'WM'5I:/P]JUY]KX%JS\;5)GXSIX_[WS]OZW1=.U>&-+W);8*0=W*]
M"!<,>(5&@/5^C]1(XFT&[?ES\/"NCM:*#E\O$)[?S:YR!$:D5.=$[+KW=:9_
MO)YS`148^!BXMQU=7R^,%-S\C%BQ'8+,_EZ.ZO>GTO-+,>0JK_,U6+?QC#'T
M_@M$_HBU+5O6?A:LQ:L_9Y3'E\?Y>QC]WT_U;*T,SO\`1W.SZY0JO=[?53N=
MON\\<QS]_B=;V]JYV4ZFQA`7`S0CB<::J&ZB19ZE],;$DU<_W/';I2XR#M6E
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M>I:L1,#.È;UK$6_1=O0:`FL/\1F"5%3F?A6)M,=5[?9$><_9X&RH<+*QJ]8
M3KDH8):?UAD'-J7K_1^KQ"IKC.U[A]W>V_:("FG\K/O[A?A.=*X8XEOT=.;0
M+JIUVXYM$>'+&I.H[IC[6KHZG;;;T1?-_=S=5(`-&G5/0L*E%Z<SQ3SGD(54
ME%A+#(%<2ZP0C`(UJW,(-!TK40RWI$VB.(M,>?B@A4J,8ZUH,=*Q2E*4CIK2
ME:\5K6M8XB(_4/Y+L6E323828[=N@G:9%85Y'?SZ"5BW-9^R?#.EMZ1/<3YU
M%<ZA7$DE@`13.1H=:J+"@-FBM%[A2S\;5KTUI%>/'$>41]GC#572'?VZZ/?T
M=L]BEZO;R:4Y`1N*`CY/I('=2+,T_P!P&;$KQ6DU\8VD-/*2Î9.7H7.5AAF
MO6\B!HD`2#0<R&ERS%>IB+<1X:F"4*5NZ\V[2]%%EP**!34226I:_837$'FM
M9M:>J]IY\_\`8#*-BJ=<].@H[<\3'QB8F)BU+UM'-;1,6K:.8\_`/8[A1Z>F
MSDL;>.X:S=F39"S04KAT%\]!]D^DN<T16]*15FD3:>F\6YV4JKGFQAI6$(BT
M82V@N!X!]')I<V@UJCG60&1>2&$"D03X?'QOMCQ?\LY&@3-^G8'*->R=56XM
M#2E7+.SG)3H38=.@=YZO3]=OFO\`J-=\>NVM#_N_#V@J">O1&J*&5@H,,$5]
M+;_%:$S26%\_3S`YYCQD0^'/Q`X'M<WMD3/M]TDMZTF/DDASYT%_IZH8RNJ@
MK2:_6Q?S\NHD#/N>Y+T@H#1'U3C@JQQL@O$U!$\C.*MO^3Q_X_[E_P#[.O\`
M\OX6^C;YFZ,(&O&5[BFC*#ATSB[M*OKK5T<UDB[7R7KWA_ESU!M]F331&;!T
MKU:SW,O4O0<$H84-"=SVZWE'56$PET=8;3:D&_,K2?+Q=;-;IJMU&:\"S8(Z
M+K$.Y.T9Q:A4U+WZ.([MZ^?E\?&/UZ:?N6V[[:=W7,G-`DJQ[=<6)F]O/J26
M:]`+W?(M,.V@W>7F>J/GK7VVJGCZ.<SHN:@+THM[6U=,RZ.?71%=;UVK]."M
M5T-)OU$J3JI'$?;X3<VW(.V;,HMH9^:S7Z,!ZRU5]:@I7GN-3#4$K'<)?M_N
M\3Y^"M9H3Y&@;(R<.=+-:,%R,[#O:^6.9)8P3V6ZYKR6EY(/Y"=5/+Q5*@LG
M1M;R'N&(1,8J1$<V?R!5O<S/W0`M!EGX]CQ70?,37UJQ/2\Y%>E;JCBU,U.G
M]VSA3_S([MH_'>_Q\?4,PILHQ#05\*?1Z'3^:.[ZQ&];+^H)'_:!P,_WVF/E
M\(Z-O<F29[6/E=[VO5`?JL'O^\</$>6[PS=ZLHK:)%C^JCJLUQ8?3$2/^6B_
MZLL@TLPVLE%%6"'.N%O,0@5%ACL>76'=A<0@\=PE[\1'E/AKT]&U64#PL_GZ
M"UTWDRW%1@4&!?XT.N6MZ7I-J6B?*>8F(\?Z=?\`^R?Z;_\`YK]=[=]D+*9C
M*Ò9'N+>]SD<1HTS7/T'$LG-258M/"U''%[2>DQ:##I',>43X734`)910ÈE
M5@4J("ZX*5$$`1TB*#$(=8K6(\HB/U>4KJLB2C7(V)=IDRZR8R)K2U>ISL&%
M%;$''R1',S/BFFIF;#.,)/.>U=85$/38P-0=3K2U27X9:[:A*G-Z:AH$"\6G
M[OTVBMJS-)Z;Q$Q,UMQ%NFW]6>FT3_1/C_2+-1=*LCN^X/<2NNM3H[;ZZOM/
M4>7$;JK-ND38:WCB8\X_1_JO[PGYU,'Z/_IGC%_J_21?5_<@^?A_XP]2/+^K
MX?#BY:FL+&Q`^X-4Q]7T4639)I475RÂ-RC3I8R#SR2P0UZ:Q-OFF:K.K6Z@
M-`"P/GRM%#CJ6D7K\:7Z+QS'V>+.:384UJS%.X:_3UDM^`(J_C,<LQQ0=(F]
MY\HB?'K5_:[5LFO[K#0T]]BG_O2V,>D4J&L1_#.P!FW]G$^5KD1/!)%;MLÒ
M6X&U#?V#J9ZC94-Y?A)6L^**V[SND>O6MDYX_5:3%>>.Y`>JM%UXGXF-80*_
M;>/'JOI"GU/JZ_I/U3R]/W/X?K_1]GUW8_=Z>SW/E[G3^9_+Q2WJX=Z=7C-0
MSE:MNZ!/1.>J7'2Y5Q"%"$DO<A+T&/IB9GGB)=OICHPOEYOUQQ+4SJ6*OZ9W
M4SS`]$Y7GZHB]D''8<1U5M$<3\T>*C%2HQTCII2E8I2M8^$5K7B(CP<JZRX"
MM7[C)À&.[!//\P]Z5BQ;^?QMS/BMIK6;4YZ+3$3:G5'%NF?C7F/%=?!S*:&
MAJ;>,BQF2>X!NU8:J-LJU>>S38NG6U16GR(2*03R\XVWD,FVJDKC>X]3,8S5
M6&*3](T7DU9U>HXK*AO16.['$7K>+QY<<>`DGCD@AWGCX<WK%IX_9Y_I.:B:
MM#-6'=DM5Q5(Q<,\AN>\4ZBV%/X9MST_R\RB-X0=S,RZ==1-!`+K+U=?#VTM
M9RT!Z6CIOX5)Z"=5+P2\3\?&EK4V!ZFOK>EHWZE.J.;$!(L`91KKW,>*9^>.
M_:'W?S"DOU7^:O;HKGX6@QJ%@A*K,\(JJJ0VPJN]IOWJ2JH7/36N,5*F:FO^
MZ^/`[^]#1N6$4;2F>OWL_'R6Q?P',\830[;35F9[;92R4=OF%`?AXTWG7C;V
M5G)7,K5J*QN=Z)&-=$KU8HLZ(M[=,&)2A:?$EB>=HT,7:SU$--%+/TZSG/ET
M46$=(KZXIJ8Z.<<;`&,TE;UD?$QTVK/G,5_4K775JZ]H:*63G+$/Z5>[CY>B
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MQ,6\_'Ê+;.+766]O>X-]EG4Q3*@J<3GM361!WLW2<"5)B37CJZ2G%T^?7'X
M?'%#9OMP%H_%2D[>I\?W9)Z7,4)Q]]6Z^'?;=RZ!PZ>BQ[D1=:;YOK/WUHW'
M"NR$8*?7$'_/FD5J9/H\I[9.*>HSNFM0'4O15MY$;23+%VS(/C297IH9Y&2V
MOV#1<7-K>7%K<MZS:U%(36*TPZE)46X$L*;VGOHW`<DUI3RCG]GA+;WN\_[E
M,&QK&T2V:OBC:F25R<ZM_PÈ2J0+P$A!UJ1B:=1+6F?T4:O!E=`5>V'30+93
M0&/XR+U`_P","?[(D7'SY]//@E$@0.Q[]QEB]KG;<+_;..&L1ELOG^(EK3$>
M7P_49[*SQLO3R62-9[XA!9BDG6*FT!A5BMA,+,+FF)CY;1:*VBT3'C3H_>VB
MUJY!\XVBZGFG;"VWI;.LYK)S*G0HV=S:O,5I$#I48XB/E_D8"M0+'.[[@1J+
MU(:'@%4QL:C3(JW_``'&FB2*7CSI>T3X;J/(SAU>&X)VM$P5JT/18,V_1B*T
MB"U=:8(0O/X[WF9\Y\16L1%:Q$1$>41$>41'[(_6:'_\9D?_`!6UÂA%T`V5
M&PD697-6+B.Ù)&41*SY6I>EN)\2VJ$E6=#I]6RRZ_HM&HG8H%`V;TVG&_3K
M#Y[8ÔHIU6XCFT\_J6E'00P+H@]*S<PK495M#*IQ'7()E<X&!5O0@[5O2T<Q
M,3X2E8'9N^$6F]:QF63L/N@$1EAEITS#C);3Q'42]K16L5^$1XFMHBU;1,6K
M,<Q,3Y3$Q/E,3'C0JO:;X07R+X%R3U$E,%:C8J*W[^:%Z"45F?.0UCXTZ)G]
M7[6]E61*4_N?-W](3]34J)2N#5.UQ$#-9N26/5^4Q,=/'C?K/PMBZD3_`,J)
M_%?Z(_\`5^C!_P"_-_\`XE_]!BLD*$BY`FSCK4@KHM6+Q3/]"*>(,T9@D#@?
MX2Q>:6^6T^`]]'/B\UQN_P!MB\UI8W5]<BG5YV]%Q'9_K\^-F'2[J.C3)';V
M.AAB<9R]/6]3I1T:$`7.D\4MA*0<+D]D2]YM'3\]ZT[D1!.FO7%?.L7X^:*S
M/QCG_8,W90K##V+ZN1H%M%Ò`=&,30J$MQ5=^!B_()/R1,VI;BMYM6K:EYFG
M5<1!WK(SK,"MT'5:#;YP-+DCIO2WG$_JQN7UL^BAD&-03-VA5!?.4LO1EVI+
M6BDK`LV*+6^$22OW^,TJ5-+W9J;K+2&#A>V4CZ&AI/I5#9I:W%($A*U61V)W
MIK>M+Q:*VCQH>Y?>'M?$4%H0I1/VMBZ%V/<63FK>H)'JVV+4R-1^;M6FPJ7!
MY?">KY/!29S4%LL3LN*DH1=Y!CS_`+OH(,5&VB?R_"2E9F/./+P1'VXI77='
M:PCMW+(,/.)'E:'="M"=\XYGS77@A>?*_;CYO`T]4?*2RTWML!I-5_R%F7]5
MYL,W+7,SPVZ!BBQ2%O>WPXCJ\"QYU5JZ1NU%%+]=+]TX/5!6O-J103I5OS*@
MM,&FGGT\>.G!2"NK$_-K[@F:!-Q^XAE#NL\S%_AW267''XJ=WP-'W"M]$<+>
M!+GN7O8V@29F*U1U.@0X-?CR`>H3S^[6T>?@=W3=-SVD:BHJ78>>-'GV$4PU
MNPT7S^%*SQ'G/$>?C7.+$TF=70G%)[.WJ,A&O[7H`"OK!M3+E"9\K/5,P>M!
MD]<(D"^?CH@MM!LF<0#@T"JNJM";AD]&"KU&O`KW9HR%0EQW%UCO6EN)\IX3
M!EMÔ-IK>I5*B&[@`+7@M1O.%I'857[PIK$$M6U[Q-8B9B>,MVV!M('S<-P'
MO9R;T>M[IURW0[3:@P.,L;)H9HPS4\TJ08;]J(YOVJEUAZ:7TU>+RRX1@80*
M=KS-5RQI'Z,@/WZEZ;4^WCPS@?Z+85/<MJ6LKH>^]F#I>QLB9B:WD!NFK7N!
MH7]FO'3\)YM7PFLXED[7IEE@7+DL&S#3(@UI?M(Z<L`M'-?*;.5_H\5QU$=C
M*(W?MZ;;:EUH0S?^TRJ^.2HG?;B>R'LEO8<WDO[GF%9<=`@7$,(`CB*C$(58
MH,=*QY5I2D<1'ZJ:9-*/DDGIX=)8E,FC'G^0,P!,-:[D3'_#I#.3F.+2/X^!
MN.@^K@-63&5$F++V$>9F>D*?KW56PQ7S@<FJQ6/M);Y8_P!+-"'UQJK>U_\`
M4:K5V+>FNH2H\3D+@&.V=4\?U"5K;]GAA'*7^C8[82K,;>JM?US`#CN,GT?%
M)VR5ZZ3Y'<[<5^,!+'CHWEZF3KY5W<P)++UK'/GIYT25G/GB/,E.\O\`;:PX
M\O"Y/4PX1VG7GJ9L?4'=&./BDNMUW,+[R>0J?&UJQY^%]`QD?;84[D*AF2M3
M:<)<@B+S?99HRNL..R2WY"MIXF>?46_#X_Q+$A\4?%SV^>#3QS^(F4]*S0_+
M]T)&K>*[#8&%L]"UZ8:+@"JGN>:V$ULMJ'K0P2VK:P5J7K%J"Z[_`.]CI_V/
M/NCR$NDAH&VQUM'8;70A-=)DP>/_`!`3#5*4+'$V#U5MU16G1^JPH7U>I['Q
MY!;USFOH9AM1?W![8]P)0)!IJXDLHA<"PS4#`YZ25XCY8\;>SKRA&CMLJ$E7
M-DQ4T@HI#1#%660KF::/6G)"=L?R]-..*<SX]B:BM95T7?\`4GV3[;=>4N15
MIWV_L:G8T\5PZ]AD:S'1>5PWF:?LY\#`N(0`"K%!!".HA#I7X4&.D12E8^Z/
M$UO6+5GXUM$6K/\`3$^4^&E1NYT>WWO=2/NX][@/.V-M)Q'2^GAM%O2V`5_.
MIP>?G&"9%%)XB_Z"K-`"RL>DC,NP*A@&';XT*(D6H2D_=,>+FSTNV>](#Z@Q
MV76!K5GFB0#NF8*L@+]P`YJ&GV5_1CYT:+*=L?W"-LQ$V&DCL%KA;%"H)/)E
M$<;`0NT(:8GI@<],^=N/%_;X580OES>PU^\9GU*C)RE'I499M9AJS9;6[]KS
M8D,=?5,^5K>`_P"9<:KO::6:)`FG$:O64_@"U*HG7KIKC^RA^N*_9QX7S\U-
M9!%0<!533`-95<5?@,(ÙH,=(^Z(_0(ZP^M_.+#:/314ANY7RO1;U\Â78.+
MD<&)6_:BTS$<^,TR&@BU;33;<6A)B60EIG,`2TY`>1!DE$7F*BMS6ENJ?.L?
M#]2U4E>L9+IB)2?.+C,\L*]+1/E:EZWXF/MCQ=L8>IFT=NIBS);KK\_*FGU?
M*FF./@,45KY<SS/G^C$?/F(&T@YNSZ;0*FN1P%:&R(X$U<<G%_$GX3]L_I]Q
M%7347(77B+$``8KDI]+S"\$M2L3/YQ+VX^^TS\9G_9D<O)RHU]5]71?HN5^F
M8L)'+E,;)2MVÙ/=NQH@&*D#GJF_,S6M9GQN/64:3=S_`*7AF7:(N3L\Y:?N
M&\5]/-Z5+U;\"+Q>];67B:SQ^NP_;=$<@YD?_P!X79W)T?2KO>W7DQYDKBS'
M$2W-1QV+7O>]ABI$<C)UQ$+7I@MCAW=]FYPC^F8-G`5]RH>W6V?4:5>@/JU[
M;!(%Y16\0.>/F_E-NI%A8E3YP2OV!ZFN6BWI**:.O9>?E+&2@8C'%OD_+^;Y
M>?&],:-/<2F4P%3*]QUJG'J*OJK/:B,DRQ+9;1E&ZTZS"'69ZHI?FX[3XKI*
MS*K"[B"QM<0*,,XV1H:":ÛH!&09AV],CR2>NEQTZ():LQ3Q1##:CW9BUGW%
M5+1T&ED*:(DT?:QNY]42QF`.SEZ+[`:7&.E2\S%IM8,S/MI_0M-WW<#';>O:
ME1VNVSGKF9M(ZT'6DR:\^45B(^[^10F1JWOQ[8/DESU3&Q_\>:9QK']QHNC(
M6RUF`9`^^M,=LY!Q:9YL3J6HU:MV:+AJQ>DVFESU'6"VI-^+S6Q.>.?/^7S/
ME$><S/PB/$T2`31%9I/\T/X7)7="<J>*/S-NZ,C#/31>LCY_&2GBY$C]R0V[
M;`+UN!M0O]BXH:HV5#>7X25K/@0SR9E]F+>BR<\4MZKW1^+TZE)Y@-/WS7F@
M!?&]ZQX3TCYC`P(+Z@'7<[JU\M&6CI=@%],À"=8I1299E.K*ZU_EL7][Q0Z
MYA,`+'4,P25*(E?ZU"4F:VC^CP1S0:`FJ*/S#L$J(=>?*M>;3'-[SY5B/.T^
M4>--^%W%UW].6$ZOKV4.1:F?GJ0?TI>&`#,5:UJP6M"<><UCG_9E2,W>692[
M\*O9F@WF.B$W6E&P0RF41)79J.O76?+JI6T<6K68.+,7],)FZQ"#@A25Y3S4
M<E?I[M[S6*(YPJ_MFO,^<S/ZX(]G,3TJ+VM<,-!J7MR2O06*S/G%#4\KU_#>
M/*W/BT?3DXBS2;UJPN.*RYG46$@SQ%>.\F-(51S^Y`Z\?#^7%!TK2E?PTI6*
MUC^BL<1'Z_1_(]QWW+^Y<6<!D%M3_+%/:G^%?4Q.0,GT*HNQ1V&1L5]40EJ]
MOG\F:F=I2QG3]42VS>3F$O-YO1)6;?*FB'X5$**4\N9YMS/BC%N\GHAKTKZV
M>7TNDO7X]$'K$U.#GXA-4@;?;2?#!]QP>K9J1>JH!`>6'3@$=`+;E0F,34M0
M<<=J;42^V%XGQ08Z5&,=:T&.E8I2E*1TUI2M>*UK6L>4>+OX#Y,#1)?N&[08
M:R="W,3;ZGCVN()KW^TP;KL_];QY>!Z.LT7=UQ\R)QRE*+HS/$3&3FT_NN;'
M'EUQU,6CRN6__D>7%U.^N7_":J$$!AR7#:E=._;H!0)2TA06;-KS/V6\O%P>
MI?,>&Y26"MC:[)-(]2MKD^DU"E?ZF$+*!1W('J'2U?.?.LR^.Q6AC7N+T#5$
M7V%]D9\W"T0QFD"K-3/E_P`P!I52.6)G]W[F:6T&*61S&]9^MLO4Z\]9"7*M
MC='Z3N+.ÒG'K(;1!.H<UXZIB)%F6IHAH08X(VQFZ`*H/%U(RJ(ZP2J5+DV(
MR471<_12_>KQ/$\^`4"R_<C4S9</T78[Q5(3MH4TJ!]#W9RSI4FXS\=LG'%9
MFWEX'T-Z%[D8(I8`\/9*PNR-Q+.[+8A(WLM<KVDN(?5QUW/7C]CSH:MORMG_
M`%$":B>C=T@:+]T]G0>AYR0K&M412&^49+1%^F?+QL^BU*&^@KG<T)@+$1"2
MMV1'<7Y%_?%AF3+3J'U?-7]M>>S5I\-^:4CUF+L)1)"%RAC#%FD11)K4W%"]
M/Q[+%;_#GC9@17=!K$R]/5:32SG+DD>5=P;`:DL&H*FL1`L5ZK1%NGGP?.N=
M^N@`B0?13C:L-&OH-617],'T?6>OK*2.UJ_+3CF9Z?/QO$'+(,S`R<[9/JMJ
MMJKLHZ$Z\U:2H=<96DX#D3>AAQ>AHO'1SXA#^]JCZ"4,SH).9TJ:`RTI].<5
M<6"PM>U"1:"7X'/5$1/,QX@H"ZC%"6")6R^#M%C0:+6MY2SIHA,.O+5MR85.
M;AZ;=41T7Z3#4T['@'TONL52>])7ZP3.$C%FI6@-+6MK+]46F.B"<SQTWZ=6
MV?%[*YSH%!M6ZJU>J;-1T89#2]*$J'AWICG\?3U1\LQ^HT_:JH!ET4,R6@W*
M\``6]`0EV6<N:Q!F5[+*:*A9+([5FI_*)D=O&8VO[24NML;QL+-9_P`S1"[O
M;698IJ*W^B]1<MB4C5&3IB2=,7K$CO6WBZ3=V":$+5-``)N&!!3B<*BJSH"7
MNDD;0^GE@7=M7GH_HY2O8S4NNCMT92F?H:&EWQ=$'6JJFJ4Q"#ZIO'$<$%2Q
M*\TB9\']0^R.`S6E;3EZ<#:8[R:Y$TB64J-IQ5C0#0PJSUAM?B_'3;I3$N0K
M;;NGDYPT_3LK'I]4)A_WHU60#D(%U?<*Y)ZN.9MV_P`?,1KA+ZQEW'I^>`:+
MU5R,R@+6C/#HRK*)="V43U%0UO8EJ5GB.?`HEML?5:PV)+E:@JYAH=<SJ+Z]
MKJ17+88?SS!%0W1);TXKSS'.<4;KG:TZW*N2<C6@0UJ-IH^L;+Z/M)I2UH`K
M!236GYGQ\K<+Z1XTDC&$L6^9?)U#O4HPB;1]0((4INWG"45+>61Q(>!3Y\\1
M-YK#8K1H.J#LRFX-0JB&TKB$UO7"586'GL,MT[%K3'=F>/+YIJK5;5N<CC@D
MEA"0?N4LG'4P&8%5:2>B,*\6J7CIF.?NMP"&VF,M@]7K^D>39H8%$VM1:DL=
M`[C'=Z,<]P5YZB5KY><UYP;75U[+^X$=716/7)?FRZN4L%J\MJ=CUH2,T/7M
M4[?5:?$76:>9YH.>VOCZQBP<NJ[B"0F@T[3]1+I9K`X#^/@%[_@CJ\,M*NL:
M-P9!]<:BR+E66:@S9UI1%1@(>G2^G1WI!?I)4?G,>4^#IB?88=`;T\(K9N@R
MZVQ0]UF0H*A6N9VZ+`KU/VXGL]$]7$>?C'W!"N`6QF(Z8P$GJN(;RPV:#O/%
M>;4J3B?+^49A@E`@7$0QS$M%1B$*LW(2]I\JTI2.9G[O`R%'K("8*C10^GDO
M(`;%HWL-5H!6!5IZ>9KS?JZ;BK,3>M8F.0#/K9H2-,446H5Y4=V&B""<:P*V
M+$E8(%@=XI7FTUO6?A,>(8GW!B0O+5D(/.JAV9>IQ-TX+W^B6J1:.1_CCGX>
M!)QH*#>8LY"Z!65Z/,0@R=5D@%.[WBB&5:_G$>7'GX?[FYCCÊ=$:G7II5^F
M]R_;'Z_DT>CZR?+'<Z>9\O"U3:BM".Z*V6@'OAN9]ALZ2P;)!H2Q&5^X^/JO
M6)K2L]4^7A;(;U$Q:+-3DA26!=X`%DV'RM-TZÎ12JRMY[I.FGEQSX6)]9RR
MU<BA%>SH)D[Z]F:J7;#P?\Q0!K?F$KS6G$^`+FV,H+#1!B6`704&9@IJ"((0
M!6+%RD*,]+5BO,S%X^^/%FL[63.K5:SD,]\0Q75':U#L5[EJV@2UZ\$M,1%)
MF.?CX:E/01:A$EPN^F;`?T9A\]P37:);TY*<><6XF/&;CH:2VDWJI:&BK.<8
M+B_HLPH5VF",@)85:PR>HXXF9F_/W3Q%HWL6:R]]+BT:B/$Z?_VZ)[_$O?\`
M5?Q/V>*XH=A%K4G\22K(3F%'JZHW[W1>:CL)J\5O69ZZ_=X6[&]C&]:P11+M
M:B)/5M!Z>\LMT'GOL"ZXZJ5YM7F/"ZT>X,BQ&A:9@R-]8@I'C57OJ3=BA+`%
MZ&C8Y)%K1,1;G[_$%OO8M!63^H5)?41J.R$F]/#T7D_3*<L3T=S\'7Y<\^+L
M.ZB@1098`)[X;6?(V),X(SAT))'>H3XY_+B?*W/P_0!/WÙT:6Y90'HAZAP$
M;7SU-A@<LIB-'2A1?U/)K5B*VCRO6\1XS7T_<=T^K4Î)7S?<5B$]-WM`3BV
M%>KW^'Y_U/5DS-@<UCHZ;?+$1590C"*%98!].BN[94HWBYV.FA?/O+D%AR%<
M=2X)KS;KIUQS-IF6_INN2;1D;81:I-5EB@R.VV4=O9X9:')7AG9:]23FE>JT
M6M\!S789NX-WZ=VF_<3;&R709'.7H4WZ%U[>H*2+A.C6>+QYA'V^.B./'I\]
MN-&[>',#%;>::>'[:ULRJ*H0TLW+:^73.8X7^'1W.J)ZK<^#U0:6)<>A66[3
MNR:U-//;0WK#-6&>@!PF]O#-<7%8J,-OEBG5XD(WIDCC`<5KZ-ON78O39N2(
MS="<]NQ!9SY1<VB_329''W>&@K:"_P!.]W27'I(=2S6;>^B]*=\S/(`Q!K$.
M]JSY5GFO/QBM8B-',,^N#24;H!H?UDR;BFBYE81EI7M9@<PW7/PDS#Z.>F1]
M7QF_A.8UEW(>7U\S/ZO=5VO6%U_7KZUT[V>N0V@>=8U;]N?Q7B9CJK68C;%K
M)6<-HSTML>YH+4FBN_\`4BACJ<[96:Z#?<O6>;\EZ9^7IK&KG9NTIT^Z<&R"
M_J]SZL"N)G!TZJCRU67IK])R(>/Y!FM:U^-HZ>8UU]/WLCJ'UVEIWM>KQ'C?
M37?<&."PP#^MN,)TAY4Ò6&*;T]N9GY8Z8(\7W`-#O3&\G=?W;=%;-NV;H+L
MY`Z/463Î%O-+EK'03KM7]^\6V$<[6S\]YCVF?(_/UIT(R/;K2B`FG`)$TA$
M".4PA)4UK]NA>DOQM;KL^D\@IDMQG?X@72#*!83SD<1#MM$-Z:(]'GB''3/%
MK1]\^&ZK:"UI2:HH7J)6E;%*)$HK`M>8A@)8TP16].:6L2*Q//BMHV\B:W>^
MF4F-).8OI>7^'UGO?,]Y_P`+\?[/!;VV\BM`.1G&O;23BHM">>$2VDW`W)X_
MAS\_[/Y+Z,M(T=-[@V\YMI?4OG;9MQY8HM?,IH4,#0/;T6KV^Q2TUH.:16(Z
M*\)8+_NÈF\;8297%KZQK1E/$Q-"^>*YC6&!98N50W;':>W,_P#.X\0[/N`/
M1FC1^MX");>J/=0>I"4Z/IM*E!T[>G;I[JUR1Q\EX^QSW`'W&KQOL84Y3B&M
M;'=RZXN#Z+/1$?ZA=JNM]+<+ZKGHO<9>+#CIY\&9^J11!A8Q1/4]S%G(4F[:
M8GR*LD>(G1K0:2'ZGJFW?F+=?/63JC4#VS)5QO:V3B@7L:*JY_MK0KMHENYZ
MLTZ!F-"@K23Y(L$(Z3U1',[>IJ%>>KL-`:KGRXT#/2,'%2Q/4"6$>!6>LLM>
M._Q%HH6:_M\2]V'*$*V1YL0M)\2S[4Z+>LN9T`SUH>^?I/%,O_8WMY?AKP!L
M9-'THPGAI"S[<TU&#.9;?>U"P>/6BI](#7M6KQ?CFW,VOU!%V7EY7420$=34
M?6:HDBHYGT6A@1X+VC)/E&7S^>)B9^:M9A@?HBR!B?-:6V?3B'.FGLRN`/<Z
M1+3HHT)T1Y>=H_#/'@>=Z=^4A,B/1:=1WM=I>E!+HS3N],J`H..C_>5GSB_/
M,^+G],YU&&Z$]8T6XH<3A=(W;+$$YM16VN?L^?R1:(\^BG2DEH"9[""K":\+
MN,+V],RN-<H2V'>._28".W%^?FI'[>3Y^`4N0R5I)RCYB//$$=+7T=J"#Z=!
M)@!".;#7S!*.8@O3^".CQ5*_KF;7Q9R-`WK601H6)F1DL:)1C-/2^5&.CKZI
MF.(GSO'7X,4-=)<Q&O7".OJN@,BZ0ICMMH$$2LK&?*T633^]!;5\JSQX0R4*
M6&CF)K()CN0AKT64#0`*V,:UREM4=(YM:9M/V_RM1?5O4>8QG.AT27)V:40*
ML2C=[FYCM5JO-N;?9X]3J>Y&G^XJBK0JR2Z?J4U9B1G>Z2&`WI7#6M(/2@J5
MKSP/YI\,5O[KAG5D`!;5:Y.;U_1F5,-%8:RA;,1EL&CVE'0S^9,SU\1S2DTN
M%O7(Q><MK%$2F8DM02!/;A?;2=NQ7JI9Y90]K7-Y=VWEQ6D17Q;7IMS50CA'
M=`#6<@6YFC.[)%(7?+6YL\-)W9I:!QUDFL<6KUEB^KJ#]V$-LT*%Y=8Z8&QY
M<'VVME'UB-FH&9>;285(I"T6BD$_C5DEJ."W2SW-7"U=*A,C,Y:)[>T5]1`:
M4A&`612S([P7LTXM2\1$5Z>9TF#[!UT]$KCEU!)+RR/1<PEL"Q:Z<VAGT55D
MA6]/QQ-HGFW3,14ZY]8!&QCQ=+2'V!TB%T_=K7N:&"T;:=:&II,+$!>2%OU0
M*UNJ;<^,0V9[L>:S:/"V*L=H1HU`JZF.]A4[HB+UNOF9N"JE3N0:M@4ZXBI?
MS/"]2[#-H!H9YK]I18/J\E$C<FPFO._6IIC..&)CIFTAK,1'P\>X?;4Z]V+^
MX<&V9T\]&H'"%+Z]2VDS+<,$"37M$DJ,0>N?X<3-N6-MK2E[2=6T%W;`1!F*
MW];&(&+JK+WO*G96P15\KVZ[VM>9^$0NE;W!,C7RV/;=9C"RZS_EEE;/4(KS
M$=<[7;S1\/3-NF>>D,1/'A.GU-BBR]7J,#HL&IV8<WV-_FC43%UR#(V0<VXM
M-O*WE,>:*NK[Q5JTQ].QC*UQ\E(CJF,;*T\Y1&@HDBCE)6%)V/S>NI:UB!Q4
M,4G/O[@9[/\`>ZC&-*H@K"-3#E<2E/5V(K03?MX%[TI>`VI-QCH&LUZ;2MI]
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M<V(RP:MQ]OF.%?FK'<_%X!J&VH)I"<SW+V#CK*Y]IS6O;)`4%G#8F%^M3VU0
M=Y@G,W+-_**UIXU-GZG9<F@!ZÙIGJE*BT_[>6]O7;&8_<J:1`4H2E;#XZNJ
M)YK;B&;L;1G&&FJMV-=*LR(D:WMO6O`;N-/L]-[^VZ5^<MYXO\9Z8\,+,:]F
M0D5<36!]-!"J`&S>VBSZ0)S-6%/3[;I6U:VJ"()P,8J5BGAUWZH:E-&VF0Z]
ME[6@)'7O<3RUD:C=`J"%+^XKQ/<";K@?E-.J_-K+:$)%]95T<QE)&#!!#]GU
M$(R\]%&%XM[0',TGXP68^R/#@P[Q0.:!D6'6AYXQ4)=?0]PZ300B69793289
M]Q$F@Q'K(H'6.J\22+KY,ZS/4O16*NU5",Y)1]MX'MY6#2*X[V!'^7QFO2+5
MZNNU(FOE,9>7[?E)S3S-M[7B[D=M,I=8.R!Z]E'YUH/'&Q;BI2S;GY^NUHZ;
MYP+;]Q31;&7UJ`1%>K-,G_*9JA1/8@B)Q9KVO'YG3:>@T\16:Q/@"EMZG0',
M-[>YK[?S1S/MXZ^6O<59K>+QO=&4/A^9MT3,](:QQ$,?XZ:M"-.D"GZ,M<X*
MVB)P+@Y4#J!M+)J-?$=Q*_)_P_SDZAÌ^`(J"IS\>D=8I7_T1_(>=^L2(.GH
MF:;7^F+D+"IW<;3NNHW8O4HWZ_(Y]1%9GMWXZ>JE"1HZ1WN@>@&:RMZ$!9&Q
M/MS:]M2>#DO\]?2['7%9KY7'\>+<0[IB?*YZ@.B$-3C/Z@/U9T&B_P!;%GB@
M)26@1VX&`/%?*TWF(GP&+[MKM*8)?;J+0,;/4A=2,8^0FW*W)@&U%X:)>YI\
MB\Q7IK6/-=EG8-H$%L3LDJ92+#*>74GNWRVT\S-(*E'%KD)?S^,S'C/QH:]6
MOEHH9ZEY!`"=E)("O)>DEZWL4@IOY16*Q;I^SG_8MO*"2@3:>1I9XBDZNV(C
MJ9EJ$OT?/T4L3F>//Q026CD9XC5]*;/6>V;IY((8]H'NUEV(#N,MN7]NG)>A
M(%6MW)^:WS]P_;TLP-B3ET:HKH:(_K9<_.VU+[FFTWFZ,K:AFM2C70,1(J2)
MX+%^DOC5-+V9IHNOIO&S-1_4M7=E>7X[>JZ)/U*H!>MJ6HY]=63ÌQVQ<#K!
MO\QUG4F%EVM<A]"&#IKY'M5.@9ZBDCBFCAF/6)F>9+$S,VM?D]::.8O8I,OU
M(U7]$?UDB&1JY]]K1:;S=&R^F5Q^K7105^DG/!>YP7QE%0U%_2C2]OI:EW&M
M"C?^!^XL_:*TM"U>AEC2`L0-^NXICGXVB9CQGÒOKPNBZR82R^@S0B]V*XG3
MKQHDQB$;TP7S2]'Y0#=)YZFKWDE[^[A:!,LL^X?;JV%+`2Z!S:;`">X['VMB
MK58@+6C7:IW!BF\1-)^:8Z>/1R_GU1@*:QKA9U8/JH"T/;3,9+P/E"!')2QS
MKK=NUNNAO.!\EZS-9KB2@BXE,M!TI]0;_MHHUM@!"XRZ)`KF^H_4!=V;DITP
M"/(GR=%3]>#4-"7)_E.'=:<3T5SH6G*]=*WK?0%84L[/Y'1ZN>GMS3F?"Â?
MW+>[W:85;UU[D8=*M.%[=SEPU%IU?2O571QS$B"UO_%ZOXDWGP8P_IFWFZON
M:S[*&AHZ(AE%].]U3#6JPJJ$X5QFT05JO$.1!HKT6$&M1C=,?W)]5DRR8[$=
M>;#]8"O.#)<767`C<],X],LP^[ZH\UJ?GM<R3K%H>OS,]E<4"1]";5+&,&QO
M:%R*YQG+W-(:"P6*^?36_=CY:UF:U.J]&;W+W6Y-GL:3-M`P%!+LZS]M"W2-
M_2,/N$H.OE/XB%M\W\ASW`J3-%1A=&\28NC4U]#-Q?<N<CZL"G9J=59W67/6
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MCY\"_P`P;VIDC%.@UHO=62.RAA^WY_.B0N:DMY%=O\V@_P`KRI^"HIZ?'MUW
M1I<.N][ES?<YLVY1#4ST0L7/GHL#(.):17H,!2"M626OS]L>,R^XUM`R%H9.
MT%Y_&,VQI_3\@=ZL6S8)!,8FC+=UAUFLUX^;IIVZ1[DG*;V!5G1UFT1DT<XX
MVZ:GNP33%DJ78$6MQ>U;6HK0A5ZA/SYQ/3;PJAU:OIBX6H@^SZ_'3DU'<CW,
M)2I!"?-9756>+GUDM;,VGI[G=I'<K*C(]3<ITE[OH'=#'N&@@>Z,L:*S5!#O
M:]9]ID;D\02W<)$>?<@?@@GM34ÙULG+<)<9:;:(_;ÛT0DQZS2ZL9G?E+HI
M-%^(K^"M)O'C37K]7ÎG]Y-Z#G:T,^^B?!>UJ.-C]O,G-Z12?1%FHZ$D<TFM
MZUZ9Z+>/?#&@0_\`F/W%D8ZBICOJ]=AH9LCE#U*-8J@4O789R#X'ZB]BC\O/
MQ_\Ì_M\GL4,M/-64];DCJZZ#VRP'+*]G)$T$%$/K=5Z7J"\W8@<W+'3^);7
MJ7=6IGTJ'.%J:6(73*L;7]H&TU-RR<F4;7)1;2N'IMSÌK',6Z*UT&6G-5G<
M%EYS&0QZG+891UW-#4![C60'4V:M"]\*BE:UN6O$S,B)4O-O&2A46G]3-E:Z
M>VMFZ>/33*X;,:6Q2,/.^G1LE+4TLW6DS>.J/,E:WZK#Q^NE93]PC5'<^,+*
M5.8N_?.<+T%N=MNTD2^0@9YGBTFK$&I;`HO.K>`Z]#L&99Q0$IE_6<N&T]1?
MZJ]ZF?I,-6$23,VF+17MUO%;^$Q69TJ#$ZS:6B7Q&'SLVKD>G,ZI&L%46.*U
M'(M2ISQ>;<P&E>W6G=](SU=[M^GY6[W3ZGL=_P#XCL]KM_F_CZ^W^[U_+X__
MV@`(`0$#`3\A_>97VG_QI$`PR[<JRK)JL`]ZDB!">_\`=Z!LD#K&U^WC\"2>
MBX_OE\F=KC!PU%0=35=62;ES''=0CI!5\S:E3%D/HH"<*@X<F4FEQ0\RU&17
MH)2O&SYLVB^6XYH0N#=``4'Ò/WQ`P^;=Q7$6>028DT+AARB3P`,H0K*[):Y
M[QBBEPOSO-&3O!@TK5_3&T6QG]S5XOA.U`5HM$*H9DKU4UG&H?``_*V#.RT3
M\";1D?..`X\"0"`/!@#Z`6?.B/['IW)(!PJ'\"+:3^Y8A`HN'S256(DNK`N8
MSX?`L67PQJYR:Z0"DO+E/+;`[L^RC$8\TRP5<=P"=T4#T7NL':2<JY`3"$`!
M1#B)Z77HSQ,1\;OB'7]O0G)5(KB2))TT8S\8*KVUXU[&MH1OB7&5BY/XA<2I
MB-[$D3IB>)44Y6EK7AJS2$T<O2\#'_!,=``$0>(F@#`CHJ_CQ3%FSI#%GÂ+
M_P`;64VPN(A<3P1Z3O*.O)H1^_,?CY1-'=5GU]_TP^C*8<R&_!ET768`#*I!
MC,"I1/V##J5+E4]&X##*]DS+AH/QQ8;/PJD`+5=C4^&4WC"4;1G$B+^QEL_N
MWQ3$BV2DG5Y"<$PL?%:Y-268H6['3&\C.!J"^#$1+,!?R>G:R*D!1&\/[9#O
M.J)R-_"9=0QAFF$0G!<CGRZQZ&)68V,#%#`WW+R#S4UK;/G)VLX`[YOW$PU)
MYA#$/QOX_P!97%_MC<IQ2CE%D3QOCQZ_S@#M%/L`/Q_.N8;D?6R96AX4KAF=
M*Y9R1S<!B^=#$2?J;D)E*+RFLF.Q]2UH`;QK"3=I-/J5?9\_!9UVTHJ$$"IP
M7<7*UR/LWST%R_U4\E9J\K9K'?)F<;5C1.)Z/ZQ>0/\`/X,X2^7'?O7<YAFV
MH=I<`>Z\'WYLBZB>CI>27U%CN5B6Î7SEPP55J@GO_V/%_>OKTCS@::SJG8G
MR!P+1D<5#^11M-0,?MF_$\,IT?>XC<*6*S3>/+9A)RC/=E%@E^S42CY;U?\`
M46!Z]%<;[KW"&B61X2N<+<_LPI`?IUI(Z:1-`=7;?23')]IW8R7/P+BFK2DH
M-03RD^-U)_7Z%,'[)0T4NGB@33$!82F`;Y0_#@GP"%#'0Ê=$@X``$/@,?QQ
MY%US99CFPMIG747P$DL`````$`.`!P`SA1]*:J.=!N6&&+)Û@-/!3[TCASM
MO3V@:/`?.P>WFS`-D)$4`YZD>YW0[!V"LM1E=;]0CCH\*2'4U*>]W@30^#I$
M"FJAHRHI)!L\IE&3H0L2312N-YD99IV7JE-6B7.;<$-GK'CICG//&!ONS^WK
M))[L0!'^(JV"H%.""TQ]:C"$&R!R+R.>3+Z^4]4=HÈP<%F`%WTU5)_BYXM$
M%)X$#SC;_FTH02]P"Q$\#"+]ZQD&1^!J<?5\ID^BC&]V%=W(??M94#,_W8HG
MVJX=>:QW:IZ(-\D[AWYD>+3!B3%E6N$.,C$.21Q`P<^-IZKX0E4È/`[FBH(
M-)07>IF^J\A,Q'$5X@]@_>_*AOD,K*I*^CX-GD/`[_@7]O=Y/6[(6?;)Q9KW
M@CN.:.IZM(ONW3\_YX!"<PC7AX56MX<P?$-0ZKS:T"_VJ="(ZÊ1_@4\2OG3
M_=_1_>WO%!R$F#]U":B&2,T\@:$-/FB!$Y&?!I%#_@)@XA._@`6+ITWY%[]`
ML^C9Y,+159H4DPQS),<L-_1Z@\4&7H2P17(9?8>/4^$?KQ$/UB7B>]N'7]3?
M&D^[EHA2R1,!IJ5Y:$DUT>O7/-,1-2IM=$J>7=WD<AE(]Z!;?L1'#KWA"G!R
M6]7XK6(/*F81DW>0C0TL>;*<-AS5(Y1&].K.'&`B"(B43HCX1^Q^/R4/Q@HY
M?(_R>-],YV/71B6<&,CU=UR*`!!#%@!E;=)\*E'V'<Q5"IA&V[-@2F\=G8RQ
M^G"U=-)\T$->HR?YM^=T&N/8AI'$ILQK)'O?9!"A!!G'0J-:%AN[`&$GLE47
M+#1W-,A!*=S^2)55_0">6F#-3BE0<((`^"RTY<J"/V"(XÈ#J;N/!U>/9_4-
M'P:LARG9CC6GW&IT67=%.PAP&@'`#YCO;Q^T)"$#\.ZC[0AQ"-TB`GXD".*N
MJZL'D0.C3B-92"B.4S!_P)'Ô((CYWEC'I8)[%TD_(`,>X#?*<GW)&\H'PYC
M`,?IW^]_A[$/?#B<%E)*F=5E57G)7@DR?&7HZ(456\4%/!NLFD2,U@.`1N+]
M?H%91+<U857@)3PNZVT_<!`?XC\=EZ$-@J*&0M&4/24)O26@C"R:SNIFFHGE
M@?G#<0XF=$_>`0L!V`!?`;A\=*34HE-H8"N?!7M%^`%`^_\`![^;$+5G)T_2
MG.'@YNH[KGAT?JN\:V[BKP'!O"_42H'IZM9$A92EV@,1&TGU6F9=OHO38X&`
MP29X!\>B'T%`C9V.?`?EG1X>9>%8``Z_W+!]14:]UMDXMO+G!3R/I<MC>3E,
M3ZL9.08D12_`4'`/B>3%+,C_`(4PX9,9X(C('<X\G4B1!33(M.=CB%H<PF5R
MEB'G7!?"`%4&.Z4.R10B(]ID_P"/C3FO!SM*Z(.I^4(GA39_1^=!_`+E/PX+
MK/(*%*'Z2_1';?`>JPWX\9LI!NKJ`;[&EFM$)3Q&)]XV/IJ@=2QZGT-^0=8Z
MZWKH13\`!CB?"Q_`D,D2K6B*L])+@L*9%"$-T^4#A5=L4!8\_A9>A1FP7%(B
MA8N#K+3.UTLXXK?3>:P-+K8[<G\Z;]Q#LT%#/"/1&D68DKU,:WXRE:&=!I,R
M"*/@L"%\=8/'*XJ/'4`+?C)&S@IP%5K6`QL`P0B?/R-].#%==(&_C'W(?THS
M&(5>>/4*'$P_/ARKJLV`S?E?J_LTR1Z8X^`'V$7)>.,F:]R./U5Y@-.".R@X
MF"2D\(L7?O`!>.D:ZYV-X?[C`^)EG8]K=61?_5+'/+XD!X]BQL@FEVTVA%PB
M]XUQ=@B1$>>^]`@!0@.JKP`PW&['.US9S$B<`"+N=IX*Z0Z4CKB:NJ%9DGE1
M\JR%F4;`95D=6%%>"ZAP5^GE)@/N:\/(R2DT!4-TF:!Y)N;)D!^F[`^R,C@6
MG#-<3<T"KQ`^]EF/E<H&ND'2W=X8.:05?++)/L5C0'WB\R`/;"@K]>@``$#@
M'@/P?+)'JMXÔM,G#`Z^N9F@O)PX"C3/+IA:[+J&T&5@/O,-3HU07'6JE=$@
MX``!#)0&+18+H(@_P4G0!>.E97#^93_1ZH=B*A.<9Q#Z.[S`3-]G@%IYI/->
M";]:K+OYIB?5;1&YQ`(Q8G!\L^@X3/ZM@(JD$YU'D#\(NLXL*4@;].4V*X^S
M(\XG*/BZ,$)1_##2HB=XT3;I,@6Z5LB]D%\,5NK-[ZR(84E6_N--RB?HI$A]
MYKGRG(PP$!M8F3T?#$;+6U6*-8QN")Q*38_YJE;J09/D38!<3DFR%1/%:KX+
MU(X@29NA<@U'KU78&TD([C&-/:[<T3OW[TV'$4.2AO$Y)JY82RES">H8QQN#
M!&-$Z+&>-0Y$O,I2::85$UJK7EGT]56.)8A8Z`?;"[+PFJ:Q3.N:Z7]T/#@@
M%A2$S3X,/L+[#[5A[*NJJ::TP%*'*`BU?C52!6HR4O!DFW,+8V+NN!M872\5
MXOR@0N#"RFH7%Y=99<,^MD:Q`3P=/![EJL26_P`=4<!O-J92+M)2XY\`)`T<
M+<R`PJ13SI`METJ<%ZR+*;M/%8SP/A$/-X]$IW>?UHNX04ZJ^-<^,-[WUE/]
M3MD@5\A,:V<O<D%*>0!I,$<#,QCX"302B***BJ.NK4#C#HI00$H(UX\Z:3N0
MO*#/<$3OE&(TIA@X+IPGJ4I\6**3W9],I_['LWH@IA.$8-_(<25D$`/05"$H
M`)>GXF0V#O)F`49_B%UP[AC16M#?+"`N?^CPVV\"&\LP9WVJSP*&E#JH-TN]
MP^P,U3&`@ZII`$0TQ@@WD``.'@M5/F$?`WCR1<,#1G3>YSAP>-330"#TSU=^
MMLM8N.7C8M$NW[#S&$V9G:'=T-4KJ$ZNAIC$$-GW&K=`DY`H)`Q;KI8>T%,)
MN(V#@E(2.EY\=S0NBT@8%JM$3<Y>K58!7X$*K%JI1#7!P;G,@YR^]%:]&D(Y
M^^<6P"/6%C)*/M'>'82]<51PC-3,5*E[F^0P*..*?>V)D$SKSH[;N0-D<'E>
M,.(.D-U*L%3"P@T>.3JJF\$`TC'BAP4AOS8]_!CJ8!6VZ!+('D-D[C@>L-&5
M>^B$?N'@/:R@U8])5WY6XNQ_9+O7JT$\H,[Q-(T\;(3+]TTB/"&#H/TD9D$$
M-[2,IZ-+ES/"VO18(E<K<J!!@:\$M%_-8/=5"0O06I16++LG>I6^X2E.WC@'
M*A)?K+:`8RH\^\,_7>$.,AI!U+/-[+VW":;5RHGÛ4P(!Q'R"'Z#N#@"\R&+
M!AN%AH?FKR[-./`1LU$.`$&IC]_+A4>8J/0"(_82:2MDQ>TSZW(74QY%?.E!
M9VUIP[@@DTJ$%LU>TJ!`87!3=*!E+)8.;36Y\Q1R7%"[T6*"EG"YA:G4(MD-
M%57D:.Y/F\3<UN6-)^WAR[K^>-I/8$KTWSU`+9%Q=SL'"PW?$<\(UVU0!>%;
MKX7;P'QI2"GL*KIAW"U@@X6YU.3>SWBBX^8E(MQG[+,;LE`3WL\/*EHÛ&U^
M3IT?V)=6M19@`",!0-SP<1G43W+NAU^[H]BDMMJP=W*8)I)\HH,A'\D)^Y"!
MH(MTZ_WK01LV@6Q?4R\-0R29%?,AR?"3\K[,:!M/")E52A_D-P26ZXI0155+
MLK0WB\41B47P1'E)?-;JMDOGWUZLO5#]OL>%T65760$[M;E$)'>ND'LUA;XY
M-SH?>5M(GE$/JRKE8HM*N#C$9HFAPCEO20Z"U0XX\$H@`'IÂ.,)["EZ!_1'
M.YY_*,HG1UK<UMW<:!N1(&!@E8,LSK4<THQGE(T=O3I($A;+A::!P;'&(H,!
ML"2F>+W(#A;(3Y)\$XCIM%0JEVKL.U"?[(SE5S@*+?%0PQ;Q^3"(ND*UA<.J
M&5!YXAOZ'GT$\+C"9\G=92J4LPG_`"T6_P!88*(#5GM+I+0EZF@"].P`)*7=
MBY/877ZTR#;H/LAFNN3*G1@ECU0<7.1+&4P?5P[*EYK0FAC9@)U,TTDS0T&%
MPR+R=5D_P"#]K:J<.=A,HOR@)S7UW/=C3!%E.-T$$$GJ`<G5(%<@7F!GL@.P
M@91BU3[E])/Q`!#=EH6[L.J":3C>>9@S/$48^5\+GR_]>T,!28Q?[>7091Y7
MFF,53%.E=KKW\8]V+8:U>'`/I]Q1SX.E#4+ITI0\MF(Q@6$QH2'%0Û@I9U%
M[,YJ!#,3ZH>G:ZAKY"JV#B6R/(`3P815K.:A4$/-@5RQB[4T_/1]W=_^Q4K_
M`*K^#C__V@`(`0(#`3\A_P`7_P#_V@`(`0,#`3\A_P`7_P#_V@`,`P$`À$#
M$0``$````````````````````````````!)`````````````````````````
M``````()!`````````````````````````````!`!```````````````````
M``````)````````````````````````````````!(````(!((```````````
M````````````)(`````((!(`````!!````````````````)`(``````)````
M(`((`)```````!(`````!``````!````````(`!`)`````!)```!!)``````
M``)!```!```((((```(```````!`````!(``!``(```))(!````!!```````
M(`````)`!!)`)````(`((`````(!````!!``````((`((```````!``````)
M```(`)!)````(!)()````````````````!!((!(`!(```!(`!``````````!
M```````````!!`!```!!!!```````````)```````````!``````(()`````
M```````````````````````````````````))))`!((````!()`!)`(```!)
M(``!()!`(!)(()!`)```(!``((((```!!`(`)!`()`!!(`(!``!(`!(`````
M`````!`)(`!`!``!!``````````````````````)(())```!)__:``@!`0,!
M/Q#]Y%L*N00M&01(RMQ]R*19Q0@0FD<K-(0'L@AP),I"_M,,,0$?WQ#!,YB&
ME&;-F-8JWAOLS>E&-!@.+F*.LUD?21O5VH'7Z$M/S>)F#N@HXG"M+MWI1U>4
MX>/+07V'4#1Q/WSH8B=X!T!)L$"ZZP".C\,`='`3_1<-!R<QC-N;R:L6(8!%
MY>,_<W?'4`C0/'/Q0U"]F,A[1E4,Y]L"6@F\*4GRNJKM0SH(A%3(@9="T+1$
M``À@:=)J-)P"00@!+YLSA";WOI3^Y'*>%/3^,IQNG)^N#XG+4O$\=5/2!:E
M3H"*S!/E,R27(%3F[ZZ.',/_`,N+%Ò7T+R^*C&+`P&_P"DKA$41]`'L.1\-
MV"*'_N!/L(9>BHQT1*IM:!#_`#^M,'JA;`1ZEW/Q@=I<+MLE4T`^ZCIT].Y"
MC'BB(H:J4!<L^JQFWE+@(_B#-7(B(CN?IF.\.X+N;P?#PGB5REE3Y\S).QIX
MH21@%S5]C:S/*6>;[P^4HP6!NOBS$&@BAAT-62V!7MSZ%<WMDH;X$#RP_7EM
MO75>6A%,"D"QXL3^B?:I/E[-<Y)X`$3_`-W0UNI?D^S/\UV!#@$;]K'[F><>
MC1/V]RQR8`^/CET@A>O"P$@B#O%3*-H%]X<]$A`#I.J&J@:`G&AJ!63&0B;X
M5(267D*09@R`,C%'(Q,$_(&"\#7;=CD0#+)B(!S7,[0#RC3E(S1#`J$XR/`-
M'HJ\$$;J^_5$3<$W/%7G?42-*0EQH7D62\*`D/.#RD1,$"GG5,L^;J?!X:A
M0^:VM=!+78#L\B9&-^P6N,)"7'H&@SP_+!9#*O>"\+4V;[3GI@%L=T_5DC+Z
MFI,@!R9Y.^*T]'64\^`(+ZH11]$3"%`.T!N>:A5^3IL;>JZN?6:<IK[V,H9@
MP_HI*R^FK+1$SNKU)K$%YP<A2HL1/>39#"1-N''_`&MV,T.[:,A@[1TB2CQ6
M7:)HQA,TK*4D.R"Q=C:L!X`@.*#"+#N>G<*L6@/!)IZJ45<SMGSAY1IGQA#%
M5?P@8@I9PX5O&$4U`B@!C+1PJ`(_#3F$X/R-X`5L`SCD:BI8@"T$M/C`'="W
MS-,"-6I;2`R84JRY=SXZSPN'8,O`#\U_.7H@!P`!\"N-?Ù#`!0",F$R'V%R
M7K=@1.[%H<!P$@'`PIJCG3@0-!U:.Z9P5W5"R.F)QY&GH]>D^0?H&)5@RAE'
M)@;_`%4D^;#@NEA<"33^'QBT&L$Z3\D8O`>5*T3]Y[GEG]T?9G2YN_/4C&3&
MRO7B[1S.=B]O0P(F2B=OU?'*V#PF33C/6Q&P((-=KMX4V#[C@>8)4"53F261
M1!:_%BB%\3E<QX-&KESJW(S79N4GPLI>R5=1J[FU?JV[068;!V3[(V5;!&"P
M+8(+,SFP06Z33,)\S$LRLQ(Z6'N>4H]#Q"H;#8$=1-7L'[!XGH@HÌ$`55D`
M.JK\T)(*MY*?&\.DE6@Y+88G`@!\9F3ZP7%2A(@0CU#>SS`[C>%Z"E>H6@PF
M&<!Ì((G7Y,0DI(A/2LB74KE8$6MTV@"/>RG$G5]4KPKC/,HOP0G9$T3W;<,
MBV('5HDS4R812$Q9SY;:^/TS?3SRQ@/2`P&S^/B`M2__;)SW_2J;9YB9^M-
M&@-AA6I-#7U':W.K2<R#+>``?6&YI!T*ZL("[USIZ2<6$T\W/`T]'?G_`.I5
MY3J$M'+BGK8*RV;#_-O3T#4P);/4)X<8;U?(J+1[P>G;_3-[";33!51L*?RT
M:?0+A6Z;H80H-1I>3P[NS&:LQ`DOJS<V/CH)9@B-RU?`[J(/Q-3%7_(;G'<R
MLE8:#U/B`-BQKL=<HM6D/7/03.0`%`H!HGGXP82,T:MP6IJH7'BD9M]^=`CY
MF=0E$B_.B;;>"C]>:#,E%PR`JNV%H?!)'@'WTPA@\N;O<,7(B_@Q1<>15X&3
M[V0=X=:7/"M,R4'P7(,`,E\8UGRE3%>T%#)3]GWRQ.L^!]#47GCX&ORTI81J
M>&@DMC`!%`>^MLU\_1#FKW)'>-NC]$%HC/J8ED<K<CNW7Y"8;W6R]0/*[6&U
M2V3&@2`.`?,]$2ÎD?4*/..]$(4PRMQ?$+#)IHN2G2RE7@:`--M5+BHYSWH?
M2N@"<`0,>9Q4W"75"OR)\DX\@3.A4QF)0UG]<S.=AX/'*J^5O^_8<.O8@>J^
M)V"IT_4'XI9!3.8'(QZ3+&OF(];F0E@6SD(L(*!?T#:__P`LAPZZ!E1,*"E2
M&OHT12?$?:L^R\)O:$-`J&DJ$R%G:A?:4A/Y.T4,T2U0@8#*2&T+9%2:9,P`
MK#QEM(R'>I"'\Y=L*5<_YC2"6,8ASN!EC!4D%7D8&!D`K_/"TC:O)`$$M+/%
M=;`/PK!2B/?3>K,@KARIQX&$JRQ;S4?^P6Q\JD4#72L@1R-JCWRZ-E@@#6!B
M;O3H-<#30@2V(HE>_&'XP.H4PODUGP3!ZF`-A$F)CT8CX#!P^%0%4`%58`=5
M7@!B:8W"UN8"1A7'?@&M<2$C[=XNLNCR`Ê'0"I6R7+<8STMRA0M$L$)\E46
MTK`>Z!BI78`6$J`JB/L5IF9,1.'6?PAI"]Q7OHO'Z1`2"UZ\'QYO0.U)_%&+
M,MQ\<BG*$S"MPW*4RR<6YOH[!Z6,W[BST1P7-70BO=AH-M,)7`-1?K@4>Z@\
M(F>D:RHU1)[C]'\8/"4!#D=O(YI4D)0UXF$!7WT$F@BAE9@BO?:HD<3T:6X,
MH*6$.^Ê="@<*#$)[D.Z75)*965?1["16@SO]+FS%A=%_:AM^@?PVK*`7.XN
M'S4H(HR[8O\`./1S#%,Y\.C8XP6+@'J51":\?LK&T#]/J:Y>!^^@.][>6\GZ
MGOV3K!?,"`.AW/?]N&,LJ("_800&96'M/9YE']#96JL'<7&.%.&VOF6XX<3J
M-LEI5CCTO7QD$G<T+4_!-#JL%6"`]6^/S69!,[O?6@0F"5+E!1)1[P7U`(J\
M#JKP,L=IY-\\(32`;[7<6E=UTBR5!W'&11K`C,6ZU#IF;]O%%P(V()WRA/`-
M$\YZDD",A%4K`H7@`3D$+]*W@_I:_/",7#6MB,^!_H0C<O>=ÒF]$#285%>1
MXH%P)YY,F'S)!C@GM2\>CQ'[S0F,IIHV1@"OH"````"`$``X?*#`\/@'W&LI
M=T+S+RG,)CXM_/M_!M"H@=[^JLN'BQB;,KR@PVTA%*(2<``;I/!JM?NR@"M7
MW+C-'QM./_H\@\/3Q#7A\GBD@YM$R27_`,W,>`/?[^/_`$*-,!XMGL';L==.
M.8C^'C<5![_:>1&5!&9K"<"=JLVE_P!:WA)"9.Q#O939U'"2/:%(9È::T?;
M"*9*=Y"2.+PW>=H7;1HS!(IS5TY%E6IV'F<U]+BBDD%CJ)NKO3/IYGZX$U#L
M6E)IU6E&?.<G7^@,<J(N[;*.YO02#>]/Y6!28U\$X%4Q]B,+<,MJN5S)_5"_
MBD6`6IUQR9_'<5.ÂWS"[WY5H-JIVLW?X\1?^DT"(A>P*.R@0"6>U@A&)C&>
M%VGN3A0TM$XMZYJU#MBIPG2-.9SU!!D0^*HT%%'YQ&Q:0F"6(YFU#9["C(Z0
MF,KN#WS8N+(-QPVC^7\L8]-/J88]P+H(#PP9Ò,06&2J2<7FRBR?BAY;\![5
MS40;I@OHJK#"Q>J>*=_'9:F\?W;];HQJX`7.RNYD(M@@ÌW)NPL)[>TR14*#
M47"F'(7/IS@F3S/AYWO"%LAML!;HH0F#,S%[@U:5MX4I<4[70B%FK6<63B%!
M)ZZ\:`='<[/[)`_&TA'>*RU]WHQ"7S10\[#`K8-E81\\OAZ&2!892E'N7;GB
M\.H_O[QH</AR'PU18LRL>TF:%X",!0RE9,,?=LP0)7Z(.VV<[F+X"P;NBXS!
M#L-C_1D"(VXX)3FT<E"$)">T2UE?B!1<$[LA0?.B6.)G8:NV<R:Q[G@PHQO\
M1!C6#11[Q;;?VX,'E;.L[0.=_-IU@F@T1H``:TPL),[O,6<M:8"`=4";A9B8
M`TKH!62:S#J4IB20&TSF<YD6W]K!/5ES?,A*T6@=&[=FI<MA#,;XI"[6?'G@
MO0Y_0ZT&EG`="F8BRIC[F%`T`1@(W6:7+[0^L#*9'BP>U<+JQV?B&V4YQ3/I
M4>B$49W/96/#&-J&A:#@JS<CY75G&WV0E@W?.!AZI]8C'<B%&-06(TW@%B@/
MYHX3B='NY9ZN0O,7UK\58(A#]6T-$EGA,C&^KP(/4?/OVR1R6AP(X^(*6A()
MP?Q,,$#A)"@I!#>DN?N+J1XD=E`TQTB`N-#?P-/BDI(8NI.O@0M:GA#$`0UJ
M7M59UL'W;U)S3K0!K,0VV0E9"SRY.#X^3E&O>P_2MF_.%]A%LN8R*0[\2U3)
MWVN@AD]5=HG*GZYT<)U68J36&L[!,>B=OP`.89-7<2*`7<.UW7,STV2À>B`
M^_5FM!LQO=W'GZ::;TY&(%_DF$]!:$3&^S`#J$D!3,4*=BT!GU3UOHL/!4XN
M*,D5U;942&]5"WC!<!)JE`RM\=W,G3/M&%[T,/@(^Z@CZQSNN10WRQ[YG6#L
MF2^!X9V$-ZHGH-:CAU]6!8G,8$QL>6N0%`XC!<:5(7H%9)(8)@"/7>*D)L2$
M`%V?,_3O-4",%`D<J@A>^&L^61672YF@(03JX;\$]R6@&E9$X/@FN%=(K4/\
MS-%3HJ6MJ6*E'MW9CQ=C.>FV)40:_8YDU`'"2PDV,$1C"ZL?4'ST!C-#@N5V
M]!^3F:>8.+$;ZQYQKDE20TGB2(0X]8U7R^R4Q=B$91&.5;K?%NU@1;FDBFU(
MF-!H!`XMIIOKB%@5B?1K/*Q7)78)_1<0PN6(2ED0/Z+\\]F&UVS]6^K!4(',
M'?3J2T\T7C*J(NQ'Ì8UA`B!,K!;A?N]9Z1/&@(QYAB\H[/.E9*M)9P+M8:/
MP%N&H<+%7S&$60R#`P]*U-M8=6GV^B3K^BV)<[1)7:[3,!5%W*XB];:VCO3\
M5L->"('49J4$^`4$H:3THT'8_HS2VV^P5JSAAN5IHPYF@$^.A!HFGH'J^CW@
MX43<'H9S2$0I"@NJ9ZB1,CE%_O1OM.2\9]0*-Y48:>O'*3OS:AOVOPW6]*Q4
MN1W/>0:$"=Y(<B7B0<_VXKG_``4_=T)CY53L)Q;9,(N++RA7^-XUVNPU&%+X
M@6_2EXPLF!/XI9:!F?>K\@]Z4IA\G<>91AO"X;N?*X6H+`<T*R\B6MDC'ZOW
M-JR/PU;UP)&U%EL/O!/TM/E+O)7,VX/:UU<?C9F6"1QF@7:-$A^#CCLÒ+^J
MBP&F,1P<W,ES8H<".M.@7!`^]A]GO1'4(]`?_]H`"`$"`P$_$/\`%_\`_]H`
.."`$#`P$_$/\`%_\`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<TEXT>
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```%3@``%ET``!MF```?U__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_$`$0@`5@#S`P$1
M``(1`0,1`?_$`,<``0`"`P$!`0`````````````&!P0%"`,""0$!````````
M`````````````!```@("`@`&`@(#````````!`4#!@('``$0(#!`%1:`%!$3
M$C87$0`"`P`!`P(#`PD$"`<````"`P$$!1$2$P8`%"$B%3%!(Q`@,$!1,M*E
M-D)2,Q9A<4,D-#4F!V*B1'0E1;42`0```````````````````(`3`0$!`0`!
M!`(#`0`#``````$1`"$Q$"`P04!A@%%Q$&AP?_:``P#`0`"$0,1```!_?P`
M''1HCM\^P``````#Y*O)42@````%/E@F^-2;<``````&"<@$@.K0````<CFM
M+!-:7\;T``````'()UZ54>1;90)01VV2```HLO0%#E\ÌXYP/LFQ9119Y'P=
M)EK`$!./#KT]RKBR"7FW``!2Y:!F',ITR9I'#2`'B>P`-86B`566H>15);8`
M!JCA(V9W(:4Y1.TSE\L@M@````$:*1/0L4Q2%$L*G.JS*```(V<<G5A/@```
M``:(@AGED@`B))#*```(Z5$;,NP``````````')))R7%;&49!B&&>9L3<&@.
MJ0````````#D\EY"2TR!FH)*1@WQ`C8F^)L;(EY,@```````<YD>*\+B*W,(
MF)I")'@6<:LK`DATZ6J```````#_V@`(`0$``04"\F%Z9PS(-K'EAX]_Y=>O
MWW_'`+I66>2UTJ;@>E""OGMQ:I6?WP,\%C%ZQ(\98V%%-=BKM:R*VGI7I!L:
M)U5MTUYJ:Y)FO*52`Y5M0&03.+UH-D5:OWKEM=E)@ZLY-8Y\?OF^+P+9EI9F
M?RS\U[3*&@O@!)E)<_"_A,F-,[J-B!'5H[9]BP@>D:IK]M[;FR,=E]$@];5"
MB!(VM/'2(68]7\;)5J];UBFCW"@O@ZLE%'DK*3L7L>PNV?U"J_J]@`]^=\;&
MSP#/$883SP"PAM,8WHY`Y</#1CY\OCWG/CWG/CWG,53B/GQ[SGQ[SGQ[SGQ[
MSE?565>1XNO]AYGGA'@ESPELGE.GD%"5#;-KPP]>;F,(H(H.C%8QDFIVA&RJ
MKRXU*9@91AF8=2])RU$1*5>S%)JD"XNS"8Z]_;'(P;I.?JN[)E%3@0>6K8IU
M.E@D_NA\[=J&C64<I3JVFC6BOF%^HQ6A-AOI%7Z-3U%"B(\AJ)2QFAAC'A\[
M96&[6R:Z4'3U^C+JQ+[:XWUO7GCC8@06==LT[Q$MV<.9@[NK<?`_:M;`,8;0
M$7SX[/BFA)OS/HUYM!<`-WL9?UT7M`3$OV=OM]=2NFK:H"9?;:XGE18TSLJ1
MUKGNP=/]8O.$P45>$BSJ(7)FNL)V;,K6]ILQ<]'E5+O^??JA[$K!LT]]J@V*
M5T.\B]A98J/F4;%09LCQM/18UP%+UFX$UAG8I`M8]@1"Z]D4$#:LD`@!U7]>
M8@:X[7GC:ZF&*&HO:857KS!:WÙCFMJ$:*);[#__V@`(`0(``04"_%7_V@`(
M`0,``04"_%7_V@`(`0("!C\"*O\`_]H`"`$#`@8_`BK_`/_:``@!`0$&/P+\
MRKKWM#&#*L^5;GCMKQ[VY+U,FEC'KBW4?>]\9'8K(RO=V0)`K&JSY9^6#,U:
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MB\P`+_#GX=4Q'/,^.^65;7_;OS1"^JSXYY22Z@/@1(B?C:Y=&?L4^!F1("@I
MB.>GCX^MO%P$/&A?RK*%>1VNJKDV[!='13JA_P`??S[8=0.L+#L]N?PR9/PC
M3\C_`,KULQ%K.QLD_'\6]3<]@YK--SMDNE%"DYJAN+0E43#22$S,\]"H)M-\
M,[9=MZB$U6:S8Û%NJT0L57Q_<8(E^GW_"_(K3L#4TM.OI8EK805+'W46,;'
M3(Y6LS_='6$65$HUE(%W(X'JG\E"*,U%V]7:R\5=N^)LHYOU)Q![VVI;:YNC
M\/MJ#N+[M@P'JCGUO9^DVC:N>/[)94Z&<LT5-`/IV;HPP:S+%LJ]FK]2A-@.
MX<0T/NYZ1]'BY-[#R8I^-M\D=>W*[K2;D#;;5BJD4W\[V]6IV.NV_J.5BU7`
M_'GU6.MGHK5+^K@9->O<Q[<U:K-WQ'(W1]YY"&FÀ;5>T^V*O9_B#T#R,GU#
M]E7_`)?S_;_YG^S][_A?_-^=AMT\O/T&T?*_%FTF7::+)U&-WL]+#KDX"E1,
M4<C/'VQ/Y9,^).<C>010(C)JJ;N<%4&2,1W.P+2@>>>.J?VS^7R*CDÙFE;S
MF(I@@Y!A-,@CB"%U<N.GGG@QF8^^/7D:H7<<A6[CM51PK%K,IZ?BME?CS?)*
M./5N:]M]6\R<QL'_`+T'>Y(0Z);Z39PÒ>->,_\`4,YM3:K-T8IK=1\860EE
MSL5FT5:&E7L,K+(Y[72PN@(;$>GX(U]6/*<_Q'-S;È)+MMUSQ:3F>WN2_AS
M1-O!%#/@R)CGU;JFFNQ,:-FE2NY;3N5IFJMYV5W"(%FF4=GI[O3"FM*1#GIZ
MIU`:O=C/#5L=-S/S,,[RT=.U].J9N?9KL6VKWETHL.)EJ"`N8-4RWM.4FH,V
MM-V]IL[Y56TL[1HG=MIHK:YI.G/\FL6JZ5?&?;J0R8Z.8]ÙK=$%UP*PH&YV
M,%B^[ZAXXHZ>AW:%8A0-=NC(=I5<I`1^8ND29E5]EN@[32-E5MNJ2SO&P+M@
M8)IJ$08,A$=!1^\OB?S&XWDV/1VLUW[U:ZF&0!_<U#/@ZK8'[F+(3'[I]96!
MXSY_:;X-M^^K(R?)*4;VOXRRK3=>&/']5KE=54@5(`%H6K3\/D9\?5VNVK&H
M6I`1KVMCC3M:W;_PQO'9$@8A?,]"8$4*Y^0!CU5J5J"<T*$M+.9E`.:[.-\]
M3BILJ0OM=\_BP?B#?[<%ZT_'K.V=7+RJPC8TLP*U;9U"UJW^[HL*?0MT:RZJ
M.[UM1T$QDA(BOI^**,^.8ATZK9?7K,RZ;4I>0+6;E@Q)"+6`H8(OM+CX^BF:
M529.TF\<S73\]VN*01<+Y/FM)"N$"S]X8`>)^$?GUZ>:#;S:VIGZA%7&#28^
M.>1T/J](7]4+C2K=N?P3D2/^SSQ/!'5=#.V70U<P2WUV?>JS79`/KMC^Z8Q/
MIEFTY5:ND)8Y[VÈ*EC\2-C62(``Q]\SZÔKS]9OC?L]6O.Y[&03+M'0I:`N
M50DYUFY2EUYB;?8[4S/,?)R<+LU7ILUW#UJ?78#DM"?L);5R0&/^K\@33TO8
MB,3!C[--GN3,QP7+9B1XCU_4/\II_P`?K^H?Y33_`(_7]0_RFG_'Z+HW0#JG
MDNG'I#U3^TN"^,ÔZA_E-/\`C]?U#_*:?\?K^H?Y33_C]?U#_*:?\?K39O>5
M1Y"BS:<S-K1AT<KZ76)LDFM+JK#9=E2_EZSXF?S/#?\`WVQ_^%>_(3&&*U@,
MD9F4"`",<R1%/$",1Z\J:LH-;5^/&M@SR!@6>V1("CX$)1/YUNRFLVZZO5>]
M5-'3WK;5*(UUE=<B'<>0],<S$<SZ9G7QTF!;O_7;6K@,K^1W!N:N;8.UE5@W
MD5E)JQY-6EI!`=I"+(`+!"",*E6]F;H;K=_9/RGR(KKEXU_Q6U]4]M5J-7HF
MN8]LZF%6NI<,I/5U_+T29E"@$.LNXTA$1)S9@1)S9&([C3@8Y*?C/H;'XE6Z
MN.E5^H4)M@///01<$%A//^S:)K_\/JAYCY4*;=[ZILUJV>L"#%I?1]:YFHM)
MSS-H-O,&MURUTL(#G\/HCX?D\<3B4J5>N[R"]H[TMKV3S#_Z=U4)L7Z5#2R6
M/-EPU1$PS_$X(HGCUAU-F+,:E6G[>[[II/;WDM8N9AC#:R4%`\JZB,X5TP1%
M/QG]%I;-X^BGETK-ZP7,#^%6432B)+B.H^GB/]/JA?LU+BK;:MUÔ1S`+=7A
M%F7K&5H>\O4`[)U5Z51BP:,<,$99Q`04QAU['CU>I'DU#ZODRC9&V\,U;,Z+
MPW@9GUD5]*G4U5V(`#>ED`P(/J@.Y#-.]9LZ4A5(KE9AU!1?K5VU"TLU,$?T
M]UQ#.'`,RD^.)'CJY_\È$'KYL?_`&V=7F;U8?A\=3)1!&T(^]U2"_TI"/CZ
M!O=*K2ZA,;MRET`/V\%C>/V^N&-C^S;TH+IGXKK\3ZFSD6KV?KG\;.N5AMZS
MJ'$<<[06S-6F']WJZ22/RI)4>DT].AC.M!@ZF]9;&GH4T64YMM-<*V>N,?1,
M;EL'072XQ6LOE[A1\WI+N@E]U2V=L^GK7UC!=!]$D'4//$\3,?H+NOH&04Z%
M<[#I6!-:4#]BTJ#YFO:<P(#'Q(IB/6AX_8I^3E8\?ENW]/N4\IFUJ*\JVKK*
M09BLG3NT++3T3.OT=X3$Q^:(B1F:="MJ577+]).A40!3)-JV*_O$%SQT"QM2
M.Z(3,'*XDN.F.?TOLM&N-JI+JM@J[.KM,92LJN5^Z(S$-6-A`S(%R!\<%$Q\
M/4Z"\R*]@[(VG14LW*E:RP?:R(VZ5:PJG:KPVDMG:,)7W8D^.HBF8M9M1JVA
M5FA5[]_0NKS\\F`TL_+3=M6%9E$F*&94B%A\@QQP`Q'YEBQ<J"]UK(M85@I8
MZ.YDW2@[-21!@CTM(?WOWX^Z?2D*CI4A8)6/,EPM8P`1U%,E/`Q]_P"@NY.@
MN64[]<Z[Q`R4SI./@:FA,&IRBX("CXB41,>@M;M[6\C>+J3"/6;2@&JS$Z"\
MVHQ&=0SZ_MZC]-MCX#!G9Z3,BZ!B%_2=#7307Q/TD[%<Z!FFI]-I2<^TBY(4
M,L%UU+[O:Z$+F1DQZOU>[1ITZSZF=D^/Z3(;F[%B;)[6OJ9II=K4N<W`2D*$
M3#K0R'S3,_*,^J`9U6[H,9Y!2Q[Z!S;_`+@$V0O=;:*^T/NW`VI]@\QT\SZT
M]DJ!H.EJ>2TDTF"=6P:\32NTJ\6`L\36LV`JQUP7P$I_9ZR6W<RYDILHK3HM
M:"KR56[/BM+RF:E,Z-EEMT5JFDGJ9-?@I+ICXQ,QOZ./6RFY7B]_/S;:KQ6_
MJ.YH7%9=HZ&5V9`*+NQKI6B6@Z7V2Z>@1^>3K$%^P@%69]Y62H@FU6HV=&:4
MUV.5<4UE>J71+``"*1^/3/5Z9G.PM<-A-7O6:!GFE[1UB=!>6I[Z]ZPLTZ#<
MTOQ5=8IÀ)G3\>,@!RWU]*S;QPV*E@E-7DU-(\2>_P!ZJTY?[JOMB57I'\7M
MGS$2$QZUKU%.99\9Q[_BM-@FK03L75>2^Q7-FJ3"%2VU6Z`]*#3U-@>.H9F/
M5]N90OZD5*8E-[LA6H5[]M6E.;6MKMNJZ4K<S,/K-:3@(D?V_#-2&=HVM'5=
MJ4Z-)Ù`]U>Q]1>3;2#K-M*5+EQ$P3,ACM+GGYN!F,VKFVQOR[)&/>%4)$19
MVO&\S40TJ-RU*;M!?D8<"7P(PG^SQ)?J>AE:6%6OE:QL+ZJP[F2JYH9]_3UJ
M6?GTLVX]5S;97L@XNRKF>71`\F?'JM]/HX^[M,V:Z,_.R2RBO3L]%Q@.>WK$
M:454*L,8UD_((EQR7`RJT_!N9VG:WW^,;6<OVQ!ELMO1K:6U=E3O9V<PV;-9
MS+`]3)BV/(Q/6,'GX52F%C$:R1[.>]*T-4G_`"^\J5QJ`KVIK)H>S9*3/M=K
MMEQQQZMZ%ZG7J[U'9+(.[<R+$-.YGISEQH]T$,7%2M&LA`WF](A)P'7$<>CV
MKN<)W&U^_9"]X[HNOÈD:&&#+595*QP=JI4L*CGYV50+_9C/&/?S<.AK.M&F
MGX_5S55V/ONUDVM%7)N8">@ZIV+1.L%^&ON'SS,\[]_0S#S+^=IX.-=RG*KZ
MIYT^/TJC_&DY"\:NY]JDA.L+DLD2<!M*"XZ.!#R%OTRSH^WH:"]>,VW9@Y*K
M6;EPNT%0Z[=>:EU15Z\3-SH8/0'QCTF_IW;1EEYM>Y`VL_L8]M:D>3M-+;+\
MZ+DV<ÔGWYL538OI[<QT<PT?1[=7Q&GH6]O>CQ^*?33J7;%B?(YRE6S8TAFE
M7;?H#8ZOE/GB9CN>K&O:\>SL2[DZ/TVY0;30ZY1TZ]K-2E%*MG>YBU-JPNF2
M?;"4O+M3QW(XC2$;DKKYU5]V;3DO6#J]%+7:A"DE19467VI%HL`2ZOA$3ZMF
MW3+MT38NPU>=J.3^"5L;#4.32-=NM5.@Z'-5)K22Y@YB?5UU8#%=+3NYG4<A
M,.*D<!-A4@11*'1/(_?Q^H^3?7K7:M,\?P0U_EL2Q&7&CM?1G4.BNR9MGH%8
M_P`#K;U"/(Q\G)J]QMU+Y[%,:ME$>5%?3M]ZQ[8\B+*+*Y;$=[N=I9*]MW.Y
M'9ZO6@'DFC[BS%7R)-QWDX78T)M]6?.[;J1>HH/Z_P!DJ/:BL'=]L-?VX=OH
MY6?CVSY--3W[V]EZ-0LS\+1TPU:BIMYZ:X^ZV"8;RDB9$C'3(KZ8]-9IZKT[
M,:UQ[$,78D2</^6ÒTDRW.;'M3<-$YE)P?41])P/=B&`S8T@J%<HL-SEW^TN
M8_S6=%#(M995?:2!WP#NC/S"K@N[V2GQFME:+4-]QAQAZ&*#9\E]X/C=R<L]
M(*]!USNL\5A\'[]''MY+KX]>W9H+3;'8'ZA><#)\E/27=;USY(-^BV][1]R/
M_6IBIS*^WT_@ÔPMG<_RP0X-;\16S]*#1FEX]/C]ÛWLKM?4QH_3X"+'*OLZ
MU]SK](&ON$N@NWXI]3:RII.BQ5J;ODMA'MAI4T+4_5M1H(MF,>W7G2V3`5=)
M>I3&C-2\7E$G%S,`R\E7MSYA=8"ND:-F_P#3Q\F[H+ZU35X^R>G@O5FKGZ55
M>]]6$`TM.O;=Y7]=CR6C,L8GLHWN6;79@9!?MAB0GHE,0,W$:?DOD%C4!'DC
M/(;U2EOUK3ZT_4)\C0VO],>\*P`PH*8CNSVQD9YGB>=+:\@3@L=MNIB2MF<&
MN(QN1M5:'<R6Y\RR9M2$\G9^`>W.([<>K`^/V+%FI]2M^X9:BP+??_A^YB8L
MIKG^S[!Z?V?J/__:``@!`0,!/R'V50"#]TÈ+GIZ+J")`W@L-@<(W@WJX!.M
M?/TI^``4`*$`=57@!C&-!OBC?68RF+)D;'IX\4C1@A\4U^5/P?%*M@.T"("#
M:`"-^YALH"J`%5X`>5?H-?41(!&LZO3OSG@2ZH[["T3HZH+Y1Z.FCO,W!!KM
M8*<ME3D?'M8AV<I%)ALP-[OA3`'\<;PGE6`KAF034]=1P\9AKN`LG1A@.$K_
M`+!:*L!V1'YX<60WE+:">2`W+U=P!NHHU.;<E:!;BK^"OJ/HP?D&?+16C]#>
M(6>I4?C4BZ3O^,_\O_U[N'W967IY'S/JFR"0E!PZV,7R>DDU(.2Y\#609N.4
MZ:),''][ÒD8HYAO%V!L(3)$<5V#WM$TJGG2MY7N2X8^J%>9IV<\BG(><D*.
MWF<WP4DB9U%K#FWE<&ZCB^0*K/7?9-OLZ>@A0@__`(C6=SP8:*,DU+5W(NQY
M@IY.B4`Q,L#1118QX.OQN;SG^H521$&!K">\]2U0W!`TS+M+9*K6DG4L!+W4
M>R^KJY>,E*97K89S_H9H/LF/S*<SR980!G/#MJ`@'V,=T"Z;Y:0BD\I/3S6Y
MOHY4R0\WV444,)RV]_:%_L^VBBB@(IEE:$M$'F3W"G52V2*XE56!@#<ZM^@"
M1.)[H[Q4,LB%<X*AD#JW_8(^M?U)_P#S530'F;C8C/\`T$*$TH&K"%.*'W:E
MF]:[D)Y*(=:">]]/_:X)5G?]'8T=E@;@IUT+DÒQPEF6[GLC3KUAG]\54Q_T
M,M,IL^1Z[`NB(L<8LR^@_P".DI6:?39?J"YW^KJ*Z(G"'8X:8ZIC)(W,-NE`
MZK`/!)#-1,K`/C$=JJ/9=)?EOO`'%/@(Q+D/FGFBC.NDU&Q?V-6;==N_,+["
M;F"N6GRDJ-T@/BS^"HJY-^9_D!OGI:F&Z91A,IRKVBQ+B69^$)0'T.8>C3FQ
M10E2OW\!_O<SD>Y1CXIHUB$;`X1=\!W/SSS"8K((HV_C+_WQ_%>$.FZL];(6
M&BHS[JO#7,PL/ZY^!WQG?<ALQ$B.0)B@#!D`\\:*@*,M[F$0TY]'LX,NZS'U
M.,&G#1MY>N%=IP:<>H-+5'ZIF+92QX\9F!Q/W.VLZ[?+=#\@_IL;BCK37YMH
M^PV/Q`K9HS?Y_P"`#8&LJX;!E(81CGQ',9#SS^1UEWB1::#N,S4W!IZ$,5VR
M8<XL3"I1#:Y9N-)LKE!-.#[0J60IP-HFU;=_'&Q^6A([<,(V]P;AB@!2*,RL
M)7Z3Q$9E58?$3]1JQPFLA+6_@"FY!TF#7A.S%`<9_P`HB.#(MF:9;V<'T*`N
MQ+H?@UÒI7\W3A_8<:FFL\?^[TP=;B<F=5`<(%]R>0&)OK)G*RQ?U.T"PAG(
MI`]K?\6-2^98=>#;9K^_\,`LIE*($&@@=`DP<+^B8K7(\CNFSNHIKB2<D92S
MAZ@;=SQ20%<8Z7KV59'-%`Q2(IY@#I9Q#H;;2F<!)LCH6W+L+S35C(=LGE9'
M]A:_!__:``@!`@,!/R'^*O\`_]H`"`$#`P$_(?XJ_P#_V@`,`P$`À$#$0``
M$``!(```````(``````((`````````````!)```````!((`````!`(`(((`(
M((```!!)!)())```!``!)!`(```````((````(``````!(``!````!``````
M``````!!(`)`````````!!!(((!(````````()!`(`)(```````!_]H`"`$!
M`P$_$/8;.B,0O3E5`T1+E]+R8*#`J0!*&"D&EM#R8Ê._@!_B`;5X"57@804
MD+C+9)!391?@83=@'XP/;@,K^)346G0P="\H!Q70"-OL8B9RP`J$`%5\8Y,J
M@P::I(&"GSL[$.)'A#\))TSZM7,WN%'DU4PXN!??JWX\H/'@R]-`?$-8<9VA
MM,>._36*PS4L^7X:;];F$L3WKQ78\#M1-N`=*D])$=0^9QO@?XV7BP."(@B(
ME$Z(^$?L<H8E5#E3DE6!/8%K#XG$_?'H'SFUL=]ZS-*BU.')%AQ#-[V!)KLE
M".32/T$"DGI+R`#)`%"M!ZP9[1/HH)(*#`"_/F@/"SPW+J6UF1>+SEM#&KY9
M0`^Z<9!*\<72P#6$"C*._NFU6Z`6D319=5,B(^PZÛ*FCNI`T\NJ3E_XUBXD
MGM"7J$"T.I/YE;LZGN@\ONL9R"W5`-0X%HYM6.KV:OF.R$>L$!8^H-D&)I4D
MT:PC"=DE$ZH[1^5G]R!?'B_48@>\CE@-3&+1`H`T!Y5HE%R%&T=`JB;<"QP0
MCOU0P4K"_)0?.T9IBXO=$6KH'B>?1=O[V7@:PSH]-ÛIÛIÛI(.X>A!A`7R
M._:T_:T_:T_:T1I/1.OVI"577U_]H_X_WT3(!C`YIAP%4,HFB>ITJ'J!'W->
MIY@[$Z@NL(K^R(M??@8\S7C._5GBHIW6UMLT*9,!`/28`'$5J`$.\(ZH@'0*
MF[GCVVKF,6XZB0\#\%9@T+P0?&751['(3F$3RO`.V$?='&DOU:&')@AE9SDX
M8^8-<Z="GC1!=9>?YZT)FDV`'4>I7%YUZ@^]RT`_*^%VU9VD;XGLN$KXT=3@
M?$"AU:B!`%$0AL<;@+[QT:+;A1D>\9.!NZJ0RQ$1F@&;ZN$EY)\]A?+^HEVQ
M)#038DK%82^Z6:EZH$G0Y!_SFW'MH!^4S+,[D<@5%&C:-7$W)54JOP3H6T?`
M!E_"&YF?H`^GHQZ*RQ<#%M*!H[:I^/B&_2%3Q.0R-'%"!I`[&(!2#E4??OUW
MPKQ$8!A'&A%.)[A`MH:E5]`H-O/0:D3C*LVP)WRK!&V%AV$B1#=Z'*)H[>>9
MP#\I&1*><8]3=0"'ZJW@1UJP9U-2K8#%=N/+V@C>[^*B_%/"Q(:PQ[:((!,!
MY&E-\97?0E?T9\/'N%&!8^_').Z>K@M),JELT%3J6W>Y_&L-P"(`>BN4W7JP
M$YDR8=665/XE<KUB7/7QCTH1@C6H9M?>P7^4VH.-%OV??$`XFXA%]SV;PC*V
M$MGWH;/M65#@\VT8$DOKBA88&4U57Q8BG\$/!5_`\XBZH0X2F6#YM>)-8D=<
MC[A*'-ZSO%,H3%/&;93XP=PFU@A5FH6;'X_RP/G5R*;HÒP]%1`Z3`?#QFO8
M[/:FQ<"WR0N+ZZ_55;8R[9)8I5(DKV2M!$*;5YJCP0$+05QM0R=58,N!13"T
M.4FN9TRUX$-"0%O4GD3E)F5T%V#H?@?_V@`(`0(#`3\0_BK_`/_:``@!`P,!
(/Q#^*O\`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<TEXT>
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```.@P``1#\``%8]``!EG__;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`\0&[`P$1
M``(1`0,1`?_$`.(``0`"`P$!`0$````````````&!P0%"`(#`0D!`0``````
M```````````````0``("`@$"!0,#!`,```````0%`P8!`@!`!Q`@,!46$S87
M4!$4H#$2-6!P,Q$``@(!`@4"`@8&`PL)"0$``@,!!`41$@À$Q0&,2)!%1!`
M43)"(R`P,T,6!V$D-'&!4F-$5+34)7654)&Q8E.S9+5V8'"A<G0U1296%Q(!
M````````````````````H!,!`0`"`00#``$$`P$!`````1$`(3$0($!!,%%A
M<5"@\(%@<)'!H?_:``P#`0`"$0,1```!_OX```````````````````````4N
M705T6*0XWALS6&U`````-(5H38C9:92Y:)IR4&0`:(JHM`D0`````````!J"
M*%#'2I!R2FN(B7J>P````"%'.1?!+BK2YRB2RB9@`CYST6V64`````````0D
MAY2IF'2Y+0`5D6:````>2I3).6S+.[``0`GX``.%#IÌ\Z*)B```````>2/$
M)+4.2SH8AA<P`````!'2'%G'Z<_ERD.+0`````*"+].>#H<``````^959S*=
M0@L<YW+8(\6V`````1<B)SJ7468?$J\WQ.24@```PS'*E(T704H=+``ÙA7)
M99G`ÌHN(Y'.CSV4L=)$0)>`````"L"SSF`Z>(.?A.CR>@```"OSF\OLM4_G
M^=_GZ``"+G-!;I<0!IBBCHXI@DI-2N2TP`````?ASF;LN4YA+0/TL,VX````
M``!R`1D[>/N``#@D[$.=3HDJLAYTR08FQ"#9EB@`````@9S87>6200M(J\F!
M(`````````#\/T``^9RV=4%'EMFU``````````````````!`#%``!KCT6P#Y
M'DKL@)<!0!U0```````````5J<\&":8GAT83`````$8(`46;`^).35%Z$X`*
MV.;2["[RN"P#[@```````````````````T1O0#P>P```````````````````
M``````````````````````````````````````````````8IE```````````
M```YK++(\3,AYE$J-L;T`````````BY39)CR;$U9N3ZEF@````````ÌDM(Y
M2.P2+DG/F5(7``````````8A391QW`#%,HJ8MD````````Ì,\G+Y<!<Y8X`
M(L2D````````@Y"3XE"DA.S0`1HDH```````!4I;)6Q915Q:)2!=X```````
M``!1AOBU05@3,KTMX`````````@1H#C8[&,$R#7FP)63H````````&*5*99Q
MN=<GZ?AX!=8`````!&SD4NHO0`$.)B5L62"LRS```````#G4J`Z])8`1DWY]
MRKBT2MBR0```````"JBPB'EA&L*+-.6^1(C199M":```````%2%MF"0`LTJP
MHDO4_"*GZ28M@````````XZ-Z3$W!'B=%C&@-^8Y@&W```````!%SC<Z0,4T
MAM"ZS['@]G@]@`````QS@\MPZ<`!5I:17Q8(````````*%*'.N2<@&B-*3SH8IPT)-BN"WR
M9@````````%'%8%XF`:<GA.@``````````<J$_)><_EIET'H```````````K
M,LPCAADO``*B+=````````(T10MÌLN$]@`P"D"_@``````#1G(IE%TE6%K$
M/*G+N+Z-.4R38L@```````YM*Z-Z7H4:7N<]$<.O26%'GHNX```````'@QP9
M9R>7B34^9Z*N,<N4`````````'DXQ.B2QP5J4T=0F<``````````545@=#$#
M(Z2,WY'C;FB)<3,```````'X4*;PEI69:9NRL3-/P^Y98````````!"2OBTB
M2@BAKCZ&O-X2P````````%*F^+,!\"#F4:DR2P@`````````````````````
M`````````````?_:``@!`0`!!0+]/56B;+?@MMK1K'C=^G0QA'!LALYQK@,T
M1A%Z;&(R<&N624N5P^5(HE]M`*+_`+<WO*O:0!@"T%:O5R?D6^9(O%FQ$4`3
M=P$@8H[=66;TNIX.QUD2+W*^B2D=QZB4F4FK\)+`'A57EJB0FM0?RD8<]H6X
MQC7'II+"GL<7>H_V*IHZN`FV8K5[<3X.++R...&.UJHEXRE"N3>5JL$<KA:+
M7K0,BK,"#;HW%@5H\16_`^ZW]L]_N]EFC5=OT*@>OH_)38Y(:MZ.<XQC-EE:
M;Z6"=?OV<9K5:2WS_,+GY+.&2P3>8FRW7MB6!>JFW5O55B-=".Q"2O7SG&..
M)Y15-14`!J]]-)=!Z!6]+Z-74(8:$@A.9ZN6RS5K;8(2@---(]-M=9-:75ZV
MJRT6BN`*TS+)QZ=81IE-IY>"9M2O5VVUTU^9I\Y[X3QS+[2T#&75=D)*NFFA
M&BBL8WR`.S5Y@,F$G9G>FQ;A+,?(&(?)RQ9._3!B18=07`9TC!V$OD`+L2/D
MUO!*C3JH4X7H$$0"0?S0\!GWÔ###FV!.4"\3LUQTOS,WS&F"KA,WBL:":$C
M23>3=1`_;ZZXUQW`[?)G$*M(M3ZM$RYQ&A0Z-Y.'5]&S(]2I01>R<+IE6([B
M<L0@Y*FN@"!J^?MC]_1LR:6P*?Q:?])"C-$.Y<5B[\V>=TI'>JH*2!=Q:Y5,
MH"O%@Q`4ATBZURU3\M;4&'BJRKFF2"1Q(:GC?(GJW+N?7:@146^L"H@D<.`R
MR$RMD=R4NMK&\%TA7P[C`>O96C4>R"WJX#<CVSO'YA[LX[838L*+96^^1SN`
M[`J-FL%AW:"!4I1;M"UB\\3*%QKQ<J7J8FM2".X(@Q]7U+0`6TK9M.?8=5"K
M#U\`X`)F-#45F)^'5)662M5+E`_1_P!O-MKKOK4*A6*_<>7\0:1$$$(N%_1I
MJPE(F^(H>?$4//B*'GQ%#SXBAY\10\+I%<-$J-*K]'7>&^^D6GU(_IL+=7UX
M:H\H<V=TM@")/>7+3I[44W$5PF=Q@M!6G=.$W+KNIB*5GW(Q)7\&ZH/2=S$C
MIDEJP81/:[(NL05VN&9EU\N3"'>T$9[?R/;<*%7#6+)/XVQ.8_2?CVU;+Z[6
M=A6'":HE*(CCCAC_`$B!8M%F\<8QC_H6::$>/K&(S6H,I;8CU#]PN^,KK$H9
M1;6)DYS!9)P-CWH(,P&["2+HW"@)X$G;,:V5LX=O.:L+"@Y-<%6^,0WW_**W
M*X]86#9QMTDMNUB[@&D#"!=D(2B:-P](G:2<WTTDTI`08:?HYY,Q0=MK07=:
M+W0S[[=?".&&'PM6FF^_1YL#1[S"*S*^3NY-.]]W'N-WJ%2F6RUSR)UV5870
MNG6%./C;)[R8.SHX.SL]E7]KYDYZ#N!Y&*W1CGH;K<%U%1\IOVER7[TY/CVV
MZ=*FNNK>\MON?PI7VDRU7[KJ/[C\>Z-K8@5<VH]Q+QW]<R9[=^[N'G!-'%2#
MWO":?GL5G,,RTN"_B-5(OCZ*>:(:'5@_L'/;GR?E78LXN\N:XW/FFLI2#34B
MRV'D%7:)H/;[`\F]5P=NK4'=Q'@`M9O(=I+\@N,>]\MN,91>"+&,,_7N3DQ<
MQA[@6^$Q&?(S5>+K_3Q_^?%_W9RW?;W0U?6+>&(,.&5K:D:0CAIHJX1UW!C$
M55S\E!Z0VE!,(9(UM0_OSRO$SV2#,J9>2%T%R8>V+^$D0!CI;2(Z(XZMH*0A
MU'W.NC7+%LEYFTCG9*K3W;8"W;!R2CM+%IT+WMJX#<UZ[VMI,TIQ37<Q@XKN
MTRRP6P=(C(7$\G5+"B^2Q13Q@@`K!N@<I5-B6;5.\]LHUF6EF"&IF@&)F5SF
M*(HHA>L<>D4?,8QKX?XXSGU)?J?2CDN^0:JXN)!ODA^]>6O[8Z*[`S$R0HNZ
M0A%=]PPL\6G^MK/VWP(H4VX='7WR?>T\=V4E<>O.'9@,F`ZE=BR6-@0-7F$'
M#[$U"A!IA+`GHK_/@2I5NTUVX+,Y_;%<M[%J7Q\^:"LUH9]M%V6,56#PGELF
M4(EZ;3H[AVZJMXU1A=S4[4RH)6,3-6>LU6H97&4];3H<]-8NTZ@]G6EK$P+%
M6K>O+/6+8>:J[>5!2BQC&N.GEFAS;>-]M=%*#?3=)Y;:WF7Z]"W<J4"^FM%S
MBN<8.5(ULQG&V/(44*"/72MW]D]=FP'4KE'=%CL(L<V*V;QT.M:`N[#8NWFV
ME8D9;M:W)7>%]PGHHE7O8MI-X>P!5">\V.S<2U98DF]>ZV"Q*VDEQ<,-UO;M
M;:"VM;%/FK[:R6UI\4KGMC0<NI%07>\P%HSIF2KA-QR=.+3OY9'0;:Z[8V@@
MWWC@@ASSNCÒ8<AM-?G-AFA)BC&'AYK!!'N\L<L'`*=!_+Z3.?VQ7&R-$P76
MQ$SSX,[<@4FKI@^YQHPPX<'2NZSNS-_%"./98%[:`VMX81?Q5C8,PT>K".W;
MX1%K/>JJ-DFV5\1AK=TGUA;"G.*Z'\<5O;5124J(QU8%%?@^G;;3Q.C4H!81
M11]_FJ30B.XH"8<6]+@?-PK>.D9DNA)Y`+98]U2=6C#\"%41AOQBO_2.K2%E
MG%0K.O`D:E;/T4Z:X1RI:HL33^$F),QQ5I1K%\<1_P"$%.K`NL=4KL7_``?_
MV@`(`0(``04"_JR/_]H`"`$#``$%ÒZLC__:``@!`@(&/P)9'__:``@!`P(&
M/P)9'__:``@!`0$&/P+_`)/?@/(45\7EB8QF-%32.ID*A$QB!JO;L)U@*X:%
MN%)-8E_27*TRR>)Q57,TG7MQ@"Q9/3L-5^W13M3$5+UFM^]6DS-7XXCZ%'E;
MRZO7*0KIVML6[1#S.*M*L#KEGICS/8!;!YSI'"KN/M5[M1X[DV:K0>AH^FH,
M7)#.D_\`-/$D4Q`Q$S,S.D1$>LS/PB..XI/"RC>:X<KW*,ESH729]QH1/XAU
M'^G]9:3C[<4+K4F%:[-==KMF%&D.&NZ82PP_#OU#=ZP4<I9A<XH<?Y!3+IL3
MNUKWHV.,'47R(0_>-9ND2*G,6J7]%:C#A3,E9Z9V3Z5*HI;+60R#^7]7QV/K
M`VY>?S^ZL"F(YSRX7C;]7(>/92QSIX_.J359D`T@HG'V:]BUC[K=DZFE;B>K
M\8#QK/*(]9X,L?2S.;QM8]E_-X;'S?Q5(HG:4"P&18RO2G]IV"K?1_'MX5>Q
MMNO>J.C55BJT'*+3E,;PF8W#/*8]8GE/"@M-([=G=V6-J+.WD[Q#ZQ4I)@G,
M$?Q'I"UÎD,<^%L)1H(P`R2WIRQ4D,3*F=(VJWA/*=I$.OI,_H6\G?9T:=))
MO><`;"V!\%J7!,:TYY"`Q)$4Z1SXL6,G7RV*;4N8RI9Q]VA/?J'+2?:WI769
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M?VOY=F(Y"V.*&9\CL#;"VD+"L'6`J^$K^FG701L?E6ZCK_6")43]U8SSX@1B
M!$8B(B(TB(CE$1$>D1^LONPUR+B\7E\C@KQ0IZNAE<2[M[]71ZU2<H;RW#J$
M_"9X'/8ZNIWE:LIA\/XIODQZF6S>7HU4572HUN=1ZHA8:C=`/FL,,@@U&9N%
M+LGG+"A7D,_DC[G)V_B00TH@:5+?S&L@55P^`<-H9.G7OTW?M*]I0N7,QS$M
M#B=K`GF)1[AGG'/B*N1S&=R^"5.M;Q_(W8=0CW;NE?L0H<GFZH:1L3=>]<?B
M@O;M!2@!2E`*UJ6,`M:PC:```Q`@`C&D1'IQ:S^%<_!YEEG'*L7,=T8"\-S(
M5J+"R-!ZGXZ^\%69V-:HFA,1H6G*6G56;;EG;WN3N-.WE+Q#Z3:O.DG&`_A7
M&BE^@",<OT;F+O"1U;J20WIF2FC$\Q8EH:&IRCB"`HYB41/!9#/SE,\Q[<C4
M;\XM5RZ@TYNX-&J\;3QU8(K5BL]+:`_VQLGN(M89V^1RMM)"S97OOKN4EUAO
M<WK0DJHA[+&0M?F,EAG$%/L@!Y?5%1=>4VK6X:.-J*9<RF0,?4*./K"RS8T_
M$4#L#U.1CGP(>2X>_P"++L'_`%.[D&5+.-9!S^4FYD<>^S4Q=^?BIY"$SR6Q
MG'D\QSB?Y5^*3$Q\8GR7R/TX\HQF.N5R\ES6.C!8S'KL+[Z&9]RL05SHC,M2
MBDBX3B;,0`0'KQAL%3C2KA<70Q5?2-/R<?5557_?D5?HX13EFI@45P:V@2V!
M.I<B`H@AG]5,S,1$1K,SRB(CUF9^S@J_BE4,KM*5MS3R)/CM4HU@MEP(EF7<
M$Q^SJ00:^TVKG@:_D]8,:1%"U9>N1-P%HIT@=;)Q#<4XYG]G9@1UYÙG'\P+
M.2OTZ%>?YP_S'VNN64UUE/SJ>0$TQ@RGX1'.>/Y4I36NQXGBO)[N?OY:]2LX
M^C:SN/PUJ/%:-*;P5V6S=<>UD&(2G541!29#'Z+JM1?5>5O%,@-P!J%?+4;+
MIW'(C[$J*?[WZ=_^)<!_$_\`+YN1R-ZEY)XE6<[->-5+]Y]SMO(_'MS'WJU3
MKSK<J3.BQU->O%3,8;-TLS3R&HT/E1]]9MM&/?7531!6NX5^\À&5?CV\6K5
M?'YB;EIN`;XQE599-?'>-5T]M\XK96D&1""9+(<;8!-F+BV"K=[/:>/8-C'Y
M$"9MHY!<(=86N9_K-(X-E>_7D8UW),]GX]L\OJ'.8C6=(U^W[/[O&4M(+8ZM
MCKKTEI!;6IK,8LMI:C.A#Q2R8+)V5RV.HV<GEK;"M9.\UM932Z]QVYO0$R]B
M1VI5Z`(QP:V`+%L$@8LQ@@,"C:0&):P0E$\XXR]FNK(TH9XE@J[*E#,9.C1.
ML67\B.*T5ZME?0JK,-12J5I]Q>V=>+./JX?'5Z5U+*]RNJHD`N*<$K:%O:&M
MGJ@4P6_69UX_A+)N8_I)-_C62L%)-RF(3M@Z=EQ?M<OA-X@V9]ST2#N92W;^
MM7@BO5HS#:#<JO&RT>\/')L*JMNBG[\UUV7"$EZ;BCBC4LK%]6UGL$BU79&Y
M-E!9)&]#U_=<AFGN`M1*.4Q,<"M8BM:Q$``!@0`!C01$8T@1&(Y1P0&(F!C(
MF!1!"0E&A"0SR(2CC-6<;@<31L3Y-G3ZU:C74P2*X6Z5G`:I@OC`:1Q9QMT2
M*O:#:4@4K<HP(6)L5VC[D6JKP%BF1[@8,%'..,AB,H4.S'CUA5&];6&Q&06Z
MN%JAD0@/RTNN4V"3D^J6Z\NG*R+]7YNS%XG'8YERQAK%HZ5-%8K#FX[<UC92
M`[B:0ZE]I<_69GZ,'5@HZ)M1=F-@246JGEGAE>NY;9'J*($9%P^V8U%DZ_KB
M,R@0&)(B*8@1&(UDBF>41$<2U47[&*"9!V?K4G.P:F1,QI-X->LF-/<]0G67
M^-@SQ_*I]=PM2[^<_P#+LUN0R#6U9V;LP0,7,BQ91_>GBYC-Y/RN4Q]U&/Q5
M0)LY&V;:[502ZR]3"N)S[W'M2O\`&4<4,21%7RV,QM)%_%VQ[>_7)-=23/H'
MS=6ED>UR]Z3_`È/#'V&K0A($QKG&*E*6,:D;&',``#'K,\7<XG'YRY@+.'Q
M>.5FJ.)M7*9OI7<S9>:T(@\G9I].\&VPJNRN7/0^7%FY2S..L(I)-]TEVE;Z
M*E#),*ZF2AU3IC'.&",QQ_%&32:3))U_'\>^)@\5BF[999>J?V>6S&P3;^)*
M8!/*89O_`%8"\C99?KVM"JLK-^V0^L5ZJ]6$,?B.=%AZD41SXZV<P+L=CS]P
M7*ED<OV0<^69153#*9:1K)I[FN$?>;'KQA;R[-<Z7_\`C7D#^[!RRJ]"/+\#
M,N[B"E72B/Q:Z<5?X>H'D*=+(T<D>3>WL,?;BA9%\UL4UJS/(M?LT%L"-7_&
M_#@Z\=2K>5&YV.NAV]Y0^F_I3,BY&OHU1,5/P*>`JSU;F1<.ZOBZ`=Q?<.NG
M4Z6X0KU]?5SB6F/B7%PK_C+;=.[D+N3AN"R%?(7*0W7=7H7:%H,:;&(UYS5*
MSK\(X[/!LBSGWGVU?%W$6J5JHPHF2NY2A:57O5L=2")-A2,;]-@3O(8D:BC-
MS"-EFY<;IW&0OV"ZEN]9F.4NL-G72/:`Z".@C$1^H?:M.57K5DLL6+#C%24(
M2$L:YK#F`6I:QF2F>41Q\QFW6C']MWG?2]<5.TZ?6[KN9+H]OT?=OUV[>?"&
MXZQ_$%BX5A5&CA9"W8M/K=`6)B=T*2<.N(7.\A@2L+DM`+=Q>S^2\?;8H9?M
M^]7AS9=R>*C'R^HBY.*)*K5^G=I=-Q`G6Y7(I#HLTW<?-Z&3I6<9`F1W5V%]
M!/2C5PV#*8[9E?\`>"S:2YY%$<8YF#IN;0I.3U/)+9'5Q3:@YC"Y:PO#UY7-
MG-N>>$``?$+J#$S,-9/M_3LW[SUU:=-++-FPV=JTH2,FQAS]@C'#KMC('156
MNX_'V%Y&AD<?;1:RS%KQL-H7:B+H*N2V)%DKZ>R"*2B`.8=6782=BMTYL(!H
M$Y$-C<J7*@I-75&-1UB-?T<K\Y:^]C\9;JUZ>$,H#$;IQU"\=F[57`_-'2ZS
M.@V)8D(B-H06I3`C$"(Q`B(QI`Q'*(B(Y1$1Q@&*LY+"32\X\7S2UX=R$UBR
M2,D"E6YI6:]JFNQ$6"F3!8R9<SW<-[)&CK$P=RZ]C+60O,C]Y=O6"99LE&O+
M<6@QR'2.7"PO(WF@NI4M*8RM>I-_[:C>KDJW4;R]0*-8Y3RXNV?([][R3Y1F
M[^/QE;*36^7UE8YTKKV6X^G7JT[^2^,V'@PXG[FSZ*]S(X?&W;=4P96M6:5=
MUE)K*"#IO,):,04>FNGZW&9(AZF0R>.I6K]YOYEJTYM<&%+7%J?3@B]H1H`1
MR&(CZ*&2=A*1V_X8RLR6T^@R?G&(9JZE!Q2=/5G?J2YG?H7K$3'%UK503J52
MW:IV(U"Q4LJ09K?5L!(NKM$ACF,QQ4975`NNUJUJ[9.2;:NV6(`CL7+39-]E
MTR7J93I'+T^C73GZ:_'2?6/_`(?JFXA=TJ"KCZD7GK6MKBQZK*GVZR!<+:^^
MXI?2GJ`P-ASJ,\=D>;K6JM>J%3%W+U-[LA0JX^V]^*QTI1;J8VUCS$D]X$K&
M'=+2('4)5ELSF&T'93+LIR08ZNQ5*HJA5[172FP;+#K+AF98V=NH[0TT")GC
M^5]7LZ\5?(L9YS:S]2`TJ9RU@J.*;A;.6J1_5LC9Q9V62@VB9KUY3RC3].]B
M;1-6F\B4DU!"+TEK!*>F3$PZJ&C!CN@AUCG$QP65SN9R^1BYWU!XI$<!O'&C
ME\!7B`Q=DF"NO%_('I+2ALVM2B($`&U:/)?,CL@>YKL=13>98LNBU>?;R*0[
MJU#K,:K7J()#VZ3H,Q]-C(Y2[5QV/J+EUJ[=>JK5KJ'U8Y[B!:QC^F>,S=PU
MXVULCEIG%MM5+>/C+HHXK&U'W<1WR:_S*C#T''45NCV_9IKQCZ,NEMU>6P^1
M=4K*=;L5\?3R-=]F]:356XZM-2@F>HR!'EI'/A:=2IW&C)JJV23_`%I8_>?C
MK2&NHY2O&GWZ[&;?Q;9Y<,LVGJK5TCN:][!4I8^FIL.8$8UXR=B5-6J]G\Q>
MJ2Y1I-U2Q9DJ]B%-@6BMP<QW1$S'/]<G#Z7/(?+;H_[,\/\`'4_,<];DON-<
MA<[,91_PK%B5K$=9YZ:<8+!9JJ_`9].*HH/%Y`D3UG)J*AXXV_78VAE(46NO
M19+!C[PCPVU;>FK60$L=8L-!*$K'U-K62*UA'VS/$>1XC"9*YAJV%MXX,P^J
M]-![[%W'VX<%52W9YN*Z-4HFXJFU<3,$,&O<4(K2?89&RLF5Z=AJ&!?6N/S7
MX;(5V-H9FNO3W2AA&O\`>"LO;Q=P=-;\KG+=%ZE8G'"+K"HLI)2K&0:1!5Q5
M/4_VM@UP7X=T\N*5=FG4KU*R3VSJ.]20`ML\M8UCZA:E;K*<C0=AE^)8M>#1
M;JYNG>FM\]:_)GC[%I,:]53NE8K]JI`M."@N>1+)8I]9.2OKRF`NYC',FE0\
M>M(R/;U+"L!W=X[$MQM<8APA:AV1TD)V"!`1#MD@$I'G[9F-9'W")<OZ8B?T
M[.)_F!X\VOXC.5RCL/Y]@(L97$(J9+*6KU='E=(%3D,%80-G8=C8=4B^,1SX
M1FUY;'OQ-L0*GD*]E5FM<ZNO2&FQ!,BVQNF@BO<13RB.+C:2_*(M//Q]GB!T
MRM5\!7K:H++CY%6WJK"WJ];N!NA)S7Z8U_S8G2Y5&ST+E#>5RC=`Z5Q"0G3N
MRKV86943CF+QU24>A<9#&^-1E;3T&COKN'`18%6IDL46>QM*TPP[?.-P-[K4
M]=O7!D&@YF-8.?+,-D,IA,1Y#.1\0H^6MOV+2USC*B;)Y"G=L&VY4^8]::Z[
M\,,(YZ0.SB*-NG7?4&`V()8[$].-%$C;I-=B8^X0;2#X:<=FCRBZO$EZPVNJ
MSG%#_FU;...?ZN43S-R76H^#HGG!)H5@1##EKCU-MBRZ?O/MVG$RS;L%\381
M%_3PUM.1QUIK(>Z(0-C&W'QZ.O8PB6L['_B$DBV/X71PJ[F;19G()F#1+5]+
M'4#CTG&XW>T$$,>C6DZS_C-.7ZW/8VA,#=OXC(5*A2<+@;-BJQ22WS$P.UA1
MSXM9#)UX\\Q9NU^5Y!N*HRYIXFI4KWÛA%7%,+&L2Y<0R(+;:E@ZD$1PAUBI
M0GR2S0HU\YET*$[E\J5<*]5-G),6-W(*H5UBE9M]Q"&LQK/!T\A51<K,^\EZ
MQ8.L?=,=?N,">8E&A#/..%.NNR.:&H<'CJV:NGD*N.D=9`D)9$18L+F?:^SU
M[(_!D1]!7*YW,1::WJVVXAPU.\.1)9->LE-4-PEG(]TL0N",Z"V(X[7&U%5$
MR4L.%Q,FYQ???9<<DZS99^)C"(R^,_5-9Y1'Z1`8B8&,B8%$$)"4:$)#/*1F
M./,9PN$H8V/]BW%KK*V5ZMG(5;D7V4*VLU\=WG0'JP@5P>G/Z)NFA<W,??Q+
M:-O;$6:AMR]!+NW?&C%P])R#(B=K`F1+6)TX12HUU5*E92D5ZZ`@%*2A8J2H
M!CT!2@@1CX#&G_([7MKO)KC)C)C(Y((DSG<4P"[@@,:_"(B./[+8_P"*97_7
M>/[+8_XIE?\`7>/[+8_XIE?]=X_LMC_BF5_UWC^RV/\`BF5_UWC^RV/^*97_
M`%WBU3=5M=&W7=5;MRF4W=.PLE'MUN%&NTOLX^5>/(NHJ>W4;F6RN5+48TU$
MLG<M=&/^JO8/]'TFQABM:Q(V,,H$``8W$9D6D"(Q'.>.MO#I;.IU=T=/IZ;M
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MV<U"W%[`M,=::#4-R%>',JJ[FF#%MTI4Z$ANKQ+U]9A$.XM..[&I>U;3JH,6
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MJD+`1743"Z*F=SHV7BO3?.@QKZ1Â9PM.RBH.197KWWO7UX^52\"R2`KR)+L
M%<JB2-IZ!M9.O'R>SE:5ZI5H5\=CW-OY5%4L?BWLFIBLEX]62.,N)S"%H&XV
M2DUCO$(*('C*YG*8[#5+=^REM.AC/ZW7Q@JI5ZCW+N.HT#*YDYK!+I!*QD4J
MCW2&[Z&/)#E#9+??J5;=FIC\H?\À9.C7:NM=+[9,??'(]P\N`4H`4I8B"UK
M&`6L!C00`!B!$1CTB/\`DE]FKCZ5:Q:9+K+T54J;8<4G)-<Q8"36%+"U*>?N
MG]"=(B-TZEI'K.D1K/VSI'_N%EKVK0H9&"8XQ6N),H`(DSF!B3,HB/MF?KK\
MYB@?D\'D+96<]C-[[5U+V^M['Q/4<YK9T7M*3$1&NH>VKK8R*5RO;^8_,U=;
M%U<6$W[N37S_`#:5>OOEM;E^WY5XCG)P//CY@6`QDT/3Y"O(:^1BK7^T=\1#
M@F6]/\DW0O\`\5/W>+#%6HKLHCNR-.^)4+V,]NZ?F%2U"G5@B(Y',=,XC42F
M.?'2\1HKLHGE/DF6AR,$//F6/0OIWL_/+E*>E6G_`#C7EP%7RND.'=)0M660
MPK/CEPIT@=M\@6S&.9/[JV*^?(#;Z\!3B67LDX8-&+QXQ8O,"9TAI!N%=6MK
M^^>2D_\`6X)F136K-,]5UJ[3L=!6T=`?8(5BU^[778,!'I&[[T_4SH7PDE%(
ML6Q<[+%6RO647*C=)FO<JG[U,CW+.((=)B)X_A_R<Q.HM5E^+\@VRJG\NJCN
ME5]IFSM>P5H)-?,#$-0OK6'D9\=/QFH-&B7KY)FZ[A403$>[#X691<R$Z3[6
MOFO7^(]:.7&S.HG/8P?3/8>H47ZX\O=E\"GJ&<1\74NIK\4+CGPM>%DO);[U
MPU%'"$JS,`7(6WK<L"CBZ^[\5A@:Z3`P1>WCYE-S`;__`.7Z%CLNAKKM_B/3
MO?F6G[[M>W^'0_><,',D7CEQ"Y8^GF257G:/(F4K4,.GDT;N4$@S]8@H$O;P
M)8VJ6+QFZ)^996N87;8:_P"08@^FY"V1'[6UTRCX)*.?U6CX)V,R5WQ'(>5?
M,NXB!7%#+X_%=EVO2U*6=]OW[^6W33X\6[5V0&G6JOL6R9$2L:R5$Q\G$\I"
M%#.O%3RK)P<Y;S:YD?*'DZ98Q&.R=Y[<#C4F6LKH8_"0@$J'1:X^[$?0AV2Q
ME"\VK.M=ENJEYJ^.@DP"G9NY[?3=$3ZQ'T$M@B:S&0,#B"`P*-"$AG6"$H]8
MX=VE6O6ZF;\DAG04"Y.$>196NB#D8B2A%=8K")^XL8&.41'U1S8YRM3&1$^D
MR`27/_FX\8\JO5Z]2WG,8J\^M4ZG;),R,=B>L1LV^WXS/'\I/!1U)-OR6SYM
MF0'[ORSPFIW=15H?0J]O-VZ\1$\I(/I9T5+5UF$YO3`0ZKBT@FLVQ&]A:<YG
MG]'B^\`/9Y9C##<(EM.*]_0QUB=I1]OK]4Z7B-1?:3,B7E.74T<3$:Q$EB*`
MDB[GBCGH<$BI/K#C^[QW>+\EL9BT?OO8_PÈA'R^\SEK-%^.J*=X^>G(>F#Z
M\1ZIDM3XPN3R>$SV-Z7\KL_C6(^57,GU,@?E&`L"BC9Q*;M:\!I"2@Q*-H_M
M(">7'D?CN"Q(^/\`SS#W,<.3\@NJ7:Z=Q))<%?&8SOR$K"2D()SD2O=ND9TT
MXQ*L4ME:ICJ:<3%%XPNUC&8I8T&XRXJ.2K5$T=,X]-8UB9&8G]$JI-ATS?RU
MS?`[.63RUW)"O34N:AM[=?CIK]2JI31MY3)9%C4X['5.F)/-*I:UC[-@U5:=
M1`<S89?'08(I@9ZOEN1.4SS5X]@;=W'XJM.NH%:R*"J97,V5Z1,$4H1!1K"(
M*(+ARZ;F^68J4L"*=YR5>2U((-L15R3933S0#\`M=%_VO9/+CPC#5_%;0W*6
M#KHL6<U;KXG'`>IG$KZ7S')61T+6)&M`%'H7%'^8GE%NI=5?P`^$&5"JVKC_
M`!7N<JN_3L'-BS9;8K9:]I7?9+I])G1]L+DI#]#'R;#7\NR2,D&R!GJ'7!P0
ML]WH!=;X<_J4Y[*(N6:L9'%8WIT12;^ME\A7QU<]'N0'3!UB)+W:[?37Z/&?
M]PXK_0D_10_]+Y;_`,UPGT4HQ7YAY^NYODF.']DFO1KRJCY+)?=1;EP!1D?6
MV$C_`)K/U;S3PJ,<2"\/I^-6RR,V88-_^(JMJS`16Z`37[3M=-=Y[]?AQXE_
M<S_^@I^GQS_<]#_N`XOAEHKSBRIV8R,7-O:31E)]WW/4]G0Z&N[7EMXK]_-@
MDPZS&%._N^;'X_#9^3'F-_/YC-/3=K^9([99HW?'U1=';8R.6>'4K8;&J[G(
M-7NV==@R0(HU-_+KV#2C6--VO+CO3R&-P[1]U;"KJQE*DQZR&7R)]M:<TO3^
MJ]`53_VT<'3R]%N*O#Y1X8S69FSB[2T^48TVMI9,%@LA!824@X4.B.>S3GQL
M\=J]E0GE/D.8KM$&#I][$8<I1;O>OM<Z4(_$/6CEQ4HS7;Y%@Z%9-5-FDH!S
M].O77"P[G'KV5\L(@,:G6Z;OL0<\^`1@NOY)DVAN'&8D-SZW.1US#;$HKX(1
M.-"[LE,UB8$"+V\+SC\W3Q&556;3K8ZECPR>)33L/38:B\ZWVF0R3R96#\U1
M4HC32`^,[+OC5;-1SA=OQW))3N.>2^ZQV;*F=-4E]Z56+<C'/3BQ:O,"SF<H
MP;.5MA$].6".U%*KO]X8['*GII'^Z9>\SF?J3K#SA:*ZF.<PONK4H9-AS_0(
MQKQ_L>N>`Q1?_F<M5_VI:7S]^*P;XCM1*/1M[;,?YN<<^.IB\@[.U_O/QF=>
M/=&7.39C\PM4=%ASSZ+@-.O(22/'\VKM?QC/-;E<1_+Q=-%JI./K"=+'995H
MKF5=OQRT)9RW*-\L_="S2>$Y3*9UE?+U8=\M7AU+#%8ON`$'!*;BVNS$N$=K
M#?(Q,<U@F>?!?Q92E-4/3R#$5[5W%MU+:`VJ2AL9/$V&E,1`S#TR4Q$.DI@>
M/ZJEWB>'+_*KJE,\EN+Y<ZN/9UJF$`H]#L]9_P!J%SSX2CQKR.TBM67"TXS/
MH'.X\0`8$%@_J4LTJ.7^=&(_`/APBKY+4Q=7%4FKM/5C+[[R<_940G46]5FC
M394H5&CU&)+J]9D!&Z0@X/\`6Y3)*K'<9C\==O+IKUZEHZE9CQK+T$YWO)>V
M.4\YXLUZC\!Y/F+>.PUS",P6/REFE%W)LNF_'6JE&YD[UE:<=CVV5-7(&2PG
M>`Q&L]*A6@:DTPL+L-O58MD[M,7<<HL3K%T$I#*@'5TD>H)1,#[)/]#+SI&L
MU,1K/QG2<CIS_HUÂ^L1/]<P_*8UC_[SC_M^GS+2(C7R.O,Z1$:S_"GC,:S]
MLZ1]0H5BS3O&<2W&9.S\W1C49(K.8KG4&EBI&S4N*&#0QC>D(BÛMVK(=I:G
M<R6!M*Q;,+6HK`Z71H5O+*E:C<R[76ULLY0:*>[N`V"3L6.+G81$SBG>;-63
ML+*9.E-DJ;=K#7#JI6T5GS7?`;QU'TGE)1H4_3EO]VWO]%;PO_Y!_P"B/H\F
M_P!V^-?].;^B_P#W:?\Ì]7ZEE"[>H$H\ESZERBI6K[83=;6Ì[=2]SN@.V3
MGWE'K,\$]-6LIQK%1.4A2VDH2DA63!&"E8D4S$>FL\15R-LU-Z`6W].G>M*H
MTV-)"[N3?4KN1C*1NÀAM@EA.TN>@E,<6;]YZZM.FEEBS8;.U:4J&3893]D#
M'#;?COCOD7EN6B_6Q@>/4,<_&Y!-JZ@[-5^6C,KI%A\0Q(:S;8'3C^F>7%S.
M>5TO'[MK)&F2\>\<-R[.$H5X+MZR<ED&#5SUV.L<MW=J.[[A3&D<6KA9)%1=
M#;&15D)G'VL<9_<5>J6X58K,9/W-P_F?AUXFOCJORK%2VL_YGF:SHLW9J65V
MU12PW4K6EU6L0,$VR23VS[5SR+CI9U?5JN=,).PU"U[FG[4XW.;*F/=]BZV0
M&E8^`M?/'8XNN[+96!"6T43"PQW4'</SFX>M?&3$>JRW6)_`LN,C8NN2V[EK
M\9"R-4#"K7,<?0QP5Z\LF6M`$8\=3+23.9G:,:#'Z_&VIN_+U?Q/XNBQ8FQ%
M5?;VLY2KN2YLD`]&P+-DQ,Z%NTÂ]NRP4UJJ6V+#C^XI"ÈC6%_U0`9F>)J1
M1RN,LE15E*J<M576.]C''TQNUNE8L:")R,&MG3>K>.\!W1]#:[*65O%4Q\9;
M*'C:H6%XG%DQR@O798])$#)JND5IASR%)S`<N+F'Q9TO`_"$F*V>3"=+.^2>
M456+6V?D5.8;C<-C["F;";9AC_B(<;<Q5G)8\?3,XBN9.2$1'/)X9?5>,#\6
MU>J/QE:AXZ'C*H\AL3INL5W0O#4]VDZW\OL:D3B)YI3#['VKB.?%C)AF.KE;
M7:%915D\/7#L(L=FO&V5]XQ<IBVR"[P+B;&ON6/+:5#R.8KV@#\J&H*MEK9[
MA6"DXA$VPRK&3KHW',LK+3W`F?;QT[J9PV&(TLFH73;F;PJ8+@&P0RRKBT$8
M1J`]5Q1^)4ZQ]2R'EW\M?)W^,^09)_>9?"Y7KY7PKR6UL%>_)8PC[C%VV`$1
M-FF0'$?AGBU@,IX'<POEF.779=EU^L[Q-E2R3E(RV/S:9*U<K/96/2O%?N`F
M-I[?O\6V%G3ISG,0C">3KJ8]$JR5%!7=O8=RQ[<58Z.2>KJ;G>PHY;Q@N'V+
M=164\<7JSN,</1RF%J!$S/=46M)>4IUEQS:DP?`Q^Q/[W%A&:TP&*LH<@L6C
MHVLCU"6C98.W[T*MXG+T9=5:&]%FJZ(:F#CC(Y+(Y0\ME,F%&N^SVJJ"%T\;
M%GLZU>HDF;-K+KF&1&1$;)]!@1CBKD+..HV+]+7L[KZJ&VJNOKV]@PEJ>?\`
M@S'T,2]:W):!+:IH"Q;%E&A`P#B1,"CUB>%T\=3JT*BM>G6IH560&LZSM4D0
M")*?7[?J-O#9S'U<KBKR^G;HW5"ZNX8*#'<!>A+8,$)1[A*(F-)CAEK^7^4/
MRSQ*L!-;_+[RN^<W:%9421K\1\K?U7IVC'LK7NJF(CD8\)O995?'X;*8_<.`
M7LNV+-3(U.8YB_(]*-5._8UHT&?WQQRX8VEG<Y\Q&DC'8_(WG5,@W'8^LSK+
MQZE-IBI]5K('KDS=9=`CN;J(S!^/*5AZV577BT>;5+&TBI/BZ%2\K%V/S@8&
M0IBJS4)L_DNWJL20Z<'%C,^025FM9QV18O("+,IAW7K=U.(OM*N;#KT(O-2E
MH2NT*3F);.LSP"EB(+6`K6`QH(`$;1$8^`B,?1I$1'.9Y1IS*9(I_NR4Z_1$
MS$3(_=G3G&O*=)^&L?K6='9UNF?2ZFNSJ;9V;].>S=Z\16Q@>8LRV2P@X[R-
MN7(ZE?'>27+U!;,A@;=FNVK571H?,3@Z@LHQI6Y24QKCZ'D%"Q1[>@%2[!8F
MQ91>MTZ[$W,O'D(O122+\C7T2GI2;4G#--"U#]#(_P#I?#?^;9[Z/(?]R93_
M`$)WU/"V'T7YCÙ&W8RV'K7Z]!EBQ94I6)MEWEW'5;BJC]X]$W#[W"R(DEQQ
M0RE<ZYOQN#=X\FG;RS;337<HV;H7[!-9V-UN/RYTT$YL=PP*9E]UO-?S+YEW
M'6L[?G$XJ<EV_6/M^[^2Q&.W]/TV<]NF[W:_H9#_`.AM_P#<,X\?_P!R8K_0
M4?0^S3LHMUS\7JB#ZSEO29)S>32T1:HBÌ4T)$N?(HT^J>:^.?-*?SVMF*E]
MF(*P(WQH6?&L!T;2ZQS#&5B)9>X-1B?72?HC&8S#MS-U>,=FKBQN5Z`HQRF]
M`>FRQ!18O6FP4*7[0]D[V!RUHY*I)%5R%.M>K$0["*O;2#TR0SS$I6R.7%_*
M6Y**F-I6K]F0'><5Z:#L.V!RW%TUSI'QX^3)PB\+EGTUWX99OU\B-3%7DW:Z
M<D(*%:;-W%Y5:8LU)(1)9ZK:?!W_`)RWYXW=+'M6-JC"6-*W.(Z!=)[<54NO
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MW*S/<$3RB)P#ELJA$1\BR+#BK`#$1`8V^(ML8W2(]H$+D1Z"*_7@ZUBK<Q>)
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M"M6MJR2A!R(G\\[.'RHU[BRDJSCK@V``N&GC:S%L<JO6-MB[>R#HJ5.IVE)3
MLA9M-12J]4NFD)%8;ITCG]79Y/XK>N>!>9G[C\@\>%0IR91S%?DF$9'RSR"O
MKZ]48;]C(XQF6\GRGSC*PI;.G426-P=6TN)`WT\9#7&QDGK,,L,<8Z^S9Z<9
M#9@L4N<M$QDB51KJ.YJSK?G,6`F4]>>IKKKU/?\`>Y\8KQ;">?93Q_`7ZV4N
M91ZZRKGE(4Z#<8D<;A_(K)$RH#BR6LO<M]D(#DSX<4/'0PU>_C<<U]E`YK=F
MGS;ML)UVVVSDIL--]UQD3>>TMT\M.7$",1$1&D1'*(B/2(CX1'UC&##5R7R'
MR!>V#&2ZB\AXV3`TUUW@)1,Q\(GZ,H9D(`..ND1F4"(C%9DR1$6D",1\>,3M
M(2V8VB![9B=IC43N`M/ND/V?I82GC[6S,Y;R##UZ5(0!K+U%>1JM\AW*(&$%
M.I@NNQKHTZ7MY[I&)^HV,MF\C3Q6-J!OL7;]A=:NH?Z6-(1W%^$?4IY1SXQ=
M[%W$7:CJXF#D%KR;^<$,"=&)9TV1,@<04:\X^C&*L9*DEM?$Y-#ULL*$D/RN
M1\=#&I=$E^4V^2CZ0SI+(ÌCD,\00S!"41,3$ZQ,3SB8F/6)_1=;NV45*E<)
M;8LVG+KUT+'[S'.:0K6`_;,Z<97R:D%M7CYXC'86@ZR#:XYRQ4N9"X[*U*KM
MI_+D#<A2'R(]QJ<CJN`(OU][*6RVU<?4L7;!1Z]&LHG'MCXE(CRCXSPNIE\*
M`^1J;>^84',;X\72ZF.9C*^-IY9;+-W(VD9E("K4>J:F2,\P":F,J^68L9OX
M:OY#<O>/4/SL'O8%8L&Z;%RZ(N:=KJ5S9`,WT6BU9`<B+*)4C;U+??\`?':L
MQE%7A`4IN5<FMH7JMJM46"`:LX9T5B,E,1QAD7C#R_%>09_%^+8:U98O&9VA
MELRTD8Y>8<FN5')8S>'YEI:E65QZJ?.I<!:\LMCFCÀ8K$*65?QNF8Z2,QCR
M(SRCUE^]MDWG[@!7IQ?\D\7L6ZI5TW<ID<$D9M5LY*.MDSJI4S?->Y?M=4>H
M,%SN-/:3.E(6JV,O83RW+7:&'LX6Q@\5>LU$9#('==:QMJC1OWK5E2,9CV65
MS!@V`'\R/0IZ%.LI5::060)N13\SZG:8NVX68>5C8555\TA?6W3JU91(C[9+
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MF:$(!>8Q<K78(0TZ:;R&`RGE:@Z?LK"V0/X-L\^/+/',ED48Q?AF7K87(WO'
MU-JW/(3MXFEF%/4RTRP6`3VU\`8"B:Z6"4@\(TX/#3AZ)8YLM)M=BNIUFO2R
MO8L/<>ZPÛ80XP8TBEAB4P4SK/":$>3^1XW`6JV3O(R04U9QZ\PN:$5,-'6Q
MN1T79([-KI[(9::4KÀ!8KX.]D<#<#&,PM?'@N:(10J^4TZM&YEKK"K,L9KL
M5S9O`R)7TMN-'I%)MYTKKY037K(B.JNVFLV!88"^NJÎ5H$O`8,=T3RGD11H
M4\-QWAU'^);RC)-F_#^V\9Q;1T@AR&;A;PL6%3/NK4PLV(GD<+^]PK)^7WOX
MFR*3AU:JQ';>-XIL:R)8O!RQZR>K7VV;1V;,3]TP^[]1D2B"&?6"C6)_NQ/`
ML-*B8!08&2P(P.!D(,2F-1*`*8U^R>&2E*E2YDM=*U@$M:7WF,VQ&]D_;//Z
M/$*UC),INP/E^"\Z<JOB<EF6GB?%[?5O$U6,4TZ2)FP(]=GLB?A/%W'KRE6;
M&.QE/,VYDI"LK&WX85:WWAP-0URM>XMISL`PDM(,=5V*[5O0X!:ER3%JFK.-
MP,6P)D#ÀGE,<IXGHUTJU8;IZ:@#5K/VC9VQ'YA_&?6>":"5`R0@"8*P$Y`9
M(A$CB(F0&2F=/Z>,?CO'%TLMF\R^S7I0RS_LVDNDL&Y')9-U?J-[:@#0CI!^
M8UK0"-L%)BG+^1W6^49M!=2M9O*!6,Q3/MP6$"3IXTACEUBZUR8^\XOJNL\H
MCG,_9QYGY+*L^*/-?_W6C-RE1!>2IX?$XG"]/""B^ZR;;:UH8I=H*S6=Q&T=
M-=,2M%T1M9G'IR5.DV-MKH.4QT`\1WK19@4-_+DMVJCTUV%I]'RVS<:[)]+K
MEC<70R.:R*4<M'V:6'J7K-5!Z^TV"(E\->,R^<J=GP["Y#Y(O"46NICE\@JC
M2NY!_D1#T;TIKLO0@<>73#592\6;A$%5:B$U:M<!4BM64"$)4,:"M25P*U@,
M>D1&GU8<C1S%W"72QS</;=454L=UC'-ZW3V7$N!-NLW=*6Q]S>6HGRT!].]E
M*ML)*(:5DK=8JRF8IF,HLQEN6X^:N-^04!Y+$W!6T84[BXK4NKUY0O:3NA6J
M]4YF38<5J:D5DP1E/M`8B.#P^+K6/(O(8&)G"XGID=2#C\MV9O-(*&$K%]KS
M$SC]F#)Y<0[SBZJY6F=P>)XHG*\<3SU@<FTX5=\F9&D:]>%5/LK1/NXQ_D&.
MP]3%9/'5KE-3,4L<<E]2Z"Q;7O5JD*KW0&4@2^H,RLA]NG%6;7^5,?$3M=*T
MHIU'W[METH2\X6FM7G309DF2(_'6)%^5%91KK!5+Ô):F3R[7X"Z/[^L>HEH
M>*LY$%7U\C02;7MGMAMQ'4A$JUFN<3'NYZZ>O+@][373[/O$7"1;GN0"O0MM
MV(&M+`V)R:=!+1IG)1`>V>!I5+P6+)0\H6I;B]M8H6XB9T^F`BV=FLS&XQ(8
MUD2B/J*DVOF&0HU84FAC+]YEK'XZBJY6O?+*M<XYT#L44:@R63TT@O7IQMXB
MUB9O4503CG&HN&&+*6-O-5!4QB!Z5/YBV$KB86,;?;.P-JWY6V*.X9T:=8`9
M9OY"Q\*N.Q]8&W<A9G7[B@,M.?IQ^=-CPG`G^X2Q#?+\BJ8G]M9#N*'C:F1/
MW538M_XQ!\N)IXBBFDDF$YVS<;[3S^_9NVG$RU>ML_$UIFPOC/%AE>LA#+;N
MXMFE*UG:?TUIZ]@@&)<[HJ$=Q:SM&(^'%Y5EY51ILLK$CKW3)_8L:B\Z!75(
M!2JPE@C[I(NBPM-HS/&2;1N3>/%U3M6$)18!DP,>Q:Y>I2S8\]!"-><SP;66
M=S4&";*J=>]<A=@SKJ``8%0>JMSK0"IFD`V?NZZ3H?\`M1<],MLP*;1D4_U?
M9T@%$D^'=T'3D-8;$ZAKI/U2NW'XQ66HR!A;K*LJJ9-3=1E+ZQ7&JH6$::P8
M$:BCE,27,>"#)V?X3PFNGR_#6X=Y%D0U_P`LSBQ%.&27Q72WO^RR'IP&/Q%&
MO0J!,GTJX;=[3_:/<?-EBRV8U-AR3#GG,S/TQ:N[+"55CKUZA*]@==J&V6-F
M3+KD<U%[>0[(W>N[B4?*:<JGJZC*]?VTG+/=,[M)ZDQ_0/+TX.;V*J6B:R&L
M)J]2-@@2Q,BUB9D0*8X5MPM(>A(RK1<Q`;(0(Q$:Z;=E4!T])&-/37AEJC13
M6L-6*7-7NWN`6-:/5F2GJD)O+0IU*(G3TÎW%8ORVHJA;L.LJG*X&<KE<9W!
M]4ZM*X&6Q]5U4&%/1BPAI*#0=3B(T9D-;.4S=@.G;S^7;%S+/#7=T0;L!-"E
MKZ5ZH)KQ_@:\_I9"C%;9`H6PPZ@@<Q[#)>]?4$2^&Z-?MXK"^HJXZLR']R\=
M6LL=2^XFG]NYN4L3M^[^;/#U?*ZD+LI0AX0O2&IK.FP@"T]84Z=8X(*^%II!
MG;]0%B0@SM+,7*TF.[:9(LCN&9YQQ6E>)JA-.435(8/=7FM$BJ5'OW![)VS_
M`(8Q$%K$1$?^PW__V@`(`0$#`3\A_IXH9F2KRNID]#PU2AIU&0]-[<-$9(%?
M7XL,Q<V77=@J':C&@CO#H*>'5"`#;BFCSM8X\)JR,T?D?Û!F`;5$$)CD?\`
M#N)IP"QEO\!"R6F+4!"\8@*5-+-U.GCLSU+B@4`*C`#:JZ`,<4)]%8S%]0=P
MF+QM2NB''5PR`DS1)P4&NR.<)V'#2KB3S''<*-#?8O<-QAS/L,$)08#RQ=29
M(FX\0Y#ZAL9A6MFG3OQEWP>!*I?"(-66:X0EK?SX:(,CSJVA)[W:XHQ`BB9S
M9F1A$#B38Y)S!=&B>A&'@%8A!>TAMXNL+R!9,ZP>$<(.7AZ:IJ652Z4RCL@>
M':,`$`^3>,XVJ^&'N:;>.EG.KZ6B<MRP:MI8?)<3]*,U1!P"ML?J+(8@!P0"
M+W=0GX1+HX&/)7A#00``0PTH6K&2/Y#C>6V6PRH-1.81[2@3WL04I.+`S9FW
MT-D?C;:9F3#7G(T.K'7T!#Q*WF`?JJ)IH-V4&X`!UBR!D"4;$C$`"(Q1I''K
M(>;N%4W`1K#J&V"UP]$O[VG(_H&AJ?I!^)$SE@!4-`,98I+">#^_159);B76
MS#WO/=X+O&@Z#G/9]&`^_88:#5P?P=GI!U$6:;:Z%8=];`1;BM?/FHF$X;2
M?R'=)]"84N-YA+T:3X_L#]@@3[PH;`@*GYX&@*`JX%Y6"P4TS$`$S$1]X*%L
M6I.HRT3PS'K52_B2^$$1S3<@_17>HK2W(%H']>`+"*JMQFL9'94K:0ZB#YID
M?F:Y_1/P#WEG\QDB7`0FV0FÌB8B/Q4``!CWR9G"U8Q'29.MNY9JN>1_6#3;
MP-*^@"K`,([%N@6#XTAGRÈ^2=V6LU^TZQ@-KI1_0:N(BB?,X#;RI2!U5T&5
M95*X`57JXFDQG403C"E1%#%G&>\3L>>WQ[Q0K94\=QH_&G/X?I'ZNH`,F^F<
M,TK>QW<.9]P0,C2R!LQ&^Q+,4ZHIRLOR)J^G&4?]%'<4IWI2@:<^M_M4I/"$
MQ"[E'=,]X*C&RGQ*/[)HX9/FK2Y;6B#Q:W(5Y5P[5&Z%PM,0..:,G[M^5$>8
MN^;0%\68P_B:W,C$#0`+X5D*.K`5D10)76.M@2NY(`M_NB8\Q<[P6O%(@DW*
MW+<,2AIETC78WQ24X$F10$P)-`"(J41?X[_TT0WLLOOV^MX+\O?#9<N9`1%Q
MR;[%21HDI>W>[S.N+GB=V(`_U`-@\!(!H,04)*YK_P";#3##9ZXQTO'-YT#!
M7&Z;\]',+_,49Q^8V!9%8=[S7&X;V%,D(Q1-GRKH7HKD.C7+<$Z$E;(/M=9U
M11<X`$-!H#@,655N_:T!>FFBF(Q+"686VYT(`Z:$I$00@@\Q1_Y\1]&)$3,5
M;Z0G"<Z^;W5$`]X5LI>9M._/JA]&"`"%G9<*RXU,'&COE'I,LN]N(>X%1B@A
MA.E$%PP]-)3Q6*2D@>QC_9<G.9.H,KL(7\9@[SITET)(BS^B2&8[#IAM8?C?
M"K4A'1J-SJD/&VL!MY<&ML+.Ù;D2(GRJ'*'!O6U@?[7`85*H3W1=EH"$/0
MAM0V@(1;S-T&EV!O'D08<Z5`?TDÔQ83N5%S"$Y1J2X$R.#%#<"QH37?*/+-
M@8*O&%/`VR;Y9I/8>3#E&0\"7P`%!"8%IG7*.@W=G\@'>#JC[S22^@LS@E9\
MSV%%49J'6.484/)@DF>T!@(9WI=`^HW-&XG7_B5<]:!B2!I-(B%[M>]$D..0
M>37[F#(VT93JMWIRHB&AG$8?[BQ#FN$?.<6GF)B(0WK5VC,Y^\C<M:S<K6WR
MF8$8`58RH0FS-^'CN".G-$JMAVKS6IRC#(F1$$\T<A7;F"((.(J!4YP'H-=:
MCHI636-H=6RSY,T(1X-NG2N?:/B*!0`JK`#:JZ`.Y^Q,SA"NXCI,]MD?E#EN
MF2EZ4[>J+T#K0,*0XYH;'X<<@@T']'=.'?R@.7"/1WJU:M6K5ZTAW[7B;Y47
MTX;VB2+A0:\'T]3UJI?U)?*(`9_D59W\@>S+^]IIN7%+VC@#ABK3&+($@T%'
M(8\B@G$)`06W*B^T?(-Q-+QYZA=IMM4'%,A"-KOJ1+$Y*%GA-^YL+T$(72PF
MI+M./:0"=!W[IZZDE41L$TQ<1KU4-;G%ZV]_'P<:/9[#[T'4<EH#:#!=Z])9
MY+<A0$>[],1=BBU$Z%"#FQ:O@-MYA*S9Q'OO(&'&>R?N<B5.>=DFXX]_1,"(
MJ@A`!9)V(W1+UEP5R(QUXS/6HQ!I'3)DE2*JVV[D^_U`B7L,:.E=#BT3F'*!
MCQOYC4:``#^DNX.UP6%9*E%V]BS0I`.\IZ,KZ#_H41\)=>1#2Z`;?->;+=+Z
M0-19&+?CP?&Z[.])#PSRT]:(OYQ`$;'Q%\';"N0!K1-XL'$79*#?J/7AG96U
M'.J-UN^<GHJJ^NOY!'3<,M3QH7DI\W32/$!L1=I#W+'O(1$6(;W$P)OY8MZD
M'N43?UX6>K],`#;NM;NFBCX>+.3M61"+*!&-(7U)[O-<'I>["6C/YBUGB>*`
MQ5S6";6W5+:*@>+F3RL$'=/BSD;&Z:J`)=D!U,9DS44%VXDP9WG(Y3`.>!'Y
M0H,13JU$7J*((F#^]8J_,^1(*1X9(E8$!$;BXH7NRGM#P\[]Q7K6RM9BZ`$_
MUU<2RM\.C1DJ4-]/]A@#9&+0@\15F0CGJ\F1=,K87*QZS*L!`MNMF'=:&Q9D
M/1Q5XYK[M('FI+CR_EB"G@5U0.RT06P4!:(ZWU%AX(CT!,C(0:4##HÎ^H"Y
MKP9S,'9^-2L`*:);FJJ"Q8TC%X!N6@W0+2VEU[!';/G_`$^@5Q@2OH\+VA27
M92>_0&%#'A_AQ6^__B9_X=$RNJSU>;I</#,%%[!C=C2'BA4;B)?\B5S,G?8O
M=:V&_2AQ?]_+C@T7;<(`_GY*EX86F\EYPLE'$Q$0T$PS1(M$U]D6*A3<&Z.:
M=4[H0TOF"W(-B]<JA4!!@>_*H5+*ZH`G)=GY1`+&W<.'RI9QM;#@96"[RNZ$
M;`Z28*"K583R8<4F?#W4KA6@[%OK\,B:#V%SL",)JK:8!_E1<3GS)BF]?6NM
MWLX'MWB"/]E:%)A`(K\/FJVFPV0>R(":^P+[B5:AGJ7C0UARG#U)2O08V7J1
MD/%O*'\QAYGXA[PD"3>AXQUNJA2>:A-$9U,WSYO/K:C8]HX`"@0C/)*3ZO0@
M`XQH8T$T]6)!ZANR%@%?1X$9>^$QR#-5\&3=I-H/A9BD1&0>,?#L62S3[U*R
M,V-T1/KHM$%'G->%:FF%:P!ÒFR*C8P*\VPL(^\*_P!AWZK6(3=#>;N5\<9]
M(5>`7'ZN0:^J%L23<!P:RN)EW,[AK\9;4"M%<@.&M%BW.W\,JB#4Z-@CX@0L
MI\I3AQ4JV^9.-N]`=XQUI>$&/)CAJ\`(,:#PF.Z/S6V=%/Y1%/P4_/!DF*^)
MO[KCKESC)E+C0B$,$3=`,;3@46>J"P>,X',$IEL?8#(,5K1B!0<-]A/'`854
M(`;+93($+M[*)>TZ6@R+1MME]<S-*^$2U0#"',0'8-NMX=C5\51:GZ+AI7`H
MHNTSLNU.\193Y;5SFC8XLS1$@2V4NQ6FG@T=K#$È72.7)5DZ[74OL/1VJAC
M3TQ@$3.4,33G=9J"K;OP3CRE5G+I/%V!(9%%_4#FUP*<*A%@@%2E4/)Q#H];
M2>&2CE2-8B-\+KDJ&0"OJ[,ZC>W9P@-;AC4;H`!Z.AT:QD-4";1/M;T:FTH%
M1LB\!GKY?\V$S^KIN9H>[2']/SHH3'%8LX`5%CC'O@8SG-@?K?7WH\./'$%-
M3OPEU)K:(U5,4G"U7(";_D7H/UQ8V'O60\45AF%1KQ35$3Q#@A0H$4NDBXTG
M22E,IMWN?ZX<V:FJVBJ0*V.LM>UTAZ1[@5K+2=@D;]]<ZY,@J5#+-?[0YL9/
M;P=4%!!IBL/QJ-],`7!F`7PXTK2/:;Y1P,UA8#1E,U7XJ<MHAH"D6!M/1BA6
MG0,*A"-'1;$<Z!2B-Y1?CHN<3OW12.G&`-OFA8F0Q-"M(:0(/S3"=E58(4%)
MOV#?A?5*^&UVH(#1@Y`.,C^ZA?,A3!$#%\<!J`J=5I`!J#?:+&H""EEBRC!.
M"@.,+4=]MJ<QJ@V205+XWV/2$X,^Y_-!FOB]Z":-Z2)R3,@)V;;F&@X<-"PF
M:A9:`8PPD<_&]8_1"A&1T''@Z`0`:/(]:_BP+^QBÒ)T>B*CU6$JI`,_0=,N
M"=K:V=PNG/NP(4`6)/A)9WP]P8.#$"R`H,@44SW!#'%#P]+'(\D/32505(=D
M#P[9@!HG/:(3,@5!O<F&'5:;96&FD9W@/I*+A3PZ7)S0,TR'F;1D/:A<$1T2
M[V'J'_%5.+@46&1[3[^FJ3"ÌU^;(T<(NRN!-L5#ÙL;Z720<&TT!L&%]M!@
M]0+N=,<B(6+J<3N/*!#TF^YX(!(!P6H!MR>)M'?%.DB=&N2A5$H`\T'$*O`=
MV!8-::`:XR^`S4F_Y&[YTUEE$YOABRCQVC9%"?;6C_X"55,DG-!P'?B]!LD(
MLY;2,##_`)6"3,!$HURD]X\+L>^:LR718X(M(6SP91J?0R!VÛ[3.%`H3`;X
MWPZ2-U)J1CP`9Q!#?0$3'$[>"1I2!M#AR2QV2E;I=V734H7F5SV`4P6AR.P7
MA<AG!&WDS?Y[H.N*D&F?5CC;FQA__<<+!KY<(HQ,%/O'H!2I]*<K/;(R7-])
MFCH`;0"UXH(@!0P!M5=`&5`5$O83SYU`\K'\,,=\*:T<)U`-Q.Y$:`X%6X<-
MU',%<WABX.'_`"1:=W08'C<&0U\$\@>U*(PM%?7<T,UH]F?K,2Z\B^`1K;M2
MA["N=`B2]YMDIP.:>4BY#L"IY#+ZN>>#BMA>I%IA*.=X2TO!**#Z7F:EWZ]$
M83BVRD4P.[;0P0(M<1E,J^85K"K?P@XU\`;P16$$1!$B.Q'D3V.!2(UUN&&)
M0A1BOB$L$1DH^P^$$M+3FB)F<V`%SDFU%4A:&K(^DA`3A]8M`_O%P5D@B2C.
MKFW(#`#RN$Z7%4F!B;W0NÈV@&L];S7K`P4,$C1H\&MH+4H@LN2Q"AX>O0J
M@H:Z_P#<<,YWYT*DHX!<WM9D@;725_U(\V=5\B^)VX/#(1S2[/>1P=1HXL28
M`(;H8#`!6;T?P8^X19`P\TF-F*#.@,<._4&2$Z'AB#;>J54-BRE$6FD&U.[
M=6E-BZ,V%2^@*0%U1(YPYX#?U88+_=>)FF0!K(Z/]HOP,W"H#`WR8<KH8IB)
M1J&X4(TK_P`'6<__V@`(`0(#`3\A_NR/_]H`"`$#`P$_(?[LC__:``P#`0`"
M$0,1```0``````````````````````````@``````@`$```D````````````
MD`$@`````@D$@``$``````````D@@`$`````````````@````````$@D````
M```$`@@`````````````@D$$``````@$D@@```$$$````$``@@$```````@D
M$$````$$$@```$````$```````@`````````$$```$@$@D```````$$`````
M`````````$$@``````````````````````$`$@`````````````D$@`````@
M@```$`D````````````````````@`@``````````````````````````````
M```````````````````````````````````$``````````````@@$$``````
M```$$DD@`````````$`$D``````````D`$$``````````D```@`````````@
M@`$`````````$$```````````$@$D`````````$$$$$`````````$$$@````
M```@`````````````D@`D`$`````````D@D@D````````@@$@@D`````````
MDD@`$````````$D``@@``````@``@@`````````D`$```````````@```@``
M````````@$@@`````````$`@````````````@@```````````$$@````````
M```$`@``@```````@$D``$@`````````$D```````````@`D@``````````$
M@`D@``````````@@`D``````````D`$D``````````$D``$`````````$@`@
M@```````````````````````````````````_]H`"`$!`P$_$/Z>(;.FR'83
MHNU#]`R5D#]G,V2Y?:>J.KM(BF)EZO/$IKK@``@BG9B)_52B`%<-G)UX^-X2
MN(@?'?V@20H=#9%++9MB#@CK>ZNÈ>84!-RARYY5_%\&8G<;@*A_XI'U>È5
MT&`-+U3OLHL&C`@#5+5\-F)@0$+]B&PIP!8"`N"9)Q-:LPNE?6MD*TD8JN_7
M3,H%/8R>!`^ÛK3V(+$TG<@@?%7BM['VD?6V0&`(Q:D1B=F5?B_BD7MXFT7N
MA2ZC?2D#10H5%"SBDC/UP3#N0?\`B>.=?[.1?B.5MLHÔ$[Q3&QUK!(>8;&F
MB]K$A4``$/D'6O38/+]8FE?M"EKBO)!#CHK&L^?Y6UX90À>J@'0XZ2.%]47
M=J`;@W&(!_PQ;_,YB@`##IJ]I_Y9P,C(>1A>I&$E3Y%#LO1.;B1Z[&,'``XI
MRX-`9U:LE\1,U6`":GX9ZP6!V.`(>5Q*QAQ\13UMUD85E.RPE(X(C$QT^,"&
MU^`[\E++"RPD@%QRI6J]NU35B(>9L1]?$_8&9QA#:JH`5R@))/2H.BX=&,G:
M1O.N:4LW,C8>H^?L,F(!4[HDN>48\?2-$\PPT<N3Q!TE4[@+76/+]SS)F,ED
M&=X?#E6JG-)O3N*NX$O+$X!6(%HA:&V-/P!7FHJOEHIX#;B2RB)9$M3*!%,X
M1X/F$FS!`Y<-M)52JDG"(IAZVR@J2JPPV`.]KJ4IF>HBIWZA+4#2U/OS:OH`
M269EV*9:,OH<A-[Y@(*`G_`]=VVR3@`,>LI)\`03U2(CD:),VB(`5,!WWCZ8
M=R#8TY3$`,L\-_#5.@]\@DF7KW[&).IOH!``7V1D/=4<A\J<-VMF;6L`59BM
MPQ54C"N<-9#G\CH8AD>"4PT[29#Y%L,X<X-&$+:<LNP^\2)<D>8R2[*H&5-"
M85FP0=`!J/0E+;X2_=0PUAMV:M3*I!\CQZ$8?*BS`8"K%:+VY.9<`L<JL31O
M#$T'W`8R9P8X;*H#5L@TY+\`NAR:L3+DL;(-:R9DTU<"G-*:(;,++&`Z%I$J
MA@,8O3PGIIV`N^(?";]&X@"OO15?:`N;:>"4FW05'\SQ2,CEG]&&4>B'T\E8
MM-:\W#EW#2_-M@(J7"S4WG!TFP&P]PKKEN,PW``P@4"!_P!!SA#,CAR+!L[1
ML82".B%[7F._L=5)4BO`'E1E48*```"9K0P"+R?Q)PPL!^8Q,=@QI0)JPSM*
M[(!<;=7BÒ-'!$Y>W3TP@'@E"]UI%(?*)97G%Y>EPQ0,Y(57\2#ZSN1`````
M`!``T`8T^L!V&\)W740$QY](C6Y!0.+(5>M`8PZ08HO!\0?;:V`-&<GJ'2?\
M2KY6LD]C*M3<3-"Y#^FI2Z?'?C=WSN1``````(`:`#0!WP.O@,Y"E%);$8_T
MO8XBBYX*ATQLS4(VF8/8),\5AC:/`G5`VAA^Q,[)'Q\]O0);A*\#R^(ZPVGJ
M_P`11I#_``Q23M@_6B/B)B`;0RXKF>U;BX6JS\@-(M$"*YA0`>UQ`<16].*Q
MO)HC$PG9_&B$+P)&U-L<OPC-RG2H]3B_6Z,>A++2YP0^CA(80262O`*_!HCB
MKD8V7/RUI(,./`6I(BA=]G-EKTIQB(_0$>-8RC#6$OÈ2--M4.Z(`/ES$1R;
M*`NP-R;6RSRQ:/8B#2F+V63-(6]5[J?SJZX&(G#2"(Z]B_8SG`680<_=AQ,<
M->C#:Q:$P,)2")9L374*0L9U=O/08+;H=@0`$YH@7J6+=,0*;Q&L3JW82Y"P
M?(0\^:K6O(6B%,9'+(?IWV9R@ISL*\'X]Y&;F[&,QF4WA##PN>0`N7<JPCIB
MB@:\-8PC5B$GVAD0B1!#R[Q#L@>'*8`*KH.YU*DE0Q5/4(B."NJ?M\A,J'BE
MZ,4\8*^</B@?0X\<5D0Z?4T,?T9H\W,U8W0+T`!WERY<N7+D'_8BZ7/RHH:2
MU+5Z@]AT3J(`=$#*`14J))RH"Y_C:/?_`-=";Q6)>`QPEC2"T*_W*B`MNCL.
ML.?7M0QL<>,B'8O\AMM0Q?<Q%X/,H<,>!6:E'(_&*9S%CS^:)+77J1!\O^&B
M.[[UX+H`'!EN]A<1V_Z57"80LQ#:=AY=5;\<@2J+Y2J.''>B1)N]Q[?GU)25
M"#7:VK6Z6'377Z$1>*<UK,R(K4/JQ#0DL+HE-_@H0^3+/S7#RYWAL5'#'4C(
M,E5"(4"NQQ<`S;L!^X@\UI<7]"T.&(HQ%!W@JL4>@9^F+T&-BV_O$\I!"']2
M&B?4&``/Z2S2$GG-59^!9Z@GH$T<@2W8S<!_T*.*BJWWX4-2`?,J*\"3GS>R
M)#[TEUS9HLJ.R06U<PO:J4:"EK*H0+"*-L2@(=6+H,O22P\KJJV\98#7$P,0
M?%ABBKD7+""E`T3,+7Î=CX05XGB]F5B$?0V?+`2-/+1Z22H?VC,CX0;&5AS
M`31L!L"!_5K4Q82U%N4WT+?`\G:J!OSKZI">5BE9YS722(>UZ<9"C]",#A>+
M6W2<?)8CW,[O\I"238]:ÙHHZQEY;28)2M1@=%E;JZV!)62M7*@``````@!H
M`-`&./7G)>W*3(B.547AGEBWAJ\3B`G-R`S`8,W,2TTJ')7H0U=L#XX$L>#8
M6B-^JZ<@@ZKFYLE0Z+2B!@LUAUSPQ*^(WEZSNX@<#%,!@'AF9FO$?R8<FA1(
M%83.D6TY/-"KF=[.;D?=^/S!)WU-LJ<,N=O3'VD8L"/"C4&C9+["UR7&Y4N>
M6.4VL`90,[I:T20,7+*MQ*L,`RW@HX*.[[?7^S+!V[B288"[IQ=`F,OA.7XM
M!LYJI+U7_,?3C(2IU58,KZ"'T=-Q/;'01'%!YZ<`'&N_P2.7WXP4(0PSQC"H
M&`1VG+K>MZR+"$JZ#1!<2H)@C=W-K7>)QX<KNN`@U,S$Q#$;:35FC:N.8FM]
M097KT*>C!87]!UQCJ$N2X/1[WS4WTJA<HH1AL&T4H11FE70Q6EE:3K1G/N4-
MN&M1[$5X.SB_24/#FU0<^GLE@[;>"T@X9<")J5>#/8&0Q3)'&ZE,X_A@Q>PU
M\L+-U96&P@#QPH^HR&5@6`@]'Q?!>696F!%OQJ97>1*"T5LGE@>"+W`+YFR?
MD#W9]-6T&NZ%<(@EC'BPN!^8)ND@63/^T.@H&8L58,`H%TFTXOL%1*<O1%S=
M5E0L4!-:2\]3NUM,,$(BC`X#P'QGWZYJZ<?&P>RP:I'2G@-P_P`[AZ+38PS7
M8FCBB.)I$FC]XU955U=JME?:]&,32%2F8<%>>@(A-%%%B1*/A;8;0TT-%22N
M55[PDM]<01`%*!%'`3]ZJP\X$01$01&B.Q$TB8/C?,8'HK!<0`FUWU9HHZ6Q
MP!0Q;!R+)%VXOF&$U32))+VIY9S6$<IFJP*\Z!L#B=D<GA3/C+(^=9.8QAGA
MIX.*KR/&]'&@W!*09:%Q1D@VL=V?YPW"R!1]8<>"1(J7[^GRMOP\>NS@K9^P
M>&N"EL.=;0[@P$G+J&&I:FG!JU$HU4!6K,("\W<#:=6/"3,M:O<"A(HRT2%V
M(9-=A-X7[Y?K:]A0[1=*W@>6D>,0)`0IC?XI##CL`$;S9X[,02$U=.*T,>-#
MPCWLPS8G7L<1=`\-CHJ->2'29&:<H>5Z)7(;[9$K5D1'`XJ5@8@`$4J*7P7=
MX?[PTN/E%6/=K.ZBE>U0VAGH`Q)4D\CEH`JR6/)>X;V/&%[JZ^R'_MWZ5O<!
M07?)(I:(.J$5]#1@``Z*5=&50B'G24JJ]&H"S>V05&@JCKY8N48$7K5H7\NS
M>(.4`*'>(V-B]LM8!!R2&7,>^4D!!*J"2P.T,Z]"^&BL+]6;9&)C_"CL$&5!
M?1?Z>:PA.CI7Y4$.2NQ1W0.KZZQ)1&7H!-*N&XSPTYS4Y&;K]Q`LM%>R:TIQ
M+U+Q5NI>%^V,1*V8PR+Y/,ST*1HN55T8%$TEFC8=6ZJTTG(%0=D!(DF;T'F,
M$8!OZJ/Y`%P_6-\+<[L==6R=%!<0F\Q<+UA43$8+0C.Z,=((&UT9+0NJ?JMV
M'$>BUT8\"ZIN17@./*:B?G1NBMS]L:ÀR*WL8N7!3O<\&;_.R8_57%K7NS?U
M'Q%M^HTV!19_(-8A^4LH(E3`>$0/5\PZ3N(AGRWEMMN)#_SA`9?_`#3R\,]/
MQADC;QH31AWCZGUÒE6MH4;*:8O@:*O$'AA:]I5`"&]L-UXH%`-RL%^W"KI`
M*#^>[5D(H-0628$!+K41:(@``(>1!M"N@!K%$F4$<95I@_XMA3*H&&3QY<N9
M"@2N[#N#,5#G/F"OA<GJIW[Z6Z9*Z<#8I9-`B488&BZ!L+RTR4WG7V9IHO:U
M(?((&G;R$E2%N%!=Y3P2TTM`P^YQ,./M[!1749#9"J&-9M6RX-=1X,(&8)YG
M"@LFPXUEZX"FY.6[ZAO&WE77Q1ACPS$G0\]X2R+D'=/X@NOKQ9C%1D61A.%$
MZJC@G@E?!],54%3"E.GN502[0%,@%M5IJRW+<'P<2[_#T/M5GY]@R<(PH]\*
MUZ`KB.NYHQXKV$H=,ZV9"?C@+"@$5$_%#*'T;QJEP&/<VBH$35V_7Z&RRF!Z
M#[+'LVR5/`<<VBR)M4#(X($%CZ##XZZ*$A:T,\/`V65HG(-WP3.7E6:G8A4V
M`[(Q8C@;EH@_K1D2&@F)@ND!RI&R%7I);@I;0SCF\\0PTDOE&DR>8L-G!K:Y
MZ-R1&Y/%C)^ZY_'IZ3%#:`#J2>@Z!2[Y`#G(XJ/,V]"D9*P52$@WL>(&^H1M
M7`)5=!E\A6$Q]#N)P-ERI?M\9B.JR",[:<,B<I,%`)/+I*&K$-SV6,N*(HUB
M@%0`\8E<A<$P%=8>;9%_O++%&#9OA#IME9]Z9N>:3E3#:CFZ"JR"F1@4&>!^
M^D9P/!UB0%KHL0C\Y9'(JV]'ORJ.%$*(0415@006F3#;M\28R"J0$Y`VC#JU
M>5B0-]M01'/#)4L>"ZB9P``B%`,1YQ7<VV*Z\5>30GZ^Y[1'(7[A\$-!)#+@
M`<B$.B&03@(\O3N9B'#)$2N.Ì8%IA$//=R+OFM&HY1YPQJ?P4L\H&"&/=?I
M>F=AF#/`GT8.TN!*DEUO$3U/=QJ^:V_FR&23O0&GJ2^'O6@=QQ-GO,U6I<IH
M4*Z']!TY*W%C2[6747C4U_I?&@X]4_&DCB`MV0)HL#G$RVV,*#IN9?XL571"
MH"D?"/.VO;_-.70LDDF2MWU&#>'Z@Z1*'7*R'5@K`HK),EY?V,/829&6(R?U
M?&A!4`%SI4IOU(I@,#!4YVBV-S?^#M4?_]H`"`$"`P$_$/[LC__:``@!`P,!
'/Q#^[(__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<TEXT>
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```*P0``,VD``$`!``!*\/_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`X`$B`P$1
M``(1`0,1`?_$`-\``0`"`P$!`0$````````````&!P0%"`,"`0D!`0``````
M```````````````0``("`@(!`08$!04```````0%`P8!`@`'(#`00!,4%181
M$C874*`Q-#=@(C4G&!$``@(!`P,!`PD$!0<*!P```@,!!`41$@8`(1,4,2(5
M$"`P05$R0B,S0"06!V%Q@4,T4%)B1+5VMF!R4V.4)775)C9SLV1TM$56$@$`
M``````````````````"@$P$!``(!!`("`@,!`0`````!$0À,1`@,$%`46%Q
M4*!@@9&Q\?_:``P#`0`"$0,1```!_OX``````#C(TIT"7(?0````````````
M`!X&K.13M$X2.P#P)P````#1FA),;0```````$/(@?1R,=4F@.C``````4T4
M2=&%G@``````%$$@+7!5):Q0Q>Y]````QB#E@E'D'.J""$K-@````"/%2'V<
MB'5)+S+(6;@VI;````(:0<UI%2VC!*3.B"NRB#H\NH```%,%S@Y[.A#"*;+Q
M`````*:-D6F4\7":(YC.N3Y*D-P30V(``,8XO.V#7G+IUF1XBQ90```(>8A"
M30FV(`3LOTY$,,N4C!"#4GL=H``_#^:Y,SM0JTRSGDB)W"3P````@!0),CHL
M&J-J`#F`Z)-L`````"/G)1V89(`````````.;2?%J`````$;,P_#1'Z9)[F(
M3`````K@V!F'B81G'H1\LH^@````:4X7)J:8EQ'#T,8F!U@```#5G+QYFE/<
MD)&#<$I.D0``````````````````````````````````````````:(U),P`0
M\E1[``````````````'"9O"4EA'D?!"2WBQ0``````````````#GXZ!!01?H
M```````````````!419IFG&!VD``````````````<''>(`*C/@FQ*0``58<D
MG39=P`````````.:SI0`$8,(F@```*Z+%````````*M(@>9Y'@3,MX$$(R6\
M?8``-:0$J8OHEX```(*0$TITD```0(I@ZD*8+G!P\=P@``Ì@DQ/BGBY````
M4H3DA)+R<@``T!"BS3FHL8G)QN=0D$,DO8``JH'B1HZ```!2)NBLCJÀI1Y9
MYZ%H```HDO0T919TD565:=3```$,*C.CP`"F"@#HLMLA9`",'2IZG.9SL?T5
M``*@+?(L5V7:5.38D0``!%"DS>EG$L`,4CQ*#[``!H#(-N`8)S27`0PT19I7
M))BYP```14IXCI:Y:P```````````````````!09IC#-:;DU9\D*+)+J)D``
M89&3)/$U1.C*```(P5Z;4]B8F]`!##6&G*\)4586D24]RP#,``(2<Y&8?9C'
M0Q-P``#7'-Y@&^+R)```"&E9&K(^;0O,E@!__]H`"`$!``$%Ò6!N,\&KCLI
MSN.5=01!\9_''OLDD<,:]DN;"Q,#_P#T/MMKIKU/_P!B5-:A6*PY*ZKE)])B
MR`4!KK,@;\#-$8C>X-VOTS7[8V;2,*@)*7&)?A>[)D5C>#4(:&IC>I>`MYU*
MNISVUI3$9%;K'KU*[:VEW8_^3]F/UQR^XQ\GC\?P]"66(>)-:J]8).=EDCC]
M?]*$0;]7\=69%7L"EBG#^DT;+4H?SULLW/N1M7N=;6A(JMTP%RL,XUIP/.VM
M82\J)+=)#LV1\LXD"(..]!^WPC5B)1[#K9J;NVF`<7(28"KB#ENZ>Ù+7VBX
M-;.EK:M'FQ+8:LL86YXF.ICILY]$@04J^>REHDBMOP@8<R#K<$,*D^G??TU2
M_P!-\=?JSDS-</Q$L^'VGS.<:X3N*,3H;9ZLGU'+%+QY330CQ)NT:78+O_7A
M98HÙ#O54=N^,6H"F*FB$@5/T';L-`"CL`KW55V#7W8I"BRW2'5HXJNC>['L
MSZ[5#ABN6[KYE83`J`Y6/!KFNCF.83WI6?6+19MEM,L]79)UUD063QÔ]B_0
MM*C6^QYPE"M<NWK+1)P2H:SDU6N1*6E1O-EM;U77PULOHV-']>#8TMS\ÎZ[
M$3M_8*"$#X]GBB&+P?['U&T!92NKUG&6<4,0\7NEN-DWL-):&.JMZ?UA1\+Z
M@!\;ZBOS&-8TAC#-B28G(>I1((7"DC4A^G&U]':W5K4H*QI3\1O4<V\=BK\V
M(K17YV.;"@U@C>*]YIV=8<S8QC&/29!89+OVB8C[$]39+'UZO-(/DZMC*Y-U
M%*5'CJ/?\W[.XDDVZS_,U]`T74X+3J[603]K/]YG4/S7+!U=F;6'J\;&JWIT
M0."'JSX$E>H&R9Q_I;#-;G538D#_`,6]@1H-(Y(Y8_?6'534]>T_<!?-5NXZ
M/9H/F[#8.9FLM<Y/?$NXGP[&0RJ266NUKW]XJ5[WOV"*UY%__@-ACE@;BE#&
MP9SC7B:RNI2??4T3'#7P<IX@]4:[#&*%&E'8^5U,9KZME^T@<T4]PP!]T$G(
MS>O!UC?*BNXDPC]"K$3E*/<6;ME\UM08F/-F]DJ6L5E<7"'7K-8/."X>!$^Q
MS8UB/;Z8[?<UUQIKY%EB@P;3N77/G#Z5*M=A,]O0LK>9"E37M>8K=7[98Z\[
M3^F.DO\`$7+UO%&E]EZ_S1Z%U_MJG/.75<XQMB%>$LM'H/-LO6Z1&&A'L5,"
M>[5QQEXI\FH7U)71ZWFG5"26.&-B_,ML2FV"FDL6:].(_#LEEMZ*T*;!R[]F
M5&@1T1Y<+"'XV\(XQ?43U$BAO<E*R2O&LG[?R_,?96_VT3R*0JG-OZ\?,]U:
MZLIS747VT3RML"]_,Y.%8K5C&-<,E:]P+44()$W+6C6,UW7?656J,'FU0K7&
M:M6PC8_&[/&2$("W65^\HAN651X]5[-`5A;Y8`Z6O+7/III'IRRD$[6O'9MN
MRC\51@A=JX>Y7K9*,4*4%RP/U,(RC&<*?-XW@0)E5SJZR/;L:NXX$]3,3?;)
M##-PU$D91ZZXUQY,52MO#\@#G3VDR2PC95V6Z\Û4?RA6UR31JZ3.5P^L+2^
M'27SX:6G"@Z^@\51/4^W6:+=^1U#6R]:[6=J_O\`PF^61Q6@7MT/76IGV"6F
M=L.S?B:A=DQG8![95GCQ=K"YRP[</V!SV5#KM76$S:O^,Y$`L.MBK^PY+I:+
M!FP(=8M;4DR3#-"3#YN&,BE<#>5)*.*ZU:2+[RJ^V%C"%LM\&M>1O=OM*N_,
MV:6MI`V0/7U1$?0T)%S+/J[+7!=&'R/4*A\K-4U$SH<>`0?QL"6*P+"Î!Y,
MZ=3APYCZNT#W"ZD"#FKB76O)O,L?4P4OKW4EB+U(F%GWZV!V*4KXU*ORL"?5
M\I>U5X_.;=<"G%P=5#0\7]9!@M$*K5$D]O\`_]H`"`$"``$%ÒY`S__:``@!
M`P`!!0+^0,__V@`(`0("!C\"`9__V@`(`0,"!C\"`9__V@`(`0$!!C\"^F_B
M/-<L2I/Q3E=6UPP,;2<VK5P$Y6(37.N`Y9&2J(QHNL.LM*K,',;5P2YZY??X
MWC7W\?C^#*S5*SY<(N,/D0M<RI6[5N+%[3)UO+@@D?3R]1BJ=DSOC7*-BAF+
MTX2]7QN1"I26MD6K-.G;KS57?L49NJL^N6M<IW^1I;1UZB=)C6-=)]L?T3IK
MWC]N-SFÌ2@)C6L*`6M81N,S,I@0`1C69GV=!>Q=^GDJ3=87;H64VZQR,Z%`
MN09KF1GM/?M/5O%^NM_#(_D]6O1CO4N]!%Z>8L1-R*F_T\6Y1[GDV[MO;73H
MC.8$1B2(IG2!&(UF9GZHB.N0<KY"BM9#F7(>2CB;*J%/'Y!7$*V2FCAZ)9"G
M7KW;,(+'R8FTS+V=](CIE)%>&KL>HFXRUML/O%;L6+5F;C#'\Z'6+;2V_<C?
M.D1';IELTG+792CF6_G-A9W\;472I,)<%LD$*2$P/W?($%[8^C=D<G;11I5X
M&76;+(6H-YBM8ZS]YC6'`@,>\93$1K,]5OAN6IVBN%<776MNCR9C_%-Y)5SV
MO4ZI#PE@$,$,'&L=Ê7:-A5NH^))-A!PQ3(@I"9`Q[3$$,Q^PT@75.Y<REWX
M=CZPL!`,M>DMWIFQ89K%>N%:BPB+:9=M!$IF(Z"SRRP&7V$+$810DOCE0QTD
M".D<R>7L++^]M[QB?>6I4],RV$LNXUG&:>7(8P%^GR&R-`'-XH_W#+A$=MYP
M-@![+:'3L\[CF,R1'_+%&`BS1S84<8Q@<I.]Z]Z[B79/'J)<[92"[A"4=C*.
M_3ZW(,XFC2MH=7LXSC%>42:'C(,2W.9'U%T]RRTWUU4S^S3I?\N27"/X=J;L
M`W\.8XUYMJ+>OXLCCVM\%Z/ÊV-["$ÊKY-=FA7+B^3J\HGXJQB<6U.(!YV
MEWGI58956-1AL!T+9X7`![2VZ=4.<NR=96/S++F6`>+9W+HCT5K!X7%X@Z^6
MJIQ3[QV$X\F6)D5#I*PB"\>Z</@[30>_'5R0;5L:T6?GM8)>5XBYA;#C<1=Y
MG]@YUAHQQ4IX5GU8*;$V8?\`$?)13=]3"X0KTVGEV[=3_KZX3_O2W_A7D_RG
M_NHK_:[ODQ;:&O\`%:\JF.(^./?9DS$XLHLZ=_@;<;#?B'^;5$B'\T5]1K[?
MKT]FO]'T+'O:M*4@3&N:8K4I81N-C&',"``,:S,]HZ>G#Y6M<=7C>:1\BG$B
M9T"XA3P4=K'NG].PN"0S$3\G,H>Y:IM<9SM&J)GÈ:O7,5;13I5AGWGV[3S
M@%K'4S*=(B9ZX51%H>NPW'<5B<O2F=MS%Y2G34JWC\C5+1]*Y78.A+8(E'R)
M^,9)-,[&[P(T:^TX5]W.73K+=:*O7'WFLV>-0]SF(Z3<I647*E@(8BU5<NQ7
M>N?8Q3E$2V!/VQ/T;,AEKU;'TU:03[+!6&\ON*#7WFO;/8`'4SGM$3/7_<R2
MXCAY^[F<Q2%V?O1K[I8_C]C1>+06GZE_5TQ_JP]CZ\7,Z0>A'L/+<*E[,/(]
M]#S6.DK%_CQ?:<S8IQ[9>'W>OYV6'71LSD>?U9Q57&P62O9>9X_3,8QE.E#G
M7(D9^^,>,([D4#WZHY1A8[BZ\1:/(8;$6J\9F[9LE4MT-_(+%:VFM4652ZR/
M!3-I`10<O+3Q]*Q_)JG\/Y!IPFN]CO48+)-G6!'&YGQI7YF:>ZBR->S/X0*.
M_4XJDBSG<_L@XPF)A;;*0/\`3?D[##72PU,M?U++%[OP0<^[TSD+,Q@Z>4;4
MBBO"1C'Y##UZ(N.P"&9+U..R=J]+3]ZQ`J5]4(^N=,_Q*\2HVQ.2XNZ.15._
MM,Z'BHY\/ZEU7Z?YW3N3Y1+$6;"BIX6@^-K,/A2,63Y5SÊD\NQ8NL_6`BI/
M]U,E]`[)>G*T0.HUE5Q9"O(_(WZV.KP32@O&N'VADRT*8'72)GMTC*9VZO/J
M\DG5QRUFKCM5J&$O<./9J62LH<N?SK7DT*-5@KJ+].SOM*.')J7[%I:Z[H$`
ME^$S%2?C'%[9@N(DJQ'7/\=<]9ZQ^$L(6ZQDV7:U2]GH6J[CSQU<+5@KH8?6
MAR.L:&1X'UYHR91M8`%NGH,MDG.SF<")\>3R,`7H]\:&O$4@B*>)3/L_*'RG
M'ZAG[>HR]-]K`<C4N%IY#AR6FZ2P[KK9)+`92S6/&8_0M+:$?@V%[W68_EVQ
MN'QV7X_C\=E,GRNDAKPN8W+%8"B6+P5S>JCE2FJ?E\[[*$S$2,-W;1<ZLMMC
M(VX'U^9R#2NYC(;?N^JOM_-E03]Q(;$*_``QVZY#RKC==E3)5L7D[[<;3W?"
M,I;&J9#:R&)7$K;80<>4F(A5ENW:1E';JG3PG)XYVJY/%++FZ<?!B&Y/DU#%
ME17<Q]:KCDU>14;+CKPR):KTQ2+)B>W*)S%;T+L;R=V-KT9;4>5.H&%P=P$G
M9I_E6")MTSUUF8@]OU?0T6V:Z;#,?QJP^@;UBV:;WY-2G/J[]80]BAVR8Z%M
M[:Z?+SRSC,/C,?9L<IV/?2HUJKG!_#O';&QC$K`B#SN,]/9O*9]LS\C:MM";
M59X2MU>PH'(<$^T&J9!+8$_9,=<<]'516]5B:-RU*5B!6;;ZRR?:L''OOL-+
M[QE,E/TC/_&.*_\`%6%ZH?\`Q<E_M2[\G"O^=R+_`&6/R7?47JB?AU==O(>6
MPH/15G>;Q6+6XH\"6>G/0BTB=D_9UR_F$9+#NQ&>Q6"XG0]/D%.M3G^.-S+,
MMCFH'LNS6'=J&Z3C86L1I\DD4Q`Q$S,S.D1$>V9GZHCHPP5_C3%ED4B88UF.
M@69-_D96+:C2&V;$5R)1]Y9LF1F=.B;?SF&QXMNOJF;[M5&^]6%<6ELU./SJ
MJ]OEU_3'3=I'3)JV$682SPME#0;"V[`9XSD)G:?C:):?84?/8^PU:$)`FN<X
MQ4I2PC<;&,.8```8UF9[1U??BLFRSB,7AUX:QR6*5L>+GEGY&'CCT<@)48TW
MPL?;O@"UB`(IZUCO$].N7K->G4KA++%JTY=>NA<>TVN:0K6$?;,]<VHX[+K.
MW/+/RT6$6Z)6/_3F`7'I/7(KQ;F9K'.B]Q;(WZ;9B9Z%U^P*88<*0N(-MFTZ
M?NUZ=5(LLV[!?4"Q(NN.4KJ2KVZN&QZ+*#V[TN766+%'L(AW`7:=)GZ'UMR+
M#=]BO3JU::9L7;UZXV$U:5-$2/D>]A?7(B,:D4B,3,7177O4+N,LQ3R6,R:0
M1>I.-*[*?(*FV*[56*SA-;%,8LHGVZP413LXSU]F;S<Y634BF07(M<?7+;E9
MJ&D'B<Y.TT:SHX&`43M*)ZVYUA\2P<MKV4X;',JVN16&U+*KE-V7RLA:QV/\
M-FN#/351=K,:%8(=RÔ%GZ7Q+"KUV\CP5&895#[Q'G>/UH8Y$:ZR=FGY53W(
MUH'J<5Q@U6EL4IU=W'GT,WF<E7<"R&TLY,\#Q7%ZE(^LR+#-DB4*KE.DS5RN
M;N#-FI%PJ.*IOL6JM-N0$5V[5_+7X^)Y_*-2N!EQ^!(CV!`^WY.9W*^2M5/C
M/&<3B<97K91].I8MT?CDNC,H6@Q;6GX@N(^]J.Z-.L3E*+,=%8^5<GY#R*B;
MG`+[-F>5C@,G2D*Y#%YE+-JK7=8]Y:PF)F5>_-#D8_PKE06QLULO82NC:4@/
M(ZQB<Q,A0R==8>\41(O6/=JE]9C#8.G8#"9;#97'%RNYOIU39=H.K(/"TC7Z
MW+HAK8DG:(KDONIC.L1\1QN'XPO%Y'`ZG@\DP\L=;&!E/5%4RBZ%::^/`K81
M5K;-WO,(I#6!ZO9/'5:/)9O'R.D*LUF6KL)JY7(ULC4NON,Q]GSB^5RNZO;O
MD5JV[]NG57%^9B*MS(QE;?PS#NCC)U#H*HLI!(4+15KK74(\2IL)530`S),E
MFSYW#G76-JHN<-?9R.0Q3KV1S,H^(\+5D\O=H6,,E:,SC\+<MN4`2^?)OT$M
MO?)82YE<_P`HX'BWX'*5B?G<HZG=SFS*AE,*[)>2'YS$JKC2L&HFLA%@](*/
M>7"L/0QU&GBDH]*K&UJJ4T0KS&V4C5`(3XRB>\:=Î;PK((IH[[N-9GSV>.^
M]/MQIIF;^`D===B?)5^KP1,[X3E.5W9Y-E$G#JJW)]/@,2V)F1+$8/R.2#EZ
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MFT$7:U:VC;R5T)MI585YJ_#>0M2WQN$P\B3C42]HSU3_`/M:_P#\H/I<E5Q]
MCT=^SC[B*5OO^ZVW5V+K6/=UG\EQ07]G6&$.$SQFEC^,9'"\MBZK%'6Y(^V.
M.6ND7I+-J>0*!R'N*W8'O#-.\N;$+0A2T(2`J2E0"M2EA&T%K6$0```QI$1V
MC]EPV#L9Q?&,98P^:R<Y0DX<W7;M0Z53X97=G:EZ@D%T[K'/'QRUJ^T3`0S7
M#Y*]XBL6$,U>A,UT7E)L.KU<G7KS,^!&4JJ"P`ZS`BV(CZ07_%,=X3?-4'>N
MK>([,'"YKBSR[2?#"@=OWM9Z;7];4\Z&(4]'J4^9+;7^&6U>_>MEC\$3W+ZN
MI=%ZGX8E@RWU*?'!)5+VC)[]L2I`R9?8,:^SHL76R51MV*]6VM0N#]ZK7`L,
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M'6(`724H22R@C^Z,C.OLZ9*<YAVPE4O;*\G2.%(AWII<R1=.Q46?R]T]M_;V
M]+Q:LM1.W8I4[],8M(V9"M>9D%(+',\FR].[&-W0K=MB(F?;'1V2SF(&LNR5
M-EB<E2A`6PV[ZIMEVP;(;HU"9W1KT%8KM=%EMNW1K5K+TIL7'T2VV8II-GDL
MPOV^[$]NJ.*:6,S<7BO-K+\=;*TO-A_3>JWGH^NFS6]:':="][K2.T1VB(]D
M1]'?QQ-:@;]*U2)Z"VO3%I!HEJ2_"U<'J,_;U2IHL8-U=]'.TLE=LXFS:545
M;Q.#PM5M*C>S=AHY1E>B9^43\0:0N0TTGJYCCS"ETGIR=-=Q.-V\A*MF\[0S
MEVS<RQVSBQF:!T(#'VH4,UCGRZ$8QU90UM6MCZ.'P`T2^'U?A>1Y/1FHFWEO
M@R;Q$NB[!X>K0L(.5[P-L![LP75IUB[0K7+K,6PWX?#*QOHAI/SC[*L7I9<R
MK%CXV7O;IG=$D6Z3GHB=F:5=_AKI%&+Q#,;BRC'LX^=*75$Y+S?O/P';:VM&
M3`Q$9'Q1,UMN6I)7Z"_5O^+&VW&[UQY]II5&0RUU/I!9R`]LF$V`VS`LB&:#
M<FSE*C0NUA%D?#[<Z-:C"U[E7PLRQT2Q'CQ&BE2G?`D(R4^/WEW!R--%6GFV
M9FF%;%0J\WU?)L3R.S1REV+>VY4J_"_!5B%AX@D-=?%&OT%NDPV+"Y5?5-B2
MV.6-A1*(U'^!@P>HS]4],1>R&+-O\.9CCE=M'C-3'BE62H8/'HOD$6WL=?K*
MPNLE)]_)M#Q@$1TZ(S037MVHOVI/$@>0&S7O9B[3"A?];$TJ>N6VO7L/RP)Z
M2'F/I25YU5>BC%QC$U@Q!1"UEPZ]Q!^BDY2O0D""\5D9-!N@Y\?D\>@Q9M85
MF/&Z_-(R`57XJMZ*$MO<*\P6%PY46D4:_%I;X_=\LGM]W2)ZN'8R*RMY"QB+
M;WU<8NMZ5V/Y9EN56@Q6MES:%:VS*RD1WE*]F^984STM-C)IM2FE9QRRG'/9
M$H/`6<!5<T<AELA^^)5;(RE?C7/W!`!ZLP.92VODQ%62]1ADOOÌ-NY<06$N
M,ME&(M^6\6]WC<4R($&PQW=5,T_*5WV*E(L=Z>AB`Q5)E8*-&A59*!N6=MR%
MT]6LUT/41B`%<?\`)=)1?IR-BU9I(*+*='7*7JO6553OT.Q5]"[R!'O!XCU^
M[/5CX)F<9EO2R$6/A]U%KP^3=XB/PF6BW;)V%]T])TF=/FI9F\OCL2%@R!!7
M[::L.((W,\?E,=T*&=2GV#'>>@:HP8I@"Q;%E!K8LXW`8&.HD!#.L3'M_;HK
M?&KB76.0<\O/0>3L/P].ER>MS1%%M3'>%<>I&<\CRCN'M+="GH>74.#8BWD,
M)@_@*^-XWD"@=EJ=G(8^YD7U;C<=60M.,1C=*%<XWF5@]8#2!.Y!9`N/9G%Q
MIF>,\E7\(Y!BV]M5,Q[YWVO>*($D>6"F8C[TZ=:8Y3>-8@O;E+]<9SUQ>OMQ
MN)L#*\6)Q'9MT2;_`/3>PNOW@'\MPP_ZS64E?)Z(1K_B*2H33SJQCVDB$V?L
M2XN_1NPKEYIP#JY8.&E6QG?;KR"[;$0P6TNTJ</JI]@).>W6/Y?1Q%'+O;Q]
M_'[>/N/LX$4D5U=X<CBSOT[;YQMPH\;X:M;6"I3(&=-G6%PCW+>[&T55VFF"
M&O#(U(E5!/WPIHDMB8GO"AC_`"!PC*GC:)90%\AKCD2J(F\*/AP'"8M2'FA<
M'WB->W]L_+R.VZJIMBMA^).3)QJ`6)=R4/5^'7PS=A2A"'2/E@!VP6G;_(7&
MLS*7-H8IF6^('74=AM==VAX%/],J">U(LCW]@E(QWTTUF%VJ=A-JLZ-RGUV`
MU3(]FHL"9&=)CK4IB(UB-9G3N4P(Q_613IUQK/-R..?'+N07,!:XRK'5EV\7
M7I#F26(7P+XBZ_@2HSZV'[E>^W:*O=U_;<#/BY/'-_XEOSS!]J,[\#/`[LKY
M8\C_`/TXS$FGT_PT:_YHG`>R8?\`-NYW$V78;(*6RW:*H-<Z63\(R91D\;:L
M5*%HS&-/-Y:[X_Z88ZI9[+V696ZT1M50:"$X[&26NWX=CJMS(5`:,?WQOLO^
MQNG;IV71B,8C*V1D;&350JKR#Q+;NAUP%189!;(UU+OI'V?/S-S#^4;Z*PR#
MJ]?UEBK7)Z@O7JU38SU5FA1)CEKVGO,(C:7LZI5.$\@M<MPK,MQD3LY++%:I
M_$;E;D<Y#%3R!./OM].ZG5KV&J@6^F;`1[D-VQFSSF@W4<KY!4%*W'9KUJU>
MWLK5ZMEE2BRQ66O[I2H9G]EA,O?*/4<K_*EK/%^7C."$O\O=L_+)QR/V29?;
M/S<G"X,F30M;!6LVLDO">D`M5+),84S]0UW3/^87LZQ<-%@,BHO>+5,2R"^P
MU.QN(:$_T361/^C'T/FLM-S?BO(5;SG4O'7Y!E*Z0_J4E8C']$?L3,5Q[$,O
MY%>V+%^_Y:&`QOD7#!FQ=E9.R#]AP7@J"R?J,U:[NO6\ASF:R6=C4JF4HWK.
M$5A#G_\`G\;1?Z:D.G8I?ZIKA]UQL#W>B_B5<\BP"1DBY3BJL!E*"`[DWD6!
MKQHU2@UD[6/B8[:E64.I=`?"%IJX2P.H<TRR296LJF/U>-X7>JQE(G7W+-B4
M5?Q!YX[=?&*&6SE;ET^4F\M9=]7D+A.%`L3D*#@^"V,:<551Z8*ZE@*X\7C+
MWND8WDN+W&Y@HJ\@P:;%G#VS(MJXNU/SK^`>>L?JRZMK_K&ON_+1KVVDS(Y5
MCDX?$5!A^4RSJR?46%T*FX99%9'OM84BI(>\PACOUNSSRQ&-+V<?Q-HO4."8
MCW<SFD^-IP7XD5/&OZB:X>A$8T$8@1C[(B-(C^R/GG9N6%5JZ]-[7'`!&LZ#
M&I>TC+M$>V9]G6W'PS!8TOO9*TB/B]D-?_UV.L"04(*/8VV,G_U'L+IE9B&U
M\'ZE[*]G)769#%6/4OES&V,]*?7<>R-E[B-D7ELHDPM%O#72#2OR(N*6+74;
M0PNR"CG0'AM)B+=1D_=<@V)+ZBÂNY5%%N195\&E97G]CK*:YV7>EK7;(TZ(
M-ESY6EIBE93È/;I-_(G423;-RNL\*ÛR&A8BF0"3EV:5`75YGR1N384ERSU
MB1[;IQF.30JS2R",4]-[*Y!V$^(_%+C*LU<,5O'3CGY#'K`6,KV+-9I^0`")
MDOH.1_\`@.7_`-GV.OY<_P"Z6'__`!0^0):541^(THUMNK)5KN+\=OD/&5;_
M`+(]1,_Z!?+_`"(_YG\T/^&:'T.!_HY9@2C^B1LE(S_7$]<9M66F^S9X_AGV
M'M+<USW8ZLQK6%/<C893,S]O4B400E$Q,3&L3$]IB8GVQ/6%IXZJFE4#CW*6
M!6K!"D+)^7XPUOB4.@*$V3KH.D?0HXFH2]*JL.8SV018LU;>+V-F>/+QUFHQ
M9)REC)UI?$EN&$5B@AGRCU835.T]ERVR_?NW[!VKMZZQ2438LN+2)**]9:Q@
M8$1!<1$=6[7GN*M6:BDMIS>N#A,FRB3'XR,SCT-7ZBNBR?O^(E&U?N$4CI$(
MN-1Z2\$LIY6ANW%C\M3.:^0I27XA59"?&?\`>*D3CL4?/R6.\GA^(4+E+R[=
M_B]578CR;-1W[-^NFL:]<<XM-OU\X#$4\7-V$^GBUZ14+\W@\CO%OT]FXM/M
MZ8YS`4E0$QK6$(+6L(W&;#*8$``8UF9[1UZ7AN*=E**FBX^1V<UDN+X)Y(*?
MW?%9'&J=E,UYM)'R)5-&/;+#TV2&*R=6SQ[D$C,_!LIXX*U`1JQN(O*(Z&9K
M#]J#DPC]0%SVZ;?REVM0II_4LVF@E43/80@CF-S&3V$8U(I[1WZX1S[!\?<>
M,X+_`!+LQ^6L#ALSR=7)<>C&F[$T[:]*$401Y`C(%5*QKMT7'ORY5-C:^1J;
M?B&%R*#H9K&D6FGK,<_:X5E/W&CN0WV@91WZ2.<ODW*W/=Q?',6DLER++MF=
MH*Q^*KZO/>7;>>Q6OM+J]DN5\47P]3K0S@L8W(1=S,X[Q_JYM:EQ7I6S9[T+
M$ID8G:41(ZE\VDS'U9O.QV9Q>4.DMR4/M5Z=C=85599(*WJO%,R$,,`*8TDA
M]O5'$8ZTXG8+'T,;9I9!)4LQ4]+6777\0Q[16Y!-A>L%M\1^T)(>_5JJE@9"
M_2#?=2JPA%/$A,3(NSV6L$&/PJ9^QI^8X_36?LZIYIM$DT:F&RE,<A*7TJV0
M?D[V(M*C%T[VW)NI5:^.F)M.77&P102@V^SYV0"GE;^*P>$(L;+\;Z,797-Z
MB5_\ZW5MZ4L.$"GW(C?9)HSÊ'7_`+LY3_VC$?\`DW5Q-FR^]1O62SCLC=A3
M+URA**E#(^H<E"1FQQ@E);$#`C.-9,0,DF2ZUCO$]&VN`.OO,:>,KLG:MV0L
M:PB'%'<:J(B6O+\"%F7U=6N0SG\S23EYJ^DG'Q0I_%ZN/J+HIY)=KNQ]@0NY
MZ$^8=FP1I^`=-PSU_P"[.4_]HQ'_`)-U>PN6;YLS@FBE]B0!4Y/'6-YXG,PM
M8BJ/6H"0;LB`&TEHC&V(^?<JYJ&Y#&8C%8.W4PSFE\(.]=N9ORW;U`=%9)P#
MCUPN+'D6K341@O>ZB(B(B(TB([1$1[(B/JB.BI9.FB[6*8/Q/""VL#]-RB^^
MEZI[@P)@PGO$QU=R^1*YF<AC,_GL9B;&9MMR4XFEC\D^G77C@L3(5W^!,0RQ
MI-IOXV%\EB[:KS&0QE.Y8QN4JM;2RN.<-=A[J61JDNT@2*/>""\;/88E';I>
M<K(L9;E&7K)M97EF?L%E>17FV4`3=U]\:UD3KIXTPL-(C77V_0*;96:KU;7T
M64I,*IE*6[V^FNJT:*R_$LMRF?C$HZG,9@IS%Y6:SGIHLHJ5\?5?1S>0HQD$
MXJBBMCYR]D:T,;;,#L2R9VD(:!'S<-8Q=>;C[G)\'C&4P]+#K=:]8E;T(9=?
M6K*<0>PB,=.K^$L94>$C6M<D<#'UL);OD&)^"J5C/(UE[$F-,;Y6;)#)LD&+
MB"#0IZP=\JM2F5NJ3R"@F:]%QL>Z3OTTE)$%;*%^\AK)3M;WF9[_`";$2M=^
MJR+F-<V-REW%"8P#QCN=2VEAH>/XD-..JM!?#\H2ZJ_$KRYWÒ)2HF?'7ATV
MU$Q54)A824;I`8W:SK/5*I9PMG$4&>2KE+-C)XU\+Q#M#R2***#G/^(9A21I
M2V9&$U7.D?>GN*UB(``P``$0(``QH(B,=A$8^3#8NIDZW&67,%F;AY^:>/LY
M"V..M8V!PE,\F#:@I#UI67Q(&>T(V;??+KDMU6.'(SC>,8S(5\O1C%IQE=[+
M?(*A9DZU_(KNV,=E48M5M(+%VBCTB9ÔYN;;5M5[*G8+C_A8ARV@WTF3Y36M
M^,@*8/TMG\MFGW#[3W^2M7L.F;=TX74HUULM7K'?0F+J5Q8_TZ?:QLQ"U1W(
MHCK.36LHL0/+N4[I0Y;=N_-6S#=XR+3>$ZQ]L=_DR^,*X$VPQ-]EH0@C5CUS
M3;*RR5D8FMC_`%$Z0H6D)-F?=B>_6+B8F)C'4HF)C28F*R]8F)[Q,?097-VE
M6;%;$T+61<BFL6VW+J)-Q*JJ-B@989`:`,D,27U]8R@%QY(S-B,C6R%D:]6J
MN>4V.6YM:;1N>J:YU#P=E#!(=X,@!F-TEMQ$CZQH9KD>1XU5<A*GH78QF1/$
M.R-ERWD"\0S*>%`.[ZLM*C;&Z=+V.H92E<O8PMMÎ7L+:^K.\U?F@,S,;6K(
M)_S3&1GO$Q\P/,I;?&P'+\@"?C<ONMH;HG:P)]DQWCJ4Y'#8J^F;'K)5=Q]2
MTN;<CLFU(/48^HD(TW_>TZ@1B!$8@1$8T@8CM$1$=HB(^>-;+8VAE*XLAHHR
M-.O=2+1B8%@JLK8$,&"GOIKWZ:N:525O2NN\/3IV.KI@A2AH[-&)4)3`C/:(
MGYEAJ*Y6WJ0UB:HL6HK+0`B77%K9A2R<<;=Q3MC7OUOS+&X'C=A;1+!B!)OY
M&C;KSXQR'O!9H6"HY5B+*]8.KD,>I]<]A3KZ0:?C_>77HMH8=;(#D;,P5K)+
MO5Y583?MMC>U@3'E.9DM=9Z8A*F\KI-&5UKE0\5C^34&%K"ILJR$U\#DTC.F
MKX\!A'M2WO/3+/)FAI:VE8PM"S8>JWMW;(Y%G'PK)<BD8G]'2MCQ^[%>8TGI
M+ZGDPN1J)!%+*8?Q5+5="]/'5-?C.I=HAI_A["VI^P8GOU&'/'+R#&&/AY%B
M,FG!T6HC=!CFT6/5YC#LTTG_`+NBT3?PFC7W:[<D2<C:KGYZZ%5HJ8;'V-9F
M74,9O=OMZSWMVCL7"GOY>^GT.3PSVL2G*4K%%KD[?*L+"R61KWP0;Q@NVL=6
M<V9O:JWE:.99AK"ZMG$A<J4>15'2E#D'*UY!W)&V6QK_`(F-\:;BUNC8=?VL
M#*_"!K.]"KC[LOG;?(GV<>BEX$-8O),KD$/%@1Z)7;VZOB,M;O5)]1Z*G8KT
M%C1]9>?DKD^H17"U9-MNQ.F\]!"(C22U*?\`),Y#%+QMA=*G:R.1K65VK5UE
M:LVH&J45'URIT%@XSLWB\PU8$?R6;NU7#UJJ_A*4\<?ELDZE9LJ'^)\S<P]!
M06D7$Q1GR4IVEX;4&9C!0H()O6?HV<%:O8['6$5J=K''6\[+)<79R0Z1UGVA
M:YS%5';2$1&-0'OK,P7\/8IM]09+#(9E7-JQCOAV4Y-7XX&10OU2[-Q3[06P
M#9'N^#=,3!#!5FAQ[)KK/^"FU[;.,UJIY/DFXCC;F)7;89QDKJ??@-2KK(2+
MOJ(JM*Q.4%=NQ>QF/WE1WW>08VYC,=;P2H79.(M1?R!`LYGQM&LU@3*MAFM]
MKCV6I8LTT[A9(WXMPA1R49D<=8FK7N-M3-A^!L#(1$D`["G[TP/J<5QFRLXH
M9BXV,H8!(13QV,R6-E`0Q(W!O!?\;(@Q\+1]LC[TLI.PUZKF/.VA6I&VF\+&
M1K9%5*\A-A#_`!M'&U;2;CI[:5SG\0S'6"RMB%C8R>'QF0>*8(5"ZY2389"H
M,C.%P;.VLS.GSCL6GIK(7&K'O8"4KB9@8DV,D0&-9ÔJQ;'.X<JM0:YVK(Y.
ME->L-N-:I6'0[QI&S'Z>Z8W_`%=38*VA@^==:!0Y+6$]L*,5`,,]YD)=#)CV
M^/WO9U:>6;Q$)I,6FZZ<E3A51S?TE6F>;:AC/PP6DSU?K'=77^&FQ=RS:(*M
M-1J3C7S'J7D"R@E95,Q,>[.L_9TJQ7:MZ'K%J7I,6I:HXW`Q3`F08LQG6)CM
M/T%G(+Q]S*>E#RG4HG2"S*A[M8$Y"W2K3"@B2F/)K/U:ST6<MK?B!BA2R8X[
M(/QLY(Z.5$YQ#H32OW%1.5-1@D9.")@2.D:=&UF;QU644:N0MIMVT(;21;BK
M*_503-JS@KJA*-9VDP8_$.M3Q9S&N/():ZBI5I1-MBDG*(5!NB?++ZS%P,Z3
M+`(?:,Q&/RE:&#7R5&ID$"V(%HIN(785#!$B$60#(U[SW^;5+,8NGD2I$15I
MM)%GCWR$L7W^ÂTJ'>LM5GMC6)TCJK=9BJK[E*W<O5;5@/,Y-F]>;DG$)'KV
M&\\F+B>RC[AI/?IN6RDJQK;-^H",FJDNU=#-6:Y8;&VD`5:T#+BDO\82P""`
M[%[NO7&L=D<.+U8"B'PU_P`(/(EB<=BWT]^5R#J]>5UJU:\2FDPH]UOY@Q[L
MR.*L9BIA:]BM",?A$RNL-Z099544G'5MP.>-5]Z)C9$^'?)1I,]8)<7<9B"Q
M&13?BA$8NC03ET\;BMAW91\CM4^G@;$A5A;8B>T3N\8P+E648;&(QGIDR^_.
M-J5%_#+N6324MC'Z1Z:QZHEQ.FD&7U[HZ0%7!X<J>YENOXJZ327K*HUC8!1K
M!J=2@5Q[1\8C$=HCJEFC2/EH?%'(K"FL-><AF4!4OY1LPCU3+KJ(>#]39L*=
M1F=)A%6LI:*U9*Z]="A@%)0D(6I2PCL*U@,1$?5'SIQCS$%%?P]T]Z!L`<8G
M,4<MX#2<B!#8FEXYU]F[7O[.EMJ94*SZ]I]U0Q0:FJQSLYR/+Z7`QN3QMIP+
M7R,UCL<N8-8GK[0Z6*<JQ=9.)PU-53T0$A64QIXI5O.+WV).+&1Q6$K5-NOY
M2QGWBW3UB;..R=-=S#T*5-,7,(NUCK3*\<C!UJ_15>JD]KE<C9M_-&5L#=J4
M$0]8\OBS+*,?8Q;Q1:H);Y8Q<\7)8,/S0/O%QJ)C0=`\G:/<C6GAP=Z@*?J(
M!OBA&HOM/LP,*$C$!5#ML=_9'T%FH92(6J[JY$.FX1<LER0ZZQK$%UQI?F)>
M)X]Q.S@F/\HS<RECT@X[%39JÊ\&F'2RQ86S?^N_L'U]&P+UJ5^1-A(%7HRY
M-B,EB,I;/U<UY>:[=C$#[FL0(F4=]%[+S0RN075R^1C)YFE"Z9!>L5L_?Y'C
M(!Y(FQ372R&0G7QS^:L!B>^Z2QN*49M5C,?3QZVMV^1BZ5==8#9L@1WF*]9T
MC37Y]K%&\JPVIKS+@"&$'I[2+78"D8G?X=/[>JS;&;QX8RC>=81AGX>Q>I6P
M_<&4FY(`R^.BS;H/0Z5P?D1^8);-X1,>HHY)U%5DJ/Q-5Q;LZQXX_/)Y`CT%
MK)W6-Q13;7(EMWKV3&T!(!*-I98FJC&6*`">.3O%MGCI<<;:\DNF/\-H4#MC
M2=T;I@NU')EDCM32NQ>A#:2-C#B.3:1,R9:3$\D*=?;^5'V]8C"@Z;`8G&TL
M:#R"%DX:5==<62L9D0DX7KI'L^9__]H`"`$!`P$_(?,Y4PTI/)CAXCU@>3_@
M+LL0+8]$_P!PS4S;X\\LD)I[B[`^R+\YU#,]*>"(`"N(J!I5&[^!6AWB6J]T
M]IU`?\.88%[2DNT!5R5^S!Q:4./N`(&@#M!Y36#FY@+4X&72P%>!R?'N]_0P
M#Y%@-@$J3(@<H,^+D`5C<QK]!SX+\7,!3F[#H$H=0)HX8%E$%,!8&U$RE
M=#(4]GA@K/7%-$0BPX1U+F.@E,/REO-46UK1=\"+NHE?(U1B:"V[8\)4?+(M
M0SJ4?IC"S2]W5`N`[ZWGX`HPEJN,'F;R_0[6Q`7MCAJ9UGK7`3]`T.3@WMN7
MPO*;TG1'A``K@U&[X/S5BVZ)%?\`JEBBERSB8O=!!4I='*%(BXFM.E:XA7O[
M.^?J938+NZH?&G`G]:3KA)R5`9]VI+3R+OB*S8`_:F^H"`9/O>@"*0G8;615
M)FD$\*EGQ7IW1`D;VZ&M7LI2P2TK,^BEY"(8:;EM[-"US0A01,<VJ#C0_P"C
M-+^[G$OUG-9QCUWAOPHCH4%YTS($U&5N(?*E$`1?I(QMI0Y3.*C$.[*\X'N)
MFD86>$K"L8B9Û3T5XAMI@H'Z6D:ZÀB#!_:=!#"\([A&0F+0EV!,HX:5")]
M4^Q4#.CMB,(';B6FRVQ1<<@;-PA/$\`QVH#-$G%+[Q'H-3?O\QMIO!Z'/W0Z
M'9[Q4.4T2$/9.3>RCH\MA6&^P@?UYZ#EJK^F)=LTY,G1N[,]Y:]#H*>'5"`#
M;A3IOGU\&P`N&7[<('(E1;?<0QEY3@WDXV&[.$[T>3EOHRPD`5RKK"#(`*TF
MP)@@$`"(T1V(FD3/;E<D2]S8C`:,27;0%JR%T/?NLK-7$(^;D'%RYFM9`>8"
MG/AE.:O%'`T0?'>M+2*]UK]7!G%\>P]%0ES2V3U2&IY&4UI4(.-?2@I#!"%8
MH@<LN+(4\FC<R?#1,)8LQQV'2[G:?1Y)\T=A[#*T2E:V.8'J8,#O9I#S,'_H
M,W)D0X481A%/6*"2OTB]:P0J(@RQ-3O61H[IFT>E-CC$AVW+L>'].(012J@&
M91-2#"TD,D3JM!*/<*<WKMIRVC7MMN--10N8K13"KPQ`T-U_J0$EXWTPWB1F
M@),"-2&/?ÈVJ!N-+-,5`-?6KWCUK]5:\.U:%Q]K=`SY0XS`#CH#AFUN<Z]T
M*S:I?78IU9Y<6IHE(H<$[7M-TCB0F4U\@HF-56JZNU7=?=\NWR'':R!XD+B3
MUJW=C,R55B93@Q+S18"`(?%%I1_3%U<@\'HGO16^!:Z$$!\@PG,7*;Y`%@B5
MP43F1?\`B>7GVL$5C=SO,TBUS@N)!:MY)2F;-DTQ@FATS&J02OP;ZK3(]I8*
M9MP;3F@J0*J`11P9IU+;5$)SXZOB;^X\W8G,E3RLEV%<QI)17GIAF(C=+H61
M`(5DDO7D?,=4#S\,91;AS<TVAR@IJ32C7:ZR22F\EV_)T"<DL-D,+N^`#4VB
M)1J>\!`````0`-`'CT0\#63OX;"8:F(L%CBU`86N1],`M/X#KS_L$W^M&O0Y
M*$8ZWFAD+Q:_YRVJ0_$&DA2^S%"<&2@4SK3.I6?LOKK0D'"1[7+IJ/7H!8?3
MJOX>O;[>7=KH-`XPU#*Y.'1ISPV/=:G%68P<KNL24&Z?-8&KD$/C#%#M4/A*
MDF)')@Z*.0Y.6;T"RQNQZ9W"&L%KN=Y]"!1\#JP4!^.TB$NK_BRIZ<CT+#[1
MHIIF$#:?":_]I2B=A_C-10JDC;=0W@+U&04P*((&GSB=QC4DO(Z!T)4+?;\[
M?N>6Y0T,=N<)4"R1?HS7<7VP*7U$!X8_HI*5L/<::U019)7;JCX]@:!<LUF2
M1VM4'1L"A-_)AK1UB79_`&<QXEI(+@4LFSHU>.A=ET`8,`_P0*H@QI4>%-UQ
MP;>`2M55T#'23#J5&ANBP@`]K,X4[KL3GX%NWS@JC`_NYQA7Q)VFIKHZ*O6-
M"Z+<5BPCAA(J',@'/V"J=(4*ZY7"=ST$,5F@54%LI?%N@T1LK,H&$XIY*IRL
M>^G&K\6-@%B2M:=.;@C;L(R"E/U2Z,VA]P3%G>&AK^F>&XV$-L)`?JT/PFCD
M`M!<$%NX*,,>C\B^XU40K3"`4(5#BOP71##ZK_I+@S6CH7PD1U4-=N)VDC*A
MJ01X:]"`J"1U-T](<B$F(XXÂ`#O`P%TK;#`C%CP,#\!W[4V'PK0N`ZH`K,W
MTB+=&H:VAKK;'<0!O441W$8`9%9I.7,#>;2M/")=I3W^FC418*'032&8[!XX
M#'A(7ZM46FI%/CZ3N<\8LB%,/9?7&=.5[_\`>O\`YX>?[:P8BW@8CZ<<'A#=
M)XIN5AV0/#MF`&(Y#!!V_6H9A70>'>G7GE]V('VK$/\`15>1T^M##*PL-51J
MVGBL%!TV.:Z-=@;FG?&;"_\`SHM@E,$^Q"R';G?_`+QC<-9NTL@0`*Y3!/A-
MN-*Y4+-HZXUGL^99-XV59Q;%^T#7,%08.DQO$+"[0\#RAS,5A$J]-.8M$C(H
M$A6LR-!88_4A^=BD7<1Z0('\#2Z+O,E44!((3D^6>3&8(-4Z'`0%.5DXV$W)
M"2C`\Ù[S-8`"EP>2+-I.?;9T82?E6FD>$`@`1&B.Q$TB8FZU81@!CN\SA'W
M]B9_9W#MN?2W[LYPU3T)1WM40Â/S#];'K@PSCP)`(`-&0E?FW.F6<@E-Y[[
MMDY31H+S0,'0^X$$<.H#`"MQL&=;F2$%G@&-6U&N?VUW#TF;"L^2KU(??W<)
M)*/3_#5/1S<@S>0DYXY3ZJ5*=P2H.(S=K/&237AK!#&V1VB&2:#$&^'3MU3?
MWY.EJ7"S$ED!+K41:$0`('1*HR9[*9).DQWICCHN>HM@H]S3ND-K+;0I]?IT
M8UTN8BDW[2JLFFUIVNT.OR@T]%M"#Y6X43WS0R9APQ`"'(\>"W4=W]RN1($<
MY<9W&WRNI*3`H1Z<`HW!ENL".RCF:B^W>(H1UFQS=\?9SIDX<6@L;58N4YUR
MS`_Q`-@\!(!QWBPMXTT.0,!;WBY`M96G$HUPÒ848%S\"H`"TIAYR_XE[-Q:
M`'B4R*DO/83/D!$B#RJY7-393HLV^FVH&Z$FAL7"_CB4470KS`'W/_E^\$JD
M)D*XPP)LI-:.('A?MH9C^G`H+EAJ9HO.BT<_S/L`J^["LU3-'F-LQH;XO4;^
M*N'0";']XT?%0Q/0^!Q&$QS+$#:K?XAB>6TQY0!"[=RZQ+Q@@%<!TI"RTH%6
M0/+$Z8-?^'J=!`@AB%\^>8"D0\$!^!)H&3!*^8^GIY/6@1D1Y%)>AT(D57?<
M6@RL"&D94;<'-0W8M6`H`]\*DQ`,%("=5IRQH#TI8X7^7Z(YLK-$`2P3,"U&
M&#Y7+.T!9!IX+!0%3KAC`"(8&*C9E!ZGKZ)%FOBP"N0L]EV\@[5'E._4!OTR
MA73%]UB&(!47M<+'Q_.XO<'UH6T:0SNHQRZ69G\]TQ,.I#'5FU3FLD$*X&FY
MU*3'0QPX5.C%8A%:GQ%`?Q@#U)%?#P<Z[`06U-S<UYQ@QE.!M;9N'*$K7.*`
M.J,5]#)M!.YTK!LT0QI4Z(KT;$FW\:WO4ISR0\2@?3=,0L?<H$\^44A%3456
M4L@%O@IF'!_X:">T(B/'!W\9C'TV=NE$N#ZR'YHJ\`"$!Q2KM/0S=_HZ<!R?
MJ2,<)(K287I?TXS)9B4T!WP>XFA`%J^]%9HQ[>?+(1FM>&L5`,>YK:2YJ3WU
M:[VA^/I4A80K,X&,LN$0_=FR%>**L4DE0[/_V@`(`0(#`3\A_H&?_]H`"`$#
M`P$_(?Z!G__:``P#`0`"$0,1```0```````@```````````````$DD$`````
MD`````````@$@`````````````````$@```$``$```````DD@`````D``@@`
M```@$`@`````D`$@`$```````````@`$@$$@````DDD`````````$@``````
M$``````````$`````$@DD`````D`D$@`````D$`$````$$DD````````````
M```````````````````````````````$``````````````````@D@$``````
M```````````@````````````````$D`````````````````D@``$````````
M``````@```$`````````@@`$@```DD````D@```@$`@````D`````$`````@
M@D@```````D`$D`````$```````$`$D@D``$$@````$D``D@```@`$$$$```
M``D`````````````````````@D@@@``$$D````DD``DD`@@``$`$````D@@`
M```$``__V@`(`0$#`3\0\_C4BT[MGW&/"V89O)F3QCHCM^Â\+^G#@.$;1("
MI(Q49ÌI>?G+8F#S^-YBD`7'-8DAO]=8!`"8ZK^M,]``H9K`C&\S)V-Z$`*X
M%QCMZY:6<Y.,X!J/W,*2%\;2R5GJ;;N@R?$IHQD04(9>359S75LU`.'4P\/R
MQ2^W*X3'/7P=;KJ626+*N"5'FH)[-RN5`&"/H>N;X4#=I0#V.L3[^K;+R:OK
M@?2*SETT1HN=O$T/+ZA:*BM-/HU5!!8R>\`:-A\3'!RD)S<1#YS4-Z:\^XPL
MFI0EJ`9U[K-G-P;&MSIE"I"MQP$ZU(0E`6Z4&>%RG&['"@/$@"Y%JQ"R6L!J
M2=F`$_MS!2QM]!:P&+2Q:7-"O2C\)5@JZ64Q$DD*?.@5*)#I=I\;;E#C,U'O
M77`V:/1].[K%@RF=K6H54O`KLAZ*1,>:EG''*9,WQ,UF<'V'F\!_J,&030U=
M8)4JRH0CJR89YAIO=BM)6)VPTZ]&ATAI@D.M::J6IV0A(G`2?#)U.](F5W@A
M0Q\K"UJ)/R+/'(,8V`P0!A`S&89$C"I="O,?LJ25+9"-+<#[YZA2K['B]+7&
M_A<?2ZGPJ#LA[LCV=3(B)3H,+)WY:ÀJRG!3^L_UM#O.8)Z6)QF"5$S)?"&@
ME@LV??2O4\3W?>+"^XMN]&B(HK;@.`_*8SV\P[`#JK$!0#R2"4@,$1-"[-:>
MRHB%2#^V-2Y[<U[7&U!!#,$5CJ8BG9B)_52B`%<BÊ#'W=9HF?!X$ZW)_P"^
MP.URM4<7;XX6:C4]SKV!!/N@7)`%PJ0!2[&;K_F$[('APF*"B:3&E-%R!X@`
M#4WO!?0R(@''74Z+1YR7/A[]@@BP+H_-DC`DBL"Y\)J4.U_G`3IKMY3/K[]+
M"57',8I?AYR(GKPPZ_JQ$G(L9$Q69GEY`NWZ#J8)F(9BQL2U1#2(`9II+<$%
M&(D_A=Q_4$PF/25QJ\,R[<+.Q4H06BTY[N7AS1,UL81T(A#AJLK2'P33D"QP
M:E4XV.Q6,&UU6LV5G;7!?U;>N#GAX_.,T)O_`*3_`)5<CD8Y87J,#@N-T=_0
MW[>_"EI;01#Y#?:TÌ>`\5V4NEP#P3CI9!W#4@UE5'*9\L8_U:UQ6.]OMVTB
MLD`ZCQR2S7MWB>TELZ7XGXBQ8?!(F%&6*`6W3+Z[86LN'UC&E)#,=I=9*])I
M0;>,WC)&Q*"4JI-OOR@90$#ÀUR3Q%AA2HÀ;EI/YX1)E.>O+CRY``'Q1R[$
MIQ1<]V,C)ISNXG6**%'C2#6`!@J\=)D%T_JP`!;"?0WE["ZZ%XE>1B@'=C2@
MR2_>-"B)PH[VJ.J*I@5HG"?E!]NV$R:,[!+H[_E"XU>>!LNK(8:A\*HFMQOV
M+G:4)Q%F(?G?XJLG<7JK"L84\`)`8^#O^J<"X%XS'P6%NI16**6/Q3.?CB$<
M#8O!1^6J,\5C!'`V>ZN<Z5<4),`/^`B'@<`!`\8271/Q@,%#:FL$>[!;S"L6
M2R3'UD+^JWZKQA+DP5SX^"B_@=47<G=A[<XMG3(4_*QV]QLU1M`L[_X9^S9Q
M29T-!V:BCSHYQZ[^\ID\7X7;9RLVX6L%I#,#UHZ\Q[$J"R$5;\;S8"JRH8BS
M%SO#6"\#XQO@8.@CII(Z?X<`<!OW@TD"XN<#;HOKVNE:*<-1F6=D#!G,]_7!
M/^+XH[Y[I5:<+!4-"@\KA8COTS<>:3=L4$QOT78Z=,P8$"H46'5,4B(_.`DR
M0CRQS>VCS+T2=7I>9L4P0YR3NW>SD:#$0HO$G)]W7%T2W@WO:B9G8=O#$H2@
M8-+,L50N.SW4,)EE_P"N@_UFX(T*0)X@?/G\STO6%=_A38-RI`G0=:YV0`^H
M5'7]A<5$'8`,*1ZD+E$3!X,Z.)E3F:,*H875!"]N4"Z@P_.2+G%<L;UEK%WL
MKQ+@PW@J2`89KUU/D$4\LX"M"\PT[50D(.N],G1B0S\;AX'CNMWBU?XZ02^!
M1Z;A/U4!XA6SXBCX5OMO(R:T$>T'O/&@^``S`H,3YFPDF#W/MCB\-(0YQ:1,
MLRB-2_"6X+(U0OPW)6M[@W^K1C5OD3*L^8Z:K+$6+"B=&QP***'13H`7:O:V
MNDMQP+$9;=[C0FALZ6]+XM57K5!+C0TZ0H*3@II4XZXI<GGM0`/P=X_%0GPR
MXEKD2+US%Y2U/$NR`!Z0@[F%FJNIA*)HT@E/%:B0\$#+VATYYSWD[3CFZ<+G
M'FIH_G"ZS'PK&-([W$-(XGKKYV.(*'?=",-[S^J30((9L(@\@Q?UX9(19")H
M2<I0!-F7+;^Q(-O@:NW'31>UB2J`1&.)U+PDC`.;MJ?"[%FMH"+8#^$%#:)1
MUO"BRJ9I$9(G4+H8@D1FQO&FN$#"O=S&B`P9ZUB_WX%'VW60ND@6U3V8R=)Z
MWREF"0!<Y1,A$!J(H1^R/L*4P&%(OR2<M]CL:A"$(5+!\UX"QQ)L;6"G`[:8
M$7(D11BC:4+NQ(U"QF@6_<!0H^KOH'=0H`)KV6/7Q,QI$*W?8-B6J,([SV!C
M0GDQ]!NMH,(LQG,=^3`]#%^V`B>K(ÌFJ,M+Q[+(P.R!X<)B@HFDQAHD7&#3
MSH9%EC1[5=!``"=@'Z?\FG\[9@5P]`WP\^GB.Z.M:Q+'@0A)0+[H2A:(@``(
M8E4MS'(7\!@T#HSTK.KGE5'3^P%_(`$ZV1J%1BV+2"%<M2J=XD,Q/I)@)B"_
M=D>YI78U2GW,+BX(W%8GÒE@41V52REVW-QQY`SH"C.X4FZ$BN6(O5KDPAF#
M.7G1YA`YA@E340<GQ7M!7X@@K#!9I+P@`#IO%1]`=E5&4Y5-BC[Z/HZ;N]E_
M:J:;7/0-'TS=RBL;I0N*Y@LOH'W((Z.[H)</!Y#CDF$?#&$:>L,NX:@!1$O@
M:/.IX^)C4=J#1^/8OVC0)!PO3=C0$_@^.V214B"FI&PHKLX("G&ID#>:34'$
MS1Q5Z)A&@<@P.#@*H`4```!.\.Y=;;O)8$`%63PC0B!G1VB'J9YB0%IR]0(5
MP,]#*=V1L;%C!TZ,2/7.(S9<E>0W`B@'916,Z2O?03,T&I,-@OM5D`8$-0N(
MH!A*ZO52X=$8(IW9-U?*IN,/`2[@$*=6K18HFL]7^`.)P4/M7*'Y&050ZIM<
MF1=](&X?7(*3^*8P,RC36T9C:##?!GT#+"XCOA7.XX<54JK3-(EFYUL/("SD
MV(2XIAA<IL4(Q0?2#F4TGF9`D8DZ^V-0MGM,M2K<X[(4692F\E,4$FE*K#'5
M#U?_`&E=($5VGF-G$$^V$D&T,1CP0H@EQR%%QDK*A8T<:=M2N%C^%U"?7^LA
M8+768HK_``S,#%YBKA<X<D1'P.Q5V5*D(+Z19"U0N_4`]FDN8Q>-,3^`MP1P
ME_?T%0G/L@0W<X%<F#\!Ò80[J97\\BQ>BYD3GH%X!RFB&'-PA*(M,7&+E"K
M`KOOAPE7QGUXSW+P2?#\#W[[^.;?4!290I-H)4`TR=2)1K*&P/KL:U8U%"EU
M;N5X><2FF9YAANXPD`'<5B77;!G4`^XX:^"3J0QNQJL<5"`Y'T2Y+V:J*6RF
M5L6:9A?:[C,4D64I$\M#T)='<ZNM`'P7MO;8=U*TP*)K`9(EIW0;V&8FKLTM
M0&Q'<-BJ"&L%T0;@$LH>U$)0X.R%&@#N"KVTC$`MS7LD2C=%.X556:'Y&0EE
MA.5[S_PH/>I''#,>#A794*:MQ1T4B^0/0$0P,!)="!V?_]H`"`$"`P$_$/Z!
0G__:``@!`P,!/Q#^@9__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<TEXT>
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```)$0``*0@``#.^```]3?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`=@&P`P$1
M``(1`0,1`?_$`-P``0`"`P$!`0$````````````&!P0%"`,"`0D!`0``````
M```````````````0``("`@$"`P<#!0````````0%`P8!`@`@,!`4!U`1$A,5
M-19`D#8Q(S,T)A$``@(!`@0$`@8$!PP+`````@,!!`41$@À$Q0Q(A4&$$$@
M,%$R(S-A0B064'%28D-C=4"!D;)3<[-4=+1%MG+31&24996U)C9V$@$`````
M``````````````"0$P$!``("`@(!!0$!`0$````!$0À$#$P02!184!0<8&1
MD+&AP?_:``P#`0`"$0,1```!_OX```````>)6I^DH).`````````````````
M```````"'$Q!#29''9`SOL]0``````````````````````:`CAO#EHZQ(V8A
M9!^@``````````````````````&O(^3`K8GID$$)^``````````1<E`````!
M"S;F](238%;ED&N/`W```!"R0&<<D'7I41L2S`".FX,H`````&&<L'696YR0
M7J=%``%*$W(:0DG)%C-)D;LF119*"S````0<PR5%4$N)N9@(2>Y+P`````:<
MTYL`2`````HTU)=QH#FTZ6*9)6:T^CHÙIB&]````*$+X/LQ3**I+6``*N+1
M`!2I]ESD3)"99BF4`#$((6,")&H/HK4L0BY]&_/DB))C;GR2PW````!51E'B
M1HVY[$*)V8Y:QIRBCI(`%?$>-B9)7!/S5D=+"/$LHJLQ2W@1\WI79.S,*'+X
M!SL665&7D:XUQ90````(J:8L,AI,C\*Y+#.-2YRUC8@`Ì<M\R"'$R*\+#*K
M(2;\NL`ÀA+3V`!1I+R/&`3HAY=(````,,K4AAOSY(T3D@QT6"GB8F_-N`",
MD1*Z+`(N8Q8A!#H$C!%#8%A````%1%$FD.BR''2!Z``````ÀAMS>$4*V/@L
MPE9SZ7F9X``!619H*4).5N=$F.4"=$@^#[!^'Z?ABD6-@4J6.4V=5@``````
M``&@-<3Ì$N@]@`````5V3D\2KBXC7G$IOB$FP-J2HZS-610GX,0RP````<:
M'F70;@L\`'À*"4%U$9+G`!6!0!J3W,XZ@)>58<Z&06L;$L,E@``````````
M`/D^@```>16!:ARD=,&U`!X'N```:$T!.SD$[`````````````````*=+@/H
M``````'B506Z`?_:``@!`0`!!0+OR21Q:9:L&_/+6!5Q<W#9X]I6#&,I/#&/
M^@X95/4.5]!3[!HJTQG&GLYH+(:N#??WFC<!/#-^:BV(%@&QB)>:_.T>RA9_
MK[0*$&.@7HEBR3C\`6;@X\`L.VNN^J8>$(K]*LGEF[EA63.$ZP3=>MY]&AR_
M\$C!J6=PHL4`<!@`T&ZWN=M`PS1&$&\FD6M:O))C[EA?RBXJCDEVL\634!3#
M#)\Z'N3S:P14.ZDN2^6@JSAKOR#U"\A46!Q+7ILC2R@3EM\C9-KS-K!!8'M?
MGC;-K%H=7VRF=;>=9>>:LY_%9TTNW+MF,D:MJ35W9,1PS30(,2S[+5V_&ZT\
M>4.MA1!CCP"0^#\\E>`"E$#G[C`C80`57%\4BI9+J&','GLMOY9ZBV5P@7A%
MBM0*S_'J7<G3:UFZZX;/K(8)9+ON\@AK3NSNU"D)CO8^$F"!87L@&L'9L-G@
M7,M=L;8Y%/#/CEPFAA6].;@DPUZ+#?4%9)!N8YQ_'V^D:2#;7>#GSX<3=$\\
M(L"6TJWLW@P>J56S);/*;K8@\ZZ'6)_*OB/1#YMJPZ`%$]^"0]T%E"P%<RN+
M>P5MK;-$&+#9!)HMRECN0`*)>+V7%/5.BR<M4F-!3'N#:X6`2,Y=E8DJ0A<8
ML-BK<PC-T[$EA<)N:;ZR:,CXE@2NL;'R]#*LJ6TD5(4P&%L6J?75%YW,:MO5
M]XRW3?A]/%D@'=OD_-]+*;P78U.;RUFBZ!H*V0O*\#5@3#F,8UP[-KFNP\\)
M,'`*$`N>>#,61`])JZÙKO%+9K6S=ITNC<;ZFO2VQ,]F[3W[+6O]+F?O_A4/
MXOMMKIJ@57$9T]2,BH`_+9$ZKS]GA_Q<3^%GÛ\NT$YE6K`%NB+E4[B/NENA
M7/(X],1Q]#:T)/-?B57Y"$+5FUQKK1T0SGU$1H*F0J)[1$$14&FKI!@QNUL!
M`M3)$T+M^4AT"YC:\BUPI1%86AT<FFVF^DF^D6BID1\[8]OKJ`;`Q#Z&BR-I
M!]78)M<0O[7M&C9*-Y;X+]1&IA)LF@#X'@K3S5HXWW%\DK;-BUY#HH''9LSK
M5#.)ZD.SEEDT];+'$N$L!8!^'*M]KMKOKWFJ!4ZRL7C*%O'*S#8"LM1@@;18
M`_(I5GTE=Q@ZWK;04F$T;K/J")D5X7%3@@<"P`Y";31V-SC&-<3PQ$PI[3L-
MMX8SC/5)!!+OO7*_).W*@#6MJPZ;XU5Y@KM)LIK`W]&S`C:Ì&$C`/A=?76L
MF./2*/N/H9H<031$PEE1!#+ZB!&7PJ.686*M6D)/&D]1]N+T_J(<-)3[P6=A
M7ZI9G4I+T.RX9DS`XJ&/4GPC@@ASVFEK:P%_-]0<+B&[C5E5#VC`+HDN%]P)
MI^>V6&K4PU&W,0XF%J9GRM>BYBEE5A_9+-5,&VCU#E$CMU^\Q%:[\6S0%'G)
M.75@R5UDJT6+ZUA'ZJVT>GUK1:DL2+'E$K'9F#^H]V/?V-]](M%!0CAMRY_4
M(68/F_)=$D<<NG6Q9@*!J[%\`&<8VP#E['8/8+<=9H5CW>[O;_'G0&!..Y\?
M_]H`"`$"``$%ÒW*O__:``@!`P`!!0+]RK__V@`(`0("!C\"2K__V@`(`0,"
M!C\"2K__V@`(`0$!!C\"Ô-K3!:EB1L8PH```8U(S,M!$1B.<SQL]O*!=6>4
MY_(*/L].7FQ=+53\H7V,F55OG!L^[QU*UP_<2)\UBGD>TJ9'=,S)GCKM=-6E
MSUY(<`C]C0CEPV$$:[-?;%NC:65:]3(XU&+%9FAB)Z3M.-5LTU`BC^$\I$Q$
MQ--T3$\XF-OA,?./BR=/^#IC73_OK^6OPR-PO>`V*-A'N[TF%87')]'HY+]W
MO2\"P#L#WS-U)Q=W,;AV\]-_%NF_VXÛ[E;C;*J_NB<ZE"Z]1GM7T^MB@)5W
MO&LKV_V?MR7%,B_:I9OX&)\8&(G^/3^#[M1)`#K%9JE&V"E0M()Z<L@)@I7N
M\=.>G"Z&9K3ALFR=BE-9#:%\_P#RK);5KMS/CTB%5F(\5Q'/@6W7;2:72JUE
M+98NW7_*O1IH$[-M\_R0&=(YSRY\,M@&=MX'*>\JC#K06K,+CZ."K-DT)W[S
MPF5(34U4:[+H1,1^*<Q+J;H:(EL8.A+<AD>*K-=H@^LX?F!B)1P=+$UBS&06
M6QP).%4:1_/U+(R)JK$/^3"&V/ZO3@4^XJHXPIF!#(I:5G".*=(B.]):F463
M,_=L`N)GD)GQK'.)_A!E6Y73:K.C:U#UBU1QX^8#B8G2?\$\$^LEAV2#I=W<
MLV;]L:\%N"HNU=:]ZJB_DL2@?[_/X5'$!`]MÂ3:^NUM5[:C[0`ZJUU8U,;7
M8,Z2$S,<!7JI570J-JTH6*E!'CH`!$",:\$!C!`42)"41(D,QI(E$\IB8XS-
M*J/1J(MURKUA(NA6Z])#6A67,R-=),F2V!H$3/*/[FR/5.3Z.3M(7KIY5!"M
MH<HCE&OUES'(<*'6!5TV,C<K<IZG['AH4,0WI[3&8D2&9B8F.,?0999<92HU
M*C+;?S;1UT`DK#.<_B.D-T_IGX3G2Z?5'&Q03ÀM9JQTLM->S=HZ)6M0KC3\
M/0_Y?QSJ,C6E*:=[9CG#5LUU-JRRP`#U+0KFS8$$BPR7$IT:.TIYQ'#KEVRB
MG4KA+'V;30172$>)M<TA6`_QSP%W&W*M^HW="[--Z[""D"D#&&*(@W+.-"CQ
MB8TGZA+Q2]XU<AC[3@JI.P_H)MK)QK0O5KNF'FD0B3F(Y1,\N`M4K"K5<_NM
M2<&.L?>`M.8,">1#.A#/*>-[#!81I$D90(Q)3`CYBTCS%.G%?%9*GCJ%W*V?
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MC\SDYR-!3JN2OSCD!C6/@<A9%\`S<ZNCF(_/^=IMGVX=\7TJ5K#/9E\GCE.N
MY5-7]XO;5:SD[-%N!4O'9&KB;+Y$`[B!$F,VSTHXM(B_F<G@UXM;,==S%`*C
M;+)RV243!:-:L5I<(6(K80@35C!Z3KU#^BV,52"Q4[*NQ;0QMS(/"Y+K4,4:
MJ]A?7!^Q"XVQ$IAA,*9$>5>HNHVWE[-?N`QR2$8`1V@QMFVS1%>JMI[=TZD7
MZ@E/+AK<ED!9=C0Z./K/R-'#4F"0%!2S'VJ64N6X@=!L&>BR\X)&8TE=',5K
M.22<]-`G*/69VC_P^VÙ<;[I&(C7IQ%3);8_(=//@2]OJG&8IPB4>X,K5.+%
MA9CK!8C"OA3IUB>3K?3"/&%-'CU#"W<DX^F,W+)6G9'(6FCNU._BKME6+RE2
M1TB%UNP>B(T24Q.SCM\CC;G>;F)2S#5+N4HW["!$GUP@:X7L1?2);F5KZJYK
MCP(QC?Q^R8ZGA$S_`-HS#8OW=OVCB\8Z*T3_`-*[K'S'BQCK\AZI0V=:0"5+
MN56[NUR5=<D>U-G9,$.L]-P&&LZ1,\5*(.6N[6R>$RU:+"FOHMMULO6]-H74
MUX.P0Y.R,B$@)2J5RW287I.9MY*:0WL[ERRMBMC>K-"G,4*&-6I+'@IMEC$X
M\6-;(+WM,O+$?4E>HN;B<F6FZ[3VZ6-L:".0J'$U<@OY>>.H,?<,/'A=W-VO
M6;J3AE<33V^+HL'7:='%]1P"X=>37&]\?(XCEP,'0I'"PLK""JH+8NX0G;`=
M0\H6C")9'Z\QSXQU'%6C.G?=80>.O6GC4KP%1CX=%A$>J.K*Z.WLX:"V;]-P
M#&G#J>1VY@+8J&RBZA'IFQ,[E(J8>!].IUE'SB("3F>9F9<^%5JJ$UJZÀ::
M]=8)2E8\A6I2X$%@,>$1&GQ!E3I18L9+#8T#<!,6GU7+4\:;Y6)KEI("U)0.
MZ(F8X*Z<LO9-@R#,G=D6VMDSK*4:"*:5;7^B2*P^<Q,\_K;MI<"1UJEFP`GK
MMDDI-@P6DQ.V9'A=RZP\C=VZB^S`].OO&-PTJ@_@5!TY:Q$L*/O&7&UF/I%'
M;+IQ^S*B1J*+>FN!0,$"4GY@&-($N<<^##O76*FD=!-K\9]>=9U&+DEU7IT\
M.IO./Y?R^JQO^Q4__=QXI*]N5'7\Y=LL>JJC'MR1SC<0KO\`)ZUTD$A%S:JE
M#=?P67!/GIIQ2R%:8=4O5JM^J<C]Y3UA8KLTGP+:43^B>,)_9E+_`$`<6\7>
MNHM52/WE$5U>EL.@>"]SQC,<!KQY]_CP9CYG=WL3+F:2$QSCC"S$1$FZ_)S$
M:24Q0(8DOMF!CBQ0/W!3]O(HU<'8QU*QCAR#O=#LE=LHM)2J"B\\$]`$P%/1
MJF,WLU':,X5WMJ4*S#<W5J]1]4'KL4(3:O6<79=*V,IT\FRB"B<.DJDH..<:
M<#DD4*HQ8R.>&%YYES%Y&FJMG<E5K4W4$8MPSVM5(!OZGGTUYQYI;/N'L>ZJ
MK9E<>-([!HN,M;Z!6]+`!(%A*.VJ(1KIW),GFV-.%%;LHK0]ZZR.NT%]:R[7
MI5U;ICJ.9IR&.<\39QUI5M$-8@F*G6!<J=&*+721,)\8^JF8QN2OI]L5?6,_
M:I=ET<91O5KJ0,PLVT6+;5UTL>:T`PA4'\HA$H(9U$H@AF/"8GG$Q_''P*4.
M4Z%L-1RI@L@&KG1BBVS.U@3XQXQ\*!.:I(S[G]H#!-8"XDOWGQ4[8DYB)+2/
M#Z7I/4M[^^C$S>["WZ1&7)<-'%3E.EVD7I&8C;NTZD]/7J>3Z-^GE7BBQ2P0
MYY:C?42>143[M>*>/"Q845B[U*?W?#SCSY\4T>EY%&-RE[(8S#YMLTII9&]C
M!NG84*5VCOU@:&.>2#:H1;"I\-0W\9@V&"P'%WY(V%``,=JWF1%,",<),"$P
M-2R`P*"`Q((D2$AU$A*/"?@->7*BP2Y:*.H/6)0S`DP5:[Y6)3I,^'T76;#`
M37KJ8][F%`K4E02QK&%/(0`!UF?LX97J1>18&LJ^M&2QUS&MM8ZP1`C(50N*
M43ZC#'36/,$Z;X'6-?@P,A=76)..M9=D'#)V8ZBQ"K5J=@%Y%,LA'VSNY1Q6
MS%$:]FQ7K]&:=LC4JPJ'C:6:;*X*:UI;!Y20&!:Z3$?>AXFAZ,E55+&XFUV]
M:["H*(-RC<\*=BD'B3UM)(QXE\N`G#2JM5"?+DBAT81&DZ;J8#-:][J>,>$Q
M-7'?SFS&G%/'-$\I0KJ143?0L1NJ@(%0S?IKVK8/VM1X?-<1YN'C[:L57Y0\
MIEL/M;2N3MR.!9(Y534`%=CW5UZFJ"8I;X(9AD`6[A-FQFGKNJL.MA-P$Y(C
M;85"6C:6$UZE6KTHT"M3Z0KGG+6%)%(GD<$.3!6Z8NX)JVN7KY2.<9D"K6%[
MA_50VR4\,R@V-S7U0.G2G<#*.*:]R@EZ2B)7=M6J1]>)\RC7"BYKG7(*'&4W
MX;#_`+NQDK,WW*R7_PÀNLI`=*G%%E9\5)@2(2<!'&L#ST@J^2!Z49/&'9OX
M^''TQMKJ4WVLK0<R8F%5K6,0R),O(MFPYYB/"G#1SXPU8-@3]O9D3&&#!1!C
MV?E.-><<(HN"ÂRGULI77;H7<>33QEI%B"25RLL70INSJ0//:7Z>%5$RP@7O
M*6./J.:QK#<YSF<M[G.81%/SF?JFVK+,BCO*JJ&6KTKSJE7-4$&TU4\HE?YZ
M1[A@^60,EL("F0G3BY>ATY?%A#[;*3H0C(TE#N:88^R,)KVT+C78IVPXCÊG
MD/!'D;@HQ_4:DL3BK)><TF27IRF45TW-);1D32GIA$Q(D3(X*_@.FL=H#VE%
M=/&VDK7$"*D;5JQF4KQ$<D70W1K.RPOA5-6/0%UR6.B[;&Q4J*2EL(:=C%MG
MU$+8-+3HP1*/QBQISX>S)669/*.2:8R5Y%.T%,6Q`L5CL790_%U*[!C:<0J3
M8$Z,,O'A5-"9N43*%H2,V7XN?D*T,/N\G[;9,1R6V;>/^0L1KIQ7N8NG4QM.
MVH'*LY8YMVNFP=T3Z908*?\`#;C^+CU9N5NYQ01IE*,UJB@"GXE:Q-:G6!W<
M4_O2LS<3E;HC4]G`F$[@,8,2CPD2C6)_OQQ8NN$SA(QL2N-76'L(55JJ!_6L
M6K!BL(^9%'`W6Y*VG%3GA]P/P2AJLHM]PUVKL/L5,C*HOEB(S2Y>(3IU'!OB
M>D6SZ.3;=4PSR^%C`7)%Q!KCA9<;`JT_*=OO,\\<_#[..[39RRQ58NW<?2')
M.]/Q-_(];O;V-JSJ"GN[EO(MZPAS(`1$YC@`LA5R(.EHHR!V%XT$]&LZVUF7
M&18"DJK5S*6H@M=/RAXBQG+7J;_OH0*X7B:)Z3L95QY]9=AZM=1;8ZQQ/,=L
M<N).A,NH24D44ZLG4F2G[U[`5])IL*9U*QB]!DO,=2?'AJ4+7A%5W%6N6R--
M^V3E[9:&,7MFL*]"Y.?$S_4?/@)H2`7EL[@[5\3M6;SX'0&6,H)KS55R]/PV
M5WKZ6LQM(/)Q*,KC[=Y*VU*\$70[P2NVE4:I)R4#5Q.8JE:>`D1=G;4,ZFD_
MO<:=?'X)4_Y$"R^0T_0QT5:%=FG]79'A-"[:MY2ED"+L\E:%)6:]Z!)K:-R:
ME>NB$6`&30>P8&8)<_T>O'I%A'=AFDVZUU&\PD,+TNGEK&JXEF^56!0F(YG:
M>H?GK`Y3)Y:]E[X8M6)J3<31KS1Q_4"PU)Q06"K-VPY8==WW2Z0[!&-=?@4V
ME2S=0OXV=&,#]CR?;]XOR$/-G:AYOO#IRX@8\!B(C^*.4<#4S:ZUIB*_JJZK
ML<S),%*K**G<H2NM8*3&Q8`?+&[G]FO";-<Q;7L*6]#`^ZQ+0@UF/\T@+7X8
M[.HO7(L4O7>X1^%%;(EF;UJZAMH-NL6,3%YJDF.DDH]#UT';\*V3I@15\A::
M71#_`%NW`SEL>,:C$>L+0-M$?._6D==;7"\U:QJ7Y)7:[;#);,;J)L928=?J
M=LQM-C2)1D$DLN<3'%BK840T,7T^[4R/NTDV8=4HF$Z_B^X,E4BTX?\`4*E>
M"C2S/"F9?*4,8#SE:"O6DUH<P1DR!75,>H0A&LZ?+A=K'V4*MU97D\3>,IFK
M#@7,CUC7SFA=K,)3M/Z%DS'/3B*]%MCK'4B^B+%#(4E7Z&\%SD,6Z]5K!DJ'
M48,=56L:&$^!AK]5E_[,O?[JWB]_Â]S_P#,&1^"O['L_P"Û?C@?[,J_P"C
MC@C,H$!B2(BF($1B-9(IGE$1'&-DG7+&#O7_`'KFN^?D!NÊ-OW[D8^F:9L_
MMF)OU7*LTH&2BO/4"=H].(1:]6M6#QKN\"FFK54#_(2'RO:$N[]--K)J3OVA
M8VG,3MCBM-/9V?;I[7I_E]OTQZ.S^9T]-/IM_P!CS_\`ROF^%?YL/\6/AE?[
M9N?XJ?@']L>V_P#F3$_#-4*C'+NY&DVA3[:YV%PWV1V0%*W#4FFW(:["$H*)
MC6./<2LO:8KHW,=5Q^39T;B\U0J8Q2QR2Z_6B*%EY%I9#;$=R!R,;)&>*>4O
MWW7Z]N45"ZR*ZQJW*\D6(`90"]M)EA[9D2W%-N4SKY8B/H].^#I_!*ON19?6
M/H,LT[;%:I8&X&NH*W1.L$,;9Y3,<`N-9A8"$24[BF!C2-Q3SF>7T?0,OCY=
MWGN"G@`K7`HMKVF-JT,DN]L-QC-51W%#$3'6ZNF@?/C_`.O8;_TZK_U7`S1K
MIJ83/N4FPA"Q4BEGH6"*=J!#007EZZAKG_7*3IS87&"MXIX*9B79`FA.6R6$
M8U=VIV\=._BZ]EX[#C60D=I?WN&1=1W3755T)HJ>9=[<N"-0*2K+1!D]P]FW
MJ$,3`^>=-)XH6;^9=E?1L0S!X515*]7LZ#SI$^;34^;(W6#C*X=710;5\EQ)
M%/U;JSQWHL*8AP;B#<IH2#!W!(F.HEXQ,3'&GX_N+$C_`)O]X:8?/7\I&;6/
MV_AVO\^<\,IX#?-$=HLL5YM4"DM(ZJLAE+%9;,5*BG:5>HM][6.95_'A#ZV;
ML5<E662D=N@(PBT,9UFTYPQF4O0YOG-IOFZ1\Ô&NG&#QGN#'G6?FK5JH&0I
M,"QB537"I";-DV$JU4KWKEU=<-X3L>8C,[9@^*&<]0?4QMVI4R>/EG1.[CUW
M*XN&OCZ$+G'4[JEMT.\_O'ZZPJ$QSX6C`YNXBJD8!6.R\>M4@`1T$`:YB<NO
M_P`5(Q_)XHXSW#3"OA[*[MJ]:Q;6W1RPXU863PL)8BN^M#ZL,LN#\3JU:K5C
MNW3P!+D260B2R"8D""8U&0D?+(R/AP;6$(+6)&PRG00`(W$13/*!&(XOUL;C
M6V:2S1:B&-34G'NR*YN,QA">[5@`86-L?E#9$.6FG!3&"(YB)G8.2I[BTC[H
M[]HZS^F8CBO=K;NC87!C!CL:N?`TN#Q6]+(D#'Q$XF/H@N;%FFY#HL5;=-@@
M^N^`-6[:P&U["S4TA-;0-9B7,>-GN!(-KC'DSV/4<4ITUTG*5-7/Q)3IS9$M
MK?.3#[O$&Z%UL9,Z@+U/],TUW`:J#HJW?<38Y:-MC6HQ.DBA_P!Z66</E;-Z
M7'+KV/SCNLB\\M-[Z]M289B++(CP6!U?L2/WN,E@&T[^-R]5F!J+EP5'I:[W
M`>,K=:H2[,JMÂV,PCN@UB8$QF-8*.&/SF1N1U&I::ZMUD9&VRHZ+%-N0S"5
MU#2NM9&&JIT5U:JCCS=;QX_9,P.33&FE?.("'Z1\@R>.6B8_C97<7Z>)5G4E
M2MTG10PU&"[BF#+=`K?JQ6MJ][LJI5A%:=D;(JN#D9R,\$FV)L"X84Q6N8AI
M,=/(U$4C"RKC$MD_Z,5R7RXK6(Q<V@8'X=SNT5HO)$B%-\*YQO2N\H8:(SS@
M3X6[(8EM:G+TH?;"W6>-2+#(2NQ8")`XK"XQ@RC7IQ.Z?+$S'U/M_;BF9&,S
MG"I6%TZO=7HE&"RV25:KI&1ZK5'BP&9G[J]?LCC(9Q=+$U:.!75=E<==[L,M
M>"U?LJA>/T="Z;AK)@%]07=Q=WI\FW=QFJ2:OL/V3[>'OEC>NV;?NC/V*E<F
M=O?JIB<-A,>U@+%H=9NJ2TUF-->*=F/=1EUJZCW3BL*V2F0C4I92<^H>Z>?X
M9D'V<8RQE\D65QZA:_'+&@BJ/>`BP.4!T)W2V^K%$3Z>FFX%V`TDI">!,"@P
M,8(#&8(2$HU$AF.4Q,?7QZG6[D8H9+&RLC,5G3RPUQNK,0(=9.*H:%XA,:QI
MQ0Q5.#BIC:56A5AK3<V*]-(5T]1S9)CF=-<:D4R13SGX,K0SH60-5JA;VP14
M\C49#Z5H8_6A3PC</@8:C/(IX93R%JE0BM88JM1=:TLX\1Y/QC!8(;J]"W!A
M58.HLJ=*?XUJH6:61=8LIKJQR[($W)W7&*\;C=HZ[:EBZ0S:9/(*H,U\>$5"
M;-FQY[%ZX0[3NY"R9/O7#']7KV#*8'P`=!CE$?#,(Q^+OYE445>YLK5JE20.
M(0X[:'/K%:L*[RQE2QS&#6"(_$2PI.)8,37N5CZE>VA5E#-)CJ)>L6J/2=)C
M<!1/U"[MNJ9VDY['^Y$N&P]9JRN,JU:5=@=,QT25:F`L5^6S3S1/Q#*JZHMI
M+E5PZT:V?39<JSW5<8B9.[@KR%7J_C,RHUQ^;/%6<AD\0-[H+[OM;H'6E^V.
MH5<CVGT3+F.O.(GBOA:EI%FNZN16RJNAO9X748RC&D.G3MYIDA13$3N&O-@X
MGY<0(Q`B,1`C$:1$1RB(B.41$<.K6%BU%A3$N4<:@Q31D&+*/F)@6D\4,;9J
M9&SBCRUWVO0]T/.GI<R6.==KBJQ3"RRX*]]`ZW=3'X]A>[8(F,_&=)B=)TG2
M?"?LG[)Y_20QJ5,959+JQF`D5=I);7)J2*)E3)0XPUCGM*8\)XIVCP>)*SCY
MDJ+RQ]66U)EYV=:Y]+<J>Y83.7@R9+QXNOL64U%Q7:,/L/766+&!(*CK-58`
M")DQ$?ALY_JEX<88EVJ]<:>/(;$'>N]=[R\:S&TZM-#,=<5JM^Q*&%!:_J0$
MUZ5X#RMC'5TV`%3&@UEW'S%JJ-5\EW`DMRA%93.Z8CS:ZSQBJ<Y;#Y>OD?;)
MYFS4Q%,*G[J6E/QR4XED*LO*$/BXU8`^!L0=,_YPA_<=BDPS5U1B5/7^;5LJ
M,75;:9^3JM@!8/\`.'C]J$59&FTZ&40.NU5ZO`]25Z\^WM+(7)Û+!GX6;]O
MO$5^F>&%F.R%W'GF,6MA]U7R/:O6-G'G;-D*C2"@=\B6ULQP"E`*U+`5K6$0
M(``1M``&.0B(QRCZVOG*:S9<P_4-B%Q,G>Q3MGJ=$1B?.W8L7)CYO2$>$SPF
MS78+46%+<EH3J#5-&#6P)^8F!:QPZT[7II"3F!C4SGP%:Q_7:TM!&/F4Z<(R
M]I=@;D6GY?TP<A</"4<S>!T6[U7'&\ZT7"&RR"/3;+#-D")',_"RI#NW>U#E
MIL1&Z4--9"MT#\^F<Z\#6P?ME7M_)Q2Q>.RF3HYNO%W-6:PVRL9.(59K!:5-
MJ1.7V6IOLAI;HT&5L1D+&7R`7!V.=1'(T/3Î7M>U86OMTU]AJ94]6ED1/G(
MAU\%;<-F";GP9Z7'4K7LSCUY"7WZ6)9F6B`"-6MWP5V+I`P=U*Q.^14,^6+S
M+F60T4]>FWUVOUZDUL?[[JXNE8V=1)W@C*X^+30B5NF"U,]"UR1W[=Q]1MH9
M=5Q-_'4+%FMU;DU(P-NQ9:...JLJ\6=X5NK`GIOGS%7M6KSAKIRJF'37=HS4
M?2MY+W(W+.MJ13K=U:*K8I2);0\XZB(SNUX/T\*[+?*%1;8Q5<=9B)8R5+:P
MH6//;&F_334?&`R.4L'F,FN9)-BP$!5H3/*?2L?$FBCRY=3SV"CD3"^+"4E2
MB<?4<2U@$M9_E&2,1)G^F>?U?N6?WA"CDL;8S=;&^T?2:]MCZ-+`/OTLN9[/
M40&PT8?W4GV4#^!(2SGQ3L7LU?Q46_<'MVC5W5/:US)-I99E&MD3N]ICGXQ0
M(:9S6Z<0<1,]7=Y=/;*%(95HV<_D<+E(R=-7?7PK>W\M?J9&@VG<.M7IOM4(
MF9-<&7AM#YY`LN=8[=3/YW'P=2NRJB:U'(O14VJ:U[-8KB.XI*=Q:S^CZ.*-
MZ(I5;*_<G=Y=*8R%I=.E[HQ6/]69B/2EQ69B,)9>\%[FBW9J0G$<7:GL_P!]
MU:6*IY;HJ]VY+VW3S5_(TF8ZDUJ,:"BQ.'L%C\A+5]QT2`M=O,E%)90<K[J]
MV>Z+>3J4[-K*Y&W:QZA=4)J0KT:F&Q.-P=94@^9D>X8_E'EVQKPY=;(99-@@
MGHLG+Y,@AD>8(8/<SJDIC0].>V9TTG@\$8,6-)75Q?5DC*,:#9K-QK6EKU+7
MM^X,UBGQ)/19K,G/T<W&/=DT9%.,O6<<6(LV*UXKZ*CRJ+7-:88[<_3\/G!S
MRTXO(I*<^CC5J!!Y7&YK+&=%U!=EF>L9R+0C=<G,.[*,?&E@XB"CEIQ<15HM
M!Y4LBO%VE>V,H+,FF`S0KS\0]\IQ%BIVE8PI/B3?+>7Y@0-U+L9-:@IJD3E)
M]NYBX^C5ZT+1E8H5]DY?U2O^(253!U)/S1,`7!X].**LNPRC7&[:]M94%XZ9
MOXRO<LDOO.BT&TK;7K@K'E@(W>!1.*MY2OVF2L4:[;U;I,1T;1+CK!T6R351
MU/U2F9C[?AD[^'C7)(BKV@[8/>;+U91!,$I\")K.8DMA;(G73EQDJ?N/)G[)
MPZ+UL%9''A3R8#83@/:URABQR.0PA5Y&VS(7+'F1U&FKH@?ED9QMU_O^/96*
MMXK&ML8O"Û:?[PS:.HKO9?DLRZZ&.EK]QB`5]ZH+9/,=95BV7_<5CTVQ:J+
MMW\OG(N6U]8G=P_KT\*N2,G3IT$]"!B(ÌTX"RN_E%A48+VDS(W[05I`@;6R
MO;L>0.+$6U`^0+4#5!Q,3.G`N<KM[J6,J9&MSF*]^M.RP"RG\RN<^=)_TB2$
MOG_=.ND:Z::_/3[-?LÎ-C#%:UB1L890(``QN(S(M($1B.<\7,OC_P`6D%5=
M!5Z:%A*[Y=66FS'Y!EN%7Z2MNFX*_3DI\K2YQ'%SIS[IKUV8"7X"?:M>X<6?
M=O6LK;ZMV"6"9Q752A$7M*,AU=_ARI^H0N+_`&M?O83^3%OI!W,*_J^MKI^C
MZ,K:`,"=-08,&$Z3$QJ)1,3I,?4%<R-I=6O!0$$>LDQI_EH0H()UBPV>0+7!
M&<\HB>"?T"K=_:L7A0VBW'65"\HVQ:K.NWC&Q,#K/,/'F`SK'$B41,3&DQ/.
M)B?&)CYQ/%-03[E')![GR:<E5:BZ/L]7LQ<7QQ14BZ486)BD%3IRHN]FWOAG
MDWQ'\`@_W3D"?1;8THTGUFI]OU2C9TIR1B+*C[1']TKC.GN_+`2XC3333EIX
M:?+3]'UYPLA!DB73(QE@">GE(@@UR8Q/C&Z-?MX%=^\>0]S](B39RB30<J(/
MQQP"F*52"L(_F14WEI^<13SÂ__:``@!`0,!/R'SHQ6I><$TH`#*MYU5J=.B
MVK417<_:*0'<J].GF&S2Û!_IA(M@_<R;)`((440]<_<3]RC&G<O7YX/GU8!
M;@P-["$E.P()Y791W=`Y]@@ET`[][_;S^YI0-&9W&R;P%[<RKZCG3:#>%E:,
M2K1(6KT`1KNPA7P&2I?ADKCPO_W]MXD8[?X1-`-C;*;%L4YZV-N*]WD3!`(`
M$1HCL1-(G[ANO!%(ÀA$>P$WG>=-#P7B=8U'@'51_,B56Q.@=YLVM9-V)A='
M;C@-O*A)71'28X%21)GV831"OZ9'H"0MBV%?==^1C4"46!WM[=A'\=HP[W5M
MK]G`3[?9EPH7M$EJ<,]/J%9P[-,OBRI0-V@%KV!BNV9-Q=,V5@$3P%DU(02W
MW00UBKSGT`J'1#`@),:K`FXI0$(ÛF;N(NC-(9TL-7-6P5CFC2_UD8_BM`$R
M[U!!S\#_`,?Z6,1COL>ÂZV(ZN^>A/+U%6MH6(2`;<1PW$"49\OD3P>$.]O,
MJDOV!#/3+[".]LK,.;$TX78Q=3449^06@U<Ì"(EEABB%JSI:;)E:QQ=X8OI
M8``K%#*NH;@W2>F5LK<:/>6<EYZ=LQ1QS12;=W4[Z(RZ,[@;A*7#4V'01R'*
M/ZJ"2?E,(EVJ,+_+US@<'=U!/#Y;594<-OMGTW[2VG$/"3NH>^!Z!V]^&$%$
M^/$=OTH<Z24!H!>X&Z!&T,:+!LS:^BB5>J&,[;;NGUX@!D*!.2>D*`0.>I^9
MR4M&9<4+E`V0WKO:[:FPKR>BZ<#ZY(8C,UJMJH6P;9K)W,_GU)+1\L>B=L(J
MWN"VQI`%1V(/%.76Y39N%=HBMHMGBD,\W4?O\G"KL?,3:D+TPA&!/@!)@%(A
M?1,[HG0K_C,Q<N144]/7C`=KH*3BUE"YRL4V5C'>2I0_1'\G1R<')$U&`KGK
M?DPTXK1PPD8%>("/B+]X*<1W6)#'"!\9%1Q#V)Q281B))]&\3LX9>4)@$,*Q
MN#]?*J:.5'#3>=$V_BHQ*762/R0^VT(*FH,%Y\EW##^/[.QP?:H&/K2ADG(-
M!1.N%1!<*,2<0D*'Q8/L)U+'Y&@8D3<C5?@L*@KG-[[:]I@OG<*;AI(-,%14
MD3È"7,L'8!%301QVI:O1=+69.]J*^B/I>]F0^C.+;_,!^0D,LXS$!1[O7ON
M$LE,OMU-V$-V%:CAM6J2#30F#4,Q=:N=7#3PO:'(/$A$71=US:T:\7U-5,,^
MAP+@^$I9*%IV0K$[ZQO[XI1RM\5,X3FWG9;E99$F(@0<40,*2,!:9+'$%"?^
M*[.D[%GI6`_1P!03Y+H$`.N],.$_2E)KB3B,+(5EVOKZM`PD"(QGMFVR/OGO
M,_:D?S?R=A1`,`;T5$'_`ÈS_P"31XKU*VV48`5M%SJ_0,_A]:B.6.\K7O\`
M1@#H;^.$%,K91&]BL]G,:3Q%N:;:+LT2RLP=EG;K/8ÌAPFD`<-QG.W!0YW[
M'T0PQ9C]3;/R9*[&9"*_?0<7%CP#/M#<Ô1(^W(`99,Q7LFL%/'3>2Q#?C4/
M5@\!&E9,HJS['D)42-S`!UC2?D!6F;"+N!#>]!C\V=[EE8Y=\E&QV&6I?-(/
MP\$&C5).ME;TJ\X6Y24NV#TP-N66'U[GKAV!E0$GJO.('0?2UH#&7'W9LM45
M(*XM9HZ(\5"6NFT42JT,9L=\8QGFO)+&>]']EC^3A0[0V&];6!_*O`]`&S$2
MD#JKH,E/9#]U)MTL61,(VCS'V,S;."V+).>L]3_$\(U`H"J`%5T`=J^@SMQ1
MDZ5</<*,^B\;(ZIS/"A]P0,Z2]LÀF"')#1PD$->2%,T3_)&`)W[#QD6Z4%Y
M%6A8&VPS9>WXMTL-/R/FJ=I$Y^-@[_DFUBD""C(_*O2R)K$/L1A!T(4L->R@
M(B$.*_Q_ZG$9%&>*+\X45CVX]H".+2U48(%J$!55.]C*0774Z6C]]#B%+`18
M":]NO<8(=!_:Z=-4S1<IA93=&7<N4J/G>.Q,FM?A_3-U9+194#<0D&%7^%W6
ME<*-)U@DWK.,:4E7HRF6CVQ4>S@PT@BS:NB47R&P[0Q4EM+"N553VIL^,QTO
M!]<HWT-J--G`*'2Q$B]J`<[#`RDP:E`X,/5`-O+\CE`!2XT0!*BS;V\S>P8A
M]T8/^6!8'K2XBWL*>>U^WDV]F:M&OG&[X,!VTU76$*A@;KQOJ67-32#G0^/%
MXAQ!SSQ,[2'TMT%4]Z-X2RK12\"KC`)M0B#X"J6$]9;(@+;C06UJW&TP$O0K
M[2GR\X,?:&0QB5]$TGG5X1K2]'W50K>".\IEIJ;&`BO$XD,E$OXÈZT12"`;
M0=28AGMQ[6)'G4?<:410KJ2@O049V7IK&(SY^@]^8X',#8-\`P"*<0=^!*W)
M1!ZG=1I43CU!\3X1MB`1K4QR`J@YF$C('9D;<>HF*F($YT/^!(_IX!`.L^WA
MQB_M`>QPOH0+O(088A+O'T[+&8++T#7Y^-'K?K^SO_,5`F?H$)R:[X%:W3;B
M^$2LA-USLIX1211I*(VY'C(]N[,QNAK`NT&C!?QEPNA2S>9GBDCW>T_2&Y1I
MSJ!U?=0M-8EUGJE#[[SMMM>!T0P1U]SC''6#9JM:À8!H#RN:4^>A2W>NFUQ
MX<>GYT83V.(-JRH]/40]D&W)_*21/#T:'E8T8DE&`TR3[F4<&NIT[[2-Q+L]
MB@0<H^Q94,EI3AHE";G=L9>.<:[4P`SH(V9-1,-([ABWU,#QLDM<*@AI(>#^
MLN).7O,Z7;9'*,7&#^1,U+:Y0\)@XBM(/9XP\.&C0=!U1ABY-S@'N3<%H!*,
M.8AT'ISH`LXM(!K=TW4@H8(/@JVF%\T=`;QB.^FQ[!`%&69Q4TZ_Y!8Z)^T8
MM0I+QT2%BAV()I2JI:5)0RU"+XÛ[++"WCR<ECH]2NUU\JH-0"YCI!P^!O!F
M:HS>%;WZT3!,<2JP^(T[!I*AD=X>Z"R.50CTJ7A/3^.VFC%Q%L:="_!530=`
M#!5"&"[ZF1%U5L"BQ%V`YJ%!B5`B[@+SK.4'I,8=*]D9YO4_4G_Y)1V7[-O7
MA<-%+6I*I1`#*I4XZ(I%IT2G$#N[BSQ^[T(O?+;IF94V%:?\;X_2A=LS!)-:
M3P/2UNR`99V5&UCN"[%HA_OO`#X/0<>#HA0#LQC'-DL3Y5W:3]BX2&.E=)`9
MK9,K^`KHZ/1K3SDI5*C9+ET5&H[R6;`$+I0J1CX*_]H`"`$"`P$_(?\Ì5__
MV@`(`0,#`3\A_P"E7__:``P#`0`"$0,1```0````````$@``````````````
M````````````@$@``````````````````````$`@D```````````````````
M`````$`$```````````@`````$$``@````$@D`$@````````@```@@D@$```
M`D``````````@$`````D@```$```````@`````@@```@`$@$``@D````$@``
M@D``$D@``@$`DD$`D$@``````$`DD```$@`@@@``@```@D`````$@DDDD@`$
MD$D``@````@$@```````@$@`@``````$@`@$$`D``````````$@@``````D$
M$$@D`@$`````D$``D`@``$$@D@``````````````````````@```$$``````
M``````````$@``````$``__:``@!`0,!/Q#SH^2R[RYR#E0,%DH[<A%]HH'X
M%85R[.LG=``8$,\\;Z_B7%`_N<@!KS9%210B,>1)8GU(;>@VE:IF^.R4H:"4WL7LIMD*:.[O]O!WJ)%@)K]S=,;J4MV5'LHB*F51^S$`
MWJ-JF7E<>SY9;3[/5#_BQD_PP@Y&F3'3'XTJ@L(7.6H[Ê<1Y5X*F'9`\.$Q
M0432?N`4$A4RRI6H`È>A[;D"0`%-JL(BJ#]N)XT;@-OB^#QO"@51=JXG#=K
M9FUC*$28"(BTJB"Q%SMÊ#C/I#X>!M/9?(`KE/-($6&H+Q`L)@J^@RUKMWQI
MJA=-AE9U"`YQG@#&#P47P4ER9U8P,%!N$+4S0=('YY8>V!'S&"&1/GC9+.0D
M6&!%!]FT!EX!.:*C&556G%4,;[T+=HE8,#*X`WNP"<F_R-?'V(S?&!IZ(%\)
M'\7`ZR<K?0J`H9H0!&/LH:2H=>5->P@9@B<M5AO#Y<VW=I=?!-4=OJ2;;BTJ
MKE1H"9C23.&?F(S;PCX&@;<*!6E`:*R3$.@S#WETTP]^^**>.5"Y67N4^>A1
M_5#0>:,HHB:WFL-AX$491L*S[',]I$U;,!C!CY>J_E+^6EZ02-8+GJ(I,'GG
M'H`!E_&!\48<AYC;&N6D;U0#R0ON^"D^#KNN[^\/#9(["!Y-!UGVS&&8@=*2
M?W+ÙY@J>+#T]JT58*O<;D%L^X'YG5&LWGJ1]@)4`.93E:M95!ZM[A49'#"`
MA,S/*1'L_P`9RB6],&([P;8DI(2+-1#@H_*SUA\7%L$0(N&"C"\9M&1XF6D%
M*#%*=;'8_6!_2E=`F**KSD8_%JR@O2<(@QU';DG7RE<X*!)9?#)R9>=7*&:A
M#0&,Y0439&FH++TOD,LU9:48&`H*_;A+-N7&0Y^(2=7S*/"<);HJK452O.G9
M!`Q\@<)3$TYD'Q$0M4QDCA04+@-Z&(3="$3L>.Y0E[4.,O3`\`X"28SJ6BU!
M$GQL=#I67#*&\P"^#_\`%CL]7;%#<,"#:V5;SLBEGX(5=Q^FT=C#MPBE)D":
M99.*1'@NEIOO@CPKB*'Q66SY<*!."JL,#4:N@>A`"MOG$9FJB?2975#@Y%)4
M*H<']ZS"#C/`:(@:Y$Q%UEXS6,$00<0785WKQ%KL<YN44'SMR?:&@TKÙSF)
M<5\S!B##@_RZJ-L(CJXRW<KHAG^`<8<PN*>G;,\P"',^=B!JYO'%M]O.8W4E
M4S2ZP4NRC5@@%681<7+GQFW30@L\2S"<YBN%!`94#/\`62Q>@@`P?VZ\F@%G
M[/.CP,CS:4>6'P.;;'5QW*(=YMK(-9NC9L%'+@;2?$3(.3/K`5T;K![K^NB_
M(`:'RQCJ+DVF*ZD:-%>5!3Q^'!J$E-)Z%NQO!;FO+9=\H]?)/Q*X"[T(1?4P
M0O6$;<#>K]'\>@[+8L9IZY=&2,JF!6:.=HW4%A`3!HI.YQ(A<0<I!;WB'?:`
MS!ACVGWGNCNP,%MDR;4KLAZL!/1BDEL[)CI@.\L5_&,!V[M,X;Z2O200PI-S
M!&?HBF<J\4&#'DI"D@I(8,R4Y]OZ2S#T)4!7>2["((\)^`BR>BB9E88HO6&C
M7`NQ]PS-@XQY[%9JNS*U-KK"C8+[Y:V15L.90@<;8M+ODK24;G2J-*U*.P!O
M'M-Z$#$[(Q#=&%/X`G]&$^2M).N?A^]W]WAC0!R(@"B>PB>G@&@(%`17,TP'
MM9Q>?AO-\S:U@"K,/;(8=)T[L&9(X9_"3*\&>/0_ME*5DFBT$$D^?8>A6]![
MOQP/1,Y8`5"`"J]<Y2)V2"@0[*&OJGWPI5;W>'@Q/P5/F*-^LG'R[-4TS]0$
M/)%>NVQ,[S2#3`26*QX85-"-.]1>_B/7Z?A1$B>D;B1*/64-U".AA,D'*@0A
M+VAB%L08K!H:+W._8"7M#='-1OC!VAKA;Ì5C3$Q`C%$6M%M.6R!:$Y=.>;5
M?X6I\(%5)KHGP=FQEE1$K\$'2(AS4)OPW5_T>+F30NPRSM)$QZPPS@9!KJ+0
MA3@P^)Z+X$!6BI,7VG/9<03`!7#O]<DUH"H*F'`BLZ"Q8_>/#:(@V>5!V7(Z
M%J?$'-%$5N$%3F6$M2DN<2'8C2\8.R.\(9L$$QVM,8K?)G@84D@+'WXI6C<Y
M5@2%`6,.Q/0T)PPJ].`&IA!V(RJ<1=/9;Q_9SBDLQ;I5$"S`4WR3G)LB,?-!
M8),(I;V$CM#6O$%KHI'6J8O==;H0?U(BGK8X[@PZJR.64E"^2PJ61/3XZHV=
MN,V#1\961*1B]XU-D20]M64",?.21YN_>']BRW&^7]I2,8E""7"90^3&/<.T
M_P``%><WT]``8VL5=4]1XINF)+F:I'LM@4,0)>$$0DGVYLTLQ\HK[*NA^$!!
M"#KP=/U#"04J4L/(`!\:@D\P%;<Q1SDJ(T$.-K-%%S%T5YJO0AUP.A]*Z`!P
M``0UAT$O+J6FD:4?"$YB<%BND*6*%-R3`RE%BHP/OF@@H+T7;"L^X<%"@"J(
MQ(&>T1^L9\#-LBC>LUQBU%"?D=Q*PI5V^]?+MBE<18Q+2;MN@-P1FRN_*.O3
M((9,\!1E[B!<2AZB_2%X8/S\`B.:U:BG3\+TU=C]EP!PRQ0:O8EQBD'C$B?U
M(*08`#RVW9;<`(\AJ&,.BEG6J@3-"<(DUM<`'M6+8!A2'G"X(Q"?3:<M=`3Q
M!W>E/O`CC=UC;Z,K'$-T%P-77]09,"JK3+:GA;MXS7<]I.]8>OL@;@-#C.KQ
M#0>9*$8@O!?VAXJL6GSZ.]`\(HGDTIM7L>*+JC"C@S=RSQJM"[!+XR6+TGU8
M0B.<IU?0UP(SC.0Q!V;P>/E4+1J85]C)JGT/&(?'EJ+QH@P]%18']\Q<R$);
M9US]*[?X'YL%+#L),833@R7$0YB1.D*\LUMNRJ_`F@MU[4R,`:J8#S2K2%`T
MFM&%!R)BA3"?<XM4D)EZJA";@6ILE;A&\1YI&7+Ù6NJZS0RGA6'XU,PE.04
M!@74L`?,XJ2!B3L*(B!!PWC,>;*P*YYK1,#&"'A`/Q8H:&*R;LKZX,'J4B0`
M?J/MI3>_5NQ=I<A]==?UUQ)U_/R2LX!M2MDG*@+CXGTZ"+''.%.AQZJR5[WN
M::M@C04R221,.M.WQ37Z8Q4\+THDV'@<MBYY$SNPZDP=QHM\=#&%/:H)=:B+
M5$((C'`2:TO8?SX/_8HOWJ<Q"547:ZQ__.#M_1$FIYW%!WH5U8%*%8,%=PGB
C^^D:`/G_V@`(`0(#`3\0_P"E7__:``@!`P,!/Q#_`*5?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<TEXT>
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```;DP``CPX``+3F``#6P?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_$`$0@!?@'/`P$1
M``(1`0,1`?_$`.T``0`"`P$!`0$````````````&!P0%"`,!`@D!`0``````
M```````````````0``("`@$"!`4$`@$%``````0%`P8!`@`P!Q`@0!41$A06
M-A,T-1=0,;À(C(C,Q$``@(!`@0#!00&`PL(!@L``@,!!`41$@À$Q0Q(@80
M03(C%2`P44)`85(S0R1Q)1:!8E-C-'2T-76V!U"1H;/4E;5V<M-$5":6L=)S
M@Y2%U39&9M82`0```````````````````+`3`0$``@$$`@(!!0$!`0$```$1
M`"$Q$#!!42!`87&14/"!H;&PP?'1_]H`#`,!``(1`Q$```'^_@``````````
M````,8R0````8IE```````````````````%?&<;DX].LB5`K8LD````%9EF`
M$>(\3LY"+W+-``````````````!$C7DB(R6"`"J"UP"-E/F09!;)NP5*6T#R
M*[+`*J+>`````!\/I\/H`-*9YE@```ÙY#3+!S>=6'*IT,3\KTL(`P3--(;H
M^GT%<EC&&:DAI)SE0Z\.?22%]````@9%#0$H-`2DS"R"@RTB5````$6*:.BB
M`F4;@BA98!!"=@````@I)"IB<&]*Y+<*;+H````!4Y;!6Y9!HS!(X1<]"\0`
M```10E8`/P?L%3DI-<5(>!=1.````5T6*`#\'[!K#9G@>!KC:F4`1DKT]3&-
M<3\K\OXJ8E!YDU``*^*S,P\3')J34DARN=4@YL-H5B:$I8[/.A0`"%%?FH,\
MC)9QNR='.!>QN3FDL<Y_-04^7H=G'H```"'&`:`M\I@FQ,0`<X'1Y619I7)8
MQSB3$D!/0<W&<5N;<DQHS8E+$O.TCZ4(7V5T6*0\F!5!J#Z7:"G38%<`KTR3
MKDW(```-`5V4"=8D#+L``*\*$(1\]"3FJ+L.8RS2PCS/AKSW-F:$^'Y/(EP
M(.00UY[G[)B:PMLYX)X24DP``````!H2M2<$K*5+$)6```:4W0*7,XWY.SFX
MZ1``````!JS./8KLVA6I?1SD=!&6```````:TA!9)IS8GN````#6D9*'+A-Z
M3(````````QB.G-!T,:,M@```$>,\UYJ3;F*8YFGB0HW98P`````*=-*34F1
M2!T(````````0@J0FA;QSF="GN```5(:(CY@$.,@@AKSJHK(M<N<``````BI
MY$O(`3\````````&G(T3T@I-3U```*A-*5^0PV)&"-'1)TZ`````````````
M```````````#3FA(L:PEY6A+RWP`````````10PB<``KHL4````@)/@``04C
M1;X```````````````!SD28N<`%;%D@```%>EA`&$>9L3E$ODF9@&Q``````
M```````!610QU"4B60>)0!V@"MBR0```"O2P@"O"D"_BK":GPI8Z\```````
M```````!#29$`)N9`!2Y<!D$$($8YB%WF\,`K,ML``JPM,KPL,$5)2?0``",
ME0G0@```````/P?LKP_9KC%*.+K*#.P")ED@PC-``!7A89\(^2$J`D1H3!*1
M+T*O.GS:```T)&3*)T```````<_&^-V8Y:!"22F:>1D@K8LD````KTL(IHG9
M%C>$W(H28]0```1$EI`R8F8`1,S"0`````_)#B9E:%EE=&$6D``5.6P````5
M@6*5@6R<Y'1I4)ZEL@```J@D96Q:A7QE'L6:4@7.;4````J,_)-BD#<$=+))
M*3,``\ST````.?R7$G*4+,*K+A)2;0```%'%V%$%XE=FM-F8AAER@```$1-H
M;H``````````K@L(]0``````#%*:++*T-R3LYR.HSG8M<_!.@`8Y3A9Q5I+B
M6&(2`JPD1,2H#V*E,(J(NHZS``!IBI"<E8DJ)29Y)REBQB1D**T-2>ARV68=
M(%M````TAIR'EQE(%C$I`*%+P*%+X*M,H^'F1HOX%0&04L;XYQ)8?T$``!2Q
M=)11>I6Y*R!FO->7R"%E;FC-P<FDG.CB_0```1$IPK(Z6(67X`"GB8%-EQE?
M$K-.6*5\2\D)F``````K4P"'%G$#+"-66*542PWAL@``````#%(^:PG)1A9Q
M*0`08G!71NB6'/I?9SF=)E8EB&4`````#6FR(8;8WI3I(RI#IHJDL4V(````
M``!KS%-T`````##(4:@M@J@GYN````````#X?@K$M$I@MXR@``#P.?SQ-@8A
MI26&`>9I3>DB+D````!"3GLTAU.5V7D````````"!%"D=.KBJB_SZ```?DUA
M&38GB08B9NRQ3U/T;0W0````!\*B+=*<+#)"````````#6E:%NE6$X-V````
M`"BBMRPB^P``````#5FP/0``````````\3V``````````-:?HV```````!X&
ME)"`")DL````,0RP``:X\3;@`````$&(::\B)OCHL```````K0Y^.S``5J64
M````5:6D``#G4PSI8``````@)/B!D\``````!&CDPZU*](H3@HDZ=)B5J64`
M```5\6"`0`YV.M3ETNPKHKD[3/H```!1Q-B#$N-\2@``````À))3U*:+Q`*
M[)>;4\R+&4?LW!D`KXL$``KLGY##6EE`````J`GY("/D@```````!&CG(OD\
M3GDZ+.>"^#))";\T9!#'/8GYNB,F@+%`!&#F,Z$-*4X=''+IT^3$`$?/<R"J
M"Z#\GZ-21$L0`````J8TY*30%MD?/ÈY`RP`5J64````5\6"5X>!D$7+J((;
M4SC5$M``(N:H@ALCW-024D!718I,0````"'$Q($3TT!K"7G[`!6I90```!7Q
M8)7Q8)798A$38&^```!#3)(J;(VY7Q8A69*B?&6````:<ITL<JLRB"%J$*.A
M#:@`B9+````"BC;$H*E,8P"=&R+=````($>AMRDCH\I4L$T!BGPLX]0``"KB
MQ3,,,S``>)ZGX!\/0^@```B()*9)AF8`````````08TA:A"B*EO@À!OC'(2
M6N:\V!$S#)P#E0V!MSE8S"W#L4``%=$Y*F)X2DUQL2$&42T$!($1@RBDC]'0
MQ?H```.536$U/0Z#/H!41.BF2UB)FI)8>!!"]#;@YX-@:@J,\B3'9(`!3)8A
M1I=I7)F'L2`JTZ$,D$`((0XD9SH91:AUJ```#6&&:L^$.+E`*?+&*5+2,,BA
M*C7'[+%/<^@````Ì4M,H<OHKXS#W/8Q"QC]````````À9-```"!$@(R:<M
MLI(L8IXM(PR9F>`````"LR=E?&86,4L7$<X%V&D+`/4`````%-'&!89WB```
M```#X0(B1=96YFD[````````->1<B9<A31."6@`````````````&(<C'N7*1
MPOL````````$(.>S3G4A5IT"```````````````?"#FU-"8Q98````````/A
M4Y:I4I+"9```````````````\2NRR@`````````#2&G)F````#__V@`(`0$`
M`04"]=%-#/ITMIX=9?\`#M+&"MW`=BF3'&8$@Q:;P3A'.:6H\$<4<+'I!QQ[
M6OQ/:!K=8;!IK+O)I'AO;+3'+537!@/KG?S^WK:XM6</7!,X:UKB11Y%)D.M
ME\6QVRU?OW$70PM+\M7F9[@I<<7':,@?!*9$?8O#?/PUJX\65$L,1$2`:'1C
MZ,]B`K'@G@*AZ4Q8HVS0B0T86P+2,&OPA>5SN(*EF.8A+8RG]VV(K!+4I+Q/
M_*>,PT)&>!+@U_/ACR!?D_)R(!89#X-N(SH5HT[U3`-+?I:<\C9K9@&UD=[,
M*0?:2]>@U9%P$&U#!D,;.VIL?;I;;06*QU^6(RQMX1?=%9G'I663U(JC2*^B
MR:1KN-ZJWL.==<:XL::1R+7E&4JQHI6/`*]44-7'\4T!>D_2@&*AL1IHR\<X
M)U8XZ\H]C4L0]6(%9KDZ:;;77?5+V]J-=*Z3/7;=]QNP!WWX:<&+Q%MKNEMH
MV6:5-7[%&.A1PUUSTI?YOR?-K\?"6XJH;$0^4CA*+.G=X([MTX>:/N]4)&M;
ML`-I2]"R_M/)G;77QE-#@FY')'+K]2/\_NJOYL30YSXL5`+3!PMLS$MI*<3#
MR=M7!ZXO#L(<M;6;;#D')+!QP1*<;](XXO-(P7Y=FA3#9CI;*_.)>\M=#4UL
MUX!W`TUS[C:F'%;'5C!_KD:K>QO/ÈS7M;H9M3HUH#>HJ#[G+VS3.Y[7V>7+
M*$>HQIY3&_R%,U]K@U#[@8SJ<ELK\02Y-4L_OC@[BM@7M/RTB:OVBX:0)?RV
M(U#%[(H:1DUM$,FY:Z!I,]_JVN*8%E=J::?7;7?7H/%?NP,>;)%'7L;1,N6W
M::.:OR-)4GDI/\KP/X?=W'GP^NY<IK2.0V66=H!6I()4_@4^!TN)K6IY5"OT
M(.]L+1K&<2/M\$PKUTK$1MP[DCU%N1W[7?2G]XX08?"+\]XW^'NW'_P]EY:\
M-]H4>UR.3U(.0(GP>T\9ZP*JÂFY?;B-M-<>W$%X%T[+C^XX[/1#*%P<:Y?T
M&C(50!%>D$NSWN@HW<>X,,\KANSAIY=EYZS+"2QV&5548TL;"Y[`M@J-'M*2
M':P(:.8,0OXN9-";'L9;8M1R(BH,B"[;R!ARQ0J%0\.JU?K%F*+.\B5/-S*5
M/M'A&EQM*@13Z>!BJ7ZH]I92<+Z)K%EM:3:EH!7O>>;*6XG$Y4WN?'C&?-E^
MIN'%;#+"#KLUHC<'%"K^DK[.^%.G_BXT]K>(VL;Q1YY5R\B7PF3E`6!Z2S(4
M5L&(%1R.PS@V/K$A!FXCCCACX[73S;[,#\ZTH#Y?"UN-ZZS@DVF@ZY>Q6@X]
M?Q*3PY>"S@CCCACZ4Q@@^9+-7(8:GW$J+5F?;5@`R*/7*[T,DT46=7J3<G^R
MZ-]YR6-;%I7R(7<_08MÈ489@S`6%LN(GULB38K+95B31ZEDV"L2%C!LY4Z;
MLWBE-G:_T_7"BVUM]/U+'3A+(0)0E_-H1X'QH<#`1"UC4%>A=HX'NBOMW$MT
M8*5"=3R68:GM8Y-)H_/;]$>XRQ'62A`8:4.Q/650R&2ET8E;/7J.*J]L[6E3
M"%]K#X;!0D]L%C[*U/2:O45-69^J>2RUW6K)0]^;5I5LT]$:1,-$*M82E<;U
MU8[VTTUCT\]QF1#BJPZ:0&U5]NSC-5?:DTBQ@4?1"3<.VQM?5A=IGSJ#M'4`
MMO\`)%@"'9BKB6''V+6<&_UY6HX_M9-D;':3M[C2&AU4=KZ1J[5I=`[&D8&>
M34IB&^Z,9[(QSYG#\=/NENZ1\Q_P/<8N),"DHB.OF>1C^2]%/_*>,Y(XL>"Q
M=I>=USXU005=3+ILYQKC!8NWK;4I-=`*JQ<`)<M@XM+4H8WY:&ÊCE?;,6BK
M>J7"8KP8_DO13_RGC8T.+!"H[=G*,S.8PM7U5+O,4;5DIP\!-L2O^MB9B_7,
M]--S>6O77>L1?_/QMA4RR>+;;>/C]K.I%CN^\A!-^B%)'OFV(UION('"I_IA
MJD5EG#Y7/Y!RV_B_A[ZDQ%T&[.).!GN*J@)]!C;7;P(LZL9@6,U.Q-9XU^K/
MZ^S+?OVQ47F+-`ÛSV_L)FJN&<=:Q_)?#(\.T_F3_PÌX!-E;+;A-MTA8DJ9
MSMS;`P5<+#+N:Z5QW$[<\Ô-M(TO;.0[((_T@7F9E;@K\5Z$G`]:1#1=<N:S
M/]PZ:(N&#*<$$?::_)_&Z(=OL((.`)MKKOK##$/%X,?R7HI_Y3BJ':TKC$R\
MW4#9@0;K7$FA_&B-4ZUTTTCTZ!;Y.`3RRSPQ)X"("HO%JVC5:JF0S@#I9SC'
M$&<95<"*%S:>-K,`G(06]39)_+.3`9;.BJ(@C?RS10:TG?7%<XJMM:WNW'EJ
M]G*KMM%L<O0>F3_7X0*XPHP'J+:%0'%B5&R6$+A6CU=O#!5,PD0$<FVQ:'0(
M0JT3HV5]D2"O_6.5\BR+6>N,'[W=]VSJCV-.)W7!DVIRR?5=7U*F7RXUUUZ3
MQAAWK6@3,`'*!"IJXK<FYL5/K5K5(J7;4V=*O7M-8`@Q<]"Q9CT>;[Z1Z,[<
MDFQ!/`5"XLZ=?FINE<RJP8#;X2T]8H'@'$K#OHO=I-5(*\)9!Z6U_P#5+III
M%IUYH82(C:7J1&M4@*8WM>-TQ65<VBXY:O9Q%"[TAWIOI)HVEVM;7V`3@/ZP
M!WDEEB@C+N<<.P#(%I#87T<XB6RK7>##@E\*YH`VBY9W4ZC%?8SMDG+=-8XX
M@G+G;D=LN,;2\62\#$R6WNVPV[>V"YMV?F-/#71,;$^"POLBEC`Z9-;"$DMX
M;+A=A4!S+6D3'PM1[""=1N?*IY8\,LH`=KHN56(Z^0.G1EQ+1_5]]/IP(>Z0
M>:-O8-ZMT&`$+(6-65%HC$U2.>6P+9F8C"*7)O%Q-\]MFAA(B9U=:&1`/`+"
MYK*J2.NIENH%B(B01B71(9'7I97[;PMT5BGB!-LW,$=P?K3CKSM6<M^^&NB4
MCO"':O-/MG6\<=(4\)O'Z=82&M$%""M4^5`Z>X9=ÙV(IFT\+'`Q)0@AW)6K
ML`%N(8IQ[:+K(A[\:KI*SW8VDK`=T@M'0>-HT:O7N)'-*[;]T6IF([;G%8,-
M]X\C@#?1YE\LR%EN]L,HCY<5EF\8';KYRU0.K*"R,P%P*N)P5H@:>_).03P%
M1=1@`1$V*N*J$6`>V/"=GX@F?U7MDSINX"U".T;,M--(\-CQU#CWF#@I<)L/
M7FAA(CD1I9B7^\,P>N/AK;?G$,1D'EIO(76D1Y?+'7![)"A6[)DO+,!,N91[
M_J1K-IK/9>&L`JX9#-$3#U-@Q-R>.D*]_"L`B5+>6.+VZ7%JK/PJ.);ÙXR9
M1H6(9<!XG7)BEFB#7B@Z]2<>`J'[3J_`!!ZVSXS`RY:KP1U8'HOEUYC7V1]R
M802ULX(8AH?/)G?6/^P((`#.YJ,>/?N,BAYOW,08YOW53R3A=P4K(R?N6@&Y
M_9:7Y2NZ:Z$+3N97I2DUV5NCNE89&L2R-A??KVU(M$NWLPO$,129MZ*Q"M3`
M@$5SB/+[2UP&7*))G";76I3]#.,;8V!"WACK*'2/9&EWD%0*!!V1U&KY<=F[
M<I]D<_;IZ5)7$4QVM>0Z<E0(Y\PK5PV>G_KA+/6P9Y;$IC790,2$J]$68*`/
M^JRL4W+$@(;3K0M5B[J6?MW7+<?KV2I7*GV[24YCUSÀ6$&NNNFOI=XXY/3%
MF"`0Z%BR>@DECACU;*I-O(<X'6D=',\&)O,46*%#H>!(3U6[V!7P<"Q,MW-Q
M*J8*P>_6C"'M[`CFZ]O&C)KU>J(U@!\EO_'>C6A!OAYNY1H2)*@[=Z(3>KK^
M4<=__7K.<FX3[_V&-P([]:.R,=60-+)S5$+R[UJOL8I>X)6]>D8RHN6_\=Z-
M:_8>-FU;2*!9K\/-`7"1SN2`3W#JRRRC&$/^X"O1D5-W!DSTEUL):ERIY]LE
MVPQ<3A08;+^N6)GKV'37*D404&"<>`J&E52N(8?&V1R25T,X-B/S??6/6%ZG
MGARV78FT;*Y.1RQ3:^%:_8>5\+$1G332/2Q@!,4M4K*"JJ.D,']Q[CJ5@97"
M%*PHOT#%RJ4<>VM^\:8>0P:[6$6:+[Y9T66>R)8A&L%Z(GJT+D9=:9YAZ^M5
MKDXO&0NYP,M)K4VY=&KQD<M)K\\R\`96%QPOE:+JI_V(_(0Z4B&A6ZT79E]R
M+8!6;:1C"!W+RA()=`P$1`7TK>O8981>1@T!5Z`L`F4)98H`]0;@%1<^./CP
M\V!:"D>R-9NFZL)0DX"%[OR)JS@G;5@QQL/#H-`Z5X<`)%'M$&VNN^J*JUNL
M8\+?^.]&M?L.;',&F=4)0G(&I\TQ51W+.XY3R,I$RN%(J/7@M0TJ)/7%_E<3
MSC@J5P&12*;(.:F11G1O*@*TV7+'Q69*N$/&O>K&/+/8/_<E1KT8W3`_DN'_
M`,YQBT!4P#V%&5+KMC;'DM_X[T:U^PY6_P!CR+\LXT>J4O!V:\O?H/OF]N2R
M0;J6-O4@25TZ"9:T;B*8EEB`Q(0U&C#$H*6%@8C!%Q!/$3#T3S-0`Z_86-AW
MW3ZZ;?=S'+MU01;'`"T[G5@WV1XSQGM<HQD$74$/R,5,;27HF%L:D$F8GV"'
M95,/*KM;9Z0Y[;1L)$;_`+F0%$5,YEHCI26O%=%@A@*W55]>JXP`@,CJE>>P
MXX]KPL/$[#5D"^/ECY%3TF--E42+?7?7?'G2K(2M(1X!\<^G@_7\FN^F_AC;
M7;/S:\^?3YNB_-F7)`TH8LD,,(\?(QX(M_1Z(8(.%AÛ$<L6-9$E6K\Z:3R,
M;``MD!8!LH6#0%7'5G()8/-"A99N/&NB14E;2L_&K57"Z2T5]D6GK24Q(2?V
MF.+T"[:[2NJ;324%G\Q5H5#$#D0%PW1F+$G5N5[B/@Y8I>..FTJSB-KH[5>%
MGF:CI`G5F$3V-]<1';5\\AI?WGW1C=U=]W;ETKA-EWJG0_L4F8@U]W-L(]0&
MM'L!\S-:^\EP9$+A(%*R`1Q7-DXZM0('QK3EYV5*N5O!)7A@\+[G6&8I;H6T
M.0@ÈL'@GH>4W#:F?,.EH>]>G:]F9&!Z[LI@0VK]J-JR_P#*^*DW>2J%DP3)
M$6@X`G7+82Z8+J4O10M5[31=5X\6>O?#!H5S;0PPCQ>%G]VRD`)N0:>S3W30
MX@RWZ*IVO>N$M1GO%IM2#NXDX70E"#GC,.7)Q$.)O;["/(0GJ9+2?;QN0$QX
MD+$"<2QV/0L12W#8:NGXZ;5"?N$&8]@UXIIZ)+.]U]LUCEBFCZK^#])]*>%"
M,X?;N)1#13M#K+B,]<RC7KV&1W?%-:3I8B<:)FGQQZ,5&)`7YSJZ"9,`M"61
MV='&]3UE":K\+4J_2U3L<-5]D9E'NAZW7Q8)1ATA`Q0QL'4DJJ[:8404&"T5
M[9Z+5E9JM/QH-E&;%)I-')-FUV3V))SYA*]-IOI)IU+C76-BQKV@OFXU8[76
M*OVKK?[Y'6U\.DX$5><\LXNK()`HD40>A*%@-&]@$XN%UK]@Y8(MV+A$JU1I
M_6S[YCAQ?GLN7`_=*V!(@V4J>64Q'8/16)D2H3[7QY]:_6]UV>^H!NVM;VE6
M._\``.'@*O"@;<-99X3Y5-6U9Z@>C>M`R=M<?+K:AS=N5_#75)ZZ3'S1U["#
M7TS'320%#[)[?TO_V@`(`0(``04"_P"+@__:``@!`P`!!0+_`(N#_]H`"`$"
M`@8_`BX/_]H`"`$#`@8_`BX/_]H`"`$!`08_ÒT[J(:MR]2'>HQ8&X"D#'<$
MS&H&,Q/X3'W:T$Y0O<)DI),&&M%>G4):YG>8KW1KIX:_\D'7'6[?"!DJ=<U#
MV\,_='D+3V*IXU+/=+C&3_)!SRX[)H.QV4$9,\9>@5V9".1.JD)&B_6C_"(-
M@1[])Y<-(!ZUF%$:*HS\QY[@4$:1!$*Y>T!(]-H;M9Y<558T"R1/0FQ=>&%^
MGEC<E.*S-JW@-,BP$3VMFHCF<]4=^PIDB'3'V\ATXMVZJ;304EM<538"'0GH
MO(W`21/;.[GK'M]5K2L%!]=0S8L8`.H[T]@F-/:.D;FLF2*??,Z_=YQQ`$M7
MB<Ì;9&)8M9NS9FL#GS"!E&LQ'C/V`FRR>HZ9&M52!ON6SC^'5JJ@G.*/?I&
M@QSG2.`3EJ-K!,>>VH5\JQ5;.^9Z:XNU'6*B;A:?N3,3F?@WQSXB3(1B2$(W
M3$:F<[0"-?$C+E$>^>,E]*63;,6+B:F%G"6MZ,2./[BAZAF\S8#2LVM@=,M`
M^=T](-9SQ;^N)Z-VIE;]*(E0J,ZR3&:SCZ1'6:35'$[E>3^[K^GD`-<CK6L=
M7)E=A)?"K.1J5W0IP>=1DEDQN'0AUUC2>!E:NJP&&U1-@=J#9\1I5$0`N+\S
MIW/9^<RXZ%ZN#P$H8N9WÙ+1^%U9ZY!]9X>XUD)Q[IXQ]QNKK;ZJB=9;.]S3
MZ2D2PBG\[%UPW3&F[;K/V?56+F&]U+\;EHF$M*MVC\1CJ`05L1FLNUW%`_D$
M4-Z>T]NPHG[#[:T%::'14BN)"$NLVGJJUE[SF!$2>X=9]T<=0\7FV],-7$BI
M4T#1<.F3$\C\F)08,B)+78R/U\-I]-Q32.M]2;M7(H!R^H25!UQ)MH=Z_P`!
MB"UC=MVR,PF^8%SWK4D]D=4T1+5A8)P:L0[EMUB%3,QIMUK7U+:I5I?64#^G
MU>D4STR*%,:$=0/-IKK$3STGE[?5340VÌ_2,2WKI;69-NF-^PZ5IL`MQU)"
M^'3=$=)O/9)1&OM*8]PS/_1QC,HR)=DLGBL?9O7W3U+3V/JI<8RR?@1#"\JA
MVK#W#'!I>I;DM&08IH"Q3`GQ$UG$B8S^$\>HJ>V2K8K)5:N.4TV.BI6?A\+D
MBKKEI'/1"Z4FN)UZ7@&D<OT2;61MHIUX(5]6PP5C+#Y`L=?C8<^`QSGA5FLY
M5BN]8-0]!BU+E,C<#%,"9`P,9UB8Y3]VA=BS70=EG2K`YRU%8;_@D"91+6?J
M'6>#3C*_?-4VK9CY@HKF=*W5N17[DA(8*R*3`2B"$6#H>G%@7,G&V:2^M>I9
M3;3LTU;MO79O/HLJR7*'*,TE/@7"5(ZF4NVTB^GC\9`6;%E!SH%G?O&M6IS/
M\=QK3_?:\N*/I#UWB[7H;,[IJ8E^5<FQZ<]01!3T/I'J5&W''=:O29J.Z-B"
MG2!+QX!EVP"(:P4I&=QML..=`370N#?8<7[("4Z<&BB%H[3<DZK>H_1^BG!5
M!]2T*./?5R;ZK:]N<CAFFPB/KCIJV(`5R/%9N;7*LG#\@BR$KA<_RF2MU4E.
MT06SJ5TB74"!6S7>,0,Q'L]5_P"VJG^[6!^PF7#OZ#1<L=QP'5#X#)<%`,E<
M\QW1.TM)CG$>QO:JD)><L<9M:]K"DS/S->;&2(DPMHZZ#KR^SZ@_V9Z=_P"L
MSGL.Q:>FLA4:L>]@)2N-=-38R1`8UGW\"I$]T;ML?R^C!$#Z$]0V1/3B(39%
MD1KJ:]9'73C$^G<CNI9*M1JT4P^-M?)%2J@LV8VUS19W"O?TM8>(_$$<%;[Y
M#U0^:HQ3+OG.MQXTZ]>IUG6+?^+`9/\`5QF+WK'TMF\!Z5]06Z5RCZK^1E*&
M/->,HXV:WJ>OC"LV/3N\J<&+3ZE?0]#,"B8X#*IR%)N+8B+*\DNT@Z!UIC6'
MA;$YKDF8_-NTX%F&[DZK$X9N$IQA;34>H!MW7)S!6;K*XGCXQ]08,/,K2-&3
MU`*!XM!ZF2Q9QC\%=K$Q"ED3+]5Y7U[JZ*RAZ#TZ=$AEJ?SD6X=/N*^/QZJW
M=61W=W?9(TJHRR%!JE4]S=L,.?(H=D3I.Y@<M>L[(.MYH3%J\G<@M$;8YHQZ
M:;:A8=4S^>J:['*-[&<XGM[6-^MCU$5JS&6Z]1\-LMZ%>69#H!3R%/J3&\^C
M7N*'^`[XI(_4]X;9&!=+%40V8*D4CH)E7L09YIZIY[K<$F9YB@.%U8#ZKCRG
M:K:3)2$1$Z#!M-]S$SM'D)S9J>Z#K1H/"GT*M'"5+"Q:JSDRG)WI2T(,"^G4
M7)J**8+WVST]X\)JY"Y9S-7(:PK('6K+;2O"$F59ZZ%="@H65AJDYC4&1(F<
M[P]F+QF//I7\3?[I%SI#;2J\>,M+MJLTR97ZM2KALCJXA8!BVW6@9\Q<5,8I
MIOBL+))S(`2<Y[F6;#=BXA:H8]Q3`#Y0CE'*/NE+BO:O7;6_LZ%)6]]B5[(8
M4L.5UJJ%]4=S7&"QUCGK,1)VK98>F_(XAN$N(-3LG]*J'<.TNYA[1=IMRHB?
MG+8(2U:BC]UH6@QI'.?[I3N*?Z2*=9_7Q5%!UPL4,C3R2`N)E]*R=0]W;7%"
M0G*3UW1,?NVB!Z3MTX"F9I8V;%^VV:R>WJK/(9"UD2JTTR;"52J';D%#,SY8
MXL8O,X^GE,=;#IV:-^NJU5>'X,2X3`M/=^$\*K8BJX0K@Q-4[MZ]E;%.J;"9
M%&I:R=BW8K4%;M`2!0`C$<N7V,Y;MUNT^HY:'UT$U3FQ6K8W'8T&NE!,4!6#
MHD<#!%H!1KH6L1]UD+4HW4K^,QH!9%B_DV<>Z_O0U)%#?G+NB0$,$/E*"V^7
M<5JV<@H26N-H&UC&O8*4)2E0FUSGN.!`1B2(IXKV&4:6,'&Y.KD\52RLS>*]
MTZUZJV,U6K?)IQ(W(8@08XU.6)ESC9%;'2Q;F*ZYL8E/;IW6+3[<IK)W,E-*
MJ5B5H#=.Q0Q'%VB3&)BY5L5>NKDY'<)-/627Y7*WZC/X\6K-HL9#74<3C5HQ
M%$J-.$X@+8+MFLVMGO+47-"TY`M8!J6W7@@,1,#&1,"B"$A*-"$AGE(S'%VS
MAL0%$+]H+S,:JQ:^B(O#NUNT,$3RQ&.M,W>8T)"9F-?NZÀ$F0KJ.D1YE"EW
MYZC9CQZ8;HUGPC7V)IC;KE:K9;!S81#0ZB.YO!VXMC7R,?MG:,^8H\/8I-BR
ME+KLL1349C#++861D*0^)FP(W%I\,<YXQ!`0F,XRCH0%!#/\LKP*-8GBW@TV
M65[F94=2L2+#ZMB!C:RRQ5JK$OJ2NO$_-C3:4C[YCBX&5]274//*WVK9BOIQ
M#9IR0!2L.Î8JV=6TRNN):I4PD63.WEQ<4VY=R!Y-;'X^[D20;AB;#+F5I;T
MI1!.;=L=QNTW&K:'P5QT^ZH?[+RWÊ8;[,#K&Z8F8'7G,1IK,1XS$:^T/3)C
M8[]CTUA*)IROK6,>[)KCH=Y]2E7:H+<V$2H9Y27&3O\`?5K"<0ESK\5'ILM1
MT`81*):V3(O+IS`C.DR7+BKV%F2;:QZ,E%<U,%B4O6IG1L%$$A5Q0O'J)W]0
M-?#3GQF*TV;3;F"1ZH=D*5=*G7%_V5R&.Q=E,5A?U9?D[N44%$9B.YF?=QC<
M5ON!.4HX[(HNL"F%5=?*8BYG*Y/7-WZB`!0H,ZK(1*4E&TSB>*.>Q@V@I9`7
M$D;J"JVAZ%AU5@OKE,FDX:B>4\_N<?\`^8O3?_C='[/FF!YQ'.=.93I$<_?,
MÛ-9UNLFQ8_<(:]2W/YZ?)410;.?X1[(8I@-"==#64&,[9D2T(9F/*4:?T\=
M+KIZO4A/3ZH;^L2I>*MFN[J$B-\1X[>?AQ5#ZE0WWO\`(A[RONN<]O\`*QU-
M;'FY>77B(AJYDC-8Q!CJ3%;NHN.?,U[9UCQC3["IM+*'UI(J=VNPZ]ZD9QH1
MU;:I%RMVGF'78<1H43'+CZ:JPJZAI>7,!:^D7E+'7<G)+KU'=6#B?WM*:["F
M--%?O.`.ZE65L!U)7W-<(HU)=^^+'XZ98FNYWYWG+;;?XCCXHSA`/*C9RU.M
M.-N2QYJHPJW9OA0M;A=%@Z]?1$/(PAN@ZP,\JGJJ\HV/S5-#RK-!ZEPF?,M+
M$VI*U"/+!=L<PD2YRO?J7!-IB_$6"YR_#O/'R1?M-KI_DK4__;*9P5?,6/J8
M75K[#+O4E#PQ\$"6TS75!%06T\BP#<0K#K*L@7A7+V)Q5+:%A+DN&YMDRIW%
MRIYM&-1$EUL><PX9Y'W2E^!EI_KA/_=8?]JXLXK(FH[J1BW6<I?0"]CF%LAP
MJEC-KJK_`);8B9T\A<NI$?:8C!+44+8U#\K<@NR0Q+CKN&O6$EV,BY;5&/*5
MIW#/S-8D>"O4WVLW3*!.T-G^;@SB(ZFÂ3J!<Q@?L'1&U$1\=4IU;P-;#8')
M7,R2EM.JW8C$U4.-JE7[/J`>O09CVMKM$.WZ]F240RF"$X%68C+'=S*Q8':8
M[HT<=3K-Z1LK4,?=ZB<K)L4/4FY84;-ORF5O#B:F<QM]%\6]LN<9C<C=&U;E
M1O"H6/!#,IBKS4J,X!X2@@&958:,27']78*MB$S$2-GU';$K$\ORXG$'9Y3_
M`(RTDA_9]W!%*YKVZS9K9"F103*=Q<#)JDHTWK(2@UGX,40E'*>-9Y1'!YRC
MV<UCRF"OJR=L;`YG&5,7L+Z=BMJC06.S]8.K/SES";QR:RW#'M##-Q1'E&97
M'L&\-D.I]2C`6W5K$5NL+>V3BU&LBB--9^&?'C,]O11DP/)8M61QU;QO9:QE
ME(QE:Q%ABD2+LHP8+?/2TUW^76.+=1&+RV`R:,IC0N8RC;ME0^H97,IK_+76
M>S$BEL=$B+:O6J4+B(T((K8/.^FVWK=DTYJLN.Y?4N6O5_K;$(N@]96NW8)Y
MRC6M-6^.AM5H,>(3:LU?1PVJ6.]4Y3$379<I15F,#A<S=7=KA=R959PU[%7+
M:ZE:=HLW;)6,#&E_TW@?3%ST[B\#VSEBV:4U"9GNMF>@L:]^X]%SHVAL-4R!
ME0V%_CI'V3QN/KSD,H*U-8G?T*M13Y9"77[9"<*!G2+00%CBV\@TY\+R5/)M
MNWQW2^G7Z":`)\L@BGB;4BF^.NN^76T6"_($^7/;7L+E"RW6[-%7%U'V0O7
MNC+YJ?S04V8:U%<":09"*ZX4,D#6A&_@G9*VO%FLT6L;@\7<-0(M5V@^N_*9
MV*CGV;2#'<(*1%4#CSA8'CZ?ZKH6F0`&SZC5I_S@H5$2VQ9Q]/JHR59(SJ=C
M'2R1CFVK7CC3#>G+6R=T1>]0.^B5?U$-3IW,T7]!UDZ_M<,Q>8BJO*I7W(E4
MAH4[](BT[FF+S8V.V,NFX)*9`M"^%@>RI1K)QN1;4IYNK..S,6/IQMM)Q_4R
MBSK(M[;>$U!?F$=W=F`,$XG2C3;89<;4IUJS+;?WMIB$@H[#.9?,<0[IYSSG
MV5'7?4%3&WCK8=5&@]R0[DL?Z@7DAEJC:!V%66C"1B-///*9GEQF[R_4#0&[
M1L*HU["S*GB;$K'IW(B;6QD)(-TQH&NOCP#,#ZOQ.8Q.,7?=CDW+?3C'Z*FS
MDR8>'M5<>U-FWDH<\V5RV*E<QSF#XRGJ1?K5/I_(9&ZW.4.Z878U*^._X?W/
M2ER_%(LA7KV;>/"]W?=:1TEC`3RY$39_P"(.&7C_1YXQ%)=D<95C'5;WJ?&
M>KJ..S(KL@H5W"2T*L!%>2!H2.NWG@,TOU-Z:53].Y?U=ZD4\7T4H'"Ô;>6
M*E779F]TD4^YOC`MYA8-7ET]PF!"8&,$!C,$)"4:B0E'*1F/N20,K"TJ>O2:
MV))06(Ù['0/F*K:0PTNB.<I86G/A:^RPQ=,!#<S,Y`V%M&!W&<X74SG3G/O
MXS-:Ê=?**-3@%;SM);B[DL>NU7L.378V79#KB[4!D3"!^"%S/&"8GNE1WMM
M=RYBJ:KV=K43H/(OIU<JMUTI=?77&Q*TL*`TY1'F'&,S0=/*'445T=H++JZ>
M+5JF5*>0Z2P1\HGK$<OL^H_Z$?[Q^L?9G=--/H'IKP_'ZCZKW?W=?9Z7\-?[
M0<_QT^@Y_37]7C[)L^DP[DD83,_4Z-95$K-JX[Z:C#F+7^<+^/AC7IÌZ;E@
MP)YR.EZD.5PU4;`&N!'%7CEJ9+6:K['U<)6NRKY;2`-\"4R&DZ<5B4,@S5P7
MUE`BQ.46XUY)+1'RB:;@D.D>6!B-OET]HX4\"IA,S&."<GNM=2,F6`M7*UN?
MZN^G1T**)3I-N'3KR"8XSW8XRC?_`)VAC<G3[3Z8JSD,EDPQU.;EME4(A:[K
MMQ/CJ2J(DXYZ:Y'#,]*=*S3NX3'WYI%:R=%UNSZC,$.=E^SB=*UJSW/4L[&2
MZ2"?,&O%3&V?3"<SU,5@*CK=AMP[,TH]1H1BJTO["VC^4RFVSU+5BN.^-=TS
MQ0Q!>GL30R]K$A6711CYV]EV&0I'6.PAÙ60-.S93N*=Q`4_C'&8Q&)Q1UV*
MS9JA>.Z+OJ-:M73CF^H&;C1"ZU=F-*OIJ;.F@)&)@HB%8AN(NY`WXW'WUOK=
M64!W_J.CZ>A=MBZCUT5+F[U>JTA`MNR.<\9)^-PT7RQ_J3*8>%CDG,BSB\?A
MLKF*^>&,7B,M96G)#A7K!<J^7([F&(\^+33]-VH[4ZK9!N4QX]3&L])SZOMW
M%,3-E)/31&5I1NW6&QXB//VW_P#,L9_HF3]GI7\?J]S7\=/[.YW37_I]F3_'
ML[&W^GI%X?KT]F,CT^Q*LM]5J'!-4AN['*8+,BAL,$FKI6X$$N8KYBX9!1SB
M.*+[C:6)M6*\L=6R6,.YDJC38R>C8[/*5*)&D9B/+$Q.GOXS%?)."QFT-2HW
M`HDK;B)ZS<;:0LVN+^?>=AMB=TZW9='P"'MC(MNVD,77Q:5+4QPU]<9F0S`%
M9KA877O@TPV;'"8C'..?&>[C*Y5E;/8VUC6TIL:UJ:K:80QM)91(J=`ZZ3S\
M>+MO-96;-RYB+>'WT*C,176EU6O6KNBM6OE+'(Z9D<&9`S?$;1$!CBC7S&1:
MB:&.]4XU18\7UX(/4-+Z=7L'T[:F$5&L`R2YF4O/76-O+BUD7>J<PUF5R.-R
M.96`*I1:/!Y=.0P8T;%`ZM_&SCJ2RJ0?68?3+49'33@\=C<[V5AGI_#>G69$
ML-5LV&5L3E\AD>Z/^84V<C:K9`J_<0R'JYL`X9.L4<>H5`JA3K4UÀ4I0*ZJ
M02Ì3+'2I0B'E'<6V.6L_<V,E<DXK51@F=)9-9.XQ6`@L/,1&PXCB!$[OE<%
M>\7TÛT\2UMUF-3&5;"Y74A]U)`,ZR/EDO@\W%(O3>%]5YZYALK.-R>4IX"W
M1]-U*3[:Z68K9'U#FOI>-E2"7#1E)N^<@?=KQK&#M3$^$Q<QFDQ^/^6<93)7
MD%3MIWX_'4&L4QE+&H=TKA,E1$N+UK*5RZ\#,[5K1SF)@B^RQN$)+4FUSVXB
MZ4K43'M.P\J5\`8ZH;7M(MK!:K<7+I^/!4J=>]AZ@Q`6HN+/'P+/X@NR%2T5
MK)*_9#'&D#CX[8_!QU,?DK8Y$E(2VPR`FBQ%:6FBD.'5T:57'H.RR0%'3;$L
M(B81$1%_9RY4.K>LCA*U3)5G*.HW(9JW:K'7K]RB9&S1KHBS`,"8:O?IKTRX
M[[,7[K;W4[A8T,A>K!6M=$ZXVV718J_E+JT.,!)TQ7`#D5(5$S$M+$92GF"%
M9="GZA1T&&<!.P/JV*%,`,GIS.JTO[[AHZV#RDF%W+ON`"K5RY;':ZR2@DH0
MNO:K-IPG7^7FI*O`(F>,N_TS1IV<;;K5[61C)9!]"N.1@IK8^]296Q^1DFYC
M$(%K5R`[4!6;KJZ8XEC,'@V+7YV+J^H+[;1@/,QK+;Z<0ICY'X!(P@BY;H\>
M$V:YPQ+U@U1Q^8&#!#//G'*>.J5:O+.J#Î*5R?74OI+=OV[NJM7E@O&!Y</
M0VK68BR,A92Q"C58`M8(7K(9!HE$\X+7CMT8V@E&T`Z*JB%KVJ>=I4;1"(^7
M983(_!DR7CPM,4JTJ5714`22!Z5JLP5=&IP4RM)QJ,3X3S\>(;*URP>0LD!W
MQ'/E!Z;H\>*_5Q6-9V<*BIOHUB[:$E)IBOJOY,**=1VZ:3PM)XN@U:JJ:(0Z
MHEÊ.LQ;T5=S0,I0EZA,1GE!C!>/"BC#XN"KU1I(*,?4@DT@580%14]+5=8$
MVVA`1Y8%A1IH4\"MV%Q+E@VH\`;CJ9@#\>KH4'"))F!;23&Q1>*QY#I'M9D\
M79&GDF*4IW65W%*\NOU>@NVG<#5ROK%`L48'&[GOCR\#C:F*MX[)24Q8>H$V
MJ))_*_'YMX]E7"9^+KUF6A_+5+XHBY>RV1G*0[O$NQ]NPA5.X29KE9GN#LMS
M-LJYDHF7NN/3F1!:@G9Q2'/*3D$6'78+*T=:@U:-+'E9[_*5&]2$1W6U3"49
M`,'U9@`@H&,SEK5BQ&2IQ*D=8A:JA>4#>QAR80--&V8@QK"LV[?FM;[M<3G6
M[8UF*F<3]6K_`/HC:%M3*C_2;W:?AQ8#,*4&8;!(U0PF4TJK_-73I$T%MV6*
MYQ8W3&K3Z@_P.7&+7@:ZK&:K-.D[KO*O2M8]M>+>6JW'*KV6I#%#VCH;`'ML
M6%*B/G,T_P!3^F__`)CR?_\ÈN&=545KM1QU,A3ADM[:VN!.1%LK3+4.4P6J
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M$NL\`7;206[%4.WO&I%B)$MRK"#G2>X/C()3@\K!%6/4%V,1!V%#YW5`8O)F
MQ,W%1*NH(D:]^X8DHCBKTW*M,MC%Û=2.Q5RS;$6&Y(?PZL#H"`_AH``\!]C
M,-770&L?J*,?])F;!9HUWL7&7L>H*WS^BO$A:842'1V>4YZL'\O[_;<J5K0]
M-Z=ME"GCT;2Y395HP2CIV$SM./ÀY3P"E`*U*`5K6L8`%K"-H``CH(B(QI$>
MRO>I"16T$N"%<J%AK!G42Q?7-22;5;,\B,8)#7!KY^)@<'D1+2=I2[#%$3[I
MD?JT;M)XRF1MP?U+O;.*)3Y65JG7J66.+NB5)*[W-6K!9!LA,A(V%@,R"PGV
M%<IQC:EBS@;UM]K*%:[?*EA&+FGA*BD6$!]5L?4#VLT8V`C2%LCX4N)1H)JE
ML)+/WB2,(*5'IRWKF=)_7^@,*DE5BURA*GOFLF2(HC5KA4\P`(G6=`*9TY<*
MR.=L?6,@DNK5È]+%8QGNG&XZ28`N'_WALML?@8QY?9VV1IU;U>2$Â;0NPK
M>'PGL:)#N'W3P"4@"E*`5J4L8!:UA&T``!B!``&-(B/#[LH?:KHD4E8*&N6N
M1K@0@;Y@RC1(F<1)>$3/&0L.S^&37Q,Q&3>W)TU)Q^K"3'>M-PKK:N&0\\QY
MXF/&.,UB_3>2=G\74VWU7\+B<OD\73;<<R+>+'(TJ#J39&Q'67"S+0&2/*`C
M4[!IRYER771&!S:SMVV^2K323L>M7<6WS"U[IB),HCBM;EZ[C[R^^;;7,FMA
M7=+$C6(_,--<3`K'EY!C7GÂ+AK5KES(2F#,0EK9$CA2]TQO9(!,Z1STC@:8
M9?&E;-,V`KC=K$XT0!,EHA#-TKA826O[,3/AQ4HX#U#5]07\L,T<SCO32K7J
M&:Y5%.=3RMEF%KW:];MX`J[=YB1"8?X+3@VL#+`M8$PRGT]Z@T$`C<13_5GA
M$1QD,[N80D\<?2JN%BYITZ6K46#K-$>G8RG<]T)Z:E68G\/N4MNL8$6+Ù*X
MIJVKCG6#6UL*57IIL/,NDDBY#R@>*]ZDX+%2VE=BL]?P-2T8-9CX3H0SP%9%
MI;'LG)""XW;BG#VUT<E',?\`V2VT0+]<\N+-3Z@H&4Ô%@VBY-02JFI5H!ON
M6%%K:K7B+!!DDLIT+2>#3.3Q\.7!$Q4W*\,`0#JD1AU-PP*_-/ZN?#`#+8TR
M5TÎ`W:\R/5J]ZKP9SZE/YL?B'/PXFS1S&.LUX:M$M7;3(=9TR*%ZR<>:Q,?
M+_PGY=>#6>2I#*R);)*RJ`6T60HD,;)=,+$,*(Z<SO\Ù<5AR=Y5.;D79K=7
M?\V,=1?DKNW:)?Y/1JFR?U#Q=_KRNPL=6P%RVE"K5FPNOZI,5>GRBK7KLL.+
M*L,86("1:E&L1K'`5<1EZEVT=$LEVJY.+2Z07&8XVOKL`'5I7>4:B%D"<,"8
MTUB?O>XLV;"2'%6<8J$FX(";-NG;[@X381#]DTXCIGJ//A5?-]AG\92QHXC'
MXV[B*LHBFO(5\DD\F+CLJR=Y#Z2=C-BH$@D]NXYGC%)2A205C;@(!2*H`H-R
M]07I4ERA_4#0'\1GBQ2M#N1942F1$[2C7P-9QS6U9>8"CF)1$QSX;@[KG6"+
M+=CWJ*<CBJ^9M5N_.CW&^"!V2`NZV0KHH=8E,,GR#Â8]5EC050R:<EM2;5&
MZ4HLI%760U+DQK8UU&?=IX3Q4I?4NYP]?(KR[*3J,%:L7E8KZ1L.^=H_ZO96
MB-RI61ES'J;)D>*='%XO'XVBO)8_IT\?C\?7JAHZ-LC6[%U<=)]\!!1[BCV/
M+=:?4=0M7/I^/J3:;5Q%$TF=NU\Q0JKX=UHP3T^HUJ&BH5ST!X6U10Q30%BS
M&=1,#B"ÀGWP0S]QBOKR7VD!F4E4IHK]UW=[L<@(*:G86Y45R8?Y>81S]T^D
M+M2VYJ<9CJ7T`VN%+'TQ!<U9:EB5,,MD#RVC/#,IC,S0HY1&9S=#(-9-`++[
M66]0C;R6.N0U2GEOLXLDURF?*O68W>/%JLSUL:,;<M7LFN@K+8D*27MMAGLH
MW=*)8]9,W-T:9PD6GMTC3:.,QGJ.I%Y]5$4K3;.)LN9'7R:$M-0H7W6]V4-<
MCX%(B,QRF)R'JY^8O%B*S++<M<6NK*;$T\JMMQBQ1C]ZTGE*(%!5]H],=`^6
M7&"Q`9V\RR_)YO`X]E<(A-^[AT6;&94YU?'Q2,(KY&5+84[)(A!>I<I0\\KG
M23VZ,?7BU@GHBMC?4E!]#$W;+`P43VS59+15VR<SU9'>6O+C&5/49,R08H\J
M=>"54A9_4\=?Q0RY+*[EDRA3O?*.-)ZH0<^^..NRWGK1M[,<@-K(BZOE*V.O
M8"]CZ=JI-?MEHI_V:K*'HBHY5N@BF9UBF_&G<_D,7D,-54YJC4%'(9H\W(:"
M@#F:[RZ:YUY*C2=9\WWPU<92%KV!NFY;/IXZI&I1JW9,VK+N7)2QC7\QAX\-
MLW,C<R5ZQ`BUK3E-18CS%5'&J+M:BAGW^=Q?G8?L^K2M_7[H+\H[NQV!9)=6
M**\D5#J=L5T*8P$'I[HGXHB?T/=7INO/,NFM"B6N-TP4[WN<0@E`Z>8O-/X"
M4\N%W\OD#-JMTU\;CC;6Q=:2';JWF%C*N@9^)VBO>*@GG[%G=&S!@BQ3(ZER
MS3.QC[G2FYC[)5F+EU.S*1W#/X<ICGP*UB(``P``,;1$1C01&(Y0,1]QBVY^
MIWR(S*8J5R+'B@KTT<A`3:G*V:E#HC7ZG[PX\^FG/3CTA:40!T<;1+TRN[>9
M6N=I*U'4`:LV%]P0CMCF)\-KV\JY-RK?-5A"K;PF+%G)Y;*S+E$@P[=>1R#Y
MZ^FQ4QMWQI,<*K+S-LQ`,GE8CO;?9$RSW]G+/Z[D2`6KDVK-DP$AEHNE@Q(;
M-%9NY=OXK'>KLFD`M/9M32R?J.S+#RS.H]'T^WT1E0NZFQ'EG9,QSR^(<>:9
M@,SZ,N^MFT`0"U!AYR%RS;33?#!A>0MR4MBO)Z=L$%&@Z\8HZV,]05<AE<_D
M_I#@8:<?B\[BKIY_()QK\9<?B?YD\;O.4383TUB!D$S$3C9QJ[^*7C'X:T%;
M'VX13MV\#4*EC[F1J=$Z]ZX*#\S3&3D]#UWB)1_RE5FV@7]E9BY6@]=J[$)?
M7AFW7:>BK!QI.L<^,9`45_U,I:<9,FTIJ*5ITP"9.=8#;[]>+&0&D\+EMC3L
MN7D<BN7"]]BS8K'`6A$J=AUHY-7P%KI,:1$1235JE553NT+FP6M;#HQMM-VG
M7/K&R(4MU98\N?1@E_"9<4J;$,?5QF2IY;&H=9L&%"WCU@NIV_S-W23MW;"D
MADBF9\>-G]FZÔ3)'7[B]W?:%C#PY4>\[GN?IY8]A#T-W2UG?MW^;A.93C.E
M=KW[.43LN7AICD;:W*==^G19[";&RTW:73\G5+337]%4S)6HKP^60H84^PUG
M17+7F**RW.E5=4;F'MV+CF4QQ-"G?!]G1TA`K?"GQ6Z/<=I:-0U;G0[@-_2,
M]N[G]E5"T]-RCE4W[%&1K]O:H,I%6DJK2%A+MUVIL:B>T#`@Y[MWE^YMU*JZ
MB<;BC2B^^Q#6V[=JQ43=A-):V*774A%E4DTÎN(I&`C;NG[2%%5R%^S81<MC
M5QJ`>\:6.A/>VSAC4!TD%96.D3+#)D0È/!8W'DYC.E<>ET]M*;":#ZU=[1%
M5EMJN&^V&SKK5U(GRZZ3_PÀ8SU!#<@BVG+8OTVEN..F+(1ZRS6)P=C>-^K<
MKD*&FI\>7=N3'/29B:MW&B];JJ[]<9)D'U*U[LOD-F1U(:_8+V3\7XZ_9]-_
MYMGO^JH?=>J_]LT_]V\%]B76GIK*B8B6O:"5Q)<HB39(CK/ÙQLUR>:>X!$.
M7+3KS.D/%<%O).OYO#V>E;?9Q9=DO6?IWTD;(NY&@U6+]5Y%&/RH@[&VJK3Z
MB@&=A3*Y(!G348X18HT55FUAO@DE28[`R;D6+B]N[;*S;6"8'P#;H.D<3,S$
M1$:S,\HB(\9F?=$<)VV:Y=Q&Y&CESUX_%.A?,C^C]-JTJ3PKS]5Q]BT;.KLF
ME7=U+"R6IU<GP<1\&\8GC'2\^\OT[=-L9IN;M0@<16I15L8,\?/6ED7+`DWG
M!Q$-B9/J*'5IVV=C"`ZK>[T5TTDYJ$L,M96/<DF9`==\Q[M>%XVH/T7'5\KA
M<TG)Y.NT[-RW@,M4S-):<1#*SUT'VJ(0UCC4WIS.Q?.#A='U#3^CWV%"TNAO
M<8;(LG6(^GY*05M:S3DBP*7_`+(G'FXO5,%U(>8P/=#8FENA5@NZJU[8Q+$/
M<-5E>61H:#8)_KX.W4LV<710Y+\7B+&8N7+=50Y'&,MUIN*R?;BRTJM8,>IW
M:U@^%QRC3V^F_P#-L]_U5#[KU7_MFG_NW@OL8ZN5@JP4\K7R)DL0)ABA-E?3
M7U!8L"(GQSD2Y1QC5*R./D,?>IY,<D5!DY?JU<0.&[`6=85_3V)'?X_FE>W2
M=W&F02U#S*`KH2)VCNM/KL"K1%8PVU9"NG>W:.Q>OQ:1,Q1#-L9@Z.+RM#/8
MJI1*N_*AE\2_N<9=R-E@6:$!6?$'VJQ:!?F:4:CQ"_4JTD@=!'U!CUF-`M9V
MP62I&;7X@Y]Y;G5O?+`^'BQ12*JJ7=LW^?6PHLE5MJM32N5AD"BI8.IT7CSA
ME=TR,^Z6Y)MRE3<=RA>5C<?7#Z74.IFJV2;523ZW=BFP%;<1)FN16&F6FDZ?
MI^`WB);<JXXW1!:&&&RLB<:^!#/A/L]100P4?0\K.A1$QJ-%Y#.D^\2C7A?_
M`*`__1'V,'E:=8\G?19MU*^#1H-S+!=JS+UT6GI718JQ5AN]Y+K[!*#,-8*%
MF:R29`)&DI`B41#$DLB61K(@GEJ,S'L2RM5*VY]GHPL-LF*E5K-ZRP%D:^LR
M*U0X`=>9S'NXK)_LYF8"Q:14FSMK]NEC;`5#EDRT3VHM20EI$_#KPZL[`YL=
MECHH=VXFJT'<2DK"^B3#!<+&6>>!F8Y<;;F&R)/`R%TU$$2HU=*P):R^>83T
MG>$$6U6[3S:15O=!E:+2H<*6DLF`L]>GOE1&&X@TG37EKI['V.B^ST%,;V]4
M(99=TQDNDA<D$&T]-!C6-9XRV9E15?JN6)OT]_EOXV*="ABÛRBO_9LC_(]1
MBN?3WQ&I>,_9]'?Y_E__``*_[/4'^Q\A_HS/;UYS&*A/<%4ZWU"ITNZ&-Q5N
MIU=O<"/.0^+[EM]JFOV,JUU5T;.M8M7K:*%*NOJFM0E8MV0#4B$1UUF8CBQC
M\A4NT<I4=1JV*)0NQ_,9"\FFD%V:YG7,-ME3=TR/RS_:B1C]`G28G;.TM)UV
MEI$Z3^$Z3["QA%9.R+E4Y)=1\TQR-BO%NKC&7Y"*:KUI!#(`1Q\81.DF.J+*
M&5J3Z;^ZIJL)-X,GIW:Q+N;32Q86:=H?A\R6Q^>.4B&7Q]Î>(GP%2FAN8FT
MJJL6V;M*:"S<VBA9QN)BU'!%`[=Q#$VZ&)-5'&97&L5&?:(7.K7R-,H!V*H"
MR!?'3=$]1Y`/X`?Ù?\`BAB@^D#M4K_B)Z8K6'^GI'D('ZDP\=QDO2S2_,S^
M8H[I_>A'+CMO2I3EE652)>HZ+$GA,>+DZA83D)DD92TO?!0FOU.?[R5\(5U:
MF'KJK*591%RQF0O99&+RU5OJ"1M+5'7MV;J>9?-^5O+S1'&.KVRWVD4:B;)R
MTW[GJ0L'%UV?,=N9$^8N9>/'IO\`S;/?]50]H62")>H#6LYUG8+--^V-=L26
MGCXZ?;]6?[:J3_=_LU@8U_Z/:X<?D*=TJY;7#5L*=*Y_OH64\IGW^'L;25C;
M3DJR2\%]0ZM9=;ZZ^@O(5J,A+)MPEJWK"7].1%IQ'AJ4)M-N2B[2>Q^-8E0$
MNH1KLU2ABF;NX"Q3?`M&9^*)D"'EHBI9Q4Y+)L1D;W2Q+U`H\7BNSBW>_K%E
M?HMZE]8"C>R9,OCVZE#%E>9B_3>6Q_RIQ;-N9R-._6U%Q7&ITQ(2MO(%B3O\
M8/,>/Z^J6O\`B5Z.5_\`R'#5%+]<8>N/Y\Y@*\*J>H4)'XK-'IOTB2)$^/'2
MQU.Q0P60IF#\MDU6L=D75[E4Q_JG%.!-ZNZ(;$]:U"=DQR6SQ@3O91%8EXKZ
M,`8*D>,25=.-OX]%EH=R[6T7UÌ./AZ8`$>&Z:E69$IK5:]>2`.F$]%0KU!>
MI;!G;RC7E]NY;6`L970;%@<R($<1Y(,A@B@-WCIQ9+-O9F6W$'6<MVY6.578
M0F2:6.!DJ1&Y8SU"EEC48^9RC1B4XU,`[I2^3EC6V"1;*ÎEE[C-UAHW"W[S
M*2U]_P"@2BA$XO&G+([E;I6;%!8<C=8O+D;2S/HR7;TX%FFFZVJ9V\*C'6WX
M_)K@I+)TU5T=T1D1[;]$5]ID$P1\NO#+$1_%WZGQ8QUKLD6:$U6/MU882K=>
MSU#0Q-=VXJIG-4P:HB9H):BS7@+QV<DS2W4R+J9VHFE;R="NNK3R5I?3ZC+:
M$(7X'`$2@(ADAU]E9Q6K]"W4&TI-W&V(KV8KW16-RM)&MRY38Z(3/EW"2Q(9
M$HUXJT:BX35IUTU*R1UF%5ZZQ2E<24R4P"PB.?!`8P0%$B0E$$)"4:2)1/*8
MF.%H0I:$J`5J2D!6I2QC006L(@0`8\(CV^F_\VSW_54/NO5?^V:?^[>"]E7*
M9ADG4MC+581,DO'B$-*`B]_%RAZ!SAFB/\7[^$[T]!M4-E.W3*:ERD.FV!JV
M$;#6O3Q7^[+P(9CC)8JY>ZZ\652>Y!"T6+BK8A95%KI_(ZBN@0,V`*W`SX!X
M5DQH*[U$+Z;I)LZ&FMV2K!*)DI.XNG\J'$,MA?EW:<O8H,G3"U">ITYDFK,1
M>'3L*ZB36R:]E?)BYG8R/BB>!6L1``&```B!``&-!$1CD(C'A'W(4[F1K(L%
MMF5D?[D3Y+.V<1(4UN+D!-D(,N0ZS[+@,.(982:JZH@C?8;R^770N"<]FGN&
M)G@7UG+>D_@8HX,"]TZ$.L<I^Q3B:UJ]:R%OLJ-*E".XLV(KV+AQ!6GU:J@5
M5JL,B8P8B!_&8B:^1J=2$V1+R.#IN2Q3#2^N]>L['UWK(#C68W#]WK,Z1ÔA
M&DQ.C;L3I.NDQ>LQ,3^N)]F?IQ9KS<#&X)YU(<N;()(\H(N-$%U141<H*8TG
MV=O85>=*J@Y"^RI6ZR<7CC>5<;]\MX2")-;/@@SVJ,MN@S/%JMC^XZE5*[)=
M44Z%7=8M55LB:[['2DFTS\C>FW3GMTÛBZ]1H6&8JEESR?1*&10FUV"JJK1#
MJ*;%F1*07/GD0*=-(^Z]3T6-!=MUZC?37.8%KZ18/&5(M)">;4]S2:$S&NA!
M.O&]S!6.HQJ<Z1J9BL?^<SB/[O&.JR41:I*FO<K3.CZCX:W55A4^=+-/<41K
M'/V9W"CFZ'U.\C%NH52=`3D5U4O1:^FL/:C(G4;&C101DJ?BB/992..FVC&8
MZGELN_NU5SK4;UVS33-*N8&60L1V3C(-5\AB(*3*!XZ5>I<K3&'QF6.;5>PB
M/ZR;>4*$S80F+4*FE/S5[EEKRG[FAC(N/HU;LK6YU%83?8VPPUI2JPXNG21H
MLI8P0)OALD9\W!4:Z)JJ)DN)E=K!LLL$,B5BQ8,C9=:P2F#Z_4ZD<CW1QT*U
MVJ..=8IU:\](C`.\LB@]F-F17C[%>#W#*6]HS_W=?O=+(9:L65&FQ<M,D[;5
M'$P2X:.SMU<_@5"PCW1QW6)O:H*=UCNC,K0`(SI+3T->:6/A\_;;@?"S^7BA
MD,EF;"%WZ5.[V&%",8H(LH!W2*[)6<H>W?IN6Y.OX1P5T'A7].R+&9DLAD"V
M8Q@`1QF.[R#S*5-TV6!(_':R/`]S>@Y;>@XJ[NF4%TGA`R:CT^%@P4<OU\'4
MC<6+Q+IZ;T-?5>%ZMW%:U?J7:C$6DMBP14E[3@2A=N"@HV\(HT4C7J55PI*1
MW3`C'XD<D9F4\R(IDBF=9G7[IU7%V5SDTMQQ9#HIG(6<1B;5U"+>3.BJ#DB1
M69)@)1X1OVD(E''<9<VO7%F_6K=2M-$<E058N5ZN1?2D0(._IL&9&8V3("P!
M'6(XF[4EE6U)0QT5C%:K^W^'<28FAA''+J;>J/N+AE6_;NJ4S%U+>28G%EB'
M87,,<8W/3M9]A,R]8+_B1N<O9NZGS0TK'-1^(R]#>6+]38.RS&Î<<YD[F-5
MEU[K%J&ES8NSUE-_.)<6,)D\IZ9S%`5C./\`6QUWU,U"MTB2,GZ8KKC&6LF`
M<Q>JPBO/C*?R2GO[&4R-@5$BW:LY%ZVY2N=DK<U,DNI-:K8HB\IVHZ<*`2(!
M&`(AGK8^H-9G9KH20D?GK*>^RL6:E/4,'63G=/F\WC]HMHB.XMQ:1$;BG2)(
MM/$N7W6S`)MWF8J]3F[DL<D`9%%CÊEZ6!S#^FDLEV\:.[<]T+U#=#=L<+=F
M!LG;BQ=[4<BT+%Q&.[JZ&,BV2S8GO_I;P!Q1,R6D;Y(HF>%WQ2`92J,]I=$W
M(9$Q$[46&5C6RS1(_C2>Y9?AKPU'J->7.C].QOU"OF+JG#;]2+.S]3*D%.P0
M%A&`0?*G2L?EV+C0^(PV?P]._CU[9K+(.BV@U<1"K&,LUY59QMI.GD8@@,?=
M/%K$O_XA9/+>EIA?TV+]-+/6%(//#*#/5/4_FZFW3:XZTW(_PL3$%Q1'Z129
M]-(CI,L*BT]+#=W)M[FSU;#''9^;)D1%+?/\7/@9K5:Z)"NFH,I4"]M6O)RB
MM&V(T0F6EM'PC=/W.")[5U539J$%BSO55-E9SI*KW6R:Z[C8?'269#+=)VZS
M'!,80@L!DS,Y@0`!C4B(IT@1&(YSP@%N<:DWL;;&R%9[4V*J+HE:N582#+#L
M=4`-66]G:1[F3.NB[%9RK%=PPQ3T,!J6@7PFMBY(#&?QCAM1UB3=I*;'0'JA
M2-RBE06C'D-A_+IUQW66Z^191SXP^*[L$Y6IBL?7LXNW!T<FEJ*:5M$\?<%%
MO0#'QV;?U\3Z49N8S*52=;A8J8-3'*9'S[8-U"56[`=$`GFSSZ<@/2Q7/7)B
MW(7+B2R`+<=5%DXE-`"F/F(HI`5K(M3D!C=,SSX%-9"*>']3-T$$K6E%3U"E
M'E`1"!%:LO11RCD,6$_MN^ZN=-K4F0K7U4G*W!#7+4<K8/F6>PYT*.<>[CMJ
M%959.Z6$*XYL:7QN<R=6/>S3S&<R9>^?T9@3\+<A@TL'68AB7YS'*<H]/B6Y
M1R)1X$,Z<"M8"M:Q@``!@0`!C01$1T@1&/"/T!B+"EO0T9!J7`+5,`N1`Q9Q
M(&,Q[IX"C7REBOANLMY8JPA64"L:H^7.*9?ED4XC7]VX+2%\I4M91!084D;"
M<4'9L,-EBY;9$:0VY<>3+-ID1X293I'*.7%=GI-A8BV[-4[V0E#950<NJNTX
M^[H[N@2K]CIKM2H8<P"UUU&)C%Y#.4H7ZD[(8NDYR[KJCV:]=*K*Y)&[2=IL
M5IU=.>O'0R-&I>5'.%VZZGB,_M!U!+8?ZXY\=]1ZY87*FMUQ;6.NNCL:71M4
M@L6IL6X55QZ.]IJ@ML="VL8U>$0+%D)@8P8&$P0&!1J)"4<B$HXGTÂA1C$.
M5-UJ2D#_`*KOU[=FVEX3#$O3D:JZ=8PD2%L6BCS5XX_RO-__`##G/^W\,Q33
MLV*S5E<QMJPQME@B)`-RC8M-DV$:6,$U2<ZDL]L?N_LFYS`2I8R;&M,5K6`Q
MJ1F93`B,1[YX0ZOB[EK%-;T(R4FFE%II#J(X>K=)+<IX>/RX;'[CK%Y>)?0L
M!8`3E3(C<#4.'XT6:[1!]6P'YEL$3'WQQ?HX>L>7L5O->:ID(Q>.BJQ;VA=R
MAÙ46($-.BH7.B?B$1\W`@DBK7>EUBQ]KIC9Z.NG<5S4QU7(4YGP?68U,_M:
M\N)L7[=:DB.4NM/777K^&]I".L\&^@_KK6R5'.QJB$X@2YK<"V;3`H(9TT,9
MB8UB?9BP2_'X\,A>96L9;*@3,?C5KHVK0F]8VZ.I6G(%(;G+#<?C,[1+&9*U
M6[2Q=IIL-1YX$2,==RX;`MA3?B#=$%MF->?LQB_3@-)[[MD;4J[4-M=6(R5A
M.ZQ<H9*N@&7U)'65ZEKMB8UX].HL85[9R.*I6<GD!AE55"XVOOL)94)+97(M
M'X99J.[3B^JS@+`8VYDX+!V[&.MDI.+3-BD5=\8SO+D6\B^HMRB>M6R+G,9%
M?.L?HK'QDL98]-6;S+!5+!2F]&>P-9!5PBC8FY9G&VK,]J4IW#$GN\G&1K4\
M#E*!V?4K;N!>W$TZG_P?.']4=O5?8M)RM9%Z,CA:C2[A2WSWPJVCY2XR:/4]
M.PI`XK#7*K(P]K$U*UFQ55WE%D7ZJG-O$W5ORG6E+"=LD)1I/VNM<<*0DH!<
M:$;7-+X4UT+$WV'%[@`2*?PX7DIPJT8C=(DBVQL9(@V[NZLNK"^CAE_LP_<,
M_P`5E?AC@LC5*NCN;5>](5GU:^FO<-@CZ95)]SUD:#_*<\,7Z=Q^N.0VI>/-
M9%%CI79QUNOD%U\+BE$B_DXL,KP,NDDIVSN5+IY<+KW5_3;QLFN($R64K-D?
MBKU+IK07=1[ZUA=>X/O3ISXFJ5KN+L:_U?CU.R5^)C]NG1![U1^LX$?U\/'H
M6:=FM(18HW@6NVH'1)5W$"FO7*;`1.TH*><2,Z$)#'&.KT[.2JU"&VS)6,)C
MEY;*I9T"^D!%(ZM^8J6["F[CZ4^98C,B)%/&,;E5`G*,Q],\BE>FQ5XJZYMK
M'0CC:#YF/&?Z9]F8C#;XRTXZW&.E<C!Q<E)0B0(XD1*&>_W<7US4#+9%6=:N
MF%BX!+^C'40U;%W7]BVQLL%(_,C?NUCF(Q/%>UA,9-G$U,;-:U5EE7^:R.14
MYO>@@MK["\*VL@8@7JWP]T<]!*,1_9\&KSBO4>`#)'<QLT:S,2=I;;[;%0[5
M@QK3CSCK"ILL`M8Y3&D;BH9&?_@_+X5D@S#"V?5UBKD\I0]0(1,2WMZCUU:(
M3);/F%)!,QNXZ60MYBQ7KV?6B&#0'"7K!U(Q-1_INW1OY&K1*Y8BZ;13#P6,
ML\K(D1&9Q9>J(?&;_G(LS9%"[!I'(6AQ['KKB"UM9CH411I!Q,^:-VOW)U7R
M8Q)+8MJI@75["&"ZO904B4"Y#@@AUB8UCG$QRX!2LU?6I8BM:UU<*`+`(VB`
M`.*@1$1CE$<93'NGJ'E-F3Q]R5H3+JJ%KKV<;TJR45USCK!]70!&#BW)\SZI
M3QA:BE5,I*9OW;.Ò/?5J7ZW;=F%I]A5:X`%1LVAE8L"1*9F1\X1IBZ%VU-V
MY3Q]2M9MS)EW#TI!;&[F:M/<4>)>:??S^QBJ=A86ZAKHP-6SN964YWUYI7!K
M[H2=L?IRX`C@MD:[=)G7AB+"EO0T9!J7`+5,"?$&+.)$QG\)XHL05U:[N1HX
MYJ`N/6/8D+^K1EZB"X['LTCY#6&I>GRQ")F)77K)57KI'8I"%@I*PCP%:P@0
M`?Z.+-]:SJ.2%F[,5"Z*V6X0<C;VQ'\M>$N?<(Z3YTT(I'R\8O)G6&SDWXÊ
M8;DKQ'>ORUM99L(;=LG.5!$7PA(A'NCAWJKIW7=G7"M>Q^/4M]C+):\4TU+4
MQJ1FW4M6-53KK(F8<]T:2U1737U["5'6QF0O@\4-E776>.JV@V,F-8@I@_QB
M.,CFVKM5E(<>/74M(L4["E5]T5:MBM96IP]1;INLB1T+N41_`]N+3Z=8:FG=
MLS<8-@:@P@,1DCKPVQ-'(DL"R4)^%4[IY>''IY;\7#E6,529F[[6UJSZF0*O
MK97-(6QYNM'.`B1C7EX<5NUB^5@L@V,XO)5:X8.LF,V@,?&&>E$/=59B.I+"
M$F%MTEFUO+BF&-5/]JT>J,,K(0VMMH3B7ÎES<F3E7FQPXÒ.:XEP!_?\;IQ
M.1,5^F?4N,>:J^(U/U3<#U!>P>7JI9I:.IC9JX^J&H](HL'+!F1XQ-#+!<N8
M`,O;39<N,=8!U(ZE1G6M9><11,ZE/JD2_D56L;O5$GLB9^TCP\V*QZM2$2D0
M/Û3F0N2B95U655[MNDELC7E'L]/,7CJT=?U(HC7*X*O!_2\NPC36+6N@W,$
M29("/4(1(M9&)]F2O.IJ*U&+NK-NDCW"XJMV+MB,P%Q:2\RX;!0L_,.D\^$)
MIUJ]1/2`NE62M*]9"-9V+$8UGA7J*GCRR&5J.HXU%1=KL^_1E\I2HLJ,9(,!
MD@3NHB"C]\,1J,$4\!D,?@LK?K/L9%=>Q2+&B@UTLG=QX[YR.1Q[56)BKJP)
M#Y9S(\].+N5R=5U&Q0>:(H622359"Q77+'S-=KT&BKBVJKUB$O-N>?\`%]N8
MKX@R5E'XZTJ@P&R@UVS40I,70:I5(G/C!#,?C'%^NAE+(7OKK2I'D7WG5OHK
M*B""%38R-K(`2[.Z-'/9.NZ8T"1&+#,?-_JL3A?I%JGE!J8G&]%K"SR\GCRM
MKFXRVJ=%%*K'Q!I*I"3XO5\P]MY]O"4%T+-810BI?JX]PW1=OOVR"RZVT?FQ
M.C9C72-.*U=63&SD55O2.1.V>77CD38]/X%YY#!-'KYAEIN;SYJ&V[Y:;2UE
MK*X*./4MM67R5;ZK7]26<343FQ-E&U/K!%O`T7=_<R&/0!>G))<%2"K`+U!D
MRS84>MK/J1R&X2\_&'Z7"OD"L(K5D_4$N2%(ZE=E%I5XKF_660QY%(E(Z:?<
M6,HU+;"ZY5A)28(FE%FVBK\L`!AL(>MKMB)(M-(Y\9*:^(?-+"6ZU?+/MN.A
M:4N[EG8FLVICK%.+%D]]8S-9]&8'2`WE.W@'5/1N%]+8;!YE5D,YZASD9/,7
M:M>U-9[,;@<+*D*')43->VU>#Y;><06G$3WWIWGS_P!4Y+_]:XS*,]VWUJPV
M!$ZP-57&MCUB(8ZL+FN.5"NQ%T"UU9%P^42HXC[%/.&BW9J555X(:`PZRAU:
M<F,-94TEUJJ2LH6L)W-@@C09C7B+]9_?(.3$9I_.\ZQW-!LZBNI*8CYDN)8J
M_/,<5W8G$(LXZC>1?[MMHJ=:Q%:&P57%VV)9]7LNEG[T5JHCMT&PW76.D39H
MW(:NN>.R.VI>"PX6&I4)86C^L"3D"5+%L@"VE.D\/QF$QX7R:DUR?7'MÊ:2
M0IMVKZI94Q],H+>/[^VX/A1I._BC1R&.?,4ZE:K-S'?UA6/H(!74Z("&0#=M
M\.B41^/!XVGT;&'QD@S+.8N9[C)!T;-3%UA/:0LQ^]5FP?\`#*4AXD>UB,?5
M332VU;O,4@(`"MW[#+=Q^V.74L66D9?B4\5<P9BO'9&4XW-1)1$5RE@IQ67F
M/<M5JQ%5Y?LO61>57'^ML=_^,1_]?@7UG*>D]=C4F+%EMF1+0PF1G:4:3Ô[
MT,[6K1D)"K7K'2AL5[(]L61VV*1L(:SFDO*,&5-D!GE,'$^).6P>X6T4.IW"
M["U3>R-5JMU'#.0WM_ABE+F._AB<<^*F0?V^,I4;<9"I7R-8HMW7A5M5EA%-
M+=^'HD%PIDG,?:,HC52=-DTU9B)Q%F_D4XFH%B>HBWD+"'V$)J6UCTFPY=4]
MN[86L;9B"D8F3J-32P=BLV$-%<L7=JWJ\BFT9V%*L62E#H8"E"A8'\3FZ2O@
M`96KY-0"(]6D?:6MHQISIVSFN4_T6!_HX9N)B%4>HI6.>,JL-M)FL=FW:3/Y
M:O75"8_O^KS@E3QM6`@.XRT`8&-S"DS+2/S&93,_C,\4[0E)LM@FGD:*%FZP
MVNVQT,;=4E<23'5[K9#;'F-)L+GT>7^29?\`[GR7_9N(>B2D-QK*#6:F+8HY
M6Q;5-$&+8!CI,3'Z!*GJ6Y4R!2MH"P))9BQ<R)1,:@P8F/PF.$W&XG',MUVE
M818.F@G*>;.L3A9(;H9+HWZ^._GX\'C(8'>7X`:]?YTL*(:$DTAJJL/6@-OF
M9MV#[YX&/PB(_P":.,3>3#*0M8U%_.5\8S+V:ÙJET\<(4859`9=8M,7UY44
MB+"7&DMUXQ=K*U^TR5BA4=>K0,AT+3$@3U],I(E;63\,S,CX:_9[ZWC:[K&H
M2V9WBJW*N:9OU@,:V1FO/-?7!G3GF.GLQZ;#31&/R,9-3%#'77:50OU:CZ[9
MG^7L4K-P7@?/S*TTTGC%8D['>'C<?4I';Z,5NY.ND%F_MQ-@HZQ#NV04P.NF
MOLJÎ,<'S^LI;U[H`6VI$:REL*?*"\S6TIF4\AL#39/),\+9M,.H`GL8,@P=
MT1.U@3S`XUYQ[IXN7+"F+Q^$>"A2X2`HL)F'8^H8%$;6QNC(6!GG$LIC/F2<
M>QCKEB%4LIO<*%IL6K,9"NO=:8BI30^P==M,.HTH':J5R1?'PJQ78#D/6#DN
M44&MJFC!K8LQU$@,)UB??'WJKIU:YW$`:D6R2LK*5M_>+4^1ZJP9[XB=)]B:
M^1%AI0Q[1!9]/4WT;=#=NTDQ-(7)-9#(D#1$HGEQC\6@W-1CJ56BEE@H988N
MH@$`QYB(";C$-2F(C6?=[%9]$@KH&J+IF4+4,#N6BS8/P"O(-*N\_P`BF0V?
MW`\1_P#$.#B=/#ZOC]8_5RL:<7O4MDE-17LNKTY0X;%4\@(E7?VMA?RK%;!4
MS[(&#Y3MLO''E,?9JNM?R#,M6?<G&8U"VV(^D@@+F3B;%FJB%0AZ%&.[>9]/
M8,S,\5;U1G5JW*Z;=9L1,0Q%A8N2R(*(*-ZSB>?Z!*TV#JD4CJ]8+-@AKY^G
M#1-8F0\HF1+3\."[=?G;,$][")UFP<?GL6&R36E'NUGE[N7WK:UE*K%=X$IR
M'K%J6K.-#6Q9Q(&!1XQ/'_[>PO\`W93_`/5<3CZJ55</FV,?22E8J12S(KEE
MRL``,""\FA<O&/\`"K;^W'L3VERWC+&%0]<Y2GVY-$LJ*.MCH5<K6JQZUT@X
MID=RRZ4Q^:.*6-J#(5<?4KTJPD4F0HJI!"8(IYE,+".?O_0_A'_FCB9C0,9Z
MD.-8Y0%7UÈ.D3^ÀF*2?Z.NC]IWLM=83^FX3N,6NU4LVJ5JSD;'3C,5UW*5
MA#NPKJ`$M#7:;]VOF2,\*KUU@E%=2TI2L8%:E*&`6L!CD(`$:1'W#"6(FP0*
M0`SZ8F<#.T29M/IB4^_2=/PXQMVYC&C]0;;,DT;`W)3B*]++7U9R#:JE#J5F
MKB28,<F=,HG29\O!-16R5P*[:X9`PKPL,<++5:I8FQ+#@R?4=8V$H!,NK&V=
M/'A/7KY9!6;5>A5!E->ZQ=LVRQH5@Z=@]ICE1[4I/:,-*.>SS\:HK9BXO9O-
MM:DOIJF*MNTU3)=93/6K#C[`,&-=C4&$\XYUDXK&9?*]Q>&E!I4BN!;K]7'@
MY'=.7UA<YY;(\L_+\^R)$IHU:0V3BR#FV7.7*(H*''V,DB7!,$1';JU^H`Q_
M"*"XJ]Q7RRBN5^YKKFJDFFHZ[;=/R+M'(SD:R").O+EH>PN7!ZT,T#%+-K5,
MJ(@E)&Q6H@YA#;,(4V_;!(Z21;M9TV1NXIVDX;,6&W1@EUM*BYT&M;;;T;-D
MA.:5NG-8_P`6S$CJ'GXF@I.6;>W]M%0*0[RR,,2#<5#">->+J>X$IU.$R/PG
M.G$8]";JVDRZH',3I5EU(BDZW4DA;%GMHZDQLV1X;IGQ^Z(\(`LR/>XD5@8[
MERAF6HKO=71;2%,4"9O*!D@'68YQPT;J[ZG!EJZ\55H8];L)>QQ>HKB<F64R
M#*'5K!7P@A*2(ZY3&TAZI%(\?6O4O_$C.9$,?DJF0HX'"TL9Z8P`$G(*;55>
MA-VMELB*>7QY-6Z8\/R\?O\`+?\`?F9_[?Q:Q!1;M5+)G9FPTW6F*LR)&NX]
MS9-G0RM94B4S.T+E8_"'!'Z'75AK79VQRN*<=CQ@*:;R678)>]</$ZPE$KU\
MW"BO/NVK'UE-E.9#,=+'T\&%^PR_C[.%[@A?8R%:9Z?RVB/67$F';CQ3SN4O
M>J/5^<IY*DZID/57J&_E(J,[@-3JXE>/MX*O`QX0-"-/V@^+B8G$8S28TG^1
MK>$__=\6L;;FMC\&!@-&[9=6IU6];<5.!)K%BR_TUFBP,><Y2M\ZR\YC[B8F
M(F)C28GG$Q/C$Q^$\*KG3JG70$J2@JZB2I1(.K*U*D=BPFJPEZ1RV%(^'`K/
M%4K6RW>OP=VNJXWO,D\K-ZQU+`F4'8<6L_T1'NCAS3Q&,-M@A)["HUB-I`HD
MB3#E6XB%)R,?WLS'$5@H5F!NLF16%!9:UEQ]VS;8UKH,V'9L9&P1Z^,N/]J>
M.GD1P^/N+7&=C=CQZHPR_4Q49`"56+YI9"TI>L>?<43ÔC*6DVZTM3ZCLX._
MVF-R&0L5<[B<%$V,>JO2HV'(7CL!3G7ICT04!<_BX?7P*/3E^SC`189%3'5O
MDKN]1B'(;VPK:LRDXW+DH$MPSI.L<5<BS%42MTEO75;-97RHL,2UA"&W9U=]
M<="TW#ST\9X\N%Q0^:N7+'U8\U11(K%^Z\:Z3D0_9&9B.'2[#8MLV`Z;Î0J
MEU@ZO<;6:J\\=?S\_P`W/QX$J]"G7(2(Q)-5"I$F#L,AD`B8(QY3^,?>:SRB
M/&>/IV'K.O4B<L;^:!P5,;7!38-@T;3*]KZK;U7IM2LDQ/(VA/LQK$U*N5JU
M>^BUA[EY^.199:0"Z=WN$)?JS''!:#(\H;)C\P`XQE.[:F[<J8^G6MW"W:V[
M**ZU/LSN\VKV#)<^?/\`0V6[MA-6LJ-6.>8K6/NCS%IS*>41XS/"(#'A1P"W
MK>=C*A9#)9/HGO7V..6ZLW'(WQ$]6U/4GPZ&D[_92MU+%%5BI5RM#IY/'_4J
M1U\PNJ#V]"+%:8M([0=L[M"`C">1ZQ0QP,8X,?2JT@:Z=6M&J@$"QL^]AP&L
M_K^]3D\PMYVZU`,?48';?R8KR]#-1:J]>J\D7.YQX#)Q/[J2'WZ\&#_K%U+S
MFS=KY#)3=1>R1T<_09EGA82SIWF*]1O*>CTE=05S`1MYY+)XVQDWV<I7JUK$
MWGUV^2J3&"1$BK7;9<3&SYG$V5A\M>Q<;?T":MU(6*Y$!&AFLJ9TR@Q%H:[6
MKW1S$M1+WQP(`,``1`B(Q`B(C&@B(QRB(C]&'J`![#%@[Q@MK`YB8Z^!C/A/
MZ,5F]:K4JP2,%8MO572,E.T8)KB`(DBG2.?`=.S79U"@%['++>95XMB`:%.X
MBJSU(C_!^;P_0#<Y@*4H2-C6$(+6`QJ1F93`B(QXS/%8`R>/,[H=2F`W*Y%;
M7K,;ZPPS5X:C/,=?#[-5-M-M:+9K2.1A._'ILO;"*]>TX"DZQV&E`@1C"Y(H
M'=K,1]T-:7*BP02T42P.L2QG:3!5KOD(GWZ:?;*Q=LUZE<=()]IRT)&2G:,$
MQI"$;I\."IKNU&7!"&E5"RDK(K(1,6$B#EL`0G$ZZ::3]]"84=JX80:ZX:@,
M`9RH&/?L.%@;8VB(PQQS\`%I/!7K>3M8HX">Q56Z8H44Z<GXMH-BR@Q^*;#.
MO/Y!K3P=CU%@\G>/>M%$_2="QF/K%MQPNO3KT!F;F/N/*?A=,UX_P\\*S/J+
M&X+TKV.13D/3.!:3L[=2LJ&2Q]N?5#Z]FK1FV]-^#4NI/\J8<V,UF.,?8')V
M;#*.6/)[=;"J9]3TX6!-"\<-PJ-?:9RQ90$D"]%>$;OT"^37"E=#M\R<LKS;
M2<8.TG+]"S4AB9LUK'9;#""&9&>,?ZOK90X5ZA_LUZJJU4TYI417]7GU,"#H
MFUIP+$61CXM1L;V_FVQ]C(_T5?\`3:_W64R4I`LA;SN?78NF,'98FEF+E"HC
MK3YXKUJE58`$>6('\=?MU?5=]P!7]-Y&NZ4NH'DZU@LQ/]G5"RHI]=F];<L)
M"<3Y(B>6D\8RZ.6?:+'6S?TC7`5B6?IM."F%(@S[=HFG<$[I@4ST_P"^^^=_
ML&K_`.(7/9@?]O5_]"O_`'^5G&[OJ,8V]-#9`R?>Q5;VNR&:A)=?337EQ<1:
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MCQU,LE!K%)1>Z`=U$K"(`?G:^$1'ZH]F1_HK?Z;7^ZM_^8/5/^\F5^P:\(1A
MD&7<0L3!D*D:IY>B.1+JRFQTAC'2W<4`1#'.(UTX"+XYI]ROD*X4%5%478>Y
MB59JVO+3E+C*]<RLEB`_ES/H&?R2$=\MCB8$M&#+!)9:B6J2A;ML%$=1:VSM
MWCJ.OOXRGH_TUTW/MV<4QN9L22\%2G$YFAEF(.X`-9<L.['I;:X-Z9%\R1TY
MQC+]=^$SFV2^DY'9!V("-6.Q=M9%3RU8?VDE)!'[P0GEQ<]&^G;?U7UP6-R+
MTT,=69D58AU>D^Q7//6%1-'$==BX!(637+6D,>$Z\79PC<TW'5*>1M8U^8K5
M,=D[5M2,*8UWU"P93;$7LLPA1!4ZWGCJ;1ÒNZM9./761E`R[L7:*YUG'7PF
M21C;YW*<51[%^MD6*'>V)TV,E9\N!MIR+D940D.[Z8NKL61]::KZ13$-I"XI
MD(WBU<3H+(X95M8VN[Z;&"C-V:]TU],_4&09CZ18RFZH3+HB8;F01KTUVA+2
MB8X&UF+T]9,M*A3QTRJECF&LTC9WL'K9"\M;)T-L0H9GRJB>?$Q87-E$LT!U
M<2)JQ-C>F+4^8RTW*7$CNDIW&6V/T"X>FC`0<+8,R#5=7Y+)2T)AB2)1R.HS
M$Z3PNK3KIJUE1HM"%BI8>^=`"(C69YS^,\,KVD*LUW#L:AZP<EH3XBQ3((#&
M?PGB_?Q&(J4[^7R&1;DKXB3;]SIY"PM*WW;!-M%6KK6(J5NZ:QC08C[&4A2F
M.,$"_I)"6-,*[EV&0I8^9C.FN=!CF4\HX"U0M5[E9GP/K-!RY_5O7,QNC7G'
MC'L(S(0`!DS,I@1$1C4B(IY0(QPNP&2I"MH[PZEI"RD)@"$]IL@A@@:!<^>A
MQ^/"$=VF2L*%RCA@=$@8SI)T=KTY*PS6%C$ZGMG3PXG9DJ![9D9VVZ\Z2*5V
M"CDS\M=P'_Z)1/OXWI8#0W&&]9B8[UF2V#N&9C<M@R,Q[ICVV_\`S!ZI_P!Y
M,K]K&`8#(V,I5KVXYCW5057&]H^0TEM;J^:5EY)]\<"M8B``,"`!$"`",:"(
MC&D",1QD4WJRK2PJ67KAHZRIZD,)3TG&C$6%%S%@3!C/A/%?'>GL33Q50@![
M0K+^99L,&"99N63D[-VTR9\S6D9S^/W;K>5<UE2EE\A6J8E)DBANQ.2=63:O
M0!0S(NDJL'`LGH!/@O=&[BS>JXÊ6N7)F;=I%9*K%B9+>76:`P9[C\TZ^)<_
M'V5K]G'TK%ZGIVMMU9++%?0I,>DXADPVG.L:>$\_T%/U/(5*'<$0I[IX)ZFS
M;U"C?,?+5NC>7PAK&LQQ=])>C/2UF]-2RJKGO4_J#N<)Z7QL1*G/KT&RAE_U
M!D>C/(:RN@$E$DW3EQ8^KJ/#E543W-M%KCB2)"$NKY*(&NP=QQ&T^F[G\'""
MPZV9MEN&37BCIVL=(R4TKE\_Y6D*7#(D)3UMT3`@4Q,<-J?\0L#],P)7+3*/
MK;!,LYCTXE5RTVPM'J(.W5D_3[U2_9+V**F<\^H'PQ4NJO)R"\B&_%ABRC).
MRL::Q.-73ELVPT\3'Y8QS(HCGQD(Q_UI-UUV[JP[=5>"'`-B/I:J(J=UT99)
M=/JF,0S6'ZE(RGAU?.,-MM63R8I839?!8^;;"Q_3>R9L-"*I#&K9EFOCQDV5
MW,KNE(J%Z2V.5W#EUR8DXYK<`,G:7Y2Y\12Q=*M0JP1,Z-90J$VLYM>W;&YU
MAQ<S86IF7.9F?99I`8KBVHZS6$,E(H>,K?*XUCYW2*=FO*"\=>&&W'"SJ3ND
M"8WI074>PB%>_8,EW$Q/][$1[N*JG)M].E311K@K(WDB"*W5Z.HK>(F82Z9W
M3K.O#'MKO,W-!S-;EG26@4EO&(9$+*=TQY=.7]SBMCZ@R%:JN%*&9W%MCWD4
M\S.9\9GG,^RS11D[^':\1@,CC"KC=KR)B7RILU[*M#TVEY==LSI,3I,5JW10
M@J#\CC&#5AD(8[&9&W0=:"'&U_\`.,KRV=YF>I^8BGS3]A&.LY&HF_9@9148
MX(L-WR8JVKUW:N)90O\`PDC,#K,<4['IGT@VIZ1QEL[3,]ZM99P-S/L2IZ5I
M].X7M79!=>6,U[JZ"0*(T$)^+@[.4)F%E+@KN3E![<AL'!$"T,&3KWH,%D4$
M@V#MB?PG2QB_3]7ZI9M4])OF9(P=-5ZK!HL.R4`R+F]+A,558:91,;M@SNXJ
MX#_B9BX]%Y%DKJ4,[#RN>A\ZR-`#Z?Z@(%?3;+=->UOC7;'@,L\>$4@,[EZS
MTY74HA-IH(:0C%RSTYV5:0P6O480"6F@ZERXH)%N81,]M_:1N3RÌJ,R@KO$
M]F%9C'Q<1AY/;Y5[!F)3Y=T.XPXYB3G+#C:8Y*6=/?-X4!%J2E.BIU=KX?9`
M[CMDM+970M;;%NTR/X=2G7!MJTR(]RQ*=..XHV%V%;I64A/F4T?C2]9:-0]?
MY@.!,??'#;=VRBG50.]UFRT$(4/AN8UDB`1K/OXN55N)=MF5S>254MU[%&T[
M'7LO<L5+Z*UQ2'/I6$M&18,2'/377E[--8UF)F(]^D::SI^$:^RYD+,E%:A4
ML7;$@.\H152;VR(Q\1;`GEQ:J6L:[%W*M;'W^@RQ6M"=#*]W%)T.JF00WJ4'
M`P/RD'*2&8*?NYQ^,HG9N;@5UV*:VN#F*ZXI361,6+KQ1YRU)%<!GSO#AM^_
MF[U;*,D)KRM_<)2N!G5%S&ZCA34<S'D4F&KT_PÌ.9W\+QV3QX3<=!E4M4&Q
M-"\"25W$P%@QLTK"4LZG2/<)1&@M*>.X/*C2M/Q=_"VX537;3]+RH4INUZ_7
M)>UX6*FY3BB8T+0UGI&B:RM>E74M*]TR1;%!`!J4\RG:/CQ-3KG58%JA>K60
M`6]&YC+U?(TV&D_(]46:H[PG3<.L:Q/.+0LLS<M7[]K)WK'1&LMEJU([NA6$
MF0A(+6(Q&XBY:D4E,SP0&(F!C(F!1!"0E&A"0SRD9CBR/I[!XS##<L-LV!QU
M1586->6]G)8Q`+D^>P=`B?"/;D?Z*W^FU_NK?_F#U3_O)E?8Y6'A=1";%FF[
M+7%]31]1S*MD*%#<,O)3U$/4:0+B8U@61QU\=FLEWLZE8G*O/)4[Q?X^F1)5
M3\-([/MH'\)CEPW''CP1E4*6YL38AN/E#^Z&M;2\1!YUW/IDN8E8N64ZR$CS
MX999E3Z%ZQA+66K135ON/].VXN8TD6>IK2$C4N'#`G!;/)TY(I]F-MU+O89#
M$VG6:;SK1<1_,T[%&PM]66HZ@DBS.DB8$)1'/349H8FN;&*H5EUQ8W;U&;(\
MS#@($!DRYZ#$#'A$:<6,=DZ=7(4+:R3:I74+LU;"B^);D.$UL"?PF.$8O!8V
MIB\?6`5IJTU"I8B$:#KIYCF(]\S,_:DJS(4YEBE6%LKAO2BU<16-@K(A$V`#
M9D=?+N\=8Y<!>Z)V+&3IJ*S:OE%JXY-A0LFNQLC`"B-W[I8@F/<,<*N8+)OQ
MTZK6R#,FM57'3R5[#.K-E"H\*UP;*8CDKH?%QCL[GK+,YE#17N5^Z`5XW%L:
ML61]*Q025:LP-VG6/JV?\9IRX*U5;-&_U.X@_FLJG9@1"+$I6ZN^G;V#IW%1
MM:S^)D/EXM4<EZGO=&@59$C0331;;+:52TP;&6*MUW@LW2`&I55LA$24R6L\
M%8Q"QK9E9=:OE+3;%VTUH^->_=LL?=L4;(^1@2<\IW#H4#,0"+M1EF"R"+"$
M6!=T+>'L)I9>M)Q`ZEC[CQ6>L1\4?CQ7PF):BSD;$J;80+%L^2;NC3IM'S[0
MREL9ALZ>6DFR?B$<="E6KI-@I[IJ$]+N&I2*1+;N/IJ`1T6N)V*'RCR^\SO^
M=4O_``VK[/3_`/\`FW^BK]D6<A8A"C:"%^1C6N>S=()KH0#'V'2(S.T!*=L3
M/A$\`FOE:36LQ09L`%X<\0;22.0\=(K=89'=[ICB"&8(2B"$AG6"B><3$QRF
M)C[.1_HK?Z;7^ZM_^8/5/^\F5]ES_P`P>I_]X<G[,A/_`/7L/_XEG?8GZG=7
M4Z\-)<%##GI(V=Q89"@.4U*W5'J./12]T;BC7A:ZUM+C<%QBH66[J+Q]H*5T
MP]TC7M,@"_7/W,F*W-Z-O'/,$*-[NBC(5FN,$J@FME:@DMHQ)3IRB9XQ\5[*
M+8*J5T2ZN>]1&A0*9$>!#,$/.)B"CWQKP*H,[?\`,16<RJ/54ENOFKB0;BO9
M'3PJ5H=9U\0B/-Q1I_,1>IX^F%JA:65:[7D4+"9979H?3W<H,=0+W3QO?O8P
MA8:ZZ8'J&*M.JPC82Z]:NK=&]SC6H->91QD;UH;5&I>L56HNV:=I>.9`XVFA
MA!D"3".B+U%`L/8+(C<&X9B>!MUC7?ZY"FD%5RV1<LLUZ25-"2#GIJ1>`!$E
M/*)X/)65]X=FODÒ8^T%:UBWV<CEPS!79KNK<[=5@0E;.4R@0@M9$9BOD,5B
MJ*;V+85BN-6I70;E&N57*8RM8Z%9K%,#_C('7EPJP@X8EZP:HX\"6P8(9_'G
M$_=6;9`3>@AS00O3K634HVQ70,_&]VS08]\\.K=7%!(4,3E>]P[RO)4G+KO2
MN@1.';&0IMI1)ZQHU#(G:$\=>C:L4K>D#+MTV5V!'7IKNUW%MLBL9VP6HM@>
M4''$XD4XS_6[/3XIEC_J<7`P<Y>,R=+7_4TE&W;NW=.8/J?DX4>6S6>'-56S
M9QF=P^1?AK.%M2'3WXFK6,J0*()VF%@+/6#DW?PG#Y_"CZ_QMB25CO5OIV:&
M(R*C@")2_5>#O6J].OOVZ3<I,)7XI&9TX3=RV430R56Z%_$HQ-=3ZN'+M+U!
MR6/O*ZF8*W3OF+3($#'+I@$QN('+R.7[T#&>Y:]3U.5$HLE5LX\E1CG57Y6O
M%I@]*-S)F-8"=O%6F$[AJH4@2Z24[H4$!KT:RTUU1.GP@(C'NC[-3NK-KM*K
MEV2QRY4%2Y80P753N3T9LM"NX(*%PP5D4>>"^ZS#I70MT)N/OX]S;;*K4.S6
M75-D,FOMF!&.Q]G(FX[('J-<=)#6-Q7P:^FI=#(6,8ZWB&,--\EUU,)U%YZD
MI<!=@"T+>FT@QW''$OQ-R:?5?+[5-Z^ZQ]DVLEEEL*WJ;4LN(I+>HQ"3G<8'
MQ%*G]'J-OT\A=K3N?>M81>,RM;'/KYRE!U_Y^PNSN6.]8BU3`G=`[I5F,=ZG
M]283UE6`@3ZJKW.X)P$?5[')X)VF!OX?J\ÛZ"Q#Q"0*9*7^G_4OHZI=OJ1U
M*'J[!Y!-?TEDUP8KW9&M<8S-8.\,%N)`*N07/86G$/R6>:.2=3R.,NNQM*I7
MK%B,H5<WXVLBT-QBN@5:.D\C-NI%KK$P(KN8U4J<NKDZA%HO5ZLGDU9.>N<!
M!L*L:8!<Z_!XZSS^Z;9IN9B[[AVNM516:K8[9#IY*BX2J9!<C.FICU!CX3'@
M&+#N+@*Z$7;`JZJT^/;U%J6JMCJG^)K@M?XQ,\^(82%,MU88R@XHVMKV-DP)
M*=&AJW3\6DZ3'CP=7U<7UBM0I>G1Q+[MOOVMM5*UTKK[RC^6>0K/MPKKSKUX
M4#?CUTXG.XBF-3*58=-HL:H46<A0>$KO*B%0,-OK7\ZN4Q)=90AKL,XE;]ZS
M:.@/E7[HCV`P7IUY]O;0P7*_Q;(X10J:S:>:C(0.0+9U-M>OO"=R^^L#H4^(
MU@<<?!Q'70U[RU98?WEY/7L,*6/=TDV@4KJN*2VC$#&O+A5_$5[)!O!.2I`^
MY;FQ4:4#W"4N:[^9H,GJ>7F2MX\YD>-0(3C68U&8*-1G28UCWQ,?<4L[D39D
MLHY`6$NM;95CNX7$RK&5!B*].(&=LLB.N<?&9<$-="4";":<)6"H-I_&PH"(
MW,/WSXS[.YZ*NYZ?1[CIAUÊNW=+JZ;^GNYZ:Z:_9+88EMG:6THG:7X%IX3[
M"&"&9"=#B)B9&9C6(*/=,Q/'Q#[Y\8\(Y3/]R>-FX=\1K(:QNB/QV^.GW66O
MUMG<4\=;L(Z@[PAJDF828:CN&"CPUCAMEF^]>L+E-B_>D7V6I*=2KCY136J3
M/\%0@K]6O/@$H4M"5QH"D@*UA'X``1`C'L:U2$K98F">Q:P`W$,:"33&()DC
M'AK^B'%2YD::C8QO;UK`BA9-,F'"A-1R"]Y3H.NT?"-(Y<5,P=JW<KU)-5R+
MC`;VU:Q$!.05M6O0Z4_%,^%=C?9DJLV74SR%5N,KV*PR=E=K(C-*L5<(-<DX
M7.B8\P^'C'CQDGN1BL>-Z,<`8K!PV,:@J-8DLN1U4UY[N])Q!Z!&BU+C4IB2
M^SVY=>W<@18=+'IFU92DIB(?8$9@*RIU\N^1ED^4-Q<N.O2>#UP4K/346*:/
MQIL).!=7>'Y@,1,??'`'<=M)Q=.LA8&^W;;_`(&I42)V++?U`,Z1SGEQ3QNY
ME7*4J*!LXVZ'0N#"AA1/4&XUVZDG')R"8KW;M=8]CJRK*&6*\!-BN#EFY$-W
M=.7*$I-4,V3IK$:Z>RWDS43XK"O:D2%?5<]RZZ`)I^1*R<T=QSR`=2GPXR2;
M50*=[$9#Z=<4BUWM66%2IY!3*UJ:]0F`56^&L$L"$]8T]\^S*EB_45!]I^*G
M'V&TXHM+'9'ZGDK8/)512.MY;6V>ZECM5_%IKQA:]_U92I,Q=XLG&4O)37B[
MG*S)=@%R!.!2T5V3)'$21E*QTCQX&.GZ=<3)?5LWZC'#E\E$6[5JQ?R!F$"V
MS78P`)7S)WL(NH$>3B_2+UM0BIE@]3T<NFTR;`4\7>]<?VOOT\;64=%@1V/3
MKV^J[4>H4Q,1I'%*YF_6&$R&<O4X78KUW*KV,OCY_P"'L>EÒUW*%>>(K-ZO
MW1`-@JFR2F!Z@P?%7(GF</96ST=C,0Q*6]S>R#<5C\#C.[K]=/6IT*S<8V9Z
M;3!Q6(W@)!J7VIKZVK719*KCZ-5URM09`R73M-3!?.B!F26O>Q8QN,1#S<+L
M57*LUVCN4]#!:I@_M`P)D2CC)XD).UELCB[@4\94&'7&0:3#KL'<"ZE,"^)[
MB6D?>6O!G2=JQ$P%JHY;*UZDR8UA5VD\0LUCF/#<,04<QUCG[&%4LU[0J:2&
ME7<MT+>&F]+)610#0W1J,\XU]F-35J!<NY?(?3::GVNRJPV*5W(,.S:BO:)0
M#5H,TVK,B/2-.>L5,F"2K]S#(-)&+.DZNYE9X"T/(]8O26QD<C'0O?[;;,()
MGDÎ177A8`9Z/R%5+R&&IL*'968<[B68AINF)B.$G>PEG)Y+ZSE:+EA(I8JE
M7OV5T;;&(HPBS#:@A/4!20/76(CBVK%XNX6""HK'1>7C@N&G*F5?(6\HA(MF
MY;KT\.30`.E*F6Q@-TEY.,[8P!W\MZCI5SL8KO<&52W=2R^:*;2H+0(L!HI9
M$%"ER0CU.E$3&M!5GTU<^FU?4F<3ZBFEBRN5EX6Y?##^FOI]YH8Û>&D<G<<
MU-<R-`QO$!G=QBQSU4P*QE/1G?=;""Q\8W.8BV[,$JQ370JTAQN14,&#$-;7
M^$SG=!<97(9RW<*ZQF<=B],&FMEJF-K=5&,EN*'Y5K)/&OW,+TB)ZPK]VL_<
M8ZBG$#3=DGY"LJ]E;$U\2LZ63L4H;UUB;&J<%:=L:!)/8L/S:Q2'T;@/1R:%
MRDZ+N?\`4N7O7:`VE7K^/LHQV%QE-5K)U#"J+DN8Y"W*</+QXI5[7J;&W;5#
MJ4+%I.'K&IK*K"7'3[3U!=$``-!B#/J\O/$%QB&YJXB[C17894E-&:8!<A;!
MNM=K:L[[-/'3+4Z:1->+6L20A]FA*&-4%F[:7;FN0JLG5JX#-Y64U[!`WM6.
M=C@'J0,D(S.W2=)AE%=*OVC]W<)8N'C:EG[P[<NZA6V,_,3)(B]_&1S>%R-B
MB='%WGBLM;!AVE-KJR%O:<D^@+0C6O9BPL`_<]&>?'>?,MY&RH>XR=TNM=:,
M^?I0>@A6K07@E0K5'[/'7IZ8ZU#IM1TH/MIM3XV84EM=U*X7OL565WE^8BCR
M\6OK&7R]]-7*97'*J]T./2=>C==55-J<4NB^ZTEK\_4.0*?R\5'^GZM'%VZ3
M=1%*1K5KE5Q!WM*YT%ZD-@!@A/22!P"7/G$KNULQ5&JVJBV+K930#I6'WJP"
M7>PC8^'XUPDN?..SG'AP&"PU^G>ITU0W+E6=7NUF=XMBÂ9`9:E]5%*3D@."
M`[#D>,"R.(JXÎ7I5A(CA%5()7O.=QGM7$1)G/C/C/MNE6S%GK7<.6,Z^T]]
M1OU"]?&Q1^?$UUQWLQ*XGQ&)UXQ.W*5K]W&5LQ2-V>H,R->TC,]+JN-'>"R+
M=44"(3OF)41A.D'K&,M4LFZXW'EDE$&0;;-+*N5MXXG&M/<&BO<35IEY@".J
MPN>D:\9>\GU-8J3G+GJJ;J^V;92K&>K)P:K]:E4?=*C7N30Q3%$_I3U>MJ0S
MMTG#6[?J`L@."/T_6IUVXY2T/POIZQZB[.E>2MW2987C\V"08$+`.WUV:%MC
MT_F$YH&(POI].#.H-$U]9=8,JI"J^ZXRO2I_UG#"B%R[J)C1FPS'[6(PS&.C
M'7J5QMI-9LUF6&C?Q-1(MLK^?%40N')`$A+)TU+;K$CC64*O8KV]*L*A6I$A
MS`Z\+@>W:LIU$PT(9YQ.O'=XO,W*RKV5P=%D0*F6=N5S>/QUDG,<+:UQPU;)
M2M[$S;$XC>U@^7AR:U>/YJ=UUSY*S:OG,2,LO6GRQ]LY&=//,Z1RCERX1<QE
MEV+[?71:-=:RIF2(<4[=#*"]><UIZM`_S5]?-Q1MYVW>S;+52I98BX[I8W>Q
M`,D?I5$:M!H:E_%!I?KX+U$LJ^*Q6/J%&;0FHR4-QR!,DN35HJ,^]I-+R;0G
M<LB&?R2+"/,XY`K=*=UFVBL)D*U-U23S7#U2MPS!CJ,Z^/':56TLIA*L[[FG
M;7Z72K.8M8Z3UDQ>R.25/3+XU5JDD.G7&>%HKJ6A"0%24I`5*4L(V@M:PB``
M`&-(B.4>VV.#DQR9LHK02Y`3$&7ZH6BWFFQ"X&H1S);#D8YQ$SPD&XWZMDQS
M&4K.Z]NLK9BUWK,8^P%@AH1<@J?3\W3`R]XZ\9?Z-]7[H2&,*A%2DS`LQ,X;
M=:?:L,23(RX96&PL)."DH3$!*R9/'K5!K_KZ,=DK'I;Z=7EE633Z>H=L-=MI
M<`=@LV\M`=\1:_ECBN/TEUH*?J''9;)%C5X^*=STQ6]/>EU7L)3+(PJRVW>R
M=_(.G;'5%]7:,]/EQ<._8O[&7?35NLLZN+MR=-OKJ[2SE.?ZOHSC"'TKTFR$
M3:VK\XL@YF./6QÎ:EKNT7KD^F5V*]"M)#T[4JIHZ8UU/4LQ5HTY-1;^32\V
MGW!)=4K-28R!*:A3%D!'#2$@(9&1ED;M/QY\=>X]%&HK8H-V@#KIHJO74,;F
MM+30%A$D7A$<0UW<_P`P^Q86-L,@JRM+63*@<G)V[EI!0/Y-1@?V`\.+TUJ:
M;^0JH;>Q-=\>0LM46;L?^=>FMD8B?-$$,S$\IGC(A:9DK.-3&/\ÌUS,8H,-
M?*P=<YR=7L@J4([2HR%],Ê'F,PW%`1/V,?L%LIKWK1W&)25EM>M;]/9S%=P
M%5?SK/2L9%<D(:EMUGW<=\FY693B)DK4.7T0V?'U&;MJY"?BB=)&?'B_@\71
MM9*[D\5=160F-EAO=U6(19A+=D5L=U6>:U:*NB8_=DR>7';A+*]ZLL.[QMP.
MWR%7E`[FURF=R2GX6A)I/\I3Q'469L+;LW0Q:)(YF%KA@J:VS89(SM166^P7
MN#3GQ9/)XW)XP;F4RN145BM#8&M>R#K%?NNQ9;[)O29$D+=FSPGGQ2K8PZ^1
MOY-A!34IHL2*4;)NW[)JDME.BLXW?M,(%QYCCA[Z56=UFEB*+1L'W"I'"IL5
MZE@5,B07<8FQ,.8.DMVQKSCA'J"JG_5(G&12E<;K&#9,%>@0&-3;1VQ97$<Y
MZ9!'[R>`:I@,4T!8M@%!`Q9QN`P*-8(2&=8G[[#Y>Q))QM.E<58MPLWÀQ9#
M$6DQ8A>I(KL749JZ8Z83'FTUX&XRTB*IP,K?#!);>I^[Z,C,]8F_E@=9+W<+
MQ6,Q=ZZRGF,#>M="`WU$XS-4<E9F_#"6BBPJM4NE7-G>L*8^3`^;B65FPR!+
M8P="!J61XJ>AD"Y#8_9.(G@<92Q]J\SJ2NTR!)(+B.3!J"82W(/'WR`Q6#^(
MX)Y<4*>438QC:U.I68=I>M3J*0`%,7Z\NI0.X>6XQG]7'T9>VQ4<L+&1L);Y
M4UX/?46EJYF)LV7JUCW0L"F?$=;":56.G8OW,AM?H_H-O,ZK4UI9$RBH!?NU
M1Y5CRCEIPO("`+HY<Z]+)R(P,*OZ#7Q=]FD>#HTJ',_XGW#/'CÂSD7D[(Y+
MS[+U\A:RLL_%%%0`NM03IRGI`,G'QR4\_N"M*9:QEUFWKV\8P*[+0C^6XIBG
M5+4Q^4S635_D(9X)5)$*ZARU[)DVV+3I^)]NTXCL6WE[S81%QD:8J1WS\=D*
M5.TW<ME6;]5E5O3M)CNJT,6>A2OGQD"S#Z^3M?5'GBLA,$RX&)^G8R@@+#&K
M&576!0_F.G.QI^?Q+2.)S^.F*-^LO9=MI7\PJ0O7:!]CIQ#+2L;;2+F+G7J5
MNLOQ..$VÊ*&SO3:K3.Z:MRN9)M5]\<F"MX3M./*P-"CE,<4?36*:Q3]\,LO
M7K'1;TX;U2]Q*Q%-L62B?+-IM,)\K"X163A<6*:ZEH5$T:Q3"U!`!$D2Y(I@
M1\9Y\!?J)KT\>8RK+`H4U:Z0&"-&3./EJ#MIU!I?X,]9_=QPNS3L(MUFQ,JL
M5FK>AD1,C,K:HB`X@HTY3]Z3*S;^-0XY9;H8VV5.C;87Q,E0#NI..)G>RJ5=
MC8F8.2CA=6E735K*C1:$+%2@UG6=`"(C4IG6?QGA":KNPLQD\5;;?09(MBK&
M6HMJV-6,DTDO&"%9_++F)>69XK)RTTVYB>N>1M4NI*7M9;L/'IF\1L2E8.T`
M2^".7L7E:"]E:Q8#O*J8V+9;(1KZ],=`WY*N(JB?_>55_<1\+<HMZV@+%E'@
M0'$$)1_3$\,HZ2>(QX,!X%'RG55V239-H3&T_J^3I%65N_\`9:=F?!X3Q_J?
M%?\`=]3_`-5P_K,JX[!O&+`M<U%.E0NP0*:C5DK4I=Z"$PB/XD,_:X%BR$P,
M8,#"8(#`HU$A*.1"4>$_>^G1QN5;ARQ7J)>6M6ZQ+BU-0<-FL?*JPV*EZHQI
MOR"]8:N0V1,_%`\&FSZEQ!C9]'X;T0Ô!Y4Q5C\+7PKD9$6N$Z]BXS+U+ID!
M5AW+N3!,*(V1ALI]<2S$XRQGC<H7NZCZ=RWZE/&XZOCAHHI8VKTLVAEA:3%'
M6IAM7Y1G[_2><3XQP"DNS"4K&`4E6>S2U*6/(%*6-_:M2QY",<ACE'%3-@=E
MU2XE6"R3+URU?91AMGJ8RTAUQKV(K'=;T;`C,"746<\E>Q.)$]MJY=HOJZJ&
MPD3Q-VME>K=KDQ77QPG4$7#N'?![(F"*.+O7>I]K)9*UE;4UD35IK?:A0RJI
M7EKR6H13&LR4DQDD<\RT_0GU+2^K7L+)30U(=P'&DZ&$B8%'N(9@AGG'/C_*
M\Y_\PYS_`+?Q;J[G,IÎ=MVK:M/?;LCE:%-5:UCFV[!M<Q;<=5!U<2*=O3?[
MM(]F$I4#5&3Q16,[NMUYMXU"65;6(7%]`6*KNI;[QO;R!:[D'/PP43C\2#BL
M11KBCK2$+WS&LE(*&2%"MT^1<3,`&@^[].9+4PXB==)D1F8UTY^[BB%NI
MCO2ZK6%Q^4/*9I16Z0V+%&U:FD(4<F&R;AH^3!L%L`HXVD<AQT:%GTEZ0P&3
MPU,[#+^-R?J+U+!WL:EN1J%CFLQ6*I=O8::ADILE,#ND8GR\8TK'J#*F^*BE
MM82L61-8H>D3C*QZ?INDW2&Z=RQYS_=X"UD+S[]*RE=7J6%U`[.FQRPAZNUK
M5A'M<DP1M?MIL*/PKEÂVLA3K=Y9056%UO\`#=>Y7KD$>=406QLZ3)0,3X\N
M+J6T:>-*E?KUZN(MJ8_)^HA=F&8YU?&/K7YK#:HUP$SD(L#JT=T+#G++5S-^
MD/3N$QF5KWZ=+"XO)9O.744[X'7BQE\@J:^-?82.A]#'V-L$0ZE&L\#/UW)Q
MK$3^YPWOC]>'B>,SC\G89;R=^T%AEYXI!CP%!!C.B*$I6N@W'52V!$:!;1:Y
MSN&9_P"0!KLZUK(6P/L\305W>3M\IB255$@VH&?B<PEH7^<QXI5F1M-:1WAM
M@)`BU.5R(V+8;E[M)T8<:QRGADXP&E>4^H8S5[<;XU)M)7EOIK+6B59%F(-X
MIF9CSE'/BQ]2[T0G(VIQ090UMRB\5/3[<,@Q9,W.ZO4V[B)D)V0<[]WZ(?IR
MK#K^3L]`7UZ->+<8U!L$^\RIS:I5Z28`=8$WÙO\,3GEP(_A$1_S1_=XQEBF
MF\:1MDK,EA92G.%C)JVB2FI8,TNA'U6$$T5G!R,?ANXQ@YN=<K%5?>S,JD^K
M[NL5?^7*Q`:=25_+EFNWEI^GF.XPU`HWKTZ@:Q\0:B<;Q]W*>+8X@Î=%@QE
M3M]Q];-T:P!Y3Z@(9+S1^[ZD0&WX/+^C618VZE?3U8S'0^;T`,P116[5;;74
M,8T^7'4Y^72>?`?0.U[#>>O;>/<\NOW>[Y_?;OWO6^=N^/G]W__:``@!`0,!
M/R'[Q)F,^#YF4K4#L[>CL#SO#L*$A>?Z1[\Ô04`GC'O;I0P]5#N/,`/6H$@
MC1'I"#-)MF@O3,(^!U@V2P(L*RSJD#>Y8ZZMX/'L)PR0KE57MB9>%%"(D@`5
M^#<I)VZT_"N2-'"C0@D9J@"Y9!ALZC%FJ*ARDAO%A7++A1EU"T3**,ESR7!E
M0A`G[[3FAÔ)&NVP0$E(Q*0I0_B<I6#GM#1-[F_&$Q3)-[?`MÈ11W\=8B0U
M4:5M6%?`7VDG20#56Y$%UB");K;#$RPY"2/6*@7D(A)L+4PE,U4?-B65&XU@
ML.H'@#=`5`!0=(5L>_&:4JI>>I.>!?L29SF$95HVKE4*<T]&'&^01P45D-/U
MKN%Z,'>XV_&Z3M#=O'A*^(PW3E8)VL)(.NV5-S(LB+KQ?@Q3FE=WCH"KFR<O
MM7*-8[P3%<ETHP193[T2"A<<7]!]4Q)G'#O+P+4^2DR607/)U;*/[(:2>]"%
MW4+,N%,G3/\`9_\`,;_!\$*U,3LXJ)B,3#_[S^?'_#!)BR0LX_:,@!GX#WQY
MJ_\`7`FC0:`\=26A6CY9+^+T+01V$%Z1%1MQYZÙUW0_0D!JP#)EMS-2ODD@
M+C<\`;32;ZD;0"XE(,6SUK3..&W.TPFJKB!3/.>>6F;DX6YX[2YHFY::+:K2
M[(C5-PK^+=29L`"K3'$T.>CK4,J"RF1_GVT8'*1,X5)N%=+*(ZQN&TSB&GV&
ML2X#0EG9LUI'^*<:LM+WVÎ.ZF.++#AGFOOH3$&0@4/;%=3!)J.T9+"`Q8M.
MB9.0/6(?Z"M>-JQ#&&E&@%:F2L)RJXAVJW`NKA9:U+;.\%JAB&(-8J8TCKM'
MNZ;4H4CBG'%1\MDQP-'P>]>_%!T#B[[9^'1PL7OS)Q`PFA;&+H"=P@7$I].%
MH1E?5>6NB;1OED!VS9E0J;%UMQ/6#'C0"'4RU=*PJ_8F9PA7<1TF),XQWXHM
M$<Y;[9OR4ET'1?5B\G1#]ZR#\KE,"A-]*'''9OMG($'0;Q?YIBRK14\9IQ/4
MT,`N`ZQL3THO_P"UZN7AQQ'S?!WZ"L#I?0>T&FH@<ZC0[ZO6]W=L21"4"\;8
M%"_Z$2!SLHWA:'B"'6K(H%H*^X'A1?9J!FN;#YP%;DV;]$9#H0U]&'>/Y!UW
MNQ`C(T@D.HJX'EZH2B.EPI^YNWT5D99H4@J5O03$6C#W&M>5,-%GEB"!Y</[
M)!NL5;''HE*TJY5X^!:20-9KL;`F/1DM)KL0FDF-7-TU4-X04T8G`&XOQ\&Q
MN$:#F>X*%JO<HCNP.>1)X6YNÂ^,2/P[.%2LF!(<8]@7.PG"`;!'0W2_,D$V
M$F?5KC^-FAR*SHLZ87@,+1-!;K#3CG]&<&^:`<SAC)[YY1->09=1@JV#I`CY
M'Q3C\M(R`.K6V^/\Z;@72-A+P%;#2IQ0*`%58`;570!C#&5,8A-[+A"=/\U\
MZ`%[7'W%RJW:!N$3-N38BR0CE`0UJE.&OKI0:,:!#;K@&Ì(ZPY1@>$<&5HT
MZ-`7;:GY'EGOJMU-G1*!"2;*U0HAX(3E-MH3=!VQ*A1%#72'G\$P"H6YQQJ-
MVG4M]FZI3`FH]O/CO1R1DL4+*1BNMI1B>*`R=60=.&&XJO'_`&.;5?*&WHS]
M`C91CCYL`P3VYJN#IX9D1E9I7D/QD'R14+''C$Z:SPF+SX<"04X&^2I66O;S
M72`F'2PF8/L#,XPJJB:3LF]!5Q=8TBI$(0ZC')A'+1)M;Q@IA923AH!?IQK>
M626YJLQ&C.R]9-?F2L:[3'S\_P"@@FIPURW\].`X>L_G+;3_`#T9F@T&SDC:
M(*G%Z%KK@"]Q<YHU'GF);27TRZ^)A-U&BDB;\>IN4"Q$(I#U82,7M/?3,F3A
M5R*#+P8<>B@D@M1[7\9:-B`(EP&6ODCC,<PWL&H729Z`Q',._"G%XWW:#K[7
MR)$VUGXDNX;SXKAXN>!_Z5+I_GIS$\I+R??EX\7H$U"5BI5NB1RVCQ*G8,+2
M5<KB2I]YFE5O`KI=(BN+WKT-6H%9HR%BE"YT`KHW$@=]:^TX@NB%6;<("SN?
MP.!&3O)27;MPD6:QU7E;J@@!&F1KZY.=IR*\=*O8T*LX;R(R'MW#*_[!1-@:
MF!*!QQ8*=1"N[!S?(`!`H4;`FPF-UE>8SEU+^2!;CM(`8@1R0(7"WR<*]&57
M`V5RH(R_;9.WLD.@@%(_$)8T9<U@Y2VI(0I:?D-;BZW],"L.:W@?8^1]VSN2
M:]%!+!<!0.@S%4.8G`@@]KH40L6Z'<$PP([!!'3O&J6]Q0])-;N,9K!2J@!3
M$B`#7`)V;@R#WTF3=<T)(7^\WK"''E@N2I'G%!MP^<>;J)MX3UX0:F*2W]72
M1'#P!'`W,X%#ZM#+H*,^?J`-+A'-M'5_)D6RUB>8K4,:[N)#DP\T!\DPVRCM
M.6@(UF^LCEI.M/!F/P41O:0NT9OX"ZI@!5\EYQLF_P!X\8VH[9(UA_\`V1`=
M![E=_PÙ9Z]A$Z6C@;6%F*96Z5UÂ3R:U-`DA8PU+3GDR[Q5M#F1DIJ.GG1?
MPV4=JRKG<G;:+R:^T_+C:N?6"=^/\=@``,K<-H;<4ZCL//0LTAG9CS$KJ;-Z
M6Z%[`T`%Q^1I#.F#^0@A@0*^S6X/P>YT=-V=O@R99Y:?OCML=0$N^9YZ@FL`
M?BRB%!P``$.BKQ]EO&-?N)L27"1F/&;9*7WFN`+;TT;HUX(]K5O77Y=6*PY,
MS%%WÂ=Ò#Z!^X,5G;SI2@5PA@\$2MY/#EM&<2-:[5M4K.BEPQ),]9:```"'
M;0-9_"D6F:@6IB0('7(.0R'RL"A-8IEMQ$</ZG..-$*HDK`WGZ!QVR")>1MG
MZ0:%A#(H(]J60<=YM\,ZQ*$$7-L`:RS6_BV-8'Q(\Y4XK+C*1SX52KH']U=
MB_JTWQW9J"E@8EA>%KQ$!8@GG>:E,[B-`&U<\@WG#,0[NUX>3*&5;!5LIG]$
M`W:S]L,R)1H:;&?+#RS7B0_@`-PWA\?D-H!D`TX$EPC:,C&UYNE88@GEFNW<
M874BJ-?=&?<U:9B[E;7P<6#:!>G\,U**W\A'Q(LU/'*$^MÀN/X$?JP`,^,6
M(3R`.5QZ$.VS!VU<`^BTE!3GSY7;S"F;,_ZR\R0R\F=%:VHL\18GE:[Z+U%A
MSWHH:$@;#BP^-U-"$?(]A*\*&">5E6,@.C["(XB9A<(.;&A]?6H%024`((H)
M%SDE>)B&6+-U[A"9.,"3X[:CV-S28PEQ<&T%0Q'HN3KH"^DQ,H$R[+F+SU(J
MJ0ZQI<:3\/5M('0%R\SGC&'$]:O;KN[Q*/Z'9E8`<-,/-><>TIAXZ=@)E?LG
M$V-1B<99OTCHTQ/+_!619$@P5VTT$P-(Z[T.B3PBB.7L#;6@D&B'B(%@!H.Q
M&RQQXEWO2\K+P.RZ\!%`#0%,:O0RU8?E<U4,$?;(LX!R(!.-OZO=@VG8[$Q%
M9M?<9<+;@TDC?<K\RX7A!Z4X?1=$$0GF_J8-N*0$Z`)&/)E!`/N9JG>D3Q&#
M&)7Z!X+R81G*%M=X4C+`NS(B/UJ2M1O80XXA7+)H5IE%VVP$%!Z4Z`4C-IM]
M4+,+Q(AJ?`$$SG+1HZ^@,0-/C2'10P=<54$P]HQ`^:53_A7S@`F<.*29MVHL
M$-G>$"9GO?W&?T%G!"+$@RX2`P31%:%4P<3DT;KZ952W&B542JZ"[PO)KN@
M,0I)OYZ2@@PF%M5.31"PHH.75>H1`ZL<,Y\"5"`#;C84BOCS8G[L^Z?(."F%
MSH_(74;T]IO'P.JU<>/%^K^QMP'K*=,II'\&<TTX6`"M<S<!!(V$6`5,+C/A
MF#W-4A%T2:1NLW`:5OHRJFM._IOG`(E"5$O#R`_$-5D3PL&04'"K2814N/6Y
M)IR-VHD@9*S3C+5THAKEV`$"L0]'#UW-`F%\_9MH9#V0X!]X!%!F$%#RP;.G
MA/?Q`!(`?"7/Y2OY5E?ROP>MK=/H!$`R%B\SYM!(.DJ:4WT<9;0H86\1->6>
M0.+B-PYS'B=0],`/=0M$2\K.<DSL'!B5T\:U&HXA,AK0N9L>B%N%\A56\;`7
M',8VH`XZJ`D'EV*E_=/(=7D"0+D\]Z$&Y@B4V.Q.$[!DL`M\,)5K*A<4?V6&
M-.S;B0^C1@OS"0(FNE8[CTM`.9C(7R>P#E!Z>7(8PC5USJWUG!/FKVGDM)8_
M4,[A0KP^*&ZA.JDUS?\`@`LG6IQPDÔT$BN<K9<[DYI93+B<60!U1$2_--OP
M*L)29'(/HT2>*S7S(0)73RE+\H/XZ*!70;5X#-R<67H6(1#D1!H]'VJ*,>[0
M1)!.6=_?7*.U:=FJQ`,P/RR5O/Y`8H7S*:OU/J<@NU]4I%IP%74L!N*YM:!F
M"$."$<`=:1K?=9@SI3P2VR";^Y:JHU?GSEHS]P0&A9QD^3<.=RB+B.ABJ"(,
M*#]L?-`'T.+JB9)\F%FL`)C"K4K3X6T2R*\B>\:\=,H^)H$",?J0#HZNZ?`X
MV6_<2\HSA@/Z%LXG"EUO'`;>$"2NB.DP(5B<1PQ@`#OE5*;'='%B(!<K[EG^
ME,*U&>-B9P+$3A0'/M"UJ6PN$I29U5`STXM,RGC*2N@>'`08ÈUJ(M"(`0.R
M=ÙIN%EX.FMHP1!&CL3A/9BK2#(HYC#7MR&$(E8W+04")R)'X7BRY@2\>YH7
M*5.I%NC$3H!(IOM@P:-H#;#;[7.(`<:.;@T3D>CLEUW,720)H>B]KEF0%#TR
MZ9*D:M,"H5XA[7R'0Y`2CTPDY9':4`;]M%`R6.C5X(.;S"/!0<&`B2H4T=S`
MA`41Z:NFNL>^@+N5;]*R9Q/(YGUH"VZ8P+=+F/9+5-Y]8GAX.I8<-K`%\:`B
MR")G.Q$T$V^*92^\F$08B.%31SV+O%"$*QHN8@@V.,;'U%]GW/6G?$1;;"@"
M8&X5*X_RP2.2[2E;`9Z6JU'-GMPT5;H*T=V+*@$I+V@[+KZYI+$*+'/'ZA_;
MT(L8W(US!`5>0E8#A-9S]X49-+F+&M<IE.KT`N4D^9X3!&)TH(>[UPMW!R8G
M8Y8\!I:\B\MI`%?>::^5]8M>J`%@%=Z[3?PG$M3:S2IP*3#L6U6Y%T1*/;6F
MEO@V`;XG'BM[1BE(38<P4R)Z%$C3I;`,F8J4:&$XDDP<+.^]][TK!1"4&%`)
M9E.N1#WP-O9D[&LBJ0+`C8,13NU$_JI1`#&1A7>4@TA!@@P([-"5#3\(CFU.
M`6"A2BW%H`S7$>(0@$I32,\.Ô5BUY#5!=D<DE-6Q\X2@2!B":1JK1(0R[>R
MZ$BCSSN.`^T(.'_`6';U]3MVC]8E@[C`/A5?L513#G0NQ%PB``!]`4L\9N`4
MR".65N52$V2F1"97<`XY`B3P.`&:"#@R.8]3];*,1@K1>@<B:ZX(74RH624U
MXF'AS8I:OQR@K?R-`$NM1-JQ$1B8`N9G4+^<JO3T4M03HS(/==V@WXP-WX(#
MOJH`8'#+>1KADPZ1-@RI*3W;&?P$,`(]JB*7=9A>A><+=CPC)4S.8*AC8JXL
M7B+7`)S4@4+MGZV)<I).]\XJZ0%3BAL(`G("+43-*Z.J=10DV1:2SK'%Y>#8
M&\3P*I4&$F6??3?QB&1YAVE?*A](\7O:@-SWCH4M\75J@AJ`3!I^>T;]<2O#
MC_BFLKQH*\`!<7=X^%)Ì9%D=QJ*7>.R54V3@ETN"S'!T)B!,6^5Q;-:OD!%
MB->J>09'5\#2@G1;HQU/0.G0U/!UZAURD<?62%`8&N3HVR)+E08$0^4<;FM5
M(<WR2*/!)C`Z'!0P09EX-8":,@CZ@JW90T"5*PKMA3&P6J.S]H5*:XLI,@YU
M+O=+@%/LI$]NS[O^T8@H6*S:HA.``À@S=^?U"_EH`Z(\T42I$=EF7/"+E-E
M,L#T=/;4_#S.7E5HKLO@Q!0S1EA%OD$<J'%/KTC7)YR$+/CA"BX>@&1+FUZB
MXDLY:Z0>R7[!NG=$ÀA9T2L;3R;J0GSK_P"D;@E-1&+GI?O1O+RFE2]2@0JO
M(NG$02)S8\W`51H"G6*884`^((G2J+MQ'AO"&3K#DEUDY%9N1\M_`>R4'`9+
M<>?,P*P3+\L?Y_FV4T@=.6INACNFDG.L(!J.ÀZ`)!'P,\"H6[T_+*Y9%EF%
M,^98L?:/#-*)1"[<4W&[RPB<8P4$YQZ`WA^CIT3YH$V!K.?F![%K`HJ-"*6Z
MO<%&0&_K@*9]-#+%IL@(+C=\"<KF:/,*'2=J#V+$30.2K42*8J!V=T([R"@N
M>F!1B0(\7K0F0(J91$<@K]/0;H4AF8!:Q*6(N`0O_'"=$!$?&KI7K[D(&IK"
MT$\%:*YNNVBCA%:[EMH*LIY!8R^;6J?'2>`5B]ZH$`"MF/$<E>4#40A)W^T^
M<CQGY->,S10NCE;]ZGKZ"_.2XG^C7>3?MD4.@3\HARZJ(O9H([[HXO$O$*RJ
M@13"2"/8()E$=N0V26%UN>J]9UFZZABQ'68UK'T31DJU6';'9@%>R%PET'[:
M'CQRJ2VZ$*!K)."-J1DL\O(5GRA=N:T^^*Y.9T+"NA/:&,W2T:!G_"/T%3[/
M(*VJYI)LPQPY*2I"-N@XKBC=FFD!.J>H8SLKT:4#2@IA"ZSEI'\$410$D4SJ
MJ\@\RDE^)U)H%`*@:^1+>!-&@T!XQHXCA"H8KM9)<'^(1CU)5<!!2]*>D(T,
MK[.=0&89(`QKZT1)O1C34T!!4$()VZ8%1PJF%J598MX\W_-UP'1*)3NR]3CN
MM\8G>7IN=0)+LV#P-F3QCWF=L$;50<='V)%QJFP"$T[):+P5JB;2J1],RP.0
MVG!3%7<!]$K5651T(BD92$`N#>"2`ÈW]ÒK`?BBTH&-M8"IN#V!2\=H.@:=
MUF33)C.K@$3I9`F78$]86@-6CT=J'WM"SGLK8OSWK^!A?);6_I_WE_\`,#P$
MZ9A-0-X`\M:>S#),(0(+'JHY#!ND:2OP%!H#L7)IYP'N"#KMUQBQT*.Q->"3
M9@MEN*?5K"J674R]<Ù,8A!PJQ.W9Z-,T!1:(C&Y([J?HTTW/#'-N>S+[+RO
M`H,,AWJO\;)FQ@<H^4ÀIF0R@G+P>2KS$8L&8X"9T!M@M1N%:#2=,#2R$%<T
MD.VKP/K:;U&-(X8B0KWP?M6+%BKK>.!8'"TE5\Q`\Q_9MD-"A3Y?V@9`'])9
M&HY'[=I"%F"[,T0&:R+2A&+`PL6@&#`GCB+EH#G")^YD]]Z<[G)"!CLJ.&<<
M`(AI!Q\T;I+FVI"YBF0D#;1YJZ5"`T0L0B]QB4,M.$7ÈE'$F]"E^"!G72>2
M6DS?H`C:V,)6J<0SOBQMTZ8YT2`6:,20_PÀ\UY(_D!NM;Y.Z:4Y5O1`N4@"
MT?+=IG)J<`YS-I5'&](;T.NXH%`"HP`VJN@#-8CYQYF(*H!S#1/64]/^<1'F
M.HX%>W!)B%K3'9RW].6@714%0+06T`*XZ`S?L/%<L3A.A5PY@8W/X8OX9WZZ
M&VH!]?*>ZY%]6LE:36L#@CH](LPER`T<,F/>V+A&!'$1GT.B2ZHN(2,PM(:P
M^$?SA"#H!H/K0`H&O-->:#8\?6&N!AV(6`.RS+8SPZ>)$DJK\OT&T=;3&XVH
M`,,\Q70;MQM*KU\=5H/<-K7A57.R)"]@X@O\3!^:95*<2&JA3MP4L[%T$;G0
M7A.\CQ%]&2A09(\!N7`--:;PH&Z`FX\(_4ZN"-XF,`66V['F@@ER>K+C>EPQ
M7-:.^<YW5][&RDL;,F)<"\GLY2Q*_$?VCQ%_8]JHG%"-BN:BY*3\MX0<^Z8.
MN@TLU@.G5]IX=*7O/X*'[A_QZ))ZT:](O\CWR79ZW0(N'16\ZP.]VC%`>>`L
M\N9EY98^K20V<2<C`%-TA9@]?9M)E+6T^M&PE!G8/ZIE#:;:(J-Q!I95<&0@
M$SQ/I0[G^>`-'?:D',#B=XR]5Y4<`$?<"`**`F,T)X-B]L;31U,&P'KR`8F-
M_P#18L[T\N4-99\X?5ELKD?DQ9>YMESK;O?9J1YYQ_9_KQVF>Z')JN.P;0&-
MAG54QG$N$E:*I/?*Z&+.5F8^0%*-_*2\#9'3D;X`^C<M"/7?1VA"%%)MKLCC
M,@$J5A"M3E*[QLD/V\!%@)B).&;HU>8<&^$M2`4K3K^L@*F<T5#^"P<!3\AT
M2^:,XT@E5=!E^-=DD$#@`6A!E2)$/#-]4&B:G@L-6KB;2>N,#G\SN2:=(DH=
MG5BPTY#9HG^$^6P@;H02>E!VT%$%+M4@:)0`@9^8K40N\$BB<CR04Y&#3Y-O
MMEM!6$HLN5!07:V847>5NGF7;I[.X/:%N7%T1;]$)G,[2F@@=86Z&:PKW#(Q
M\8W5%--;C+BIST&FE9\TT)HA%8@5--%FEHQ2#,Y^%69][N),.TMS$2_PLE_6
M12NI<9A9?A!\,D;#&A!8#LI`BV`-F++'+B$@#7;RA>@05H+'@BI4B!1V-R;3
M*Y>$3QYP%,+(485B4Y69"7Q4A!R,;CA)#`QU_N6$NTE=O2F3@2!.QW,U:!`P
M(HA=SG7M_B27:-2'".I:@`<I$.&,)S1JI$"%-J>+P*E4GB\@W!0#26=$7)>P
MN%!+:]^6"35#BX%LXF223:YN@C[@YIUC"C+%V)T()T@F_C0WQ``5D94ILZWD
M"<ZB3%-F*C0.;;UUS-!J%1MF<FR$%ERQ+T*&:',@%*`Y*&^J=$'(@V@6*8<N
ML<7WN4!.0?,[@8Q.*.N0]@`4;8FS6LX3*?JHF-LQ^=Q"F4[GA5UB\T14NS-O
MUP/A#Q1,]*%6USC#8Q=QHT:)%DQH40&A-_ZMY%^P,SA"JHCI,&[SG*X:J:4H
MJ]]J02>6QAW^'YBQYR-J+]'C"!9$ILQ.K3RAB`T-@G_:D/,`P(-7C#T4G.B=
M361*S?=`8]@.[O;$`S_-9>S^XQ&3B8!64(.$02_*.[([]HF+8$42_#V]0T:<
M`PS.B/@!#GO$D#F%/AYK+COLWS+1:)7>T'7`!%`HI?DJJ#+0E(9;2LY36$"1
MC`'.W$9+;X:L@P!;)*H**9(Y&4`X>^YQ$\8*0'>YE5CÌ\%E?727A#&GÌEX
MI047:26E12B04,P/\0#8O*2B<_3:D*Q=)D[-6DOOI&/?Q)BH29$+M.)=`@*M
MC@NR)&U[S[2T+(D#9$=:4"(86.@HQ*6/J>C@+LGD8:;6_GX0^9;EPQ>+`)C_
M`/0+;A:$HO'(C#%X*=%<2!$(TMC>_9**4[[)XZK3A"=F2W,ULW`3H1L\"B(<
M0$6G9VF[5EFAPXC[3+[OA=7UBT)5&;@[-]V9+4/"C-B%C=@D^'_+)P](ZEA*
M;18EC):7A3)>EX(8S".8P5(B2\P-+@$5M+!S[GW5R#]-P8$>"3PV`!\5C0EL
MO,MZ9&3M%)L8=G5WB.\9@@G?"*DI;4.+U$HI4-W*$@M/8/900T1%@;I=V$WV
M#X<H+C4JCYU3FB$6]+JR*AIRY`#*,B-ZAVR$M\E4]J%2L8S=ZA#"95U.10[M
MY7DZ#51J2.+\3R"#2":PQZ#I3(4P!L$Z1U(2!DB=*Y@9":D.U\N0<CMMW3&7
MOD,K!#@_D9BB)?JDQQ61``R;8V2JKH("31$\VI?$N4K">$[$3@U%?X/CQJ'@
M7I*=T&W\G3VNMM/[KZ&?&,3<89S8S].\4.4-S?MX/VX<-A<005)(/ASG=`(\
M2U;XU/K!&6DEK"ZFGG*<4XO/CW^NS+PS*+D.278/.!!.WÌ_(AQ5TMA:'?KN
MF/`'2GAO)J2;$U#ZDC>].-5Y'"Q$#@(/A93O,P8-\X4,<@L>ZTALF(IX.1:O
M6U"*\?#W6Q1SQ@^LEQ^"],RU.[%AH'/&(FDTBJ:L\`%R`0%=>8':N^"&><A[
M([À[G.'H>_!^T'OMZ_"S==E&[,1YON`ZU'[HVT/NII<.VPNX#(J&Y!G!M^K
MJ?004",,J/#[3*&#%M>W6/\`>4VF45RRÌBT^!\^_DGP5HA8#/A"<$$#5DP^
MH5?G(N5J0S%93W'^:0OK9J/!"R\XY1874V?K)@:!)3?25'5$@=-K'O9@>:6;
MT/\`H0S@$=9A8?R'"2.%$&?KC8LN`J>Q+!-EA1"R8+2*CU7>4O(9KB!B:\V(
MTN>-""_"4P,EFTQ'\KSK8IQME;B1OL[%*QP)::207%H(Z.BN!-0),)T.,Z0'
M'K;:#FOK*.REM29<#$01$2B;$>$?(_Ò)^9?&2N`4K:UPX(-%7^>ARR`?&.@
M)UD34PK<H)E=G2K3V55W!&12=?#Y,<ÎJZ0$BDK>ZIR4&Q\@EL4TEC/O50\C
M9PU!](4O?4>!I1J@HA?=XA!TFYU]FUZI"'N[&8;"&(QDS2IRAVJZSYI@E9PS
M<(UY*JLIW[1XM+U)PC9PTG]=31C[(#;(:B!@H*:0G8&?B'+V/)1I.\$&)/`J
MV)6%(IK1M@&WM&I_XW#ULJ#T2YSLC1UU3A)Q/6,-=/\`(P<#-C*0B*KS6<O!
M4H:*DI,4GSA8PIO>#-`$VF%*,<Y1@4_D?9@/?RWQ=8"`(=2,(%J5B33)"!@X
M-%9EG!C>+N+LS&0I=SXF-04WI_M?!9/0@O'3`P4<R,-*Z$(-J(M6/V@&-`HA
MI),@WW$DSLH4L4F1?ND1)RPV.-L-W8F_[:=8A"B6`RA(T8@;#6/<:[+H$]1>
M0ANE'0+O'B#X*B9!JX;<S#TP<:`;YK0(-.3H`."QEWP[J9$UU;4B]T^$D:GG
MB?>$4'P@\CZ8)Z1LYNM4KM:Y.D(/6S\B-ZU=*<8WB6V@:T#10W1C%Y&F_H[<
M^SP`=B_BACP"B/>3CHSI].S$E@."5;RHIWV<VL#C@`9<YISS\LV5-R?^SE-2
M_K-\RI&U[U!!NNHM5`72V^NWGAC8CG30(38J\$'-U5/`C;^B0@80%7*^9$/F
M66O%F?@?R?3K#YM>[I#(N'L,<LOA8Q"_/$$ZX?G_`'"DL:5-6!FU)9N@=24B
M=FPS=8*S!%&>%O,Z:!,Y8=YAT-*%PHTQ?-6`T^>&[+31VB.@G(QEXP2@Y=W/
MRJ*Y<"!=2L)ZB2D\#&BB35@F%*1$[IU85@16+#03ICM5"H2<*2<HKMRE&/F+
MOE=S!&R_>4Y\_;9X]"N)>YJR]INQ*;24>%?6WL!AG`(R?.FKYB$C[S&HWT3,
M$?>)BYV,`2ZU$VK$08G=2[HCD<@T8:(R'$`<><*BD4P7!(*6[[:(V</>0"`!
M$*(Z1'2)@5U)V0``"`H``8M709%K,T)FH].À:P`30*&0.#3Y)2LR++EE'T2
MR)_8&^74@!`#TRU6770U*1,$0=+=J)!_VFQ)0N(GL/+=74<`(%*^\/0`Q!\-
MXOAO`NIJZ<#ACTM`!4N4`@0Y!10'1%CK>)%NG)LT0Z\"LX1$:E*?I%>0_PÙ
M"M]*H7#FS'[:<.9*D)<BJ\1K^J3E73@@=#+R#*E/R#^,(>U^TQOS?H3^@2@\
M@['>]C1_8F/V=-R\%EWBHMYSH7&4>Y+GT5$Q5RO:.G(EAJ.0I%KB$(Q4L1(?
M309HUL_#)KUIQQ'K`Z3[C:X[&\+O0@P*%CCVYSY_E%AIGTRD,T-M!S$D*Y@_
M?2A-+)(I-FEHJ</&#2`>1@HR"[-U)/K,%T""FK)OPJB/_P"G-/\`]7SY>W__
MV@`(`0(#`3\A_P#+@__:``@!`P,!/R'_`,N#_]H`#`,!``(1`Q$``!``````
M````````````````````````````````````"```````0`020```````````
M````0````"2"``""``````""```````````""``02`0"`00````020``````
M""0"````````"2"`````00`00````"````"2````"````"00``22020``"20
M00"2"``````00``20`````0``````00``"0200``"`"020````"00```2``0
M2"``2``2"`0````````"2"```"`00```````"`000````````02`````22``
M```````0"`````""`""``````0"`````````2`"```"20"""```````00```
M``````0"````222``````````````````````````"00``````````2`````
M```````````````````````0``0````0`"``0``````````````0`"`0````
M0```20``````````````""0`2`0``0``0``0```2`````````0`2`0````00
M`2"````"2````````2``0`0````0""`0````2````````0`"```0````20`"
M````""`20````"`"`0````````"02````"``"0````"``````````"``````
M``0`0"`0`"2`""002"```00"`2`000````000``02"```0```````````00`
M```0`0`"`""22``````02"00`````````20``"0`2`0`````"`0200``````
M`"0`````"""`````````0`0``````20`0````"22`````````2`"````"22`
M"```````0``````````0````````````````"```````````````````````
M```````"``````````"`````````````````2``0````0``````````0````
M````00"`0````0`""02````""````````"20`"`2"````20`````0```````
M``"0``"`2""```"0`0``0`00`````"0"`"`0````00"""0``"`"2"``````"
M`2``0````0002````"`020`````2"20```````0202````""``"2```"00`"
M0"`````0"``````````0"``"0"`0`"2```""`0"``02````"20`"0""20"`2
M0``0``2```2"`````0"`"222`2````````0`"`````````0``````2"0````
M`"``002``````20```````"`0````````0`0``````````````"02```````
M``000```````````````""0````````"22``````````````````````````
M`0````#_V@`(`0$#`3\0^\+,_CX!6G!(0.T&CB$+'"<ODD7^CZ9IP3"(`TY8
MS#;]"\W@.>\3F0.6[EGF,@B#3A)1>LK6/W6(ZHS=_IP7EO%$=&D<HE4&K(+5
M1VAZ]I;4IIQ`*"=2.T;VF*3-JCQJ,E,@[[AZÀB3SWO+.?2F`H,//G*"@\X.
M2I0M&PRQIU+G+WWK&B;N6A6A8*Q/#&&RFS*Q55P['.+A44+M51CF^4A88"/4
M1'XJWN=?PBG:IPH.4+"04N0TH`+RYH6_(!9:KA3M->A!?VZKW@$Z2/;^QO!R
M@K`:NP-)@MQ"3UD^,1M?IE5>]4B51]08\1TQ,1T4L<;IQD;"8TS7TY]HPE:3
M%U*Q*36O,.[]E""@K"O+%A[8+_CHH%``55@!M5=`'QH73-.R;2(0:1P2XT5M
MC?+$I'MB0.K:@61C&GEC8N(8ORN_]B*"S5(Y,7H=Q/(-ZC3:##/'RLH-BBD7
MM-1U$@IXV]"R2#P`CB1K@,\/R/M0$HZM&(S#9/Z7_J!PJ_*<O:B?H/@4#JF$
MN'PR"L"`%0!50`J%/M@?HP>525A%]DK3DR&R]VCV''-7]K[P``````$`#0!U
M```@"$)>4I/5Z'D*W+AW*$@<IAT>&T_D4%`-%BX:SG=5L@/7V(HW%+$*4UL`
MB%4H`0FJ08#8-JY@L#6OD2&/*0`!+6FTX80I0)ZZ.S$>5"(:L=7,[I'H*L;K
MTI-IO2"%(PO_`"`##_\`,&TRY#=LP:#"04%26ZW"E?%9!>"!4U"@T7=G;31?
M36\693J'./4EYRD"TCF/]-=ORPS)K4_>=H1E9@PD;UC-,I<&>C72NQC\QH^'
M5-BY"V=HJJX>\:!O2`%9LPQ6P\FDD-UP)L"FE[TA(R<<!-2TP9!5Q`3D.J_`
M"#/`L;;8[:A;%<)W&O0JF)KY1KC1^]*>@S=8^"S*=08!8FM$A(GWQ7[W5,LN
MC5.-`.)W`5V]U2LS!CT=U*DE0Q5/4(B.%33G#N$+K*95VFTCNHE,EPJ:-F#^
M3)BJTSXA*]&Q_8[X5/I<IN!J=@HT&2%24Q?R`*N!.*QGD8R+.7MD_@RI69$;
M;2_T$(3M_3"L:GAD[[GQ1V[FL-A`6"1O)U'MDYNIJZ:LD..\B04BKIZV"'5Y
M?U#,%1?.4:.=>*QNL1J$"1T^Y>^_R.L/Z2T%(H$P(;H=C^[>2_Y\27G?V%`:
M;:`5>NN&;4.@B)34YZ%PHM_EJ5$M(B8/6,)AP1K]>(.(_D:E@W-T"=OEK`%>
M]03:+/.CE3JX5^@H:!Y4!I&!1U=J0À>-!#,]@ZV<UO`\DXLZ[B[A_ZMA?R7
MO+JW;XCD,0?3>R8C;H^5CO0GI-&UB..CPRZRNQVG35NGS1;R4R%I>O"A\F8W
M,CF2O<%JX81=K_"3-BGF`B+:Z+<81\'3$L#.LB*[BL/3I:D!&W0;_M?.V5'S
M`W!8D,TAP$6&R`YI,^X`.R!X<I@`JN@^&LPBG#Q=<J<L$D=H-FT:@5S1DS07
ML7XBG2@R+1@>2ZO*(`??6\&JLFW>@=+46(G7#[<(^\EQ14L1Q`^3.S#6_@UF
M;ZVO$(DO"15E?`G(JDZNR3^K`8<"PM:^P16P<JY5N6AJK%PZ@$Q455KDJ?70
M#(5<`&DJR'V*PR=0#3!YF-!-R@/O>@RVNU2;7(Y6!RGY+D9:@FV-B:OS:È%
M5)R(.ZR/(D$\K0MBB8?+G8EYTVLHSY,;H:O)8XX#0H^HDPH-21(0,=UE`BCV
M7M71%DR4P[LV.$ZH4%$0PE6W(22301U!88^G%$X#>P_80_"][^GGMNJ+OB_X
MG9.2LY")?,O^.C=ZV_%4/%(\Y;N]'._VP0T<YV:NGGI/F>^*IEO0XOW,2+0C
M8]JHQ<AY`-$R%_<%'66Y(O;N`<WUP9;X<34&IB(YD%9V!$&!`8IF##`È2!U
MEB*F.9^$917YIM<2(4;-K"-+-,FN9MI;WC8IP.@<,3--7T05R)/J=RT-Z3<=
M`B"6()1&/L8CT\[Q#\+:?E#HXU.:(?%<IVZNGGI_R%CY#@W\OQ7H<%J'7C1@
MABC+,2FJ"A');9#IF1?:$^&H@]3XJK1BM*S`9*3D#I[!(XEA"$PGN!"EW$"(
M\F$L1FQ9SI_91KLOQY)$>."D)V67#?@$$`R-K&6UO=-HB]E*[I5@G6AP$5`H
MNI65Z<,'XCZB8:C+Q4FFWK/5Q7$5(M1.3(AXGDK*I3,^1!`+&I7202(%\--^
MKF4UJY71&\-+VYÈ#F&"'7CE#]4*+;YXC%5C._:W(:&WK=<=BT(I2IP'F(5D
M;)?.D*@*L#:N@#E7Ù3\JG2DÌ'+US)CF4AK90P#2_,J).6V8`)BU/<_F,*=
M!$\"1G:9E!L))&N#$)$:P]KS94J=2*VBQ5O@I84+-@X"@C.`;>W$V\.5V>Z\
MT15Q3!;IM#TBO`%-=!805)%C.8$_Q]$U)`*&=0#]^=OCNJ$43&54RO3$;\P9
M#A/4NJ"V9DFXQA.#DM'EUM4R!2W'8DMH2L,96(IJB-=A$".7*J8'GH=0V`P+
MH-QH5"P#Y[`S#_@OHS8Y+<#IZ-P.4<WTQG5D&$*AFD`$?Y$&?SMV-$W`6N(8
M!T8L$@09UB0TWRVG*;3Z(Z-7!+5R8!XJ1W'0L)T?8X=+ZNJ$@AB\Y>CF3+`+
MQ/$SD6_W3TJ9VJPJ+M+)G\&LU1MC,7.'O&K70#TB/>8KRG(AS31?<N#$<9)Y
MH\)P`!T9G=GQ.(E(03À#LGH!5A:\D6XRZ(/X=19^'0:YW;0N',5B#!DRN8D
MÌ#-25FOH5"]DH?9_P#MI8Z,L`%JC\13I=K>8+A&]<D71*X'G8%6\UF*``.V
M'8\1J93F`\`W#`;NDA:`>X:9$IJW`-<E`,%(]&(?Q?%\48#X4(#8%%CRPWT0
MF4'C\HF:E4A!ZM04]14"S&658Y,[]VV#HJM*%D297#P&1<)N;4O%BH@NR5$<
M82UO68-1C/:#LMF4A)@`@6%J>9K&*@&[823XG6K`>WA0&H_CJB1*+G0WQ+(%
M:&.;'<MK!&QQLF2B#GB+,(935OFNY2PX[Q_UEO,L6$M-NKLC%67C65CS,:.$
M:@\!KLX>[+3%?TR!^/8&\7+KS"!G@XO(DU!QOD-=JU-D6/-H=&6)]D"!%39.
M-K=1OI!D&"5C%+,`V;D`X>H&80,-QMJL6U*53T26EX##Z2F5'+\'>`8.MWG(
M-'(ZV@/84$6W1&N+AN[S")B;>W\-2!LF,52<8_GC`ZV@0,WD7%F)'3$M_8!-
M9#9`V62Z"(;.Q%N)+``VD`W%94"\[HS+2P>#'O0,T,T@1S`VZ&2Q:7:\MCA6
MKL`'28NQT]8P0>\&9[+&R.*_#"'Y7JZN@?6$="8>:`H4Z6C$$G],\WXJMQ2[
MT")@'I$6C=>%7H`5T,]?YA#B,IZ@R&EM,U^2N``$[!L3+ONA@]6G'D^'<TP+
MYG7)2S-**D@$C"/>;<"7Y.J1<*C\S$0??'Y*+SSE?+\ZXB#JSV1'5)V?Y'L1
M)2$,'RF;R00SÎ\=6C<YS2&B7%0!(^`\=K&[!+#%+70'K"XG%1"*MZYT]R>.
MF2I%$*0$,@V6S!P0<(AP:%[,P&K9J.G;(9,2GU.#5@DKNPW%$(J>Z2-*$4*;
M@WXG4NQ3N.B"+[5X%OF31DFL?B[!3V>F=^CET@<GL<)>>9+<G]"#M*REKLSA
M&^=@"W`F5"X2+MOTQ9ZR-]P%G;52T8=N\3@LK@MJ%=-B;>1%0M<(\F+MF54B
MK"6V!)?="4;5$H@!7'A2%!*)1!L*<_=WJ@1O9@;L(H8%KX']1NU6K00#J(M2
MNAEK4$$A^7AFOGC,T.->1UY.ZQG<8'@.$Q3WNZQ=66YC%4Z,G&A-3Z`L\"EQ
M'0?JTJ4<'2-S;)<.1),\#='`VW0ODK/`!KCDK46(<Q&/$!2)T+/5!8[5&XF=
M:*MW1++B#_<#1VP%O[^@:\-F4?B`?8G3\%ZÒ^D:IA$'-F=JAVH@=J*KM?A3
M:O*XQJYS[A(>7'(34+BJX++&E&IO):>?*R0Q,%5O[5Y`T<12"R-5(ID(&0M`
MWW2V^81`(P1%0\8H)Z=4=(R=8\\$*4&(6X:82^5K1$%8/DO];_N_71))10UY
M%C](QZ_B\(7[/[D>)O`"`!`4%$32)V-&FMXD59CK7T:WAWQ198M]$NHM!F`M
MA-2@9$ZÎ%$PDT^`7TY);\<('!/))Q@:<:79ED!#F]/<\[IAK9<17"+8S^[+
MJU`B&,J7BZ'W#-8XSY"CQ6]RZCK;BEZ6]Ê'M(1C3`7A23"EO'Q>K_<+0>B?
M)5;JOD#$#X`B`Y++R@/!T0(`4``55=`&;QG<:*#9=?@1B#,WF$C6D7*X5TF<
M.A63.=Z>$)0N"G4E<,."%X07RIG[)^)&%FFT@`N46_@1_-#\DW,E68$K-HNH
M?D%,^)_+>TG94=#E)7Y/M9F(%@J.UQ9EBP#^Y)/KHIB+TP'VD.35!`'?BUT`
M)H;@D]5,C%$`]Z088<2<6Q85[@K2/#$S$'&C;ANEIEE?`Q/T`*,M@FC&A*00
M1'"I:XG;=I1FUC*$1'!_F49!?4NP`'?%GEP'$'5OGR8,<!C[944D<$$Z%OUC
M7K_6W`HGHQ82OK5NI-@](O;I;]9RS.6H!3^&"_24A``'9ED:,6A,U=)3((`"
M`H*(41'3@)7O*JM=,Z5A$#X]3#"8]=6`1/A?`0[FQLXYR9":%<8@@AY:</M*
M19"5H$H`B#VLS?FJ*K.ML^"1!$Z$WRAF?'D"M#T*8OU1V&WB::@`V#S3]R0*
M"CXGG]MQ,85UFI=D<=34'EV[2)@93)[P!<*&;!4-XU=$20=IC`:4+-N@VKXR
M_OL@05MR$%A<WU.?%`LZ^`/N+^%_4-.3=-]@?+\H2E&"+*@1Y[R+@&S=BF`P
M1?V_U(B807;YQ49//,A/`4VZHF[=*PE@MYN63=N?T'*&%#QTT@0JUBA\HELC
MXT`.=V";,.BF#-A+T9ZD5V9;6%2*K[*]E-R-Z/SJX#C@"X6#FMAVVS!PME:+
M1&1CDI1T1HE84]&DQ8DO#\Y8=#I/*]N-.$_!%G(J*ND+&Y3AG3YJ4%ZDWX0G
MSX1ML?%Q%;,,B0G+(`NCM!4">J3J-0_*H"]UTK41Q2R)842%L&CJK0I@+0#Y
MMF7"JT1Y8:)P@-8DO"D%Q!JUAD=A`68J21LR2`!BT&F4T++_`"ZV%!-NPIQS
M*MI(Z7`NX]7\G;;).5`P\>=S4E&<5CFL!&6LJ+TM;%Z?Q%(+NB*V4*/M[PFL
M[#4A3=2&34QFXW)S->Z^Z]0!,F7&;.$HJ%-HP9O:LV"LMCP0U,(B\=HN/GA`
MT\N^M%N]`(AZ$"%U@&F^.7ERDP`!]!F6WS:5N1*8B84*H$I*3#6,3@ZCW!Q>
M9-D9Y"Z\/H5>[49GN\ZH_C9D&L\'Ì"\-M'6#)P@@B#:(XM]3KXB41!6&"S2
M7E"*.2.]K'=5KG&0IOD]!_HDQ$74V?T>#S$7P4)80,PBPA*H8.\]4]C.A\Ù
MG=EO:0(<1-(*</84O1;;$O4K.T*7'9%*`&!C@"$\'24IQ:4V@7%+PKIWL3\]
M.,%V2J?*9@2X1U3MO(CCIYX$F*_B]9"N(9@GFZK)I"\G*^&%=;_/IO\`-,[,
M?4&GJ_-<S%MS+5G0$:U%^:`J2OF?$^?G::L[RH\H;RNTP=1S56I-+8Z4X2U@
M9:;ZTM^KG"^".@T!R]H:(154.#]()B#&@S(X+%N*9/<NVR%!5^TB>(*U]'X3
M*")XV7%IS'2>)Y@+IN5X``\:/-E@AP8=&P1&%3.Z),=AL[;>XMHZ"<`&519"
MK$OG3/C\W%08*4U]IP!$S$JWZQ)%"-SBFV@$GH(>;8L.PWX_=@6RT@XE`?+@
MZ71A!P`!DP@-6F?V;8-T09<WK&`SM=;;0=DI[ABP(8KU;0AQ%)DSMO$+-L7E
MG+C"5I,+7\T&Y0EF\FMC2<U-A!84O&&FYRII];O0FR\/506Q>UZHP+EDY#Q#
MR1SR`DM@3I+/BP2S6-^VF<PL#DLK'2[;9(4N0X"OJC?3/5M@]=IH:YKYMQ<L
M((W-D`?>A2F^('N"PYUPV7I,&DMEA8BFS('S^5SM=D";>$#@&AB<8[5H@NG5
MCH"HI`'!8^"E0+!:`2.R1[CI]JN!,,,-0+P<RR)&=4`\8%O"#(.%*,_OQT#"
MLZARFM1MOSD\89#("BB3;4+#*+O@_7Y./"83F>A6Q^)S81@9ÔE8$Q8!]GLB
M:'[6'-@CFTY#Z53MW8&"`&B5+F4Q`.GM86$?@)8OYD<@>`!:&@M5E*VTL$"G
ML(0<$.XIEC55!K>/]`^)E$@9.9V0VD!VHTA5O?\`\H21B.68L_<L89`";>8A
ME08CB=L%)A6&J9DG`CLQX!ZTU#SD`QE44I2!E&R:O#,1AK'93R4`0U<BE#AD
M7@'Z.C,D'71PV8:1PF4!#N+=[Z,LGNOIG--8/!H]$IS4(*C)ZD'6B_`:-Q`M
M(W=')4UI[)4AE&TK63/%,BCD8+-<&(&T$>'Q:LE0<`DS`*`??P1K)16JUO\`
ME-9P'@W3G;&C!V/WT?!!0[ZPD`>Q=WB8<"<;#,L6-7,%0B\5K.;$K"JA*W.5
M044#L`-*"^NC.C4E:LV>C/J(VS'SI9ZKJ_@`D7Q(*974<,``````"`!H`P5Y
M7:Q[08R?B($I?Q[4P+À810FCET,+6)N)CF(VRB^'!6S#,U!#+`G"-%X"PV,
MZ\\$'.H"B&A).E=DHB=WUH?5YL(TPEG2HU:<%+)5)(Q-Y)4,C_T5!08L;C9X
MO74H`08!L`X8J6T5$FE-Y'5C5!RO8C:!A+`4Y:=O4/GX'3UTVB?`=`&GT!)O
M`8V6.Q,<#"V0'^!0PJ7F@]QO\Z-Z3);LB)T(APXSQ@7QD*'X,&E:C[?O)3F4
M$DT&"D,:X5M^D@B((D1V(\B>1Z4!N@3OXD7YFE7,?_H&'I/%;RGTRZ4CLPPO
MR'?`8"'8;!2PV093LSHT?Z(>EY9[6*XQ*'P2TARS43D$6V4%+?T`N8QB08H`
M5IR^3+-\1.#6S_@,KA*3T5'6W:+GCP+3OU/-&0TBA8:GNT)1C<6#/X;93YY2
M-.'0=YU1QWK+.><P`Z9QR<PL)[<PKOS":-E[FA*(A;)#!<D6-V0T:.30LY84
MT,UIL"PC9=2/\O[Q7I-=UB?3PQU.!M";RR1C,-=BLC9FL_6A)Q@")>C7#!!J
MX6N3DW;%AT+$3+&__O=SX$W2`B"(B438CPCY'L)?)&<*5R$1$8XS5J=GAF5R
M!5NBAP6@S4D<,JS6&WCXJC"""6[BQNCO%$UIA([UAO#<<A&)FIWQ(,7PLA!"
M8+I3(6P841&LWJ]C0<A6.7.=?@4S(&-Y9I@R<[(5)H:B)L=T!$[W-1!'>-D=
M.X?D"1]3`!5=!@3<9.%@%8)5$0%@#?.B;DWC,R7(BP,,H)Q*P'>/K9UE:VT_
M3`F^G9K:\03(5*F"VC(!Ì"*R.G;69D%,%2N`SD/OZX"X"D[M&G;\1:[R<LX
MT10NL7\YNJ<Q?OOCI8SO81??NY<SU&*<2+M0#ZF`!C^,```/K"D(XH*GX@MY
M#]8/("&VXT`3"J&"H#PZ`C3V6`4?0MS:V[4OI!E4#"#23UX$#)P6J?"[04,V
MUJUP=HN"-;*<0#W"046?,>&]'-+K0K@59AEAW5#<5R)*I[K8B:>#"A8$VY:G
MCD28GZ>H/YPOK\"UZ>')='*TBTH*;DQ<YY^)+E'#;X_Z`!H2GG6W'%SR%+J7
MF#$M=(WXQ&H,0H,5A1@*/(E.UJ]'U8QSY-'SK=BBJ/0,8J!3@Y.$;N4IVC&9
MWA&@.T%FV/30_2]&!*J4C!%/"!]CWW\0;R(*G4A"T9OW2&TE9.>,&,P3(V.3
M+D`&J\G_`&[SX$,`0<.<CZW7V8EG'(WS-M?:Q)/Z,%^8XCG[39R"AZ$Q=V3%
M`3(H/H4T4<ZC7I_.2>4&7O3>K3NRHHQW!J(A<8O((H<.4@3G%>5@",2V,M%0
MD7-MRYR7-`4'!FW4#P"GU8/,EOF<)"H=[!V*X\K:_'CM)H&LUYG+U&2JK.I"
MKKWÌ@NG1JN-HACV+(G&"A]C0B(3SFC/(U$1:42BQ?0),`^DU3<*B&XH?9;=
MP8HV&4K/]WJW34BFS9BMSÀ4`HLJ-/A2U>"NBI1@@(EF*@&/T1`$8#KHE9-R
M\HXN`*H&$T,FV5GVK-N#Q(`W)UF\.F?'(.4Z30)#\[C'[P+4F(KJ/A`Z`(2:
M":<E&H?2)\CA&-5YS^P<&%!@^-Q$<..```8*Z@[H,\7+ZXY?TI.8Z2A]U`G:
M4=LS/<WRV5`FCF0%)-J[$-QZ/\F-`'&]XB4OH$'Z#!Y*7C`(R.[0XS1U2D[A
M0^$)W!A=+EJXD=?B)?::[&>#&TY0%GJ9MR6Y2Z"\@D+.7BD*.)'G%)N4S#LA
M*)<%C8ODK^#=WQT,A7$,MHSE';"!X7!GC5XH/(_4Y+BKJL^^GD5-!`4%=IKY
M'T^LA0!CCFZ+>^J+@MV1)Y3MGRTC$&HN(3DNX6S.ZLG)'1=+6ETX4OQ"%V=9
MCUIN2"_ECXR-:"LB"0.%0D#E.XO#=FQ#_@Z4.N.)&!B[J%=53HL4T><<0<DS
MJN&$=EH.D2VK3E(JB!0I4^"9,<PÒQ&.7`D><-ZQ!1I?8)`)Z/AQJQ&Y#A;F
MP2$D-H9H,:>:!8'<`>@3<"%)YTP6@BMR=$/2,MÀN,I`YS;0+'KL"!).X9$E
M!<,(>'7-A@[/@43J?!D4\.X00ZNAXR?IBMV"VNFL..)D#*2K.2N!+<JK@[9(
M5D$[FTPF0"(U+',<-JP6NI<D(&.XRA$1R-H3F0WS$J2'O317.\`D!*)Ì*2"
MM:HZ%`)`H'K3-=CKB=?23YB-AGI;[S,_2A;0X;!4V!C1>53?[6[<U]I.(AN&
M-L$+>+3`R@X.=MY&]`4E6@#Y;UG/LEB?D$S!OP+.K%.OM8%Q`Y5(QI<=[SDU
MR91#8T(&X23!D:AR@I533I*1BO6ZOH=9*S&&(ZPB#1@A4]+%N-71J[&TOQEN
MT[:*!ECF>@:+AM"K=QQ'NX-WB=\49/V"=#,BY"Q=È.B^>@2(D>JKU*UQB&:
M$9,F=]?C,)@<'`50`H@@1&?1FBO[EZO^G3C@MM+(HE`LYAT2)JU?"5H3+7')
M](K(,E1!BB/9FRCH(A.`=Q,0:*[@X9/&]-`@9K=3UPI.A;PED(=3O@#$Q)V5
M9N#_`$ND*U,>"%.XO5.0D_,`!JY_GU$WX*"&V<@_BAIV#7A4%$U/5<-.6,"X
M;XH#(L@)I!$[2R$RW+KZTB@,8$H9+;R*?1O(G%4V^HR/>TE"(I%`?:M!"J9W
M*^55D+LZ5.2&K^B8QH2HT_BÊT4#>JBG0U64R5+Y!#LG,@YUNY8FA>SX^#K!
M2\>R7JQBNW7VEI<(Y&!E-_RN@96L*00&#(-:B5-9H*"X$$W_`&0J<$YJ:'BZ
M)AU.ZQZC/.7DQ=&M'4'!:M)$C.,A%L)N\@#YXE0H>N.RZNN(XH>2N>RHA<(=
M-/\`DF.""3&W0=E)'4.[Q:C$\0.%L\X.E,:5^])],<-'&#?]=%\@,=A@,*`5
MEZ0Y:,#Q#)VE]5\,+50'W9!:!&V`LW,+JCR:?&C5`Q.P%D-7Y=\+*PC!]REI
M@<PI5ÌG0!$R%$,'LC_91OXNH8">(G^1`>L@("!05(%Y1@><&TZ`[M,DBDFD
MQ(0EQ!-#0)1TM.\$[%C:`5D`1*F#H&4$`J]!!JGSQV4O)+<V-R4J1;BJ#4H=
M0IJN#*CRLPX:3WL:J^>BVFR774.:7!#ZBVDN:(*`@"SF4;9L=2SPTY13(B"-
M'8FQ'A'-APB/^S=IS(V&CS/)Q0F+X^X4M5`K0BÀ_C&02T.;`;)X<;LXD]G:
MCOC3E")UN!GU"Q<WKZ3D\O50?%RIR>C%?K/]H2YG<!,K.H:H09I!-?JT3WZT
ME<W,@6!A,GWUV2NY,-DK[=]CGE^9U<-I*/S1A3$+\D/K+L(W+R8(H^=#5F&A
M]1Q+YQOU)U8[<D#6&)/$W0!N<C43D<)ZYQ0NU&[`"S);RX&0YI0#H=%Y1L=*
M<XP"!%PU0M@]>^%[',=WQ=-M.4A#"`Z+A;(:8I,1Q=5&=0A(^K(?(UF'W=$<
M33<6LBI^T,:S'_3,/4@=1.,D_#/B,ZD7.)3RK':7!\MJ?M&%'TH&3H88"Z4X
M/(VKKB6R+C8=N(#GF6BRP9$8JPC8`3VAX"BX"9RP`H%`-$Y^"&:H%'P3=TEP
M(?";;#804"5^'RO>2,1&E&>;]KRWETHL31O!X*$JX]\5Y1EE[=`9%]G5&4:C
M=(!,#+>5]^>UA6(@^NA:KT:9'0+762$6>R-?!':E91"ÎWU9:.F>D&]0Z4C^
M+4"4(*F[)P24$>YFZ<'IYB%$>!MW^DS)]@B"@"8"7H?Q,S,:E@8LQ]W80!OD
M:WU1G!)H@O!Y!"5XI8D)\@M@I)BUE`&8PJF<)@@6.*'PDK?@:`,YI3D_.B<D
M:(JBJ%5-*$3N]YD$/K'(N!>B6C'#?8?-2P149K-\'XOLWBY``'4X]S@]8XI*
M9_-8'0<A<FJ`,0DL[,(T0X;D768<BSP<A4]+5_FK!)7IQN3MV(C15HBVJ@W-
M:]BE>_VJQ=FH5+D/3/\`"8)'&3.;TC*%`P)[$Q[E5"?6/>+&4X>``JJ?(UO3
M&=S?D4$0!FQUJ_''&PCQ_>PQOQ0D.5+)8$@A-#[_`"\GMI^+F3I-=N("L+O#
MYO9HR\0DRJ<IXN//NF4-?8H]\U:RL$M<."[=K`.N!U5[C)F`PDTN3:`FBDQ*
M$L>^M"<BC@B41/8T_P!=TII&C00WD#>,`S2TLE:`$2%4$C?P0QYPD*ZH3)=_
M]&K(DY%A%9DPINU[R2H<QM9Y(3QX!(%:A)T?EB!A5K<<@L]N5!%AK/,>JJ)?
M&[G&D`KGO[$_^X-V;'8GGZ3]DG;2D7,N"5_,/T]\\FD(.QH1I7;;@!L`*A2`
M-5[M)CZJGZ($T\Q.]6E-*:="$2C23:^,5FXJY/%@B)Y1O=823MZ:4'P7&V1$
M@O,5T`1)15<4"Y1]P&[%LN8(:AHWP3P%FQ.Z]/$U%O*%7&<MPBFDD&$=QJ+0
M,0'B.@Ò%B]D&ZC%>(."X,$$1*.D=B/(F,"'/NS)`2A#D8F:6`$A9Y08[#%0
M'_MDQL=G/2U.^R)È+XTNG=13^&"_24E"*/=OTR+#&^:,0P,I,K1J7-<;4-8
M:V7;46R@O?8_\4CZ/*2(Z3#9/OGDG`4$$#8>X6%CD@OT.3_1P2@T%E-U8$UL
M4]BWZGZ4*@/_`&.`H1&1PGKBUR\?E:O[QK=.]ÙLLA'T,::D+M&2=Z!3KGLH
M3$&IEE?=@QB4C=#0FPXWC[(W9^^93;9*93+;2;N0^Z<DC%Z;&`.`"`#$^F%L
M%BQ-)+OIM>G]U#E!`#%;BP2TPWUHQ\N.>V2/LH-.Z@<>)+DC1(HF5;R'60K:
M#7JAQB?]`@08````%,W3(^$N%>#&<*_>UX5C&\%H>\-G.6!F`7OP'B`KMI5,
MO![MOV2BN#3?24)1:J"HDIY*&O#@"*[>L+4[<8910-Y#+)8O`8>W%#Q#%V"6
M!Y@&X)W=B`(Y<!L_OB5J"5[VL;14MGV`[8X0]P>#KZK`G)M%O44UQ.7^>0_\
BA;MD'__:``@!`@,!/Q#_`,N#_]H`"`$#`P$_$/\`RX/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----

Glyconix SB-2 Registration Dated 10-13-05

Caricato da

Informazioni sul documento

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Glyconix SB-2 Registration Dated 10-13-05

Caricato da

Copyright:

Formati disponibili

-----BEGIN PRIVACY-ENHANCED MESSAGE-----

<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="ARIAL" SIZE="2"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New

<IMG SRC="g97153graph1.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g97153graph4.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g97153graph5.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<IMG SRC="g97153graph6.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g97153graph7.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g97153graph9.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<IMG SRC="g97153graph2.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<IMG SRC="g97153graph10.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<IMG SRC="g97153graph11.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g97153graph3.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New

<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0"

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P

<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1"> </FONT></TD>

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P

<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1"> </FONT></P> <P